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Scenes from the Life of Moses, detail of the Daughters of Jethro by Sandro Botticelli – Fresco in the Sistine Chapel 
1480s. This exquisite scene depicts a young girl obviously in pain as is depicted by the facial expression and red glow 
in her cheeks, The girdle she wears consists of apples, the symbol of fertility and acorns symbolising slow growth and 
long duration. This is believed to depict and fend off infertility and chronic pelvic pain which are two of the most 
important manifestations of endometriosis. 
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Abstract 
The aim of this thesis was to improve understanding of the underlying genetic and proteomic alterations 
potentially contributing to endometriosis. Assessment of the genetic mechanisms and pathways 
controlling angiogenesis, apoptosis and inflammation allowed identification of potential aberrations 
contributing to disease. 
Tissue miRNA expression experiments show that, the ebv-mir-BART2-5p is detected in endometriosis. 
Endometriosis cells contained higher levels of ebv-mir-BART2-5p compared to eutopic endometrium and 
this finding was confirmed by quantitative PCR. In situ hybridisation for EBV on tissue microarrays did 
not confirm the presence of active EBV within the endometriotic epithelial cells (Figure 4-24) but 5 of the 
42 endometriotic samples on TMA-A gave a positive reading for EBV presence in some of the 
lymphocytes. PCR on the peripheral blood monocytes confirms overall higher levels of EBV DNA in the 
monocytes of people with endometriosis compared to controls (see Table 9-39 in the Appendix). There 
were no detected EBV levels in the surgically confirmed control patient samples. The presence of ebv-
mir-BART2-5p is a permissive event for the development of endometriosis potentially acting as an 
initiator for engraftment of endometrial cells to the peritoneum causing the development of 
endometriosis. It also aids in disease development by suppressing T-cell function and encouraging 
adhesions and angiogenesis in affected tissues. Alterations in cellular genotype also enable the ectopic 
endometrial cells to evade NK cells and Lymphocytes, promoting proliferation and metastasis. Effects of 
genes on various stages of the cell cycle checkpoints and pathways have been explored as contributors to 
disease development. 
Downstream proteins from EBV upregulation are also confirmed to be affected. Tissue microarray studies 
demonstrate the upregulation of Cyclin D1 (Figure 4-22) and downregulation of E-Cadherin, Maspin and 
BCLAF-1) (Figure 4-11, Figure 4-13 and Figure 4-15). Galectin 3 (a prominent anti-apoptotic and 
angiogenic member of the lectin family) proteins were also upregulated in endometriosis. Galectin-3 had 
already been shown to be a good therapeutic target in humans and may provide alternatives to current 
surgical or hormonally repressive therapy. A set of in vitro experiments have been performed and show 
effective disease repression with Galectin therapeutics (Galectin 3 inhibitor GCS-100), potentially 
opening a window for the development of novel therapeutics. 
Serum was analysed for miRNA and antibody protein expression profiles. Pathways linked to identified 
biomarkers have been explored aiding in the understanding of disease development at a molecular level. 
Identified miRNAs are seen to interact with a number of important pathways listed below. There could 
potentially be effects on cellular mitosis and meiosis, cellular structure, intra and intercellular signalling, 
vesicular transport including exo and endocytosis and cellular apoptosis. All of these changes can result 
in endometriotic cells that replicate at accelerated rates, adhere to ectopic sites, enable angiogenesis and 
growth, evade normal apoptotic mechanisms and evade immune responses. Certain identified pathways 
act as tumour suppressors that could potentially explain the non-malignant properties in the majority of 
cases of endometriosis. These include the p38 MAPK
1
 pathway and the p53 tumour suppressor genes
2
. 
Other pathways involved are known to be associated with tumorigenesis and have pro-oncogenic 
properties, these include the RAS, WNT, TRK receptors and MAPKKKK pathways. It is the fine balance 
between tumour suppressors and oncogenes that probably control the transition between endometriosis 
and endometrial carcinomas. Identification of protein and miRNA expression profiles predicting the 
presence of endometriosis allowed us to work towards developing a panel of non-invasive biomarkers 
(Patent P063434GB) for earlier identification and treatment of disease and aids in unlocking new methods 
of molecular targeting as treatment. 
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The aims and objectives of the research 
This research aimed to analyse proteomic expression in endometriotic tissue from standardized pelvic 
sites. Assessment of the genetic mechanisms and pathways controlling angiogenesis, apoptosis and 
inflammation allowed identification and definition of aberrations that could affect control of the 
aforementioned processes causing or precipitating disease development. Comparative studies of 
proteomic expression from specific sites were carried out to assess for possible variations in 
pathophysiology of the disease processes. The identification of tissue and serum inflammatory gene 
expression profiles or micro ribonucleic acid (miRNA) expression profiles that potentially predict the 
severity and stage of endometriotic disease allowed us to work towards a panel of markers for the non-
invasive identification and physiological classification of an as yet surgically classified disease. 
Identification of pathways linked to endometriosis provided an insight into potential novel therapeutics 
and were tested successfully in in vitro experimentation. 
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1 Introduction 
1.1 Definition and overview 
Endometriosis is a common gynaecological disorder found almost exclusively in women of reproductive 
age, characterised by pelvic pain, dysmenorrhea and infertility causing numerous psychosocial co-
morbidities and severely limiting the quality of patient’s life3. It is a chronic oestrogen dependant 
condition with an average age at diagnosis of 25-29 years. Optimal treatment for endometriosis is as yet 
unclear with a delay in diagnosis of disease quoted at around 6.7 years in one multicentre trial
4
. US 
studies report an average delay in diagnosis of 11.7 years and UK studies estimate 8 years of diagnostic 
delay
5
. The disease in itself affects around 5%-15% of women in their reproductive age varying in 
prevalence between populations. It is estimated to affect over 70 million women worldwide
6
. Diagnostic 
incidence rates have been quoted in 26.4% (95% CI: 20-32.7%) of African to 54.5% (95% CI: 44.2-
64.7%) in South American countries
7
. Endometriosis is prevalent in 0.5-5% of fertile women and 25-40% 
of infertile women making it a leading cause of infertility
8,9
. In one Norwegian study the lifetime 
prevalence was documented at 2.2%
10
. Pain experienced by women is not directly related to the 
classification of disease severity
11
. Characteristically, ectopic endometrial tissue is found outside its usual 
site in the uterus, within the pelvis and these respond to hormone changes during the menstrual cycle. 
Rarer cases of endometriosis in peripheral sites such as lung, brain and surgical incisions have been 
documented in medical literature
12,13
. 
There are no defined causative factors but risk factors associated with the disease vary. Suggestions as to 
age (rare before and after menarche and menopause respectively), social class and race
14
 (increased 
incidence in higher social classes), in utero exposure to multiple pregnancies and Diethylstilbestrol
15
, 
infertility
16
, low parity
16
, oral contraceptive use and age of commencement or stopping of OCP
17
, family 
history
18,19
, smoking
20
, diet
9
, exercise
21
, body mass index
22
, dioxin
23
, a history of immune disorders
24
, 
association with Non-Hodgkin’s Lymphoma25, association with pigmentary traits26, links with 
Melanoma
27
 and association with ovarian (serous, mucinous, endometroid, clear cell, other subtypes) and 
endometrial cancer have all been published. Most studies describing links to diet, exercise and familial 
inheritance show conflicting evidence and are by no means definitive. 
Classic theories as to the origin of endometriosis will be reviewed in this document. They have however, 
failed to propose a precise pathogenetic mechanism, confirming the limited knowledge of the 
pathogenesis and pathophysiology of the disease
28
. Although endometriosis is a benign disorder, recent 
studies have suggested that it could be viewed as a neoplastic process
29
. Genetic factors and familial 
aggregation are associated with the disease process and the risk for first-degree relatives of women with 
severe endometriosis is six times higher than that for relatives of unaffected women
30
. The disease has 
been documented in medical literature for over 300 years; nevertheless, current diagnosis and treatment of 
patients has not progressed; treatment encompasses invasive, surgical solutions with limited outcomes 
and substantial side effects. 
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Endometriosis, be it superficial peritoneal or ovarian and its associated adhesions, is not always 
detectable by trans-vaginal scanning
31
 and peritoneal endometriosis is only visible at surgery. The current 
gold standard diagnosis is laparoscopy. In this surgical procedure a rigid camera is inserted into the 
abdomen and pelvis usually through the umbilicus enabling pathology visualisation and treatment. This 
technique is invasive, and carries surgical and anaesthetic morbidity and mortality. Diagnosis of disease is 
based on the visualization of endometriotic lesions during surgery and is therefore operator dependant. No 
reliable serum marker is currently available. Over the last two decades, proteomic technologies have been 
used to identify molecules, serum markers and novel proteins as probable aetiological factors in 
endometriotic pathogenesis. While some molecules identified by proteomic technologies may have a 
relevant role in the pathogenesis of endometriosis, the research of potential serum markers for this 
condition is still in its early stages and far from any clinical application
32
. 
Current pharmacotherapy for endometriosis includes gonadotropin-releasing hormone (GnRH) agonists, 
oral contraceptives and progesterone receptor ligands
33
. Being able to use proteomic technologies and 
genetic analysis to flag molecular targets and disease patterns, would aid in unlocking new methods of 
molecular targeting as a treatment for this disease. 
1.2 History of endometriosis 
Three hundred and nineteen years ago in 1690, Daniel Christianus Schrön in his inaugural dissertation, 
Disputatio inauguralis Medica de Ulceribus Ulceri, described sores throughout the “stomach”, bladder, 
intestines, and broad ligament which had a tendency to form adhesions that linked visceral areas 
together
34,35
. This is now believed to be the first documented description of endometriosis. Arguments 
against Schrön’s identifying endometriosis lie in the fact that other lesions in his dissertation could also 
be attributed to alternate inflammatory or infective lesions. In truth, without the advent of microscopy the 
definite presence of ectopic endometrial tissue could not be confirmed in the 17
th
 and 18
th
 centuries. The 
description of these unknown lesions remained unchanged for the next 79 years until in 1769, Arthur 
Duff, a Scottish physician added an additional facet to this pathology, describing the intense pain and 
suffering of women with this condition. He described morbid symptoms that manifestly changed the 
disposition of the entire body
36
. Less than ten years later, in 1776 Roederer, Broughton, Tailford, Duff, 
Ludgers in the De ulceribus utero molestis observationibus described the disease of endometriosis and its 
symptoms. 
In 1800, the advent of microscopy led to the visualisation of the endometriotic cells and in 1860 Carl von 
Rokitansky observed that this pathology involved the presence of endometrial glands not only in external 
pelvic sites but embedded within the uterine muscle (myometrium). A dissertation by Batt in 2008
37
 
describes three phenotypes from Carl von Rokitansky’s observations. The first description, when lesions 
were seen invading the uterine muscle was labelled as ‘Sarcoma adenoids uterinum’. Where lesions were 
cystic in nature and associated with myometrial hypertrophy, they were called ‘cystosarcoma adenoids 
uterinum’. The second described phenotype, called ‘cystosarcoma adenoids uterinum polyposum’, was 
observed in the invasion of the endometrial cavity forming a polyp. The third phenotype, called ‘ovarian 
cystosarcom’38, described invasion of the ovary. Arguments have arisen as to the possible malignant 
nature of the described lesions, though Batt, maintained their benign nature, as asserted by Rokitansky. In 
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1896, Von Recklinghausen disputed Rokitansky’s findings claiming that the ‘Adenomyoma’ lesions were 
displaced mesonephric or Wolffian tissues
39
. Up until the 19
th
 and early 20
th
 century pathologists refuted 
the hypothesis that observed glands originated endometrially. They were however unable to describe their 
origins in tissues. 
Up to this point in history, little was known as to how this disease progressed. It was the surgeon Thomas 
Stephen Cullen in 1917 who researched the visualized ‘mucosal invasion’, noted to be a characteristic of 
this disease
40
. He observed that a uniformly enlarged uterus was caused by a diffuse myomal ‘tumour’ 
occupying the inner portion of the uterine wall. Studies of multiple specimens showed how the 
endometrial glands continued diffusing into the myometrium causing this pathology. He also noted that 
the stromal cells decidualised during pregnancy, providing proof of their endometrial origin. In 1920 
Cullen depicted the commonest sites of adenomyotic lesions within the pelvis which included the 
myometrium, rectovaginal septum, fallopian tube, round ligament, ovarian surface and hilus, uterosacral 
ligaments, bowels, abdominal wall and umbilicus. 
Until 1921, attention was focused on the deep sited endometriosis in the pelvis, referred to as 
adenomyosis externa. The disease, irrespective of the sites affected, was regarded as one pathology. In 
1923, the surgeon Dr. John A. Sampson created the term ‘endometriosis’; he noted during his operative 
procedures that the observed peritoneal lesions bled during menstruation similar to eutopic uterine 
endometrium
41. Sampson’s initial theory was that superficial endometriosis was caused by the rupture of 
an ovarian endometrioma. This theory was however altered when it was noted that the free superficial 
peritoneal implants reacted like eutopic endometrium, responding to hormonal stimulation. These 
implants were recognized as implants from menstrual blood regurgitated into the pelvic cavity. In 1926 he 
was the first to hypothesize the theory of disease causation by retrograde menstruation
42
. It was from that 
time that adenomyosis externa, ovarian endometriomas and peritoneal endometriosis came to be regarded 
as the multifaceted presentation of the same disease
43
. 
In the 1960’s the advent of laparoscopic surgery, enabled direct visualisation and treatment of the pelvic 
lesions. As retrograde menstruation could not describe the localisation of all endometriotic lesions, 
especially the disseminated ones, theories of peritoneal metaplasia, lymphatic or vascular disease 
dissemination, embryonic remnants and stem cell or bone marrow transformation are all debated. 
Assessment of “normal” peritoneum at surgery often shows the presence of endometrial implants many of 
which resolve spontaneously leaving minor scarring 
44
. As yet there is no definite cause triggering the 
development of these cells into the pathology of endometriosis. Studies have however hinted at a 
multifactorial aetiology in the peritoneum, uterus and endometrium of affected patients. 
The current definition of Adenomyosis was given in 1972 by C. C. Bird who stated that ‘Adenomyosis 
may be defined as the benign invasion of endometrium into the myometrium, producing a diffusely 
enlarged uterus microscopically exhibiting ectopic non-neoplastic, endometrial glands and stroma 
surrounded by the hypertrophic and hyperplastic myometrium’45. 
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1.3 Symptoms and signs of endometriosis 
Women suffering from endometriosis can range from being completely asymptomatic from the disease to 
having a range of non-specific ailments. Chronic pelvic pain, ovulatory/mid cycle pain, dysmenorrhea, 
perimenstrual symptoms involving bowel and/or bladder, fatigue and/or infertility have all been reported. 
It is estimated that 25%-70% of women and adolescents with chronic pelvic pain and/or dysmenorrhoea 
suffer from endometriosis
46-50
. Children as young as 10 years of age have been found to be suffering from 
the disease
47
 with an incidence of 12%
50
 in girls between 11 and 13 years of age. This variation in 
symptoms experienced by women serves to highlight the difficulties encountered when diagnosing the 
disease on clinical history alone. If clinically severe disease is suspected, the European Society of Human 
Reproduction and Embryology (ESHRE) advises early patient referral to tertiary centres where a 
multidisciplinary team approach is available
31
. 
Clinically, women may have unremarkable findings. Abdominal masses may indicate ovarian 
endometriomas and enlarged ovaries, whilst a fixed retroverted uterus with a tender pouch of Douglas 
(POD) and tender uterosacral ligaments are all suggestive of endometriosis. In severe cases, deeply 
infiltrating nodules of endometriosis can be seen in extrapelvic sites such as vagina or cervix
51
. Rarer 
manifestations of extrapelvic sites have also been reported in lungs, bowels and brain
52,53
. 
1.4 Historical developments 
The first attempts at a classification system was performed by Sampson in 1921 where the retrograde 
theory of menstruation was proposed and categorisation of adhesions and haemorrhagic cysts was 
attempted
41
. Over the years, classification systems have aimed to look at and classify endometriosis from 
its histological and anatomical presentation. Attempts have been made to correlate the disease 
histopathology with findings at surgery and its clinical presentation of pain
54
. To date, there is no 
correlation between pain experienced by patients and the severity of diagnosed disease. In 1966, 
Beecham
55
 claimed that there would be no purpose in creating a detailed classification for this disease, 
suggesting a simple four stage classification using operative findings and physical locations. In 1973, 
Acosta et al.
56
 proposed a different classification system which tried to assess the probability of surgical 
success and pregnancy rates according to the site and distribution of the lesions. Most physicians rejected 
this latter classification arguing it failed to distinguish unilateral from bilateral disease and was not 
specific. Kistner et al. tried developing a classification which directly related endometriosis to infertility. 
None of the classification systems developed before 1978 received widespread acceptance. 
In 1979, Buttram et al.
57
 proposed an expanded classification over Acosta’s, according to laparoscopic 
findings, malignancy lesions, lesion site and location as well as therapeutic response. These classification 
attempts failed to predict outcomes of infertility and pregnancy rates and were therefore criticised. The 
American Fertility Society (AFS) classification was then developed as a classification tool
58
. 
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1.5 Classification of endometriosis 
An ideal classification system has a good scientific basis, is unambiguous in its terms, is applicable for all 
cases, has a true reflection of the disease and is comprehensive and reproducible. It should aim to 
accurately translate physical findings into verbal descriptions which are easy to discuss with patients. 
Ideally it should standardise the disease irrespective of who is performing the assessment, be a reflection 
of disease severity, and be a good measure of the effect of treatment on disease
54
. Classification systems 
may be of value in the prognosis and management of infertility
59,60
 but there are limitations to the use of 
these classification systems. Endometriotic lesions also have a wide spectrum of appearances varying 
from black/blue/brown puckered lesions termed, peritoneal or ovarian ‘powder burn’ or ‘gunshot’ lesions, 
to overt haemorrhagic cysts and nodules. Milder or more subtle lesions, which may be harder to spot, may 
look like red implants or serous clear vesicles. White plaques, as well as peritoneal discoloration may 
manifest when fibrosis is involved
31
. Lesions can cause extensive scarring involving the large and small 
bowel, the fallopian tubes and in rarer cases, other extraperitoneal locations such as the lung and brain. 
The depth of lesion infiltration is known to correlate with the type and symptom severity of patients
61-63
. 
Deep lesions will extend over 5mm beneath peritoneal surfaces. It is these deep infiltrative lesions that 
invade abdominal structures such as the bladder, ureters, the intestine, uterus, uterosacral ligaments and 
occasionally the vagina and cervix. 
1.5.1 American Fertility Society classification 
The American Fertility Society was the first society to propose a quantitative classification system in 
1979
64
. It consisted of a paper document with defined classification points and the ability to be flexible 
for its use in varied cases of the disease. Its aim was to define the severity of disease by its location and 
extent. It did not however enable a correlation between disease severity and pregnancy rates so in 1982 
Guzick et al.
65
 proposed an amendment to the original classification by adding on a nonparametric 
monotonic estimator where a dose response relationship between AFS score (dose) and pregnancy post 
treatment (response) were used to improve the discriminatory power of the classification
65
. In 1982 
attempts at the use of clustering techniques for the anatomical findings to predict pregnancy rates failed
66
. 
Other reviews within the same period provided additional recommendations to the classification system 
but recognised the failure and difficulties encountered in creating an “ideal” classification system partly 
due to the wide spectrum of disease
67,68
. The AFS classification
67
 was revised in 1985 with additional 
details. These included quantification of ovarian adhesions, differentiation between superficial and deep 
lesions on the ovaries and peritoneum, recognition of minimal disease, creation of a tubal endometriosis 
category and the recording of the presence of other pathology
54
. In 1992, Canis et al. proposed an 
additional stage for endometriosis which he suggested could be added on to the AFS
69
. This Stage V 
classification was meant to be attributed to cases with severe bilateral disease that would require early in 
vitro fertilisation (IVF) intervention to achieve fertility. Irrespective, fertility itself is found to be reduced 
in severe disease
70
. In 1996, there was a re-publication of the classification system with illustrations for 
pelvic pain
58
 and the AFS was renamed as The American Society for Reproductive Medicine (ASRM) 
classification system (Figure 1-1). 
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1.5.1.1 Limitations of the American Society for Reproductive Medicine (ASRM) classification 
It is maintained that although the ASRM classification is useful in documentation of disease, it fails 
clinically to predict prognosis or management options for pain or infertility
54
. Identified limitations 
include wide scoring ranges, possible observer errors in recognising disease due to its variation in 
morphology
71
, fluctuations in disease presentation according to hormonal stage of the cycle
72
 and 
variations in reporting of disease depending on operative technique e.g. laparoscopy versus laparotomy
73
. 
Articles assessing the reproducibility of the ASRM system identify substantial intra observer staging, 
especially when assessing endometriosis within the pouch of Douglas or ovaries
74
. Disagreement in 
reporting multiple lesion types in the same patient make the classification and staging of disease 
difficult
75
. The ASRM (except in extensive disease) also correlates poorly with infertility
76
 and there is 
also poor correlation with pelvic pain
77
, dyspareunia, dysmenorrhoea and extent of disease
78
. The ASRM 
is therefore unable to encompass the role of a disease predictor or monitor of outcome of treatment. 
Other classifications by Chapron et al. in 1993
59
 looked at deeply infiltrating disease and its surgical 
implications. Alternate classification categories have tried to modify that of the ASRM by focusing on 
varied aspects such as pregnancy rates
79
, pain levels
80
, radiological, histological and morphological 
factors or biomarkers and genetic markers. Classification systems for disease affecting a particular 
location such as retrocervical endometriosis, were attempted in 1993 by Adamyan et al. and updated in 
2001
81
. The multitude of attempts at classification reflects the broad spectrum of clinical presentations 
and symptoms. 
The ESHRE have developed a guideline for the diagnosis and classification of endometriosis. Disease 
severity is assessed by describing surgical findings or using the standardised ASRM classification. 
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FIGURE 1-1 
 
The American Society for Reproductive Medicine (ASRM) classification of endometriosis (1996)58 
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1.6 Theories of causation 
Theories of causation vary with literature supporting or refuting each respectively. Theories include those 
of: in situ development, Müllerianosis
82
, accentuation by genital tract anomalies
83
, genetic 
predisposition
84
, coelomic metaplasia
40
, induction
85
, transplantation
86
, retrograde menstruation
42
 with 
implantation and growth of endometrial cells, endometrial stem cells
87
, physiological phenomenon
88
, 
alterations in the endometrium
89
, exogenous endometrial hormonal production
90
, angiogenesis
91
, the 
evasion of endometrial tissue from the immune system
92
, cellular protection from apoptosis
93,94
, the 
potential of endometrium to implant
95
 and invade
96
, and differences in peritoneal fluid
97
. Below is a 
summary of the historical theories of the causation of endometriosis (Table 1-1)
98
: 
TABLE 1-1 
In-situ development 
a) Germinal epithelium of the ovary (Waldeyer, 1870) 
b) Embryonic cell rests 
Mesonephric (Wolffian knob, Wolffian duct) (Von Recklinghausen, 1895, Breus, 1894) 
Paramesonephric (Müllerian ducts) (Cullen, 1896, Russell, 1899) 
c) Coelomic metaplasia (Iwanoff, 1898, Meyer, 1903, Lauche, 1923) 
d) Metaplasia by inflammation (Hueter, 1918, Meyer, 1919, Tobler, 1923) 
e) Metaplasia by hormonal stimulation (Novak, 1931) 
f) Metaplasia by induction (omnipotent blastema) (Levander, 1941, Merril, 1966) 
g) Secondary Müllerian system (Lauchlan, 1972) 
Transplantation 
a) Implantation, retrograde menstruation (Sampson, 1921) 
b) Implantation, mechanical transplantation (Greenhill, 1942) 
c) Benign lymphogenous metastasis (hystero-adenosis metastatica) (Halban, 1924/1925, Javert, 
1949) 
Combination of in-situ development and endometrial transplantation and implantation 
Theories on the pathogenesis of endometriosis (modified from Hingst, 1926 and Ridley, 1968)98 
 
At first glance, the theories appear to contradict each other. Whereas one theory speculates the origin of 
endometriosis from the uterine endometrium that has refluxed back in to the pelvis at menstruation, others 
look at the De Novo origin of endometrial tissue from the peritoneal serosa. These theories can, however, 
be complimentary. Metaplasia and the growth of mullerin tissues can be induced experimentally with 
menstrual debris, supporting the theory of induction
99
. 
Studies assessing post-mortem human foetuses have shown the presence of ectopic endometrium at 
known sites of endometriosis including the posterior uterine wall, rectovaginal septum and pouch of 
Douglas (POD)
82
. These findings give support to further theories that endometriosis develops as result of 
abnormally dislocated primitive endometrial tissue during embryonic organogenesis. 
1.6.1 Retrograde menstruation, endometrial implantation and growth 
This is today the most widely accepted theory on the development of endometriosis. Initially in 1921, 
Sampson proposed that endometriosis arose from seedlings of diseased ovaries
41
. In 1927, his theory 
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changed and Sampson postulated that retrograde menstruation acted in the form of a vessel, causing 
metastatic like transport of endometrial cells intraperitoneally, resulting in endometriosis. Cells within the 
pelvis would be ‘showered’ by endometrial cells which were viable, would live on and grow in external 
peritoneal sites
42
. Another study related the causation of endometriosis to women with increased amounts 
of menstrual flow and factors influencing endogenous hormonal levels
100. At the time when Sampson’s 
theory was proposed, menstrual debris was regarded as being solely composed of dead tissue. Sampson’s 
theory was therefore refuted due to the perceived lack of cellular viability. Over the years studies have 
shown viable epithelial endometrial cells within menstrual and peritoneal fluid
101
 capable of growth and 
proliferation. Menstrual debris is now known to be composed of single viable cells as well as glandular 
structures
102. Sampson’s theory of retrograde menstruation therefore holds. During laparoscopic surgery 
in women who are menstruating
103
, there is evidence of menstrual reflux within the pelvis. It has been 
noted in a study performed by Halme et al., that in women with patent tubes, 90% had intrabdominal 
blood compared to 15% of women with occluded tubes
103. A case report in the 1980’s of a 31 year old 
lady who underwent the Estes procedure is also used to support Sampson’s hypothesis where unilateral 
endometriosis was seen to develop at the site of ovarian implantation into the uterine window. This could 
be a human in vivo representation of other endometriosis inducing experiments in rhesus monkeys where 
intra-abdominal menstruation was induced
104
. Distribution of endometrial lesions within the pelvis are 
also in keeping with menstrual reflux patterns
105
. Peritoneal fluid flow is anticlockwise in pattern and 
diaphragmatic lesions are found more commonly on the right
106
. Left ovarian endometriomas are 
commoner than right sided ones. This is believed to be due to increased peritoneal fluid stasis on the left 
side due to the sigmoid colon
107
. Nevertheless, not all women progress to develop endometriosis and not 
all women develop the disease to the same extent. 
1.6.2 Development in situ 
A commonly believed theory in the formation of endometriosis is the development of ectopic t issue from 
local tissue. This theory encompasses the development of disease from ovarian or intraperitoneal tissue
108
, 
metaplasia or embryonic Wolffian or Müllerian remnants
109
. 
1.6.3 Embryonic remnants 
It has been proposed that the localisation of endometriosis in the uterosacral ligaments, broad ligaments 
or pouch of Douglas occurs due to aberrant differentiation or migration of the developing Müllerian 
system (derived from the coelomic epithelium) across the pelvic floor. Lauchlan et al. introduced the 
concept of a secondary Müllerian system
109
 to describe epithelium (including endometriotic cells) 
disseminated throughout the peritoneum, over the ovaries and within the retroperitoneal space. 
Supporting this theory of ‘Müllerianosis’110 are observations that women with known Müllerian 
anomalies have an increased incidence of endometriosis
111
. There is another case report in the literature of 
a patient with complete uterine agenesis having endometriosis thereby promoting the metaplastic theory 
and refuting the theory of retrograde menstruation
112
. A further observation supporting the embryonic 
theory is the presence of ectopic uterine tissues expressing CA125 and oestrogen receptors in newly born 
female foetuses
82
. 
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1.6.4 Coelomic metaplasia 
Embryologically, the fallopian tubes, uterus, cervix and upper third of the vagina all develop from the 
Müllerian (or paramesonephric) ducts. The Müllerian ducts are themselves formed by invagination and 
proliferation of the coelomic epithelium
113
. The surface of the ovaries (germinal epithelial layer) is 
derived from the mesoderm during embryonic development and is closely related to the peritoneal 
mesothelium. In the theory of coelomic metaplasia, the germinal epithelium of the ovary and the 
peritoneal serosa transforms into endometrial tissue by metaplasia
114
 secondary to chronic inflammation 
or hormonal stimulation
115
. Further studies supporting a metaplastic process within the peritoneal 
mesothelium have shown that the pelvic mesothelium itself develops characteristics similar to epithelial 
and Müllerian type structures
116
. Markers for epithelial differentiation (antibodies for Ber-EP4 antigen), 
and markers for Müllerian differentiation (oestrogen and progesterone receptors) were positive in 
peritoneal mesothelium and ovarian surface epithelium adjacent to endometriotic lesions but negative in 
otherwise sited tissue. Between normal ovarian surface epithelium and normal peritoneum, there was an 
increased frequency of Ber-EP4 positivity showing fundamental differences between tissues. This finding 
has also been suggested as an explanation for the increased prevalence of epithelial neoplasms in ovarian 
tissue
116
. The metaplastic theory of endometriosis would be able to explain endometriosis outside the 
pelvis such as the lungs, diaphragm or pleura
117
. It would also explain how endometriosis can be found in 
uterine or menstrual absence. Male cases that were reported to have endometriosis were found to be 
receiving high doses of unopposed oestrogen for prostatic carcinoma, and in these cases arguments 
against the pathology being classified as endometriosis exist. 
There are a number of arguments against the metaplastic theory. If spontaneous alteration of peritoneal 
cells could occur, then its prevalence in males should increase. The disease, as with most metaplastic 
processes, would be expected to increase with age and affect peritoneal surfaces uniformly. Another 
counter-argument concerns embryological development, as the thoracic cavity is lined by the coelomic 
membrane, the disease should be more prevalent within the chest. 
1.6.5 Transplantation theory 
This theory postulates that endometrial fragments can be disseminated throughout the body either via 
lymphatic, haematogenous or iatrogenic spread. Iatrogenic transplantation is believed to be the 
development of disease secondary to intrabdominal implants left during a surgical procedure. These cells 
implant within the pelvis causing disseminated endometriosis. Case reports of women undergoing 
laparoscopic subtotal hysterectomies with ovarian conservation and the use of the morcellator as a means 
of removing the uterus have reported post-operative endometriosis. On analysis of operative techniques, 
the procedures themselves had no complications, no endometriosis was visualized at initial surgery, the 
abdomen and pelvis were irrigated at the end of the procedure and any possible endometrium remaining 
within the cervical stump had been cauterized. The histological specimen removed was reported as not 
having adenomyosis or endometriosis. Nevertheless, within eight months, patients reported new onset 
symptoms of cyclical pelvic pain, dysuria, dyspareunia and dyschesia lasting 5-8 days with a 20 day 
interval
118-121
. These symptoms were not responsive to antibiotics but did respond slightly to GnRH 
analogues. A repeat operative laparoscopic procedure confirmed disseminated, extensive visualised 
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endometriosis (also confirmed histologically) which was treated, leaving the patients asymptomatic. 
Alternate explanatory reasons for finding endometriosis include the possibility of missing pre-existing 
endometriosis at initial surgery. This theory is unlikely in view of the extensive lesions easily visualized 
at the second operative procedure. A second theory postulates that endometrial tissue within the cervical 
stump causes retrograde menstruation and endometriosis. Analysis of the operative technique in question 
shows that the stump was cauterized and covered by the peritoneal flap approximating the bladder. 
Should retrograde flow from this area be the only causative agent, then one would expect to find 
endometriosis in its proximity and expect the patient to complain of menstrual loss. Neither of these were 
reported. 
Iatrogenic dissemination of endometriosis causing endometriomas at varied points within surgical scar 
tissue is reported in around 0.1% of women undergoing Caesarean section or other gynaecological 
surgery including laparoscopic ovarian cystectomies and one case of laparoscopic appendicectomy
122
. 
Other rare reported sites include the rectus abdominis
123
 muscle. In case reports between 1948 and 2011 
endometriosis is described in scar endometriomas. Most of these cases were initially confused with other 
surgical and dermatological pathologies presenting with cyclical pain and/or swelling. All lesions were 
confirmed radiologically and some by fine needle aspiration techniques (FNA)
121,124
. Fine needle 
aspiration has been documented as a fast and accurate method of diagnosing ectopic endometrial lesions 
where endometrial-like epithelial cells, stromal cells and evidence of decidualisation have been noted
125
. 
Excised lesions were then re-confirmed histologically and a 12 year post excision follow up showed no 
recurrence
126
. 
1.6.6 Induction theory 
In this theory, uterine endometrium either releases biochemical substances into the blood or lymphatic 
system, or alternatively induces immunological responses within the patient causing undifferentiated cells 
within the body to differentiate. An early study with rabbit models in 1955
85
 claimed that the implantation 
of dying endometrial tissue into the rabbit’s abdominal cavity caused epithelial differentiation within 7 
days. They based their findings on histological analysis. A similar study performed 41 years later by 
Merrill in 1996 using Millipore filters which prevented cellular dissemination from the implanted 
endometrial tissue showed the presence of endometrial-like glands adjacent to the implants. There was 
however no evidence of stromal presence and this did not enable the definitive diagnosis of newly formed 
endometriosis
127
. 
1.6.7 Familial inheritance and genetic predisposition 
Some small scale studies have hinted at a genetic basis and familial inheritance of the disease
128
 with 
endometriosis reported as being more severe in women with family members suffering from the same 
disease
18
. Women with family members who have endometriosis are susceptible to developing the 
disease
129
. A 79%-93% associated maternal lineage has been reported
129
, with a stronger link to the 
mother compared to the sister. The overall incidence in first degree relatives with family members 
suffering from endometriosis has been estimated between 3.9%-4.9%
18,129
. Rates for second degree 
relatives such as aunts and grandmothers are reported around 3.1% to 4% respectively, whilst 4.8% of 
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sisters have been affected
18
. Further publications report an increased disease incidence in monozygotic 
twins
19
, further supporting the theory of a genetic basis of the disease. Its mode of inheritance is however 
unknown
128
. 
1.6.8 Endometrial alterations 
The endometrium is a unique tissue that undergoes transitions between the phases of proliferation, 
secretion, regeneration and regression in response to hormonal influences during menstruation. All these 
processes have complex mechanisms providing control and stability. It is possible that alterations, even 
subtle ones, can cause a dysregulation of this tight control and result in pathology. Differences have been 
noted in the eutopic endometrium of women who have disease and those who do not
130
. Endometrial cells 
have also been found to have stem cell properties proliferating at a rate significantly higher than umbilical 
cord stem cells which were used as controls. The mononuclear cells collected from menstrual blood also 
contained a population of adherent cells. This could explain the ability to adhere, differentiate and 
proliferate in ectopic sites
131
. The menstrual cycle, hormonal influences such as oestrogen and cyclical 
cellular shedding have been referred to as the triggering stimuli that activate the inflammatory and repair 
mechanisms stimulating cellular infiltration, adherence and implantation as endometriosis
132
. 
1.6.9 Hormonal stimuli 
Endometrial cells are known to respond to hormonal influences throughout the menstrual cycle. 
Oestrogen is responsible for endometrial proliferation. Prolonged periods of unopposed oestrogens are 
associated with hyperplasia and malignant transformation
133,134
. Analysis of endometrial tissue in women 
with endometriosis has shown defects in 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD) which 
hinders the conversion of the potent oestrogen 17β-estradiol into the weaker oestrogen estrone135. This 
increases the oestrogen within the endometrium acting as a stimulus for cellular hyperplasia. Menstrual 
fluid has also been found to have higher estradiol levels confirming these theories
136
. Reports of an 
activated positive feedback loop leads to the production of further oestrogen within the endometrium 
stimulating endometriosis
137
. Oestrogen stimulates the enzyme Cyclo-oxygenase type 2 (COX-2) and 
increases prostaglandin-E2 (PGE2) which in turn stimulates aromatase (P450 enzyme) activity
138
. This is 
the key enzyme for oestrogen biosynthesis. Endometriosis related pain as well as severe disease are seen 
to decrease when treated with an Aromatase inhibitor
139
 with varying responses
140
. Limited long term data 
exists and these are not currently advised as treatment modalities
141
. 
1.6.10 Lymphatic spread 
Surgical excision for improved quality of life, symptoms and pain reduction is well documented
24,142
 
especially in cases where post-surgical adjuvant treatment is not given. Recurrence post-surgery is not 
uncommon especially in severe cases with deep infiltrative disease
143
. Surgical recurrence figures of 25% 
increasing to 37% at 1 and 3 years post operatively with the figure reaching 40-50% at five years have 
been found
144
. In cases of deep infiltrating endometriosis, studies at re laparoscopy show recurrence of 
growth at the previous site of disease
145
 or in the ipsilateral ovary
146
. Theories of recurrence solely due to 
retrograde menstruation have been contested as case reports of endometriosis recurrence after ablative 
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surgery or hysterectomy exist
147,148
. The involvement of lymph nodes in endometriosis was identified 
incidentally at the assessment of pericolic lymph nodes on patients with bowel endometriosis. The 
thickness of the primary lesion was directly associated with the extent of regional lymph node 
involvement
149
. Their current prevalence is estimated at 20-30%
149-153
. Microscopic implants are not 
visualised at surgery but are potential causes of disease recurrence and dissemination. Lymph node 
dissection itself entails significant morbidity including abscess formation, lymphoedema and cysts
154
. Up 
to date there is no indication for routine surgical node dissemination in the management of endometriosis. 
1.6.11 Endometriosis and high risk human papilloma viruses (HPVs) 
HPVs are the causative agents in all cases of cervical dysplasia or malignancy
155
. There are around 40 
high risk subtypes which are associated with malignant development in the anogenital epithelium
156,157
. 
There is an 80% prevalence rate in sexually active women with the majority of infections eradicated 
within one year
158
. Studies looking at the miRNAs present in cervical dysplasia or cancer in patients who 
were HPV-16 positive have been published by William et al.
156
(Table 1-2,Table 1-3). 
TABLE 1-2 
Overexpressed Fold change 
hsa_miR_124 58.2 
hsa_miR_449a 35.3 
hsa_miR_449b 30.5 
hsa_miR_301b 24.3 
hsa_miR_517c 22.4 
hsa_miR_545 17.4 
hsa_miR_223 14.2 
hsa_miR_135b 11.1 
hsa_miR_21 9.6 
hsa_miR_512_3p 9.4 
hsa_miR_542_3p 7.8 
hsa_miR_181c 7.6 
hsa_miR_517a 6.9 
hsa_miR_518f 5 
hsa_miR_106b 4.3 
hsa_miR_192 3.8 
hsa_miR_16 3.8 
hsa_miR_141 2.8 
 
TABLE 1-3 
Underexpressed  Fold change 
hsa_miR_433 -18.6 
hsa_mir_218 -5.6 
Tables showing miRNAs differentially expressed in cervical cancer tissue compared to normal cervical tissue 
(P<0.05) 
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In a study by Oppelt et al. an assessment for the presence of DNA of Chlamydia trachomatis and all 6 
herpes virus family members was performed on the endometrium of patients with endometriosis
159
. The 
DNA was not found and they then looked for the presence of HPV via polymerase chain reaction (PCR). 
Controls were women without endometriosis but with a prior clinical bias for human papilloma infections 
including the presence of abnormal smear tests or cervical carcinomas. They then concluded that both 
high and medium-risk HPV types are associated with both endometriosis and control tissues
159
. They 
postulated that viral spreading or HPV infected endometrial cells occurs pelvically causing pathology. 
They also proposed that chronic HPV infection of endometriosis cells can contribute to malignant 
transformation. 
Alterations in miRNA expression have been linked to the development of malignancies
160
. These changes 
are identified close to fragile chromosomal sites or integration of high risk viral strains such as HPV
161
. 
miRNAs have been shown to regulate the Ras and Bcl oncogenes and tumour suppressor genes pRb. 
1.6.12 Immune system deregulation and altered cellular properties 
Endometriosis has been described as an immune system disease. Autoimmune diseases are widely 
believed to occur as a result of genetic predisposition often triggered by environmental and other external 
factors
92,162
. When endometrial cells within menstrual fluid fall intraperitoneally, an inflammatory 
response is induced and activated proteloytic enzymes and phagocytes act on the cells to clear out the 
‘debris’163. This system may be deficient in women who develop endometriosis. 
Studies assessing characteristics of these ectopic endometrial cells indicate that they are able to escape 
immune surveillance and phagocytosis, enabling them to implant and proliferate (Figure 1-2). During the 
inflammatory response CD56+ natural killer cells (NK cells) are the predominant cells present to clear 
out the debris. A smaller proportion of CD14+macrophages and CD3+ T cells are also present
164
. There is 
a reported defect in NK cell activity towards these autologous intraperitoneal cells
165,166
. Elevations of B 
cell levels are seen in women with endometriosis positive for antinuclear antibodies (ANA) antibodies. 
This would hint at the B-cells playing a role in disease pathogenesis through autoantibody 
production
167,168
. 
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FIGURE 1-2 
 
Hand drawn illustration of various immune system deregulations contributing to endometriosis development 
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1.6.12.1 Major histocompatibility complex class 2 (MHC class 2) 
The human leukocyte antigen receptor (HLA-DR) is a αβ heterodimer cell surface receptor found 
predominately on macrophages, B-cells and dendritic cells. Its purpose is to present antigenic or foreign 
substances to the body’s immune system and elicit a T-cell response. Studies showing aberrant increased 
expression of HLA-DR antigen in the endometrium of patients with endometriosis indicate immune 
anomalies contributing to disease formation
169
. 
1.6.12.2 Major histocompatibility complex class 1 (MHC class 1) 
Surface HLA class 1 molecules are known to impair NK-like T lymphocytes lysing cells. Endometriosis 
is seen to have elevated levels of MHC class 1 expression which is attributed to defective functioning of 
the NK cells
131
. The HLA-B7 allele inhibits cytotoxic activity
134
 and is elevated in endometriosis
131
. This 
supports the theory of escape from immune surveillance and suggests a genetic component. 
1.6.12.3 Intercellular adhesion molecules 
The intercellular adhesion molecule 1 gene (ICAM1) codes for the ICAM1 or Cluster of Differentiation 
54 (CD54) protein. This is a cell surface glycoprotein expressed within endothelial cells and binds to 
integrins in turn mediating cell to cell interactions and allows cellular binding of fibronectin, collagen and 
laminin (Figure 1-2). ICAM is also responsible for binding integrins such as CD11a, CD18, and CD11b. 
Endometrial cells of women with endometriosis have shown decreased expression of the CD54 protein
170
. 
This might explain the reduced binding of leucocytes to these ectopic cells. In vitro models show that 
endometrial stomal cells from women with endometriosis have increased levels of soluble intracellular 
adhesion molecules (sICAM-1). This competes with ICAM-1 binding the leucocyte functioning antigen-1 
(LFA-1) which is expressed on activated leukocytes. Once bound, they are less able to adhere to target 
cells and transmigrate, preventing further leukocyte activation and function. This failure to recognise and 
remove pelvic endometrial cells through these mechanisms is believed to attribute to the pathogenesis of 
the disease
171
. 
1.6.12.4 Heat shock proteins (HSPs) 
HSPs are the most conserved proteins in eukaryotic cells and are induced in response to stress, 
inflammation or trauma. They function by enabling the correct folding of proteins which would otherwise 
be disrupted during stress responses
172
 causing aberrant activation of cellular pathways. Intracellularly, 
they protect the cell from lethal insults and interact with cellular apoptosis. Extracellularly they mediate 
immune responses
173
. Their presence in serum is associated with stress conditions varying from 
inflammation to viral and bacterial infections
173
. In mammals there are 5 families of HSPs depending on 
their molecular size. (HSP 100, 90, 70, 60 and the small HSPs such as HSP27). HSP70 and HSP90 are 
key regulators of the immune system. They present antigens in conjunction with the MHS class-1 
complexes
165,174-176
 inducing an antigen specific CD8+ T lymphocyte cell response
166,177
. Certain HSPs 
such as HSP 70 and HSP27 are increased in cellular exposure to stress. HSP27 are at increased levels in 
cancers such as endometrial, breast and leukaemias
138
. Increased levels of HSP27 are also implicated in 
increased cellular tumorigenesis
138,178
, metastasis
179
 and prevent apoptosis
137
. They are elevated in 
endometriosis
180,181
. Elevated levels of HSP70 have also shown to increase cancer cell tumorigenicity in 
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experimental mice
178
 and are implicated in the endometrium of women with unexplained infertility
181
. 
HSP70 and HSP90 are correlated with the histology of endometrial carcinomas
182
 especially the poorly 
differentiated tumours which often expresses p53 expression. Elevated HSP70b levels are reported in the 
serum of women with endometriosis, implicating an oxidative stress response in the pathology
183
. The 
HSP70 is also seen to increase the production of vascular endothelial growth factor (VEGF), Interleukin-6 
(IL-6) and tumour necrosis factor-alpha (TNF-α) in the macrophages of women with endometriosis184 
enabling disease proliferation. 
1.6.12.5 Natural killer cells (NK cells) 
NK cells are analogous in function to T lymphocytes. In general, cells express antigens via the MHC 
complexes initiating an immune response. Whereas cytotoxic T cells form part of the body’s adaptive 
immune response, NK cells provide a rapid response to tumour or viral infection within 3 days. They are 
able to recognise affected cells in the absence of antibodies or MHC
185
 class 1 presentation. In 
endometriosis there is a defect in the function of the NK cells
92
 which seems to correlate to disease 
severity (Figure 1-2). The eutopic endometrium of women with endometriosis is also more resistant to 
lysis by NK cells
92
. NK cells are activated and can attach to endometrial cells though the LFA-1 antigen 
via the ICAM-1 dependant pathway. It is postulated that in endometriosis, the eutopic endometrium, 
peritoneal fluid and endometriotic cells, all secrete soluble forms of ICAM-1. This binds to LFA-1 
presenting lymphocytes preventing their recognition by NK cells
171
. Peripheral blood serum analysis has 
failed to recognise changes in the amounts or functions of NK cells despite variances within the 
peritoneal fluid
92,186,187
. HSP70 is identified as a triggering factor for NK cells which have a high cell 
surface density of antigen CD94
188,189
. 
1.7 Infertility and endometriosis: prevalence figures 
Studies assessing the prevalence of infertility and the amounts of couples seeking medical help, provide 
an insight on the severity and prevalence of the disease. Humans have an estimated monthly fecundity 
rate of around 20%
190
. Endometriosis has been reported to be prevalent in around 0.5-5% of fertile 
women and 25-40% of infertile women
191,192
. In one study of over 6,000 randomly selected women, that 
around 10-15% of couples in the UK alone, experience infertility
190
. In 2009, out of a survey involving 
4,466 women, one in 5 women in the North East of Scotland attempting to achieve a pregnancy reported 
infertility
51
 with endometriosis being one of the leading causes, infections (Sexually transmitted 
infections (STI)), chemotherapy, obesity and other health problems being listed as causative factors. 
There are other studies debating the quoted numerical validity of the reported current lifetime prevalence 
of infertility and the true values of those seeking treatment modalities as they recognise limitations in 
numerical data due to sample size
193
. Another limiting factor to assessing the true prevalence of 
endometriosis is its definitive method of diagnosis. Laparoscopy is deemed to be the gold standard for 
definitive diagnosis. It is however an invasive method with associated co-morbidity and only performed 
in women with symptoms. Its true prevalence rate is therefore masked by its diagnostic limitations. The 
prevalence is reported as 40% in infertile women
60
 and is found in more than 33% of women with chronic 
pelvic pain
194
. In one study, where laparoscopy was performed for unexplained infertility, it was present 
in up to 47% of infertile women with regular menstrual cycles having normospermic partners
195,196
. 
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Findings were unchanged between symptomatic and asymptomatic patient groups. These figures make 
endometriosis the most important cause of infertility in the abovementioned group
197
. Degrees of 
endometriosis are classified according to the ASRM
58
. Whilst there is evidence supporting the strong link 
between endometriosis and infertility, controversial issues in this relationship still exist especially in the 
case of mild or minimal endometriosis
60,198
. Endometriosis is also known to occur in women with male 
factor infertility
199
 and in those with irregular anovulatory cycles
200,201
. These patient groups have not 
been studied in detail to provide actual prevalence figures. Over the past 25 years, changes and 
ameliorations in both classification methods and diagnostic optic equipment have led to improved 
methods of recognition. This might indicate a bias in reported previous prevalence figures of the 
disease
202
. Today, there is recognition that subtle peritoneal lesions can also manifest as endometriosis, 
leading to an increase in diagnosed cases as compared to the mid-1980s
203
. Overlapping symptoms of 
endometriosis, pelvic inflammatory disease (PID) and irritable bowel syndrome (IBS) all contribute to a 
delay in diagnosis
5,204,205
. 
1.8 Endometriosis and pregnancy 
The effects of pregnancy and endometriosis are largely unexplored. Due to ethical issues, the effects of 
pregnancy on endometriosis in humans are unknown. Symptoms of disease during pregnancy are 
subjective and the ability to achieve pregnancy itself can affect the woman’s psychological wellbeing and 
her perception of symptoms. Early studies from the 1960s
206
 assessed 24 cases of endometriosis and 
found that the effects of pregnancy on the disease were variable. Whereas a few cases were seen to have 
endometriotic lesions which regressed, most lesions progressed. A few case reports have been since 
published, supporting these findings, however, good quality studies in humans are limited. Animal 
models have been used in limited studies, to assess for the effects of pregnancy on the development of 
intraperitoneal disease. Studies performing laparoscopies on pregnant baboons in the first and second 
trimesters did not show significant effects of pregnancy on the growth of endometriotic lesions
207
. Other 
earlier conflicting studies showed a regression of endometriosis in pregnant animals
208,209
.  
It is now well known that diseases which are inflammatory in nature such as Chron’s and Rheumatoid 
arthritis have adverse effects on pregnancy
210,211
 such as preterm delivery and its associated risks of 
neonatal morbidity and death. There are some publications linking subfertility to conditions such as 
preeclampsia and placental abruption
212
. A link to endometriosis has been postulated in this publication, 
but studies with improved designs and numbers are advisable. In another published study, the link 
between endometriosis and preeclampsia has been explored. The theory behind this association lies in the 
fact that both endometriosis and preeclampsia are associated with defective junctional zone remodelling 
of placental bed spiral arteries
213
. Other conflicting publications have shown a reduction of preeclampsia 
in women with endometriosis, attributing this to an increased level of angiogenic factors and increased 
vascular perfusion
213
. All these studies have limitations due to small sample sizes. In a large study of 
around 3000 women with endometriosis, there was no link between the presence of disease and 
preeclampsia
214
. An Australian retrospective cohort study looked at the pregnancy outcome of 630 
women with endometriosis undergoing fertility treatment. There results imply that women with 
endometriomas have a risk of small for gestational age babies and preterm deliveries
215
. It was postulated 
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that endometrial abnormalities potentially present in endometriosis might be the causative factor of the 
observations. It was however noted that assisted reproduction itself might attribute to an increased level 
of pregnancy complications. 
A Swedish retrospective birth study analysed data from around 1,400,000 births between 1992 and 2006. 
Their data shows an association between endometriosis and the risk of preterm delivery, preeclampsia and 
antepartum haemorrhage as well as pre-labour Caesarean sections
216
. Various confounding factors in this 
population are recognised. In this study, it was suggested that altered prostaglandin levels in women with 
endometriosis
217
 could partially be the cause for preterm birth and preterm premature rupture of 
membranes. None of the above theories has been confirmed. 
Endometrial fluid analysis has also been utilised to identify possible biomarkers for endometriosis
218
. 
There is some evidence of differences in this fluid between cases and controls. The endometrium 
covering the uterine lining is known to secrete proteins which change in response to the menstrual 
cycle
219
. Proteins and enzymes secreted from the endometrium can be found within the endometrial fluid 
of the uterine cavity
220,221
 and have been suggested as key players in embryonic implantation
222,223
. The 
analysis of these proteins could provide insights into embryo implantation and deregulation of the process 
in the presence of pathology
224
. Their dysregulation has been associated with failure of implantation and 
infertility
225
. 
1.9 Location of endometriotic lesions 
1.9.1 Peritoneal endometriosis 
Peritoneal lesions vary in their presentation ranging between macro and microscopic disease. Their 
appearance varies with early active lesions appearing red, glandular or vesicular, advanced lesions 
appearing black or puckered and chronic healed lesions which may be white or fibrotic. Peritoneal 
endometriosis appears to be a dynamic disease
226
 with atypical subtle lesions visualised at laparoscopy 
appearing and disappearing
227
 on the peritoneal surface. Their importance has been attributed to the 
reduced fecundity experienced by women even with clinically mild disease
228
. The clinical significance of 
mild disease is still a controversial topic
203,229,230
; it is believed that the disease is progressive though 
further prospective studies without therapeutic interference are required for its verification. 
1.9.2 Rectovaginal endometriosis 
Deep sited endometriosis often found in extensive disease, has been classified into three different types 
by Koninckx and Martin
231
. Type 1 has been described as the conical infiltrative type, Type 2 is the 
retracted type covered by adhesions and Type 3 is the spherical rectovaginal nodule. In rectovaginal 
disease it is the Type 3 lesion more commonly described. Rectal ultrasound has been used to identify 
deeply infiltrating bowel lesions during the selection of patients suitable for surgery
232,233
. 
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1.9.3 Ovarian endometriosis 
Disease on the ovary can vary from small plaques to enlarged ‘chocolate’ cysts. Small endometriomas 
may go unnoticed unless punctured at surgery. Most of the ovarian endometriomas are pseudocysts in 
nature with the invaginated ovarian cortex comprising the cyst ‘wall’. This invaginated cortex is then 
covered by a superficial endometrium-like tissue. In a paper by Hughesdon
234
, a non uniformal 
invagination of the ovary occurs with the inner cortex being obscured by smooth muscle metaplasia, 
whereas the outer extended cortex thins out and loss of the original layers occurs. Hughesdon supported 
the theory or surface implantation or metaplasia. Two different cyst types have been described
235
. Red 
cysts are lined by surface epithelium and highly vascular stroma without glands covering the whitish or 
slightly pigmented wall. Black cysts have dark, poorly vascularised and pigmented tissue. Suggestions 
have been made as to different surgical techniques required for the different cyst types
235
 with superficial 
ablation advocated in the red cysts and excision of the fibrotic wall in the black cysts. 
1.10 Diagnosis of endometriosis- techniques 
Certain lesions are overtly visible at laparoscopy. In these cases, visual identification of the pathology 
may be adequate; nevertheless, it is ideal to verify the nature of the lesions by histological assessment, 
confirming the presence of ectopic endometrium within the biopsied samples. ESHRE advises that in 
deeply infiltrating endometriosis or of ovarian endometriomas over 3 centimetres, histology serves not 
only to confirm clinical visualised pathology, but to exclude rare instances of malignancy
31
. 
1.10.1 Current investigative/diagnostic tools 
Surgery, albeit an invasive option, is the only current technique giving a definitive diagnosis and enabling 
direct treatment, excision and removal of visible endometriosis infiltrated areas. Endometriosis is a 
multifactorial condition with widespread effects in the body depending on the sites of its implantation, 
amounts present and its rate of proliferation. Patient symptoms (when present) may aid clinicians in 
diagnosing and locating endometriosis. The use of magnetic resonance imaging (MRI), ultrasound 
(transrectal, transvaginal, renal or abdominal), intravenous pyelography (IVP) and even barium enema 
studies have all been utilised to non-invasively attempt to identify location and severity of disease. 
Interpretation of radiological techniques is user dependant and, even in the best of hands, is found to be 
very limited in the mapping of this disease. 
1.10.2 Ultrasound and magnetic resonance imaging (MRI) 
Ultrasound is the technique whereby cyclic sound waves (in the range above the upper limit of human 
hearing) are used to penetrate tissues and media, generating a reflection signature. This signature is then 
translated into an image and used as a non-invasive method of diagnosing intracorporal pathology. The 
technique has its limitations. It is useful in diagnosing the presence of ovarian endometriomas and in 
expert hands, can be used to identify rectal or bladder disease infiltration. It however has no role in 
diagnosing pelvic or peritoneal endometriosis
236,237
. Assessment of adenomyosis has been possible with 
radiological screening both through the utilisation of ultrasound and MRI
238,239
. The junctional zone 
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(visible as a low T2 signal layer on MRI) is a region beneath the endometrium representing the inner 
myometrium. In adenomyosis there is thickening and loss of definition of the junctional zone, making it 
an important diagnostic feature of disease. One review of 2,312 women showed that for adenomyosis, 
transvaginal ultrasound retains a sensitivity of 72% and specificity of 81%, whilst MRI had a pooled 
sensitivity of 77% and a specificity of 89%. This shows that the correct diagnosis was obtainable more 
often by the latter rather than former method
240
. When comparing MRI to laparoscopy, MRI has limited 
value as a means of diagnosing endometriosis
237
. 
1.10.3 Blood tests 
Serum cancer antigen 125 (Ca125) is also known as mucin 16 or MUC16. It is a carbohydrate antigen 
first discovered around 1983 and belongs to the mucin family of glycoproteins
241
. Ca125 is the marker 
most consistently elevated in ovarian cancer and is used as a prognostic factor in assessing response 
during primary chemotherapy
241
. It is however expressed in other gynaecological (endometrial and 
fallopian tube) and non-gynaecological ( pancreas, breast, colon and lung) cancers
241
 and in some benign 
conditions such as endometriosis
241
. In endometriosis, it is however not related to disease severity and not 
necessarily co-related with the presence or absence of the disease. Compared to laparoscopy, it is of no 
value as a diagnostic tool
242
. Studies looking at Ca125 levels in peritoneal fluid at surgery claim it has 
better sensitivity in detection rates compared to serum levels
243
. Studies looking for an alternative 
diagnostic test for endometriosis such as the use of the expression of chemokine receptor (CCR1) mRNA 
in peripheral blood leukocytes and Monocyte chemotactic protein–1 (MCP-1)244 have been performed. 
This study quotes a sensitivity of 92.2%, a specificity of 81.6%, a negative predictive value of 83.3%, a 
positive predictive value of 92.3%, a likelihood ratio of a positive test result of 5.017, and a likelihood 
ratio of a negative test result of 0.096
244
. It indicates its potential usage but up to date none of the studies 
have proven to have adequate sensitivity or specificity for clinical use. Another described technique is to 
quantify the expression of aromatase cytochrome P450 in eutopic endometrium
245
 to distinguish between 
disease free women and those with endometriosis, adenomyosis or leiomyoma. Again this has not proved 
applicable to clinical practice. 
1.11 Methods of treatment 
1.11.1 Historical treatments 
In the 1940s the advent of androgenic steroid hormones led to their use as a primary therapy in 
gynaecological disorders. Published articles at the time reported amelioration on disease both post 
operatively or as an alternative in women who declined surgery
246,247
. Their use as the mainstream 
therapeutic for the disease was discontinued due to the androgenic side effects experienced by patients 
including acne hirisutism and irreversible voice changes. In the late 1940s a non-steroidal synthetic 
oestrogen Diethylstilbestrol (DES) was developed and was tried for the treatment of endometriosis. With 
today’s medical knowledge it is know that chronic unopposed oestrogen therapy, not only causes 
endometriosis proliferation but also leads to endometrial hyperplasia and malignant transformation. 
Despite this knowledge, in 1948 Karnaky et al. claimed to achieve good results with high doses of 
unopposed oestrogens causing amenorrhoea
248
. It was also noted that pregnancy rate increased when 
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oestrogen treatment was terminated. Today, there is a known association between foetuses exposed in 
utero to DES and clear cell vaginal carcinoma. At the time this association was unknown. In 1958 a 
publication by Kistner et al. claimed that treatment with unopposed oestrogens was unwise due to the 
unpredictability of disease response and development of endometrial hyperplasia
249
. 
It has been reported that endometriotic lesions do not correlate to the eutopic endometrial cycles
250
, they 
still show responses to hormonal treatments or modulators. In 1975, a combined hormonal oestrogen and 
progestogen treatment regime mimicking a pregnant state, called a “pseudo-pregnancy” was reported to 
improve symptoms
251
. Today, combination regimens are used to obtain a partially inactive endometrium, 
amenorrhoea and quiesce disease
252,253
. 
Current treatment modalities for endometriosis work by suppressing ovarian steroids causing a 
hypooestrogenic state which in turn causes atrophy of the ectopic endometrium. This suppresses rather 
than eliminates pathology. In women with pain symptoms and a history suggestive of endometriosis in 
which a diagnosis has not been confirmed, one can opt to pursue various conservative management or 
therapeutic strategies. Therapies available are limited not only due to their side effects, but by the fact that 
they inhibit ovulation and therefore are counterproductive in women wishing to conceive
254
. Current non-
surgical treatments for endometriosis are unsatisfactory. There is a clear need for the development of 
more effective novel therapeutics with improved efficacy, tolerability and safety
255
. 
Counselling, analgesia, alterations in nutrition and the combined oral contraceptive pill (COCP) are 
regarded as first line treatment modalities
256
. Progestagens, oestrogen-progestin combinations, danazol, 
gestrinone, medroxyprogesterone acetate, levonorgestrel intrauterine system (LNG-IUS)
257
 or 
Gonadotropin-releasing hormone (GnRH) agonists are all hormonal therapies currently used to reduce 
pain and suppress, but not eliminate, the disease. In confirmed moderate or severe disease, suppression of 
ovarian function for 6 months reduces endometriosis. All hormonal drugs which have been studied show 
varying side effect profiles but ultimately have an equally effective role. Once these treatments are 
discontinued, symptoms often recur after a period of time. These therapies are limited in their use 
duration due to the indirectly induced hypoestrogenic side effects which have long term health 
implications e.g. osteoporosis with GnRH. Reviews assessing possible future therapeutics have been 
carried out but there is a large discrepancy between promising pre-clinical trials and the clinical ones
255
. 
This reflects the poor understanding we have of the mechanisms underlying the disease and further 
research is in dire need. 
In women, who decline surgery and are happy to proceed to treatment without a definite diagnosis, a 
therapeutic trial of hormonal medications which reduce menstrual flow is an option. 
1.11.2 Overview of medical treatments 
Medical treatments serve to control pain and repress disease but there is no treatment that currently cures 
endometriosis. Analgesics including non-steroidal anti-inflammatory drugs (NSAIDS) have been used in 
the clinical setting. Cyclooxygenase-2 (COX-2) inhibitor rofecoxib was used in trials but has been 
withdrawn due to cardiovascular side effects. TNFα inhibitor (pentoxifylline) use is being researched but 
is not routinely used in clinical practice
258
. 
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Hormonal treatments including the combined oral contraceptive pills, progesterone only pills and 
intrauterine progesterone (LNG-IUS), progestins, gestrinone, danazol (despite its masculinisation side 
effects) and GnRH analogues are all used. Hormonal therapies have substantial symptomatic side effects 
including menopausal symptoms and infertility whilst on treatment. Immunomodulators such as human 
recombinant interferons (IFNα-2b) and members of the immune modulating cytokine family have been 
used as in vitro therapeutics. They suppress the growth of in vitro endometriosis in a dose dependant 
manner
259. Clinical trials looking at effects of intraperitoneal administration of IFNα-2b has shown 
improvements in the severity and stage of endometriosis but recurrence results are ambiguous
147,153
 
necessitating further studies. 
1.11.3 Non-steroidal anti-inflammatory drugs (NSAIDS) 
There is some evidence that this class of drugs may improve pain symptoms experienced in women with 
endometriosis
260,261
. They function by blocking the COX-1 and COX-2 pathways. The newer ones are 
selective for COX-2 and therefore minimise gastric side effects. They therefore reduce aromatase activity, 
oestrogen production and endometriosis proliferation
180
. This class of drugs is not suitable in women who 
are asthmatic or have a history of gastric ulceration. When taken at mid cycle, an anti-ovulatory effect is 
noted. There is insufficient evidence on the use of other classes of analgesics. 
1.11.4 Hormonal treatments 
1.11.4.1 Levonorgestrel intrauterine system 
This coil is a slow release system of 20 micrograms levonorgestrel into the intrauterine cavity per 24 hour 
period. It thereby suppresses the endometrial proliferation reducing the endometrial thickness, menstrual 
loss, dysmenorrhoea and progression of endometriosis. The system has proven benefit in producing 
amenorrhea or hypomenorrhea with good patient satisfaction
262
. Again, hormonal side effects of 
abdominal bloating, breast tenderness, weight gain have all been reported. It also has a contraceptive 
effect preventing ovulation thereby reducing the fertility of the patient during its usage. 
1.11.4.2 Oral contraceptive pill (OCP) and gonadotropin-releasing hormone (GnRH) 
analogues 
There is a limited amount of studies and data comparing the two methods. So far there is no proven 
benefit of one treatment modality over the other though it is recognised that the available studies are in 
small numbers and underpowered
263,264
. GnRH analogues are a group of drugs used in the treatment of 
endometriosis for the last twenty years
265
. Side effects range from hot flushes to osteopaenia (especially in 
therapy lasting over 6 months) and may be reversed with hormonal add-back therapy. Even with 
effectively managed endometriosis 5 year recurrence rates with GnRH agonists range between 33%-
75%
266
. 
1.11.5 Immune modulators 
Women suffering from endometriosis have an increased risk of immune system and endocrine diseases 
such as rheumatoid arthritis
24
. One cross-sectional survey
24
 assessing 3680 patients with endometriosis 
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showed that endometriosis patients had higher levels of hypothyroidism (9.6 versus 1.5%, P < 0.0001), 
rheumatoid arthritis (1.8 versus 1.2%, P = 0.001), systemic lupus erythematosus (0.8 versus 0.04%, P < 
0.0001), Sjögren’s syndrome (0.6 versus 0.03%, P < 0.0001) and multiple sclerosis (0.5 versus 0.07%, P 
< 0.0001)
24
, Human recombinant interferons (IFNα-2b) members of the immune modulating cytokine 
family have been used as in vitro therapeutics. They suppress the growth of in vitro endometriosis in a 
dose dependant manner
259. Clinical trials looking at effects of intraperitoneal administration of IFNα-2b 
has shown improvements in the severity and stage of endometriosis but recurrence results are 
ambiguous
147,153
 necessitating further studies. 
1.11.6 Therapies- surgical 
Clinically, endometriosis may manifest as palpable lesions, with certain studies suggesting that it is in this 
subgroup of women where the maximum benefit of surgical resection lies
267
. Surgical excision is still 
described as the ‘gold standard’ in diagnosing and treating endometriosis. The Royal College of 
Obstetricians and Gynaecologists (RCOG) guideline on endometriosis
268
 advises that the reduction of 
endometriotic lesions by ablation supersedes diagnostic laparoscopy alone in pain reduction and that 
radical resection of all visible lesions reduces pain. This approach has recognised limitations in 
identification, treatment and symptom relief of the disease. There has been no demonstrable difference 
between ablation and excisional treatments as far as postoperative pain levels are concerned
269
. Both 
treatment modalities have been noted to provide good symptomatic relief and reduction of pelvic 
tenderness with no difference in morbidity
270
. 
Laser laparoscopy is quoted as a safe, simple, and effective treatment in alleviating pain symptoms in 
women with stages I, II, and III endometriosis
271
. Good practice by ESHRE advises that lesion type, 
extent, adhesions should all be recorded in the patient notes. Ideally findings should be recorded on DVD 
or video
31
. A prospective study by Sutton et al.
271
 confirmed a marked improvement in pelvic pain in 
patients with mild or moderate endometriosis if treated by laparoscopic ablation compared to those 
receiving placebo. Certain retrospective studies into advanced disease showed improvement in those 
patients actively managed by laparoscopic CO2 laser ablation
272
 whereas others show conflicting long 
term results, with success rates falling even over short time intervals
267,273
. Studies have failed to show 
benefits of uterosacral ligament resection or presacral neurotomy
274,275
 over conservative laparoscopy in 
reducing the medium or long term severity of dysmenorrhea
276,277
. Laparoscopic uterosacral nerve 
ablation (LUNA) has been employed in some studies to assess the impact of the procedure in the 
management of endometriosis. In the absence of endometriosis it has been found to be effective for 
dysmenorrhoea though no evidence has been found for its use in chronic pelvic pain related to 
endometriosis
278
. 
With presacral neurotomy, the argument of incomplete nerve resection is debated as a reason for its 
ineffectiveness
279
. This led to the usage of uterosacral ligament resection as a uterine denervating 
technique
280
. Its effectiveness and validity in achieving pain relief has been inconsistent
281,282
 with some 
studies being suboptimal
277
 with others showing no benefit over direct lesion ablation
281
. Placebo studies 
have hinted at the presence of a post-operative placebo response which disappears within a few months of 
treatment
283
. 
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Diagnostic laparoscopies with ablation or excision of the lesions are carried out improving fertility and 
pregnancy rates
284,285
. Timing of surgery to a particular period within the menstrual cycle has not been 
proven. Nevertheless guidelines from ESHRE also advise women being off hormonal treatment for 3 
months to avoid under diagnosis of patients. 
Extensive surgery involving bowel and bladder resection has been shown to improve symptoms from the 
disease but shows an associated increase in concomitant morbidity. 
1.12 Quality of life affected by endometriosis 
Women suffering from this disease report mixed feelings when questioned about future outcomes of their 
management and their quality of life. Those women experiencing the most severe pain are the most 
pessimistic. 
The presentation of endometriosis ranges widely from mild to severe disease. Symptoms experienced by 
patients vary ranging from those who are asymptomatic to those complaining of severely debilitating, 
chronic, incapacitating symptoms which adversely affect their quality of life, mental health and social 
interactions
286
. Patients suffering from endometriosis report a deterioration in their work life productivity 
at an average of approximately 10 hours per week compared to 7 hours in non-affected women
7
. 
Increased levels of depression and anxiety also occur
287-289
. 
There is a poor correlation between findings at laparoscopy and histopathological diagnosis
290
. Symptoms 
do not necessarily correlate to disease extent or severity
11
 and a proportion of women are only diagnosed 
coincidentally
291
. Thus a proportion of women with minor disease are over investigated, treated and even 
subjected to surgery, whereas a proportion of severely affected women might go unnoticed or under 
investigated and treated. It is believed that the location, rather than overall severity is implicated in 
symptom intensity
292
. Pain recurrence and re-operative rates in conservative surgery for symptomatic 
endometriosis are high and underestimated
293
 with operator dependant outcomes. 
Assessing patient quality of life has been performed in a number of studies using standardised validated 
quality of life questionnaires such as the Short Form questionnaire (SF36 or the SF12)
294,295
 and pain 
questionnaires such as the PIQ6. Other recognised tools include The Hospital anxiety and depression 
scale
296
 as well as the revised Sabbatsberg Sexual Rating Scale
297
. Two studies from the USA by Ballweg 
and Whitney utilised focused group interviews
298,299
 and pictorial forms of expression to describe disease 
severity and its impact on life. An assessment of differences between patient groups for dyspareunia, non-
menstrual pelvic pain, psycho-emotional profile, sexual functioning, relationships and overall satisfaction 
of treatment
274
 have been performed. These assessment tools give us an indication as to the overall 
outcomes of laparoscopic interventions on disease and patient quality of life. 
Current medical treatments include pain relieving and hormonal agents which apart from their side effects 
(hirisutism, acne and weight gain) may induce amenorrhoea and menopausal symptoms (e.g. GnRH 
analogues) precluding fertility
300
. In addition to these effects, reduction in pain is only achieved in the 
short term. Laparoscopic surgery using laser ablative techniques in combination with excision of 
endometriotic lesions and laparoscopic uterosacral ligament resection are techniques used to minimise 
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disease and pain. Surgeons aim to maximise the post-operative symptom free period but publications vary 
in their outcomes. 
1.12.1 Pain 
An estimated 70%-75% of patients with endometriosis suffer from pelvic pain
301
 most of which is chronic 
in nature. In 24% of cases, reports of 2.5 days of bed rest per month due to pain are documented, 22% of 
women report sexual dysfunction and 25% report dyspareunia
302
. In a study assessing quality of life in 
patients with deeply infiltrating endometriosis, complete resection of lesions was associated with 
significantly improved outcomes in painful functional symptoms including dysmenorrhea, deep 
dyspareunia, dyschesis during menses, lower urinary tract symptoms and chronic pelvic pain, irrespective 
of the number and location of lesions or concomitant medical issues or characteristics. Reported pain 
levels in infertile women did not vary in relation to the success of their fertility outcomes post-surgery
303
. 
Catastrophising and biopsychosocial variables have been recently implicated in the severity and chronic 
pain experienced in patients with endometriosis
304
. Where these are present, an average of 37.4% 
reduction in interval pain has been reported but nulliparity and referral to physical therapy showed worse 
outcomes in interval pain improvement. 
1.12.2 Dysmenorrhoea and dyspareunia 
In one study, recurrence of moderate to severe dysmenorrhea within the first postoperative year has been 
quoted at 29% post uterosacral ligament resection and 27% after conservative surgery
274
. Results 3 years 
after initial surgery have been published though their validity is debatable as the independent analgesic 
effect of surgery (irrespective of the nature of surgery undertaken) is seen to reduce over time. Up to 40% 
of patients express distressing recurrence of symptoms within 3 years of their primary surgery. This 
highlights the importance of long term follow-up. 
1.12.3 General health and quality of life 
Pain scores are subjective with exacerbated symptoms reported in patients with concomitant systemic 
disease or depression. The site and type of pain varies between patients but is commonly associated with 
those having endometriosis
267,300
. Overall, irrespective of whether or not uterosacral resection is 
performed, laparoscopic surgery is associated with reported improvements in general health, quality of 
life, emotional wellbeing and sexual satisfaction
274
. Overall surgical dissatisfaction figures of 25% 
increasing to 37% at 1 and 3 years post operatively have been quoted. This might be a recognised 
overestimation as figures have included those patients lost to follow up
274
. 
1.12.4 Sexual function 
Dyspareunia is the commonest reported symptom in sexually active women and is linked to the presence 
of adhesions, endometriomas, uterine retroversion or affected uterosacral ligaments. Patients in this group 
report improved outcomes and less side effects with surgical rather than medical treatments manifesting 
less anxiety about the long term effects of surgery even in sub-groups experiencing multiple 
procedures
305
. 
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1.12.5 Fertility 
The impact of mild endometriosis on fertility is a controversial subject with divided opinions on its 
significance. The direct incidence of infertility secondary to endometriosis is difficult to quantify but 
around 30%-50% of women with endometriosis suffer some form of infertility
46
. A large multicentre 
prospective study by the Canadian Collaborative group on stage 1-2 endometriosis (using the American 
fertility scoring system) in the 1990’s looked at the fertility and treatment outcomes of women with 
endometriosis versus those with unexplained infertility
306
. This study showed a reduction in fertility in 
those patients with endometriosis but findings were not statistically significant. The same study did show 
a statistically significant improvement in fertility rates after the treatment of endometriosis
307
 which has 
been confirmed in other publications
308
. A conflicting Italian study failed to show statistical significance 
in birth rates between treated and untreated patient groups
309
. Current data indicates that it is reasonable to 
treat stage 1-2 endometriosis when discovered during laparoscopy for fertility
307
. Surgery itself is shown 
to be superior in outcomes to medical therapy in achieving increased pregnancy rates although there is no 
statistically observed benefit in ablation over excisional techniques
310
. Laparoscopy for severe 
rectovaginal endometriosis is less likely to negatively impact fertility outcomes compared to 
laparotomy
311
, with recent studies showing improved In vitro fertilisation (IVF)/intra-cytoplasmic sperm 
injection (ICSI) outcomes and live birth rates (both for spontaneous and assisted conceptions) in patients 
treated for stage 1-2 endometriosis
312
. 
1.12.6 Social interactions 
The utilisation of forms such as the Short Form questionnaire (SF36 or the SF12) includes ‘visualisation’ 
of the impact disease has on social interactions. Endometriosis has been attributed to reduction in the 
quality of patient social life. The inability to interact has been attributed to strain on personal relationships 
resulting in break ups as the patient or her partner were unable to cope with constant strain. 
1.13 Socio-economic impact of endometriosis 
1.13.1 Direct costs 
It is currently estimated that in the UK alone, 2 million women suffer from this condition. Published UK 
hospital statistics in 2003 show that 0.06% (31,238) of hospital bed days were for endometriosis with the 
mean age of the women requiring hospitalisation being 35 years
313
. In a US study
314
 annual costs related 
to healthcare and general loss of productivity were estimated respectively at $2,801 and $1,023 per 
patient. Extrapolation for a US population, assuming a 10% prevalence rate, amounts to $22 billion in 
estimated costs making it a higher cost than that incurred by other common diseases including Chron’s 
and migraine
314
. Debates as to whether surgical or medical therapies are more cost effective in treating 
endometriosis exist, with no solid conclusions, especially since the development of chronic pelvic pain 
results in a lifelong ailment. A recent Canadian study in 2011 estimates the mean annual cost incurred by 
society due lost productivity as a result of endometriosis at $5,200 per patient (95% CI $3,700 to 
$7,100)
315
. Extrapolated, an estimate of a total annual cost of $1.8 billion (95% CI $1.3 billion to $2.4 
billion) due to surgically confirmed endometriosis is made
315
. 
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The costs of endometriosis related infertility are largely unknown and lacking. With an estimated 
incidence of 30%-50% in women who are infertile
46
, its cost impact should be substantial. Estimated 
costs in 1998 for diagnosing endometriosis in infertile couples were £363 per couple. Where women were 
younger than 40 years and required surgical (laparoscopic or open) intervention, costs were estimated to 
range between £801 and £1,622
316
. 
In the UK, estimate costs for women with mild, moderate and severe endometriosis requiring IVF ranged 
between £2,115-£4,475, £2,002- £4,622 and £2,002-£4,899 respectively
317
. 
1.13.2 Indirect costs 
These encompass loss of productivity at work, decrease in social interaction and its psychological effects 
such as depression. Between 1997 and 2002, 75% of all endometriosis admissions were in patients aged 
between 18-44 years, with the vast majority being labour-force workers
316
. A survey performed in 1996 
suggested a mean loss of 177.6 hours per year (1 month in loss productivity) due to chronic pelvis pain in 
endometriosis
316
 amounting to $1,595 loss for the respective employer. If each woman with chronic 
pelvic pain lost these hours, an estimated cost of $14.7 billion loss of productivity is suffered annually by 
the US economy. An estimated additional $1.8 billion was incurred by patients themselves in the 
management of chronic pelvic pain
318
. 
Despite the current scarcity of data, results above show the significance of the financial impact this 
disease has on society. Hospitalisation and medical costs are on the general increase making admissions 
and treatment of a chronic illness more costly over time. 
1.14 The cell cycle and an introduction to basic cellular processes and 
tumour suppressors- an aid to understanding disease processes 
FIGURE 1-3 
 
Diagram demonstrating the basic phases of the cell cycle 
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Cellular division and death is controlled by a series of specific mechanisms which if aberrant can lead to 
the formation of abnormal pathology. Knowledge of the cell cycle is imperative to understanding the 
balance between cellular proliferation and death. 
Interphase encompasses the G1, S and G2 phase (Figure 1-3). It is a growth phase where cellular 
metabolic activity occurs in preparation for mitosis. Cellular organelles double, DNA replication and 
protein synthesis occurs. Chromosomes are not clearly visible in the nucleus, the nucleolus usually is. G1 
is the phase where the cell grows, organelles are synthesised and cytoplasmic volume increases, a cell 
which does not divide again remains in this phase. The S or synthesis phase is also known as the Swanson 
phase where cellular DNA duplication occurs. G2 phase is the phase in which the cell resumes its growth 
in preparation for mitosis. 
Mitosis (M phase) is subdivided into further components: Prophase, Metaphase, Anaphase, Telophase and 
Cytokinesis. In prophase, the chromatin condenses becoming visible in the form of chromosomes, 
centrioles move to opposing ends of the cell, the nucleolus disappears and fibres in the cell form the 
mitotic spindle. Prometaphase is marked by dissolution of the nuclear membrane and proteins attaching to 
the centromeres forming kinetochores. Metaphase occurs when spindle fibres cause alignment of the 
chromosomes forming a metaphase plate. Anaphase is marked by the separation of the paired 
chromosomes at the kinetochores and their movement towards the opposite poles of the cell along the 
spindle microtubules. Telophase starts once the chromatids arrive at the cellular opposite poles and new 
membranes form around the new daughter nuclei. Chromatomes are no longer visible, spindle fibres 
dissipate and the commencement of cytokinesis occurs. Cytokinesis is the splitting of the original cell into 
two daughter cells. 
1.14.1 Cell cycle regulators and checkpoints 
Checkpoints within the cycle assess for DNA damage. Should this be identified, the cell cycle is stalled 
until repairs are made. Alternatively, should repair be impossible, an effector mechanism causing cellular 
destruction by apoptosis is initiated. The cell cycle is controlled by proteins called cyclin-dependent 
kinases (CDKs) which are activated by another group of proteins called cyclins. They enable the 
movement of the cell between phases, acting as major control mechanisms. 
FIGURE 1-1 
 
Schematic representation of cyclin alterations within the normal cell cycle phases319 
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The maturation promoting factor or Mitosis promoting factor (MPF) includes the cyclin B and Cdk1 
which trigger movement in the cell cycle. In the G1 phase, the main implicated cyclins are the D cyclins 
together with Cdk4 and Cdk6 , followed by cyclins E and Cdk2 in the S-Phase, Cyclin A and Cdk2 in the 
G2 phase and B cyclins with Cdk1 (Cdc2) in the Mitotic phase (Figure 1-4). 
FIGURE 1-4 
 
Diagram demonstrating cell cycle regulators and checkpoints 
 
The replication of DNA in the S phase of the cycle is dependent on the expression of required proteins 
activated by the E2F transcription factor. This transcription factor is regulated by the protein product of 
the retinoblastoma gene pRB. Between the G0 or early G1 phase, the E2F is inactivated by pRB. In the 
late G1 phase the CyclnD/Cdk4 complex phosphorylates sites on the pRB releasing the E2F. This then 
produces proteins for DNA replication to occur. The activated E2F, stimulates in turn the production of 
further E2F, and Cyclins A and E enabling the formation of the Cyclin E/Cdk2compex. This further 
phosphorylates pRB moving the cell cycle into the S phase. The formed Cyclin A/Cdk2 complex acts on 
terminating the DNA replication by phosphorylating the E2F. 
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1.14.2 Apoptosis 
FIGURE 1-5 
 
Cellular signal transduction pathways320 
 
The caspase class of proteins regulates apoptosis. They control its initiation (e.g. caspase 8 and 10) and 
execution (caspase 3, 6 and 7) by destroying cellular proteins. Initiating caspases cleave to inactive 
caspases at specific sites, resulting in the executing caspase degradation of cellular proteins by their 
proteases. Inducers of apoptosis vary. Some of these include the Fas ligand (FasL/CD95L), a type-II 
transmembrane protein belonging to the tumour necrosis factor family, TNF-related apoptosis-inducing 
ligand (TRAIL), the Apo 2 or 3 Ligands (APO-2L, APO-3L) and the tumour necrosis factor (TNF). These 
bind to apoptosis inducing receptors such as Fas/CD95, TRAIL (TNF-related apoptosis-inducing ligand) 
death receptors DR4 and DR5 (DR4/DR5), DR3, and the tumour necrosis factor receptor (TNFR). Once 
the ligands bind to receptors, recruitment of cellular adaptors such as FADD (Fas-associated death 
domain protein) and TRADD (TNFR-associated death domain protein) occurs and caspases are activated 
(Figure 1-6). 
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FIGURE 1-6 
 
The role of Caspases in cellular signal transduction321 
 
1.14.3 P21 
P21or WAF1 is also known as cyclin-dependent kinase inhibitor 1 or CDK-interacting protein 1. It is 
found on chromosome 6 encoded by the CDKN1A gene and binds to and inhibits the activity of CDK1 or 
CDK2 complexes regulating the cell cycle at G1. It is tightly regulated by p53 and in response to stress 
stimuli meditates the cell cycle arrest at the G1 phase. It also interacts with a DNA polymerase known as 
proliferating cell nuclear antigen (PCNA) regulating DNA replication and repair in the S phase of the cell 
cycle. Unlike p53, mutations in P21 are not associated with increased incidence of malignancy. 
1.14.4 P27 
P27 is a member of the gene family of Kip/Cip CDK inhibitors (CDKIs) which acts on cyclin-dependent 
kinases (CDKs) to exert positive and negative regulatory functions at the G1/S phase of the cell cycle
95
. 
Mutations of the Kip/Cip genes are rare but knock-out mice models of P27 have increased predisposition 
to tumours. Numerous studies link reduced levels of P27 with worse prognostic tumour outcomes
322,323
. 
1.14.5 P53 
p53 is a tumour suppressor protein encoded by the TP53 gene located on the short arm of chromosome 17 
(17p13.1) with an important role in the cell cycle and apoptosis. It is found at low levels in normal cells. 
Stress signals within the cell or damage to the DNA elevate p53 protein levels. A defect in the protein is 
linked to abnormal cellular proliferation and malignancy with around 50% of tumours containing p53 
mutations. Its role is to arrest the cell cycle in the event of minor DNA damage and to induce apoptosis if 
the damage is severe. The presence of a genetic defect in p53, also known as Li Fraumeni’s syndrome, 
leads to a high frequency of cancer in affected individuals. Whereas increased levels of p53 induces 
apoptosis suppressing tumour growth, excess elevation of p53 causes excess apoptosis increasing the 
Gene, protein and miRNA expression in women with endometriosis 
60 
ageing process. The gene Mdm2 via the Ubiquitin system is the major regulator of p53. DNA which is 
damaged activates protein kinases such as ATM, DNA-PK, or CHK2. Phosphorylated p53 secondary to 
DNA damage cannot bind to Mdm2 increasing its levels. Once DNA damage is repaired, the kinases are 
no longer active and p53 dephosphorylation occurs and can be destroyed by the Mdm2. p53 is also known 
to induce apoptosis via the mitochondrial release of Cytochrome c when it binds to Caspase9. It activates 
the expression of the Bax gene and Apoptotic protease activating factor 1 (Apaf1). The Bcl-2-associated 
X protein (Bax) gene stimulates the Cytochrome c release, which on binding to Caspase 9, induces 
apoptosis. A few studies have looked at the relation between p53 and CDKN1A genotypes in 
endometriosis. p53 is responsible for the transcriptional induction of the p21 gene 
(CDKN1A/WAF1/CIP1). These two molecules are known in literature to be associated with pathology 
sensitivity to cancer. In this study
324
, it has been suggested that there are significant differences in the p53 
but not the CDKN1A genotype in women with endometriosis. It is postulated that the C (prp) allele of the 
p53 codon can be associated with development of endometriosis and potentially serve as a marker for this 
disease. 
1.15 Associated pathways- inflammation and angiogenesis 
During surgery, increased levels of angiogenesis and vascularity are seen around the sites of implantation 
of endometriosis. Studies have postulated that the endometrium itself of patients who develop 
endometriosis has the increased capacity to proliferate, implant and grow predisposing to increased levels 
of endometrial angiogenesis when compared to normal subjects
325
. Angiogenesis is therefore postulated 
to be a major pre requisite enabling the development of disease and studies investigating angiogenic 
repression and its effects on endometriosis have been performed. Once endometrial tissue adheres to other 
tissues, it induces an inflammatory reaction thereby becoming a chronic process over time
313,326
. 
Studies have assessed the importance of the angiogenic process in the progression of endometriosis and 
regression of ectopic endometrium has been noted once angiogenesis is repressed. 
The levels of inflammatory modulators such as interleukin-1β (IL-1β) and tumour necrosis factor-alpha 
(TNF-α) have been found to differ between endometriosis patients and controls. Interleukin-6 (IL-6) is 
found at higher levels in endometrium and endometriosis tissue of cases compared to controls
327
. 
Endometriotic tissue was found to have significantly lower levels of TNF-α327 and significantly higher 
levels of IL-1β compared to normal endometrium from the cases or controls (Figure 1-2). The 
endometrium from patient cases was also seen to have a phasic response to levels of IL-1β with their 
levels increasing in the luteal compared to the follicular phase. The concentrations of IL-1β in 
endometriosis and in endometrium from controls were positively correlated with IL-6 levels
327
. IL-6 
activates nuclear factor kappa beta (NFκB) and is responsible for various pathways within the body. It 
plays an important role in the body’s defence system against pathogens including viral infections. 
Activities controlled by IL-6 include terminal differentiation and immunoglobulin secretion in B cells, B 
cell differentiation and growth, haematopoietic stem cell colony formation as well as the differentiation 
and activation of macrophages and T-cells
328
. 
Gene, protein and miRNA expression in women with endometriosis 
61 
1.15.1 Prostaglandin E2 (PGE-2) 
The cluster of differentiation 36 (CD36) is an integral cell membrane protein found on the surface of 
various cell types. It belongs to the class B scavenger receptor family and is involved in inflammation and 
angiogenesis
329
. Apart from being a receptor for thrombospondin-1 (TSP-1) and forming a complex 
which mediates cellular interactions between tumour cells, it can act separate to the TSP-1 receptor with 
other proteins, cytoskeletal proteins, integrins and signalling molecules to exert its effects
329
. 
Prostaglandins (PGE) are seen to inhibit the expression of CD36 in peritoneal macrophages via the 
prostaglandin E2 pathway (EP2) reducing their ability to phagocyte cells
330
. In mouse models, 
endometriotic lesions were seen to increase on treatment with prostaglandins. This growth was reversed 
when prostaglandins were blocked with cyclooxgenase inhibitors. This indicates an immunological 
mechanism which may be utilised as a future therapeutic regime
330
. 
1.15.2 Association with malignancy 
The presence of endometriosis has not been attributed to a general increased risk of cancer
331
 in the 
patient population. Chronic sufferers over a 10 year period, have an associated overall increased risk of 
developing clear cell/endometroid ovarian carcinomas
332
 (Table 1-4, Table 1-5, Table 1-6). There are also 
numerous studies showing a histological transition from benign to malignant endometriotic lesions to 
malignant ones
333,334
 supporting the theories of progressive disease development with chronic worsening 
of disease. No direct single causative factor has been identified; rather, it is suggested that a cumulative 
combination of factors is necessary for a chronic progression of disease
332
. Risk factors exist predisposing 
to the development of endometriosis and associated ovarian carcinomas, some of which include hormonal 
stimulation, nulliparity, obesity, early menarche and the use of HRT post-menopausally. Studies reporting 
links with malignancy have limitations leading to misinterpretations of the null hypothesis or 
overestimations of results. There is however increasing evidence of its links with other malignancies 
particularly melanomas and Non-Hodgkin’s lymphomas where microenvironment and inflammation may 
play a role. Two large independent cohort studies confirm the link with Non-Hodgkin’s lymphoma335 
though statistically significant results were only obtained from a small number of cases and larger studies 
are required. Humoral immune anomalies, B-cell activation, a common aetiological cause and disease 
development as a consequence to medication supplied, have all been postulated as theories linking 
endometriosis to Non-Hodgkin’s lymphomas. 
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TABLE 1-4 
Studies on the frequency of endometriosis in patients with ovarian cancers according to the malignant histotype 
  Ovarian cancer histotype 
Authors Serous Mucinous Endometrioid Clear cell Other Total 
Aure et al. 0% (0/357) 1% (1/203) 9% (20/212) 24% (14/59) … 4% (35/831) 
Kurman and Craig 6% (7/118) 4% (2/47) 11% (4/37) 0% (2/28) … 7% (15/230) 
Russel 3% (7/233) 4% (3/69) 28% (20/72) 48% (16/33) … 11% (46/407) 
Vercellini et al. 4% (8/220) 6% (6/94) 26% (30/114) 21% (8/38) 12% (11/88) 11% (63/556) 
De La Cuesta et al. 0% (0/10) 6% (1/18) 39% (9/23) 41% (7/17) 45% (5/11) 28% (22/79) 
Toki et al. 10% (9/88) 9% (3/33) 30% (16/54) 50% (22/44) 0% (0/16) 21% (50/235) 
Jimbo et al. 9% (8/92) 3% (1/35) 23% (3/13) 41% (13/32) … 15% (25/172) 
Fukunaga et al. 10% (6/63) 6% (2/35) 42% (13/31) 54% (27/50) 67% (2/3) 27% (50/182) 
Ogawa et al. 7% (4/60) 0% (0/17) 43% (3/7) 70% (30/43) … 29% (37/127) 
Vercellini et al. 3% (2/61) 3% (1/30) 20% (13/66) 14% (5/35) 6% (1/17) 10% (22/209) 
Oral et al. 4% (3/70) 6% (2/35) 22% (4/18) 9% (1/11) 8% (4/49) 8% (14/183) 
Frequency of endometriosis in patients with Ovarian cancers331 
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TABLE 1-5 
Relationship between endometriosis and ovarian cancer 
Studies Study design Entity of the association  
  OR, SIR, or RR 95% CI 
Brinton et al. Cohort 1.9 1.3-2.8 
Ness et al. Case-control 1.7 1.2-2.4 
Ness et al. Case-control 1.7 1.1-2.7 
Berglund et al. Cohort 1.4 1.2-1.7 
Brinton et al. Cohort 1.3 0.6-2.6 
Borgfeldt and Andolf Case-control 1.3 1.0-1.7 
Modugno et al. Case-control 1.3 1.1-1.6 
OR: odds ratio, SIR: standardized incidence ratio, RR; relative risk, CI: conﬁdence interval 
Relationship between endometriosis and Ovarian Cancer331 
 
TABLE 1-6 
Relationship between endometriosis and non-ovarian gynaecological cancers 
Studies Study design Entity of the association 
  OR, SIR, or RR 95% CI 
Breast cancer    
Moseson et al. Case-control 4.3 0.9-20.4 
Schairer et al. Cohort 3.2 1.2-8.0 
Schairer et al.  Cohort 3.0 0.7-4.1 
Brinton et al. Cohort 1.3 1.1-1.4 
Weiss et al. Case-control 1.1 0.7-1.8 
Venn et al. Cohort 1.0 0.7-1.5 
Olson et al. Cohort 1.0 0.8-1.2 
Borgfeldt and Andolf Case-control 1.1 1.0-1.2 
Brinton et al. Cohort 0.8 0.6-1.1 
Cervical cancer       
Brinton et al. Cohort 0.7 0.4-1.3 
Berglund et al. Cohort 0.6 0.5-0.8 
Borgfeldt and Andolf Case-control 0.6 0.4-0.9 
Endometrial cancer       
Brinton et al. Cohort 1.1 0.6-1.9 
Olson et al. Cohort 1.2 0.6-2.5 
Borgfeldt and Andolf Case-control 0.6 0.4-0.8 
Brinton et al. Cohort 0.8 0.3-1.9 
Melanoma       
Wyshak et al. Case-control 3.9 1.2- 12.4 
Frisch et al. Case-control 1.1 0.5-2.3 
Holly et al. Case-control 0.9 0.5-1.4 
Brinton et al. Cohort 1.0 0.7-1.5 
Olson et al. Cohort 0.7 0.2-1.8 
Brinton et al. Cohort 2.1 1.0-4.4 
Non-Hodgkin's lymphoma       
Brinton et al. Cohort 1.8 1.2-2.6 
Olson et al. Cohort 1.7 1.0-2.9 
Berglund et al. Cohort 1.2 1.0-1.5 
OR: odds ratio, SIR: standardized incidence ratio, RR; relative risk, CI: conﬁdence interval 
The study from Schairer et al. focused on two different cohorts: patients who underwent hysterectomy and those 
who underwent oophorectomy. 
Relationship between endometriosis and non-ovarian Gynaecological Cancers331 
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Interestingly, other studies have mentioned a possible reduction in the risk of cervical and endometrial 
carcinomas. Rather than a direct link to the disease itself, it is believed that possible frequent visits to the 
general practitioner (GP) might ensure closer checks of the patient with the earlier identification and 
management of pathology
336
. An Australian study from fertility patients looking at a cohort of 29,700 
women failed to show an increased risk in breast cancer
337
. A Swedish study assessing records of around 
20,686 women has assessed for types of malignancy in endometriosis patients within this population. 
Apart from those mentioned above, they reported an increased incidence of breast cancer
336,338
. This has 
however not been replicated as a finding in other studies and a population bias was thought to be 
attributed to this finding. The lack of other current databases in multiple populations could also mean that 
other studies have not shown similar results due to sample size bias. Further research is necessary in this 
area to enable adequately powered studies. 
Links with other types of carcinomas are mostly documented as case reports. Most will describe links 
with colon and rectal carcinomas, 66% of which were histologically endometroid in nature. Sarcomas 
were the next most frequent histological type (25%) followed by clear cell (2%)
339
. 
In ovarian endometriomas where malignancy is suspected, a combination of ultrasound features and 
Ca125 levels are used in calculating the risk of malignancy (RMI) index. It is however to be noted that 
Ca125 levels can be elevated in endometriosis without a co-existing malignancy
31
. Case reports of 
malignant tumours arising from endometriosis both within and external to the gonads have been 
published and it is believed that the frequency of malignancy arising in endometriosis may be higher than 
previously believed
340
 and the multifactorial aetiology has been implicated in multiple studies (Figure 
1-7). In one reported review, 78.7% of malignancies arose in the ovary with 21.3% originating from 
extraperitoneal locations
340
. Endometroid adenocarcinomas were found in 69% of lesions, clear cell 
carcinomas in 13.5%, 11.6% were reported as Sarcomas and 6% were rare malignancy cell types
340
. The 
malignancies reported were predominantly well differentiated and most responded to oestrogenic 
stimulation
341,342
. Interestingly, just as there tends to be a predominance of left sided ovarian 
endometriomas, believed to be linked to the left sided stasis of refluxed endometrium, there also seems to 
be a higher predominance of left sided clear cell carcinoma (54%)
343
. This relationship has not been seen 
in other histotypes of ovarian carcinoma. The addition of progestin to cases where endometriosis co-exists 
with unopposed oestrogen therapy has been shown to reduce the incidence of malignant change arising in 
continually stimulated endometriosis lesions
340
. Young patients with endometriosis tend to have an earlier 
diagnosis of ovarian cancer with lower grade lesions though survival rate is unclear, this again might be 
attributed to increased vigilance within this female population
344-346
. Conflicting evidence exists where 
variations in age and stage of diagnosis are all reported making above observations debatable. 
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Multifactorial causations of endometriosis 
 
Endometriosis has been subdivided into typical and atypical variants of disease. Atypical endometriosis is 
classified by the presence of cytological atypia and hyperplastic changes in the invading endometriotic 
cells and has clinically relevant implications
347
. Atypical endometriosis is often regarded as a lesion that 
potentially represents a transition from benign to malignant disease with genomic instability and loss of 
heterozygosity in these atypical tissues
332,348
. Loss of heterozygosity is usually linked to regions where 
tumour suppressor genes are inactivated which in turn leads to malignant change
349
. Some studies have 
shown that the loss of heterozygosity in atypical endometriosis is seen to increase in frequency as the 
disease clinically moves from its moderate to severe forms. This possibly implies a cumulative genetic 
effect in the progression from endometriosis to malignancy. Certain identified loci of loss of 
heterozygosity at genetic locus 10q23.3 and PTEN tumour suppressor gene mutations are seen in both 
endometrial ovarian cysts as well as endometrial and ovarian carcinomas, strengthening the theory that 
development of pathology is a transitional spectrum of mutations. Studies in mice, demonstrating the 
inactivation of PTEN tumour suppressor gene through the induced expression of K-RAS oncogene, have 
shown the development of endometroid ovarian carcinomas. This supports the role of tumour suppressor 
genes in control of disease
350
. Other mutations in tumour suppressor genes have been linked to 
endometriosis and malignant potential. Mutations in tumour suppressor gene TP53 encoding for p53 
nuclear protein is linked to ovarian malignancy and causes nuclear accumulation of this protein within the 
cellular nuclei. There are various studies investigating the frequency of p53 mutations in endometriosis 
and ovarian clear cell carcinomas
351
. Chromosomal loss of TP53 has been seen in late/stage 4 
endometriosis
352
 with endometriosis adjacent to clear cell carcinomas and endometroid carcinomas 
showing p53 accumulations
353
. The increase in p53 expression was also noted to be more prevalent in the 
transition from atypical endometriosis compared to typical lesions
354
. Not all studies have however 
successfully shown these associations in all endometriotic lesions especially in the absence of malignant 
development
355,356
. My TMA studies support the findings of an increased prevalence of p53 expression in 
endometriosis compared to normal endometrium in controls (P=0.0090) and normal endometrium from 
cases (P=0.0101) (Figure 4-18, Table 4-7, Table 4-8). Other mutations in presumed tumour suppressor 
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genes such as ARID1A have also been identified in malignancies associated with endometriosis such as 
ovarian clear cell and endometroid carcinomas. Its associated BAF250a protein lies within the heart of the 
SW1/SNF chromatin complex which regulates cellular differentiation, suppression and proliferation, 
avoiding malignant transformation
357
. 
1.16 Overview of current literature on biomarkers 
An early non-invasive test would enable earlier diagnosis and treatment of endometriosis, preventing 
chronic effects including pain, scarring, psychological trauma and infertility. This test would also serve to 
reduce surgical patient morbidity and mortality and enable the monitoring of the response of disease to 
therapeutics and management. The search for biomarkers has as yet not led to a clinically used or 
validated non-invasive test for endometriosis, but various studies are emerging in the literature with the 
aim to do so. Biomarkers reported in literature include the following and they range from the use of 
cytokines, non-cytokines, serum and endometrial biomarkers, the presence of nerve fibres within 
tissues
358
, gene aberrations and miRNAs. 
Cytokine panels References 
IL-1β, IL-6, IL-8, IL-12, IL-13, TNF-α 359 
IL-6, CA125, CA19-9 
360
 
IL-6, CA125 
361
 
IL-6, TNF-α, MIF, MCP-1, IFN-γ, Leptin, CA125 362 
IL-2, IL-6, IL-8, IL-15, MCP-1, IFN-γ, VEGF, TNF-α, GM-CSF 363 
IL-6, IL-8,TNF-α, CA125, CA-19-9, hs-CRP 364 
 
Non-cytokine panels References 
CCR1 mRNA 
365
 
CCR1 mRNA, MCP-1, CA125 
244
 
Neutrophil to Lymphocyte ratio, NLR, CA125,  
366
 
ccf nDNA, ccf mtDNA 
367
 
Urocortin, CA125 
368
 
Follistatin, CA125 
369
 
 
Other biomarkers References 
CA125, CA19-9,IL-6 
360
 
IL-6, CA125 
361
 
Annexin V, CA125,VEGF, sICAM-1, Glycodelin 
370
 
 
Endometrial biomarkers References 
WBC: CD3+, CD16+, CD3-HLADR-, CD3-CD45RA-, CD3+CD16-, CD3+CD56-, 
CD56-CD16+, CD16b+ 
371
 
AromataseP450 (Polymerase Chain Reaction (PCR) and Staining) 
372
 
AromataseP450 mRNA (PCR) 
373
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Gene aberrations in endometriosis/ adenomyosis References 
HOXA10 
374
, 
375
,
376
 
PR-B 
377
, 
378
 
Aromatase 
379
, 
380
 
ER-β 381 
SF-1 
382
 
E-Cadherin 
383
 
 
Upregulated miRNA Downregulated miRNA References 
 miR-23a, let-7b, miR-100, miR-125a, 
miR-143, miR-195, miR-199a, miR-
199a-AS, miR-21, miR-214, mi-R22, 
miR-221, miR-222, miR-23b, miR-24, 
miR-26a, miR-29a, let-7a, let-7c, let-7d, 
let-7f, let-7i, miR-10b, miR-125b, miR-
145, miR-27b, miR-99a, miR-107, miR-
146b, miR-191, miR-30a-5p, miR-30b, 
miR-30c, miR-30d, miR-451, miR-103, 
miR-126, miR-15b, miR-16, miR-17-5p, 
miR-193b, miR-19b, miR-29c, miR-30e-
5p, miR-342, miR-423, miR-494, miR-
92 
384
 
miR-145, miR-143, miR-99a, miR-99b, 
miR-126, miR-100, miR-125b, miR-
150, miR-125a, miR-223, miR-194, 
miR-365, miR-29c, miR-1 
miR-196b, miR-20a, miR-34c, miR-
424, miR-142-3p, miR-200b, miR-141, 
miR-200a 
385
 
miR-1, miR-100, miR-101, miR-126, 
miR-130a, 
miR-143, miR-145, miR-148a, miR-
150, miR-186, miR-199a, miR-202, 
miR-221, miR-28, miR-299-5p, miR-
29b, miR-29c, miR-30e-3p, miR-30e-
5p, miR-34a, miR-365, miR-368, 
miR-376a, miR-379, miR-411, miR-
493-5p, miR-99a 
miR-106a, miR-106b, miR-130b, miR-
132, miR-17-5p, miR-182, miR-183, 
miR-196b, miR-200a, miR-200b, miR-
200c, miR-20a, miR-25, miR-375, miR-
425-5p, miR-486, miR-503, miR-638, 
miR-663, miR-671, miR-768-3p, miR-
768-5p, miR-93 
386
 
 miR-9, miR-9*, miR-34b, miR-34c-5p, 
miR-34c-3p, 
miRPlus_42 780 
387
 
The miRNA in bold text are mentioned in one or more of the other studies but do not necessarily correlate in 
them being up or down regulated 
 
Dysregulated miRNA in eutopic endometrium References 
miR-17-5p, miR-23a, miR-23b, miR-542-3p 
388
 
miR-9, miR-34,  
389
 
miR-21 
390
 
 
There is the postulated use of proteomic analysis of endometrium and patient blood using 2-DIGE and 
SELDI-TOF MS technology
391-394
. No biomarker panels have so far been identified from this. Peripheral 
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blood studies using SELDI TOF MS report proteins altered in endometriosis
395-399
. None of these have 
maintained sensitivity and specificity to be used in clinical settings. 
Plasma Protein/ Peptide peaks using SELDI-TOF MS References 
2058 m/z, 2456 m/z, 3883 m/z, 14694m/z, 42065 m/z 
395-399
 
2189 m/z (Use of MALDI-TOF/TOF MS) 
394
 
5830 m/z 
395
 
 
Endometrial studies using SELDI-TOF MS References 
90.675kd ( T-Plastin protein) (upregulated), 
35.956kd (Annexin V protein) (upregulated) 
1.9kd, 2.5kd (downregulated) 
391
 
6898 m/z, 5891 m/z, 5385 m/z 6448 m/z, 5425 m/z 
400
 
15334 m/z, 15128 m/z, 16069 m/z 
401
 
2072 m/z, 2973 m/z, 3623 m/z, 3680 m/z, 21133 m/z 
402
 
 
1.17 MicroRNA (miRNA) studies on endometriosis 
MiRNAs are short (approx. 22nt) non-coding RNAs discovered in 1993. They are now regarded to have 
major translational or repressive effects controlling cellular function, proliferation
403
, death
404
 and protein 
production
405
. They regulate around 30% of the human genes
406
 and repress over 60% of the protein 
coding genes
407
. MiRNAs are also believed to be responsible for gene regulation
408
 and are now believed 
to interact with messenger RNA (mRNA) encoding proteins on the ribosomes enhancing their 
expression
409
 (Figure 1-8). 
FIGURE 1-8 
 
miRNA biogenesis: miRNA are transcribed by RNA polymerase 2 into primary miRNA transcripts of variable size 
(pri-miRNA) (a). These are cleaved in the nucleus by RNase3 resulting in hairpin pre-miRNA (b). This is moved 
from nucleus to cytoplasm by exportin 5 and processed by the enzyme dicer (c) giving a transient duplex 19-24 
nucleotide length. The strand of the duplex (mature miRNA) is incorporated into RNA-induced silencing complex 
(RISC) (d) leading RISC to cleave mRNA or cause translational repression depending on the miRNA target 
complementarity410 
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Currently, there are approximately 700 identified human genome miRNAs. Predictions from genome 
wide studies indicate that we may be underestimating their numbers by 10-100 fold
411
. A study by 
Creighton et al.
412
 assessed 13 different types of gynaecological tissues ranging from normal 
endometrium to endometriosis and cancer. In this study, looking at 103 tissues or cell line samples, they 
identified 7 novel miRNAs and 51 predicted novel miRNAs indicating that further novel miRNA 
information is yet to be discovered from future studies to increase our knowledge of disease. 
MiRNAs were discovered after the observation that the gene lin-4, (a gene controlling c.elegans larval 
development) resulted in the production of a pair of small RNAs which, rather than coding for a protein, 
repressed the gene lin-14
413
. The pair of RNAs resulting from lin-4 were of different lengths, one was 
around 22nt and the other was around 61nt. The longer of the two was initially believed to fold into stem 
loops and act as the precursor of the shorter RNA. Further studies indicated that the lin-4 RNA’s had 
antisense complement codes to multiple areas on the 3’ UTR of the lin-14 gene413,414, which were known 
to repress the lin-14 by lin-4. It was noted that this regulation, caused translational repression of the lin-14 
protein without changes in the levels of lin-4 mRNA. This 22nt lin-4 was recognised as the founding 
member of miRNAs
415-417
. In 2000, another gene let-7 in C.elegans, was found to be similar in structure 
to lin-4
418,419
 and it was then discovered in other species including insects, mammals and humans. Since 
that time, increased numbers of miRNAs have been reported and are now implicated as regulators of the 
cellular cycle, neuronal patterning and modulation of hematopoietic lineage differentiation in flies, 
nematodes and mammals respectively. These miRNAs are also found within the plant kingdom regulating 
growth development and reproduction
420
. The discovery of miRNA in both kingdom Animalae and 
Plantae indicate their presence in the common ancestral lineage through evolution
421
. 
Since their first discovery, hundreds of miRNAs are now known
415,422
 and are noted to be evolutionally 
conserved especially, but not uniquely, in closely related species
423
. They are now regarded as one of the 
more abundant cellular complexes. Certain miRNAs are extremely abundant within cells (e.g. miR-52 or 
miR-2 have more than 50,000 molecules per adult worm cell)
424
. There is debate as to whether this 
reflects molecular stability or slow decay. Other miRNAs are expressed at lower levels, reflecting either a 
high expression in a few cells or low expression over a larger volume of cells
415
. There is now a registry 
which is set up to catalogue discovered miRNAs and helps in the naming and identification of newly 
discovered genes. Most of the human miRNAs are isolated not clustered. Clustered miRNAs are usually, 
but not always, related to one another and they may have functional relationships
425
. miRNAs are also 
seen to be conserved through different animal lineages (albeit with differences in size of the respective 
gene family) with nearly all cloned miRNAs conserved in closely related animals such as mouse and 
human species
426
. 
Most of the miRNA genes are believed to originate from separate transcription units
427
. Approximately 
25% of miRNAs lie within the introns of pre-mRNAs, suggesting, that like for many small nucleolar 
RNAs (snoRNAs) their transcription does not occur from independent promoter regions but are processed 
from the introns themselves. This combination will allow for the combined expression of both proteins 
and miRNAs and maintains the relationship between miRNA and mRNAs. miRNAs have distinct 
expression profiles that are seen to vary between different stages of development in-keeping with the 
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wide variation visible in gene expression. This explains why certain miRNAs, despite being abundant in 
cells, can be missed in cloning efforts
428,429
. 
Computational methods
340
 such as MiRscan and miRseeker
426
 are now being used for the prediction and 
identification of related miRNAs as well as genetic orthologs and paralogs
423
. Another identification 
method is to search for the neighbouring stem loops of miRNA genes which might belong to the same 
cluster
416,429,430
. Mammalian miRNAs can be difficult to clone and are less conserved in some co-related 
species e.g. fish. This implies that they are less likely to be identified in computational methods thereby 
reducing confidence of the upper bound estimate of precision on the actual number of human genes
431
. 
MiRNA transcription processes in mammals vary and are not completely understood. Around two thirds 
of miRNA are found within introns and are believed to share their transcripts with their host genes (pre-
mRNA)
341
. Other miRNAs are not within introns but within coding exons
424,432,433
 and are believed to 
have their own promoters which are as yet unidentified
434,435
. They can regulate gene expression by either 
inhibiting the translation or degradation of mRNA. Its expression is deregulated in malignancy
436,437
 and 
has been linked to deregulation of oncogenes and tumour suppressor genes
438
. This relationship has led to 
their use as possible diagnostic or prognostic tools
439
. 
1.17.1 miRNA and endometriosis-published studies 
Endometrial tissue changes throughout the menstrual cycle in response to hormones. Data from sampling 
of eutopic and ectopic endometrium reflects the particular moment in time when they were collected. 
Animal mouse modelling has been used to give a longer term visualisation of result fluctuations in an in–
vivo model of disease
440,441
; data provided by mouse models is reported to closely reflect human 
profiles
441
. Various mechanisms controlling inflammation, implantation and neovascularisation are 
implicated in disease development
442,443
. In small limited pilot studies there is evidence that altered 
expression of some miRNAs occurs in endometriosis. Expression of these genes is controlled by ovarian 
hormones and may regulate the development of endometriosis. There are four published studies on 
miRNA analysis in endometriosis. 
Pan et al. published a study in 2007 where a total of 16 tissue samples in the early mid secretory phase 
were assessed
384
. Four samples were of normal endometrium from unaffected women, 8 samples were 
paired ectopic and eutopic endometrium from 4 women with endometriosis and another 4 samples were 
from ectopic endometrium from women undergoing hysterectomy for leiomyomas or severe 
endometriosis. Cells were cultured in vitro and RNA was extracted. The quality of RNA and its miRNA 
fractions were assessed using a bioanalyser. The miRNA was then labelled and hybridised to mirVana 
miRNA Bioarray Slides. Real time PCR was used to verify seven of the miRNA expressions which 
targeted genes linked to endometriosis. These included transforming growth factor-β receptor 2 (TGF-
βR2), oestrogen receptor-α (Erα), oestrogen receptor-β (Erβ) and progesterone receptor (PR). 65 miRNAs 
were globally identified above a set threshold with 48 differentially expressed between tissues post 
ANOVA analysis. Cells were further separated into glandular and stromal endometrial cells and 32 
miRNAs were listed as differentially expressed. There were no direct comparisons between eutopic and 
ectopic endometrial tissues from women with the disease. In this paper, only hsa-miR21, hsa-miR26a, 
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hsa-miR142-5p were confirmed to be dysregulated between ectopic and eutopic endometrium (Table 
1-7). 
TABLE 1-7 
Pan et al.- differentially expressed miRNAs 
hsa-let-7a miR-19b 
hsa-let-7b miR-21 
hsa-let-7c miR-214 
hsa-let-7d miR-22 
hsa-let-7f miR-221 
hsa-let-7i miR-222 
miR-100 miR-23a 
miR-103 miR-23b 
miR-107 miR-24 
miR-10b miR-26a 
miR-125a miR-27b 
miR-125b miR-29a 
miR-126 miR-29c 
miR-143 miR-30a-5p 
miR-145 miR-30b 
miR-146b miR-30c 
miR-15b miR-30d 
miR-16 miR-30e-5p 
miR-17-5p miR-342 
miR-191 miR-423 
miR-193b miR-451 
miR-195 miR-494 
miR-199a miR-92 
miR-199a-AS miR-99a 
 
In another study by Ohlsson et al., seven patients were recruited to compare paired eutopic and ectopic 
endometrial samples
385
. Fourteen miRNAs were upregulated and eight miRNAs were downregulated in 
endometriosis compared to eutopic endometrium from the same patients. PCR was used to confirm six 
identified transcripts. The program TargetScan was used to assess for predicted mRNAs. The mRNAs 
identified were then confirmed to pre-published studies looking at mRNA analysis
442,444
. Twelve 
pathways were identified, and these were associated with cell cycling, proliferation, movement, 
angiogenesis, death, connective tissue, muscular and nervous system development as well as disorders 
attributed to the endocrine and reproductive system (Table 1-8). 
TABLE 1-8 
Ohlsson et al.- differentially expressed miRNAs 
Upregulated Downregulated 
miR-145 miR-200a 
miR-143 miR-141 
miR-99a miR-200b 
miR-99b miR-142-3p 
miR-126 miR-424 
miR-100 miR-34c 
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miR-125b miR-20a 
miR-150 miR-196b 
miR-125a  
miR-223  
miR-194  
miR-365  
miR-29c  
miR-1  
 
Filigheddu et al. performed a third study looking at follicular phase eutopic and ectopic endometrium 
(from ovarian endometriomas) from 3 patients
386
. 27 miRNAs were found to be upregulated whilst 23 
were downregulated. 5 miRNAs were confirmed by PCR, 3,093 mRNA targets were predicted controlling 
49 functional networks (Table 1-9). 
TABLE 1-9 
Filigheddu et al.- differentially expressed miRNAs 
miR-1 miR-25 
miR-100 miR-28 
miR-101 miR-299-5p 
miR-106a miR-29b 
miR-106b miR-29c 
miR-126 miR-30e-3p 
miR-130a miR-30e-5p 
miR-130b miR-34a 
miR-132 miR-365 
miR-143 miR-368 
miR-145 miR-375 
miR-148a miR-376a 
miR-150 miR-379 
miR-17-5p miR-411 
miR-182 miR-425-5p 
miR-183 miR-486 
miR-186 miR-493-5p 
miR-196b miR-503 
miR-199a miR-638 
miR-200a miR-663 
miR-200b miR-671 
miR-200c miR-768-3p 
miR-202 miR-768-5p 
miR-20a miR-93 
miR-221 miR-99a 
 
Six miRNAs are mentioned in all three studies (miR-29c, miR-145, miR-143, miR-99a, miR-126, miR-
100). Filigheddu’s and Ohlsson’s studies show concordance in the direction of regulation (upregulation or 
downregulation) of the 13 miRNAs commonly expressed in both studies. Pan’s study was discordant for 
the directions of the expressed miRNAs except for miR-17-5p which was also downregulated in 
Filigheddu’s study. Discrepancies in published studies might be attributed to limited data obtained due to 
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the small number of patients recruited. Some patients were also reported as having surgery for 
concomitant pathology such as leiomyomas, which has been shown to cause miRNA deregulation 
irrespective of whether other pathology such as endometriosis co-exists
445
. Their presence in subject 
samples could therefore distort the presented miRNA profile results. 
1.17.2 Differences in miRNA of eutopic endometrium of cases and controls 
A study by Burney et al. looked at normal endometrium from four cases of endometriosis and three 
controls (day 15-18 of the menstrual cycle). The controls were women undergoing surgery for 
leiomyoma. They identified six statistically significant downregulated miRNAs and confirmed three of 
these miRNAs by PCR (Table 1-10). Software to assess pathway analysis showed networks related to the 
control of the cell cycle, cell death and links to the molecular mechanisms of cancer
387
. 
TABLE 1-10 
Burney et al.- differentially expressed miRNAs 
Downregulated 
miR-9 
miR-9* 
miR-34-b* 
miR-34c-5p 
miR-34c-3p 
miRPlus_42 780 
 
1.18 Proteomics and endometriosis 
The proteome is the entire protein content of a cell, a tissue or an organism in a defined state under 
defined conditions, it is the protein equivalent of the genome
446,447
. As there are more proteins than genes, 
the proteome is larger than the genome itself especially in eukaryotic cells. Proteomics is a science which 
analyses the proteome. Due to the nature of the human body, fluid proteome has a large dynamic range of 
protein concentrations resulting in problems with quantitation
448
. Proteomes are studied at two levels i.e. 
the structure of the proteins and their functional interaction. The common technique of analysis is 
twofold, the first being two dimensional protein separation by gel electrophoresis and the second being 
mass spectrometry. Proteomic profiling has been used extensively for tumour marker discovery
449,450
. 
Identifying biomarkers for a disease has the advantage of their use in the clinical setting. Patients can be 
diagnosed and stratified according to disease severity. They can then be offered specific treatments. 
Alternatively, therapies offered can be monitored for tissue response and effectiveness of treatment
448
. 
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FIGURE 1-9 
 
Hand drawn image demonstrating the contribution of various pathways and IL-10, IL-8 and VEGF in the development of endometriosis 
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There are various studies showing differential protein expression in the peritoneal fluid
451,452
 or in 
endometrium
218,453-455
 of women with endometriosis compared to controls (Figure 1-9). Elevated levels of 
IL-10 in the peritoneal fluid of women with endometriosis has been noted
451
. These studies used two-
dimensional gel electrophoresis for protein analysis which limited them in being labour intensive and 
required intact proteins in large numbers. To date, a non-invasive test for endometriosis does not exist. 
The majority of attempts by researchers towards producing non-invasive diagnostic tests for 
endometriosis have looked at levels of growth factors and/or cytokines
456
 involved in inflammation, 
angiogenesis and tissue remodelling
457
. Most of these investigations have looked into single markers of 
the inflammatory process. This line of thought developed after previous studies noted elevated 
concentrations of macrophages in the peritoneal fluid of endometriosis sufferers
458
. Studies have 
suggested increased levels of TNF-alpha and IL-6 levels in endometriosis
459
 associating these elevated 
levels with infertility (Figure 1-2, Figure 1-9). Other conflicting results on reported elevations in 
inflammatory cytokines interleukin IL-1, IL-6
361
 and TNF-α exist 359,460-464. In one study assessing 119 
prospective surgical cases it was reported, that the use of IL-6 in cases of minimal to mild endometriosis 
with a threshold of 25.75 pg/ml shows a diagnostic sensitivity of 75% and specificity of 83%
361
. 
Confounding factors, including the presence of non-malignant ovarian pathology and uterine leiomyomas, 
are noted in the study. 
An increase in the number of leukocytes within the peritoneal fluid of women with endometriosis has 
been identified. Chemokines are responsible for the recruitment of monocytes to inflammatory regions
465
. 
In the peritoneal fluid of endometriosis patients, 70% of monocyte chemotactic function is mediated by 
regulated upon activation, normal T cell expressed and secreted (RANTES) gene
365,466
. The cognate 
chemokine receptor-1 (CCR1) has a high affinity for RANTES and is expressed on the surface of the 
monocytes
465
. It has been shown to be elevated in its levels in the peritoneal fluid of women with 
endometriosis
467
. In studies looking at the CCR1 level in peripheral blood leukocytes of women with 
disease in the follicular phase of the cycle, an increased level of the CCR1 levels has been shown
365
. 
Again, controls were women who did not suffer from endometriosis but showed non-malignant pathology 
such as uterine leiomyomas. Elevated expressions of CCR1 were also noted in women who were pregnant 
or who had inflammatory pelvic pathology
365
. At best, looking at symptomatic women with chronic 
pelvic pain and with disease, the use of CCR1 as a marker for endometriosis showed a sensitivity of 94%, 
specificity of 71% and a negative predictive value of 80% with a positive predictive value of 91%
365
. The 
ability to identify disease in women who did not report chronic pain was reduced with a sensitivity of 
90% and specificity of 74%
365
. 
Angiogenic factors IL-8 and vascular endothelial growth factor (VEGF) are also reported as elevated in 
peritoneal fluid of women with endometriosis
452,458,468
. Other studies, which are small in number and 
sample size, have looked for alternate serum markers with less definite results obtained
359,469,470
. 
Tumour markers such as CA125 and CA19-9 have also been assessed as potential biomarkers
471,472
. In 
one study looking at CA125 levels in moderate to severe cases of endometriosis, the CA125 with a cut off 
threshold of 35 IU/ml gave a specificity of 97% and sensitivity of 47% for endometriotic cases
361
. A 
smaller study looking at 45 women, gave a CA125 sensitivity of 27% and specificity of 97%
360
, they 
attempted to combine the CA125 with CA19-9 and IL-6 but failed to show an increase in the validity of 
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obtained information over CA125 alone. The resulting sensitivity and specificity was quoted at 42% and 
71% respectively
360
. A combination of CA125 levels and analysis of endometrial leukocyte subsets has 
also been attempted
371
. Using a multiple logistic regression model, combining leukocyte subsets, CA125 
levels and risk factors, a specificity of 95% and sensitivity of 61% was obtained. The positive predictive 
value was calculated around 91% and the negative predictive value was around 75%
371
. 
Two-dimensional gel electrophoresis (2-DE gels) has been used in one study in combination with peptide 
mass mapping identifying the following dysregulated proteins possibly having a functional role in 
endometriosis. The proteins assessed include molecular chaperones (including heat shock protein 90 and 
annexin A2), proteins involved in cellular redox state (such as peroxiredoxin 2), proteins involved in 
protein and deoxyribonucleic acid (DNA) formation/breakdown (including ribonucleoside-diphosphate 
reductase, prohibitin and prolyl 4-hydroxylase) and secreted proteins (such as apolipoprotein A1)
473
. 
Two studies have been published showing some promising preliminary findings in the serum from 
women with endometriosis
457,474
. Zhang et al. reports thirteen known protein spots from patient serum and 
eleven known protein spots from endometrium as being differentially expressed between women with and 
without endometriosis. In particular, vimentin, beta-actin and ATP synthase beta subunit hybridised 
substantially differently between the sera from controls and cases
474
. Another paper by Liu et al. 
examining plasma from endometriosis patients, reports twenty different protein peaks with a sensitivity of 
87.5% and specificity of 80% in the diagnosis of endometriosis
475
. Even as this technology continues 
evolving, to date, it has not yet led to a single new therapy or tested biomarker partly due to the 
multifactorial nature of endometriosis itself
476
. 
A recent 2011 study by Kyama et al.
477
 looked at protein expression in the endometrium of 29 patients 
with endometriosis and laparoscopically confirmed controls in the secretory phase of the cycle. In the 
preliminary study, ProteinChip technology was used to assess the expression of various protein profiles in 
endometrium of women with and without disease. Transgelin (a smooth muscle actin-binding protein) 
was identified as being upregulated in endometriosis cases
392
. In the evaluation study, protein profiles 
from 29 patients were obtained using surface-enhanced laser desorption ionisation time-of-flight mass 
spectrometry (SELDI-TOF-MS) allowing the identification of proteins and peptides otherwise poorly 
detected by other methods
477
. Precautions which could cause sample bias were documented
478
 and peaks 
with mass-over-charge <1.6kDa were excluded avoiding interference from matrix ions
477
. 73 mass peaks 
were seen to be expressed differently in the secretory endometrium of endometriosis patients at all stages 
compared with controls
477
, whilst 30 mass peaks were differentially expressed between controls and 
patients with minimal to mild disease. Their data using the SELDI-TOF-MS techniques and the use of 
mass peaks identified by stepwise logistic regression provided clinically relevant biomarkers with high 
sensitivity (100%) and specificity (100%)
477
. Other studies using similar techniques but analysing plasma 
samples, report decreased sensitivity of 92% and specificity of 80%
479
. T-plastin (a cytoplasmic protein 
regulating actin assembly and cellular motility) and Annexin V (a calcium phospholipid-binding protein) 
were upregulated in endometriosis. Validation studies are pending. 
Further studies are required into this new field which has already shown high potential of clear pattern 
identification for this disease. Additional studies of proteins already identified will assist in developing 
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diagnostics and treatments for endometriosis. None of these have shown adequate specificity or 
sensitivity for their current use as a diagnostic marker. 
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2 Protocols and suppliers  
2.1 List of materials and suppliers 
Supplier Material 
Agilent Technologies Feature Extraction Software 
Agilent Technologies Microarray Hybridization Chamber  
Agilent Technologies miRNA Microarray System with miRNA Complete Labelling 
and Hyb Kit 
Agilent Technologies RNA 6000 Nano Assay 
Agilent Technologies SureScan Microarray Scanner C 
Agilent Technologies SureScan Cassette 
Applied Biosystems TaqMan 2X Universal PCR Master Mix 
Applied Biosystems TaqMan MicroRNA Assays 
Beckman Coulter Vi-Cell XR Cell Viability Analyser 
Biogenix SS-enhanced Polymer detection system 
BMG Labtech FLUORstar OPTIMA 
Bristol-Myers Squibb Etopophos (Etoposide) 
Custom Biogenic Systems Liquid nitrogen Dewar tank Isothermal V-1500 series 
Dako Dako-autostainer system 
EBOS Healthcare BD Vacutainer SST 
Genetix ARIOL imaging system 
Hirschmann Ceramus laboratory dispenser 
IKA Vibramax 
IKA  KS501 shaker 
Kimtech Kimwipe 
Life Technologies Invitrogen DMEM (Dulbecco’s Modified Eagle Medium)  
Life Technologies mirVana miRNA Isolation Kit 
Life Technologies mirVana PARIS 
Life Technologies MultiScribe Reverse Transcriptase 
Life Technologies RNAlater 
Life Technologies RNaseZap 
Medline Scientific Shaking SI-600 incubator 
NanoString Technologies nCounter miRNA Expression Assay 
NorgenBiotek Total RNA purification kit 
Olympus BX61 microscope 
PAA Laboratories Lymphoprep LSM 1077 
Promega Corporation Maxwell 16 Blood DNA Purification Kit/ Standard Elution 
Volume Instrument 
Promega Corporation Maxwell 16 SEV Instrument 
Qiagen TissueLyser II 
Select Science TrakMate tubes and rack 
Sigma-Aldrich Ficoll 
Sigma-Aldrich Quadriperm dishes 
Techne  Circulating water bath 
Thermo Scientific Nanodrop Spectrophotometer/ Fluorospectrometer 
Thermo Scientific Nalgene Mr Frosty 
Thermo Scientific Nalgene rack  
Thermo Scientific Orbital shaker 
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Thermo Scientific Sorvall Legend centrifuge  
Thermo Scientific VisionMate scanner 
VWR International Virkon 
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2.2 Methods 
In this chapter, I describe and critically analyse the optimised techniques of surgically obtained tissue 
processing and its miRNA extraction. Data obtained for identified tissue miRNA markers of interest was 
confirmed by real time polymerase chain reaction (PCR) and the downstream effects of the identified 
miRNA markers were explored through immunohistochemistry of endometriosis and control tissue 
microarrays. Cells from the tissues obtained at surgery were also processed for storage and cell culture. 
These cultured cells were used in therapeutic in vitro experiments with Galectin inhibitors. Blood taken at 
surgery was processed, serum and lymphocytes were separated. Proteomic antibody studies and miRNA 
extractions were performed on the serum samples. RNA extraction with quantitative PCR was performed 
on the serum lymphocytes to substantiate miRNA serum findings. 
2.3 Subject recruitment and sample collection 
Research participants for this study were women between 18 and 50 years of age recruited with informed 
consent (Ethics reference REC 10/H0711/24) who were known (or strongly suspected from current 
investigations) to suffer from endometriosis (Figure 2-1). Cases (n=17) were defined as women, between 
18 and 50 years of age (mean age 30.75 years), in a haematologically confirmed phase of their menstrual 
cycle at the time of surgery (n=8 follicular, n=9 luteal) (Table 2-1). Hormonal analysis for FSH, LH 
Oestradiol and progesterone levels were used to define the cycle phase at recruitment. Samples were 
divided into follicular phase and luteal phase samples respectively. Cases were further subdivided into 
patients with ovarian (n=3) or peritoneal (n=14) disease. 
TABLE 2-1 
Cases: ID Age (yr) Ethnicity Cycle stage Endometriosis Other pathology Medications 
1 26 Asian Follicular Peritoneal None None 
2 32 Caucasian Follicular Peritoneal None None 
3 33 Caucasian Follicular Peritoneal B thalassaemia trait None 
4 37 Caucasian Follicular Peritoneal Mildly elevated T4 None 
5 40 Caucasian Follicular Peritoneal None None 
6 32 Caucasian Follicular Peritoneal None None 
              
7 31 Asian Luteal Peritoneal None None 
8 40 Asian Luteal Peritoneal None None 
9 30 Asian Luteal Peritoneal None None 
10 30 Caucasian Luteal Peritoneal None None 
11 40 Caucasian Luteal Peritoneal None None 
12 30 Caucasian Luteal Peritoneal None None 
13 32 Caucasian Luteal Peritoneal None None 
14 26 Caucasian Luteal Peritoneal None None 
              
15 44 Asian Follicular Ovarian None None 
16 32 Asian Follicular Ovarian None None 
17 37 Caucasian Luteal Ovarian None None 
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Controls Age (yr) Ethnicity Cycle stage Endometriosis Other pathology Medications 
18 27 Caucasian Follicular None None None 
19 30 Caucasian Follicular None None None 
20 24 Caucasian Follicular None None None 
21 42 Caucasian Follicular None None None 
Summary of recruited patients for tissue miRNA analysis 
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FIGURE 2-1 
 
Overview of recruitment criteria and consent processes for study participation 
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Women undergoing laparoscopy for non-endometriosis related reasons such as sterilisation or women 
who at surgery were not identified to have endometriosis were recruited as controls. The revised 
American Fertility Society (rAFS) classification system was used to classify disease at surgery. Exclusion 
criteria involved the presence of any metabolic and/or endocrinological disorders, malignancy, or the use 
of steroid therapy or hormonal therapy in the preceding 6 months. 
Information about the study was given in the gynaecology out-patient department (GOPD). A patient 
information pack for the project titled “Gene Protein and miRNA Expression in Women with 
Endometriosis” REC ref-10/H0711/24 was distributed to all possible candidates. Any questions from the 
participants were answered and further explanations when requested were given. In the situation where 
language difficulties existed, qualified hospital interpreters were used for translation and consents at both 
the preliminary recruitment discussion and later in the consent and follow up meetings. These translated 
the written forms as well as the verbal discussions. It was emphasised that recruitment was completely 
optional and would not affect patient care or management. Information leaflets about endometriosis and 
the study were given to the patients prior to surgery enabling ample time for reflection and decision as to 
whether to participate or not. Patients taking part in the study were given the option of being provided 
with the results of the study should they wished to be informed. Women taking part in the study were 
provided with contact information which enabled them to easily ask questions or gain access to the 
investigator should they wish to do so. 
Consent was obtained on the morning of the surgery together with the routine consent form for her 
planned surgical procedure. On the day of surgery, candidates for the study had a full medical history 
taken by the chief investigator to assess and reconfirm eligibility. The date of the last menstrual period 
was recorded for all candidates to establish the menstrual cycle phase. This was furthermore confirmed by 
hormonal profile assessments taken on the day. Quality of life questionnaires including SF12 and SF36 
together with a pain score questionnaire PIQ-6 were completed by the patient prior to surgery enabling 
assessment of the impact endometriosis was having on daily life. A pregnancy test was performed to 
exclude pregnancy. 
All samples collected were from recruited and consented patients undergoing surgery with no additional 
invasive procedures incurred by the patient. To minimise confounding factors, all the cases from whom 
the samples were collected underwent laparoscopy by the same surgical team, utilising similar operative 
techniques. In the anaesthetic room, at routine patient cannulation for surgery, blood was taken for the 
following serum tests: Ca125, CEA, Ca19.9, TFT, serum oestrogen, serum progesterone, follicle 
stimulating hormone (FSH) and lieutenising hormone (LH). Another blood vial was taken for serum and 
white blood cell extraction in the research laboratory. All blood and tissue vials were stored at 
approximately 4ºC until the end of the procedure. They were then processed on the same day. All samples 
were assigned a random coded number ensuring anonymity of patients. 
2.3.1 Sample sizes 
Initially 17 patients and 4 controls were recruited surgically. These patients were used to obtain primary 
tissue samples used for tissue miRNA analysis and serum samples which were used for serum miRNA 
and antibody analysis. This small sample batch was used to perform preliminary miRNA work to 
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demonstrate whether there were changes between samples and controls for the disease of endometriosis 
(See section 2.3.2, 4.4.1). These primary samples were also used for tissue cell culture and the therapeutic 
experimentation (See sections 2.10, 7.3.1, 7). 
Once changes were demonstrated from the tissue miRNA studies, an additional 179 tissue samples were 
obtained from Barts and the London Trust tissue bank (histologically confirmed cases of endometriosis 
and controls) to perform the tissue microarray studies (See section 2.7, 4.4.3). 
An additional 52 patients were recruited for the serum biomarker studies (Total sample size 73). These 
were either patients with previous surgery confirming endometriosis (Cases) or patients who had previous 
surgery which was normal (Controls) (See section 2.6.1, 5, 6). 
2.3.2 Surgical procedures 
2.3.2.1 Hysteroscopy  
The patient was cleaned and draped in position. To minimise its risk of injury during laparoscopy, an in 
and out catheter was used to empty the bladder. Bimanual vaginal examination established uterine size, its 
position and degree of mobility. At the same time, it assessed for the presence of pelvic masses. 
Endometrial curettings were taken prior to the insertion of the hysteroscope to minimise the risk of 
distorting uterine tissue during surgical manipulation or laparoscopic dye insertion. The saline 
hysteroscopy was performed at the end of the laparoscopy to avoid the dilution of collected intra 
peritoneal fluid with saline and disrupt the endometrial milieu. 
2.3.2.2 Laparoscopy 
The abdomen was insufflated using a closed Veress needle technique. The abdomen was insufflated with 
about 3.5 litres of CO2 pneumoperitoneum to obtain a port entry pressure of 20mm Hg. All ports were 
inserted under direct vision to minimise the risk of entry injuries. On entry with the laparoscope, initial 
assessment of the abdomen, liver and pelvis was performed. Patients with evidence of infection within the 
pelvis such as Fitz Hugh Curtis syndrome or the presence of hydrosalpinges were excluded. When 
identified, endometriosis was graded using the AFS classification. Biopsies from cases recruited for the 
study were excised without the use of concomitant thermo coagulation avoiding thermal damage to the 
tissues which could have distorted the results. A section of the collected biopsy was sent for histological 
analysis using formal saline as a transport medium. The tissue samples for RNA extraction were stored in 
separate vials in an RNA stabilisation medium- RNAlater®. The samples in RNAlater® solution were 
left at 4ºC for 12 hours to enable adequate tissue permeation. They were then stored at -80ºC till RNA 
extraction was performed. Where possible, photographic evidence of the lesions were taken and stored in 
the patient’s file together with the documented operative notes. 
Postoperatively, surgical findings were explained fully to the patient. Any questions were answered and a 
routine six week follow up in the general gynaecology clinic was arranged to assess recovery and 
outcome. Patients were invited to repeat the SF12, SF36 and the PIQ-6 questionnaires at 4 and 12 months 
post-operatively either in clinic or telephonically. They were given the opportunity to meet with the 
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principal investigator in the gynaecology outpatient department at St. Bartholomew’s Hospital after their 
procedures. 
In a rare circumstance, where unexpected and important clinical information was discovered whilst 
analysing the samples (e.g. the discovery of a cancer or borderline tumour from the histology of the 
samples), the participant was contacted and invited to an early hospital consultation where the 
information was disclosed and appropriate clinical management offered. They were then excluded for the 
purposes of the study. 
2.3.3 In summary 
Current diagnosis and management of endometriosis leaves a lot of deficiencies in the understanding of 
both the mechanisms of disease and its therapeutic options. Surgery and the induction of chemical 
menopause remain the two options for treatment and are unsatisfactory. It was therefore the aim of this 
thesis to investigate the mechanisms related to the development of disease and relate these findings to 
potential future therapeutic and diagnostic options. 
2.4 Tissue miRNA extraction 
Total RNA from specimens was extracted using the mirVana™ PARIS™ kit (Ambion) as per their 
supplied protocol. The first step of the mirVana PARIS procedure is to disrupt samples in Cell Disruption 
Buffer. The samples were all between 10
2–107 cultured eukaryotic cells or 0.5–100 mg of tissue. All 
samples were weighed prior to commencing the extraction. Tissues were blotted on absorbent paper to 
remove excess RNA Later solution which would interfere with the RNA extraction technique. Extraneous 
material was manually removed from the samples to ensure that only areas of interest to the study (e.g. 
endometriosis infiltrated areas) were dissected in the laboratory. Initially pulverisation of the tissues was 
attempted by using a technique which involved manual lysis of the tissues with a mortar and pestle and 
liquid nitrogen. It was noted, that whereas the normal endometrium was relatively easy to pulverise 
giving high RNA yields at good purity, the peritoneal tissue and the tissue infiltrated by endometriosis, 
gave substantially lower yields of RNA concentration using the same technique. Maximisation of yield 
from all tissues was obtained by manually dissecting and cutting the tissues into minute pieces and then 
lysing the tissues mechanically with the aid of the Retsch TissueLyser2 (Qiagen). Dissected samples were 
placed in 2ml vials together with a 5mm stainless steel bead and 625µl of ice cold cell disruption buffer. 
The plates of the Lyser had been pre cooled to avoid sample heating and possible material degradation. 
Tissues were lysed with a program of 30beats/second for a total of 20 minutes. 
2.4.1 Organic extraction 
The homogenised lysate was mixed with an equal volume of 2X Denaturing Solution (at room 
temperature). The high concentration of guanidinium thiocyanate in the 2X Denaturing Solution prevents 
the RNA degradation by cellular ribonucleases. Samples were incubated on ice for 5-10 minutes to ensure 
complete cell disruption. Acid-Phenol:Chloroform equal to the total volume of the sample lysate plus the 
2X Denaturing Solution was then added. Care was taken to withdraw the bottom phase containing Acid-
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Phenol:Chloroform and not the aqueous buffer that lay on top of the mixture. Samples were vortexed for 
30-60 seconds to ensure good mixing. Samples were then centrifuged for 5 min at 14,000 rpm at room 
temperature to separate the mixture into its aqueous and organic phases. If a compact interphase was not 
achieved at initial centrifugation, re-centrifugation was repeated. The upper (aqueous) phase was 
carefully removed without disturbing the interphase or lower phase and transferred to a fresh labelled 
tube. The volume recovered was noted. 
2.4.2 Final RNA isolation 
1.25 volumes of room temperature 100% ethanol were added and thoroughly mixed with the aqueous 
phase obtained from the abovementioned step. For each sample, a filter cartridge was added into one of 
the collection tubes. The tubes were labelled according to the sample being processed. Up to 700µl of the 
lysate/ethanol mixture was pipetted onto the respective filter and 30 seconds of centrifugation (max of 
10,000 rpm) were allowed for the sample to pass through the filter. The flow through was discarded and 
the procedure was repeated until all the lysate/Ethanol mixture was passed through the filter. 700µl of 
miRNA Wash solution 1 (working solution mixed with ethanol) was applied to the filter cartridge and 
centrifuged (max of 10,000 rpm) for 15 seconds. The flow through was discarded from the collection tube 
and filter cartridge was replaced into the same collection tube. 500µl of wash solution was then applied to 
the filter cartridge respectively and the above process was repeated. After the flow through from the last 
wash was discarded, the filter cartridge was spun in the same collection tube for 1 min to remove residual 
fluid from the filter. The filter was then transferred into a new collection tube and 100µl of preheated 
95ºC elution solution was slowly added to the centre of the filter and centrifuged for 30 seconds to 
recover the RNA. 
The RNA extracted was assessed using the Nanodrop ND-1000 spectrophotometer (Thermo Fisher 
Scientific) to determine RNA concentration (ng/µl), minimal contamination from protein (ratio 
Abs260/Abs280) and from organic compounds (Abs260/Abs230). RNA in the remaining eluate was then 
stored at -80ºC. 
2.4.3 nCounter® miRNA expression assay for tissue samples 
RNA quantification and integrity was assessed using the Eukaryote total RNA nano assay by Aligent 
Technologies™. Following validation, 100ng of total RNA was used in the nCounter® miRNA 
Expression Assay (NanoString Technologies) enabling an ultrasensitive miRNA detection in total RNA 
across all biological levels of expression without the use of reverse transcription or amplification. 735 
human and human-associated viral miRNAs derived from miRBase were scanned for. Unique 
multiplexed annealing of specific oligonucleotide tags were ligated onto their target miRNA followed by 
an enzymatic purification to remove all unligated tags. Excess unbound probes and RNA were washed 
using a two-step magnetic bead-based purification system on the nCounter Prep Station. Remaining 
miRNA was attached to a cartridge surface and polarised. The Cartridge was scanned and data collection 
was performed on the nCounter digital analyser. Digital images were processed and miRNA counts were 
tabulated. 
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2.4.4 miRNA real-time PCR 
Microarray data was validated by real time PCR using individual TaqMan® MicroRNA assays following 
supplied protocols by Applied Biosystems®. TaqMan® arrays can detect and quantify miRNA over six 
logs of dynamic scale and can detect low levels as little as 1-10ng of total RNA allowing conservation of 
limited samples. Assays detect mature miRNA excluding precursors with a single base discrimination. 
Complimentary DNA (cDNA) was synthesized from total RNA using a commercially available specific 
EBV-miR-bart2-5p assay. RNU-44 and hsa-miR-26b were used as the mature miRNA endogenous 
controls. Each 15µl RT reaction contained 5µl of RNA containing 2.5ng/µl of RNA, 7µl of master mix 
(0.15µl of 100mM deoxynucleotide solution mix (dNTPs) (with Deoxythymidine triphosphate (dTTP), 
1.00µl of MultiScribe™ Reverse transcriptase 50 U/µl, 1.50µl 10X Reverse transcription buffer, 0.19µl 
of Ribonuclease (RNase) Inhibitor 20U/ µl, 4.16 µl nuclease-free water) and 3µl of the primer (Table 
2-2). All reagents were available in the TaqMan® MicroRNA reverse transcription kit. Reverse 
transcription was performed on a thermal cycler by incubation of the reagents at 16ºC for 30min, 42ºC for 
30min,85ºC for 5 minutes and held at 4ºC. The resulting cDNA was diluted in nuclease free water at a 
1:15 ratio as advised per protocol. 
2.5 Critical analysis of tissue sample collection and RNA extraction  
RNA and biomolecule extraction is one of the most fundamental and crucial steps in sample preparation 
for analysis and downstream processing
480
. Tissues vary in their biological composition making certain 
samples (e.g. fibrous peritoneal tissues) more difficult to homogenise, process and therefore extract 
nuclear material compared to others (e.g. endometrial tissue which is cyclically regenerating, 
proliferative, glandular tissue). To ensure successful nucleic acid extraction in a pure format, four 
important steps need to be adhered to. First there is the requirement for effective disruption/ 
homogenisation of the cellular material, followed by denaturation of nucleoprotein complexes, 
inactivation of nucleases (RNase in my case) and avoidance of contamination. Both the quality and 
integrity of obtained nuclear material is known to effect results obtained
481
. 
2.5.1 Patient sample recruitment techniques 
This project involves the collection of fresh patient samples during surgery. Samples from case studies 
included: intrauterine endometrial tissue, pelvic peritoneal tissue infiltrated with endometriosis, pelvic 
peritoneal tissue clear of endometriosis and in some cases, ovarian tissue infiltrated with disease (ovarian 
endometriomas). Cases conforming to all inclusion criteria were difficult to recruit. Most women with 
suspected endometriosis undergoing surgery were on hormonal therapy at time of surgery making them 
inappropriate for inclusion. Timing of the menstrual cycle was also variable in patients (even in those 
with a regular cycle) making it difficult to time the surgery within the follicular proliferative phase of 
their cycles. Adequate biopsy size from peritoneal samples was another limiting factor. Patients with 
endometriosis, fitting recruitment criteria, were either found to have small localised areas of deep 
infiltrative disease or extensive nodular areas in the pouch of Douglas, adherent to bowels, making safe 
excision of large biopsies difficult. Thermal damage to biopsy tissue during surgical excision is reported 
to cause alterations in gene expression profiles related to tissue stress responses
482
. This was avoided by 
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performing sample excision without concomitant thermal coagulation. Bipolar or monopolar diathermy to 
bleeding sites were performed post biopsy if necessary. 
2.5.2 Stabilising RNA 
Once extracted, RNA is an unstable molecule with a short half-life. Biologically it serves its purpose as a 
transient message from an activated gene. In the cell, once gene transcription stops, the existing RNA is 
degraded preventing unwanted translation of proteins
483
. Transport between surgical theatres and 
laboratories can take up to a few hours and due to time restrictions it was not always possible to extract 
tissue RNA on the day of sample obtainment. These factors would be responsible for RNA degradation 
with subsequent molecular profile alteration and erroneous results. To avoid this, samples at time of 
biopsy were immediately placed into an RNA stabiliser solution called RNAlater®. This aqueous tissue 
storage reagent rapidly permeates most tissues to stabilise and protect RNA. Reports have shown that 
tissues can be stored indefinitely in RNAlater® solution at -20ºC or below, with RNAlater® efficiently 
preventing RNA degradation
484
. Where samples could not be processed on the day of biopsy, RNAlater® 
was left to permeate the tissues at 4ºC overnight (data from Ambion® shows that RNA is stable at 4ºC for 
up to a month in RNAlater®) and samples where then stored at -80º till RNA extraction was possible. If 
the tissue stored in RNAlater® is poorly permeated RNA degradation can still occur. To overcome this, 
all samples were cut into sections less than 0.5cm in any single dimension. Fresh tissues were also put 
into 5-10 volumes of RNAlater® solution as advised by Ambion® guidelines for the use of RNAlater® 
solution. RNAlater® is reported in Ambion® guidelines to be compatible with mirVana™ miRNA 
isolation kit which was then used in the next step for miRNA extraction. 
2.5.3 Effective disruption and homogenisation of cellular material 
Disruption and homogenisation are two distinct steps for nucleic acid purification. Complete disruption of 
cell membranes is required to release nucleic acids within the samples. Incomplete disruption prevents the 
lysis buffer (which inactivates nucleases (e.g. RNases)) from contacting and protecting nucleic acids 
stored within the intact cell. Homogenisation reduces the viscosity of the obtained cell lysates. If these 
steps are not performed efficiently DNA and RNA yields are significantly reduced with resulting biased 
results. Various techniques were attempted. Normal endometrial tissue was easy to disrupt but substantial 
problems were encountered with the peritoneal tissue, both normal peritoneum as well as peritoneum 
infiltrated with endometriosis, due to their connective tissue/fibrous nature. Initially, manual disruption 
and homogenisation of tissues was attempted. Tissues were placed on a bed of ice in petri-dishes and 
scalpels were used to shave off fine layers of cellular material from the biopsy samples. This process was 
lengthy, resulted in unequal thawing of the tissue and did not result in adequate complete tissue lyses with 
probable ensuing result bias. RNAs obtained from the samples using this method were of good purity but 
provided low levels of ng/microlitre of RNA per mg of tissue. Small sample size made this process even 
more difficult and this method was abandoned. 
Manual disruption by pulverising tissues using liquid nitrogen and a mortar and pestle was tested. This 
method improved, but did not complete, sample disruption/pulverisation to the desired level. Small 
sample size, incomplete sample pulverisation and repeated thawing and re-freezing of tissues during this 
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manual disruption technique were not ideal for maintaining RNA integrity during extraction. RNA levels 
of ng/microlitre of RNA per mg of tissue and RNA purity obtained, only marginally improved when 
compared to the first method. 
Manual lysis was shifted to a mechanical one. Mechanical lysis was performed on the samples using the 
TissueLyser from Qiagen®. With this lyser, disruption and tissue homogenisation is achieved through 
stainless steel 7mm beads which beat and grind the tissues at speeds from 3 to 30HZ (180-1800 
oscillations per minute). RNAlater® was removed from previously stored samples and these were 
weighed. 0.5–100 mg of tissue was required per sample for the mirVana™ PARIS™ Kit RNA extraction 
step. The samples were manually dissected into small sections on ice and immediately placed into a 2ml 
microcentrifuge tube together with one 7mm stainless steel bead per tube and 625µl of ice cold cell 
disruption buffer containing a non-ionic detergent (the first step in the RNA extraction protocol of the 
mirVana™ PARIS™ Kit). 5mm tungsten carbide beads were used in an attempt to maximise sample 
disruption with smaller beads but these were seen to react with the mirVana™ PARIS™ Kit cell 
disruption buffer and their use was therefore abandoned. Tissues were mechanically lysed at a rate of 
30Hz for a total of 3 minutes or until most of the sample was disrupted and homogenised within the cell 
disruption buffer. Normal endometrium was seen to disrupt and homogenise more quickly and effectively 
than the peritoneal samples. Despite rigorous mechanical grinding, some of the peritoneal samples 
remained intact. Nevertheless it was this method which provided the best level of sample lysis and 
homogenisation. RNA levels of ng/microlitre of RNA per mg of tissue were substantially higher and good 
RNA purity was maintained. Due to the rapidity of bead oscillation, heat damage to the tissues during 
lysis might have occurred, this was reduced by pre cooling the adapter sets holding the 2ml 
microcentrifuge tubes for a few minutes at -80ºC prior to the start of processing. 
2.5.4 Denaturation of nucleoprotein complexes and inactivation of nucleases (RNase) 
Once the sample was homogenised as described above, an equal volume of 2X Denaturing solution from 
the mirVana™ PARIS™ Kit was added. This solution contains a high concentration of guanidium 
thiocyanate which prevents RNA degradation by cellular ribonucleases. Prior to processing, the sample 
was incubated on ice for 10 minutes to ensure complete sample disruption. Acid-Phenol:Chloroform 
equal to the total volume of the sample lysate plus the 2X Denaturing Solution were then added and care 
taken to withdraw the bottom phase containing Acid-Phenol:Chloroform and not the aqueous buffer that 
lay on top of the mixture. Samples were vortexed for 30-60 seconds to ensure good mixing. Samples were 
then centrifuged at room temperature for 5 minutes at 14,000 rpm to separate the mixture into its aqueous 
and organic phases. If a compact interphase was not achieved at initial centrifugation, re-centrifugation 
was repeated. The upper (aqueous) phase was carefully removed without disturbing the interphase or 
lower phase and transferred to a fresh labelled tube. The volume recovered was noted. 
2.5.5 Final RNA isolation 
1.25 volumes of room temperature 100% Ethanol were added to the aqueous phase from the 
abovementioned step and thoroughly mixed. For each sample, a filter cartridge was added into one of the 
collection tubes. The tubes were labelled according to the sample being processed. Up to 700µl of the 
Gene, protein and miRNA expression in women with endometriosis 
90 
lysate/ethanol mixture was pipetted onto the respective filter and 30 seconds of centrifugation at a 
maximum of 10,000 rpm were used for the sample to pass through the filter. The flow through was 
discarded and the step above was repeated until all the Lysate/ethanol mixture passed through the filter. 
2.5.6 Avoidance of contamination 
Contamination by RNases from surfaces such as skin is possible with ensuing sample RNA deterioration. 
Gloves were used at all times whilst handling samples. Experiments were carried out in a hood which was 
thoroughly cleaned with RNase Zap® prior to commencing the RNA extraction procedure. RNase Zap® 
was also used to clean equipment utilised for the above process minimising RNase contamination. Care 
was taken to ensure appropriate sample contamination even though a level of contamination affecting 
results may still be possible. 
TABLE 2-2 
Component  Master mix volume per 15-μL reaction† 
100mM dNTPs (with dTTP)  0.15μL 
MultiScribe™ Reverse Transcriptase,50 U/μL 1.00μL 
10✕ Reverse Transcription Buffer  1.50μL 
RNase Inhibitor, 20 U/μL  0.19μL 
Nuclease-free water  4.16μL 
Total volume  7.00μL 
† Each 15-μL RT reaction consists of 7μL master mix, 3μL of 5X RT primer, and 5μL RNA sample 
 
Real time PCR amplification was performed on triplicates of each sample using the TaqMan 2X 
Universal PCR Master Mix (Applied Biosystems
®
). The miRNA 26b is a commonly expressed vertebrate 
miRNA and was used as a control primer for the reactions. The mir-ebv-BART2-5p miRNA was 
validated. Each 20µl reaction contained 1µl of the specific TaqMan
®
 MicroRNA assay (20X), 1.33µl of 
the RT product (diluted 1:15 with nuclease free water), 10µl of TaqMan universal PCR Master Mix no 
AmpErase
®
 UNG, 7.67µl nuclease-free water. Reactions were incubated in a 96 well plate at 95ºC for 10 
minutes, followed by 50 cycles of 95 ºC for 15 seconds and 60ºC for 60 seconds. 
2.6 Blood analysis 
This section describes the techniques used for isolation of peripheral blood lymphocytes and the 
extraction of serum from peripheral blood. It proceeds to describe the techniques for serum miRNA 
extraction and processing. 
2.6.1 Peripheral white blood cell extraction 
Samples were taken from a cubital vein using a sterile vacutainer and needle. Blood was collected directly 
into EDTA vials, was inverted 8-10 times and was stored at a temperature of 4°C until processing. 7mls 
of Lymphoprep™ (LSM1077), a separation solution made with Ficoll™ density gradient media, was 
placed into a 15ml tube. Ficoll™ is a 400 000 Dalton hydrophobic polymer used for the production of 
density gradients for cell separation. Sedimentation is achieved via centrifugation due to gravity. 7mls of 
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blood from the vials was gently trickled down the side of the tube creating a second layer over the 7mls of 
Lymphoprep™ (Figure 2-2 Step 1). 
FIGURE 2-2 
 
Figure depicting technique of Lymphocyte separation and isolation from peripheral blood  
 
Samples were spun at 1500RPM for 25 minutes and the middle layer of white blood cells was collected 
and placed into a fresh tube (Figure 2-2 Step 2). Cells were washed with 3mls of Dulbeco phosphate 
buffered saline (PBS) to maintain cells at a physiological pH range of 7.2-7.6. Cells were then spun down 
for 7 minutes at 1500RPM. The fluid was poured off and the cellular pellet retained (Figure 2-2 Step 3). 
Cells were re-suspended in freeze mix medium (Mix of 350mls Roswell Park Memorial Institute medium 
(RPMI) + 50mls Dimethylsulphoxide (DMSO) + 100mls heat inactivated Foetal Bovine Serum (FBS)) 
and stored at -80°C for future use. 
2.6.2 Peripheral blood serum extraction 
Samples were taken from a cubital vein using a sterile vacutainer and needle. Blood was collected directly 
into a gold topped serum separator vial (SST™ tube), was inverted 5 times and was stored at a 
temperature of 4°C until processing (Figure 2-3 Step 1) The tubes contain silicone and microionised silica 
particles to accelerate clotting. An internal gel composed of a polyester-based proprietary formulation 
separates the serum from red blood cells during centrifugation. The silicone coating reduces red cell 
adherence to blood tube walls. Samples were spun at 2500RPM for 10 minutes. The top serum layer was 
removed and stored at -80°C for future use (Figure 2-3 Step 2). 
FIGURE 2-3 
 
Figure depicting technique of serum isolation from peripheral blood 
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2.6.3 Extraction and processing of endometriosis serum samples 
A set of 51 serum samples were used for the purpose of extracting circulating total RNA, including 
miRNA, and analysing the miRNA profile of the samples. These samples were taken from individuals 
with endometriosis, at various stages of the reproductive phase, (‘case’; 36 samples) as well as healthy 
individuals (‘control’; 15 samples). The samples were randomised and then sequentially numbered (1-51). 
Subsequently, an additional 21 control samples, taken from healthy individuals, were also received and 
processed (see section 2.3 for recruitment criteria). 
All the above samples were processed as described below in the “Norgen Biotek total RNA purification 
kit protocol”) for RNA isolation. Serum was collected in blood vials containing EDTA as the 
anticoagulant. 200µl of serum were used for each sample. The original serum vial was aliqouted into 
smaller volumes preventing multiple freeze thaw cycles possibly affecting the samples. 
2.6.3.1 Lysis 
For cell lysis, 200µl of serum was added to an RNase-free microcentrifuge tube. 300μL of lysis solution 
was added to every 100μL of serum (600µl of Lysis Solution (containing 1% -mercaptoethanol) was 
added) and the sample mixture was vortexed for 10 seconds. 400μL of 95 – 100% ethanol was added to 
every 400μL of the lysate. A total of 800µl of 100% ethanol was added (equivalent to every 100μL 
plasma or serum used). The sample was vortexed for 10 seconds. 
2.6.3.2 Binding RNA to Column 
The RNA extracted was then bound to a column. 600μL of the lysate with the ethanol was placed into a 
column and centrifuged for 1 minute. It was ensured visually that all the lysate volume passed through the 
tube. Spinning for an additional minute was performed if any lysate volume was still present in the tube. 
The flowthrough was discarded and the column was reassembled with its collection tube. 
2.6.3.3 Column Wash 
400μL of 95–100% ethanol was added to the column (for washing) and centrifuged for 1 minute. If the 
ethanol was not seen to have passed the column, the sample was spun for an additional minute. The 
flowthrough was discarded. The steps for washing were repeated twice. The third wash was performed by 
adding another 400μL of 95–100% ethanol and centrifuging for 1 minute. The flowthrough was discarded 
and the spin column was reassembled with its collection tube. The column was spun for a further 2 
minutes to thoroughly dry the resin and the collection tube was discarded. 
2.6.3.4 RNA elution 
To elute the RNA, the column was placed into a fresh 1.7mL Elution tube. 50μL of Elution Solution was 
added to the column and centrifuged for 2 minutes at 200xg (~2,000 revolutions per minute (RPM)), 
followed by 1 minute at 14,000xg (~14,000 RPM). Note the volume eluted from the column. If the entire 
50μL was not eluted, the column was spun at 14,000xg (~14,000 RPM) for 1 additional minute. The 
purified RNA sample was stored at –20°C for a few days or –70°C for long term storage. 
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Once extracted, the samples were quantified (OD260 units) using the NanoDrop ND8000. All samples 
(51) had a final yield over 100ng. Each sample was assigned a new random number for further sample 
randomisation prior to the miRNA labelling. Samples were randomised and the new order for processing 
can be seen in the attached Excel spreadsheets (see ‘Extracted samples_HTS’ tab on the spreadsheet 
[“Endometriosis_HTS_working plate_20120423.xlsx”] and “HTS_Endometriosis Ctrl Samples for 
normalisation.xlsx”). 
2.6.4 Microarray processing 
Microarray processing of all endometriosis serum samples (both original and controls) was carried out 
according to the manufacturer’s procedure outlined in the Agilent Technologies miRNA Microarray 
System with miRNA Complete Labelling and Hyb Kit protocol (Version 2.4). 
Gene, protein and miRNA expression in women with endometriosis 
94 
2.6.4.1 Spike-in solution preparation 
FIGURE 2-4 
 
Spike in solution preparation485 
 
Agilent’s miRNA Spike-In kit (p/n 5190-1934) consists of two miRNA spike-in solutions for process 
control. Their use is to help distinguish significant biological data from processing issues. The labelling 
spike-in solution was spiked into the labelling reaction while the Hyb spike-in solution was spiked into 
the hybridization reaction. Components in the kit were thawed and spun for adequate mixing (Figure 2-4). 
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Five tubes were labelled as ‘1st Dilution Labelling Spike-In’ and an additional 5 tubes ‘1st Dilution Hyb 
Spike-In’. 198μL of the dilution buffer was added to each of the 10 tubes and 2μL of the labelling spike-
in solution was added to each of the 5 tubes that were labelled ‘1st Dilution Labelling Spike-In’. 2μL of 
the Hyb Spike-In solution were added to each of the 5 tubes that were labelled ‘1st Dilution Hyb Spike-
In’ tubes. Tubes were briefly spun and mixed well. One aliquot of the ‘1st Dilution Labelling Spike-In’ 
and ‘1st Dilution Hyb Spike-In’ were used at a time and the other aliquots were stored in freezers at -
80°C. 
Four new tubes were labelled as follows: ‘2nd Dilution Labelling Spike-In’, ‘3rd Dilution Labelling 
Spike-In’, ‘2nd Dilution Hyb Spike-In’, ‘3rd Dilution Hyb Spike-In’ and 198µL of nuclease-free water 
were added into each of the tubes. To make the second dilution solutions, 2μL from the ‘1st Dilution 
Labelling Spike-In’ tube were added into the ‘2nd Dilution Labelling Spike-In’ tube. 2μL from the ‘1st 
Dilution Hyb Spike-In’ tube were added into the ‘2nd Dilution Hyb Spike-In’ tube. Samples were mixed 
and spun briefly. 
To create the third dilution solution 2μL from the ‘2nd Dilution Labelling Spike-In’ tube were added into 
the ‘3rd Dilution Labelling Spike-In’ tube. 2μL from the ‘2nd Dilution Hyb Spike-In’ tube were added 
into the ‘3rd Dilution Hyb Spike-In’ tube. 
2.6.4.2 Sample labelling and hybridization 
Agilent’s miRNA Complete Labelling and Hyb Kit (p/n 5190-0456) generates fluorescently-labelled 
miRNA with a sample input of 100ng of total RNA. This method involves the ligation of one Cyanine 3-
pCp molecule to the 3' end of an RNA molecule. 
2.6.4.3 Dephosphorylation 
The total RNA sample was diluted to 50ng/μL in DNase/RNase-free water. 2μL (100ng) of the diluted 
total RNA was placed in a 1.5mL microcentrifuge tube and maintained on ice. The calf intestinal alkaline 
phosphatase (CIP) master mix was prepared from the following protocol (Table 2-3). 
TABLE 2-3 
CIP Master Mix with labelling spike-in solution 
Components Volume (μL) per 
reaction 
Volume (μL) 
per 9 reactions 
10X calf intestinal phosphatase buffer 0.4 3.6 
Labelling spike-in 1.1 9.9 
Calf intestinal phosphatase 0.5 4.5 
Total volume 2.0 18.0 
Protocol for preparation of calf intestinal alkaline phosphatase (CIP) master mix– Aligent miRNA Microarray 
system with miRNA complete labelling and hybridisation kit 
 
2μL of CIP master mix was added to each sample tube for a total reaction volume of 4μL. 
Dephosphorylation was achieved by incubation at 37°C in a circulating water bath. Denaturation of 
samples was achieved by adding 2.8μL of 100% DMSO to each sample and incubating them at 100°C in 
a circulating water bath for 10 minutes. Samples were then transferred to an iced water bath after 
incubation to prevent re-annealing of RNA. 
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2.6.4.4 Ligation step 
Ligation was achieved by the addition of 4.5μL of the ligation master mix to each sample tube for a total 
reaction volume of 11.3μL. Samples were gently mixed and incubated at 16°C in a circulating water bath 
for 2 hours. The samples were then dried using a vacuum concentrator at 45 to 55°C. Samples were 
deemed dry when pellets were seen not to move or spread on tube flicking. Completely drying the sample 
ensured that there was no residual DMSO which would adversely affect the hybridization results. 
2.6.4.5 Hybridisation step 
For hybridisation, a water bath was prepared at 100°C. The dried sample was re-suspended in 17μL of 
nuclease-free water. The 10X blocking agent was reconstituted in 125μL of nuclease-free water and 
4.5μL of the 10X blocking agent was added to each sample. 22.5μL of 2X Hi-RPM hybridization buffer 
was added to each sample for a total of 45μL. The sample was mixed well on a vortex and was incubated 
at 100ºC for 5 minutes. It was then immediately transferred to a water bath for 5 minutes. Samples were 
then quickly spun to collect condensation at the base of the tube. 
2.6.4.6 Preparation of the hybridization assembly 
The slides were successfully scanned (Agilent Scanner C, at 3 microns) and feature extracted (using 
Agilent Feature Extraction software, version 10.7.3). 
For instructions on how to load slides, assembly and disassembly of chambers, the Agilent Microarray 
Hybridization Chamber User Guide was used (G2534-90002). A clean gasket slide was added into the 
Agilent SureHyb chamber base with the label facing up and aligned with the rectangular section of the 
chamber base. It was ensured that the gasket slide was flush with the chamber base and not ajar. For 
Agilent scanning and feature extraction, the slides were positioned so that the barcode label was on the 
left and samples were loaded left to right. Slow dispension of all of the volume of the hybridization 
sample into the central gasket well was performed. Care was taken to avoid bubble trapping. An array 
‘active side’ was slowly placed down onto the SureHyb gasket slide so that the ‘Agilent’-labelled barcode 
was facing down and the numeric barcode was facing up. Verification that the sandwich-pair was 
properly aligned was ascertained. The SureHyb chamber cover was placed onto the sandwiched slides and 
the clamp assembly was slid and tightened onto both pieces. The assembled chamber was vertically 
rotated to wet the gasket and assess the mobility of the bubbles. The assembled slide chamber was placed 
in rotisserie in a hybridisation oven set to 55°C at 20 rpm for 20 hours. 
2.6.4.7 Microarray wash 
2mL of the provided 10% Triton X-102 were pipetted into the wash buffer 1 and 2 respectively in the 
cubitainer. The caps of the cubitainer were replaced and the solutions were mixed. 1000mL of Gene 
Expression Wash Buffer 2 was added directly into a sterile 1000mL bottle and placed in a 37°C water 
bath the night before the washing of the arrays. A slide-staining dish (dish 3) was placed into a 1.5L glass 
dish three-fourths filled with water. This was warmed to 37°C by storing overnight in an incubator set to 
37°C. All equipment was washed copiously with Mill-Q water to remove contaminants. 
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Slide-staining dish 1 was filled with gene expression wash buffer 1 at room temperature. A slide rack was 
placed into slide-staining dish 2 and a magnetic stir bar was added. Slide-staining dish 2 was filled with 
enough Gene Expression Wash Buffer 1 at room temperature to cover the slide rack and this dish was 
placed on a magnetic stir plate. The pre-warmed 1.5L glass dish was filled with water and contained 
slide-staining dish 3 on a magnetic stir plate with the heating element. Slide-staining dish 3 was filled to 
approximately three-fourths capacity with gene expression wash buffer 2 warmed to 37°C. A magnetic 
stir bar was added and the heating element maintained the gene expression wash buffer 2 at 37°C. A 
thermometer was used to check the temperature. One hybridisation chamber was removed from the 
incubator. The time and presence of any bubbles was recorded. Any significant loss of hybridisation 
volume was noted. 
2.6.4.8 Hybridisation chamber disassembly 
The hybridisation chamber assembly was placed on a flat surface and the thumbscrew was loosened 
turning counter-clockwise. The clamp assembly was slid off and the chamber cover removed. The array-
gasket sandwich was separated from the chamber base by grabbing the slides from their ends. The 
microarray slide numeric barcode was kept facing up as the sandwich was transferred to slide-staining 
dish 1 containing Gene Expression Wash Buffer 1. The sandwich was opened from the barcode end whist 
submerged in Gene Expression Wash Buffer 1 and a forceps was used to release the slide form the gasket. 
The slide was then placed into the slide rack in slide-staining dish 2 containing Gene Expression Wash 
Buffer 1 at room temperature. When all slides were placed in the slide rack, the rack was stirred on 
moderate speed for 5 minutes. The slide rack was transferred to slide-staining dish 3 containing Gene 
Expression Wash Buffer 2 at 37°C. It was stirred once again at moderate speed for 5 minutes. The slide 
rack was gently removed to minimise droplets and slides were transferred to a slide holder. The slides 
were scanned immediately to avoid effects on signal intensity by environmental oxidants. 
2.6.4.9 Scanning and feature extraction 
FIGURE 2-5 
 
Image demonstrating the microarray mount for scanning485 
 
Gene, protein and miRNA expression in women with endometriosis 
98 
The protocol from the Agilent microarray scanner user guide was used. The slide holders were placed into 
the SureScan cassette and miRNA settings were verified according to manufacturer’s recommendations 
(Figure 2-5). All original serum samples and additional endometriosis control samples were successfully 
processed. The attached Excel spreadsheets (see “Plate3_(1-53)_ExperimentalSummary.xlsx” and 
“Plate1_(1-21)_ExperimentalSummary.xlsx”) outlines the sample hybridisation layout scheme for the 
respective sample sets (i.e. the slide number and array area used for each sample). The slides were 
successfully scanned (Agilent Scanner C, at 3 microns) and feature extracted (using Agilent Feature 
Extraction software, version 10.7.3). 
2.7 Tissue microarray (TMA) 
Tissue microarrays consist of tissue cores from paraffin blocks which are situated in a sequenced fashion 
to allow multiplex histological analysis. Tissue blocks containing multiple samples were first introduced 
in 1986 by H. Battifora named ‘multitumor (sausage) tissue block’486. In 1990 this was modified and 
improved and renamed ‘the checkerboard tissue block’487. The current utilised technique was finalised by 
J. Kononen in 1998 and it involved the production of a block with similarly sized and shaped tissues, 
enabling a more precise and dense platform to work on
488
. Modern microarrays provide a platform 
enabling collation of hundreds of patient specimens, at different disease stages and sites. Thousands of 
genes and proteins can then be analysed in a single experiment. Analysis of various tissue pathologies and 
their gene or protein expression profiles helps in establishing and understanding the diagnostic, 
prognostic and therapeutic response outcomes of the pathology in question. 
The development of endometriosis has been linked to inflammatory, apoptotic and angiogenic pathways. 
The genes and signalling pathways involved in the above all hold a key into the development of the 
disease. It is through identification of these genes that novel understanding and therapies are possible. 
Due to the stringent criteria used, the number of patients recruited at surgery was low. To create a 
microarray with adequate numbers of tissues, 200 tissue blocks were retrospectively recruited from the 
histology database at Barts and the London NHS Trust. Identification of confirmed histological 
endometriosis was performed by a consultant histopathologist and samples were subdivided into groups 
according to the site, type and extent of the pathology identified. Malignancies were excluded and all 
slides were duly coded. 
Tissues of interest were identified and confirmed by histopathologists from a haematoxylin and eosin 
stained section. Criteria relating to the tissues themselves such as hormonal influences, site of specimen 
biopsy and areas of pathology were recorded. A hollow needle (1 mm
2
) was used to remove tissue cores 
of interest from the original biopsy and these cores were then inserted in a recipient paraffin bock in a 
predefined and precisely spaced array pattern. A microtome was then used to cut sections (5-10 
micrometres) in thickness to produce between 100-500 arrays which were utilised for immunostaining. 
Most endometriotic lesions are histologically heterogenous in nature with the possibility of creating a 
false representation of the pathology. To minimise this discrepancy, triplicate cores were taken from each 
sample. 
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2.7.1 Immunohistochemistry protocol 
2.7.1.1 Slide preparation 
TMAs were mounted onto adhesive coated slides to minimise compromisation of tissue adherence during 
heat-induced epitope retrieval especially with fatty or bloody tissue. Slides were labelled with the 
appropriate information and were incubated at 60ºC for 12 hours prior to processing. 
2.7.1.2 De-waxing and de-hydration 
To de-wax and de-hydrate the slides, these were placed in de-waxing xylene in the fume cupboard for 5 
minutes. They were then transferred into IMS solution for two minutes. Endogenous peroxidise activity 
was blocked by placing the slides into 2% hydrogen peroxide in IMS solution for 5 minutes. Slides were 
then transferred into final IMS solution for 2 minutes and were afterwards rinsed in running tap water for 
5 minutes. 
2.7.1.3 Antigen retrieval 
Three litres of vector antigen unmasking solution (50mls of Vector unmasking solution 3300 diluted in 
5000mls of distilled water) were placed into the pressure cooker and the temperature was set at 450ºC. 
Once the solution boiled, the slides were inserted and left within it for 10 minutes. The solution was 
cooled down with the addition of running ambient temperature tap water for approximately 5 minutes. 
Preparation of 500mls of wash buffer (Tris-buffered saline with tween (TBS-T)) was performed by 
mixing one part of wash buffer solution with 9 parts distilled water. (i.e. 50mls wash buffer with 450mls 
distilled water). Slides were removed from the ‘cooker’ and placed into a trough with wash buffer. 
2.7.1.4 Tissue microarray immunohistochemical staining and analysis 
For Maspin, E- Cadherin, B-cell lymphoma 2 (Bcl-2)-associated transcription factor (BCLAF) and p53 
the SS-enhanced Polymer detection system (Biogenix) was applied using the Dako-autostainer system 
(Dako). Incubation with optimally diluted primary antibody in BSA and sodium azide (Table 2-4) was 
performed following antigen retrieval. Staining enhancement was achieved by adding enhancer reagent 
increasing the antigen location-specific horseradish peroxidase (HRP) activity. Subsequent incubation 
with chromogen, 3,3’-diaminobenzidine (DAB) produced a brown precipitate at the antigen site. Sections 
were counterstained with haematoxylin. 
The ARIOL imaging system (Genetix, San Jose, CA) was used for TMA antibody staining quantification. 
Slides were scanned at low resolution (1.25x) followed by high resolution (20x) using the Olympus BX61 
microscope with an automated platform (Prior). Training and stain quantification was performed on the 
high resolution images. Training of the system for detection of stained and unstained cells by the colour 
intensity and shape of stained regions was performed. Positive staining, as determined by appropriate 
isotype negative controls, was classified by manually defined hue, saturation and intensity limits. Only 
epithelial areas were analysed through the use of the manual include/exclude drawing tool (Figure 2-6). 
The software generated the mean intensity (0-255) of all pixels considered positive, which was 
subsequently corrected so that the higher the value, the greater the intensity. Results were exported to an 
Excel sheet and non-parametric statistical analysis was performed on each of the subgroups using a 
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Mann-Whitney U Test. A P value of <0.05 between the groups was regarded as statistically significant. 
The resulting data was then plotted graphically. 
TABLE 2-4 
Antigen Clone Dilution Supplier 
Maspin Clone EAW24 1:100 Novocastra 
E Cadherin Clone 36B5 1:200 Novocastra 
BCLAF Rabbit polyclonal Dilution 1:100 Sigma Prestige 
p53 Clone D07 Dilution 1:3000 Dako 
 
FIGURE 2-6 
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2.8 Protocol for protein biomarker serum study 
Below is the protocol used for the assay of binding of human serum antibodies to protein arrays and their 
detection to determine the binding profile for particular samples. 
2.8.1 Assay precaution 
Virkon was not used in the vicinity of the assay work as it could cause increased general fluorescence 
across the array. The work area, assay implements and gloves were all kept scrupulously clean during 
assay to prevent contamination of the assay solutions and arrays. Slides were not wiped on coloured paper 
towels as these may contain soluble fluorescent dye. Buffers were prepared and ready for use (0.1% v/v 
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Triton/0.1% w/v bovine serum albumin (BSA) in phosphate buffered saline (PBS)). Three litres of spiked 
assay buffer (SAB) buffer were required to assay 24 arrays. 
The computer was switched on and the VisionMate scanner software loaded. The workstation and a 
laminar flow class II cabinet were cleaned. A disinfectant bath was prepared using a 1% solution of 
Virkon or Trigene for the disinfection of wash, probing solutions and plasticware. To avoid interference 
with results, Virkon contaminated materials were kept away from the assay work bench. 200 mL cold 
SAB was poured into a slide processing box and left at 4°C until required. 2 litres of SAB were poured 
into a 2L Duran bottle and equilibrated to 20ºC for 30 min in a designated Techne circulating water bath. 
A 50mL laboratory dispenser was fixed to the bottle before use. 1 litre of SAB was poured into a 1L 
Duran bottle and equilibrated to 20ºC for 30 minutes in a designated Techne circulating water bath. A 
10mL laboratory dispenser was fixed to the bottle before use. The required number of 15mL Falcon tubes 
were numbered from 1 up to 24 and placed in order in a polystyrene tube rack. 4.5mL of SAB (20 ºC) 
were pipelled into each tube using the designated Hirschmann laboratory dispenser. The Quadriperm 
dishes were labelled on the bottom below each chamber with consecutive numbers corresponding to the 
number of samples (up to 24). 24 Pap jars were placed into a suitable rack and labelled with consecutive 
numbers corresponding to the number of samples (up to 24). The lids for the Pap jars were placed in a 
box ready for use in the work area. The bowl of the Sorvall Legend centrifuge was cleaned to remove any 
dust. Samples were checked and numbers confirmed by two independent laboratory personnel to ensure 
correct labelling. Samples within the assay rack were not allowed to thaw unnecessarily unless ready for 
processing. These were placed into the scanner rack according to their designated numbers and the 
VisionMate software was run inputting the relevant sample details for each. Each sample was visually 
checked to ensure that each of the tubes had sufficient serum (22.5µL) for the assay. The plate was 
carried in a containment tray and placed in the Medline shaking incubator to thaw at 20°C for 30 minutes. 
When completely thawed, each sample was vortexed for a count of three at full speed (IKA Vibramax). 
The tubes were placed in assay order starting at position 1 in a designated Eppendorf microcentrifuge. A 
plastic Rawplug support was required in each tube to support the TrakMate tubes. The serum samples 
were centrifuged for 3 minutes at 13000rcf using a designated Eppendorf microcentrifuge. 
The tubes were then removed from the centrifuge and replaced in the TrakMate rack in the same order 
and positions that they were taken i.e. A1 to B24. The serum samples were diluted in SAB buffer to 
provide the assay solutions. Care was taken not to disturb the vortexed samples with movement. 100µL 
pipettes were used to pipette 22.5µL of the sample into 4.5mL of SAB Buffer. In case of sediment, care 
was taken to tilt the tube when aspirating to ensure that the sera were sampled from below the lipid layer 
at the top but did not touch the bottom of the tube. The samples were gently vortexed. 
2.8.2 Assay set up 
2.8.3 Washing and probing the arrays 
The slide box and rack containing 200mL cold SAB were place in the containment tray. Each array was 
removed in turn using forceps from its storage buffer. The excess liquid from the array was drained by 
touching the edge of the array on the rim of the Pap jar. The assay rack was lifted from the slide staining 
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dish and placed in a slot with the array facing towards the second slot. It was replaced in the staining dish 
solution. Each slide in the slide box from left to right was in turn added to the slide rack with 200mL cold 
SAB making sure the slides were all in the same orientation. When all the arrays were added, the rack 
was gently shaken up and down five times to aid mixing at the slide buffer interface. 
The lid was placed on the slide box and shaken at 50 rpm for 5 minutes on an orbital shaker (IKA 
KS501). 4.0 mL of each diluted sample from the 15mL Falcon tubes was pipetted into their 
corresponding chambers in the Quadriperm dishes. When the slides finished washing they were removed 
in order from the rack. Slides were gripped from their labels and the back of the array was wiped using 
colour free Kimwipe tissue paper. The long edge of the array was blotted three times on a wad of lint free 
tissue paper. 
The array was immediately placed into the probing solution in the correct chamber of the Quadriperm 
dish. The plate was gently swirled to cover the slide with incubation solution after which the next slide 
was added. Sample identification was double checked at all stages ensuring no sample errors. To prevent 
slopping of solutions between chambers, the lids of the Quadriperm dishes were replaced and it was 
ensured that the dishes were kept horizontal at all times. The dishes were placed in the Medline shaking 
incubator and shook at 50 rpm during incubation at 20ºC for 120 minutes. 
2.8.4 Washing after serum binding 
Towards the end of the incubation period the 24 Pap jars were filled with 30mL of SAB using a 
laboratory dispenser (Eppendorf). An empty Nalgene tube rack was used to hold the Pap jars on the 
horizontal shaker (IKA KS501). When the incubation time was over, each array was removed from the 
Quadriperm dishes and washed individually in a Pap jar. The Pap jar was capped and inverted 4 times 
before placing in the Nalgene rack on the orbital shaker and shook at 50 rpm at 20ºC for 20 minutes. 
After the 20 minutes incubation had finished, the first array was taken and the wash solution was poured 
off into an empty beaker. Another 30 mL of SAB was dispensed into the tube at the back of the array and 
the Pap jar was inverted four times and again placed in the empty Pap jar rack on the shaker at 50 rpm at 
room temperature for 20 minutes. The remaining tubes were each processed in turn. 
When incubation was complete, a slide staining box and rack were taken and 200mL of SAB was added. 
The first Pap jar was taken and the buffer was poured off. The array was placed in the second position in 
the slide rack with the array facing towards slot 1. The rack in the buffer was placed in the slide staining 
box. The remaining arrays were added sequentially until all slides were transferred. The slide rack was 
replaced in buffer during the addition of each array. When all the arrays were added, the slide rack was 
gently moved up and down five times to aid mixing. The lidded box was placed onto a shake (IKA 
KS501) for the remainder of the incubation time and was shaken at 50 rpm at room temperature. 
Preparations were made for the secondary antibody probing solution process. 
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2.8.5 Incubation with Cyanine dye 3 (Cy3)-anti Immunoglobulin G (IgG) 
200mL of SAB were measured at 20ºC into a volumetric flask and 200L of Cy3-antihuman IgG was 
added. Mixing was performed by repeated inversion. The resulting solution was poured into a fresh slide 
staining box and covered until required. 
The rack of arrays (described above) was removed from the wash solution and placed on a wad of 
Kimwipe tissues. Then it was gently tapped on the tissues five times to remove excess wash buffer. The 
arrays were then immediately placed in the Cy3-antihuman IgG solution. The rack was shaken up and 
down five times to help mixing of the probing solution at the surface of the arrays. The box was then 
covered and placed in a medline shaking incubator at 50 rpm at 20ºC for 120 minutes incubation time. 
2.8.6 Washing after incubation with Cy3-anti IgG 
Towards the end of the incubation period a slide staining box was filled with 200mL SAB buffer at 20°C. 
When the incubation had finished, the slide rack was lifted from its incubation solution and placed into 
the fresh SAB wash solution. The rack was agitated gently up and down five times. The lid of the 
container was replaced and shaken for 5 minutes at 50 rpm at room temperature (IKA KS501). After the 
first wash, the slide rack was lifted out of the dish and the buffer poured off into a beaker and replaced 
with 200 mL of fresh SAB buffer (20ºC). The rack was gently shaken up and down five times, the lid was 
replaced and the container shaken for 5 minutes at 50 rpm at room temperature (IKA KS501). This was 
repeated for the third wash. 
When the third wash had finished, the slide rack was lifted out of the dish and the SAB was poured off. 
The box was filled with high purity water. The slide rack was placed in the water and shaken gently up 
and down five times. The lidded box was then placed on the shaker at 50 rpm for 10 seconds to ensure 
that buffer components were washed from the slide rack and arrays. 
A wad of Kimwipe tissue was placed in the containment tray and two layers of Kimwipe tissues were 
placed into the bottom of a dry slide staining box. The slide rack was removed from the dish and placed 
on the wad of tissues, banging it gently five times to remove any excess water. The slide rack was placed 
in the fresh staining box on top of the Kimwipe tissues. The box was lidded and moved to the Sorval 
centrifuge. The staining box lid was removed and the box placed in a microtitre plate holder and a 
balancing rack was added. The arrays were dried by centrifugation for 2 minutes at 240xg at 20°C. The 
slide rack was moved to a clean bench and each slide was loaded into an Agilent type 2 slide-holder. 
Once all slides were transferred the lid of the holder was shut and the slide holder was placed into an 
Agilent slide carousel. The samples were then transferred from the slide rack into a pre-labelled slide box 
in preparation for scanning. 
2.9 Protocol for DNA extraction from peripheral blood lymphocytes 
In the section below I outline the technique used for DNA extraction from peripheral blood lymphocytes. 
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The Maxwell® 16 SEV Instrument and Maxwell® 16 Blood DNA Purification Kit enabled extraction of 
DNA from 300µl of patient lymphocytes suspended in elution buffer. The lymphocytes were previously 
extracted from whole patient blood (see previous protocol for peripheral white blood cell extraction). The 
manufacturer’s protocol for the Maxwell® 16 Blood DNA Purification Kit was followed and the resulting 
extracted DNA was checked on the Nanodrop® machine for concentration and purity. 
2.10 Cell culture from primary patient samples 
Primary patient samples were used for in vitro therapeutic experiments. Below I describe the techniques 
employed to create a cell culture from primary patient samples obtained at surgery. I also describe the in 
vitro therapeutic studies performed in 96 well plates to test for Galectin inhibitor effects on primary 
patient cells. All cell cultures were tested in the laboratory for mycoplasma every three months and 
remained negative. 
2.10.1 Fresh medium preparation 
The base medium DMEM with high Glucose and Pyruvate (500mls bottle) was purchased from 
Invitrogen®. This was left to warm up to room temperature prior to usage. 50mls of heat inactivated fetal 
calf serum (FCS) (56 ºC for 30 minutes), 5mls of L-Glutamine and 5mls of Penicillin/Streptomycin was 
added at room temperature into the above solution. The bottle was then labelled, dated and used up to a 
maximum of four weeks. The medium was heated to 37ºC prior to usage with cells. 
2.10.2 Primary patient cellular sample preparation 
Primary patient endometriosis samples were taken at laparoscopy. A scalpel was used to scrape 
endometriosis cells and fragment tissue from the surfaces of endometriotic plaques and endometriomas by 
manual techniques. This manual fragmentation technique minimised the destruction of cells as happens 
with automated mechanical methods such as morcellation. The collected tissue samples were also 
separately sent to histology to confirm the presence of endometriotic cells. Samples were suspended in 
growth medium between transfers from the operating theatres to the cell culture laboratory minimising 
cellular death in transport. In the laboratory, cells and tissue debris were filtered through standardised 
cellular meshes to remove debris. Cells were washed and re-suspended in fresh medium and subsequently 
placed in 0.1% collagenase for 1 hour. A Vi-Cell® XR Cell Viability analyser was used to assess for 
cellular concentration and viability. Cells were then centrifuged at 1200rpm for 5 minutes and the pellet 
was re-suspended in culture medium for tissue culture. The cells were suspended (at a concentration of 
1x10
5
 cells per ml) in flasks and allowed to grow in culture incubators at 37ºC at 5% CO2 for 5 days or 
until confluence was seen at the base of the flask. Endometriosis cells were seen to be adherent to the 
base of the culture flasks and were slow growing in nature. 
2.10.3 Using the hood in a cell culture room 
The hood was wiped clean with 70% IMS. It was ensured that flow and lighting were working correctly. 
All solution bottles and disposable equipment were opened inside the working hood to minimise 
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contamination. Disposable instruments were utilised at all stages. To endure optimal growth conditions, 
the correct media were assigned to the particular cells being cultured. 
2.10.4 Cell splitting 
At the start of splitting, cells were viewed under the microscope for assessment of their starting density 
and confluence. The adherent cell lines were grown on the inferior surface (A) of the flask (Figure 2-7). 
FIGURE 2-7 
 
Diagram of a culture flask 
 
The flask was rotated by 90º onto surface (B) and a suction pipette was placed at point (C) to remove the 
‘old’ medium in which cells were growing. Maintaining the flask in the same position, surface (A) was 
then rinsed with 5mls of sterile PBS. This enabled the removal of any remaining FCS allowing the next 
trypsinisation step to work effectively. The added PBS was again removed carefully from point (C) 
without disrupting the cellular layer on surface (A). The flask was maintained in the upright position 
whilst 6mls of trypsin were added on to surface (A). The flask was sealed and placed gently back onto the 
incubator at 37º and 5% CO2 for 10 minutes. This enabled cell trypsinisation and detachment of the 
adherent cell line from surface (A). The cells were assessed under the microscope every 5 minutes to 
ensure that the amount of time trypsin was in contact with the cells was kept to a minimum. 
When the cells were seen to detach, the flask was replaced into the hood onto surface (B) and 6mls of 
warmed medium (at 37º) were added onto the 6mls of previously applied trypsin to dilute the latter’s 
effect. The resulting mixture was gently pipette at point (C) to ensure that any clumping of cells was 
minimised. The mixture was transferred into 15ml tubes and centrifuged at 1500rpm for 5 minutes at 
21ºC to obtain a cellular pellet. The supernatant was poured off into a beaker with Virkon® leaving the 
cellular pellet behind. The pellet was then gently re-suspended into 10mls of fresh medium. Minimisation 
of cellular clumping and adequate re-suspension was ensured through gentle pipetting. 
500microlitres of the new suspension were placed into cell counting containers and the sample was run on 
the Vi-Cell® XR Cell Viability analyser to assess for cellular concentration and their percentage viability. 
The Vi-Cell® is an automated haemocytometer which takes up the sample delivering it to a flow cell and 
camera (Table 2-5). It utilises the trypan blue protocol (1:1 mixture with cellular volume provided). Dead 
cells are seen to absorb dye whilst live ones do not. The camera elicits grey scale alterations between 
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viable and non-viable cells which are software predetermined. Fifty images per sample are used to 
determine the final outcome
489
. 
TABLE 2-5 
System specification Acceptable ranges 
Cell Diameter Range  3 to 70μm 
Cell Concentration Range  5 x 104 to 1 x 107 cells/mL 
Viability Range  0%-100% 
Counting Accuracy  ±6% 
Sample Volume  0.5mL to 2.0mL 
Acquisition Time  2 minutes 
 
2.10.5 Re-suspending cells for new culture flasks 
1x10
5
 healthy cells were transferred into a new flask for growth. Parameters used to calculate this depend 
on % viability, viability of cells/ml x10
6 
and cells/ml x 10
6
. The following is an example of calculating 
volume amounts for transfer into new growth flasks (Table 2-6). 
TABLE 2-6 
Cell type Viability% Viability cls/ml x 10
6
 Cls/ml x 10
6 
Endometriosis Cell line X 97.4 3.99 4.10 
 
This table indicates that there are 3.99 x 10
6 
viable cells per ml resulting in an overall 97.4% viability of 
my culture in this sample. I aimed to re-suspend the cells into 20mls of fresh medium and needed to 
calculate how many millilitres of the original medium with the re-suspended cells I required. 
In 1ml I had 3.99 x 10
6
 cells i.e. 39.9 x 10
5 
cells. There is a current total of approximately 10mls of this 
mixture. I needed to calculate how many millilitres of this mixture would enable me to transfer1x10
5 
cells 
into a new flask. 
Therefore the calculation is as follows: 
1/39.9 x 20 mls = 0.5mls of medium with the re-suspended cells 
 
This will be added to 20mls - 0.5mls = 19.5mls of fresh medium into the new flask. The new flask is then 
labelled, dated and annotated. Any remaining cells were frozen in liquid nitrogen for future use. 
2.10.6 Freezing cells in liquid nitrogen- cryopreservation 
When culturing cells, cultures can vary from the initial sample due to variations in cell growth and 
proliferation. There is a tendency for the most rapidly proliferating cells to dominate the culture with 
slower or less proliferating ones eventually dying out. This gives an altered cellular picture which is not a 
true reflection of the original or primary culture. Senescence is the natural limitation of normal cells to die 
out after a fixed number of replications. It is a multifactorial gene occurrence and is thought to be due in 
part to the terminal DNA sequences situated in the telomeres to replicate at each cellular split. Telomeres 
will progressively grow shorter until the inability to divide further is reached
490
. Tumour cells are not 
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limited by this mechanism, being able to replicate terminal DNA sequences in the telomeres. Instability 
within genes or phenotypes also renders the necessity of cryopreservation. Overall, finite human cell lines 
are genetically stable
491
, but care must be taken to avoid and recognise cellular mutations once they occur. 
In vitro spontaneous rates are noted to be higher than in vivo ones and once mutant cells are present they 
are not eliminated as would occur in an in vivo scenario. Other factors including the possibility of cell 
line contamination by microorganisms, cross contamination with other cell lines, misidentification of 
cells due to carless handling, incubator failure and the future need to possibly distribute to alternate 
users
491
, all make cryopreservation a sensible, time and material sparing step in current laboratory 
practice. Minimising the intracellular ice crystal formation and cryogenic damage from solutes of high 
concentration on intracellular freezing is what enables the best recovery and growth of cells after they are 
thawed. Four steps are advised in cell culture literature
491
: slow freezing to allow water exit from the cell 
but not slow enough to encourage the formation of ice crystals; using a hydrophilic cryoprotectant to 
sequester water (called a freeze mix (Table 2-7)); storing cells at the lowest possible temperature to 
minimise the effect of ice formation within the cell; and ensuring a rapid thaw minimising ice crystal 
expansion and solute formation on the melting of intracellular ice. The prepared samples are then stored 
in liquid nitrogen. 
TABLE 2-7 
Freeze mix composition 
20% DMSO 
50% FCS 
30% Medium- Invitrogen® (Dulbecco's Modified Eagle Medium (DMEM) with high Glucose and 
Pyruvate 500mls bottle) 
50mls of heat inactivated FCS (56ºC for 30min) and 5mls of Penicillin/Streptomycin. 
 
Liquid nitrogen is a colourless liquid with density of 0.807 g/mL. It is produced by fractional distillation 
of liquid air and has a boiling point of -196°C/-321°F and a freezing point of -210°C/-346°F. It causes 
rapid freezing of living tissues and is therefore perilous to the user if not handled with care. It is used in 
laboratories primarily to freeze tissues for storage to minimise cryogenic tissue damage. 
2.10.7 Preparing the cells for liquid nitrogen storage 
The cellular pellet was re-suspended in 3mls of freeze mix (Table 2-7) and pipetted gently to avoid 
clumping. 1ml of the cell suspension was then transferred to cryophials and these were labelled recording 
the cellular concentrations at which they were frozen. The cryophials were then placed into Nalgene® Mr 
Frosty™ Cryo 1ºC freezing container (Nalgene Cat. No. 5100-0001) enabling slow freezing. The 
container was left overnight at -80ºC. After 24 hours, the cryophials were transferred from the container 
into the liquid nitrogen Dewar tank (Custom Biogenic Systems (CBS) Isothermal V-1500 series) for long 
term storage. 
2.10.8 Thawing cells 
To minimise ice crystal expansion and solute formation on the melting of intracellular ice, ampules were 
quickly thawed under hot water or in a water bath. Ampules were then swabbed thoroughly with 70% 
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alcohol and opened in a laminar-flow hood. Cellular contents were transferred into labelled 15ml 
centrifuge tubes using a 1ml pipette. 10ml of pre-warmed medium were slowly added dropwise to the cell 
suspension over 2 minutes. Cells were then centrifuged at 1200 rpm for 5 minutes. The supernatant was 
discarded and cells were re-suspended in 10ml pre-warmed medium with 20% FCS. Cells were then 
transferred to labelled culture flask and were counted using Vi-Cell ® XR Cell Viability Analyzer. 
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3 Clinical perspectives- symptom analysis post-surgery 
3.1.1 Methods 
Patients were asked pre-operatively and at 6 and 12 months post-operatively to rate their symptoms over 
the previous month. Their general level of health was compared to that in the previous year. Detailed 
questions assessed their limitation on daily activities, social activities and work due to physical and 
emotional problems secondary to disease, levels of bodily pain and its interference with physical, social 
or emotional activities (Figure 3-1). (See section 1.12) 
3.1.2 Discussion 
FIGURE 3-1 
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A comparitive graphical rapresentation of limitations experied by endometriosis patients in the pre-opeartive period, 
six months post operatively and at one year post-operatively. 
 
Within 6 months of surgery, there was an overall improvement in general health of patients with 61.9% of 
the study patients reporting good overall health levels 6 months post-surgery compared to 31.6% 
preoperatively (P=0.031). Within a year, reports of the same patients reporting good levels of health fell 
to 35.3% which is similar to the pre-operative value of 31.6% (P=1). This is in keeping with the short 
term reported benefits of surgery with high relapse rates necessitating future surgery with increased 
patient morbidity. There was a small observed increase in the percentage of people reporting excellent 
levels of health at 1 year post surgery (11.7%) when compared to pre-operative levels of 5.3%. This 
however did not reach statistical significance (P=0.576). Interestingly within six months of surgery 0% of 
my study population classified their health as excellent and values were only seen to rise within the 6 
month to 1 year post-operative recovery period. 
In the pre-operative questionnaires, 5.3% of the study population described their health as fair to poor. 
Within six months of surgery these reports increased to 14.3% (P=0.329) reaching 17.6% at one year 
(P=0.329). The reason for this rise is a question of debate. Whilst some might argue that post-operative 
scarring can contribute to worsening of pain and discomfort, others might attribute perceived increased 
levels of poor health as a result of the negative psychological impact on patients once a diagnosis of 
endometriosis has been made. 
Interestingly, when patients were asked to compare their post-operative overall health levels, one year 
following their surgery, to the one year prior to their surgery, the responses was positive. Within 6 months 
of surgery, 23.8% felt their health had significantly improved when compared to 10.5% pre- operatively 
(P=0.186). This percentage increased to 41.2% at one year (P=0.096). There was a decrease in the patient 
groups reporting the worst levels of pre-operative general health, with a reduction from 26.3% to 0%  
(P=0.021) within 6 months of surgery and a further increase to 11.8% at the one year follow up 
(P=0.267). From the 5.3% of patients who believed their health was progressively worsening pre-
operatively, there was an observed reduction to 4.8% within six months of surgery (P=1) and this fell to 
0% at one year post surgery (P=0.329). 
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The ability to perform moderate activities was reported as limited in a total of 21% of the study patients in 
the pre-operative period. This percent fell to 9.5% within 6 months and to 0% at their one year follow up 
(P=0.162). Within 6 months of surgery 71.4% of patients did not report any limitations in performing 
daily vigorous activities in comparison to the 57.9% in the pre-operative period (P=0.213). This 
percentage totalled out to 70.6% of the study population at one year post-operatively (P=0.747). 
Restrictions in daily functions such as lifting or carrying objects, climbing flights of stairs, bending and 
kneeling, walking a mile and bathing or dressing showed improvements at the one year post-operative 
follow up in the patient groups reporting the worst pre-operative symptoms. Respective results were as 
follows: lifting or carrying objects (10.5% to 0% (P=0.162)), climbing flights of stairs (26.3% to 0% 
(P=0.021)), bending and kneeling (10.5% to 0% (P=0.162)), walking a mile (15.8% to 0% (P=0.082)) and 
bathing or dressing (10.5% to 0% (P=0.082)). 
FIGURE 3-2 
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A comparative graphical representation of limitations due to the negative emotional impact experienced by 
endometriosis patients in the pre-operative period, six months post operatively and at one year post-operatively. 
 
In the questionnaires I also assessed the activities which could be impacted by psychological rather than 
physical symptoms. 
Patients were asked whether they had cut down on time from work (See section 1.13.2). In the pre-
operative period, 58% of my patient group had never cut down on work due to symptoms of 
endometriosis. In the one year after their operation, this number rose to 77% (P= 0.54) potentially 
indicating a positive impact in patients pain or psyche after diagnosis and treatment (Figure 3-2). 
Other studies confirm the deterioration in the work life productivity of patients with endometriosis, at an 
average of approximately 10 hours per week compared to 7 hours in non-affected women
4
. At one year 
post laparoscopy, 82% of patients reported that their health no longer restrained or limited their work 
achievements compared to 68% pre-operatively (P=0.77). The percentage of study patients who felt they 
required an increased level of effort to perform work tasks and who had difficulty performing their work 
tasks fell by 19% at one year post-operatively. 77% reported no work impediment in the one year post-
operative time period compared to the 58% pre-operatively (P=0.576). (Figure 3-2) 
Patients were also asked how they felt emotionally (Figure 3-2) and how this impacted their work. Of my 
pre-operative patient population 58%, reported no adverse impact on their work. This improved to 67% 
(P=0.266) within six months of surgery and 88% after a one year (P=0.296). Reduction of 
accomplishments due to emotional barriers was also assessed. At 6 months 71% (P=0.004) and at one 
year 94% (P=0.04) of my post-operative patient population felt no reduction in their work of life 
accomplishments due to disease. This contrasts with the 42% of the study population who had claimed 
they were not impacted by disease pre-operatively. This confirms an increase in patient accomplishment 
previously impeded due to the emotional impact of endometriosis on their lives. 
Non-specific bodily pain levels interfering with work was assessed (Figure 3-2). Pre-operatively, 21% of 
my patient population had no issues with bodily pain affecting daily work. At six months post-operatively 
this increased to 38% (P=0.162) and further increased to 71% at the one year follow up (P=0.042). 
Gene, protein and miRNA expression in women with endometriosis 
118 
In my study I also aimed to identify effects of endometriosis on the general emotional wellbeing of my 
patients. The reduction of emotional problems after treatment of disease is visible (Figure 3-2). In the one 
year post-operative follow up, 77% of women felt full of life and were not depressed, this contrasts with 
the 26% who reported not feeling depressed pre-operatively (P=0.028). Energy levels were elevated in 
59% of my patients at the one year visit, this can be compared to the 11% reporting good energy levels 
pre-operatively (P=0.002).A feeling of nervousness fell from 74% pre-operatively to 53% (P=0.378) at 
the one year follow up and during the same time period, the percentage of patients reporting feelings of 
calmness increased from 21% pre-operatively to 47% within six months(P=0.05) and 59% at one year 
(P=0.03). Depression was seen in 37% of my pre-operative patient population, interestingly no patient 
(0%) reported feeling depressed at the one year follow up visit (P=0.004) (Figure 3-2). 
An improvement in social activities was also seen after surgery (Figure 3-2). 65% reported no impact of 
pain or disease on their social interactions at the one year post-operative visit. Pre operatively, only 16% 
had felt that their social life was not being adversely affected by endometriosis (P=0.016). Patient’s 
perception of being less healthy than other people they knew fell by 21%. Pre-operatively, only 26% 
believed they were as healthy as their acquaintances, this was seen to rise to 47% at the one year follow 
up (P=0.329). Overall, 11% expected their health to deteriorate before their operation, this value rose 
slightly to 14% (P=0.576) within six months of their procedure and then fell to 6% at their one year 
follow up (P=0.576). 
FIGURE 3-3  
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Respective graphical representation of patient subjective pain levels (y-axis pain levels 0-100%) for dysmenorrhoea, 
deep dyspareunia, dyschesia, ovulatory pain and pain on micturition pre-operatively, at 6 months and one year post 
operatively. 
 
The perception of pain was also assessed (See section 1.12). I asked patients to rate their pain scores (0% 
indicating no pain and 100% indicating the highest levels of pain) for dysmenorrhoea, deep dyspareunia, 
dyschesia, ovulatory pain, chronic pelvic pain and pain on micturition (Figure 3-3). All of these 
symptoms have been attributed to endometriosis although there is no direct link between severity of 
disease and pain scores
11. The patient’s perception of pain varies according to the psychology of the 
individual
304
 and therefore pain scores will be subjective rather than objective values. Looking at the 
graphical results (Figure 3-3) there is a notable decrease in overall experienced pain levels for 
dysmenorrhoea from the pre-operative time period (Average dysmenorrhoea pain score 59%) when 
compared to the 6 months (Average dysmenorrhoea pain score 51%) and one year post-operative levels of 
pain (Average dysmenorrhoea pain score 26%). Overall pain levels for deep dyspareunia also showed an 
improvement. Deep dyspareunia is not usually experienced by all patients with endometriosis. It is 
believed to be a result of deeply infiltrating disease in the Pouch of Douglas. Though deep dyspareunia is 
mostly believed to be due to pathology
268
, psychosexual influences of each individual patient will also 
affect pain scores during intercourse. The average deep dyspareunia pain level pre-operatively stood at 
30%, these fell to 17% at 6 months post operatively and 18% at one year post-operatively. Dyschesia is 
another symptom that is related to endometriosis. This is usually attributed to disease around the rectum 
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and Pouch of Douglas and changes in bowel habits are also known to be linked to presence of 
endometriosis
268
. Confounding factors such as irritable bowel syndrome or inflammatory bowel 
conditions might also deteriorate pre-menstrually so the values of pain are once again patient dependant 
and subjective. Pre-operatively, pain scores for dyschesia stood at 23%, these fell to 19% within six 
months of surgery and 10% at one year post-operatively. Pain on micturition was also assessed though 
this is a clinically rarer reported symptom of endometriosis. This is usually attributed to disease in the 
vicinity of the bladder on the anterior aspect of the Uterus or the uterovescal fold of peritoneum. Pre-
operatively, pain scores were around 8%, they were seen to increase to 14% within 6 months of the 
operation and fell again to 3% at one year post-operatively (Figure 3-3). This interesting rise in the 6 
month follow up could potentially be attributed to an early recovery period or increased pain awareness 
once a diagnosis of endometriosis has been imparted. Pain perceptions vary with patient psychology 
which is multifactorial
304
. This makes it difficult to attribute pain levels to the presence of physical 
disease. 
Mid-cycle or ovulatory pain was also assessed in conjunction with chronic pelvic pain. Pain perception 
varies according to the patient in question and typically patients who complain of chronic pelvic pain will 
also report mid-cycle ovulatory discomfort
302
. Pain related with ovulation was reported at 38% pre-
operatively, falling to 11% at six months and slightly rising to 15% at one year post-surgery. In a similar 
pattern, chronic pain was reported at 34% pre-operatively, fell to 8% within six months of surgery and 
there was an increase to 12% at one year (Figure 3-3). 
Therapeutic laparoscopic surgery shows benefits in the symptoms and psyche of patients with 
endometriosis. Surgical risks must be balanced against the benefits which are obtained with symptom 
resolution. Due to the chronicity of the condition, long term follow up is required in endometriosis, with 
high recurrence rates reported
274
. A multidisciplinary team follow up will ensure both physical and 
psychological benefits are achieved in women being treated for this disease
492
. 
Gene, protein and miRNA expression in women with endometriosis 
121 
4 Analysis of tissue miRNAs in endometriosis  
4.1 Introduction 
Micro RNAs were discovered in 1993 and revolutionised the thinking behind the control of RNA 
expression. There are over 800 currently identified human miRNAs. These are now regarded to have 
major translational or repressive effects controlling cellular function, proliferation
403
, death
404
 and protein 
production
405
. They regulate around 30% of the human genes
406
 and repress over 60% of the protein 
coding genes
407
. MiRNAs are also believed to be responsible for gene regulation
408
 and interact with 
messenger RNA (mRNA) encoding proteins on the ribosomes enhancing their expression
409
 (Figure 1-8). 
As a first step in this project, I aimed to systematically identify miRNAs expressed in patients with 
histologically proven diagnosis of endometriosis. Previously published data has been poor, being derived 
from small sample numbers and from patients whose disease phenotype had not necessarily been clearly 
defined to ensure other pathologies such as fibroids and malignancy had been excluded (Section 1.17.1). 
This could potentially be a cause of bias in the published results. I was meticulous to identify, document 
and operated on a set of patients with clearly diagnosed endometriosis without compounding additional 
pathologies. Following ethical approval and fully informed consent patients were recruited, their disease 
phenotype annotated, entered into the study were ensured to be free from other pathologies such as 
infections (e.g. pelvic inflammatory disease, evidence of Fitz Hugh Curtis adhesions on the liver or tubal 
hysdrosalpinges) and samples from a broad range of associated tissues stored and analysed. The patients 
were screened to ensure they did not suffer from endocrine disorders, autoimmune disorders, 
immunocompromisation or benign masses (such as cysts on the ovaries or tubes), uterine polyps or 
fibroids. Patients on any hormones or taking medication for other diseases were excluded from the study. 
4.2 Aims 
 To obtain a set of tissue samples at laparoscopy from patients who suffered from endometriosis with 
no other confounding pathology. 
 To assess for differences in miRNA expression between tissue infiltrated with endometriosis and 
tissue not infiltrated with endometriosis. 
 To confirm identified miRNA through a separate confirmatory technique such as quantitative PCR 
(Section 4.4.2). 
 To identify and confirm predicted downstream protein effects of the relevant miRNA on a larger 
sample of tissues though tissue microarrays (TMAs) (Section 2.7). 
4.3 Method 
Patients identified were initially screened for eligibility and then offered recruitment into the study. 
Following fully informed consent, pain score questionnaires and quality of life questionnaires were 
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performed pre operatively and at 6 and 12 months post operatively (2.3). The tissue for the study was 
obtained from the consented patients at surgery (Section 2.3). A biopsy of tissue infiltrated with 
endometriosis and a biopsy from adjacent unaffected tissue not infiltrated by endometriosis were obtained 
from each recruited case (Section 2.3). MiRNA from the biopsied tissue samples was extracted according 
to the described protocol (Section 2.4). NCounter® expression assays were performed on the extracted 
miRNA (Section 2.4.3) and data was obtained. Statistical analysis on the data was performed 
(Section4.4.1) and subgroup analysis of the results was carried out (4.4.1.2). Results from the tissue 
subgroups were plotted in Venn diagram format to eliminate overlapping miRNA from the patient sample 
subsets (Section 4.4.1). Analysis of statistically significant (P <0.05) differentially expressed miRNA and 
their fold change (FC) between individual groups was calculated (Section 4.4.1.3). Confirmation of the 
relevant identified miRNAs was carried out through quantitative PCR (Section 4.4.2). Tissue microarrays 
were performed to identify and confirm downstream effects of the identified relevant miRNAs (Section 
4.4.3). 
4.4 Results 
4.4.1 Tissue miRNA expression in endometriosis-statistical analysis 
In this chapter the processing and statistical analysis of the data obtained is described after miRNA 
extraction from tissue samples (Section 2.4). 
4.4.1.1 Differential gene expression analysis 
The R project (R version 2.12.1) (http://www.R-project.org) was used for statistical and clustering 
analysis. Quantified gene expression signal levels derived from the nCounter® miRNA Expression Assay 
(NanoString Technologies) were logarithmically transformed (base 2) and quantile-normalized prior to 
further exploration. In order to determine the miRNA expression detectability threshold the log2 signal 
values were ranked in increasing order and categorised into 0.5 expression levels. Subsequently, the 
differences in successive expression level frequencies were calculated and the expression value following 
the most significant signal increase was considered as miRNA expression detectability threshold (Figure 
4-1). miRNAs expressed was counted at any level (above log2 expression value of 3.25) in each group 
and subsequently performed chi-square test to assess if the numbers are significantly different from the 
expected average. The global expression of miRNAs between all groups was not noted to be significantly 
different (chi square p-value 0.82664147). 
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FIGURE 4-1 
 
Diagram showing the expression data distribution with selected threshold level of miRNA detectability (dotted 
red line) 
 
Analysis of variance (ANOVA) was performed per each gene across all samples assigned to appropriate 
groups in order to identify differentially expressed miRNAs. The Benjamini & Hochberg multiple 
hypothesis testing correction was applied to control the false discovery rate (FDR). Genes that remained 
statistically significant (corrected p-value <0.05) were selected for unsupervised hierarchical clustering 
performed based on distances calculated by means of Spearman correlation coefficient and ward 
agglomeration method (Figure 4-2, Figure 4-3, Figure 4-4). 
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FIGURE 4-2 
 
To assess similarities between samples in terms of miRNA expression profile Spearman correlation coefficients 
were calculated and further used to compute distances between samples. Generated distance matrix was used for 
principal coordinates analysis to allocate studied samples in two dimensional space. The groups are clearly 
differentiated in 2D space. 
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FIGURE 4-3 
 
Heat map illustrating unsupervised hierarchical clustering of studies samples. The distances between sample 
miRNA expression profiles were measured by means of Spearman correlation coefficient technique and clustered 
using Ward agglomeration method. The colours generated and their intensities reflect miRNAs expression levels. 
Green and red colours indicate relatively low and high expression levels, respectively. 
 
Gene, protein and miRNA expression in women with endometriosis 
126 
FIGURE 4-4 
 
Heat map illustrating similarities and dissimilarities between investigated samples. The distances between sample 
miRNA expression profiles were measured by means of Spearman correlation coefficient technique and clustered 
using Ward agglomeration method. The colours generated and their intensities reflect miRNA expression profiles 
similarities. The red and yellow colours indicate relatively high and low similarity level, respectively. 
 
Subsequently, pairwise t-tests with corrections for multiple testing were applied as a post hoc analysis. 
Computed t-statistics and signal intensity fold changes were further used to determine significantly up 
and down regulated miRNAs and to generate Venn diagrams depicting the overlap between miRNAs 
differentially expressed in investigated groups (Figure 4-5, Figure 4-6, Figure 4-7). 
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FIGURE 4-5 
 
This Venn diagram depicts the miRNA which are statistically significantly differentially expressed (P<0.05) in each 
of the respective specified subgroups (NE, NP, ES and OvES). Those miRNAs that were statistically significant in 
any other of the subgroups were indicated in overlapping areas corresponding to appropriate groups (e.g. 39 miRNA 
expressed in both NE and ES). Those miRNAs upregulated are depicted in black text whilst those miRNA which are 
downregulated are depicted in red text. miRNAs not significantly differentially expressed in any group were excluded 
from this Venn Diagram. There were 466 miRNA out of the 734 scanned miRNA for which the P value was not 
statistically significant. 
 
From the above Venn diagram ebv-miR- BART2-5p and hsa-miR-564 are shown to be the most 
significantly different in the endometriosis samples compared to all other subsets analysed (Table 9-33). 
Ebv-miR- BART2-5p is particularly interesting as it has downstream effects on the control of the 
following proteins; (upregulating Cyclin D1) (Figure 4-22) and (downregulating E-Cadherin, Maspin and 
BCLAF-1) (Figure 4-11, Figure 4-13 and Figure 4-15). All of these proteins are associated with 
tumorigenesis seen in head and neck cancer, which is known to be caused by EBV
493
. 
Ovarian endometriosis samples show miRNAs significantly up or downregulated in this subset when 
compared to all other subsets analysed (Table 9-34). All the identified miRNAs in the depicted subsets 
have been listed in Table 9-35 to Table 9-38. 
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FIGURE 4-6 
 
This Venn diagram depicts the miRNA which are statistically significantly differentially upregulated (P<0.05) in 
each of the respective specified subgroup (NE, NP, ES and OvES) with a positive log fold change. This diagram 
depicts the miRNA described above irrespective of whether they are concomitantly downregulated in any other 
group. There were 506 miRNA out of the 734 scanned miRNA for which there was no significant positive log fold 
change or the fold change was negative. 
 
FIGURE 4-7 
 
This Venn diagram depicts the miRNA which are statistically significantly differentially downregulated (P<0.05) in 
each of the respective specified subgroup (NE, NP, ES and OvES) with a negative log fold change. This diagram 
depicts the miRNA described above irrespective of whether they are concomitantly upregulated in any other group. 
There were 543 miRNA out of the 734 scanned miRNA for which there was no significant negative log fold change 
or the fold change was positive. 
 
Gene, protein and miRNA expression in women with endometriosis 
129 
4.4.1.2 Subgroup analysis 
Further subdivision of data analysis was performed on the cases, looking at values obtained in the luteal 
phase and follicular (proliferative) phase separately. Application of pairwise t-tests between specified 
groups to identify any significant difference between group means was performed. 
4.4.1.2.1 NE from cases and ES cases- follicular phase of the cycle 
29 miRNA were significantly differentially expressed between (NE cases) and (ES cases) in the follicular 
phase of the cycle. Please see Table 9-1 and Table 9-2 in the Appendix. 
4.4.1.2.2 NE from controls and NE cases 
There were no (0) miRNA significantly differentially expressed between (NE control) and (NE case) in 
the follicular phase of the cycle. 
4.4.1.2.3 NE from cases and ES cases- luteal phase of the cycle  
60 miRNA were significantly differentially expressed between (NE cases) and (ES cases) in the luteal 
phase of the cycle. 30 miRNA were upregulated whist 30 were downregulated. Please see Table 9-3 and 
Table 9-4 in the Appendix. 
4.4.1.2.4 NE from cases and OvES cases- follicular phase of cycle 
130 miRNA were significantly differentially expressed between (NE cases) and (OvES cases) in the 
follicular phase of the cycle. 53 miRNA were upregulated in the ovarian endometriosis samples (OvES). 
77 miRNA were downregulated. Please see Table 9-5 and Table 9-6 in the Appendix. 
4.4.1.2.5 NE from cases and OvES cases- luteal phase of cycle 
54 miRNA were significantly differentially expressed between (NE cases) and (OvES cases) in the luteal 
phase of the cycle. 28miRNAs were upregulated in ovarian endometriosis in the luteal phase of the cycle. 
26 miRNA were downregulated. Please see Table 9-7 and Table 9-8 in the Appendix. 
4.4.1.2.6 Normal peritoneum from controls (NP control) and normal peritoneum cases 
(NP cases) 
2 miRNA were significantly differentially expressed between (NP control) and (NP cases) in the 
follicular phase of the cycle. One was upregulated and the other downregulated. Please see Table 9-9 and 
Table 9-10 in the Appendix. 
4.4.1.3 Analysis of statistically significant (P <0.05) differentially expressed miRNA and 
their fold change (FC) between individual groups 
These values were obtained by performing a T-test between the particular group analysed and all the 
other groups. The P value for each miRNA is demonstrated as well as its fold change (FC). A negative 
Log FC indicates a downregulation of the particular miRNA compared to all other groups. 
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4.4.1.3.1 Normal endometrium 
The following miRNA were significantly expressed in normal endometrium (NE) compared to 
endometriosis (ES), normal peritoneum (NP) and ovarian endometriosis (OvES). A positive log fold 
change indicates upregulation whereas a negative fold change indicates downregulation. Please see Table 
9-11 in the Appendix. 
4.4.1.3.2 Normal Peritoneum 
The following miRNA were significantly expressed in normal peritoneum (NP) compared to 
endometriosis (ES), normal endometrium (NE) and ovarian endometriosis (OvES). Please see Table 9-12 
in the Appendix. 
4.4.1.3.3 Peritoneal endometriosis 
The following miRNA were significantly expressed in endometriosis (ES) compared to normal 
endometrium (NE), normal peritoneum (NP) and ovarian endometriosis (OvES). Please see Table 9-13 in 
the Appendix. 
4.4.1.3.4 Ovarian endometriosis 
The following miRNA were significantly expressed in ovarian endometriosis (OvES) compared to normal 
endometrium (NE), normal peritoneum (NP) and endometriosis (ES). Please see Table 9-14 in the 
Appendix. 
4.4.2 Polymerase chain reaction (PCR) results- confirmation of miRNA findings 
PCR was performed to validate the ebv-miR-BART2-5p miRNA results. Three miRNA were quantified 
using qRT_PCR analysis. In concordance with the miRNA data, the pCR showed significant differential 
expression of the ebv-miR-BART2-5p miRNA between eutopic endometrium from controls, eutopic 
endometrium from women with endometriosis and endometriosis samples. Statistically, when comparing 
ebv-miR-BART2-5p levels between normal endometrium from controls and endometriosis, the p-value is 
significant (P=0.0067). The p-value is also significant when comparing normal endometrium from cases 
and endometriosis (P=0.02) (Figure 4-8, Figure 4-9). However, there was no statistical significance 
between normal endometrial samples from cases and normal endometrial samples from controls. 
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4.4.2.1 PCR EBV results 
Sample with ebv-miR-
BART2-5p primer 
Ct Sample with 26B 
Primer 
Average Delta CT NE Control 
Calibration 
Delta Delta 
CT 
Fold change Endometriosis Normal 
endometrium 
Controls 
Normal 
endometrium 
Cases 
51 ES BART 44.77 51 ES 26B 26.13 18.64 13.04 5.60 0.02 0.02   
54 ES BART 40.49 54 ES 26B 26.87 13.62  0.58 0.67 0.67   
57 ES BART 40.94 57 ES 26B 24.58 16.36  3.32 0.10 0.10   
31 ES BART 40.74 31 ES 26B 25.79 14.95  1.91 0.27 0.27   
3 NE Control BART 44.18 3 NE Control 26B 27.38 16.80  3.76 0.07  0.07  
8 NE Control BART 44.63 8 NE Control 26B 26.17 18.46  5.42 0.02  0.02  
10 NE Case BART 41.38 10 NE Case 26B 26.44 14.94  1.90 0.27   0.27 
12 NE Case BART 41.72 12 NE Case 26B 26.39 15.33  2.29 0.20   0.20 
27 NE Case BART 41.70 27 NE Case 26B 25.06 16.64  3.60 0.08   0.08 
30 NE Case BART 42.30 30 NE Case 26B 26.74 15.56  2.52 0.17   0.17 
32 NE Case BART 42.75 32 NE Case 26B 26.06 16.69  3.65 0.08   0.08 
35 NE Case BART 46.84 35 NE Case 26B 26.93 19.90  6.86 0.01   0.01 
38 NE Case BART 45.74 38 NE Case 26B 25.87 19.87  6.83 0.01   0.01 
42 NE Case BART 46.73 42 NE Case 26B 26.86 19.87  6.83 0.01   0.01 
44 NE Case BART 42.42 44 NE Case 26B 26.02 16.41  3.37 0.10   0.10 
46 NE Case BART 43.37 46 NE Case 26B 25.73 17.65  4.61 0.04   0.04 
49 NE Case BART 40.43 49 NE Case 26B 26.68 13.75  0.71 0.61   0.61 
53 NE Case BART 40.51 53 NE Case 26B 28.00 12.51  -0.53 1.44   1.44 
11 ES BART 39.43 11 ES 26B 25.07 14.36  1.32 0.40 0.40   
17 ES BART 41.67 17 ES 26B 24.32 17.35  4.31 0.05 0.05   
14 ES 37.01 14 ES 28.66 8.35  -4.69 25.80 25.80   
29 ES 43.75 29 ES 27.15 16.60  3.56 0.08 0.08   
34 ES 40.58 34 ES 27.62 12.96  -0.08 1.06 1.06   
36 ES 37.58 36 ES 27.48 10.10  -2.94 7.65 7.65   
40 ES 37.54 40 ES 25.53 12.01  -1.03 2.04 2.04   
43 ES 39.96 43 ES 27.79 12.17  -0.87 1.83 1.83   
45 ES 36.52 45 ES 27.36 9.16  -3.88 14.68 14.68   
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48 ES 38.72 48 ES 28.55 10.17  -2.87 7.30 7.30   
51 ES BART 41.23 51 ES miR44 27.69 13.54  0.50 0.71 0.71   
54 ES BART 41.63 54 ES miR44 27.70 13.93  0.89 0.54 0.54   
57 ES BART 37.94 57 ES miR44 25.60 12.34  -0.70 1.63 1.63   
31 ES BART 37.33 31 ES miR44 26.57 10.76  -2.28 4.87 4.87   
5 NE Control 42.56 5 NE Control 26.39 16.17  3.13 0.11  0.11  
25 NE Control 43.16 25 NE Control 27.09 16.06  3.02 0.12  0.12  
16 NE Case 43.00 16 NE Case 26.84 16.16  3.12 0.12   0.12 
14 ES BART 38.48 14 ES 26B 27.63 10.85  -2.19 4.56 4.56   
29 ES BART 36.39 29 ES 26B 25.66 10.72  -2.32 4.98 4.98   
34 ES BART 36.33 34 ES 26B 26.90 9.43  -3.61 12.20 12.20   
5 NE Control BART 38.77 5 NE Control 26B 25.73 13.04   1.00  1.00  
16 NE Case BART 35.90 16 NE Case 26B 25.63 10.26  -2.78 6.84   6.84 
25 NE Control BART 40.72 25 NE Control 26B 26.74 13.99  0.95 0.52  0.52  
36 ES BART 41.86 36 ES 26B 25.41 16.45  3.41 0.09 0.09   
40 ES BART 40.83 40 ES 26B 24.94 15.89  2.85 0.14 0.14   
43 ES BART 38.24 43 ES 26B 25.71 12.53  -0.51 1.42 1.42   
45 ES BART 37.07 45 ES 26B 25.47 11.60  -1.44 2.72 2.72   
48 ES BART 38.75 48 ES 26B 26.50 12.24  -0.80 1.74 1.74   
Average        3.75 0.31 0.71 
           
T-test 0.01 NE Control and ES        
T-test 0.02 NE Case and ES        
T-test 0.44 NE Case and NE Control        
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FIGURE 4-8 
Quantitative PCR EBV BART 2-5p 
 
Quantitative PCR results with outliers included 
 
FIGURE 4-9 
Quantitative PCR EBV BART 2-5p 
 
Quantitative PCR results with outliers excluded 
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4.4.3 Tissue microarray results- downstream effects of EBV presence 
Immunohistochemistry was performed on tissue microarrays from endometriosis tissues as described in 
section 2.7. The downstream effects of EBV on expected protein expression were explored by quantifying 
expression levels of E-Cadherin, Maspin, BCLAF-1, p53 and cyclin D1 (predicted downstream protein 
expression patterns under BART 2-5p miRNA control) from the endometriosis tissue microarrays (Figure 
4-10). Galectin-3 expression levels already proven to be upregulated in endometriosis were performed 
with the aim of potentially using Galectin 3 inhibitors as a novel therapeutic for the disease. In-situ 
hybridisation for the EBV virus within cells was performed with the aim of finding evidence of in vivo 
viral involvement in endometriosis. Data was analysed by non-parametric statistical analysis performed 
on each of the subgroups (endometriosis (circles on graphs), normal endometrium from controls (squares 
on graphs) and normal endometrium from cases (triangles on graphs)) using a Mann-Whitney U Test. A 
p-value of <0.05 between the groups was regarded as statistically significant. The resulting data was then 
plotted graphically below (Figure 4-12, Figure 4-14, Figure 4-16 and Figure 4-18). 
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FIGURE 4-10 
 
Hand drawn diagram showing the downstream effects of EBV virus on BCLAF1, E-Cadherin and Maspin 
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4.4.3.1 E-Cadherin 
Downregulation of E-Cadherin is demonstrated in endometriosis on tissue microarray (TMA) analysis 
(Figure 4-11). There is a statistically significant downregulation of E-Cadherin in endometriosis 
compared to normal endometrium from controls (P<0.0001) and normal endometrium from cases 
(P=0.0017) (Figure 4-12, Table 4-1, Table 4-2). 
FIGURE 4-11 
Normal endometrium Endometriosis 
  
Images showing reduced E-Cadherin levels in endometriosis compared to normal endometrium tissue 
 
FIGURE 4-12 
 
Figure illustrating the levels of E-Cadherin in TMA studies 
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TABLE 4-1 
Table Analyzed E-Cadherin 
Column A vs Column C Endometriosis vs Normal endometrium from 
Cases 
Mann Whitney test   
P value  0.0017 
Exact or approximate P value?  Gaussian Approximation 
P value summary  ** 
Are medians signif. different? (P<0.05) Yes 
One- or two-tailed P value?  Two-tailed  
Sum of ranks in column A,C  1720, 1206 
Mann-Whitney U  342 
 
TABLE 4-2 
Table Analyzed  E-Cadherin 
Column A vs Column B Endometriosis vs Normal endometrium 
Controls 
Mann Whitney test   
P value  < 0.0001 
Exact or approximate P value?  Gaussian Approximation 
P value summary  *** 
Are medians signif. different? (P<0.05) Yes 
One- or two-tailed P value?  Two-tailed 
Sum of ranks in column A,B  1461, 3293 
Mann-Whitney U  82.5 
 
4.4.3.2 Maspin 
Reduction of MASPIN is confirmed on TMA analysis (Figure 4-13). Comparing levels between 
endometriotic tissue and normal endometrium, there is a statistically significant downregulation of 
MASPIN in endometriosis compared to normal endometrium from controls (P<0.0001) and normal 
endometrium from cases (P=0.2760) (Figure 4-14, Table 4-3, Table 4-4). 
FIGURE 4-13 
Normal endometrium Endometriosis infiltrating bowel and 
peritoneum (below) 
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Images showing a reduction in Maspin levels in endometriosis 
 
FIGURE 4-14 
 
Figure illustrating the levels of Maspin in TMA studies 
 
TABLE 4-3 
Table Analyzed Maspin 
Column A vs Column B Endometriosis vs Normal endometrium 
Controls 
Mann Whitney test  
P value < 0.0001 
Exact or approximate P value?  Gaussian Approximation  
P value summary  *** 
Are medians signif. different? (P < 0.05)  Yes 
One- or two-tailed P value?  Two-tailed 
Sum of ranks in column A,B  1939, 2815 
Mann-Whitney U  398.5 
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TABLE 4-4 
Table Analyzed  Maspin 
Column A vs Column C Endometriosis vs Normal endometrium Cases 
Mann Whitney test  
P value 0.276 
Exact or approximate P value? Gaussian Approximation 
P value summary Ns 
Are medians signif. different? (P < 0.05)  No 
One- or two-tailed P value? Two-tailed 
Sum of ranks in column A,C 1852 , 563.5 
Mann-Whitney U 311.5 
 
4.4.3.3 BCLAF-1 
Reduction of BCLAF-1 is confirmed in endometriosis on TMA analysis (Figure 4-15). Comparing levels 
between endometriotic tissue and normal endometrium, there is a statistically significant downregulation 
of BCLAF-1 in endometriosis compared to normal endometrium from cases (P<0.0001) (Figure 4-16, 
Table 4-5, Table 4-6). 
FIGURE 4-15 
Normal endometrium control Normal endometrium case Endometriosis 
   
TMA images showing downregulation of BCLAF-1 in endometriosis 
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FIGURE 4-16 
 
Figure illustrating the levels of BCLAF1 in TMA studies 
 
TABLE 4-5 
Table Analyzed  BCLAF1  
Column A vs Column B Endometriosis vs Normal endometrium 
Controls 
Mann Whitney test   
P value  0.3731 
Exact or approximate P value?  Gaussian Approximation  
P value summary  ns  
Are medians signif. different? (P < 0.05)  No 
One- or two-tailed P value?  Two-tailed 
Sum of ranks in column A,B  2520 , 2040 
Mann-Whitney U 1005 
 
TABLE 4-6 
Table Analyzed  BCLAF1  
Column A vs Column C Endometriosis vs Normal endometrium Cases 
Mann Whitney test   
P value  < 0.0001  
Exact or approximate P value? Gaussian Approximation 
P value summary *** 
Are medians signif. different? (P < 0.05) Yes 
One- or two-tailed P value?  Two-tailed 
Sum of ranks in column A,C 1297 , 783 
Mann-Whitney U 22 
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4.4.3.4 p53 
TMAs, confirmed an elevated level of p53 in endometriosis compared to normal endometrium in controls 
(Figure 4-17) (P=0.0090) and normal endometrium from cases (P=0.0101) (Figure 4-18, Table 4-7, Table 
4-8). 
FIGURE 4-17 
Normal endometrium Endometriosis 
  
TMA image showing increased levels of p53 in endometriosis 
 
FIGURE 4-18 
 
Figure illustrating the levels of P53 in TMA studies 
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TABLE 4-7 
Table Analyzed  p53  
Column A vs Column B Endometriosis vs Normal endometrium 
Controls 
Mann Whitney test  
P value  0.009 
Exact or approximate P value? Gaussian Approximation 
P value summary ** 
Are medians signif. different? (P < 0.05) Yes 
One- or two-tailed P value?  Two-tailed 
Sum of ranks in column A,B  1876 , 1445 
Mann-Whitney U  542 
 
TABLE 4-8 
Table Analyzed  p53  
Column A vs Column C Endometriosis vs Normal endometrium Cases 
Mann Whitney test  
P value 0.0101 
Exact or approximate P value? Gaussian Approximation 
P value summary  * 
Are medians signif. different? (P < 0.05) Yes 
One- or two-tailed P value?  Two-tailed 
Sum of ranks in column A,C  1181 , 250 
Mann-Whitney U  145 
 
4.4.3.5 Ebv-miR-BART2-5p 
This MicroRNA was uniquely upregulated in pelvic endometriosis in the proliferative or follicular phase 
of the cycle (P=0.0163829) (Figure 4-5). It shows a positive fold change (FC) of 1.449 compared to 
normal endometrium, normal peritoneum and ovarian endometriosis. It was found at higher levels in the 
endometriosis tissue compared to eutopic endometrium in paired samples. It was identified by the 
Nanostring expression array which did not require an amplification step. Findings were confirmed with 
PCR. In situ hybridisation for EBV on tissue microarrays did not confirm the presence of active EBV 
within the endometriotic epithelial cells (Figure 4-19) but 5 of the 42 endometriotic samples on TMA-A 
gave a positive reading for EBV presence in some of the lymphocytes. 
FIGURE 4-19 
EBV negative stain 
– control slide 
EBV positive stain 
– control slide 
EBV negative stain 
in normal 
endometrium of 
control patient 
EBV negative stain 
in normal 
endometrium of 
case patient 
EBV negative stain 
in endometriosis 
 
Figure demonstrating stains in various tissues looking for the presence of EBV 
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This finding is in keeping with previous studies discounting the presence of active viruses within the 
tissues but might indicate a viral effect on lymphocytes. This does not discount the importance of the 
influence of the effects EBV has on the development of disease as implicated by my analysis. Potential 
mechanisms of function may be developed through viral derived endosomes recently shown to play 
important roles in carcinogenesis, selectively placing EBV miRNAs into the endosome to transfer them to 
epithelial cells and alter growth characteristics. 
4.4.3.6 Cyclin D1 
Cyclin D1 is a kinase activator involved in cellular protein binding and cellular mitosis. It has also been 
implicated as having a role in spermatogenesis and is regulated by oestrogen in the body
494
. 
It is involved in the cell-cycle (Figure 4-20). The Wnt signalling pathway (Figure 5-14) and the 
Phosphoinositide 3-kinase pathway (PI 3-kinase pathway) which incorporates a family of enzymes 
involved in cellular growth, proliferation, survival and the development of malignancy. It is the PI 3-
kinase pathway, in conjunction with oncogene phosphoinositide-3-kinase, catalytic, alpha (PIK3CA) and 
the tumour suppressor Phosphatase and tensin homolog (PTEN), are responsible for cancers which are 
insensitive to insulin and insulin-like growth factor 1 (IGF-1)
495
in dietary restrictions (Figure 4-21). 
FIGURE 4-20 
 
Cell cycle pathway496 
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FIGURE 4-21 
Figure split over two continuous parts: 
 
 
PI 3-kinase pathway in conjunction with cyclin D1496 
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In endometriosis elevated levels of Cyclin D1 as well as c-MYC and growth regulation by oestrogen in 
breast cancer (GREB1) (all oestrogen regulated genes) have been reported, potentially explaining how 
cells proliferate survive and invade in this disease
494
. This study also shows an increased level of gene 
MYCBP responsible for the production of c-MYC. The increased levels of Cyclin D1 in endometriosis 
has also been attributed to an increased mitogen-activated protein kinase (MAP kinase) in endometrial 
cells of women with endometriosis in turn decreasing  the inhibition of Cyclin D1 by 3,5-cyclin adenosine 
5-monophosphate
497
. TMA studies confirm the increased level of Cyclin D1 in endometriosis. Cyclin D1 
is also a substrate on which tested therapeutics such as GCS-100 are known to act, increasing evidence of 
this galectin-3 inhibitor as a potential novel therapeutic medication (Chapter 7). It is also regulated by the 
gene TOM1 (a potential identified biomarker in my study of endometriosis) and is explored fully in later 
sections of this thesis (see TOM1). 
FIGURE 4-22 
Normal endometrium Endometriosis 
  
TMA images showing elevated Cyclin D1 levels in endometriosis 
 
Gene, protein and miRNA expression in women with endometriosis 
146 
4.4.3.7 Galectin-3 
FIGURE 4-23 
Normal endometrium Endometriosis 
  
  
TMA images showing increased levels of Galectin 3 in endometriosis 
 
4.5 Discussion of patient data 
4.5.1 Tissue miRNA studies- salient points of note 
 The ebv-mir-BART2-5p is detected in endometriosis. 
 Endometriosis cells contained higher levels of ebv-mir-BART2-5p compared to eutopic 
endometrium. This was confirmed by quantitative PCR. 
 Ebv-mir-BART2-5p suppresses T-cells and encourages adhesions and angiogenesis in affected 
tissues. 
 Downstream proteins from EBV upregulation are affected. This study demonstrates the upregulation 
of Cyclin D1) (Figure 4-22) and downregulation of E-Cadherin, Maspin and BCLAF-1) (Figure 4-11, 
Figure 4-13, Figure 4-15 and Figure 4-10). 
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 Ebv-mir-BART2-5p may be an initiator for engraftment of endometrial cells to the peritoneum 
causing the development of endometriosis. 
 The presence of ebv-mir-BART2-5p is a permissive event for the development of endometriosis. 
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4.5.2 A summary of the data 
4.5.2.1 Upregulation of Ebv-miR-BART2-5p 
In my study I have shown that the Ebv-miR-BART2-5 is uniquely upregulated in pelvic endometriosis in 
the proliferative or follicular phase of the cycle this was confirmed by quantitative PCR. In situ 
hybridisation for EBV on tissue microarrays did not confirm the presence of active EBV within the 
endometriotic epithelial cells (Figure 4-24) but 5 of the 42 endometriotic samples on TMA-A gave a 
positive reading for EBV presence in some of the lymphocytes. PCR on the peripheral blood monocytes 
confirms overall higher levels of EBV DNA in the monocytes of people with endometriosis compared to 
controls (see Table 9-39 in the Appendix). There were no detected EBV levels in the surgically confirmed 
control patient samples. 
FIGURE 4-24 
EBV negative stain 
– control slide 
EBV positive stain 
– control slide 
EBV negative stain 
in normal 
endometrium of 
control patient 
EBV negative stain 
in normal 
endometrium of 
case patient 
EBV negative stain 
in endometriosis 
 
Tissue microarrays on which in situ hybridisation for EBV was performed 
 
This finding is in keeping with previous studies discounting the presence of active viruses within the 
tissues but might indicate a viral effect on lymphocytes. This does not discount the importance of the 
influence of the effects EBV has on the development of disease as implicated by my analysis. The 
presence of these miRNAs in my case tissue samples further helps to substantiate the role of ebv-BART2-
5p as a key player in endometriosis. Potential mechanisms of function may be developed through viral 
derived endosomes recently shown to play important roles in carcinogenesis, selectively placing EBV 
miRNAs into the endosome to transfer them to epithelial cells and alter growth characteristics. 
Metazoan organisms encode miRNAs which regulate gene expression by binding to the 3’UTR terminal 
of mRNAs. Herpes viruses are known to induce persistent lifelong infections in their latent stage by 
evading the host’s immune system498. miRNAs have been identified within DNA viruses of the herpes 
family
499-501
. Identified tumorigenic viruses associated with latent infections, evasion of the host immune 
responses
502
 and epithelial, endothelial or lymphoid malignancies include Cytomegalovirus (CMV)
503
, 
Kaposi’s sarcoma associated herpesvirus (KHSV)504 and Epstein-Barr Virus (EBV)505. Problems with 
predicting viral miRNA targets with available algorithms exist
506
 as both cellular and viral targets can 
interact and should be analysed
507
. As viral targets are poorly conserved this is not always possible and 
their experimental validation has been limited
499
. 
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FIGURE 4-25 
Endometriosis
Ectopic implantation and invasion
Peritoneal adhesion
Viable endometrial cells in peritoneal cavity
Retrograde menstruation
• BART2-5p miRNA activation
• MICB reduction
• Defective NK cell recognition
• Reduced T cell cytotoxicity
• Galectin-3 upregulation
• E Cadherin downregulation
• Galectin-3
• BCLAF1 downregulation
• Upregulation of cytokines
• Maspin downregulation
• Increased angiogenesis (Gal-3)
• Cyclin D1 upregulation
• Defective NK cell recognition
• Hormone cyclical
 
Figure illustrating the various mechanisms involved in development of endometriosis 
 
There are a series of identified mechanisms and pathways which I theorise result in the development of 
endometriosis (Figure 4-25, Figure 4-10). My findings indicate an EBV viral effect on lymphocytes 
which potentially plays an important role in development of disease. During latent infection, EBV has 
been reported to induce certain host miRNAs which play a role in viral oncogenesis such as miR-155 and 
miR-21
508
 (Figure 4-10). miR-21 controls the oncogene Tropomyosin alpha-1 chain (TPM1). TPM1 has 
been identified in my study as a potential antibody marker from the serum of patients with disease 
(Section 6.7.3.8). miR-155 has also been identified in this study as being upregulated in Ovarian 
endometriosis (P=0.00001720) (Table 9-4) specifically in the follicular/proliferative phase of the cycle 
(P=0.0004878) (Table 9-5). It is also seen to be upregulated in the normal endometrium of cases (average 
value of expression from all case samples 6.308624) compared to the normal endometrium from controls 
(average value of expression from all control samples 3.818766) (see Excel analysis-Thesis excel data 
(my modified lists of miRNA decideTests_resultsV2).xls).. MiR-21 is also seen to be dysregulated in my 
study and is expressed in Ovarian endometriosis (P=0.00140219) (Table 9-14). miR-21 is also seen to be 
dysregulated in this study. It is expressed in Ovarian endometriosis (P=0.00140219) (Table 9-14). miR-
21 was also seen in the normal peritoneum of cases (Table 9-12) (average value of expression from all 
case samples 12.30429) and in the normal peritoneum of controls (average value of expression from all 
control samples 12.29785). The data from the normal peritoneum does not necessarily refute the presence 
of this miRNA in peritoneum of women developing disease. It is recognised that small sample numbers 
might provide a limitation to their true expressed levels. In addition, the location of a peritoneal biopsy 
well away from the growth of endometriosis might lessen the incidence of deregulated miRNA in these 
sampled tissues. 
EBV was the first virus to be associated with a human tumour
509
 (Figure 4-27) and is seen in lymphomas 
and epithelial malignancies such as undifferentiated nasopharyngeal carcinoma. In vitro studies show the 
pivotal role of EBV in oncogenesis. It is capable of transforming over 50% of resting B-cells into 
continuously proliferating cells with latent virus within a few days
510
. Infection of epithelial cells with 
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EBV is not completely understood. There is the possibility of virus as well as exosomes transferring 
genetic material. This results in epithelium demonstrating the default program of infection
511,512
. Unlike 
B-cells, epithelial cells are unable to become memory cells and the LMP proteins cannot “turn off”. Thus 
even in immunocompetent individuals infection can persist. The same theory could be true of 
endometriosis. Publications show that the presence of healthy, functional NK cells is inversely 
proportional to the presence of EBV virus and its effects
513
. There are a number of predicted human target 
genes for EBV BART2-5p which have particular roles enabling ectopic tissue to engraft and survive. The 
BCLAF1 gene linked to apoptosis, the CDH1/E-Cadherin linked to cell adhesion and the MASPIN linked 
to p53 signalling are all implicated. Over expression of the BCLAF1 induces apoptosis and T cell 
proliferation. The expression of BART2-5p provides a survival advantage to ectopic endometrium having 
reduced apoptosis and avoiding immune surveillance by the t-cells. This study demonstrates the reduction 
of BCLAF-1 on tissue microarray analysis (TMA). Comparing levels between endometriotic tissue and 
normal endometrium, there is a statistically significant downregulation of BCLAF-1 in endometriosis 
compared to normal endometrium from cases (P<0.0001) (Figure 4-16, Table 4-5, Table 4-6).  
CDH1/E-Cadherin is a master regulator of the G0/G1 stage of the cell cycle and its role is to reduce cell 
adhesion, division and cycling. Its suppression in ectopic endometrial tissue predicts an increase in cell 
adhesion (observed in endometriosis) and removes the suppression on the G0/G1 cell cycle stage moving 
cells into the S phase. This study demonstrates the downregulation of E-Cadherin in endometriosis on 
tissue microarray (TMA) analysis. There is a statistically significant downregulation of E-Cadherin in 
endometriosis compared to normal endometrium from controls (P<0.0001) and normal endometrium from 
cases (P=0.0017) (Figure 4-12, Table 4-1, Table 4-2). The reduction in E-Cadherin enables the tissues to 
metastasise and infiltrate causing disease progression and creating an invasive pattern often seen in 
endometriosis. Maspin is expressed in normal endometrial cells and its suppression by BART2-5p leads 
to an increase in ability for the endometrium to migrate and survive. An activating p53 binding site was 
identified and showed Maspin to be the downstream effector gene. My study confirms the reduction of 
Maspin on tissue microarray (TMA) analysis. Comparing levels between endometriotic tissue and normal 
endometrium, there is a statistically significant downregulation of MASPIN in endometriosis compared to 
normal endometrium from controls (P<0.0001) and normal endometrium from cases (P=0.2760) (Figure 
4-14, Table 4-3, Table 4-4). 
4.5.2.2 Downregulation of hsa-miR-564 
In my study, hsa-miR564 was the miRNA found to be downregulated exclusively in the endometriosis 
tissue samples. Overall, most cancers show aberrant miRNA expression and an overall level of 
downregulation of relevant miRNAs when compared to normal tissues. This miRNA has been found to be 
downregulated in leukocytes of patients with chronic myeloid leukaemia
514
 and in papillary thyroid 
carcinoma with lymph node metastasis
515
. It has been postulated that the downregulation of this miRNA 
is mediated by the activity of BCR-ABL tyrosine kinase gene and its protein
514
 (Figure 4-26). The ABL 
oncogenes play a role with Cyclin D1 and K-RAS to induce cellular transformation both in vitro and in 
vivo models
514
. The predicted targets of miR-564(Target Scan predictive analysis tool) include E2F 
transcription factor 3 (E2F3) and Akt2 gene. The E2F family of genes play a role in the cell cycle, DNA 
replication and the upregulation of E2F3, an oncogene with strong proliferative potential. It is associated 
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with poor prognosis in hepatocellular carcinomas
516
 and in tumour studies it has been proposed as a 
marker of poor patient prognosis. In studies involving lung cancer patients, the targeting of E2F3 by a 
tumour suppressive miRNA (mir-449a) induces remission and improved survival of patients
517
. E2F is 
also a target of transforming proteins and gene products of DNA tumour viruses such as adenovirus E1A, 
papillomavirus E7, simian virus 40 and poliomavirus large T antigens
518
. The Akt2 gene codes for the 
enzyme RAC-beta serine/threonine-protein kinase and has been described as an oncogene in ovarian 
carcinoma
519
. It has been associated with poor prognostic outcomes and increased tumour aggressiveness 
when upregulated
519
. Ak2 has also been found upregulated in EBV virus immortalised B cells
519
. 
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FIGURE 4-26 
 
Hand drawn diagram showing the effects of HSA-miR-564 
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4.6 The EBV virus- its role in the development of disease 
4.6.1 EBV associated malignancies 
Tumours usually result from multifactorial changes resulting in genetic alterations that enable the 
immortalisation of the implicated cell
520
. Viruses are amongst the implicated causative factors of these 
changes. The existence of viral oncogenes created a window of understanding as to how viruses function 
towards the development of tumours
521
. EBV (Ebstein Barr Virus or Human Herpesvirus 4) of the Genus 
Lymphocryptovirus and subfamily Gammaherpesvirinae (gamma 1 subtype) is a lymphotrophic gamma 
human herpesvirus and infects around 90-95% of the population within the first 40 years of life. It was the 
first virus to be associated with a human tumour
509
 (Figure 4-27). Whereas the infection is prevalent in 
early life in underdeveloped countries, it tends to present towards adolescence in developed countries, as 
a benign lymphoproliferative disorder
522
. In the acute and latent phase, EBV is in itself benign but it has a 
known association with various cancers including Burkitt’s lymphoma. 
In vitro studies show the pivotal role of EBV in oncogenesis. It is capable of transforming over 50% of 
resting B-cells into continuously proliferating cells with latent virus within a few days
510
. Interestingly, 
when B lymphocytes from chronic carriers of the virus are cultured (in the absence of T lymphocytes), it 
is those affected by EBV that proliferate forming lymphoblastoid cell lines all carrying viral copies and 
showing the Latency 3 program of infection (Table 4-9). EBNA-2 and LMP-1 are the viral protein 
essential for this clonal proliferation of in vitro cells. 
Burkitt’s lymphoma is associated with translocations in chromosomes 2, 14 or 22 causing the 
downregulation of MYC proteins and enabling increased B-cell proliferation
523
. Other lymphomas such 
as Hodgkin’s and Non-Hodgkin’s Lymphomas are also associated with EBV infection and latent 
transcripts in the BAMHI region of the EBV genome are also identified in Hodgkin’s Lymphoma524. 
Other associated epithelial malignancies include undifferentiated nasopharyngeal carcinoma 
demonstrating expression of the EBV LMP2A and LMP 2B genes. Nasopharyngeal carcinoma has also 
shown the presence of latent transcripts identified in the BAMHI region of the EBV genome in the 
opposite direction of the conventional mRNAs transcribed in this region
524
. In undifferentiated (non-
keratinising) carcinoma of the nasopharynx, there is a visible lymphocytic infiltration near the tumour 
cells. These tumours have been shown to be monoclonally EBV positive
525
 (Figure 4-28). 
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FIGURE 4-27 
 
Pathways affected by the Epstein- Barr Virus (EBV)526 
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FIGURE 4-28 
 
Diagram representing an overview of EBV associated malignancies 
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It is believed that in all EBV associated tumours, the starting point in malignant development arises with 
a persistent EBV infection
527
. It is to be noted that though 90-95% of adults have latent EBV, not all 
develop tumours. This supports the theory of multifactorial agents causing disease. Depending on their 
location, the effect on infected B-cells by the EBV virus varies. If the B-cells are found in peripheral 
blood, the virus is often dormant. Conversely, in the lymphoid system of the nasopharynx, the active virus 
is found. In the nasopharynx, the virus is believed to have been transferred through saliva
528
 and crosses 
the epithelial cells. One of the mechanisms of infection is believed to lie in a primary infection of the 
oropharyngeal epithelial cells with the EBV virus. The virus is then transferred through direct methods of 
contact to the subepithelial cells causing them to invade B cells. The affected B cells stimulate a CD8 T 
cell response which attempts to eliminate all the infected B cells. Most but not all B cells are eliminated 
resulting in cells harbouring the EBV virus causing a latent infection (Figure 4-29). 
FIGURE 4-29 
 
Schematic representation of latent EBV infection in B Cells 
4.6.2 Survival of EBV 
When a B-cell is activated, it migrates to the germinal centre producing antibody generating plasma cells 
and memory cells
529
. Studies have shown that infected B cells attain properties enabling them to 
proliferate into cell lines containing and expressing latency associated viral proteins (Epstein-Barr nuclear 
antigens (EBNA) 1, 2, 3A, 3B, 3C and LP) and latent membrane proteins (LMP) 1, 2A and 2B
530
. In EBV 
infected B-cells the activation process occurs but due to undefined signalling in the follicles, the default 
program of infection occurs where EBNA-1, LMP-1 and LMP-2A provide signalling for differentiation 
of lymphoblasts into memory cells maintaining persistently infected cells. Apart from being seen in B-cell 
cellular mutation, the default program of infection is also seen where the virus inappropriately infects non 
B-cells such as nasopharyngeal epithelial cells. The method of viral transfer is not completely understood 
with the possibility of virus as well as exosomes transferring genetic material. This results in epithelium 
demonstrating the default program of infection
511,512
. Unlike B-cells, epithelial cells are unable to become 
memory cells and the LMP proteins cannot “turn off”. This explains how even in immunocompetent 
individuals infection can persist. The same theory could be true of endometriosis (Figure 4-30). 
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FIGURE 4-30 
 
Hand drawn diagram depicting EBV survival techniques 
Gene, protein and miRNA expression in women with endometriosis 
158 
One would therefore expect that malignancies linked with EBV express these proteins too. Interestingly 
not all EBV associated malignancies express these proteins due to the presence of genetic aberrations and 
deregulations which will in turn disregulate oncogenes and tumour suppressor genes causing 
malignancy
531
. An alternate theory explaining the failure of immunohistochemical studies to find 
significant EBV in germinal centres is due to the fact that infected B cells do not always give rise to a full 
germinal centre or they alternately differentiate and expand outside of the germinal centre itself
532
. 
When looking at malignancies associated with EBV, one may look for cell lines which express similar 
aberrations due to clonal proliferation
533
. These are often used as malignancy markers. Interestingly, 
tumour development is also associated with errors in DNA repair causing aberrations which are not 
necessarily clonal. The DNA breaks can and are lethal to cells when they divide so new aberrations will 
be seen with each new cell cycle. 
It is interesting to note that the EBV proteins expressed during latent infection, in themselves cause 
genomic instability and chromosomal abnormalities
530
. EBNA 1, 3 and LMP 1 cause instability in the 
genome associated with DNA breaks and phosphorylation of histone H2AX which is implicated in the 
checkpoints of the cell cycle and tumour suppression (Figure 4-31, Figure 4-30). 
FIGURE 4-31 
 
Schematic representation of the functions of EBV proteins expressed during latent infection 
 
As is described above, the targets of EBV associated proteins affect cell cycle checkpoints and therefore 
destabilise the integrity of the genome. Several types of cancers associated with EBV do not have high 
expression of viral genes as the viral genome itself is seen to be heavily methylated. 
Survival of the virus within the system is attributed to the fact that affected cells do not express growth-
promoting genes, surviving in the peripheral circulation as resting memory cells
534
. Apart from the 
latency programme maintaining the viruses in check, the body’s immune system also serves as a 
controller of virus containing cells. Cytotoxic t-lymphoctes identify and destroy expression of any virally 
infected cells outside of the memory pool
535
. Any dysregulation within the host’s immune system will 
adversely affect the t-cell function enabling continuing viral existence or active pathology. In 
immunocompromised hosts, the EBV infected cells are seen to proliferate and give rise to EBV 
associated tumours which typically regress with cytotoxic t-cell lymphocyte therapy. 
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4.6.3 Genes expressed in latency and associated pathways affecting the immune system 
Latency programme of infection resides in peripheral blood B-cells accounting for lifelong benign 
infection. Persistence of infection is described as stable numbers of affected B-cells (Table 4-9). 
TABLE 4-9 
Gene 
expressed 
EBNA- 
1 
EBNA- 
2 
EBNA-
3A 
EBNA-
3B 
EBNA-
3C 
EBNA-
LP 
LMP- 
1 
LMP-
2A 
LMP-
2B 
EBER 
Product Protein Protein Protein Protein Protein Protein Protein Protein Protein ncRNAs 
Latency I + – – – – – – – – + 
Latency II + – – – – + + + + + 
Latency III + + + + + + + + + + 
Table showing the 3 types of expressed latency programs proteins of EBV536 
 
The infectious state is associated with salivary viral shedding. Associated cytotoxic t-cells and antibodies 
are seen in the presence of viruses and these are usually at stable levels. It is mutations in the virus that 
lead to the development of oncogenesis, carcinomas and lymphomas. A resting B-lymphocyte, once 
infected, can rapidly proliferate giving rise to disease
537,538
. The EBV associated proteins affect the cell 
cycle at various checkpoints and all have a role in destabilisation of the genome and dysregulation of the 
cell cycle and its pathways (Figure 4-32). 
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FIGURE 4-32 
 
Figure illustrating the genes expressed in latent EBV infection and their associated pathways526 
 
EBNA-1 (Epstein-Barr nuclear antigen-1) a nuclear associated viral latency protein ensures the 
replication of the viral genome in cell division. It enables this by linking the viral nuclear material to the 
cellular one enabling its replication with cellular division
539
. 
EBNA-2 acts as a surrogate for the Notch intracellular domain within the Notch signalling system and 
controls the transcription which halts B cell differentiation in proliferation
540
. It also activates the growth 
program viral proteins and activates cellular activation through the C-Myc pathway acting as a 
protoncogene
541
. 
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EBNA-3C has a poorly known mechanism where there is inactivation of the retinoblastoma (Rb) tumour 
suppressor. This enables cell cycle progression from the G1 to the synthesis phase enhancing 
proliferation
542
. 
LMP-1 (latent membrane protein-1) interacts with TRAF (Tumour necrosis factor receptor-associated 
factor) an intermediary of the TNFR family of cell surface receptors
543
 for the delivery of both survival 
and death signals
544
. Its carboxy terminal domain is a functional homologue of CD40
545,546
 (though differs 
in its signalling pathway) with interchangeable signal domains
547
. This rescues B-cells from apoptosis 
thereby driving proliferation. There are various pathways which are activated by LMP-1 binding. LMP-1 
not only interacts with TRAFs but also interacts with the JaK3 (Janus activating kinase) activating the 
NFκB pathway, the activator protein 1 through c-Jun N-terminal kinase (JNK) and the pathways for the 
signal transducers and activators of transcription (STAT) pathways. 
LMP-2A (Latent membrane protein-2A) contains the same ITAMs (immunoreceptor tyrosine-based 
activation motifs) found on the α and β chains of B-cell receptors. This enables them to interact with the 
tyrosine kinases (Src family) mimicking the signalling of a B-cell receptor which has been engaged by 
antigens. This promotes signalling for growth through the RAS pathways and alternate mechanisms. 
Usually in the absence of an antigen signal, the B-cell receptor maintains B-cell survival by controlled 
signalling levels. LMP-2 mimics this signalling thereby preventing the death of B-cells which lack their 
surface immunoglobulin
548
. 
4.6.4 EBV and exosomes 
The role of miRNA in the repression of mRNA translation into proteins has been well documented. This 
regulatory role is a finely balanced process in healthy tissues but is dysregulated in tumours or virally 
infected cells
549
. miRNAs are not only human in origin but also viral and are actively secreted through 
vesicles called exosomes which serve as protection from RNases
550
. The vesicles (approximately 50nm 
diameter) were seen to contain transferrin receptors that enable the process of endocytosis and cell protein 
recycling. Exosomes of EBV transformed B-cells are known to have plasma membrane lipid domains rich 
in cholesterol
551
. Functionally the exosome can enable the combination of ligands which would be able to 
bind simultaneously with different cell-surface receptors which might not happen in a “normal” cellular 
scenario. The response of activation of multiple ligands can mimic cellular interactions without the need 
for actual cellular contact. Exosomes can also transport new cell surface molecules to cells enabling them 
to achieve new properties such as adhesion and they can also enable transfer of cytosol and proteins 
between various cellular types. This again might alter cellular properties
552
 (Figure 4-33). The horizontal 
transfer of miRNAs which are non-coding is emerging as a possible evolutionary conserved method 
enabling intercellular communications. In vivo evidence is scarce. In vitro studies have indicated that 
mature functional miRNAs can be secreted through exosomes and have been seen in B cells
553
, stem cells, 
immune cells, placental cells
554
 and cancer cells
550,555,556
. Once present in the host cells, the transferred 
miRNA cause alterations in the cell triggering oncogenic properties. In the study by Raposo
553
, the 
exosomes secreted by EBV transformed B-cells, triggered CD4+ t-cell stimulation, mimicking antigenic 
activation. The T-cell response was however less potent
553
. Interestingly, exosomes might also have 
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immune-suppressive effects which are independent of antigens. Certain viral proteins within exosomes 
such as LMP-1 inhibit anti CD3 and anti-CD28 induced T-cell proliferation
557
. 
The analysis of microvesicle and nano-exosome carried miRNA is today used in the understanding of 
cellular processes. Understanding their cellular impacts might provide insights in their potential use as 
specific disease biomarkers or therapeutic response markers. They are also being looked at as transporters 
for immunotherapies as novel future treatments. The role of exosomes in B-cell mediated cross talk in 
humans has also been explored
555,558
. The presence of such vesicles explains how miRNAs can exert 
functions outside of their producing cells and possibly serve as intercellular communications
559,560
. There 
are papers exploring (through quantitative RT-PCR) how virally EBV infected B-cells transfer their 
miRNAs through exosomes
550
. In diseases affected by EBV, the EBV DNA is seen to be present or 
restricted to peripheral blood lymphocytes but the miRNAs for the EBV have been found to accumulate 
in non-infected surrounding cells. These transferred miRNAs cause gene repression in neighbouring cells 
enhancing evidence of their presence and function
550
. Once infected, a B-cell can express four different 
types of programmes. One of these programmes results in the production of an active virus, whereas the 
other 3 code for latent infections (Figure 4-34)
541
. In the latency programmes the infectious virus is not 
produced, but latent proteins are expressed. In the growth programme all nine latent proteins are 
expressed. The latency programme is what is found in 95% of adults carrying a benign lifelong infection 
and it enables the in vivo virus to last despite being transcriptionally quiet
541,534
. 
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FIGURE 4-33 
 
Hand drawn figure depicting the effects of exosomes from EBV-infected B-cells 
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FIGURE 4-34 
Latency transcription programmes 
 Genes expressed Proposed function 
Growth programme * EBNA1-6 
LMP1 
LMP2A-B 
Activates a resting B cell to become a 
proliferating lymphoblast 
Default programme ǂ EBNA1 
LMP1 
LMP2A 
Provides necessary survival signals 
(i) infected lymphoblasts to differentiate 
into memory, and 
(ii) maintenance of persistently infected 
memory cells 
Latency programme None 
(LMP2A§) 
Allows persistence of the virus in resting 
recirculating memory cells in a way that 
is non-pathogenic and not detectable by 
the immune system 
' Sometimes referred to as Latency III ǂ Sometimes referred to as Latency II. § The transcript for 
LMP2A is often detected in these cells. EBNA, Epstein-Barr Virus nuclear antigen; LMP, latent 
membrane proteins 
Figure showing three latency transcription programmes. Taken from Nature article by Thorley-Lawson et al.541 
 
4.6.5 EBV associated with immunocompromisation 
Endometrial cells are dynamic tissues that regenerate and differentiate in response to the hormonal stimuli 
controlling female menstruation. Their function is particularly important in preparing the uterus for 
embryo implantation during pregnancy
561
. Pregnancy itself is an immunocompromised state, one can 
theorise that any defect in the immune system potentially caused by viruses such as EBV, will affect the 
immune interactions within the endometrium causing failure of implantation. Excluding other 
confounding factors, patients with endometriosis have higher infertility rates when compared to women 
without endometriosis and the mechanism is not completely understood
34,198,562
. In understanding how 
EBV acts in immunocompromised patients could potentially allow us to understand the link between 
endometriosis and infertility. 
As mentioned above in the in vitro studies, EBV affected B cells proliferate in the absence of functioning 
t-cells. Clinically this would be replicated in immunocompromised individuals such as in those with 
immunoblastic lymphomas where the disease is stimulated through EBV affected B cells in the absence 
of other genetic alterations and regresses with optimisation of the immune system through therapeutics. A 
classic clinical presentation is the development of tumours in transplant patients who are being 
immunocompromised to prevent organ rejection. In these patients immunosuppression leads to cytotoxic 
t-cell loss and the accumulation of EBV infected B cell proliferation
563
. 
In an immunocompetent person EBV is still associated with tumours. In these cases it is believed to be 
one of the contributing factors to malignancy rather than the sole causator. Burkitt’s Lymphoma, 
Hodgkin’s Lymphoma or nasopharyngeal carcinomas are all linked to earlier EBV infections527. 
Natural Killer cells play an imperative role in the elimination of cells which are either virally infected or 
transformed
564,565
. In 1992, a published study showed decreased NK cell activity on the peripheral blood 
and peritoneal fluid of women with endometriosis
566
 (Figure 1-2). Tumour cells lacking major 
histocompatibility complex (MHC) class 1 expression preferentially cause NK cell recruitment and 
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activation causing lysis of the affected cells
565
. It is reported that increased levels of MHC class 1 on 
endometrial stromal cells of women with endometriosis helps in the evasion of NK cell response
567
 
(Figure 1-2). Monocytes from peritoneal fluid from women with endometriosis show an Interleukin- 10 
(IL-10) dependant down regulation of expression of MHC class 2
568
. 
The prime role of this miRNA is to bind the MHC Class I Polypeptide-Related Sequence B (MICB) 
normally expressed in cells to ligate NK cells leading to death of the cell (Figure 1-2, Figure 4-33). MICB 
is induced in cells experiencing ‘stress’ or insults such as viral infections, inflammation or malignancy. If 
in endometriosis the MICB expression is suppressed by BART2-5p, this leads to the evasion of cell death 
by NK cells in the ectopic environment permitting ectopic endometrial cellular implantation. 
Observations of reduced NK cell activity in women with endometriosis supports the role of EBV BART2-
5p in the avoidance of immune surveillance in endometriosis. Other publications show that the presence 
of healthy, functional NK cells is inversely proportional to the presence of EBV virus and its effects
513
. 
There are a number of predicted human target genes for EBV BART2-5p which have particular roles 
enabling ectopic tissue to engraft and survive. The BCLAF1 gene linked to apoptosis, the CDH1/E-
Cadherin linked to cell adhesion and the MASPIN linked to p53 signalling are all implicated.  
BCLAF1 gene encodes for Bcl-2-associated transcription factor 1 which is a Bcl-2 family protein. It does 
not however share structural similarities with these proteins
569
. Over expression of the BCLAF1 induces 
apoptosis and T cell proliferation. The expression of BART2-5p provides a survival advantage to ectopic 
endometrium having reduced apoptosis and avoiding immune surveillance by the t-cells (Figure 4-10). 
My study demonstrates the reduction of BCLAF-1 on tissue microarray analysis (TMA). Comparing 
levels between endometriotic tissue and normal endometrium, there is a statistically significant 
downregulation of BCLAF-1 in endometriosis compared to normal endometrium from cases (P<0.0001) 
(Figure 4-16, Table 4-5, Table 4-6). 
CDH1/E-Cadherin is a master regulator of the G0/G1 stage of the cell cycle. It is associated with uterine 
tissue and the formation of correct placentation between the embryo and maternal circulation. Its role is to 
reduce cell adhesion, division and cycling. Loss of function or mutations in this gene are seen in 
gynaecological cancers. Its suppression in ectopic endometrial tissue predicts an increase in cell adhesion 
(observed in endometriosis) and removes the suppression on the G0/G1 cell cycle stage moving cells into 
the S phase. 
Studies published show a reduction of E-Cadherin in endometriosis cells compared to normal 
endometrium. In vitro studies looking at collagen invasion assays show increased invasive potential with 
E-Cadherin negative cells. This is not seen in normal endometrial cells. This study confirms the 
downregulation of E-Cadherin protein in endometriosis as predicted with the BART2-5p up regulation. 
My study demonstrates the downregulation of E-Cadherin in endometriosis on tissue microarray (TMA) 
analysis. There is a statistically significant downregulation of E-Cadherin in endometriosis compared to 
normal endometrium from controls (P<0.0001) and normal endometrium from cases (P=0.0017) (Figure 
4-12, Table 4-1, Table 4-2). The reduction in E-Cadherin enables the tissues to metastasise and infiltrate 
causing disease progression and creating an invasive pattern often seen in endometriosis. 
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Maspin gene was first identified in normal mammary cells but not in breast cancer derived epithelial cells, 
implicating it as having a role in tumour suppression, inhibition of cell migration angiogenesis and 
metastasis. It is expressed in normal endometrial cells and its suppression by BART2-5p leads to an 
increase in ability for the endometrium to migrate and survive. An activating p53 binding site was 
identified and showed Maspin to be the downstream effector gene. My study confirms the reduction of 
Maspin on tissue microarray (TMA) analysis. Comparing levels between endometriotic tissue and normal 
endometrium, there is a statistically significant downregulation of MASPIN in endometriosis compared to 
normal endometrium from controls (P<0.0001) and normal endometrium from cases (P=0.2760) (Figure 
4-14,Table 4-3,Table 4-4). 
4.6.6 Diagnosing pathology associated with EBV 
Amplification through the polymerase chain reaction (PCR) or Nucleic acid sequence based amplification 
(NASBA) of viral nucleic acids of EBV is a technique used to identify the presence of virus. It cannot 
however differentiate between latent or active infection. PCR is however a good method to quantify EBV 
viral loads, which clinically is important when assessing for patient response to treatments
570
. 
Serum from patients with EBV associated malignancies can be processed with immunofluorescent assays 
or enzyme-linked immunosorbant assay (ELISA), both of which are EBV protein specific and are used to 
distinguish between latent and active infections. Viral antigens as well as immunoglobulins to the 
antigens can all be targeted in this approach but not all malignancies express these patterns to the same 
level making the technique unreliable for the identification of all known EBV associated tumours. 
Other techniques employed include Southern blotting, the culturing of infected EBV lymphocytes and 
their study using electron microscopes, gene expression profiles and microarrays. 
In my project I used tissue microarrays to analysis the miRNA expression between diseased and control 
tissues. I then used EBV in-situ hybridisation locating the virus within lymphocytes infiltrating the 
tissues. Quantitative PCR was then used to assess for the presence and numbers of EBV virus within the 
peripheral blood lymphocytes of cases versus control patients. 
4.6.7 Treatments for EBV related tumours- research and therapeutics 
4.6.7.1 Immunotherapies 
Cytotoxic t-cells have been successfully used to directly target EBV antigens
571
. In the study by 
Heslop
571
, 114 patients were given EBV specific cytotoxic t-cell infusions to prevent or treat post-
transplant lymphoproliferative disorders. Apart from local areas of irritation, the therapies were 
successful. Out of the 101 patients who received infusions for prophylaxis, none developed disease while 
11 of 13 patients who were treated for proven or probable lymphoproliferative disease had complete 
remission. In a separate study, peripheral blood was collected from allograft recipients prior to starting 
their immunosuppressive therapy. The t-lymphocytes were then stimulated in vitro to function as EBV 
specific cytotoxic t-lymphocytes. The primed lymphocytes were then transferred back into the patients 
believed to have high risk of developing post-transplant lymphoproliferative disease due to high initial 
tissue EBV levels
572
. The treatment was tolerated well by the recipient patients and despite the 
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immunosuppressive therapy, cytotoxic t-cell levels and functions were maintained. The EBV levels as 
assessed by their DNA levels were seen to fall in the treated group. Similar cytotoxic T-lymphocytes 
infusions were studied in patients who received T-cell depleted allogenic bone marrow transplants
573
. 
Once more, no major toxicity was reported and none of the transfused patients developed post-transplant 
lymphoproliferative disease compared to 15% of those who were not treated. Caution as to the efficiency 
of such therapies in advanced or rapidly progressive disease has been mentioned, making these therapies 
an exciting possibility for chronic slow growing diseases such as endometriosis. Future studies in the use 
of immunotherapies for endometriosis look promising. 
4.6.7.2 Combination therapies for induction of lytic EBV infection 
Inducing a lytic EBV infection within tumours through lytic-inducing chemotherapy releases EBV 
kinases that in turn activate Ganciclovir to its active cytotoxic state. Combined treatments are seen to be 
more effective than individual ones. The identification of CD70 in certain EBV positive tumours creates 
another target for anti-CD70 monoclonal antibodies. Monoclonal antibodies to CD20 (Rituximab), 
another protein expressed in EBV positive cancers, is another form of therapy used to target the EBV 
positive B cells in post-transplant lymphoproliferative disorders. 
Combinations of therapies leading to cell cycle apoptosis (Gangiciclovir) and therapies that would 
upregulate viral enzymes (Butyrate) seem promising. 
4.6.7.3 Cytotoxic therapies 
With cytotoxic therapies the balance between the dosage and its resulting morbidity and mortality is vital. 
Therapies tend to be reduced in strength to prevent extreme morbidity. Unfortunately one sees a higher 
level of relapse at lower treatment dosages. Certain therapies show increased cytotoxicity in those cells 
expressing EBV virus which makes them ideal target therapies. Such a compound was Tubacin, which is 
seen to inhibit histone deacetylase 6 and was toxic to EBV positive cells through a caspase independent-
3-pathway
574
. Cytotoxic therapies would not be ideal in women of reproductive age for the treatment of 
endometriosis. They might however be useful in women with severe endometriosis expressing high EBV 
levels and who have completed their family. 
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5 Endometriosis serum miRNA biomarker discovery study 
(molecular)  
5.1 Introduction 
Following the tissue miRNA study, other potential miRNA markers were examined for disease presence 
in the serum of patients compared to that of controls. The ability to predict presence of disease through a 
non-surgical technique would reduce patient morbidity and enable earlier disease identification and 
treatment. 
5.2 Aims 
 To obtain a set of serum samples from clinically well characterised patients who suffered from 
endometriosis with no other confounding pathology (Disease samples) and samples from surgically 
confirmed women without endometriosis or confounding pathology (Control samples). 
 To assess for differences in serum miRNA expression between the serum of patients with 
endometriosis and the controls. 
 To identify a panel of potential miRNA serum markers that could be used as a non-invasive 
diagnostic test for endometriosis. 
5.3 Method 
51 serum samples (endometriosis (n=36) vs control (n=15)) were taken from the patients recruited at 
surgery. Samples were stored at -80 ºC until required. They were then rapidly aliquoted from thawing to 
circumvent degradation of the samples during repeated freeze thaw cycles. Polypropylene sample tubes 
were labelled with sample identities ready for use and serum samples were then thawed at 20ºC for 30 
minutes. One 300µL sample was taken from each tube for miRNA analysis and 22.5µLwas taken for 
autoantibody analysis. The remaining volume was dispensed into 5 x 200µL aliquots in labelled sample 
tubes (Table 9-16, Table 9-17). Any remaining sample was left in the original sample tube. The tubes 
were frozen and stored at -80ºC together with the original sample tubes. Due to variation in sample 
volumes some samples only yielded 2 or 3 aliquots. Samples were thawed directly prior to the assay and 
were randomised and split into assay racks of 23 samples each. Each assay rack contained both case and 
control samples and one pooled normal human serum control sample which was used to monitor assay 
performance. The serum was assayed for the presence of miRNAs using the Discovery Array v2.0 and the 
standard biomarker discovery protocol (Section 2.6.3 and Section 2.6.4). 
5.3.1 Validation of miRNA in serum of subjects suffering from endometriosis using qPCR 
For quantitative PCR (“qPCR”) usage, Life Technologies’ (“LifeTech”) TaqMan® miRNA assays were 
used. These assays are continuously aligned with releases from the miRBase database and they represent 
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all known miRNAs from human beings, as well as all known human viral miRNAs. The TaqMan® 
miRNA assays employ a novel target-specific stem-loop reverse transcription primer to address the 
challenge of the short length of mature miRNA. The primer extends the 3' end of the target to produce a 
template that can be used in standard TaqMan® assay–based real-time PCR. Also, the stem-loop structure 
in the tail of the primer confers a key advantage to these assays: that of the specific detection of the 
mature, biologically active miRNA. Using the significant markers identified in the miRNA microarray 
experiments, a sub-selection of miRNAs were analysed using the LifeTech TaqMan® miRNA qPCR 
assays, according to their standard protocol
575
. 
The TaqMan® miRNA assays were scanned using a ViiA™ 7 Real-Time PCR System using an 
excitation wavelength suitable for the detection of the labelled miRNAs. The qPCR scans produced traces 
for each TaqMan® miRNA assay which can be used, to determine the amount of specific miRNA within 
a given sample, relative to a passive reference dye (for example, but not limited to, ROX). The raw qPCR 
traces contained raw signal intensity to which an assay threshold was applied after the raw traces have 
been baseline normalised, which removed aberrant signals. This threshold line intersects the qPCR trace 
at the point on the qPCR trace where the trace is logarithmic. From this, the qPCR cycle (Ct) was 
determined. The qPCR traces were analysed using LifeTech’s proprietary analysis software. The median 
Ct and mean quantity was taken across the three sample replicates for each TaqMan® miRNA assay. 
Testing for statistically significant associations between the two groups (case vs control) was carried out 
by applying linear models to the normalised sample data to identify general miRNA changes between 
case samples and control samples. Statistical differences were calculated using a t-test. The data from the 
microarray and TaqMan® miRNA qPCR assays were analysed for Pearson correlation to assess the 
cross-platform robustness of the observed results (Figure 5-1). Figure 5-1 demonstrates that there is good 
correlation between a subset of the miRNA probes used for qPCR compared to those identified on the 
microarrays. 
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FIGURE 5-1 
 
Scatter plot showing CT versus pNorm for microarray signals 
 
5.4 Results 
MiRNA microarray assays were carried out to identify putative markers for distinction of endometriosis 
cases from healthy control samples (Table 5-1). All samples passed quality control- arrays passed all of 
584 scanning, labelling and spike-in quality control metrics to a standard of ‘good’ or ‘excellent’. All 
arrays passed the cut off for the minimum number of miRNAs detected (100). Pooled tissue control 
samples show good Pearson correlation (0.9) of detected miRNAs with those run in previous array 
batches. 
TABLE 5-1 
Cohort Reproductive cycle stage Total samples 
Endometriosis case 
Follicular 21 
36 Mid 3 
Luteal 12 
Healthy control 
Follicular 9 
35 
Luteal 26 
Pooled tissue control   2 
Total samples   73 
Table showing the categorisation of samples used for serum miRNA experiments 
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5.4.1 Data handling 
Data was filtered to only include miRNAs detected in at least 75% of either cases or controls (217 
miRNAs). Signals below the limit of detection were set to half the value of the minimum observed signal. 
Signals were normalised to the 95
th
 percentile. Logs of these signals were used for statistical analysis. 
There was a difference between the 2 batches of arrays, with more miRNAs being consistently detected in 
the additional batch of controls. This difference causes clear artefacts for many of the miRNAs and the 
batch data was therefore included in the statistical model to attempt to mitigate the effect of this bias in 
the analysis. Samples were checked for clustering via Principal Component Analysis (PCA) and 
hierarchical clustering for all provided annotations to look for general patterns in the data. None of the 
provided sample annotations appear to be driving large scale effects in the data and so have not been 
included as factors in the analysis. 
5.4.2 Differential expression 
The probed and dried arrays were scanned using a microarray scanner using an excitation wavelength 
suitable for the detection of the labelled miRNAs and to determine the magnitude of miRNA binding to 
the complementary detection probe. The microarray scans produced images for each array that were used 
to determine the intensity of fluorescence bound to each oligonucleotide spot which were used to 
normalise and score array data. The raw microarray scan image contained raw signal intensity (also 
referred to as the relative fluorescent unit, RFU) for each oligonucleotide spot (also referred to as a 
feature) on the array. The images were feature extracted using Agilent’s proprietary feature extraction 
software. The resulting average intensities of all oligonucleotide features on each array were then 
normalised to reduce the influence of technical bias (e.g. laser power variation, surface variation, input 
miRNA concentration, etc.) by a percentile normalisation procedure. A linear model was fitted to evaluate 
statistical differences in miRNA expression between cases and controls. In the volcano plot below, the x-
axis shows the log2 fold change between case and control and the y-axis shows statistical significance 
(negative log of the p-value to the base of 10). A selection of significant hits is highlighted (Figure 5-2). 
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FIGURE 5-2 
Volcano- case vs. control 
 
On the volcano plot, the x-axis shows the log2 fold change between case and control and the y-axis shows 
statistical significance (negative log of the p-value to the base of 10). The volcano plot analysing case vs. controls 
indicates a selection of significant hits in the serum miRNA experiments seen as dots above the horizontal line. 
 
The hierarchical clustering of the significant miRNAs according to the type of tissue (i.e. case vs. control) 
is shown in Figure 5-3, where black signifies high expression, white signifies intermediate expression, 
and grey signifies low expression. 
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FIGURE 5-3 
 
Hierarchical clustering of the significant miRNAs according to the type of tissue case versus control 
 
5.4.3 Differential expression- additional samples 
The addition of a further 20 control samples (to balance the numbers of case and control numbers) 
changed some of the significant hits, generally allowing the removal of probable false-positive hits near 
the lower limit of detection from the original data set. 
The plots below show the results from analysis prior to inclusion of the additional controls (Figure 5-2) to 
that with their inclusion (Figure 5-4). The most significant hits remain largely unchanged. 
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FIGURE 5-4 
Volcano- case vs. control (batch model data included) 
 
On the volcano plot, the x-axis shows the log2 fold change between case and control and the y-axis shows 
statistical significance (negative log of the p-value to the base of 10). The volcano plot analysing case vs. controls 
(batch model data included) indicates a selection of significant hits in the serum miRNA experiments. 
 
5.4.4 Case vs. control top hits- downregulated in disease 
8 markers are significantly downregulated in disease (p < 0.05, no multiple testing correction). Below are 
the distributions for the top 2 downregulated miRNAs by p-value i.e. hsa-miR-150 and hsa-miR-122 
(Figure 5-5). 
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FIGURE 5-5 
  
Boxplots showing distribution for the top 2 markers (hsa-miR-150 and hsa-miR-122) downregulated in 
endometriosis in serum miRNA experiments. 
 
5.4.5 Case vs. control top hits- upregulated in disease 
4 miRNAs are significantly up regulated in disease (p < 0.05, no multiple testing correction applied). 
Below are the distributions for the top 2 upregulated miRNAs by p-value i.e. hsa-miR-1224-5p and hsa-
miR-4274 (Figure 5-6). 
FIGURE 5-6 
  
Boxplots showing distribution for the top 2 markers (hsa-miR-1224-5p and hsa-miR-4274) upregulated in 
endometriosis in serum miRNA experiments. 
 
5.4.6 Expression- all significant hits 
The heat map (Figure 5-7) shows the expression in case and control samples of the 12 significant markers 
(8 downregulated and 4 upregulated). Samples are in columns and are coloured by disease stage, with 
green indicating controls and red indicating the cases. miRNA data is scaled by row, with red signifying 
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high miRNA expression, yellow intermediate miRNA expression and blue low miRNA expression 
(Figure 5-7). 
FIGURE 5-7 
 
 
The heat map shows the expression in case and control samples of the 12 significant markers. The x-axis 
demonstrates control samples in green and case samples in red. The y-axis lists the identified markers, each 
categorised by miRNA data intensity expressed: red signifying high miRNA expression, yellow intermediate 
miRNA expression and blue low miRNA expression. 
 
5.4.7 miRNA in serum- qPCR analysis 
A set of 5 differentially expressed and 3 control miRNAs (451, 16, 20a) were assayed via qPCR across 
the full set of endometriosis and healthy volunteer samples. In the qPCR a positive reaction was 
determined by fluorescent signal levels. The cycle threshold (Ct) was used to define the number of qPCR 
cycles required for the fluorescent signals to cross the background level threshold. The higher the amount 
of target miRNA present, the lower the Ct level. Data of Ct results was plotted in a scatter diagram 
against the normalised values of the gene signals obtained through the microarrays. These assessed for 
any correlation between the data obtained through these two separate analysis techniques. 2 of the 
markers show poor correlation between the microarray and qPCR data (Pearson rho less than 0.2). These 
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are the 2 markers with the lowest levels of detection and were not significantly different on addition of 
the further controls (miRNAs 3663-5p and 3194-5p). 
4 of the selected miRNA markers show good correlation (Pearson rho 0.5 to 0.7). These are miRNAs 150, 
122, 342-5p and 451 (control) (Figure 5-8). 
FIGURE 5-8 
 
Scatterplot of Ct results (y-axis) against the normalised values of the gene signals obtained through the 
microarray (x-axis) in cases and controls 
 
There is evidence (p<0.05) for batch differences between the control samples from the first and second 
collection. This has been corrected for in the analysis. T-tests show that miRNAs 150 and 122 are 
significantly down in disease (p<0.05). These markers are also showing good correlation between the 
platforms. miRNA 342-3p is significant at a less stringent confidence (p < 0.1) and is also down-regulated 
in disease (Figure 5-9). 
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FIGURE 5-9 
qPCR Microarray 
 
The left boxplot shows results obtained from PCR. It plots on the x-axis each identified miRNA marker against 
the median Ct value for case (red box) and controls (green box). The right boxplot shows results obtained from 
microarray. It plots on the x-axis each identified miRNA marker against the pNorm gene signal value for case 
(red box) and controls (green box). 
 
Some significant markers have been identified in case vs. control samples (uncorrected p<0.05). The most 
significant markers have low signal strength, near the lower limit of detection for the microarray platform. 
qPCR analysis is supportive of three of the markers that have significant downregulation in disease: 
miRNAs 150, 122 and 342-3p. There is a significant batch effect correction in this data. Some of the 
selected markers have been influenced by this and one cannot be sure that the correction is working 
perfectly. Therefore, some caution is required in interpreting these results. 
5.5 Discussion 
5.5.1 miRNA serum analysis 
A minimum of six on-line prediction databases were accessed for each analysed miRNA (Gene cards, 
microrna.org, Target Scan, Star Base, Diana Lab, miRDB).Prediction targets for each miRNA were 
assessed from the databases and hits ran numerically from a thousand to seven thousand in number. The 
PCT is the probability of conserved targeting for highly conserved miRNA families. Target gene tables 
were sorted by the highest PCT value (0.8 and higher). The top 100 predicted targets from each database 
were selected and each predicted target was counter checked for similarity against each database. Targets 
that gave hits in at least two of the databases were selected as potential targets for the respective miRNA. 
Results were inserted into gene prediction programs such as STRING™ and a literature search for each 
assessed miRNA was performed to identify pathways of disease. Panther™ program was used to predict 
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involved pathways regulated through identified miRNA and an extensive summary of their functions and 
pathway involvement was performed. 
The following section is aimed at analysing the molecular and cellular functions of the proteins which 
were most highly associated with the respective upregulated and downregulated identified miRNAs. In 
Section 5.8 I proceeded to look at the overall cellular functions affected by the identified miRNAs and 
their proteins which could give us a better clinical understanding of how this multifactorial disease 
develops. 
5.5.2 Summary and salient points of identified pathways linked to upregulated hsa-mir-1224-5p, hsa-
mir-4274 and downregulated hsa-mir-150, hsa-mir-122 
 Pathways affected by miRNAs expressed in endometriosis could potentially contribute to 
development of disease through the deregulation of their control. Below is a summary and list of all 
the genes and their associated pathways. It is beyond the scope of this chapter to determine which are 
the most likely proteins or genes or pathways to cause (or enable to a larger extent) the development 
of the disease of endometriosis. This would require a separate body of work with functional models 
to determine important molecular or protein roles (Figure 5-10, Figure 5-11). 
 Table 5-2 , Table 5-3, Table 5-4 and Table 5-5 summarise pathways affected by the respective 
miRNAs, which will been discussed in the following sections of my thesis (see sections 5.5.2, 5.7 
and 5.8). 
 Identified miRNAs are seen to interact with a number of important pathways listed below. There 
could potentially be effects on cellular mitosis and meiosis, cellular structure, intra and intercellular 
signalling, vesicular transport including exo and endocytosis and cellular apoptosis. All of these 
changes can result in endometriotic cells that replicate at accelerated rates, adhere to ectopic sites, 
enable angiogenesis and growth, evade normal apoptotic mechanisms and evade immune responses 
(Figure 5-10, Figure 5-11). 
 Certain identified pathways act as tumour suppressors that could potentially explain the non-
malignant properties in the majority of cases of endometriosis. These include the p38 MAPK
1
 
pathway and the p53 tumour suppressor genes
2
. 
 Other pathways summarised below are known to be associated with tumorigenesis and have pro-
oncogenic properties, these include the RAS, WNT, TRK receptors and MAPKKKK pathways. 
 It is the fine balance between tumour suppressors and oncogenes that probably control the transition 
between endometriosis and endometrial carcinomas. 
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FIGURE 5-10 
 
Hand drawn figure summarising the function of identified miRNAs, their associated genes and proteins and the pathways they effect 
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FIGURE 5-11 
 
Hand drawn figure summarising the function of identified miRNAs, their associated genes and proteins and the pathways they effect 
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TABLE 5-2 
Pathway Genes regulated by hsa-miR-1224-5p 
Apoptosis signalling pathway Cyclic AMP-responsive element-binding protein 
(CREB1)  
B Ras pathway Dual specificity mitogen-activated protein kinase 
kinase 6 (MAP2K6) 
Cytokine-mediated signalling pathway C-X-C motif chemokine 6 (CXCL6) 
EGF receptor signalling pathway  Dual specificity mitogen-activated protein kinase 
kinase 6 (MAP2K6) 
FGF signalling pathway Fibroblast growth factor receptor 1 (FGFR1) 
G-protein coupled receptor protein signalling 
pathway 
SEC14 domain and spectrin repeat-containing 
protein 1 (SESD1) 
Gi alpha and Gs alpha mediated pathway Cyclic AMP-responsive element-binding protein 
(CREB1)  
Gonadotropin releasing hormone receptor 
pathway 
Cyclic AMP-responsive element-binding protein 
(CREB1) 
Transcription factor Sp1 (SP1) 
Dual specificity mitogen-activated protein kinase 
kinase 6 (MAP2K6)  
Heterotrimeric G-protein signalling pathway Cyclic AMP-responsive element-binding protein 
(CREB1)  
I-kappaB, kinase/NF-kappaB cascade C-X-C motif chemokine 6 (CXCL6) 
Inflammatory pathway mediated by 
chemokine and cytokine signalling 
Cytohesin-2 (CYTH2)  
JNK cascade SEC14 domain and spectrin repeat-containing 
protein 1 (SESD1) 
C-X-C motif chemokine 6 (CXCL6) 
MAP kinase-activating death domain protein 
(MADD) 
p38 MAPK pathway Cyclic AMP-responsive element-binding protein 
(CREB1) 
Dual specificity mitogen-activated protein kinase 
kinase 6 (MAP2K6) 
P53 pathway NAD-dependent deacetylase sirtuin-6 (SIRT6) 
Rod outer segment phototransduction Cyclic nucleotide-gated cation channel beta-3 
(CNGB3) 
Signalling pathway of heterotrimeric G-
protein 
Cyclic nucleotide-gated cation channel beta-3 
(CNGB3) 
Tyrosine kinase signalling pathway Fibroblast growth factor receptor 1 (FGFR1) 
Ubiquitin proteasome pathway  Ubiquitin-conjugating enzyme E2 W (UBE2W) 
A table summarising pathways affected by miRNA hsa-miR-1224-5p expressed in endometriosis. 
 
TABLE 5-3 
Pathway Gene regulated by hsa-mir-4274. 
Alzheimer’s disease amyloid secretase 
pathway 
Serine/threonine-protein kinase N2 (PKN2) 
Cadherin signalling pathways Protocadherin-9 (PCDH9) 
cGMP dependent pathways cGMP-dependent protein kinase 2 (PRKG2) 
Endothelin signalling pathway cGMP-dependent protein kinase 2 (PRKG2) 
G-protein coupled receptor protein signalling 
pathway 
Rap guanine nucleotide exchange factor 2 
(RAPGEF2) 
Pituitary adenylate cyclase-activating polypeptide 
type I receptor (ADCYAP1R1) 
Gonadotropin releasing hormone receptor 
pathway 
Pituitary adenylate cyclase-activating polypeptide 
type I receptor (ADCYAP1R1) 
Hedgehog signalling pathway Golgin subfamily A member 8A (GOLGA8A) 
Heterotrimeric G-protein signalling pathways 
(G1/Gs α and Gq/G0 α) 
Regulator of G-protein signalling 20 (RGS20) 
MAPKKK cascade Rap guanine nucleotide exchange factor 2 
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(RAPGEF2) 
Muscarinic acetycholine receptor 1 and 3 
signalling pathway 
Serine/threonine-protein kinase N2 (PKN2) 
PDGF signalling pathway Serine/threonine-protein kinase N2 (PKN2) 
Transmembrane receptor protein tyrosine 
kinase signalling pathway 
Rap guanine nucleotide exchange factor 2 
(RAPGEF2) 
Wnt signalling pathways Protocadherin-9 (PCDH9) 
Golgin subfamily A member 8A (GOLGA8A) 
A table summarising pathways affected by miRNA hsa-miR-4274 expressed in endometriosis. 
 
TABLE 5-4 
Pathway Gene regulated by hsa-miR-150. 
Alzheimer’s disease presenilin pathway Catenin beta-1 (CTNNB1) 
Angiogenesis Catenin beta-1 (CTNNB1) 
Cadherin signalling pathways Catenin beta-1 (CTNNB1) 
Cytokine-mediated signalling pathway Interleukin-7 (IL7) 
Erythrocyte membrane protein band 4.1-like 
protein 5 (EPB41L5) 
Erythrocyte membrane protein band 4.1-like 
protein 5 (EPB41L5) 
Insulin/IGF pathway-protein kinase B 
signalling cascade 
Protein Mdm4 (MDM4) 
Gonadotropin releasing hormone receptor 
pathway 
Adiponectin receptor protein 2 (ADIPOR2) 
Catenin beta-1 (CTNNB1) 
Interleukin signalling pathway Interleukin-7 (IL7) 
JAK-STAT signalling pathways Interferon-induced protein with tetratricopeptide 
repeats 5 (IFIT5) 
Janus kinase and signal transducer and 
activator of transcription (JAK-STAT) 
cascade 
Interleukin-7 (IL7) 
Methionine biosynthesis pathway Cystathionine gamma-lyase (CTH) 
Methycitrate cycle Cytoplasmic aconitate hydratase (ACO1) 
Nicotine pharmacodynamics pathway Erythrocyte membrane protein band 4.1-like 
protein 5 (EPB41L5) 
p53 pathway Protein Mdm4 (MDM4) 
Catenin beta-1 (CTNNB1) 
Semaphorin mediated axon guided pathway Semaphorin-3A (SEMA3A) 
TNF-α/ FAS death receptor pathways Mitochondrial carrier homolog 2 (MTCH2) 
Trans-sulfuration pathway Cystathionine gamma-lyase (CTH) 
Tricarboxylic acid cycle Cytoplasmic aconitate hydratase (ACO1) 
WNT signalling pathway SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily D 
member 2 (SMARCD2) 
Catenin beta-1 (CTNNB1) 
A table summarising pathways affected by miRNA hsa-miR-150 expressed in endometriosis. 
 
TABLE 5-5 
Pathway Genes regulated by hsa-miR-122 
Apoptosis signalling pathway Interferon-inducible double stranded RNA-
dependent protein kinase activator. A (PRKRA) 
Complement activation pathways Testican-2 (SPOCK2) 
Dopamine receptor mediated signalling 
pathway 
Chloride intracellular channel protein 4 (CLIC4) 
FAS signalling pathway Lamin-B2 (LMNB2) 
G-protein coupled receptor protein signalling 
pathway 
ARF GTPase-activating protein GIT1 (GIT1) 
Brain-specific angiogenesis inhibitor 2 (BAI2) 
Gonadotropin releasing hormone receptor 
pathway 
Mitogen-activated protein kinase kinase kinase 
12 (MAP3K12) 
I-kappaB kinase/NF-kappaB cascade Mitogen-activated protein kinase kinase kinase 
12 (MAP3K12) 
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JNK signalling oxidative stress response 
pathway 
Dual specificity protein phosphatase 4 (DUSP4) 
Mitogen-activated protein kinase kinase kinase 
12 (MAP3K12) 
Nicotine pharmacodynamics pathway Chloride intracellular channel protein 4 (CLIC4) 
P53 pathway Brain-specific angiogenesis inhibitor 2 (BAI2) 
Serine/threonine kinase signalling pathway Mitogen-activated protein kinase kinase kinase 
12 (MAP3K12) 
A table summarising pathways affected by miRNA hsa-miR-122 expressed in endometriosis. 
 
5.6 Detailed analysis for upregulated miRNAs 
4 miRNAs were upregulated in endometriosis with the top two miRNAs identified as hsa-mir-1224-5p 
and hsa-mir-4274.  
5.6.1 Hsa-mir-1224-5p 
FIGURE 5-12 
 
Predicted evidence view of interactions of Hsa-mir-1224-5p576 
 
A number of pathways, proteins and genes have been identified associated with development of disease 
(Figure 5-12). 
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Ubiquitin-conjugating enzyme E2 W (UBE2W) is a gene with ligase activity involved in various cellular 
processes, regulating chromosome segregation and dorsal ventral axis specification of nuclear cellular 
material
496,577,578
. It is implicated in the processes of mitosis and meiosis as well as protein modification 
and cellular proteolysis. UBE2W is a negative regulator of apoptosis and has been noted as a key role 
player in embryonic development. It is part of the ubiquitin proteasome pathway
526
. By negatively 
regulating apoptosis and altering cellular replication processes it could potentially be one of the genes 
enabling endometrial cell survival and engraftment in ectopic sites, causing endometriosis. 
Fibroblast growth factor receptor 1 (FGFR1) is a member of the tyrosine kinase signalling pathway 
acting as a transmembrane receptor
496,578
. It is a constituent of the FGF signalling pathway and the 
angiogenic pathway. Promotion of angiogenesis is a key factor enabling survival and implantation of 
ectopic endometrial cells. 
Sorting nexin-21 (SNX21) is involved in intracellular signalling cascade
496
. 
Origin recognition complex subunit 2 (ORC2) is responsible for DNA replication origin binding within 
the cell cycle. Cellular effects of genes such as SNX21 and ORC2 are complex as they act on the cell 
cycle and signalling. Possible dysregulation of finely tuned cellular functions at this level can result in 
endometriosis cells achieving properties enabling them to proliferate and survive in ectopic body sites. 
Sex comb on midleg-like protein 4 (SCML4) has chromatin binding and transcription factor activity
496,578
 
and is involved in the cell cycle in the regulation of transcription from the RNA polymerase 2 promoter. It 
is responsible for the establishment and maintenance of chromatin architecture in the cell
577
. 
SUN domain-containing protein 1 (SUN1) Synaptopodin-2 (SYNP2) and Prickle-like protein 2 (PRIC2), 
are all structural constituent of the cellular cytoskeleton. They regulate the morphogenesis of the cell and 
its components and are important in mitosis and cellular motion processes
496,578
. Like UBE2W, PRIC2 is 
important in the dorso-ventral axis formation of the cell. Cellular chromatin structure does not only 
control intra and intercellular signalling, it is also involved in cellular growth, adhesion and proliferation. 
The presence of genes such as SUN1 and SCML4 identified in patients with endometriosis could 
potentially contribute to disease development by altering cellular structure, adhesiveness, signalling and 
proliferation. 
Calpain-5 (CAN5) is a gene which has cysteine-type peptidase activity and is involved in calcium, 
calmodulin and calcium-dependant phospholipid binding in the cell. It is involved in the processes of 
apoptotic induction, processing of the immune system and proteolysis. In humans it has been linked to 
PCOS (Polycystic ovarian syndrome) and Huntington’s disease496,577,578. The apoptotic mechanism is vital 
in controlling cellular growth, proliferation and differentiation. Recognition of abnormal or ectopic cells 
is a vital constituent of the patient’s immune system. If in endometriosis these two systems are 
dysregulated, they will potentially contribute to formation of endometriotic cells, aid implantation and 
avoid immune system recognition. 
Tensin-1 (TENS1) is again another structural cytoskeleton constituent with a phosphoprotein phosphatase 
activity and has a role in actin binding
496,578
. It is involved in numerous cellular processes including cell 
cycle control, signal transduction, cellular adhesion and motion and the induction of apoptosis. It also has 
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a role in the immune system and mesodermal development. Aberrations in the cellular cycle and 
abovementioned cellular functions will potentially contribute to altered cellular properties enabling 
growth of disease such as endometriosis. 
Transcription factor Sp1 (SP1) is involved in transcription from RNA polymerase 2 promoter and has a 
role in the immune system
496
. In humans it is a constituent of the gonadotropin releasing hormone 
receptor pathway
526
. GnRH analogues are one of the current treatments used for the suppression of 
endometriosis. They induce a “medical menopause” for a period of usually three to six months depending 
on their dosage. They do not treat disease, but rather suppress proliferation in preparation for other 
medical interventions such as surgery or fertility treatments. Mechanisms explaining their exact effect and 
function on endometriotic cells are not completely understood. The regulation of SP1 could potentially 
explain part of their clinical action and understanding endometriosis at such a molecular level could 
potentially give us insights into novel disease therapeutics. 
Cyclic AMP-responsive element-binding protein (CREB1) has transcription factor activity and has a role 
in nucleic acid binding and regulating transcription from RNA polymerase 2 promoter
496,578
. It is found in 
numerous biological and cellular processes including ectodermal and nervous system development and 
immune system processes. Within the cell is has the function of signal transduction and is seen in cellular 
stress responses. It has roles in six major pathways including: Heterotrimeric G-protein signalling 
pathway-Gi alpha and Gs alpha mediated pathway->CREB binding protein, p38 MAPK pathway->cAMP 
response element binding protein, transcription regulation by bZIP transcription factor->cAMP response 
element binding protein, enkephalin release->cAMP response element binding protein, gonadotropin 
releasing hormone receptor pathway->CREB and the apoptosis signalling pathway->Activating 
transcription factor
526
. Any dysregulation of the CREB1 protein can potentially impact the cell function at 
various levels through important pathways as discussed above. This could explain the development of 
pathology such as endometriosis that requires alterations in cellular adhesion, signalling, function and 
immune system evasion to proliferate in ectopic sites. 
Krueppel-like factor 3 (KLF3) is another gene with transcription factor activity, regulating transcription 
from RNA polymerase 2 promoter
496,577,578
. It is implicated in B-cell mediated immunity, mesodermal 
development and haemopoiesis. In my study, I have already identified the EBV virus as being present and 
potentially a contributing factor to development of endometriosis (See sections 4.5.2.1, 4.5, 4.4.2.1 and 
4.4.3.5). Complex interactions between B and T cells of the immune system could also be deregulated by 
other genetic alterations or aberrations such as those in KLF3. This gene might therefore be yet another 
contributor to development of endometriosis and is therefore another potential therapeutic target. 
SEC14 domain and spectrin repeat-containing protein 1 (SESD1) is a regulator of GTPase activity and is 
involved in guanyl-nucleotide exchange factor activity. It is implicated in B cell mediated immunity and 
cellular defence response, calcium mediated signalling and neurological system processes. It is part of the 
JNK cascade and the G-protein coupled receptor protein signalling pathway. 
C-X-C motif chemokine 6 (CXCL6) is a chemokine involved in response to interferon-gamma, 
macrophage activation and the cellular defence responses. It has a function in cell-cell and calcium 
mediated signalling and motion. It is a part of the cytokine-mediated signalling pathway, JNK cascade 
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and I-kappaB, kinase/NF-kappaB cascade. Biologically it is involved in mesoderm development, 
angiogenesis and blood coagulation. This chemokine is yet another example of a molecule involved in 
important cellular processes. Endometriosis is a multifactorial disease involving ectopic cells with altered 
characteristics of adhesion, implantation and growth as well as the ability to evade the immune system. 
CXCL6 has links to all of these functions making it another potentially interesting molecule attributing to 
disease development. 
Lipopolysaccharide-binding protein (LBP) is involved in the processes of macrophage activation, defence 
responses to bacteria and lipid transport
496,578
. It is released in response to cellular stresses and is also a 
constituent of other metabolic processes such as that of cholesterol. 
C-type lectin domain family 4 member F (CLC4F) is a member of the c-type lectin superfamily which has 
receptor activity
496,577,578
. It is involved in macrophage activation, intracellular protein transport, receptor-
mediated cellular endocytosis, cell surface receptor linked signal transduction, cell-cell adhesion and cell 
surface receptor linked signal transduction. Biologically it is involved in the cellular defence response and 
blood coagulation pathways. Alterations in any of these pathways could contribute to the development of 
endometriosis though alterations of cellular properties and evasion of the cellular defence response 
mechanisms. 
Pantothenate kinase 1 (PANK1) has kinase activity and is a coenzyme in metabolic processes
496,578
. It is 
involved in the production of Coenzyme A from panthotenate. 
Dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6) is a protein kinase involved in the 
phosphate metabolic process and amino acid phosphorylation within the cell
496
. It is involved in EGF 
receptor signalling pathway (Dual specificity mitogen-activated protein kinase kinase 3 and 6), bRas 
Pathway (Mitogen-activated protein kinase kinase 3 and 6), gonadotropin releasing hormone receptor 
pathway (MKK3/6) and the p38 MAPK pathway (mitogen-activated protein kinase kinase 6)
526
. Pathways 
such as the EGF signalling pathways are linked to the development of tumours and have been the targets 
for therapeutics in the field
579
. The presence of MAP2K6 could affect important tumorigenic pathways 
such as EGF and RAS enabling the development of endometrial ectopic tissue into endometriosis. An 
effect on the hormonal GnRH pathways could also affect endometriosis where cells are known to 
proliferate under hormonal triggers. 
Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase (ST8SIA3) has transferase activity for 
glycosyl groups and is involved in polysaccharide and lipid metabolic processes and protein amino acid 
glycosylation
496,578
. 
Eosinophil cationic protein ribonuclease, RNase A Family, 3 (RNASE3) has endoribonuclease activity 
and is involved in nucleic acid and protein binding as well as inhibits enzyme activity
496,577,578
. 
Biologically it is involved in RNA catabolic processes, mesodermal development and angiogenesis.  Any 
molecule supporting angiogenesis is vital for implantation and growth of tissue at ectopic sites. 
Endometriosis tissues are seen to implant ectopically within the pelvis proliferating once angiogenesis has 
occurred. 
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Staphylococcal nuclease domain-containing protein 1 (SND1) has transcription factor and co-factor 
activity. It enables transcription from RNA polymerase 2 promoter and binds to nucleic acid
496,578
. 
Zinc finger protein 208 (ZNF208), DNA-binding protein SATB1 (SATB1), Putative zinc finger protein 
730 (ZNF730), Zinc finger protein 107 (ZNF107) Zinc finger protein 418 (ZNF418), Zinc finger protein 
676 (ZNF676), Protein core-binding factor, runt domain, alpha subunit 2; translocated to 1 (CBFA2T1) 
(RUNX1T1) all have transcription factor activity and regulate transcription for RNA polymerase 2 
promoter
496,577,578
. These genes (apart from special AT-rich sequence binding protein 1 (SATB1) and 
RUNX1T1) are Krüppel associated (KRAB) box transcription factors. RUNX1T1 also maintains cellular 
chromatin architecture. 
NAD-dependent deacetylase sirtuin-6 (SIRT6) is involved in chromatin and nucleic acid binding and has 
deacetylase activity. It regulates transcription from RNA polymerase 2 promoter and maintains cellular 
chromatin architecture
496
. It forms part of the p53 pathway
526
. The p53 pathway is usually activated by 
stress signal such as oncogenes, cellular damage, DNA damage or abnormal adhesion molecules
580
. It 
then is involved in response to the stressors through regulation of growth or cellular arrest, apoptosis or 
repair of damaged DNA. Changes in this pathway through molecules such as SIRT6 could create an 
environment where ectopic cells such as endometriotic cells can proliferate and grow. Studies looking at 
gynaecological cancers in the presence of endometriosis, have shown common alterations in p53, PTEN 
and ARID1A
581
. Endometriosis has not been classified as a malignant tumour, though it does have 
properties of proliferation, dissemination, implantation at ectopic sites, angiogenesis, growth and evasion 
of the body’s immune system, all of which are seen in malignancies. Disruption of certain pathways such 
as the p53 pathway in addition to other multifactorial influences ranging from environmental oxidative 
stressors to viral infections, growth factors, hormonal influences, diet and an altered patient immune 
system
581
 may all play a fine balance in enabling endometriosis growth but preventing overt development 
of malignancy. 
Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) has protein tyrosine kinase 
activity and is a non-membrane spanning protein
496,578
. 
Thymus-specific serine protease (PRSS16), Carboxypeptidase A6 (CPA6), Ubiquitin carboxyl-terminal 
hydrolase isozyme L1 (UCHL1), Tripeptidyl-peptidase 1 (TPP1) are all involved in proteolysis
496,577,578
. 
PRSS16 and TPP1 are serine proteases. CPA6 is a mettaloprotease and UCHL1 is a cysteine protease. 
UCHL1 has been implicated in disease such as Parkinson’s. 
Lysine-specific demethylase 5C (KDM5C) has zinc finger transcription factor activity and causes 
transcription from an RNA polymerase 2 promoter. It has been implicated in spermatogenesis
496
. 
Dystrophin-related protein 2 (DRP2) is a structural constituent of the cytoskeleton and causes binding of 
both Actin and Calcium. Biologically it is involved in a multitude of cellular processes including muscle 
contraction, neurological system processes and nervous system development, neuromuscular synaptic 
transmission and nitric oxide mediated signal transduction
496,578
. Cellularly it is involved in cellular 
adhesion, motion, morphogenesis of its components and the cell cycle, it is also involved in ectodermal 
and mesodermal development. 
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MAP kinase-activating death domain protein (MADD) has multiple cellular functions
496,577,578
. It binds 
proteins, is a regulator for GTPase activity and acts in guanyl-nucleotide exchange. It is implicated in the 
neurological system process and synaptic transmission, induction of apoptosis and the JNK cascade. It is 
involved in ectoderm and nervous system development. 
Neurogenic differentiation factor 4 (NEUROD4) has transcription factor and nuclease activity regulating 
transcription from RNA polymerase 2 promoter
496,577,578
. It acts in neurological system processes and 
nervous system development. It has a role in ectoderm development. 
Kelch-like protein 15 (KLH15) has serine-type peptidase activity and transcription factor and cofactor 
activity
496,578
. It is involved in the regulation of transcription from the RNA polymerase 2 promoter 
forming a structural constituent of cytoskeleton involved in actin binding; it is therefore responsible for 
the morphogenesis within cellular components. Cellular morphogenesis enables vesicular transfer with 
and between cells, enabling transmission of cell signals or components. The vesicular system is also used 
by viruses such as EBV (See section 4.6.4) enabling the transfer of viral genetic material
553,554,560
 through 
endo and exocytosis. Proteins affecting cellular vesicles such as KLH15, ITSN1 (below) and SYT14 
(below) may therefore contribute directly or indirectly to enabling disease development of endometriosis. 
Intersectin-1 (ITSN1) functions as a small GTPase regulator. It is involved in cellular calcium and G-
protein binding and is responsible for transmembrane protein trafficking in the cell and controls 
endocytosis
496,577,578
. Other cellular functions involve signal cellular transduction and synaptic 
transmission through neurotransmitter secretion. 
Synaptotagmin-14 (SYT14) is a membrane trafficking regulatory protein
496,578
. It has a role in endocytosis 
and exocytosis of synaptic vesicles and intracellular protein transport. It too therefore has a function in 
cellular signal transduction and synaptic transmission. 
Cytohesin-2 (CYTH2) is a guanyl-nucleotide exchange factor
496,578
. It forms part of the inflammatory 
pathway mediated by chemokine and cytokine signalling involved in the process of exocytosis and 
cataboloic cellular processes with amino acids. 
Cyclic nucleotide-gated cation channel beta-3 (CNGB3) has voltage gated potassium channel activity as 
well as cation channel and cyclic nucleotide-gated ion channel activity
496,578
. It has a role in signal 
transduction and cation transport and is involved in the signalling pathway of heterotrimeric G-protein 
and the rod outer segment phototransduction. 
Histone-binding protein RBBP7 (RBBP7) has receptor activity and is seen in various biological processes 
including: intracellular protein transport, peroxisomal transport, intracellular signalling cascades, DNA 
repair and nuclear mRNA splicing, via spliceosome
496,577,578
. It is also involved in the establishment or 
maintenance of chromatin architecture. 
Rho-related BTB domain-containing protein 3 (RHOBTB3) is a member of the small GTPase class of 
proteins
496,578
. It is involved in the process of protein binding, intracellular protein transport and the 
intracellular signalling cascade and has a role in receptor-mediated endocytosis and the G-protein coupled 
receptor protein signalling pathway. As discussed previously, proteins such as KLH15, ITSN1, SYT14 
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and COPB1 (See below) all have a role in vesicular cellular transfer. Vesicles are an important means of 
inter and intracellular transfer of information and have been used by viruses to escape immune system 
recognition and invade new cells. EBV utilises the same vesicular transport mechanisms for transfer of its 
exosomes (See section 4.6.4 ) to and between cells, molecules such as the ones above will therefore 
enable the transmission of the EBV virus aiding the formation and growth of diseased endometriosis 
cells. 
Coatomer subunit beta (COPB1) is a vesicle coat protein and enables intracellular protein transport and 
exocytosis
496,578
.  
Importin subunit alpha-1 (KPNA1) is a transfer/carrier protein which targets proteins and enables nuclear 
transport
496
. 
The following genes and proteins have been identified as downstream targets of hsa-mir-1224-5p
496,576,578
. 
Their roles and functions in literature are not currently clearly defined: Zinc finger protein 138 (ZNF138), 
Zinc finger protein 493 (ZNF493), UBX domain-containing protein 4 (UBXN4), Uncharacterized protein 
C1orf106 (C1orf106), Centromere protein P (CENPP), Magnesium transporter NIPA2 (NIPA2), FYVE 
and coiled-coil domain-containing protein 1 (FYCO1), Cortexin-2 (CTXN2), Transmembrane protein 175 
(TMEM175), Cell cycle control protein 50B (TMEM30B), Fibronectin type III domain-containing protein 
3B (FNDC3B), Sterile alpha motif domain-containing protein 12 (SAMD12), Zinc Finger protein 430 
(ZNF430), Golgin subfamily A member 3 (GOLGA3), Zinc finger C3H1 domain-containing protein 
(ZFC3H1), Ubiquitin-associated protein 2-like (UBAP2L), Manganese-dependent ADP-ribose/CDP-
alcohol diphosphatase (C17orf48), Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1), Zinc 
finger protein 257 (ZNF257), Nucleolar and coiled-body phosphoprotein 1 (NOLC1). 
5.6.1.1 Summary of important identified  points 
 From the above list of genes and proteins controlled by Hsa-mir-1224-5p, one can see effects on the 
cellular functions of apoptosis, cell adhesion, cellular migration, cytoskeletal structure, cellular signal 
transductions and vesicular formation. Various proteins are also seen to potentially affect the immune 
system, altering ectopic cellular recognition, facilitating evasion and enabling implantation and 
growth. 
 Relating back to the information above, there are varied roles which each protein or gene is known to 
carry out though it is difficult to determine which of these pertains a leading role, or which of these 
follow on as a secondary response to alternate cellular processes. 
 It is beyond the scope of this chapter to determine which are the most likely proteins or genes to 
cause (or enable to a larger extent) the development of the disease of endometriosis. This would 
require a separate body of work with functional models to determine important molecular or protein 
roles. 
 Using the identified proteins and genes, to perform functional modelling studies, to establish which 
molecules have more pertinent roles, could serve as an interesting body for future work. 
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5.6.2 Hsa-mir-4274 
FIGURE 5-13 
 
String™ prediction protein analysis diagram576 
The following are predicted targets for Hsa-mir-4274 (Figure 5-13): 
PC4 and SFRS1-interacting protein (PSIP1) has growth factor, transcription factor and cofactor 
activity
496,578
. Biologically it is involved in the immune system processes. At a cellular level it is involved 
in cell-cell signalling, signal transduction and regulates transcription from the RNA polymerase 2 
promoter. The immune system in a normally functional state identifies aberrant or ectopic cells and 
causes apoptosis and elimination of these cells. Alterations at various levels in the immune system may 
aid in survival of ectopic cells that progress towards endometriosis. 
Zinc finger protein 41 (ZNF41) is a protein with KRAB box transcription factor activity and is involved 
in spermatogenesis
496,578
. This protein is also seen to regulate transcription from RNA polymerase 2 
promoter affecting the cellular cycle. 
Regulator of G-protein signalling 20 (RGS20) binds proteins and has small GTPase regulator 
activity
496,578
. Biologically it contributes to cellular dorso-ventral axis specification and is involved in 
heterotrimeric G-protein signalling pathways (G1/Gs α and Gq/G0 α) regulators of G protein signalling. 
Rap guanine nucleotide exchange factor 2 (RAPGEF2) is a member of the PDZ domain containing 
guanine nucleotide exchange factor family
496,578
. They stimulate the exchange of guanyl nucleotides 
through the use of a GTPase. It has functions of protein binding, small GTPase regulator activity and 
guanyl-nucleotide exchange factor activity involved in mitosis, the transmembrane receptor protein 
tyrosine kinase signalling pathway, G-protein coupled receptor protein signalling pathway and the 
MAPKKK cascade
526
. Receptor tyrosine kinases serve as cell surface receptors for molecules such as 
growth factors and cytokines
582
 and are associated with regulation of cellular processes. Alterations in the 
functioning of tyrosine kinases are associated with malignancy development
583
 and have been used as 
potential targets for cancer prevention. Subtle effects of RAPGEF2 on the transmembrane receptor 
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protein tyrosine kinase signalling pathway could potentially contribute to the development and formation 
of a disease such as endometriosis. If through functional studies, it appears to be an important component 
in endometriosis development, it could be used as a therapeutic target for this disease too. The G-protein 
coupled receptor protein signalling pathway is related to various important cellular functions. Pertinent to 
my study is its regulation of inflammation and the immune system as well as being linked to tumour 
growth and metastasis
584
. In recent years this is another family of receptors that are targeted for novel 
therapeutics
585
. Once again we can see a pathway which when disrupted, is responsible for ectopic 
tumorigenic growth and metastatic potential. Extrapolated to endometriosis, a disease where ectopic 
tissue implants grows and can even “metastasise” to organs outside of the pelvis, one can potentially see 
the importance of the roles of such pathways. Again functional studies are necessary with the potential of 
novel targeted therapeutics for endometriosis. The MAPKKK cascade is linked to the antiapoptotic RAS 
cascade and protein which in my study has been identified as one of the upregulated markers in the serum 
of women with endometriosis (See Table 6-4 Section 6.4.7). Mutations in the RAS/MAPK cascades have 
been linked to endometrial cancers
586
, it is therefore not difficult to postulate that milder aberrations in the 
pathways caused by Hsa-mir-4274 could be linked to development of endometriosis which is itself not 
classified as a malignancy but has properties of cell implantation, growth survival and dissemination. 
Long-chain-fatty-acid-CoA ligase 6 (ACSL6) is a protein with ligase and transporter activity
496,578
. It too 
is involved in the immune system and fatty acid metabolism processes. 
Methenyltetrahydrofolate cyclohydrolase (MTHFD2L) has oxidoreductase and hydrolase activity
496,578
. It 
is involved in metabolic processes which are purine and pyrimidine based and has a role in the amino acid 
biosynthetic processes within the cell. 
Lysyl oxidase homolog 4 (LOXL4) has oxidoreductase, serine-type peptidase and receptor activity
578
. 
Biologically it is implicated in macrophage activation and the cellular defence response and has a role in 
proteolysis, cell-cell adhesion, signal transduction and extracellular transport
496
. It is observed in the 
processes involving the neurological system as a negative regulator of apoptosis. LOXL4 loss of 
expression has been seen in the development of bladder tumours, with its re-introduction decreasing the 
ability of the tumour to form colonies
587
. They can therefore function as tumour suppressor genes and 
inhibit the Ras/ERK (extracellular signal-regulated kinase) pathway in cancers. If LOXL4 acts in a 
similar way in endometriosis, it could be one of the contributing factors which could prevent 
endometriosis from developing into endometrial cancer. 
Transformer-2 protein homolog beta (TRAB2B) is an mRNA splicing factor and functions in mRNA 
splicing and in transesterification in mRA binding
496
. 
Serine/threonine-protein kinase N2 (PKN2) is a serine-threonine protein kinase family member
496
. It is an 
annexin and calmodulin protein class member. It has protein-kinase activity and is involved in calcium 
iron and calmodulin binding as well as calcium dependant phospholipid binding
496,578
. It is involved in 
calcium mediated signalling processes as well as protein amino acid phosphorylationas as well as 
involvement in the following three pathways: PDGF signalling pathway, Alzheimer’s disease amyloid 
secretase pathway and the muscarinic acetycholine receptor 1 and 3 signalling pathway
526
. The platlet-
derived growth factor is one of the machrophage derived growth factors
588
 and the pathway is involved in 
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cellular growth and the process of angiogenesis. Studies showing the elevation of PDGF in the peritoneal 
fluid of endometriosis have partly attributed the proliferative properties of ectopic endometrial tissue 
forming endometriosis to this growth factor
589
. It too is being investigated as a potential novel therapeutic 
target
589
. 
cGMP-dependent protein kinase 2 (PRKG2) is a non-receptor serine-threonine protein kinase 
member
496,578
. It binds proteins and has protein kinase and kinase regulator activity biologically involved 
in muscle contraction, intracellular signalling cascades, cellular mitosis and phosphorylation of amino 
acids. It is also involved in neurological system processes forming part of the cGMP dependent pathways 
and endothelin signalling pathway
526
. 
Peroxisomal targeting signal 1 receptor (PEX5) targets proteins and is involved in peroxisomal transport 
as another membrane trafficking regulatory protein
578
. 
Pituitary adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1) has G-protein coupled 
receptor activity and is seen in cellular stress responses
496,578
. It is a member of the antibacterial response 
proteins and is implicated in the cellular immune response. Modifications in this response might all 
contribute to the development of endometriosis in preventing aberrant cell elimination. Within the cell it 
has roles in cellular glucose homeostasis, synaptic and non-synaptic vesicle exocytosis enabling synaptic 
cellular transmission. It is also responsible for intracellular protein transport. Biologically it is involved in 
spermatogenesis, mesodermal and heart development and is involved in the G-protein coupled receptor 
protein signalling pathway and gonadotropin releasing hormone receptor pathway
526
. GnRH analogues 
are used for the enhancement of apoptosis in endometriotic cells
590
 and are one of the medical treatments 
used to suppress endometriosis pre-operatively or pre-fertility treatment. Understanding the effects of 
receptors such as ADCYAP1R1 on GnRH pathways could potentially provide another window to 
understanding this multifactorial disease. 
Protocadherin-9 (PCDH9) binds calcium ion and has G-protein coupled receptor activity
496,578
. 
Biologically it has been linked to visual perception and the sensory perception of sound. At a cellular 
level, it is involved in cell-cell adhesion, cell motion and morphogenesis of the cellular components. 
Embryonically it is involved in ectoderm and mesoderm development, nervous system development, 
heart and muscle organ development as well as the Wnt signalling pathways (Figure 5-14) and cadherin 
signalling pathways
526
 (Figure 5-15). The Wnt signalling pathway regulates cell growth motility and 
survival
591
 and molecular defects or alterations in this pathway have been associated with the 
development of multiple types of tumours
591
. Molecules such as PCDH9 might be responsible for minor 
changes within the function of this pathway which in endometriosis could result in ectopic cell survival or 
growth. Genes or proteins that are involved in cellular modification, signalling, motion and 
morphogenesis, all have a fine balance in controlling and ensuring correct cellular function and viability. 
Any derangement or alteration in these molecules could potentially disrupt the normal cellular properties 
enabling a cell to grow, proliferate uncontrollably and potentially avoid or repress apoptosis. All these 
properties are seen in endometriotic cells and it is possible that it is through the understanding of the 
importance of molecules such as PCDH9 that we might obtain a better insight into development of the 
disease process of endometriosis and its associated pathways. 
 194 
FIGURE 5-14 
 
Wnt signalling pathways526 
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FIGURE 5-15 
 
Cadherin signalling pathway526 
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Cytoplasmic dynein 1 light intermediate chain 2 (DYNC1LI2) binds proteins and is a structural 
component of the cytoskeleton
496
. Intracellularly, it is found within microtubule and acts as an enzyme 
modulator and has a role in the morphogenesis of cellular components and intracellular protein transport, 
RNA localisation and vesicle mediated transport. It has a role in the cell cycle and the intracellular 
signalling cascades. DYNC1LI2 is implicated in Huntington’s disease involving the dynein 
complex
496,578
. 
Potassium voltage-gated channel subfamily C member 2 (KCNC2) also contains cation channel activity 
and is involved in cation transport. It is involved in cellular signal transduction and synaptic transmission. 
Biologically it is involved in muscle contraction and neuronal action potential propagation
496,578
. 
Golgin subfamily A member 8A (GOLGA8A) is another membrane trafficking protein. F-box/WD 
repeat-containing protein 1A (BTRC) is involved in Parkinson’s disease and three separate pathways: 
hedgehog signalling pathway, Wnt signalling pathway and the toll pathway in drospophila
526
. The 
importance of the effects of the Wnt signalling pathway in tumorigenesis, cellular survival and 
proliferation has already been suggested previously
591
 with other molecules such as PCDH9 affecting the 
same pathway. Interestingly if multiple molecules affect this major pathway at different levels, this might 
further encourage cellular changes and endometriotic disease growth. There will be potential expressed 
counteracting or stabilising tumour suppressor genes such as LOXL1 which can explain the prevention of 
development of overt malignancy. 
The following genes and proteins have been identified as downstream targets of hsa-mir-4274. Their roles 
and functions in literature are not currently clearly defined
496,526,577,578
: Protein family with sequence 
similarity 3, member C1 (FAM3C), actin-binding rho-activating protein (ABRA), uncharacterized protein 
C6orf136 (C6orf136), MACRO domain-containing protein 2 (MACROD2). Bladder cancer-associated 
protein (BLCAP) may regulate cellular apoptosis and cell cycle proliferation by a mechanism 
independent from TP53/p53. 
5.6.2.1 Summary of important identified  points 
 From the above list of genes and proteins controlled by Hsa-mir-4274, one can see still see effects on 
the cellular functions of apoptosis, cell adhesion, migration, cytoskeletal structure, cellular signal 
transductions and vesicular formation. Various proteins controlled by this miRNA are also seen to 
potentially affect the immune system, altering ectopic cellular recognition, facilitating cellular 
evasion and enabling implantation and growth. 
 SP1 has a role in the immune system and in humans it is a constituent of the gonadotropin releasing 
hormone receptor pathway. Other identified molecules such as MAP2K6 and ADCYAP1R1 are also 
associated with effects on the gonadotropin releasing hormone receptor pathway. This is one of the 
targeted pathways by medical GnRH analogues that aim to promote apoptosis in endometriosis. 
 Other genes such as KLF3 are also know to affect B-cell mediated immunity which can be used by 
viruses such as EBV to invade proliferating cells which can evade immune recognition. 
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 Molecules such as CREB1, MAP2K6 affect the RAS and MAPK pathways have been linked to hsa-
mir-4274, all of which are associated with potential tumorigenesis, providing cells with the ability to 
proliferate, invade and grow. PCDH9 affects Wnt signalling pathways which also mediate cell 
survival and growth. These are all characteristics which are shared by endometriosis cells enabling 
ectopic growth. 
 Relating back to the information above, there are varied roles which each protein or gene is known to 
carry out though it is difficult to determine which of these pertains a leading role, or which of these 
follow on as a secondary response to alternate cellular processes. 
 It is beyond the scope of this chapter to determine which are the most likely proteins or genes or 
pathways to cause (or enable to a larger extent) the development of the disease of endometriosis. This 
would require a separate body of work with functional models to determine important molecular or 
protein roles. 
 Using the identified proteins, pathways and genes to perform functional modelling studies to 
establish which molecules have more pertinent roles that could serve as an interesting body for future 
work. 
5.7 Detailed analysis for downregulated miRNAs 
8 miRNAs were downregulated in endometriosis with the top two identified miRNAs being hsa-miR-150 
and hsa-miR-122. Hsa-miR-342-3p is significant at a less stringent confidence. qPCR analysis is 
supportive of 3 of the markers that have significant down-regulation in disease: miRs 150, 122 and 342-
3p. 
5.7.1 hsa-miR-150 
FIGURE 5-16 
 
String™ prediction protein analysis diagram576 
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There are a number of predicted targets for hsa-miR-150 (Figure 5-16): 
DDB1- and CUL4-associated factor 6 (DCAF6) is a member of the nuclear receptor interaction protein 
family
496
. It has GTPase activity and is involved in apoptosis and signal transduction pathways. Through 
signal transduction it regulates the nucleotide and nucleic acid metabolic processes regulating the 
nucleobase. The control of cellular nucleic acid processes is vital for correct cellular division and 
function. 
Programmed cell death protein 4 (PDCD4) is a translation elongation factor protein involved in 
translation and nucleic acid binding as well as induction of apoptosis
496,576
. Aberrations in any of the 
finely tuned cellular processes can potentially lead to abnormal cellular phenotypes and can result in 
aberrant control of apoptosis and cellular proliferation enabling a disease such as endometriosis to grow 
and disseminate. 
Protein Mdm4 (MDM4) is a p53 binding protein and has a ubiquitin-protein ligase activity shifting ATP 
to AMP
496,578
. It is a negative regulator of apoptosis and is implicated in a number of cellular pathways 
including the p53 pathway, its feedback loops and the insulin/IGF pathway-protein kinase B signalling 
cascade (Figure 5-17, Figure 5-18). P53 is a crucial tumour suppressor that responds to cellular stressors 
by arresting the cell cycle, causing senescence and inducing apoptosis
2
. MDM4 counteracts the action of 
p53, potentially enabling cells to proliferate in situations where their growth would have otherwise been 
arrested or apoptosis induced. This could explain how ectopic endometrial cells progress towards growth 
and implantation in sites such as the pelvis, where they would have otherwise perished. 
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FIGURE 5-17 
 
Panther™ pathway showing Insulin IGF pathway- protein Kinase B signalling cascade496 
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FIGURE 5-18 
 
Panther™ pathway showing interactions between p53, IGF/insulin pathways496 
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Transcriptional activator Myb (MYB) is a DNA binding protein which has transcription factor activity 
and is involved in the cell cycle as a negative regulator of apoptosis
496,578
. It is also involved in a number 
of cellular biosynthetic processes including the purine base metabolic process, the rRNA metabolic 
processes, fatty acid metabolic processes and the cellular amino acid biosynthetic process, regulation of 
transcription from RNA polymerase 2 promoter and the termination of this transcription process, as well 
as signal transduction through cell surface receptor linked transduction. The negative regulation of 
apoptosis and aberrations in cellular control mechanisms, as discussed earlier, can potentially be a cause 
for prolonged cellular survival aiding in endometriosis growth and development. 
Adiponectin receptor protein 2 (ADIPOR2) has receptor functions in cell surface receptor linked signal 
transduction and the fatty acid metabolic processes
496,578
. It is involved in the gonadotropin releasing 
hormone receptor (GnRH) pathway (Figure 5-19)
526
. Current medical therapies for endometriosis, include 
temporary medical suppression of disease through the use of GnRH analogues. Obtaining an insight as to 
which components of the GnRH pathway are particularly elevated or altered in endometriosis, might 
serve in the identification of more specific targeted therapeutics for the disease. 
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FIGURE 5-19 
 
Panther™ gonadotropin releasing hormone receptor pathway496 
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Structural maintenance of chromosomes protein 3 (SMC3) is a protein which has hydrolase activity and 
binds nucleic acid and chromatin
496
. It acts as a chromatin- chromatin binding protein establishing and 
maintaining chromatin architecture and segregation. Cellularly, it is involved in mitosis, meiosis, DNA 
replication and repair
578
. 
Cytoplasmic aconitate hydratase (ACO1) is located within mitochondria and cellular cytosol and is 
involved in hydrolase processes within the tricarboxylic acid cycle as well as carbohydrate metabolic 
processes and cellular amino acid biosynthetic processes
496,578
. It is a component of the methycitrate 
cycle
526
 (Figure 5-20) and a master regulator of cellular iron metabolism during cellular proliferation
592
. 
FIGURE 5-20  
 
Panther™ Methycitrate pathway496 
 
Interleukin-7 (IL7) is a member of the cytokine family of signalling molecules which are seen to be 
expressed by leukocytes
496,578,592
. They negatively regulate apoptosis and are vital in the processes of the 
immune system. In my study, I have already identified the EBV hsa-mir-BART2-5p miRNA being 
elevated in the leukocytes of women with endometriosis when compared to controls (See section 4.5.2.1). 
In theory, leukocytes that negatively regulate apoptosis containing higher levels of EBV miRNA might, 
not be able to function optimally and identify and eliminate ectopic endometrial cells. This would enable 
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the ectopic cellular survival, implantation and growth into endometriosis. IL7 are also constituents of the 
cytokine-mediated signalling pathway, janus kinase and signal transducer and activator of transcription 
(JAK-STAT) cascade, the Interleukin signalling pathway (Figure 5-21) and have a role in cell-cell 
signalling
526
. 
FIGURE 5-21 
 
Panther™ interleukin signalling pathway496 
 
Neuronal cell adhesion molecule (NRCAM) is a linker protein within the extracellular matrix and acts as a 
cell surface receptor controlling signal transduction, protein modification and cell-to-cell interaction
496
. It 
is a member of the immunoglobulin superfamily of cell adhesion and receptor molecules and involved in 
the processes of cell matrix adhesion, intercellular adhesion and motion
578,592
. It has phosphoprotein 
phosphatase activity and is located within the extracellular matrix of the cell and involving various 
cellular processes, the immune system, neurological and nervous system processes and muscle 
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contraction. Embryologically, there is a role in the development of ectoderm and mesoderm, angiogenesis 
and the development of muscle organs and the nervous system
496
. 
Semaphorin-3A (SEMA3A) is a membrane bound signalling molecule with receptor binding properties 
and involved in the neurological and immune system processes and the development of the heart
496,578,592
. 
It forms part of the transmembrane receptor protein signalling pathways and the intracellular signalling 
cascades and has a role in cell-cell adhesion. Embryologically, there are roles in ectodermal and 
mesodermal development and a component of angiogenesis. It is directly involved as a component of the 
semaphorin mediated axon guided pathway (Figure 5-22) 
526
. Genes controlling or affecting angiogenesis 
are vital for the survival of any ectopically implanted cell. Without a novel vascular supply, an ectopic 
cell is not able to grow and disseminate, making the angiogenic properties of SEMA3A and NRCAM 
potentially important components of endometriotic cell survival and growth. 
FIGURE 5-22 
 
Semaphorin mediated Axon guided pathway496 
 
Interferon-induced protein with tetratricopeptide repeats 5 (IFIT5) is a protein released in response to 
interferon gamma or cellular stimuli induced by recombinant human IFN-alpha in NB4 cells
496,592
. This 
gene has been found in elevated levels in retinoic acid treated acute promyelocytic leukaemia cell lines 
(NB4 cells) and was seen to increase with myeloid differentiation
593
. It is also expressed in untreated 
hematopoietic and non-hematopoietic cell lines. The interferon induced (IFIT) gene family has also been 
recently implicated in host organism antiviral defences (Figure 5-23). Intereferon secretion indicates host 
antiviral immunity. Interferons exert their anti-viral functions through the induction of antiviral proteins 
and the IFIT gene family is one of hundreds which are stimulated. The primary interferons responsible for 
the IFIT gene family induction are interferons type 1 and 3. These are regulated by the JAK-STAT 
signalling pathways. The genetic suppression of IFIT genes or methylation by viral molecules are 
mechanisms employed by viruses to escape host antiviral defences
594
. Their presence enables the 
restriction of viral replication, stimulates apoptosis in virally infected cells and regulates immune 
responses. IFIT family members are today believed to be imperative in the production of novel vaccines 
and viral restriction mechanisms. In my study, EBV virus is believed to be an important component of 
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development of the ectopic endometrial cells into endometriosis (See section 4.5.2.1). In endometriosis, 
potential malfunctions in the IFIT5 cellular mechanisms might allow EBV infected cells to proliferate, 
evade immune detection and apoptosis and enable ectopic tissue implantation and growth. 
FIGURE 5-23 
 
Antiviral and immune regulated function of IFIT family genes594 
 
Protein phosphatase 1 regulatory subunit 3A (PPP1R3A) is a protein that directly interacts with 
phosphatase affecting and modulating its activity
496,578
. Inactivation of phosphatase proteins has been 
shown to cause anomalies in cell growth and division. Mutations in the PP1R3 gene has been shown in 
colorectal cancers, haematological malignancies, lung, ovarian and gastric cancers
595
. It is also directly 
related to lymph node and liver metastasis
596
. Interestingly, association of (AU)AT- rich element 
polymorphisms in PPP1R3 demonstrates metabolic features of PCOS which include insulin resistance, 
type 2 diabetes mellitus and hyperandrogenaemia irrespective of patient BMI
597
. The presence of the 
mutated form of this gene in various malignancies has led to PPP1R3 being identified as a candidate 
tumour suppressor gene
598
. Potentially, it carries a tumour suppressive function in the disease of 
endometriosis, preventing malignant cellular transition. Further functional studies would be required to 
ascertain the importance of its tumour suppressive effect in endometriosis. 
Cystathionine gamma-lyase (CTH) is an enzyme within the cellular amino acid metabolic process and is 
involved in the methionine biosynthesis pathway (Figure 5-24)
526
. It is also a key enzyme in the trans-
sulfuration pathway using L-cysteine to produce hydrogen sulphide (H2S)
496,578
. The CSE (CTH)/H2S 
system has effects on cellular growth and proliferation and overexpression of CSE inhibits cell 
proliferation and DNA synthesis
599
. Poymorphisms in the CTH gene have been linked to bladder 
malignancies
600
. 
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FIGURE 5-24 
 
Methionine biosynthesis pathway496 
 
Stearoyl-CoA desaturase 5 (SCD5) is involved in fatty acid/ lipid metabolism and has oxidoreductase 
activity
496,578,592
. In rat experimentations IGF-1 and FSH are seen to increase SCD2 (SCD5 synonym) 
expression in the ovary. IGF-1 and FSH are involved respectively with the MAPK3/MAP1 and 
PIK3R1/AKT pathways. SCD2 is believed to have a role in the follicular growth and oocyte maturation in 
the rat ovary
601
. SCD2 was also shown to be expressed in rodent testes and epidydimis as well as other 
tissues such as human brain, pancreas and the nervous system. It is seen to be elevated in certain 
malignancies such as Burkitt’s lymphoma602. SCD5 is also reported to have a role in the control of 
cellular endocytosis
603
 and might play a role in viral infections such as EBV. It is considered as one if the 
molecules which could potentially be altered to treat viral infections
604
 making it another potential target 
in the treatment of endometriosis, through the inhibition of the EBV effects on ectopically implanted 
endometriosis cells. 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 2 
(SMARCD2) is a nucleic acid and chromatin binding protein. It has a role in the establishment of 
chromatin architecture, nucleic acid and nucleotide metabolic processes
496,578
. It is involved in the WNT 
signalling pathway (Figure 5-14)
526
 which has been associated with cellular malignant development
591
. 
Potentially alterations in this pathway contribute to the development of endometriosis within patients. 
Vascular endothelial zinc finger 1 (VEZF1) is a DNA binding protein and a zinc finger transcription 
factor which is a regulator of transcription from the RNA polymerase 2 promoter
496,578
. It is seen 
expressed in endothelial cells where it plays an important role in angiogenic regulation
605
 and the 
maintenance of vascular haemostasis in the adult
606
 and is also thought to be involved in both normal and 
Gene, protein and miRNA expression in women with endometriosis 
208 
pathological processes of cellular proliferation and differentiation
577
. As discussed in earlier sections of 
this thesis, angiogenesis is a vital requirement for development of ectopic or disseminated cells such as 
endometriosis
29
. 
Calpastatin (CAST) is a cysteine protease inhibitor involved in proteolysis. The calpain-calpatatin system 
is involved in membranous fusion events such as exocytosis of neural vesicles and aggregation of platlets 
and red blood cells
577
. It has a role in metastatic tumour progression which depends on cell-cell and cell-
matrix adhesions
496
. Proteolytic degradation of cadherin and focal adhesion complexes though calpain 
mediation enables disassembly of cell-cell and cell-matrix adhesions which are able to invade 
surrounding tissues due to enhanced motility. Members of the calpain family have been implicated in 
integrin-mediated cell migration, cytoskeletal remodelling, cell differentiation and apoptosis (Figure 5-25, 
Figure 5-26)
496,578,592
. CAST demonstrates its involvement in a number of processes associated with the 
development of tumorigenic and metastatic potential within cells. It is not unreasonable to postulate that 
similar changes occur in endometriotic cells which have the ability to disseminate, implant and grow in 
ectopic sites. 
FIGURE 5-25 
 
The regulation of cellular mechanics by Calpain protease607 
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FIGURE 5-26 
 
Calpian as a constituent of the apoptotic cellular pathways526 
 
RNA-binding motif protein, X-linked-like-2 (RBMXL2) is a subfamily of nuclear ribonucleoprotein 
complex (hnRNPs) and a structural constituent of the ribosome which acts as an mRNA splicing and 
polyadenylaton factor
496,578,592
. The proteins influence pre-mRNA processing in the nucleus as well as 
mRNA metabolism and transport. It is important in the functioning of the cell cycle, DNA replication and 
nuclear mRNA splicing via the spliceosome. It has a role in rRNA and protein metabolism and is 
involved in ectoderm and nervous system development. RBMXL2 is a germ cell nuclear protein which is 
seen to be a testis-specific splicing regulator protein
608
. It primarily localises to the nucleus of meiotic 
spermatocytes. Genetic defects resulting in reduced levels of this protein could potentially be a cause of 
male infertility in humans
609
. 
Neurogenic differentiation factor 6 (NEUROD6) is a basic helix-loop-helix transcription factor nuclease. 
The protein may be involved in the development and maintenance of the nervous system (Figure 5-27). It 
regulates transcription from RNA polymerase 2 promoter and is also involved in ectodermal 
development
496,578
. 
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FIGURE 5-27 
 
Pathway depicting the targets of CCAAT/enhancer-binding protein beta (C/EBPbeta). It regulates 
immunological, apoptotic and inflammatory processes and is linked to Insulin signalling pathways610 
 
Brain acid soluble protein 1 (BASP1) is a neuronal axonal membrane bound protein involved in 
intracellular protein transport and exocytosis
496,578
. Embryologically, it is involved in ectodermal and 
nervous system development and in the development of the neurological systems. This calcium 
calmodulin dependant binding protein was found to be differentially expressed in a number of human 
cancer cell lines including endometrial cancers. The highest expression is seen in cervical 
adenocarcinoma cell lines
611
. Studies have shown that the BASP1 causes inhibition of Myc-induced cell 
transformations and it has been identified as a potential tumour suppressor
612
. Its presence in 
endometriosis could potentially prevent malignant change in this chronic condition. 
Synaptic vesicle glycoprotein 2B (SV2B) is a transfer/carrier protein involved in neurotransmitter 
secretion and has a role in synaptic transmission
496,578
. 
Mitochondrial carrier homolog 2 (MTCH2) is a mitochondrial transport/carrier protein found on the 
surface of mitochondria
496,578,592
. The MTCH2 complex is seen to participate in the mitochondrion 
apoptotic process in response to the TNF-α/ FAS death receptor pathways613. It is also potentially 
associated with the BCL-2 apoptotic program
614
. A study on solid cancers has shown MTCH2 to be one 
of five genes expressed in multiple cancers which may play a role in enhancing invasive properties of 
tumour cells and their metastatic potential thereby affecting clinical outcomes
615
. Obesity has been linked 
to insulin resistance, diabetes and higher levels of oestrogen and non-oestrogen dependant malignancies 
such as endometrial and colorectal cancer respectively. MTCH2 is one of the identified genetic markers 
of obesity which potentially could be used to aid in identifying an increased risk for endometrial 
Gene, protein and miRNA expression in women with endometriosis 
211 
cancer
616
. In endometriosis, which is hormonally responsive, the control of MTCH2 through hsa-mir-150 
could potentially enable growth and dissemination of ectopic cells causing proliferation of disease. 
Rho-guanine nucleotide exchange factor (RGNEF) is a gene encoding a protein which acts as a Guanine 
nucleotide exchange factor regulating integrin and growth factor related pathways
496,578,592
. It is 
implicated in various cellular processes including cellular adhesion, synapses, motility and activation of 
B-lymphocytes. It may also have a role in cellular apoptosis. In colon tumours, RGNEF has been seen in 
higher levels and promotes the progression, invasion and motility of tumours through the interaction with 
focal adhesion kinase. It binds to focal adhesion kinase (FAK) and this linkage facilitates fibroblast focal 
adhesion formation on fibronectin
617
. It might have a similar role in the migration of endometriotic cells 
and their invasion
442
. 
Myelin protein zero-like protein 1 (MPZL1) (PZR) is a protein with voltage gated sodium channel activity 
and cation channel activity with a role in cation transport, cellular adhesion and morphogenesis of the cell 
components
496,578
. MPZL1 is involved in the regulation of Ca(2+)-activated K(+) (BK) channel protein 
interactions controlling cellular death and survival
618
. PZR is a member of the immunoglobulin 
superfamily and enables cell signalling through an interaction with tyrosine phosphatase SHP-2
619
. It 
enables fibronectin-dependant migration of cells which express the SHP-2 molecule and regulates cellular 
motility
620
. It is also seen in early embryonic formation
621
. Ectopic endometrial cells with the ability to 
adhere, migrate and grow could potentially explain their development into endometriosis. 
V-type proton ATPase subunit H (ATP6V1H) is also known as Nef
496,578,592
. It has been reported as one of 
the genes which is upregulated in endometrial tissue biopsies
622
. In viral infections such as HIV1 Nef (an 
accessory protein of HIV) and a vacuolar ATPase facilitate CD4 internalisation reducing CD4 expression 
on infected cells, enabling vial survival and infection
623
. 
Catenin beta-1 (CTNNB1) is a structural constituent of the cellular cytoskeleton with receptor binding 
properties. It can act as a storage protein and aids in intracellular transport as a signalling molecule
496,578
. 
It also functions in cellular signal transduction and Cell-cell adhesion. This gene is involved in various 
pathways including those controlling angiogenesis (Figure 5-28), Gonadotropin releasing hormone 
receptor pathway (Figure 5-29), Alzheimer’s disease presenilin pathway, cadherin signalling pathways 
(Figure 5-15), p53 pathway feedback loops (Figure 5-30) and the Wnt signalling pathway (Figure 
5-14)
526
. 
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FIGURE 5-28 
Figure split over two continuous parts: 
 
 
Angiogenesis pathway526 
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FIGURE 5-29 
 
Gonadotropin releasing hormone receptor pathway526 
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FIGURE 5-30 
 
p53 pathway feedback loops526 
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Importin-5 (IPO5) is a transmembrane transporter protein of the importin Beta family. It acts as a G-
protein modulator, binds proteins and has small GTPase regulator activity
496,578
. It has a role in cellular 
protein targeting, nucleocytoplasmic transport, transporting nucleic acid metabolic processes and RNA 
cellular localisation. Certain viruses such as influenza
624
 and EBV
625
 amongst others have been shown to 
use these importing molecules to infiltrate cellular structures and evade host immune systems. This could 
therefore be a molecule potentially used by EBV in the infiltration of lymphocytes in women with 
endometriosis. 
Erythrocyte membrane protein band 4.1-like protein 5 (EPB41L5) is a member of the CRB-MPP5 
polarity complex in mammals
626
. It regulates cellular tight junctions to maintain correct cellular polarity. 
Changes in the cytoskeletal genes are associated with influences in cell polarity, adhesion and invasive 
properties and have been shown in cancer progression
627
. EPB41L5 is involved in the Dopamine receptor 
mediated pathway (Figure 5-31) as well as the nicotine pharmacodynamics pathway (Figure 5-32)
526
. 
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FIGURE 5-31 
 
Dopamine receptor mediated pathway526 
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FIGURE 5-32 
 
Nicotine pharmacodynamics pathway526 
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Wilms tumour 1 associated protein (WTAP) is a nuclear protein which is a pre-mRNA-splicing 
regulator
496,578
. In mice it is essential for embryonic development. In mammals its role is not completely 
understood though IGF-1 (Insulin Growth factor-1) is directly seen to reduce its abundance in the cell. It 
is postulated that the reduction in cellular WTAP is necessary for the antiapoptotic roles of IGF-1. It is 
believed to be a binding partner of Wilms tumour suppressor gene (WT1) which is essential in the 
development of the genitourinary system
628
. WTAP1 degradation is seen to reduce pro-apoptotic 
Survivin-2B and increase anti-apoptotic Survivin
629
, this could explain in role enabling the growth of 
endometriotic cells. 
Alpha-endosulfine (ENSA) is expressed in a wide range of tissues including brain and endocrine 
tissues
496,578,592
. It can block potassium channels which are ATP sensitive and stimulates insulin release 
from Beta cells
630
. The role it exerts on potassium channels in the brain can affect neurotransmitter 
release and cognitive function. Decreased levels of ENSA are seen in Down’s and Alzheimer’s disease. In 
endocrine tissues ENSA SNP17 may reduce the ability of Beta cells to compensate for reduced insulin 
sensitivity which increases the patient’s chance of developing type 2 diabetes mellitus631. 
5.7.1.1 Summary of important identified  points 
 From the above list of genes and proteins controlled by Hsa-mir-150, one can see effects on the 
cellular functions and mechanisms at multiple levels. DCAF6, MYB and SMC3 have roles in cellular 
nucleic acid division and function whilst MPZL1 affects cellular motility and potential of migration. 
Aberrations in these processes will potentially result in cellular mutations and abnormal cellular 
properties, enhancing the potential of disease development such as endometriosis. 
 Apoptotic inducers such as PDCD47 and WTAP1 are identified and these balance out against anti-
apoptotic molecules such as MDM4 and MYB IL7 which promote cellular survival and growth. 
Alterations in any of these genes or molecules could be responsible in part for the development of 
endometriosis whilst concomitantly preventing progression to malignancy. 
 Angiogenesis is a vital requirement for the survival of ectopically implanted tissue such as 
endometriosis and NRCAM, SEMA3A, VEZF1 and CNNB1 are all identified angiogenic promoters. 
 Molecules such as CAST, MTCH2, RGNEF, and EPB41L5 are all linked to metastatic tumour 
progression, and from my literature search, a pathway associated with carcinogenesis (e.g. WNT) is 
linked to hsa-mir-150. MDM4 is an anti-tumour suppressor, counteracting the action of p53. The 
presence of these molecules, genes and pathways can to an extent explain why endometriotic cells 
grow, disseminate, implant and avoid undergoing apotosis like eutopic endometrial cells. 
 CTNNB1 is also linked to hsa-mir-150. In its non- mutated state it functions as a tumour suppressor, 
other tumour suppressors linked to hsa-mir-150 include PPP1R3A and BASP1. These molecules 
could be responsible for preventing overt malignant changes in endometriotic implants. 
 Endometriosis is a hormonally responsive disease. Unsurprisingly, therefore, identified ADIPOR2 
and CTNNB1 are linked to the GnRH pathway which is a medical target of GnRH analogues used to 
suppress endometriosis. 
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 Relating back to the information above, there are varied roles which each protein or gene is known to 
carry out though it is difficult to determine which of these pertains a leading role, or which of these 
follow on as a secondary response to alternate cellular processes. 
 In this study EBV within the leukocytes of patients with endometriosis, could be a potentially 
important mechanism in disease development. IFIT5 is one of the molecules identified as interacting 
with hsa-mir-150 which restricts viral replication and stimulates apoptosis in virally infected cells. 
Other molecules such as ATP6V1H and IPO5 counteract the function of IFIT5 enabling viral survival 
and cellular infection. 
 It is beyond the scope of this chapter to determine which are the most likely proteins or genes to 
cause (or enable to a larger extent) the development of the disease of endometriosis. This would 
require a separate body of work with functional models to determine important molecular or protein 
roles. Identification of the most pertinent associated disease molecules or genes could enable future 
targeted approaches to disease. 
 Using the identified proteins and genes, to perform functional modelling studies, to establish which 
molecules have more pertinent roles, could serve as an interesting body for future work. 
5.7.2 hsa-miR-122 
FIGURE 5-33 
 
String™ prediction protein analysis diagram576 
 
There are a number of predicted targets for hsa-miR-122 (Figure 5-33): 
Immunoglobulin superfamily member 5 (IGSF5) is an immunoglobulin superfamily junctional cell 
adhesion molecule involved in cell adhesion, ectodermal and nervous system development
496,578
. JAM4 is 
a synonym of IGSF5 and is a cell adhesion molecule which interacts with tight junction proteins. JAM4 is 
Gene, protein and miRNA expression in women with endometriosis 
220 
involved in cellular endocytosis in conjunction with an endocytic scaffold Ligand-of-Numb protein X1 
(LNX1). This redistributes transforming growth factor beta in mammary epithelial cells
632
. The 
immunoglobulin superfamily has recently gained interest as a contributing cell adhesion molecule in 
metastasis
633
 enabling cell-cell adhesion which is a key process in the survival of ectopic cells. Its similar 
function in ectopic endometrial cells could explain its role in the development of endometriosis. 
Occludin (OCLN) is a cellular transcription cofactor involved in cellular tight junctions, cell adhesion and 
RNA elongation from RNA polymerase 2 promoter
496,578,634
. Studies from normal human vaginal and 
cervical cells have shown that OCLN can be remodelled through oestrogen receptor alpha mediation, 
thereby altering tight junction resistance. Normal cells are seen to secrete matrix-metalloproteinase-7 
(MMP-7) into the luminal solution, enabling the decrease of tight junctional resistance through oestrogen 
and estrogen is also seen to act on the cellular golgi system increasing cellular luminal exocytosis 
processes controlling in –vivo cellular permeability635. Oxidative stress responses within the cell are also 
known to affect cellular distribution levels through its tyrosine- kinase dependant phosphorylation
636
. In 
endometrial carcinoma, occludin expression levels are seen to decrease resulting in loss of tight junction 
control. This loss of junctional regulation shows a close relationship with the progression and metastatic 
ability of the tumour and the formation of cellular atypia
637
. Similar mechanisms could be occurring in 
endometriosis enabling cellular dissemination and proliferation. 
ARF GTPase-activating protein GIT1 (GIT1) is a nucleic acid binding and G-protein modulator
496
. It is 
part of the G-protein coupled receptor protein signalling pathway and is involved in cell adhesion, control 
of cellular permeability and cellular endocytosis
578
. It forms complexes with phospholipase C gamma 1 
(PLC gamma1) and guanine exchange factor beta-Pix, activates Calpains and calcium-dependant 
proteases and has a vital role in cellular integrin mediated spreading and motility
638
. A recently identified 
member of the myosin superfamily, (MYO18A) is seen to interact with other GIT1 complexes 
(PAK2/betaPIX/GIT1) affecting epithelial cellular mobility and migratory properties
639
 playing a role in 
disease and malignancy. This could be yet another molecule which explains the disseminative properties 
in endometriosis tissues. 
Lamin-B2 (LMNB2) is a structural component of the cytoskeleton which alters the morphology of the 
cellular components and chromatin architecture of the cytoskeleton
496,578,634
. It is a component of the FAS 
signalling pathway (Figure 5-34) and it has a role in cellular apoptosis
640
. Lamin proteins are involved in 
nuclear stability and mutations and are associated with lipodystrophies. Higher levels of LMNB2 
expression in tissues are associated with increased metastatic potential in tumours such as lung 
adenocarcinomas
641
, it could also have a similar role in enabling the disseminative properties of 
endometriosis. 
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FAS signalling pathway496 
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Dual specificity protein phosphatase 4 (DUSP4) is a mitogen activated protein kinase (MAPK) 
phosphatase as well as a kinase inhibitor and regulator
496,578
. The DUSP4 proteins serve as negative 
regulators of the MAP kinase superfamily (MAPK/ERK, SAPK/JNK and p38) which are linked to 
cellular differentiation and proliferation
577
. It is therefore involved in numerous cellular processes, is a 
constituent of the cell cycle and has a role in DNA replication, glycolysis and protein and amino acid 
phosphorylation. DUSP4 also has a role in the immune system, forms part of the JNK cascade, is 
involved in mesodermal and muscle development and is also involved in the JNK signalling oxidative 
stress response pathway
642
 (Figure 5-35)
526
. Abnormal MAPK signalling is believed to be implicated in 
the development and progression in human cancers. MAPK regulation in normal tissues shows that 
deregulation of this tightly controlled process can initiate or develop cancer, determine cellular responses 
to cancer therapies and alter patient prognosis
643
. As a negative regulator of the MAPK superfamily, the 
DUSP4 could play a role in preventing endometriosis from transforming itself into more aggressive 
disease serving as a regulator for disease dissemination. 
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Oxidative stress response pathway496 
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Chloride intracellular channel protein 4 (CLIC4) is an intracellular chloride channel involved in most 
cellular processes. It is a structural constituent of the cytoskeleton and acts as a protein, an anion channel, 
a transferase, a signalling molecule, a reductase, a translation-elongation factor and an 
epimerase
496,577,578,592
. It is a constituent of the nicotine pharmacodynamics pathway (Figure 5-32)
526
 and 
the dopamine receptor mediated signalling pathway (Figure 5-36). CLIC4 plays a role in the immune 
system process and response to cellular toxins, anion transport and intracellular signalling cascades, the 
metabolic processes of oxygen reactive species and cellular translation. In ovarian cancer, upregulation of 
CLIC4 by reactive oxygen species causes TGF-beta1 differentiation of fibroblasts to myofibroblasts 
which is a mark of active tumour stroma. It is therefore postulated that inhibition of CLIC4 night be a 
potential therapeutic option for stromal tumour targeting in ovarian tumours
644,645
. Potentially, changes 
within CLIC4 levels can be attributed to changes in the properties of ectopic endometrial cells of women, 
with endometriosis. If this link were to be established, it could be utilised as a therapeutic target for the 
treatment of endometriosis. 
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Dopamine receptor mediated signalling pathway496 
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Serine/threonine-protein kinase 24 (STK24) is involved in phosphate metabolic process and protein 
amino acid phosphorylation
496,578
. Mammalian sterile 20-like kinase 3 (MST3) is a synonym of STK24 
and mediates cell death by suppressing JNK survival pathway and upregulating haemoxygenase 1 
expression in the cell
646
. These anti tumorigenic and anti-cellular migratory properties
592,647
 serve to 
control disease proliferation and spread, potentially preventing a condition such as endometriosis from 
disseminating further or developing overt malignant features. 
Homeobox protein cut-like 1 (CUX1) regulates transcription from RNA polymerase 2 promoter and has a 
role in nucleic acid binding
496,578
. CUX1 is an important mediator in tumour invasion and a target for 
tumour growth factor beta (TGF beta). Wingless-type MMTV integration site family, member 5A 
(WNT5A) (A member of the Wnt multigene family) is seen to be upregulated by CUX1 increasing 
cellular potential for survival, proliferation and invasion in pancreatic tumours
648
. miRNA-122 targets 
CUX1 (CUTL1) and represses it. This might play a role in the suppression of cellular proliferation
649
 and 
a similar effect could potentially be occurring in endometriosis, moderating disease proliferation, invasion 
and growth. 
SET and MYND domain-containing protein 4 (SMYD4) regulates transcription from RNA polymerase 2 
promoter and acts as a transcription cofactor
496,578
. It has been identified as a tumour suppressor gene in 
breast cancer. It inhibits the expression of platelet-derived growth factor receptor alpha polypeptide 
(Pdgfr-alpha) which is highly expressed in malignant cells and could potentially be a target for treatment 
of disease
650
. In endometriosis, its tumour suppressive properties could be important in the prevention of 
disease progression to an overt malignant state. 
Puromycin-sensitive aminopeptidase (NPEPPS) has metallopeptidase activity and is involved in 
proteolysis
496,578
. It exhibits neuroprotective roles over neurodegenerative disease though proteolysis of 
the neurotoxic hyperphosphorylated TAU protein
651
. 
Mitogen-activated protein kinase kinase kinase 12 (MAP3K12) is involved in female gamete 
generation
496
. It is released in response to stress and has a role in a multitude of cellular processes, cell 
morphogenesis and the cell cycle. It is involved in apoptotic induction, cell adhesion, protein amino acid 
phosphorylation and is part of the immune system process
578,592
. It has also been involved in the 
gonadotropin releasing hormone receptor pathway (Figure 5-19), transmembrane receptor protein 
serine/threonine kinase signalling pathway, the JNK cascade (Figure 5-35) and I-kappaB kinase/NF-
kappaB cascade (Figure 5-37)
526
. Recent advances in genomic technologies can give us an improved 
insight into the central pathways involved in cellular pathogenesis and their survival
652
. The MAP3K12 
locus has been identified as an important locus in tumorigenesis
652
. In endometriosis, similar effects of 
MAP3K12 enabling ectopic cellular growth and apoptotic evasion can be postulated, it could potentially 
serve as a future target for directed therapeutics in disease. 
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FIGURE 5-37 
 
NF-kappa beta apoptotic cascade526 
 
Brain-specific angiogenesis inhibitor 2 (BAI2) is a G-protein coupled receptor and acts as an antibacterial 
defence response protein and a stress response protein
496,578
. It has a role in cellular immune response and 
regulates intracellular protein transport, cell adhesion, synaptic vesicle exocytosis and transmission and is 
implicated in spermatogenesis, angiogenesis, cardiac and mesodermal development via involvement in 
the p53 pathway (Figure 5-38)
526
 and the G-protein coupled receptor protein signalling pathway
526
. 
Analysis of BAI2 in in vivo cerebral ischemia models and in vitro hypoxic models showed that its 
angiostatic properties relate to decreased neovascularisation in the adult brain. In hypoxia, it is 
responsible for the neovascularisation in the adult brain in combination with elevated levels of vascular 
endothelial growth factor (VEGF) which is itself angiogenic
653
. In endometriosis, potential effects of 
BAI2 in the presence of external stressors or hypoxic milieu can account for neovascularisation 
developing around ectopic implants enabling their growth within the body. 
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FIGURE 5-38 
 
p53 Pathway496 
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Interferon-inducible double stranded RNA-dependent protein kinase activator. A (PRKRA) is a DNA and 
RNA binding protein
496
. It also acts as an immunity protein, a deaminase and a kinase activator within the 
cell. Cellularly it is involved in cell cycle control, anterior/posterior cell axis specification and RNA 
localisation
578,592
. It has a role in purine base and protein metabolic processes and in response to interferon 
gamma, regulates and forms part of the apoptosis signalling pathway (Figure 5-39)
526
 as well as being 
implicated in spermatogenesis and neurological system processes. The activation of the PKR family is not 
completely understood. It is believed that activating stimuli such as cytotoxins, stresses, viral infections or 
even chemotherapy cause the PKR activator RAX to initiate reactions and cause TNF-alpha activation
654
 
of apoptosis. Similar mechanisms might be occurring within endometriosis altering cellular and apoptotic 
controls. The PRKRA protein is therefore seen to have important effects on cell modulation and growth 
through multiple pathways including the TNF-induced activation of nuclear factor-kappaB (NF-kappaB) 
and mitogen-activated protein kinases (MAPKs)
655
. It is seen overall to positively regulate NF-kappaB 
(IkappaB) alpha kinase (IKK) and c-Jun N-terminal kinase (JNK) whilst negatively regulating mitogen-
activated protein kinases (MAPKs) (p44/p42 MAPK and p38MAPK)
655
. MAPKs could potentially play 
an important role in the disease of endometriosis
656
 so PRKRA regulation might make this an important 
target in this disease. 
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Apoptosis signalling pathway496 
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Voltage-dependent calcium channel subunit alpha-2/delta-2 (CACNA2D2) has voltage gated and cation 
channel activity. It is involved in cation and protein cellular transport and signalling as well as 
neurological system processes and muscle contractions
496,578,592
. CACNA2D2 has tumour suppressor gene 
properties which when altered is seen in the development of certain moderate dysplastic lesions in head 
and neck squamous cell carcinomas
657
. CACNA2D2 is part of a tumour suppressor gene cluster flanking 
isoform A of the Ras-association domain family member 1 (RASSF1A) gene. RASSF1A is one of the 
most frequently silenced genes in human tumours. Genetic repression is seen in CACNA2D2 in breast 
cancer cell lines, providing further evidence of its involvement in development of malignancy
658
. A 
recently published study has also looked at alterations in RASSF1A and CACNA2D2 in cervical 
carcinomas and it is postulated that they could be used to diagnose early disease and improve 
prognosis
659
. In endometriosis, CACNA2D2 could potentially serve as a tumour suppressor preventing 
overt changes to malignancy. 
Regulating synaptic membrane exocytosis protein 1 (RIMS1) has protein binding and small GTPase 
regulator activity involved in cellular synaptic transmission (Figure 5-40), intracellular protein transport 
and exocytosis of synaptic vesicles and cellular constituents
496,578,592
. It is also responsible for visual and 
sensory perception and defects in its function are associated with pathology such as retinal dystrophies. 
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Synaptic vesicle trafficking496 
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Solute Carrier family 9 Sodium/hydrogen exchanger 1 (SLC9A1) is a cation transmembrane transporter 
involved in cell migration but its pathways are not yet completely understood
496,578,592
. Studies with 
cervical cancer have shown that NHE1 (Synonym for SLC9A1) is upregulated with epidermal growth 
factor (EGF) promoting cellular volume regulation, cytoskeletal remodelling, migration and 
invasiveness
660
. This has clinical implications in the early stages of malignancy. In a similar way, it 
potentially could have an effect on ectopic endometriosis and its dissemination. NHE’s are also important 
in inflammation and in the maintenance of the body’s immune responses. Monocytes and neutrophils 
generate cytokines and reactive oxygen species as a first defence in response to stimuli. It is the NHE in 
the system that maintains the correct pH levels for optimal functioning of these immune cells
661
. If in 
endometriosis, the NHE system is altered, a change in cellular environmental pH could be another 
causative factor preventing immune cells recognising and eliminating ectopic disseminative cells. 
Peroxisomal membrane protein 4 (PXMP4) is described as an anti-tumour gene which is silenced through 
DNA methylation in prostatic carcinoma cells
662
. In the immune system this peroxisome membrane 
protein is known to bind to Pex19 which is an intracellular chaperone and is a component of the 
glycolipid membrane endocytic process
496,578,592
. This process is encoded for by yet another gene 
controlling Natural killer t-cells (Nkt1). T cells can recognise glycolipids presented on CD1 proteins. It is 
possible that if peroxisomes alter glycolipid availability for the CD1D presentation, they can influence 
NKT cell functions
663
. In endometriosis this could be another window enabling survival and development 
of disease. 
Regulatory factor X-associated protein (RFXAP) is one of three proteins (RFXB/ RFX5/RFXAP) 
comprising the RFX complex. This complex regulates expression of major histocompatibility complex 
class 2 genes
496,578
. Mutations in the RFX complex have been shown to result in severe immunodeficiency 
within the organism
664
. If in endometriosis, this protein has the same effects of causing a level of 
immunodeficiency within the patient, it could (in conjunction with other alterations in cellular properties) 
explain the ability of ectopic tissue to evade apoptosis and elimination. In combination with another gene, 
brahma related gene 1 (BRG1), RFXAP is also associated with cellular chromatin remodelling
665
 and 
with the nuclear translocation and expression of MHC class 2 genes
666
. 
Nicolin-1 (NICN1) is a mammalian gene encoding a 213 amino acid nuclear protein not attributed to a 
known family
496,578,592
. High levels are found in brain, testes, liver and kidneys. It is low in leukocytes, 
colon, spleen and small intestine. It is also expressed during development
667
. Not much is known about 
the gene’s function. 
Testican-2 (SPOCK2) is a member of the testican group of extracellular proteoglycans
668
. It has a modular 
structure indicating the potential to participate in various interactions. It has four main domains 
(follistatin-like, calcium binding domain, thyroglobulin type-1 domain and an acid C-terminal domain 
with attachment sites for glycosaminoglycans) and is seen to interact with the subcomponent of 
complement component C1 (C1q) activating complement activation pathways
496,526,578,592
. This indicates 
its importance in inflammatory or immune processes. Interestingly, epigenetic inactivation of SPOCK2 is 
seen in the malignant transformation of ovarian endometriosis
669
. 
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5.7.2.1 Summary of important identified  points. 
 From the above list of genes and proteins controlled by Hsa-mir-122, one can see effects on various 
cellular processes, properties and pathways. Internally, endocytic processes are altered by IGSF5 and 
GIT1, potentially disrupting the normally balance cellular milieu. GIT1 is also seen to affect cellular 
motility whereas CLIC4 and SLC9A1 increase the adhesive cellular potential enabling implantation 
of ectopic tissue such as endometriosis. 
 Apoptotic mediators such as MAP3K12 are also seen to interact with hsa-mir-122 altering cellular 
survival potential. LMNB2 and PRKRA are also associated with the apoptotis and FAS signalling 
pathways, they too can effect cellular survival and growth in endometriosis. 
 Neovascularisation is an essential process to maintain survival in growing tissue, including ectopic 
implants in endometriosis. BAI2 has been linked to hsa-mir-122 and potentially enables survival of 
ectopic tissue through its effects on neovascularisation. 
 IGSF5, LMNB2 and OCLN are all linked to metastatic tumour progression, potentially contributing 
to the properties of dissemination, proliferation and growth seen in endometriosis. DUSP4, STK24 
and CUX1 have counteracting effects causing metastaic repression. Potentially it is a fine balance 
between these genes and proteins that prevent overt malignant transformation in endometriosis. 
 Tumour suppressor properties in SMYD4, CACNA2D2 and PXMP4 have also been explored. BAI2 
is also seen to interact with tumour suppressor p53. The effects of tumour suppressors on a 
multifactorial disease such as endometriosis might be imperative in preventing malignant 
transformation within the majority of my patient population. 
 Endometriosis is a hormonally responsive disease. MAP3K12 is also seen to affect the GnRH 
pathway. Current suppressive medical therapies aim to target the GnRH pathway through the use of 
GnRH analogues to promote cellular apoptosis. 
 A correctly functioning immune system is imperative in the recognition and elimination of diseased 
and/or ectopic cells. Genes and proteins (such as MAP3K12 and RFXAP) affecting the immune 
system have been linked to hsa-mir-122. Other proteins and genes such as SLC9A1 affect the milieu 
in which immune cells function potentially altering their effectiveness. PXMP4 is another gene 
which affects Natural killer cell function potentially enabling progression of disease. 
 Relating back to the information above, there are varied roles which each protein or gene is known to 
carry out though it is difficult to determine which of these pertains a leading role, or which of these 
follow on as a secondary response to alternate cellular processes. 
 It is once again beyond the scope of this chapter to determine which are the most likely proteins or 
genes to cause (or enable to a larger extent) the development of the disease of endometriosis. A 
separate body of work with functional models to determine important molecular or protein roles 
together with identification of the most pertinent associated disease molecules or genes could enable 
future targeted approaches to disease. 
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5.8 Detailed cellular function analysis of upregulated and downregulated 
serum miRNAs 
In this section of my thesis I aim to look at the functional changes that are induced by the proteins and 
genes explored above. Rather than their analysis on an individual basis I believe it will be clinically 
relevant to see how their impact on human embryology the cell cycle, cellular architecture, cell signalling, 
proteolysis and endocytosis as well as their contribution to angiogenesis and their impact on the immune 
system all conforms to facilitate development of endometriosis. 
In my study, miRNAs hsa-mir-1224-5p and hsa-mir-4274 are upregulated in serum of women with 
endometriosis whilst hsa-miR-150 and hsa-miR-122 are downregulated. These miRNAs control a number 
of proteins and genes associated with the development of angiogenesis, cell cycle control and inter and 
intra cellular interactions. Other genes controlled by these miRNAs are involved in cell motion and 
adhesion, vesicular endo/exocytosis and cell survival through the evasion of the apoptosis and the 
alteration of the immune system processes of the body. All these effects are tightly controlled in normally 
functioning cells. Cellular derangement at micro RNA levels can give rise to aberration of control and 
lead to the development and progression of a disease such as endometriosis. 
5.8.1 Embryology 
In the theory of Mullerianosis (See section 1.6.3), endometriosis is believed to originate from aberrant or 
displaced mullerian tissues during embryological development. Publications supporting the embryonic 
orogin of endometriosis arise from evidence of ectopic endometrium in human female foetuses at 
different gestations
670
. The reason for the presence of ectopic endometrium could potentially arise from 
aberrations in genes controlling embryology and organogenesis. The genes linked to ectodermal, 
mesodermal and embryonic development could potentially be involved in the formation of endometriosis 
through the function and interactions of the upregulated hsa-mir-1224-5p and/or hsa-mir-4274 or 
downregulated hsa-mir-150 and/or hsa-mir-122. Each respective miRNA identified in my study has been 
linked to various other proteins and genes with which they potentially interact. 
Hsa-mir-1224-5p (See section 5.6.1) is linked to Ubiquitin-conjugating enzyme E2 W (UBE2W) a key 
role player in embryonic development. Other associations include Tensin-1 (TENS1), Krueppel-like 
factor 3 (KLF3), C-X-C motif chemokine 6 (CXCL6), Eosinophil cationic protein ribonuclease, RNase A 
Family, 3 (RNASE3) and Dystrophin-related protein 2 (DRP2). These are all linked to embryonic 
mesodermal development. It is the intermediate mesoderm that develops into the urogenital system in 
adults
671
. Dystrophin-related protein 2 (DRP2), MAP kinase-activating death domain protein (MADD) 
and Neurogenic differentiation factor 4 (NEUROD4) are linked to embryonic ectodermal development 
which gives rise in adults to the nervous system, enamel and epidermis
671
. 
Hsa-mir-4274 (See section 5.6.2) controls and interacts with other molecules including: pituitary 
adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1), embryologically involved in 
mesodermal and heart muscle development and protocadherin-9 (PCDH9). The latter is involved in 
ectodermal, muscle and heart development. 
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Hsa-miR-150 (See section 5.7.1) is seen to control a number of genes that have an embryonic role in the 
development of tissues. Myelin protein zero-like protein 1 (MPZL1) (PZR) is involved in early 
embryonic tissue formation, neurogenic differentiation factor 6 (NEUROD6) is involved in ectodermal 
development, neuronal cell adhesion molecule (NRCAM) and semaphorin-3A (SEMA3A) regulate 
ectoderm and mesoderm development, whilst brain acid soluble protein 1 (BASP1) and RNA-binding 
motif protein, X-linked-like-2 (RBMXL2) are involved in ectodermal and nervous system development. 
Hsa-mir-122 (See section 5.7.2) controls other genes with a role in embryological development. 
Immunoglobulin superfamily member 5 (IGSF5) is linked to ectodermal and nervous system 
development. Dual specificity protein phosphatase 4 (DUSP4) controls mesodermal and muscle 
development, whilst interferon-inducible double stranded RNA-dependent protein kinase activator A 
(PRKRA) is involved in spermatogenesis and neurological system processes. Mitogen-activated protein 
kinase kinase kinase 12 (MAP3K12) is associated with female gamete formation and brain-specific 
angiogenesis inhibitor 2 (BAI2) is linked to mesodermal development and spermatogenesis. 
5.8.2 The cell cycle and DNA replication 
Cellular mitosis and meiosis are imperative for correct DNA synthesis, progression and replication of a 
cell through the cell cycle. Aberrations in replication of nuclear material results in cellular mutations, 
which accumulate as the mutated cells replicate. Multiple cellular mutations are linked to cancer
672
 where 
cells replicate at an increased rate eventually infiltrating surrounding tissues. The development of 
endometriosis could potentially be attributed to alterations in molecules controlling cellular division, 
resulting in cells with the potential to disseminate, implant and invade. 
Cellular mitosis and meiosis are regulated by the following genes that are influenced by hsa-mir-1224-5p 
(See Section 5.6.1): ubiquitin-conjugating enzyme E2 W (UBE2W), SUN domain-containing protein 1 
(SUN1), synaptopodin-2 (SYNP2), prickle-like protein 2 (PRIC2) and dual specificity tyrosine-
phosphorylation-regulated kinase 1A (DYRK1A). Ubiquitin-conjugating enzyme E2 W (UBE2W) and 
prickle-like protein 2 (PRIC2) control chromosome segregation and dorsal ventral axis specification of 
the nuclear cellular material
496,578
. Sex comb on midleg-like protein 4 (SCML4) is another molecule that 
interacts with hsa-mir-1224-5p, binds chromatin and has transcription factor activity. 
Hsa-mir-4274 (see Section 5.6.2) controls the regulator of G-protein signalling 20 (RGS20) which 
enables dorso ventral axis specification and allows for the correct segregation of nuclear material. 
Aberrations in any of these processes can be responsible for cell cycle dysregulation which can give rise 
to the formation of pathology. Hsa-mir-4274 is also involved in the mitotic process through the regulation 
of cGMP-dependent protein kinase 2 (PRKG2) and rap guanine nucleotide exchange factor 2 (RAPGEF2) 
which has GTPase regulator activity. This miRNA also controls transformer-2 protein homolog beta 
(TRAB2B) which splices mRNA in mitosis. 
In endometriosis, miRNA hsa-mir-1224-5p is seen to control various genes affecting the cell cycle at 
various points. RNA polymerase 2 is an enzyme within cells that catalyses the transcription of DNA to 
precursors of mRNA and most snRNAs and miRNAs. Various genes controlled through miRNA hsa-mir-
1224-5p regulate the transcription process from the RNA polymerase 2 promoter affecting the cell cycle. 
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These include sex comb on midleg-like protein 4 (SCML4), transcription factor Sp1 (SP1), cyclic AMP-
responsive element-binding protein (CREB1), Krueppel-like factor 3 (KLF3), Staphylococcal nuclease 
domain-containing protein 1 (SND1), NAD-dependent deacetylase sirtuin-6 (SIRT6), neurogenic 
differentiation factor 4 (NEUROD4), Kelch-like protein 15 (KLH15), zinc finger protein 208 (ZNF208), 
DNA-binding protein SATB1 (SATB1), putative zinc finger protein 730 (ZNF730), zinc finger protein 
107 (ZNF107) zinc finger protein 418 (ZNF418), zinc finger protein 676 (ZNF676), protein core-binding 
factor, runt domain, alpha subunit 2; translocated to 1 (CBFA2T1) (RUNX1T1), lysine-specific 
demethylase 5C (KDM5C). Origin recognition complex subunit 2 (ORC2) is a gene essential for the start 
of DNA replication in eukaryotic cells, eosinophil cationic protein ribonuclease, RNase A Family 3 
(RNASE3) is implicated in the RNA catabolic process, whilst histone-binding protein RBBP7 (RBBP7) 
is involved in DNA repair. Ubiquitin-conjugating enzyme E2 W (UBE2W) has ligase activity which is 
implicated in DNA repair and replication whilst MAP kinase-activating death domain protein (MADD) is 
a GTPase controlling protein biosynthesis at the ribosome. 
Hsa-mir-4274 effects and interacts with other molecules within the cell cycle. It regulates PC4 and 
SFRS1-interacting protein (PSIP1) and zinc finger protein 41 (ZNF41), which are transcription factors 
from RNA polymerase 2 promoter. Cytoplasmic dynein 1 light intermediate chain 2 (DYNC1LI2) 
controls RNA localisation and methenyltetrahydrofolate cyclohydrolase (MTHFD2L) is involved in 
purine and pyrimidine cellular processes. Bladder cancer-associated protein (BLCAP) regulates cell cycle 
proliferation independent from TP53/p53 pathways. 
Under the influence of hsa-miR-150 (See section 5.7.1), erythrocyte membrane protein band 4.1-like 
protein 5 (EPB41L5) maintains cell polarity during nuclear segregation in preparation for cell splitting 
whilst DDB1- and CUL4-associated factor 6 (DCAF6) have a role in the nucleotide metabolic process. 
RNA-binding motif protein, X-linked-like-2 (RBMXL2) affects pre-mRNA processing and mRNA 
metabolism. Importin-5 (IPO5) has GTPase regulator activity whilst transcriptional activator Myb 
(MYB), neurogenic differentiation factor 6 (NEUROD6) and vascular endothelial zinc finger 1 (VEZF1) 
all regulate transcription from RNA polymerase. Programmed cell death protein 4 (PDCD4) is involved 
in cellular translation whilst structural maintenance of chromosomes protein 3 (SMC3) ensures 
stabilisation of DNA replication and its repair enabling regulation of the mitotic and meiotic processes. 
Anomalies in cellular growth and division are seen in mutations in the protein phosphatase 1 regulatory 
subunit 3A (PPP1R3A) gene. These mutations are seen in various cancers (including ovarian cancers)
595
 
and are also directly related to organ and lymph node metastasis
596
. Another gene controlled by hsa-miR-
150 is cystathionine gamma-lyase (CTH) with effects on cellular growth and proliferation. 
Hsa-mir-122 (See section 5.7.2) is also seen to affect the cell cycle through gene modification. Interferon-
inducible double stranded RNA-dependent protein kinase activator A (PRKRA) maintains anterior 
posterior cell axis specification enabling correct nuclear segregation and lamin-B2 (LMNB2) controls 
nuclear stability and mutations. Occludin (OCLN), homeobox protein cut-like 1 (CUX1) and 
SET/MYND domain-containing protein 4 (SMYD4), all regulate transcription from RNA polymerase 2 
promoter and bind nucleic acids. Cell cycle control is maintained through DNA and RNA binding 
proteins such as interferon-inducible double stranded RNA-dependent protein kinase activator A 
(PRKRA). DNA replication is linked to the dual specificity protein phosphatase 4 (DUSP4) which is a 
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MAPK family member. Abnormal MAPK signalling is believed to be implicated in the development and 
progression in human cancers. MAPK regulation in normal tissues shows that deregulation of this tightly 
controlled process can initiate or develop cancer, determine cellular responses to cancer therapies and 
alter patient prognosis
643
. 
5.8.3 Chromatin cellular architecture 
The establishment and maintenance of chromatin cellular architecture is important for cellular replication, 
function and growth. Aberrations in the architecture and cytoskeletal structure of cells, lead to the 
development of disease by altering gene expression, deregulating interactions between cellular 
components and affecting cellular signalling and cellular processes. Similar aberrations in cellular 
structure might contribute to the formation of endometriosis. 
The hsa-mir-1224-5p (See section 5.6.1), is seen in my study to be upregulated in endometriosis and 
controls the following genes and proteins responsible for maintenance of the cellular maintenance of 
chromatin architecture: sex comb on midleg-like protein 4 (SCML4), SUN domain-containing protein 1 
(SUN1), synaptopodin-2 (SYNP2), prickle-like protein 2 (PRIC2), RUNX1T1, NAD-dependent 
deacetylase sirtuin-6 (SIRT6), dystrophin-related protein 2 (DRP2), kelch-like protein 15 (KLH15) and 
histone-binding protein RBBP7 (RBBP7). 
Hsa-mir-4274  (See section 5.6.2) is also involved in the morphogenesis of cellular components and the 
cellular cytoskeleton through protocadherin-9 (PCDH9) and cytoplasmic dynein 1 light intermediate 
chain 2 (DYNC1LI2). The expression or aberration of any of the abovementioned genes could possibly 
contribute to disease formation and development of endometriosis. 
Hsa-miR-150 (See section 5.7.1) is seen in my study to be downregulated in endometriosis. It regulates 
various components affecting cellular chromatin architecture. Catenin beta-1 (CTNNB1), structural 
maintenance of chromosomes protein 3 (SMC3) and calpastatin (CAST) all have a role in chromatin 
architecture, segregation and remodelling of the cytoskeleton. SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily D member 2 (SMARCD2) is a chromatin binding protein and 
myelin protein zero-like protein 1 (MPZL1) (PZR) has a role in morphogenesis of the cellular 
components. Changes in cytoskeletal genes can cause increased cellular adhesion and enable tumour 
infiltration and metastasis. A similar effect could potentially occur with ectopic endometrial cells 
enabling their invasion and growth. 
Hsa-miR-122 (See section 5.7.2), also downregulated in endometriosis, controls other structural 
cytoskeletal components such as chloride intracellular channel protein 4 (CLIC4). The regulatory factor 
X-associated protein (RFXAP) with brahma related gene 1 (BRG1) is associated with chromatin 
remodelling and mitogen-activated protein kinase kinase kinase 12 (MAP3K12) regulates cellular 
morphogenesis. Certain cytoskeletal components regulated by hsa-miR-122 are involved in 
tumorigenesis. Higher levels of lamin-B2 (LMNB2) expression in tissues are associated with increased 
tumour metastatic potential
641
. Solute carrier family 9 Sodium/hydrogen exchanger 1 (SLC9A1) further 
enhances cytoskeletal remodelling with implications for early malignant transformation. 
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5.8.4 Intracellular signalling 
The maintenance of a correct intracellular environment enables for the correct functioning of its 
pathways. Changes in cellular pathways secondary to stressors or mutations can alter cellular properties. 
This can lead to mutations and aberrations in a multitude of cellular functions ranging from immune 
responses to programmed cell death, replication and inflammation
673
. As cellular functions are often 
interdependent, the effect of one altered pathway can have a substantial impact on numerous cellular 
functions. Sorting nexin-21 (SNX21), tensin-1 (TENS1), dual specificity tyrosine-phosphorylation-
regulated kinase 1A (DYRK1A), MAP kinase-activating death domain protein (MADD) and Rho-related 
BTB domain-containing protein 3 (RHOBTB3) are all involved in intracellular signalling and the 
intracellular signalling cascades. These are all regulated by hsa-mir-1224-5p (See section 5.6.1). Any 
dysregulation in their processes can be attributed to formation and development of endometriosis. 
Hsa-mir-4274 (See section 5.6.2) is also associated with intracellular processes. It regulates Calcium 
mediated signalling through serine/threonine-protein kinase N2 (PKN2). Other signal transduction 
controlling elements include lysyl oxidase homolog 4 (LOXL4) and cGMP-dependent protein kinase 2 
(PRKG2). Intracellular protein transport is modulated through cytoplasmic dynein 1 light intermediate 
chain 2 (DYNC1LI2) and pituitary adenylate cyclase-activating polypeptide type I receptor 
(ADCYAP1R1). The regulation of synaptic transmission for cellular signal transduction is through the 
potassium voltage-gated channel subfamily C member 2 (KCNC2). 
5.8.5 Cellular proteolysis 
Growth regulators and control of cells through various stages of the cell cycle are controlled by 
proteolysis
674
. Aberrations in the cell cycle or cellular division can give rise to mutations which are 
further replicated. Any changes in the tight control of the cell cycle through effects on proteolysis can 
potentially give rise to aberrant cellular characteristics such as those seen in ectopic endometrial tissue 
developing into endometriosis. A number of genes controlling proteolysis are seen to be regulated by hsa-
mir-1224-5p (See section 5.6.1) and can therefore be implicated as having roles in cellular disease. These 
genes include: thymus-specific serine protease (PRSS16), carboxypeptidase A6 (CPA6), ubiquitin 
carboxyl-terminal hydrolase isozyme L1 (UCHL1), tripeptidyl-peptidase 1 (TPP1) and ubiquitin-
conjugating enzyme E2 W (UBE2W). Hsa-mir-4274 (See section 5.6.2) controls proteolysis through lysyl 
oxidase homolog 4 (LOXL4). 
Hsa-miR-150 (See section 5.7.1) regulates calpastatin (CAST) which is a cysteine protease inhibitor and a 
regulator of cellular proteolysis. Hsa-miR-122 (See sectionhsa-miR-122) is involved in the regulation and 
modulation of puromycin-sensitive aminopeptidase (NPEPPS) controlling proteolysis of neurotoxic 
proteins inhibiting development of neuropathies. 
5.8.6 Cellular endocytosis and exocytosis 
In cellular endocytosis or exocytosis, the cell incorporates or releases vesicles containing proteins, 
enzymes or transmitters (synaptic vesicles) enabling incorporation of materials or their transport between 
cells. As described earlier in this thesis, viral infections use the formation of vesicles with endocytosis 
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and exocytosis to transfer and incorporate their own RNA or DNA into the cellular genome. EBV is a 
virus known to act in this way, (EBV hsa-mir-BART2-5p was identified as being elevated in the 
lymphocytes of patents with endometriosis- section 4.5.2.1) and the control of these processes trough a 
miRNA which is elevated in disease might indicate another facet of disease pathogenesis in 
endometriosis. 
Hsa-mir-1224-5p (See section 5.6.1) affects the exocytic or endocytic cellular processes in the following 
way: C-type lectin domain family 4 member F (CLC4F) is involved in receptor mediated endocytosis 
whilst intersectin-1 (ITSN1), Rho-related BTB domain-containing protein 3 (RHOBTB3) and 
Synaptotagmin-14 (SYT14) have roles in cellular endocytosis, exocytosis, synaptic vesicle and 
transmembrane protein trafficking. Importin subunit alpha-1 (KPNA1) has a role in nuclear transport. 
Cytohesin-2 (CYTH2) and coatomer subunit beta (COPB1) control intracellular protein transport and 
exocytosis. 
Hsa-mir-4274 (See section 5.6.2) regulates extracellular transport through lysyl oxidase homolog 4 
(LOXL4). Golgin subfamily A member 8A (GOLGA8A), peroxisomal targeting signal 1 receptor (PEX5) 
are membrane trafficking proteins. Cytoplasmic dynein 1 light intermediate chain 2 (DYNC1LI2) is 
involved in vesicle mediated transport and the exocytic process for synaptic and non-synaptic vesicles is 
controlled through pituitary adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1). 
Importing molecules such as importin-5 (IPO5) have been used by viruses such as influenza
624
 and 
EBV
625
 amongst others, to infiltrate cellular structures and evade host immune systems. Calpastatin 
(CAST) is an example of a gene controlled by hsa-mir-150 (See section 5.7.1) which regulates exocytosis 
of neural vesicles. Brain acid soluble protein 1 (BASP1) regulates exocytosis and intracellular protein 
transport. 
5.8.7 Cellular adhesion and motion 
In endometriosis, the proliferation of cells and their dissemination to nearby pelvic sites or distant areas is 
possibly enabled through changes in the properties of cellular adhesion and motion. Tensin-1 (TENS1), 
C-type lectin domain family 4 member F (CLC4F) and dystrophin-related protein 2 (DRP2) are the genes 
affecting cellular adhesion properties which are controlled by hsa-mir-1224-5p (See section 5.6.1). 
Cellular motion is affected through SUN domain-containing protein 1 (SUN1), Synaptopodin-2 (SYNP2), 
prickle-like protein 2 (PRIC2), tensin-1 (TENS1), C-type lectin domain family 4 member F (CLC4F) and 
dystrophin-related protein 2 (DRP2). 
Hsa-mir-4274 (See section 5.6.2) controls cellular adhesion through lysyl oxidase homolog 4 (LOXL4) 
and protocadherin-9 (PCDH9). PCDH9 is also involved in cell motion. 
Neuronal cell adhesion molecule (NRCAM) is a component of the immunoglobulin superfamily of cell 
adhesion and receptor molecules. Catenin beta-1 (CTNNB1), semaphorin-3A (SEMA3A), rho-guanine 
nucleotide exchange factor (RGNEF) and myelin protein zero-like protein 1 (MPZL1) (PZR) have roles 
in cell-cell adhesion and are regulated by hsa-mir-150 (See section 5.7.1). Myelin protein zero-like 
protein 1 (MPZL1) (PZR) enables fibronectin dependant migration of cells and erythrocyte membrane 
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protein band 4.1-like protein 5 (EPB41L5) causes changes in cytoskeletal genes causing adhesion and 
invasiveness of the affected cells. Other genes which affect cellular adhesive properties enabling invasion 
and metastasis include calpastatin (CAST), mitochondrial carrier homolog 2 (MTCH2) and rho-guanine 
nucleotide exchange factor (RGNEF). 
5.8.8 Intercellular cell-cell signalling 
Intercellular signalling is controlled through various processes and multiple genes. Hsa-miR-1224-5p 
(See section 5.6.1) controls some of the genes involved in cellular signalling. It has a role in synaptic 
transmission through Synaptotagmin-14 (SYT14) and a role in signal transduction and cation transport 
through cyclic nucleotide-gated cation channel beta-3 (CNGB3). Intracellular signalling cascades are also 
controlled through the histone-binding protein RBBP7 (RBBP7), C-X-C motif chemokine 6 (CXCL6) 
and C-type lectin domain family 4 member F (CLC4F) all affected by hsa-mir-1224-5p. Any 
disseminative disease will usually survive through various body processes. In general, the evasion of 
apoptosis, the formation of angiogenesis and alteration or escape from detection by the host’s immune 
system enables unregulated proliferation, dissemination and implantation of diseased tissues at peripheral 
sites. Negative regulators of apoptosis such as ubiquitin-conjugating enzyme E2 W (UBE2W) is 
controlled by the hsa-miR-1224-5p which is elevated in endometriosis. Apoptotic inducers are also 
regulated by the same miRNA. These include Calpain-5 (CAN5), tensin-1 (TENS1) the GTPase MAP 
kinase-activating death domain protein (MADD) and transcription factor Sp1 (SP1) through the apoptosis 
signalling pathway. 
Hsa-mir-4274 (See section 5.6.2) has a role in cell signalling through the PC4 and SFRS1-interacting 
protein (PSIP1) and regulates calcium mediated signalling through the serine/threonine-protein kinase N2 
(PKN2). Bladder cancer-associated protein (BLCAP) is another regulator of apoptosis and is modulated 
through hsa-mir-4274. The same miRNA controls a negative regulator of apoptosis called lysyl oxidase 
homolog 4 (LOXL4). 
Hsa-mir-150 (See section 5.7.1) has a role in regulating interleukin-7 (IL7), with a role in cell signalling. 
and regulates transcriptional activator Myb (MYB) and adiponectin receptor protein 2 (ADIPOR2). Both 
these genes have a role in cell surface receptor linked transduction. Rho-guanine nucleotide exchange 
factor (RGNEF) is involved in cellular synapses and synaptic vesicle glycoprotein 2B (SV2B) in 
neurotransmitter secretion. Intracellular signalling is regulated by neuronal cell adhesion molecule 
(NRCAM) and catenin beta-1 (CTNNB1) both of which are also controlled by hsa-miR-150. 
Hsa-miR-122 (See section 5.7.2) regulates different genes involved in intracellular signalling processes. 
Brain-specific angiogenesis inhibitor 2 (BAI2) has a role in intracellular protein transport and regulating 
synaptic membrane exocytosis protein 1 (RIMS1) regulates cellular synaptic transmission. The voltage-
dependent calcium channel subunit alpha-2/delta-2 (CACNA2D2) is involved in protein cellular transport 
and signalling and has tumour suppressor gene properties. Its genetic repression is seen in cancer lines 
including breast and cervical carcinomas (Section 5.7.2). 
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5.8.9 Angiogenesis 
Angiogenesis supports the survival of abnormal cellular growth or dissemination by providing these cells 
with nutrients required for survival. Similar requirements are necessary for ectopically implanted 
endometriosis cells to grow and proliferate. Fibroblast growth factor receptor 1 (FGFR1), C-X-C motif 
chemokine 6 (CXCL6) and the eosinophil cationic protein ribonuclease, RNase A Family, 3 (RNASE3) 
are all regulated through hsa-miR-1224-5p (See section 5.6.1). This can explain how endometriosis is 
supported in its proliferation and survival within the pelvis. 
Hsa-miR-150 (See section 5.7.1) is involved in angiogenic regulation through control of neuronal cell 
adhesion molecule (NRCAM), semaphorin-3A (SEMA3A) and vascular endothelial zinc finger 1 
(VEZF1). 
Hsa-miR-122 (See section5.7.2) has effects on brain-specific angiogenesis inhibitor 2 (BAI2). In hypoxia, 
it is responsible for the neovascularisation in the adult brain in combination with elevated levels of 
vascular endothelial growth factor (VEGF), which is itself angiogenic
653
. 
5.8.10 Apoptosis 
In a multicellular organism, the regulation of cellular numbers results from tight regulation of cellular 
division and cell death. Apoptosis, or programmed cell death is important in the maintenance of correct 
embryonic development, organogenesis and the elimination of abnormal, damaged or infected cells in the 
adult organism
675
. Aberrations or mutations in any of the apoptotic regulator genes can lead to 
development of diseased tissue such as endometriosis. 
Hsa-miR-150 controls apoptotic regulation via DDB1- and CUL4-associated factor 6 (DCAF6), 
calpastatin (CAST) and rho-guanine nucleotide exchange factor (RGNEF). Negative regulators of 
apoptosis under control by the same miRNA include protein Mdm4 (MDM4), interleukin-7 (IL7) and 
transcriptional activator Myb (MYB). Apoptosis inducers include programmed cell death protein 4 
(PDCD4). Mitochondrial apoptotic regulators include the mitochondrial carrier homolog 2 (MTCH2). 
The Wilms tumour 1 associated protein (WTAP) in combination with IGF-1 serves as an antiapoptotic 
gene under control of the same miRNA. 
Hsa-miR-122 regulates apoptosis through lamin-B2 (LMNB2) and interferon-inducible double stranded 
RNA-dependent protein kinase activator A (PRKRA). The serine/threonine-protein kinase 24 (STK24) 
mediates cell death by suppressing the JNK survival pathway and upregulating haemoxygenase 1 
expression in the cell
646
. 
5.8.11 Immune system 
Various components of the immune system are involved in maintaining cellular regulation within an 
organism. Genes and proteins involving the host’s mediated immune responses are implicated in 
development of endometriosis through their control by identified up and downregulated miRNAs such as 
hsa-miR-1224-5p, hsa-mir-4274, hsa-mir-150 and hsa-mir 122. Hsa-mir-1224-5p is associated with the 
following genes and proteins which I proceeded to analyse (See section 5.6.1). Calpain-5 (CAN5) is 
Gene, protein and miRNA expression in women with endometriosis 
243 
linked to PCOS disease and the processing of the immune system. Tensin-1 (TENS1) and transcription 
factor Sp1 (SP1) are other cytoskeleton constituents involved in the immune system. B-cell immunity is 
affected by krueppel-like factor 3 (KLF3) and SEC14 domain and spectrin repeat-containing protein 1 
(SESD1). Cyclic AMP-responsive element-binding protein (CREB1) is involved in the maintenance of 
regulatory T cells and C-type lectin domain family 4 member F (CLC4F), lipopolysaccharide-binding 
protein (LBP) and C-X-C motif chemokine 6 (CXCL6) are involved in macrophage activation and the 
cellular defence response. 
The control of the immune system through hsa-mir-4274 (See section 5.6.2) occurs via the PC4 and 
SFRS1-interacting protein (PSIP1), the ligase and transporter activity of long-chain-fatty-acid-CoA ligase 
6 (ACSL6) and macrophage activation through lysyl oxidase homolog 4 (LOXL4).Antibacterial response 
proteins released in the cellular stress response include pituitary adenylate cyclase-activating polypeptide 
type I receptor (ADCYAP1R1). This protein is also modulated through hsa-mir-4274 stimulating the 
immune system processes within the organism. 
Hsa-mir-150 (See section 5.7.1) affects the immune system through the regulation of the following 
associated genes: Interleukin-7 (IL7) is expressed by leukocytes, rho-guanine nucleotide exchange factor 
(RGNEF) and activates B lymphocytes and semaphorin-3A (SEMA3A). It is a membrane bound 
signalling molecule with receptor binding properties. Interferon-induced protein with tetratricopeptide 
repeats 5 (IFIT5) is another gene associated with hsa-mir-140. It is a component of the host organism 
antiviral defences and their presence enables the restriction of viral replication, stimulates apoptosis in 
virally infected cells and regulates immune responses. The genetic suppression of IFIT genes or their 
methylation by viral molecules, are mechanisms employed by viruses to escape host antiviral defences
594
. 
IFIT family members are today believed to be imperative in the production of novel vaccines and viral 
restriction mechanisms. A similar mechanism could be potentially responsible for the development of the 
immune evading properties of endometriotic cells. In my study, I have already identified the EBV 
miRNA (EBV-BART2-5p) as being present in the leukocytes of endometriotic patients (See section 
4.4.3.5 and 4.5.2.1) The V-type proton ATPase subunit H (ATP6V1H) (NEF) upregulated in endometrial 
tissue biopsies facilitates CD4 internalisation reducing the CD4 expression on infected cells thereby 
enabling vial survival and infection. 
Hsa-miR-122 (See section 5.7.2) has a role in the immune system through the role of various genes. Dual 
specificity protein phosphatase 4 (DUSP4) and mitogen-activated protein kinase kinase kinase 12 
(MAP3K12) are part of immune system process and brain-specific angiogenesis inhibitor 2 (BAI2) is an 
antibacterial defence response protein. Testican-2 (SPOCK2) has a role in the activation of complement 
activation pathway and its epigenetic inactivation is seen in the malignant transformation of ovarian 
endometriosis
669
. The solute carrier family 9 Sodium/hydrogen exchanger 1 (SLC9A1) enables 
maintenance of the body’s immune response by stabilisation of a normal pH for monocytes and 
neutrophils to work. Mutations of certain genes like regulatory factor X-associated protein (RFXAP) are 
seen to induce host immunocompromisation and make the host organism more susceptible to viral and 
bacterial infections which can further destabilise cellular control. Peroxisomal membrane protein 4 
(PXMP4) is an anti-tumour gene which can influence NKT cell function through the alteration of 
glygolipid availability for CD1D presentation
663
. 
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Interferon-inducible double stranded RNA-dependent protein kinase activator A (PRKRA) is activated by 
viral infections or stressor cell through RAX. PRKRA proceeds to induce TNF-alpha activation. 
Upregulation of chloride intracellular channel protein 4 (CLIC4) by reactive oxygen species causes TGF-
beta1 differentiation of fibroblasts to myofibroblasts a mark of active tumour stroma in ovarian cancer. It 
is therefore postulated that inhibition of CLIC4 night be a potential therapeutic option for stromal tumour 
targeting in ovarian tumours
644,645
. As discussed in an earlier section of my thesis, similar cellular changes 
might be potentially linked to ectopic pelvic cells evading immune elimination, implanting and giving rise 
to endometriosis. If a link (through future studies) shows a direct effect of CLIC4 and development of 
endometriosis, this could be used as a future therapeutic target for preventing or treating disease. 
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6 Serum analysis in endometriosis (proteomics) 
6.1 Introduction 
Following the tissue miRNA study, potential markers for disease presence were examined in the serum. 
The ability to predict presence of disease through a non-surgical technique would reduce patient 
morbidity and enable earlier disease identification and treatment. 
6.2 Aims 
 To obtain a set of serum samples from patients who suffered from endometriosis with no other 
confounding pathology and samples from surgically confirmed women without endometriosis or 
confounding pathology (Control samples). 
 To assess for differences in serum protein and antibody expression between the serum of patients 
with endometriosis and the controls. 
 To identify a panel of potential miRNA and/or antibody biomarkers that could be used as a non-
invasive diagnostic test for endometriosis. 
6.3 Method 
73 serum samples (endometriosis (n=36) vs. matched controls (n=35)) were taken from the recruited and 
consented patients. Samples were stored at -80ºC until required. They were then aliquoted when thawed 
to circumvent degradation of the samples during repeated freeze thaw cycles. Polypropylene sample tubes 
were labelled with sample identities ready for use and serum samples were then thawed at 20ºC for 30 
minutes. One 300µL sample was taken from each tube for miRNA analysis and 22.5µLwas taken for 
autoantibody analysis. The remaining volume was dispensed into 5 x 200µL aliquots in labelled sample 
tubes (Table 9-16, Table 9-17). Any remaining sample was left in the original sample tube. The tubes 
were frozen and stored at -80ºC together with the original sample tubes. Due to variation in sample 
volumes some samples only yielded 2 or 3 aliquots. Samples were thawed directly prior to the assay and 
were randomised and split into assay racks of 23 samples each. Each assay rack contained both case and 
control samples and one pooled normal human serum control sample which was used to monitor assay 
performance. The serum was assayed for the presence of antibodies using the Discovery Array v2.0 and 
the standard biomarker discovery protocol (Section 2.6.4 and Section 2.8). 
6.4 Results 
The use of a “functional protein” array technology has the ability to display native, discontinuous 
epitopes
676
. Proteins are full-length, expressed with a folding tag in insect cells and screened for correct 
folding before being arrayed in a specific, oriented manner designed to conserve native epitopes. Each 
array contains approximately 1550 human proteins representing ~1500 distinct genes chosen from 
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multiple functional and disease pathways printed in quadruplicate together with control proteins. In 
addition to the proteins on each array, four control proteins for the BCCP-myc tag (BCCP, BCCP-myc, β-
galactosidase-BCCP-myc and β-galactosidase-BCCP) were arrayed, along with additional controls 
including Cy3-labeled biotin-BSA, dilution series of biotinylated-IgG and biotinylated-IgM and buffer-
only spots. Incubation of the arrays with serum samples allowed detection of binding of serum 
immunoglobulins to specific proteins on the arrays, enabling the identification of both autoantibodies and 
their cognate antigens
677
. 
6.4.1 Assay summary 
Assays all performed well with no operational issues identified. One pooled control sample and one 
repeat sample was included in each assay. Of the 57 arrays assayed, only 55 were included in the analysis 
due to sample problems. Proteins TFPT, RPL22, POU2AF1 and TCL1A are missing from these arrays. In 
Assay 1, Arrays 13781 (sample 9673929) and 13765 (sample 227536) had high backgrounds and were 
not included in the analyses. These samples were not repeated as after discussion, experience suggested 
that these problems were sample related and would not be improved by repetition. In Assay 2 and Assay 
3, all arrays were generally good and therefore were all included in the data analysis. 
6.4.2 Data analysis from serum protein and antibody study- normalization of raw data 
Once the probed and dried arrays were scaned using the Agilent microarray scanner, the scans produced 
images for each array that would determine the intensity of fluoresence bound to each protein. These were 
used to normalise and score array data. Raw median signal intensity (also referred to as the relative 
fluorescent unit, RFU) of each protein feature (also referred to as a spot or antigen) on the array was 
subtracted from the local median background intensity. Alternative analysis included the use of other 
measures of spot intensity such as the mean fluorescence and total fluorescence. The results of QC 
analyses showed that the platform performed well within expected parameters with relatively low 
technical variation. Tools such as volcano plots (Figure 6-1), scatter plots (Figure 6-2) and boxplots were 
used to identify candidate biomarkers with combinations of strong p-values and robust fold-changes when 
comparing case and control cohorts. Several proteins previously associated with endometriosis were 
identified examples of which include CDC42, EGFR, KIT, PPARG and WT1, thus validating this 
approach. 
Gene, protein and miRNA expression in women with endometriosis 
247 
FIGURE 6-1 
 
This figure shows a volcano plot displaying the p-value of a microarray t-test on the y-axis versus the fold change 
in antibody levels between case and controls on the x-axis. The most interesting features can be found in the top 
left and top right area of the volcano plot. A dotted line is plotted in the graph to differentiate between potential 
markers and insignificant events. These cut-offs can be varied but a typical minimum selection criteria of a p-
value less than 0.05 and a fold change of greater than log2 of 0.585 (1.5-fold) was used to identify candidate 
biomarkers. Global median normalised data and not raw data is used to derive the fold-change values. Large 
differences in raw RFUs translate to small changes in this value following normalisation. Several of the best-
performing markers (CCNB1IP1, TPM1 and Sept9) in this analysis are indicated. 
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FIGURE 6-2 
 
A boxplot is used to graphically depict the data obtained through their quartiles. They are non-parametric and 
useful in displaying differences between populations without making assumptions of the population distribution. 
The boxplot whiskers indicate the variability between the upper and lower quartiles within the data, with larger 
spacings indicating a wider dispersion or skewing of results. This figure shows box plots for normalised data for: 
(A) RAN, (B) STUB1, (C) TPM1 and (D) HSPD1. 
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6.4.3 Addition of control samples for autoantibody study 
Some significant markers for case vs. control (uncorrected p<0.05) have been identified, with small effect 
size or penetrance. There was however a significant batch effect correction in this data with the addition 
of more serum controls. Some of the significant markers will have been influenced by this effect and 
caution is therefore required in interpreting these results. A table of t-test results sorted by p-value order is 
in the Appendix (Table 9-15). 
TABLE 6-1 
Cohort Reproductive cycle stage Total samples 
Endometriosis case 
Follicular 21 
36 Mid 3 
Luteal 12 
Healthy control 
Follicular  35 
Luteal   
Pooled tissue control   2 
Total samples   73 
Table showing the categorisation of samples used for serum miRNA experiments 
 
6.4.4 Raw data analysis 
The raw data included the original background subtracted data for all replicates for each spot on the 
arrays. The data was sorted alphabetically by protein symbol and by disease cohort. Any outliers (very 
high or very low values for one replicate out of four) were removed manually and annotated. A median 
and mean of the replicates for each protein was created from the sorted raw data. Normalisation for each 
protein (global median normalised data for each protein) was performed. This was achieved by 
performing a T-test for each protein (controls with low BCCP values versus endometriosis samples with 
low BCCP values). P-values for all t-tests were included with a corrected p-value (p-value multiplied by 
the number of proteins on the array (1344) to a maximum of p = 1). 
Data was edited and samples with high BCCP values were moved to the extreme right hand side to allow 
comparison of controls and endometriosis subjects with low BCCP values. Graphs for a number of 
proteins which may be potential biomarkers were included. The fold-change of each protein on each array 
was calculated by dividing the median value for each data point by the mean median value for that protein 
across all of the included arrays. Those data exhibiting a fold change greater than 2 were then selected 
and the number of samples showing a fold change greater than 2 for the control and endometriosis 
samples were then calculated and placed into separate columns. The difference in fold change between 
the case and controls was then performed and the sorting of data by the fold change difference between 
case and controls demonstrated the proteins which exhibited the biggest difference between case and 
controls. These proteins were graphed (Median_BCCPminus worksheet). Quality control steps were 
performed before the data were mined for potential biomarkers. The QC analysis gave no significant 
cause for concern (Table 6-2). The reproducibility of the raw data was within the expected performance. 
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TABLE 6-2 
QC metrics  
Average within array CV% for all content = 4.5 
Within array CV% for Cy3 markers = 5.8 
Within Array CV% for IgHG1 = 2.9 
Between array CV% for Cy3 markers = 16.6 
Between array CV% for IgHG1 = 20.5* 
*This higher value for the IgHG1 CV% is due to some samples being highly reactive against BCCP. If these 
are removed from this calculation the CV% is then reduced to 6.6% which is in line with expectations. Data for 
this table can be found in BMD012_Endometriosis_Excel_analysis_v1.2.xlsx. 
Array performance: QC parameters 
 
6.4.5 Normalisation 
The raw autoantibody array data was normalized by consolidating the replicates (median consolidation), 
followed by normal transformation and then global median normalisation. Outliers were identified and 
removed. There is no method of normalisation universally appropriate and factors such as study design 
and sample properties must be considered. For normalization, raw data was processed in 3 steps: median 
consolidation, transformation to Gaussian (normal) distribution and median normalization. This 
normalised data was used for the identification of individual candidate biomarkers and for the 
development of combinations of biomarkers (“panels”). Boxplots show ‘raw’ relative fluorescence units 
(RFU) using a log scale (Figure 6-3) and the normalised data (Figure 6-4). Boxes are coloured by cohort. 
No arrays were excluded from the analysis due to quality control (QC) failures. 
FIGURE 6-3 
Raw data on a log scale 
 
Figure illustrating raw data on a log scale 
 
Gene, protein and miRNA expression in women with endometriosis 
251 
FIGURE 6-4 
Median normalised data 
 
Figure illustrating median normalised data 
 
6.4.6 Volcano plot of data 
The volcano plot is a convenient way to visualize statistical significance (p-value from a t-test, without 
multiple testing correction applied) and magnitude of difference between case and controls. Each point 
relates to an individual protein. The y axis is the inverse of the p-value on a logarithm base 10 scale i.e. 
higher values correspond to greater significance. The x axis is the logarithm in base 2 of the ratio of the 
mean expression in the case to the mean expression in the control. Vertical lines correspond to a 2-fold 
difference. The horizontal line denotes a significance threshold of 95% confidence. Any proteins found to 
exhibit significant p-values and a 2-fold difference between case and control were assessed (Figure 6-5). 
The volcano plot did not find any significant hits for the endometriosis data set which could be of use as a 
standalone test in a clinical setting. 
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FIGURE 6-5 
 
On the volcano plot, the x-axis shows the log2 fold change between case and control and the y-axis shows 
statistical significance (negative log of the p-value to the base of 10). The horizontal line denotes a significant 
threshold of 95% confidence. The plot did not identify significant protein hits for the endometriosis data which 
could be used in the clinical setting as a diagnostic standalone test. 
 
A linear model was fitted to look for differentially expressed markers between the disease and healthy 
samples. This model also used the batch as a factor to correct for batch effects. Little change was 
observed in the most significant hits, with 8 of the 10 most significant hits prior to the further controls 
being added, remaining in the top 10 (Figure 6-6). 
FIGURE 6-6 
Prior to additional controls Including additional controls 
  
On both the volcano plots, the x-axis shows the log2 fold change between case and control and the y-axis shows 
statistical significance (negative log of the p-value to the base of 10). The horizontal line denotes a significant 
threshold of 95% confidence. These plots demonstrate the data resulting when the batch data was used to correct 
for batch effects. The volcano plot on the right demonstrates that an increase in the amount of control data did not 
alter significant hits. 
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6.4.6.1 Frequency selection of biomarkers 
In frequency selection, the number of samples above a set threshold was compared between the case and 
control samples. Those proteins showing the largest difference between case and controls for the 
frequency of responses above the threshold were used to rank the proteins. Those showing the largest 
positive or negative responses were identified as potential biomarkers. In this analysis the threshold was 
set to 2x the mean median response of the ‘low_BCCP’ controls. On this basis a number of proteins 
showed clear differences in response between case and controls as shown in (Table 6-3). 
TABLE 6-3 
Gene symbol Frequency of fold 
change in controls 
Frequency of fold 
change in 
endometriosis 
Difference 
SH3GL1 1 11 10 
LDHB 0 9 9 
RUNX1T1 0 9 9 
ALDOA 0 8 8 
C19orf50 0 8 8 
ILF2 1 9 8 
IMPA1 0 8 8 
MY CBP 0 8 8 
PCBD1 0 8 8 
PY CR1 1 9 8 
SORD 0 8 8 
TFG 0 8 8 
TOM1 1 0 -1 
TPD52 1 0 -1 
ZKSCAN4 1 0 -1 
ZNF496 1 0 -1 
APEX1 2 0 -2 
MAPK9 2 0 -2 
STAP1 2 0 -2 
ZC4H2 2 0 -2 
Some of the proteins showing the greatest positive and negative changes as ranked using frequency selection 
 
The antibody binding profiles of a number of these proteins have been graphed in the 
Median_BCCPminus worksheet. Since a number of control samples were excluded from the analysis on 
the basis of their high BCCP responses, the selection of these putative biomarkers must be treated with 
caution. However, the limited data suggest that there are differences in antibody binding to a number of 
proteins between case and control samples. Amongst these, the binding to Caspase 10, Apoptosis-Related 
Cysteine Peptidase (CASP10) (Figure 6-7), SH3-Domain GRB2-Like 1 (SH3GL1) (Figure 6-8) and 
aSEPT9 are good examples. These three putative markers could potentially differentiate 13 of the 29 
endometriosis samples from the control samples. 
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FIGURE 6-7 
CASP10 
 
Figure illustrating IgG binding to CASP10 in samples 
 
FIGURE 6-8 
SH3GL1 
 
Figure illustrating IgG binding to SH3GL1 in samples 
 
6.4.7 T-test results for proteins upregulated in endometriosis 
The table below (Table 6-4) demonstrates all the proteins that are upregulated in endometriosis. It lists the 
first 10 antibody signals with the lowest p-value for the t-test. The density plots of the ten upregulated 
protein signals shown demonstrate the non-parametric fit of the endometriosis signals (in red) as 
compared to the control samples (in blue) (Figure 6-9). The normalized median Relative Fluorescence 
Units (RFU) value is shown in the figure legend for each protein. 
TABLE 6-4 
Protein name p-value  Corrected p-
value 
Fold change Log fold change 
TPM1 0.003941 1.00 1.08 0.07 
ADSL 0.013800 1.00 1.03 0.03 
CKB 0.021877 1.00 1.02 0.02 
HRSP12 0.024406 1.00 1.03 0.03 
AIFM2 0.025824 1.00 1.01 0.01 
NRAS 0.026865 1.00 1.01 0.01 
SOD2 0.027801 1.00 1.04 0.04 
ALDOA 0.032673 1.00 1.05 0.05 
UCK2 0.039842 1.00 1.03 0.03 
TRIM37 0.041163 1.00 1.02 0.02 
SEPT9 0.102420 1.00 1.06 0.06 
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6.4.7.1 Density plots for proteins upregulated in endometriosis 
Density plots were used to illustrate the distribution of variation of the proteins identified as being 
upregulated in endometriosis. The red line shows a non-parametric fit of the signals of the endometriosis 
samples versus the control samples in blue. The normalised median Relative Fluorescence Units was 
depicted for each protein. 
FIGURE 6-9 
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The density plots of ten protein signals which are up regulated are shown. The red line shows a non-parametric fit 
of the signals of the endometriosis samples versus the control samples in blue. The normalized median Relative 
Fluorescence Units (RFU) value is shown in the figure legend for each protein 
 
6.4.7.2 Upregulated marker distributions 
As for the strongest downregulated markers, a similar boxplot analysis was performed for the strongest 
upregulated markers ((Tropomyosin 1 (Alpha) (TPM1) and Septin 9 (Sept9)). These markers showed 
some differences between the cohorts, although without very high statistical confidence (Figure 6-10). 
FIGURE 6-10 
  
Boxplots showing distributions of upregulated markers 
 
6.4.8 T-test results for proteins downregulated in endometriosis 
A t-test is a fast and simple method to test for differences between case and control samples. The table 
below (Table 6-5) demonstrates all the proteins that are downregulated in endometriosis. It lists the first 
10 antibody signals with the lowest p-value for the t-test. The density plots of the ten downregulated 
protein signals shown demonstrate the non-parametric fit of the endometriosis signals (in red) as 
compared to the control samples (in blue) (Figure 6-11). The normalized median Relative Fluorescence 
Units (RFU) value is shown in the figure legend for each protein. 
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TABLE 6-5 
Protein name p-value Corrected p-
value 
Fold change Log fold change 
CCNB1IP1 0.002807 1.00 0.98 -0.02 
RORC 0.005463 1.00 0.96 -0.04 
TAOK3 0.006992 1.00 0.98 -0.02 
HSPD1 0.010996 1.00 0.97 -0.03 
PAX8 0.011430 1.00 0.97 -0.03 
NFYA 0.011460 1.00 0.98 -0.02 
TRAF4 0.013886 1.00 0.98 -0.02 
GTF2H2 0.014579 1.00 0.98 -0.02 
USP10 0.016934 1.00 0.97 -0.03 
SRPK1 0.017187 1.00 0.96 -0.04 
 
6.4.8.1 Density plots for proteins downregulated in endometriosis  
Density plots were used to illustrate the distribution of variation of the proteins identified as being 
downregulated in endometriosis. The red line shows a non-parametric fit of the signals of the 
endometriosis samples versus the control samples in blue. The normalised median Relative Fluorescence 
Units was depicted for each protein. 
FIGURE 6-11 
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The density plots of ten protein signals which are downregulated are shown. The red line shows a non-parametric 
fit of the signals of the endometriosis samples versus the control samples in blue. The normalized median 
Relative Fluorescence Units (RFU) value is shown in the figure legend for each protein 
 
6.4.8.2 Downregulated marker distributions 
In order to assess the difference between the two strongest identified downregulated markers (Cyclin B1 
Interacting Protein 1, E3 Ubiquitin Protein Ligase (CCNB1IP1) and Heat Shock 60kDa Protein 1 
(HSPD1)), data for the cohorts of endometriosis and healthy controls was compiled. A batch of 
normalised RFU for each cohort was created and the data was then plotted in a boxplot enabling the 
median of each boxplot to be compared and assessed for fold change. These markers showed some 
differences between the cohorts but not with high fold change. Of note HSPD1 had a sizable batch effect 
(p = 0.06), with higher expression in the additional controls (Figure 6-12). 
Gene, protein and miRNA expression in women with endometriosis 
259 
FIGURE 6-12 
  
Boxplots comparing data between cohorts for the two strongest downregulated markers, CCNB1IP1 and HSPD1 
 
6.5 The creation of a biomarker panel - combining miRNA and protein data 
6.5.1 Multivariate analysis: combination of miRNA and autoantibody biomarkers in serum of subjects 
suffering from endometriosis 
Panels of putative biomarkers were developed consisting of autoantibodies alone, miRNAs alone or 
combinations containing both autoantibodies and miRNA species. Multivariate analysis was also 
performed incorporating data for galectin-3 and CA125 as variables however their inclusion did not 
improve on the performance of the miRNA and autoantibodies identified here. It is not possible to predict 
a priori which classifier will perform best with a given dataset, therefore data analysis was performed 
with 5 different feature ranking methods (entropy, Bhattacharyya, T-test, Wilcoxon, ROC) plus forward 
and backward feature selection. Classifiers were then assessed for performance by referring to the 
combined sensitivity and specificity (S+S score) and area under the curve (AUC). Data were repeatedly 
split and analysis cycles repeated until a stable set of classifiers (“panels”) was identified. Nested cross 
validation was applied to the classification procedures in order to avoid overfitting of the study data. The 
performance of the classification was compared to a randomized set of case-control status samples 
(permutation assay) which should give no predictive performance and provides an indication of the 
background in the analysis. A figure close to 1.0 is expected for the null assay (equivalent to a sensitivity 
+ specificity (S+S) score of 0.5 + 0.5, respectively) whereas an S+S score of 2.0 would indicate 100% 
sensitivity and 100% specificity. The difference between the values for the permutation analysis and the 
classifier performance indicates the relative strength of the classifier. The antigens and miRNAs 
identified from this study are provided in Table 9-19 and Table 9-20.  
Table 9-23 shows the protein biomarkers that provided good performance, as judged by p value, fold-
change, sensitivity, specificity, AUC. The best performing protein biomarkers are shown in Table 9-24. 
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Table 9-25 shows the miRNA biomarkers that provided good performance, as judged by p value, fold-
change, sensitivity, specificity, AUC. The best performing miRNA biomarkers are shown in Table 9-26. 
The ROC curves for some of the best performing miRNA biomarkers (hsa-miR-150, hsa-miR-574-5p and 
hsa-miR-342-3p) are shown in Figure 6-13. 
FIGURE 6-13 
 
Receiver operating characteristic (ROC) curves for individual miRNAs from the microarray data: (A) hsa-miR-
150; sensitivity=0.8, specificity=0.65, AUC=0.8; (B) hsa-miR-574-5p; sensitivity=0.73, specificity=0.71, 
AUC=0.8; (C) hsa-miR-342-3p; sensitivity=0.66, specificity=0.76, AUC=0.78. 
 
The best performing protein and 30 miRNA biomarkers are shown in Table 9-27. These represent 
biomarkers of particular interest as they correspond to the subset of biomarkers with the greatest 
predictive properties. The analysis methods described above were used to build, test and identify 
combinations of biomarkers with greater sensitivity, specificity or AUC than the individual biomarkers 
disclosed in Table 1. For each analysis, multiple combinations of putative biomarkers were derived and 
the performance of the derived panels was then ranked (Table 9-28-Table 9-32). Table 9-28-Table 9-32 
show 2-mer, 3-mer, 4-mer, 5-mer and 6-mer panels that provide good performance. The ROC curves for 
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some of the best performing combinations are shown in Figure 6-18 (A=2-mer panel of hsa-miR-150 and 
hsa-miR-574-5p; B=2-mer panel of hsa-miR-342-3p and hsa-miR-574-5p; C=2-mer panel of hsa-miR-
150 and hsa-miR-342-3p; D=3-mer panel of hsa-miR-150, hsa-miR-122 and hsa-miR-574-5 5p). 
The biomarkers with the greatest diagnostic power, as judged by p value, fold-change, sensitivity, 
specificity, AUC and / or frequency of appearance in the panels derived were identified and combined 
into a single list of antigens and miRNAs. Figure 6-14 show the ROC curve for a 3-mer panel of TPM1, 
hsa-miR-150 and hsa-miR-574-5p, which is one of the best performing 10 combinations. Thus, panels 
containing a mixture of protein and miRNA biomarkers also provide good diagnostic performance. 
FIGURE 6-14 
 
Receiver operating characteristic (ROC) curve for a combination of TPM1, hsamiR-150 and hsa-miR-574-5p; 
sensitivity=0.9, specificity=0.75, AUC=0.92. 
6.5.2 Mixed Auto Antibody (Ab) and miRNA panel performance 
The ROC curve for best 3 marker model from mixed miRNA and Ab data can be seen below (Figure 
6-14). It is good to note that as these markers were selected from two independent experiments and are 
being tested against the same sets of data, the problem of over fitting is compounded. Monte Carlo cross-
validation alone does not necessarily correct for this so estimates of performance are far from 
conservative and not truly comparable to the other model classes. They should therefore be considered as 
absolute best case. 
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6.5.3 Model performance summary- potential panel of markers for endometriosis 
The area under curve (AUC) summary table for the maximum performance (by AUC) from all tested 
model types can be seen below (Table 6-6). 
TABLE 6-6 
Panel 
size 
Microarray miR qPCR Autoantibody Mixed: microarray 
miR + 
autoantibody 
1 0.80 0.70 0.67  
2 0.91 0.76 0.69 0.81 
3 0.90 0.74 0.68 0.92 
4 0.90 0.73 0.69 0.93 
5 0.90 0.71   
6 0.89    
 
The final data generated can be seen in the Excel sheet titled 
endometriosis_allModels_allPlatforms_V01, which includes the data for the combined 
miRNA/autoantibody panels. The panels can be sorted according to whether they have been cross-
validated and the AUC or sensitivity/specificity enabled us to identify the best panels. Most of the 
performance of the combined panels seems to result from a combination of miR-150 and miR-574 and the 
addition of TPM-1 or RAN has a marginal improvement. Data will have to be verified on a large number 
of clinical cases to minimise errors resulting from possible batch effects, performance of individual 
markers, performance of microarray vs qPCR etc. These factors may all influence the selection of the 
combined panel (TPM-1, mir-150, mir-574) as the best 3 marker model in his slide deck. An example of 
the best panel combinations can be seen below (Table 6-7). 
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TABLE 6-7 
Model Check Output File Set 
Size 
Ref Markers Auc Max 
SplusS 
Sensate 
Max 
SplusS 
SpecAt
Max 
SplusS 
Prefix ROC Suffix 
combiAbMir_allModels_CrossVal.txt 3 75 RAN, hsa-miR-150, hsa-miR-574-5p 0.923594 1.657500 0.782500 0.875 combiAbMir ROC CrossVal 
combiAbMir_allModels_CrossVal.txt 3 26 TPM1, hsa-miR-150, hsa-miR-574-5p 0.923594 1.655000 0.905000 0.750 combiAbMir ROC CrossVal 
combiAbMir_allModels_CrossVal.txt 4 73 TPM1, hsa-miR-150, hsa-miR-342-3p, hsa-miR-574-5p 0.928594 1.652500 0.902500 0.750 combiAbMir ROC CrossVal 
combiAbMir_allModels_CrossVal.txt 4 68 TPM1, hsa-miR-150, hsa-miR-122, hsa-miR-574-5p 0.928125 1.649375 0.899375 0.750 combiAbMir ROC CrossVal 
combiAbMir_allModels_CrossVal.txt 4 39 TPM1, RAN, hsa-miR-150, hsa-miR-574-5p 0.923125 1.646875 0.896875 0.750 combiAbMir ROC CrossVal 
combiAbMir_allModels_CrossVal.txt 4 165 RAN, hsa-miR-150, hsa-miR-3648, hsa-miR-574-5p 0.925469 1.646250 0.771250 0.875 combiAbMir ROC CrossVal 
combiAbMir_allModels_CrossVal.txt 4 145 RAN, STUB1, hsa-miR-150, hsa-miR-574-5p 0.913438 1.635625 0.760625 0.875 combiAbMir ROC CrossVal 
combiAbMir_allModels_CrossVal.txt 4 54 TPM1, STUB1, hsa-miR-150, hsa-miR-574-5p 0.919844 1.635000 0.760000 0.875 combiAbMir ROC CrossVal 
combiAbMir_allModels_CrossVal.txt 4 159 RAN, hsa-miR-150, hsa-miR-122, hsa-miR-574-5p 0.914375 1.635000 0.760000 0.875 combiAbMir ROC CrossVal 
combiAbMir_allModels_CrossVal.txt 4 71 TPM1, hsa-miR-150, hsa-miR-1224-5p, hsa-miR-574-5p 0.913438 1.631875 0.881875 0.750 combiAbMir ROC CrossVal 
microArray_allModels_CrossVal.txt 2 5 hsa-miR-150, hsa-miR-574-5p 0.910000 1.630000 0.860000 0.760 microArray ROC CrossVal 
Panel demonstrating the output profiles of the best panel combinations 
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6.5.4 Estimation of classification performance: miRNA panels 
Logistic regression models were used for all combinations of the most interesting markers. 100 fold 
Monte Carlo cross validation was used to reduce over fitting of model coefficients. Since the selection of 
markers was carried out using the same data set, the validation is not truly independent and should be 
considered a ‘best case’ estimate for predictive power (Table 6-8). 
TABLE 6-8 
Marker AUC Max S+S Sensitivity at 
max S+S 
Specificity at 
max S+S 
Type Comment 
hsa-miR-150 0.80 1.44 0.80 0.65 microArray  
hsa-miR-574-5p 0.80 1.43 0.73 0.71 microArray  
hsa-miR-342-3p 0.78 1.42 0.66 0.76 microArray  
hsa-miR-3663-5p 0.70 1.26 0.41 0.85 qPCR Poor correlation 
with microarray 
hsa-miR-150 0.69 1.31 0.47 0.85 qPCR  
TPM1 0.67 1.25 0.69 0.56 autoAb  
STUB1 0.66 1.21 0.65 0.56 autoAb  
hsa-miR-122 0.66 1.25 0.40 0.85 qPCR  
hsa-miR-122 0.65 1.19 0.55 0.65 microArray  
hsa-miR-3648 0.63 1.21 0.85 0.35 microArray  
hsa-miR-3194-5p 0.62 1.14 0.68 0.46 qPCR Poor correlation 
with microarray 
hsa-miR-342-3p 0.62 1.14 0.76 0.38 qPCR  
HSPD1 0.62 1.15 0.81 0.33 autoAb  
RAN 0.54 1.10 0.87 0.22 autoAb  
hsa-miR-1224-5p 0.48 1.06 0.06 1.00 microArray  
Table of cross validated endometriosis/healthy classification performance for individual markers 
 
A dataset obtained from any population results in a distribution of data that can be graphically plotted as a 
bell curve. Ideally, when comparing two sets of miRNA results from groups within the population (e.g. 
endometriosis patients and control patients), there should be two completely separate sets of data from the 
affected or non-affected patients. In reality, as a disease is multifactorial and has numerous variables, 
there will be an inevitable area of overlap of data between the two separate groups. As is depicted in the 
figure below (Figure 6-15, Table 6-9), the overlapping data will result in false positives (Type 1 error) 
and false negatives (Type 2 error). Depending on the threshold one chooses for the data, the true positives 
(sensitivity) and the true negatives (specificity) are altered. 
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FIGURE 6-15 
 
The bell curve indicates the range of results obtained in a population 
 
TABLE 6-9 
  Condition 
  Positive Negative 
Test outcome 
Test outcome 
positive 
True positive False positive 
Test outcome 
negative 
False negative True negative 
  
Sensitivity = 
True positives/ 
(True positives+ false 
negatives) 
Specificity = 
True negatives/ 
(True negatives+ false 
positives) 
 
In the ideal situation, a marker for a disease should be 100% sensitive and specific. In the absence of this 
due to multiple disease variables, one must formulate techniques to choose the optimal markers for 
disease. In order to estimate the performance of chosen markers, data from the miRNA markers was 
plotted in Receiver Operator Characteristic (ROC) curves. An ROC curve enables the illustration within a 
graphical plot of the performance of a marker as its discrimination threshold varies. The ideal marker on 
an ROC curve is seen at the topmost left corner, which indicates 100% sensitivity and 100% specificity. 
Therefore, the optimal miRNA markers are the ones with the ROC curves closest to the topmost left 
corner. 
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FIGURE 6-16 
 
This figure explains the principles of an ROC space 
 
6.5.5 ROC curves for individual markers from microarray data 
For each of the previously identified potential miRNA markers from the microarray panels, an ROC 
curve has been plotted to assess for the suitability of the identified miRNAs as potential diagnostic 
markers for the disease of endometriosis. As no single marker showed enough individual promise to 
identify endometriosis, ROC curves were created not only for individual miRNAs but for pairs of 
triplicates of these miRNAs in an attempt to create a panel of multiple miRNAs that would be specific 
and sensitive enough to use in the clinical setting as a non-invasive marker for disease. 
From the single miRNA data, hsa-miR-150, hsa-miR-574-5p and hsa-miR-342-3p showed promise 
(Figure 6-17). However, as can be seen, none of these individually show enough sensitivity and 
specificity to be valid as a clinical marker. 
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FIGURE 6-17 
  
 
 
ROC curves showing optimal individual miRNAs that potentially could be used for non-invasive identification of 
endometriosis. 
 
6.5.6 ROC curves for two marker panels from microarray data 
ROC curves were then created for combinations of two of the optimum markers (Figure 6-18). As can be 
seen from the curves below, the sensitivity and specificity was marginally improved in each case. The 
combination of miRNA markers showing the greatest promise was hsa-miR-150 and hsa-miR-574-5p, 
with a sensitivity of 86% and specificity of 76%. 
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FIGURE 6-18 
  
 
 
ROC curves showing optimal combinations of two miRNAs that potentially could be used for non-invasive 
identification of endometriosis. 
 
6.5.7 ROC curves for three marker panels from microarray data 
An automated combination of three markers from the original identified miRNAs of interest was 
performed to identify a potential combination with increased specificity and sensitivity to the one 
identified above. The addition of hsa-miR-122 to hsa-miR-150 and hsa-miR-574-5p (Figure 6-19) was 
seen to give a maximum sensitivity of 83% and a specificity of 76%. Although this does not appear to be 
an improvement over the previous combination of hsa-miR-150 and hsa-miR-574-5p, it is recognised that 
the limited sample size and batch data might skew results so hsa-miR-122 was maintained as a marker of 
interest. 
Gene, protein and miRNA expression in women with endometriosis 
269 
FIGURE 6-19 
 
ROC curves showing optimal combinations of three miRNAs that potentially could be used for non-invasive 
identification of endometriosis. 
 
6.5.8 Estimation of classification performance: qPCR 
6.5.9 ROC curves for individual markers from qPCR data 
For markers identified through qPCR showing good correlation with microarray data, ROC curves were 
also plotted. As can be seen below (Figure 6-20), the data obtained from qPCR gives less ideal ROC 
curves. This indicates that miRNA panels are potentially more optimal ways of identifying the markers. 
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FIGURE 6-20 
  
 
 
ROC curves from qPCR results assessing the optimal individual miRNAs that potentially could be used for non-
invasive identification of endometriosis. 
 
An ROC curve was then plotted from qPCR data for the combined marker set but this did not show 
improvement over individual markers. Cross-validation was used to test the miRNA identified from the 
entire dataset. However, when the size of the dataset is small, overfitting might occur in the model, 
potentially skewing results. A technique to assess for the presence of this skew is to look at the data 
without cross-validation. Without cross-validation being used, a similar result was observed: the panel of 
hsa-miR-150, hsa-miR-122 and hsa-miR-342-3p having an area under curve (AUC) of 0.7 and hsa-miR-
150 alone having AUC of 0.69 (Figure 6-21). In the qPCR validation, the hsa-miR-451 control miRNA 
and the hsa-miR-342-3p show good correlation with qPCR, supporting their use. Individually, miRNA 
markers show significant difference between endometriosis and healthy bloods. Combining these markers 
into panels indicates the potential for reasonable classification performance on an independent platform 
(e.g. sensitivity ~35% at specificity ~85% for panel of hsa-miR-150 and hsa-miR-122 from qPCR data), 
although this requires validation in an independent sample set. 
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FIGURE 6-21 
 
ROC curves from qPCR results assessing the optimal combined miRNAs that potentially could be used for non-
invasive identification of endometriosis. 
 
6.6 Summary of identified biomarker panels 
The aim of creating a biomarker panel is based on the identification of correlations between 
endometriosis and the increased or decreased levels of certain proteins and small non-coding miRNAs. 
This thesis identified a set of miRNAs for which the expression profiles can be used to indicate whether 
or not a subject has endometriosis. These miRNAs are present at significantly different levels in 10 of the 
patients with endometriosis and without endometriosis. Detection of the presence or absence of these 
miRNAs, and/or of changes in their levels over time can potentially be used to indicate that a subject has 
endometriosis, or has the potential to develop endometriosis in the future. These miRNAs are therefore 
functioning as biomarkers of endometriosis. 
Antigens have also been identified for which the level of auto-antibodies can be used to indicate that a 
subject has endometriosis. Auto-antibodies against these antigens are present at significantly different 
levels in subjects with endometriosis and without endometriosis. Detection of the presence or absence of 
these auto-antibodies, and/or of changes in their levels over time, can also be used to indicate that a 
subject has endometriosis. The auto-antibodies and their antigens also function as potential biomarkers of 
endometriosis. The detection of these biomarkers in a subject sample can be used to improve the 
diagnosis, prognosis and monitoring of endometriosis or the differentiation between the presence of 
endometriosis and other forms of intra-abdominal inflammation. 343 biomarkers have been identified 
(Table 9-18) and in the creation of a biomarker panel at least one of these assisted in the diagnosis of 
endometriosis by measuring the level(s) of the biomarker(s). 
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Biomarkers, as discussed can be either a protein or a miRNA. A protein biomarker can be either an auto-
antibody which binds to an antigen in Table 9-18 and/or (ii) an antigen in Table 9-18. The analysis of 
patient samples included the determination of the level of Table 9-18 biomarker in the sample, and their 
levels. The levels provide a diagnostic indicator of whether or not the subject has endometriosis. Analysis 
of a single Table 9-18 biomarker can be performed, and detection of the autoantibody/antigen or miRNA 
can provide a useful diagnostic indicator for endometriosis even without considering any of the other 
Table 9-18 biomarkers but the sensitivity and specificity of diagnosis can be improved, by combining 
data for multiple biomarkers. It was therefore preferred to analyse more than one Table 9-18 biomarker. 
Analysis of two or more different biomarkers (a “panel”) enhanced the sensitivity and/or specificity of 
diagnosis compared to the analysis of a single biomarker. Each different biomarker is demonstrated in a 
panel in a different row in Table 9-18, e.g. measuring both auto-antibody binding to an antigen listed in 
Table 9-18 and the antigen itself measured as a single biomarker rather than of a panel. 
It was found that the combination of the information from protein and miRNA biomarkers as an 
algorithm provided an enhancement in diagnostic utility, as measured by sensitivity, specificity and/or 
area under the Receiver Operating Characteristic (ROC) curve. It was decided that the new biomarker 
panel preferably used at least one protein biomarker from Table 9-18 and at least one miRNA biomarker 
from Table 9-18 to assist in the diagnosis of endometriosis. 
The panel was created after multiple combinations for proteomic and miRNA biomarker were tested. The 
panel aims to provide a method for analysing a subject sample, comprising a step of determining the 
levels of x different biomarkers of Table 9-18 (The value of x is 2 or more e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 
12, 13, 14, 15 or more (e.g. up to 343)). The panels may include (i) any specific one of the 343 
biomarkers in Table 9-18 in combination with (ii) any of the other 342 biomarkers in Table 9-18 with a 
preference the panel includes at least one protein biomarker (e.g. auto-antibodies or an antigen) from 
Table 9-18 and at least one miRNA biomarker from Table 9-18. Suitable panels are described below and 
panels of particular interest include those listed in Table 9-28 to Table 9-32. Preferred panels have from 2 
to 6 biomarkers, as using >6 of them added little to sensitivity and specificity. 
To increase the sensitivity and/or specificity of diagnosis, the Table 9-18 biomarkers could also 
potentially be used in combination with one or more of: (a) known biomarkers for endometriosis, which 
may be auto-antibodies, antigens or miRNAs; and/or (b) other information about the subject from whom a 
sample was taken e.g. age, genotype (genetic variations can affect auto-antibody profiles
678
 and 
considerable progress on the elucidation of the genetics of endometriosis has been made), weight, other 
clinically-relevant data or phenotypic information; and/or (c) other diagnostic tests or clinical indicators 
for endometriosis. Known endometriosis biomarkers of particular interest include, but are not limited to, 
autoantibodies against CA125, CA19-9 and/or any of the antigens listed in Table 9-22. 
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6.7 Discussion 
6.7.1 Overview of results 
The results of the quality control (QC) assays and the low CVs provided a high degree of confidence in 
these results for further reliable analysis. There were clear indications of antibody reactivity in many of 
the samples. The identification of such autoantibodies and their cognate antigens may potentially form the 
basis of an exploration of the biology (Figure 6-22). 
FIGURE 6-22 
Cy3-anti-human IgG binding in several sera to a selection of different proteins 
 
Antibody binding profiles for four different sera to a selection of proteins on the arrays 
 
6.7.1.1 An initial overview of the Cellular cytoskeleton and structure 
The cellular cytoskeleton is composed of microtubules composed of both α- and β- tubulins. These 
tubulins are organised within the centrosome organising areas which control and recruit α- and β- tubulins 
enabling microtubule formation at the centrioles. These microtubules have a role in cellular division, 
transport and the maintenance of the cellular architecture
679. To enable the linkage of α- and β- tubulins, 
five tubulin cofactors (TBC A-E) are involved
353,680
. They support correct protein folding and recruitment 
pathways enabling appropriate in vivo tubulin dynamics and cellular function
354
. They are multidynamic 
molecules with a wide range of functions encompassing roles in tubulin association, storage and even 
degeneration. It is believed that their control of the amount of tubulin available for polymerisation enables 
the regulation of the multitude of functions mentioned above. Tubulin cofactors are known to regulate the 
cell cycle through its various stages. Aberrations in the system have been associated with development of 
tumorigenesis and ciliary syndromes
679
. 
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FIGURE 6-23 
 
Figure illustrating the basis phases of the cell cycle 
Tubulin folding cofactor C or TBCC Tubulin-folding protein is involved in the final stages of the tubulin. 
It is an important major protein ensuring the correct development of α and β-tubulins into microtubules681. 
Cofactor C is one of the four cofactor proteins A, D and E responsible for the correct folding of beta 
tubulin. Cofactors A and D are responsible for stabilising β-tubulin intermediates whilst E binds to the 
formed D/ β-tubulin complex. This complex interacts with cofactor C releasing further β-tubulin 
polypeptides. 
TBCD is mainly found at the centrosome and midbody imperative in its role for centriologenesis, spindle 
organisation and cellular splitting
679
. It varies in amounts through different cell cycle phases and in the G1 
phase is localised on the daughter centriole. In the S phase it localises in the procentriole and in the 
telophase it is seen to disappear as the protein is recruited into the mid-body
679
. Its overexpression causes 
G1 arrest of the cell cyle whereas its reduction causes incomplete microtubule retraction and mitotic 
aberrations during the cell cyle. It is seen to take part in both canonical and non-canonical centriolar 
pathways. Mutations in TBCD have been studied in various yeast
682
 and plant species and are seen to 
cause aberrations in chromosomal numbers
683
 and blockage of the cells in the G1/S phase of the cycle in 
turn causing problems with cytokinesis. Studies manipulating TBCD levels have been shown to produce 
centrosomal anomalies which cause defects in cellular spindle formation, anaphase, G1 blockage and 
cellular abscission failure
679
. Interestingly, defects in abscission are associated with malignant cellular 
transformation. Defects in cytokinesis are culprits in the development of cancer altering cellular 
properties and therefore functions
684
. 
TBCE (Tubulin Folding Cofactor E) is one of the four proteins enabling the correct folding of beta-
tubulin. It binds to the cofactor D beta-tubulin complex and interacts with the C cofactor releasing beta-
tubulin proteins. It maintains the cellular neuronal microtubule network and controls the dissociation of 
cellular tubulin heterodimers
578
. 
6.7.2 Summary of autoantibody analysis 
The SH3GL1 gene encodes the Endophilin-A2 protein which is a cystolic protein implicated in cellular 
synaptic endocytosis. Mutations in the Endophilin A2 protein have been seen to prevent in vivo models of 
endocytosis
685
. Focal adhesion kinase (FAK) is associated with endophilin A2 interactions causing its 
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tyrosine phosphorylation with the formation of a focal adhesion steroid receptor coactive complex 
(FAK/Src complex)
686
. The complex inhibits the interactions between endophilin and dynamin causing 
attenuation of the endocytosis of the membrane type 1 metalloprotease complex (MT1-MMP)
686
. This in 
turn causes increase in levels of cellular degradation. Elevated levels of this complex have been 
associated with increased angiogenesis and tumour growth, identifying it as yet another possible 
therapeutic target in disease
687
 
The aSEPT9 gene codes for Septin 9. This has been linked to tumour migration and invasion as well as 
apoptosis and pseudopod formation
688
. In eukaryotic cells, septins are a family of GTPases with roles in 
cytokinesis and neoplasia
689
. SEPT9 is expressed in a large number of human tumours including breast
690
, 
epithelial ovarian
691
 and endometrial
689
 tumours. Abnormalities of expression are linked to tumour 
development and a number of genes including SEPT9 are involved in the chromosomal translocations in 
acute myeloid leukaemia
692
. Metastatic lesions are seen to have higher SEPT9 levels
689
 and its presence 
on cell borders and secretory epithelia indicate a role in membrane vesicle formation
689
. This is itself is 
associated with roles in neoplastic development
693
. In theory, as discussed previously (See section 
6.7.3.2), aSEPT9 can have similar effects on endometriotic tissues. Ectopic endometrial cells are seen to 
migrate and invade similar to tumours. As endometriosis is not a malignancy, one could potentially 
theorise that aSEPT9 levels are kept in check though multifactorial effects of tumour suppressor pathways 
affected by miRNAs which have been discussed in earlier sections of this thesis (See section 5.5.1). 
Breast Cancer Anti-Oestrogen Resistance 1 (BCAR1), is associated with an increase in epithelial cellular 
hyperplasia in mammary tumorigenesis
694
. It is involved in the integrins signalling cellular system and 
plays a role in cellular motility, migration, proliferation and phagocytosis (Figure 6-28). 
Tumour necrosis factor receptor superfamily, member 1A (TNFRSF1A) is a key regulator of the immune 
system and is a key component activating the NF-κB pathway which controls cellular apoptosis. An 
increase adherence of endometriotic cells has been postulated as a contributing factor to the development 
of endometriosis. TNF-α is also known to increase adherence of stromal uterine cells to in vitro 
mesothelium
695
 by its activation of fibroblastic proliferation, collagen deposition
162
 and an increase in 
their prostaglandin production
696
 The TNF family is interestingly dysregulated in viral infections and is 
an essential component in the development of infectious disease
697
. The regulation of the TNFRSF1A 
gene enables protection against virally induced pathology. Diseases can be stimulated or repressed by co- 
stimulating or regulating TNF factors making the regulators of the TNFR therapeutic targets for 
controlling disease. Tumour necrosis factor receptor superfamily, member 10a (TNFRSF10A) is another 
apoptosis mediator and promotes the NF-κB pathway. Studies looking at peritoneal endometriosis, have 
found evidence for the activation of NF-κB with higher levels demonstrated in active red lesions 
compared to necrotic black ones
698
, making it a potential interesting therapeutic target for disease. In early 
stages, NF-κB inhibits tumour growth699 and in endometriosis it might act as a tumour suppressor 
preventing overt malignant changes. As a disease progresses, mutations in NF-κB shift its role to an 
oncogenic one, enabling contribution to malignancy
699
. NF-κB is also seen to decrease stabilisation of 
other tumour suppressors such as p53 increasing the potential for malignant change
700
. In theory this 
could explain why some cases of severe endometriosis are abutting ovarian and/or endometrial 
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malignancy
701
. A non-malignant disease such as endometriosis could potentially transform into malignant 
disease if tumour suppressing mechanisms are lost or pathways altered. 
Oestrogen receptor 1 (ESR1) is a transcription factor activated by oestrogen
702
 (Figure 6-29); 
endometriosis is a disease responsive to oestrogen and its signalling. There are elevated levels of ER-α 
receptors in active red endometriotic lesions compared to black necrotic ones
703
. Increase in ER-α levels 
also activate other pathways such as insulin-like growth factor-1 (IGF-1) which send powerful mitogenic 
stimuli causing cellular proliferation and growth. In severe endometriosis, plasma levels of IGF-1 are 
elevated. This elevation is however not maintained in the endometrium itself
704
. These findings are almost 
certainly related to the hormonally responsive tissue that endometriosis derives from. 
Baculoviral inhibitor of apoptosis proteins (IAP) repeat-containing 2 (BIRC2) plays a major role in 
cellular control of apoptosis by creating positive or negative feedback signalling on the NF-κB pathway. 
IAP exerts its function through protein-protein interaction of the proteins involved in apoptosis or cell 
signalling
705
. Through their ring domain, cIAPs also cause ubiquitination of the tumour necrosis factor 
receptor complex (TNFR) thereby affecting the Nuclear factor Kappa Beta (NF-κB) complex and its 
pathways
706
 promoting cellular survival, proliferation and inhibition of apoptosis
707
. In an opposite effect, 
cIAPs can also repress the NF-κB pathway limiting both the canonical and non-canonical signalling of 
the NF-κB pathway708. Biologically, this anti apoptotic mechanism serves to enable cellular survival in 
stressful conditions such as when cells are detached from their matrix
709
 or ER stressors
710
. These 
mechanisms can explain the increased cell survival capacity of intraperitoneal endometrial cells in 
endometriosis which can invade and develop disease. 
Tropomyosin alpha-1 chain (TPM1) has been identified as a tumour suppressor gene which has the ability 
to regulate cellular migration and invasion. It is regulated by miR-21 and has recently been identified as a 
potential serum marker in cancer
711
. At the time of writing this thesis, there is no publication linking 
TPM1 to endometriosis. In theory, and from this study, it could however act as a potential serum 
biomarker for this disease. TPM1 is potentially another important tumour suppressor preventing overt 
malignant change in a disease like endometriosis. 
Heat shock protein 60 (HSP60), also known as mitochondrial HSPD1, has immunogenic and 
inflammatory roles with immune and malignant conditions showing T-cell antibody responses to it. 
Activated T cells result in proliferation and cytokine expression
712
 causing the release of macrophage pro-
inflammatory adhesion molecules (Figure 6-31)
713
. HSPs function towards allowing tumour survival 
either through the inhibition of apoptosis or through the regulation of autoimmunity. Various studies 
show HSP60 activates the EGFR, Map kinases and TNF-α. The HSPE1 gene has been identified as a 
potential endometriosis gene marker. 
GTP-binding nuclear protein Ran (RAN) is a member of the RAS oncogene family and has a role in 
cellular transport enabling vesicle fusion at the nuclear envelopes of daughter cell nuclei
714
. In viral 
infections it has a role in regulating phagocytosis and immunity to the invading virus and is upregulated 
in virally infected cells
715
. It is upregulated in EBV associated nasopharyngeal carcinoma and has been 
identified as a candidate for Myc-mediated cancer progression and metastatic potential. Potentially the 
same mechanisms can be attributed to disease progression in endometriosis. 
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E3 ubiquitin-protein ligase CHIP (STUB1) is essential for T cell activation and T-cell receptor induced 
NF-κB signalling716. It has a tumour suppressor role and is downregulated in proliferative tumours717. It 
affects the function of p53 causing aberrant stabilisation of mutant p53 in human cancers
718
 when 
inactivated by Hsp90. Potentially this is another mechanism by which malignant change is prevented in 
endometriosis. 
A number of potential protein markers have been identified above, some of which may be bi products of 
hormonally responsive disease whereas others appear to potentially play a role in the process of 
endometriosis development and sustainability. The Figure 5-10 and Figure 5-11 provide an overview of 
interactions between identified miRNAs, associated genes, proteins, antibodies and the pathways they 
affect. 
6.7.3 Detailed analysis of the associations and interactions of identified significant protein in patients 
with endometriosis. 
Below is a summary from the predictive program STRING™ showing the evidence based interactions of 
all the above-mentioned biomarkers (Figure 6-24). 
FIGURE 6-24 
 
Evidence view of predicted interactions of biomarkers576 
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6.7.3.1 SH3GL1 
FIGURE 6-25 
 
 
Evidence view of predicted interactions of SH3GL1576 
 
Membrane trafficking of cellular compounds occurs by varied processes, one of which is vesicular 
transport. Vesicular transport involves the detachment of a vesicle from a donor membrane, its transport 
and identification from the receptor membrane and ultimately its fusion with the receptor membrane 
whereby it releases its contents. Studies looking at endocytosis at the synaptic interphases between 
neuronal cells have given an insight to this process
719
. The SH3GL1 gene encodes the Endophilin-A2 
protein which is a cystolic protein implicated in cellular synaptic endocytosis. Endophilins are divided 
into two families, A and B respectively. Endophilin A1 is mainly restricted to neuronal function. 
Endophilin A2 is ubiquitous in its expression, while Endophilin A3 is mainly within neurons and testes. 
They have an N-terminal domain called the BAR domain and the C terminal domain called the SH3 
domain. Endophilins are regulated by Ca
2+
 iκlux into the neurons720 and demonstrate binding to the 
voltage gated calcium channels at the centre of the endophilin SRC Homology 3 Domain (SH3). Calcium 
binding to the domain disrupts the interaction of the SH3 domain to the nearby prolene rich area adjacent 
to the calcium binding region. This allows its interaction with the voltage-gated calcium channels thereby 
permitting endocytosis through the association with dynamin and synaptojanin-1
686
. Mutations in the 
Endophilin A2 protein have been seen to prevent in vivo models of endocytosis
685
. Focal adhesion kinase 
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(FAK) is associated with endophilin A2 interactions causing its tyrosine phosphorylation with the 
formation of a focal adhesion steroid receptor coactive complex (FAK/Src complex)
686
. The complex 
inhibits the interactions between endophilin and dynamin causing attenuation of the endocytosis of the 
membrane type 1 metalloprotease complex (MT1-MMP)
686
. This in turn causes increase in levels of 
cellular degradation. Elevated levels of this complex have been associated with increased angiogenesis 
and tumour growth, identifying it as yet another possible therapeutic target in disease
687
. The 
overexpression of FAK is seen in a variety of cancers
721
 and is associated with increased potential to 
invade and metastasise
722,723
 (Figure 6-26). In my study SH3GL1 is identified as a potentially significant 
protein in endometriosis and as seen above, it codes for Endophilin A2 responsible for endocytic cellular 
processes and interactions with FAK and the FAK/Src complex. This in turn attenuates the endocytosis of 
(MT1-MMP)
686
 leading to increased levels of this complex resulting in angiogenesis and growth
687
. 
Potentially a similar mechanism occurs in endometriosis aiding the growth and metastasis of ectopically 
implanted cells. 
FIGURE 6-26 
 
Demonstrating interactions in Cellular endocytosis 
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6.7.3.2 aSEPT9 
FIGURE 6-27 
 
 
Evidence view of predicted SEPT9 protein interactions576 
 
The aSEPT9 gene codes for Septin 9. This has been linked to tumour migration and invasion as well as 
apoptosis and pseudopod formation
688
. The 12 human septins known to exist are homologous in their core 
GTP-binding region
724
 but vary in the N and C terminals
725
. In eukaryotic cells, septins are a family of 
GTPases with roles in cytokinesis and neoplasia
689
. They aid in the formation of filamentous complexes 
with the hydrolysis and binding of cytoplasmic proteins
725
. SEPT9 is expressed in a large number of 
human tumours including breast
690
, epithelial ovarian
691
 and endometrial
689
 tumours. Abnormalities of 
expression are linked to tumour development and a number of genes including SEPT9 are involved in the 
chromosomal translocations in acute myeloid leukaemia
692
. Metastatic lesions are seen to have higher 
SEPT9 levels
689
 and its presence on cell borders and secretory epithelia indicate a role in membrane 
vesicle formation
689
. This is itself is associated with roles in neoplastic development
693
. In theory, 
aSEPT9 can have similar effects on endometriotic tissues. Ectopic endometrial cells are seen to migrate 
and invade similar to tumours. As endometriosis is not a malignancy, one could potentially theorise that 
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aSEPT9 levels are kept in check though multifactorial effects of tumour suppressor pathways affected by 
miRNAs which have been discussed in earlier sections of this thesis (See section 5.5.1). 
6.7.3.3 BCAR1 
Breast Cancer Anti-Oestrogen Resistance 1 (BCAR1), also known as scaffolding protein p130C, is a 
scaffolding multiadaptor molecule, empirical in the role of intracellular signalling
689
. Its presence is 
associated with an increase in epithelial cellular hyperplasia in mammary tumorigenesis
694
. Its function 
derives from the ability to form molecular complexes with effector proteins. P130C is involved in the 
integrins signalling cellular system and plays a role in cellular motility, migration, proliferation and 
phagocytosis (Figure 6-28). In theory, BCAR1 could have similar effects in endometriosis, potentially 
causing ectopic endometrial cellular hyperplasia, proliferation and migration. The cytoplasmic FAK 
(Figure 6-28) activates integrin mediated cell adhesion and has been shown in experimental mice models 
to have vital angiogenic and oncologic roles. Its presence in severe ovarian endometriosis correlating with 
clinical severity and metastatic potential has been explored
726
. Interestingly, in women who suffer from 
endometriosis, FAK levels were seen to be higher in their eutopic endometrium in the secretory phase of 
the cycle
727
 making it a potential contributory factor to development of disease. Increased FAK 
expression is seen in a number of cancers and promising therapeutics are targeted towards its inhibition. 
FIGURE 6-28 
 
(A) P130C contains, an N-terminal SH3 domain, a serine-rich motif that binds Src kinases, and a conserved C-
terminal region that binds members of the Chat family of proteins728. (B). Activation of the compressed central 
substrate region of p130C occurs with its (C). Activation induces Src, tyrosine phosphorylation and recruitment 
of Crk through its SH2 domain728 
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6.7.3.4 TNFRSF1A 
Tumour necrosis factor receptor superfamily, member 1A (TNFRSF1A) is a protein encoded for by the 
TNFRSF1A gene. It is a key regulator of the immune system and is a receptor for TNFSF2/TNF-alpha 
and homotrimeric TNFSF1/lymphotoxin-alpha. TNF binds to the ligands of TNFRSF1A and is a key 
component activating the NF-κB pathway which controls cellular apoptosis. TNF-α is mainly produced 
by non-haematopoietic cells including activated lymphocytes, macrophages, NK cells and neutrophils 
whereas TNF-β is produced by lymphocytes. 
TNF proteins activate the cytokine cascades, inflammatory responses and cellular apoptosis. It is also 
implicated in endometrial shedding with epithelial uterine cells showing high expression of its mRNA 
and associated proteins in its secretory phase
729
. TNF-α serum levels in patients suffering from 
endometriosis tend to be higher than those of control patients even in the early stages of disease
359
. The 
levels of TNF in the peritoneal fluid of patients with endometriosis are elevated and correlate to the stage 
of disease
730
. In the stomal uterine cells, the proliferative phase of the menstrual cycle is associated with 
elevations in the levels of TNF-α indicating an altered cytokine response731. Elevated TNF-α levels also 
serve in proliferating the endometriotic stromal cells through activation of the IL-8 gene. 
An increase adherence of endometriotic cells has been postulated as a contributing factor to the 
development of endometriosis. TNF-α is also known to increase adherence of stromal uterine cells to in 
vitro mesothelium
695
 by its activation of fibroblastic proliferation, collagen deposition
162
 and an increase 
in their prostaglandin production
696
 indicating yet another facet to its contribution in endometriotic 
disease development. Cellular IL-1, endometrial placental proteins and progesterone levels are all known 
to interact and alter TNF-α expression levels within the cell. 
The TNF family is interestingly dysregulated in viral infections and is an essential component in the 
development of infectious disease
697
. In this study I have already identified EBV virus as being elevated 
in the leukocytes of women with endometriosis (See section 4.4.3.5 and 4.5.2.1), it is possible that even 
minor dysregulation of TNFRSF1A can aid in potentiating the EBV effects in development of 
endometriosis. The regulation of the TNFRSF1A gene enables protection against virally induced 
pathology. Several members of the TNF/TNF Receptor family are noted to sustain T-cell function in the 
cell after primary T-cell activation
732
. It therefore follows that any system dysregulation could be 
mirrored in alterations of T-cell survival and function
733
. Diseases can be stimulated or repressed by co- 
stimulating or regulating TNF factors making the regulators of the TNFR therapeutic targets for 
controlling disease. 
Experimental intestinal endometriosis in rats has been associated with downregulation of TNFRSF1A and 
TNFRSF1B gene expression. This is believed to be a protecting mechanism against TNF cytotoxicity. 
Conversely, over expression of genes encoding for TNF receptor associated factors was increased with 
overexpressions of ICAM1, Sele, Vegfa, Flt and Kdr
734
. Increased protein levels of TNF and the soluble 
TNFRSF1B were confirmed in the studied rat peritoneal fluid. The mRNA for TNF was also elevated in 
diseased rat intestinal segments and their peritoneal leukocytes. This provides evidence of the direct 
impact of the TNF system in the pathogenesis of endometriosis
734
. Studies using anti TNF monoclonal 
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antibodies
735
 and recombinant human TNFRSF1A (r-hTBP1)
736
 show a decrease in disease development 
in the animal models used. 
6.7.3.5 TNFRSF10A 
Tumour necrosis factor receptor superfamily, member 10a (TNFRSF10A) is another apoptosis mediator. 
It promotes the NF-κB pathway by acting as a receptor for the cytotoxic cytokine ligand tumour necrosis 
factor (ligand) superfamily, member 10 TNFSF10/TRAI. Fas (TNFRSF6)-Associated Via Death Domain 
(FADD) recruits caspase-8 to the activated TNFRSF10A receptor and the caspase-8 undergoes activation 
by the death-inducing signalling complex (DISC). A cascade of various caspases is activated and this 
mediates the apoptotic mechanism. In peritoneal endometriosis, there is evidence for the activation of NF-
κB698 with higher levels demonstrated in active red lesions compared to necrotic black ones, making it a 
potential interesting therapeutic target for disease. In early stages, NF-κB inhibits tumour growth699 and in 
endometriosis it might act as a tumour suppressor preventing overt malignant changes. As disease 
progresses, mutations in NF-κB shift its role to an oncogenic one, enabling contribution to malignancy699. 
In theory this could explain why some cases of severe endometriosis are abutting ovarian and/or 
endometrial malignancy
701
. A non-malignant disease such as endometriosis could potentially transform 
into malignant disease if tumour suppressing mechanisms are lost. 
6.7.3.6 Oestrogen receptor 1 (ESR1) 
FIGURE 6-29 
 
Oestrogen cellular pathways and its interactions737 
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Oestrogen receptor 1 (ESR1) is a gene encoding oestrogen receptor-α (ER-α) also known as nuclear 
receptor subfamily 3, group A, member 1 (NR3A1). It is a transcription factor activated by oestrogen
702
 
(Figure 6-29); endometriosis is a disease responsive to oestrogen and its signalling. There are elevated 
levels of ER-α receptors in active red endometriotic lesions compared to black necrotic ones703. The 
oestrogen (and progesterone) receptors themselves are reported to express polymorphisms increasing the 
predisposition to disease development
738,739
. Endometriosis also shows an elevated cytochrome P450 and 
decreased 17β-hydroxysteroid dehydrogenase type 2 expression740 preventing the change from the more 
potent oestradiol to oestrone. This results in increased local oestrogen production further enabling 
endometriosis proliferation. 
Genetic polymorphisms are also seen in endometriosis in enzymes from the Cytochrome P450 family 
such as CYP1A1
741
, CYp19
742
 and Glutathione S-transferase Mu 1 (GSTM1)
743
. Increase in CYP1A1 
levels causes elevations in P459 and oestrogen production
744
. Increase in ER-α levels also activate other 
pathways such as insulin-like growth factor-1 (IGF-1) sending powerful mitogenic stimuli causing 
cellular proliferation and growth. The IGF-1 has been associated with malignant development and 
metastatic potential. There is an increase in its levels in other female cancers such as cervical, ovarian and 
endometrial
745
 and these levels remain constant even post-menopausally. In severe endometriosis, plasma 
levels of IGF-1 are elevated. This elevation is however not maintained in the endometrium itself
704
. 
6.7.3.7 BIRC2 
Baculoviral inhibitor of apoptosis proteins (IAP) repeat-containing 2 (BIRC2) is also known as cIAP1. It 
is one of 8 family IAP members and plays a major role in cellular control of apoptosis by creating 
positive or negative feedback signalling on the NF-κB pathway. The cIAP1 exerts its function through 
protein-protein interaction of the proteins involved in apoptosis or cell signalling
705
. Apoptosis is 
inhibited when the cIAPs bind to and sequester Smac from X-Linked Inhibitor Of Apoptosis (XIAP). The 
latter, in turn, suppresses apoptosis
746
. Through their ring domain, cIAPs also cause ubiquitination of the 
tumour necrosis factor receptor complex (TNFR) thereby affecting the Nuclear factor Kappa Beta (NF-
κB) complex and its pathways706. Once the NF-κB is activated or altered, effects on cyto and chemokines 
occur, which in turn promote cellular survival, proliferation and inhibit apoptosis
707
. Both the NF-κB 
canonical and non-canonical pathways are affected through the action of cIAPs. 
Cellular complexes formed from TNFRSF1A-Associated Via Death Domain (TRADD), receptor-
interacting protein 1 (RIP1) and tumour necrosis factor receptor-associated factor 2 (TRAF2) domains are 
induced when TNF-α binds to tumour necrosis factor receptor (TNFR). cIAPs are recruited to this 
complex by TRAF2 and this in turn induces the NF-κB pathway through the TNFR. The ring domain of 
cIAPs activates the K63 polyubiquitination of the RIP1 which itself activates the transforming growth 
factor-β-activated kinase 1 complex. IKK is phosphorylated activating the NF-κB pathway. K63 
polyubiquitination of RIP1 suppresses caspase-8 preventing apoptosis
747
. Once the TNF-α is stimulated 
and activates the NF-κB pathway, stimulation of genes suppressing the apoptoic signal occurs and the cell 
survival increases
748
. Interestingly, the NF-κB signalling induced by the anti-apoptotic signalling itself 
induces further cIAPs. NF-κB is a negative regulator of p53700 and a reduction of cellular cIAP2 may 
result in decreased p53 function
749
. 
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In an opposite effect, cIAPs can also repress the NF-κB pathway. When the complex of cIAP, TRAF2 
and TRAF3 interact and ubiquitinate NIK, it exerts a repressive effect limiting both the canonical and 
non-canonical signalling of the NF-κB pathway708. Biologically, this anti apoptotic mechanism serves to 
enable cellular survival in stressful conditions such as when cells are detached from their matrix
709
 or ER 
stressors
710
. These mechanisms can explain the increased cell survival capacity of intraperitoneal 
endometrial cells which can invade and develop disease. The RAS and E6 oncogenes
750
, induce the cIAP 
expression and the cancers showing high levels usually demonstrate a poorer patient outcome. cIAP 
themselves have been described as oncogenes with genetic studies showing amplification of the 
chromosomal locus 11q21-23 region manifested in a range of cancers including renal cell and gastric 
carcinomas as well as non-small cell lung cancers
751
. IAP antagonists are under development as 
therapeutic options for a large number of malignancies. B-lymphocytes utilise NF-κB signalling to 
promote cellular survival and function in the presence of antigenic stimuli.  
Baculoviral IAP repeat-containing 2 (BIRC2) is an apoptotic suppressor (also known as cIAP1). It 
interacts with TRAF1 and TRAF2 forming a complex which is recruited to the tumour necrosis factor 
receptor 2 (TNFR2) and interferes with caspase activation. BIRC2 has opposing roles in the regulation of 
the NF-κB pathways. By recruitment of a TNF receptor they activate the NF-κB through RIP1 
ubiquitination. Conversely the BIRC2 represses NF-κB by the ubiquitination of NIK resulting in 
degradation
752
. Once the NF-κB is activated, it promotes cellular growth and survival including the 
production of IL-6, B-cell activating factors, cell inhibition of apoptosis, I kappa B kinase  (IKK), tumour 
necrosis factors, TNFR, TRAF TRADD, TNFR- associated death domains and multiple pathways 
associated with increased cellular survival in malignant patterns
752
 (Figure 6-30). 
FIGURE 6-30 
 
The role of cIAP1 in activation and repression of cellular pathways752 
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6.7.3.8 TPM1 
Tropomyosin alpha-1 chain (TPM1) is an alpha tropomyosin actin-binding motor protein which has roles 
in cellular motor activity and is a structural constituent of the actin cytoskeleton. It is involved in cell 
motion and cell component morphogenesis as well as muscle contraction and muscle organ development. 
Embryologically it plays a role in development of ectoderm and mesoderm. TPM1 has been identified as 
a tumour suppressor gene which has the ability to regulate cellular migration and invasion. MicroRNA-21 
(miR-21), also noted as part of my expression profile studies, is a miRNA which functions as an 
oncogene altering the regulation of TPM1
753
 and targets multiple tumour suppressor genes. Epigenetic 
suppression of TPM1 alters TGF beta tumour suppressor function causing further enhancement of the 
invasive potential of tumour cells
754
. A recent publication has identified TPM1 as a potential biomarker in 
the serum of women with ovarian cancer
711
. At the time of writing this thesis, there is no publication 
linking TPM1 to endometriosis. In theory, and from this study, it could however act as a potential serum 
biomarker for this disease. TPM1 is potentially another important tumour suppressor preventing overt 
malignant change in a disease like endometriosis. 
6.7.3.9 HSPD1 (HSP60) 
FIGURE 6-31 
 
The HSP60 as an intercellular signalling molecule713 
 
Heat shock protein 60 (HSP60) is also known as mitochondrial HSPD1. It is a mitochondrial chaperonin 
that has roles in protein folding and protein complex assembly. It has immunogenic and inflammatory 
roles. Immune and malignant conditions show t-cell and antibody responses to it. HSP60 causes the 
release of pro-inflammatory cytokine secretion and adhesion molecule expression on monocytes and 
macrophages, endothelial and smooth muscle cells respectively (Figure 6-31)
713
. T-cells, which are 
reactive to HSP60, are present in humans at birth and are capable of responding to stimulation, resulting 
in proliferation and cytokine expression
712
. They are believed to form part of the neonatal immune 
response mechanisms and are also seen to play essential roles in malignant cell survival with higher levels 
prognostic of decreased patient survival in advanced serous ovarian carcinoma
755
. Conversely, patients 
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with low levels of HSP60 responded to first line chemotherapy. Other immunohistochemistry studies 
show that in the initial stages of epithelial ovarian carcinomas, the frequency of expression of HSP60 is 
significantly higher. In these tumours, increased levels
756
 are associated with improved disease prognosis. 
In tumours of the breast, colon, prostate and liver, HSPs are vital for tumour cell survival inhibiting 
apoptosis and preventing cell death, whereas in tumours of the ovary, bone (osteosarcoma), and skin 
(melanoma), the HSP’s also have a role in immune regulation and autoimmunity757. In vitro studies 
looking at the effect of bacterial invasion on epithelial cells show that exogenous HS60, which is released 
from the invading bacteria or inflammatory cells, promotes epithelial cell migration through EGFR 
activation and MAP kinases
758
. In studies exploring the relation between endometriosis and HSP60, there 
seems to be the increased production of Tumour Necrosis factor-α by the mononuclear cells in the 
peritoneal fluid. This release is due to the induction by HSP60 which is postulated to have a role in 
peritoneal induced immunity in patients with endometriosis
759
. In women with endometriosis, and tubal 
factor infertility post Chlamydia infection, HSP60 has been attributed various roles as a causator of 
infertility by affecting tubal function and endometrial milieu affecting implantation. In my study, HSPE1 
gene coding for the HSP family was also flagged up as a potential identified gene marker for 
endometriosis. 
6.7.3.10 RAN 
GTP-binding nuclear protein Ran (RAN) is a small GTPase with GTPase and protein binding roles. It is a 
member of the RAS oncogene family, has roles in cellular nuclear transport during interphase and plays a 
role in mitosis. During the telophase mitotic component, it is the RanGTP hydrolysis and exchange of 
nucleotides which enables vesicle fusion at the nuclear envelopes of daughter cell nuclei
714
. Mutations in 
RAN disrupt the synthesis of DNA. In the nucleotide, Ran exists as GDP-bound and GTP-bound. RCC1 
is a nucleotide exchange factor for RAN which is bound to nuclear chromatin in the nucleus. It is the role 
of RCC1, also known as RanGEF (Ran Guanine nucleotide exchange factor) that converts RanGDP to 
RanGTP. This GTPase activity of RCC1 occurs through the interaction of Ran GTPase activating protein 
(RanGAP) and through complex formation with Ran binding protein (RanBP) (Figure 6-32). 
FIGURE 6-32 
 
RAN cycle within the cell714 
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Another role of RAN is that of a coactivator for the androgen receptor (ARA24). The increased 
polyglutamine expansions seen in disease such as Kennedy’s disease (an X-linked spinal and bulbar 
muscular atrophy) cause reduction of RAN coactivation with the Androgen receptors, leading to androgen 
insensitivity during development of disease
760
. 
In viral infections, Ran has a role in regulating phagocytosis and immunity to the invading virus. 
Antiviral phagocytosis can be mediated by Ran in Schneider 2 cell lines with Ran being upregulated in 
Schneider 2 cells infected with a viral agent
715
. 
Ran has been identified as one of the genes related to nasopharyngeal carcinoma which is itself linked to 
EBV infection which I have already identified as linked to the disease of endometriosis (See section 
4.4.3.5, 4.5.2.1). In microarray studies confirmed by PCR, Ran was found to be upregulated in more than 
80% of nasopharyngeal carcinoma tissues
761
. Ran has also been identified as a candidate for Myc-
mediated cancer progression. Myc binds to Ran’s upstream sequence and activates the activity of Ran 
promoter. The over expression of Myc increases Ran expression and higher levels of these proteins are 
linked to increased metastatic potential and progression of breast and lung cancers
762
. A similar 
mechanism could be activated in endometriosis supporting metastasis and progression of disease. 
Potentially we could look at RAN as a therapeutic agent in endometriosis as well as cancers. 
6.7.3.11 STUB1 
E3 ubiquitin-protein ligase CHIP (STUB1) is a member of the carboxy terminus of hsp70-interacting 
protein and is a chaperone protein. It is released in response to cellular stress signals and has a role in the 
immune system and protein folding. It plays a role in the development of pathology such as Parkinson’s 
disease (Figure 6-33). 
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FIGURE 6-33 
 
Pathway of involvement in Parlinson’s disease496 
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STUB1 (also known as CHIP) has been shown to be essential in the activation of T-cells. This role results 
from the ubiquitination of Caspase recruitment domain (CARD) containing membrane-associated 
guanylate kinase (MAGUK) protein 1 (CARMA1) by STUB1 when it is expressed. This ubiquitination 
enables CARMA1-mediated NF-κB activation. This shows a link between STUB1 and T-cell receptor 
induced NF-κB signalling716. 
Cancer cells show deregulation of the Hsp70/90 chaperones and their HOP/CHIP co-chaperones. In 
cancer cells one can see an activation of Hsp 90 chaperone but decreased expression of CHIP. The 
decreased CHIP expression in proliferating tumour cells supports its tumour suppressor function
717
. In 
breast cancers CHIP is also seen to have a tumour suppressive role. 30% or breast cancers overexpress the 
erbB2 (also known as HER2 or neu) gene. This is associated with a poor patient prognosis. In vitro and 
tissue block studies have shown that CHIP downregulates ErbB2 and higher levels of CHIP increase the 
disease free interval and prolong survival rates in patients. From these studies, CHIP has been postulated 
as a prognostic marker for breast cancer
763
. 
CHIP is also seen to affect p53 function. The inactivation of CHIP by Hsp90 causes the aberrant 
stabilisation of mutant p53 in human cancers
718
, increasing cellular ongogenesis. There are two studies 
that have attempted to link endometriosis with aberrant p53. Of note, in one study, there was an observed 
increased level of p53 expression in 82.4% of cancers associated with endometriosis and 100% increase 
of p53 expression in atypical endometriosis. Mutant p53 expression was seen in 11.8% of atypical 
endometriosis or those endometriosis cases which were associated with cancers. Potentially, this link to 
p53 expression could serve as an indicative prognostic factor of oncogenic potential in atypical 
endometriosis
354
. 
6.8 Potential pathways interacting and disrupted in endometriosis 
6.8.1 Summary of data 
From the analysis of the antibody profiles, Caspase 10, Apoptosis-Related Cysteine Peptidase (CASP10) 
(Figure 6-7), SH3-Domain GRB2-Like 1 (SH3GL1) (Figure 6-8) and aSEPT9 are good putative markers. 
They could potentially differentiate 13 of the 29 endometriosis samples from the control samples. The 
SH3GL1 gene encodes the Endophilin-A2 protein which is a cystolic protein implicated in cellular 
synaptic endocytosis. Mutations in the Endophilin A2 protein have been seen to prevent in vivo models of 
endocytosis
685
. Focal adhesion kinase (FAK) is associated with endophilin A2 interactions causing its 
tyrosine phosphorylation with the formation of a focal adhesion steroid receptor coactive complex 
(FAK/Src complex)
686
. In elevated levels, this complex causes attenuation of the endocytosis of the 
membrane type 1 metalloprotease complex (MT1-MMP)
686
. This in turn causes increase in levels of 
cellular degradation. Elevated levels of this complex have been associated with increased angiogenesis 
and tumour growth, all of which occur in endometriosis, identifying it as yet another possible therapeutic 
target in disease
687
. The overexpression of FAK is seen in a variety of cancers
721
 and is associated with 
increased potential to invade and metastasise
722,723
 (Figure 6-26). 
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The aSEPT9 has been linked to tumour migration and invasion as well as apoptosis and pseudopod 
formation
688
. It is expressed in a large number of human tumours including breast
690
, epithelial ovarian
691
 
and endometrial
689
 tumours. Metastatic lesions are seen to have higher SEPT9 levels
689
 and its presence 
on cell borders and secretory epithelia indicate a role in membrane vesicle formation
689
. This gene may 
potentially play a role in development and dissemination of endometriotic cells enabling its growth and 
proliferation. BCAR is a scaffolding multiadaptor molecule, empirical in the role of intracellular 
signalling
689
. Its presence is associated with an increase in epithelial cellular hyperplasia in mammary 
tumorigenesis
694
. It forms molecular complexes with effector proteins such as P130C and is involved in 
the integrins signalling cellular system and plays a role in cellular motility, migration, proliferation and 
phagocytosis (Figure 6-28). Cytoplasmic FAK activates integrin mediated cell adhesion and has roles in 
angiogenesis and oncogenesis. It is elevated in severe endometriosis
727
. Increased FAK expression is seen 
in a number of cancers and promising therapeutics are targeted towards its inhibition. 
Tumour necrosis factor receptor superfamily, member 1A (TNFRSF1A) is a key regulator of the immune 
system. TNF binds to the ligands of TNFRSF1A and is a key component activating the NF-κB pathway 
which controls cellular apoptosis. The TNF proteins also activate inflammatory and apoptotic responses. 
TNF-α is mainly produced by non-haematopoietic cells including activated lymphocytes, macrophages, 
NK cells and neutrophils whereas TNF-β is produced by lymphocytes. The levels of TNF in the 
peritoneal fluid of patients with endometriosis are elevated and correlate to the stage of disease
730
. TNF-α 
is also known to increase adherence of stromal uterine cells to in vitro mesothelium
695
. The TNF family is 
interestingly dysregulated in viral infections and is an essential component in the development of 
infectious disease
697
. Any system dysregulation could be mirrored in alterations of T-cell survival and 
function
733
. Diseases can be stimulated or repressed by co- stimulating or regulating TNF factors this 
makes the regulators of the TNFR therapeutic targets for controlling disease. Studies using anti TNF 
monoclonal antibodies
735
 and recombinant human TNFRSF1A (r-hTBP1)
736
 show a decrease in disease 
development in the animal models used. Tumour necrosis factor receptor superfamily, member 10a 
(TNFRSF10A) promotes the NF-κB pathway and is another apoptosis mediator. 
Oestrogen receptor 1 (ESR1) is a transcription factor activated by oestrogen
702
 (Figure 6-29). There are 
elevated levels of ER-α receptors in active red endometriotic lesions compared to black necrotic ones703. 
Increase in ER-α levels also activate other pathways such as insulin-like growth factor-1 (IGF-1) which 
send powerful mitogenic stimuli causing cellular proliferation and growth. In severe endometriosis, 
plasma levels of IGF-1 are elevated, this elevation is however not maintained in the endometrium itself
704
. 
The IGF-1 has also been associated with malignant development and metastatic potential and there is a 
reported increase in its levels in other female cancers such as cervical, ovarian and endometrial cancers
745
. 
Baculoviral inhibitor of apoptosis proteins (IAP) repeat-containing 2 (BIRC2) plays a major role in 
cellular control of apoptosis by creating positive or negative feedback signalling on the NF-κB pathway. 
Once the NF-κB is activated or altered, effects on cyto and chemokines occur, which in turn promote 
cellular survival, proliferation and inhibit apoptosis
707
. It promotes cellular growth and survival including 
the production of IL-6, B-cell activating factors, cell inhibition of apoptosis, I kappa B kinase  (IKK), 
tumour necrosis factors, TNFR, TRAF TRADD, TNFR- associated death domains and multiple pathways 
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associated with increased cellular survival in malignant patterns
752
 (Figure 6-30). A similar function in 
endometriosis might explain the intraperitoneal cell survival and its proliferation into disease. 
The results of the quality control (QC) assays and the low CVs provided a high degree of confidence in 
the data obtained. There were clear indications of antibody reactivity in many of the samples. A set of 
putative biomarkers was identified. Further analysis of this data is warranted and the generation of 
additional data should be considered. The inclusion of data generated from additional samples would 
provide greater statistical power. Data from other sources could also be integrated into this dataset to 
increase the potential for discovering biomarkers.The identification of such autoantibodies and their 
cognate antigens may possibly form the basis of an exploration of the biology as well as serve as potential 
serum biomarkers. The Figure 5-10 and Figure 5-11 provide an overview of interactions between 
identified miRNAs, associated genes, proteins, antibodies and the pathways they affect. 
6.9 Detailed analysis of potential identified serum gene markers 
A total of 21 potential serum gene markers were identified for endometriosis (Table 6-10). In this section, 
each gene is explored together with its associated protein and genetic interactions. This enables the in-
depth analysis of the genetic function and its contribution to disease pathogenesis. 
TABLE 6-10 
Gene 
Symbol 
Frequency 
in controls 
(36) 
Frequency in 
endometriosis 
(34) 
Difference in 
frequency 
endometriosis 
minus controls 
% in 
controls 
% in 
endometriosis 
% difference 
endometriosis 
minus controls 
C19orf50 1 7 6 2.9412 19.4444 16.5033 
CA1 1 6 5 2.9412 16.6667 13.7255 
RUNX1T1 2 7 5 5.8824 19.4444 13.5621 
PRKCZ 2 7 5 5.8824 19.4444 13.5621 
PCBD1 2 5 3 5.8824 13.8889 8.0065 
ALDOA 3 11 8 8.8235 30.5556 21.7320 
CASP10 1 7 6 2.9412 19.4444 16.5033 
PYCR1 1 7 6 2.9412 19.4444 16.5033 
GGPS1 2 8 6 5.8824 22.2222 16.3399 
MYCBP 2 8 6 5.8824 22.2222 16.3399 
CASP6 2 8 6 5.8824 22.2222 16.3399 
GMEB1 0 5 5 0.0000 13.8889 13.8889 
TNFAIP8 0 5 5 0.0000 13.8889 13.8889 
HSPE1 3 8 5 8.8235 22.2222 13.3987 
EIF4EBP1 0 4 4 0.0000 11.1111 11.1111 
MAPK14 0 4 4 0.0000 11.1111 11.1111 
ABCF1 1 5 4 2.9412 13.8889 10.9477 
IMPA1 1 5 4 2.9412 13.8889 10.9477 
LDHB 1 5 4 2.9412 13.8889 10.9477 
       
ATXN3 6 2 -4 17.6471 5.5556 -12.0915 
TOM1 5 0 -5 14.7059 0.0000 -14.7059 
The 21 potential gene markers were identified for endometriosis 
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6.9.1 C19orf50 
FIGURE 6-34 
 
Predicted evidence view of interactions of C10orf50576 
 
Chromosome 19 open reading frame 50 (C19orf50) (Figure 6-34) is a length of DNA which has an 
initiation and stop codon. Unlike genes, which code for proteins of known function, an ORF is a genetic 
region which may or may not be transcribed/translated depending on the presence of promoters and 
ribosome binding sites. It usually has an unknown function. Projects attempting to map systematically 
new protein-protein links and networks
764
, also known as ‘interactome’ mapping, try to link features of 
these networks to biological functions and attempt to provide an insight to disease at a systems level. 
Over 8000 ORFs have been tested, with pairwise interactions revealing 2800 binary interactions. 
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6.9.2 CA1- carbonic anhydrase 
FIGURE 6-35 
 
Predicted evidence view of interactions of CA1576 
 
Carbonic anhydrase is a family of catalysts (enzymes) that maintain cellular pH by regulating the 
reversible hydration of carbonic acid to bicarbonate and protons (Figure 6-36). The subfamily of carbonic 
anhydrase present in mammals is the alpha family (α-CA). The α-CA family is divided into 4 groups 
comprising of cytosolic CA (CA1-3, CA7 and CA13), mitochondrial (CA-VA/VB), secreted CA (CA-6) 
and membrane associated CAs (CA4/9/12/14/15)
765
. Since their discovery in red blood cells around 80 
years ago, their role has expanded from red blood cells catalysis of CO2 hydration 
(CO2+H20⇌HCO3+H
+
) to the involvement in cellular growth, implying links with cellular oncogenesis 
and malignancy. 
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FIGURE 6-36 
 
Figure demonstrating the cellular role of carbonic anhydrases766 
 
CA2/9 and 12 have both been implicated in malignancy and have been utilised to potentially act as 
tumorigenic prognostic markers
767
. Their high prevalence in hypoxic tumour tissues, creating an acidic 
extracellular environment, has been implicated in the cellular invasion process
768
. 
Carbonic anhydrase 1 (Figure 6-35) codes for carbonic anhydrase, an enzyme with hydro-lase activity. It 
causes cleavage of an oxygen-carbon bond through water elimination. Metabolically, carbonic anhydrase 
is involved in anabolic and catabolic cellular processes and has a role in DNA replication and repair as 
well as protein synthesis and degradation
496
. 
Research has explored the roles of autoantigens in endometriosis. Candidate autoantigens include 
carbonic anhydrases
769-771
, alpha enolase
772
, endometrial transferrin and alpha 2-HS Glycoprotein
562
. 
In 1996, Brinton
769
 described elevated levels of autoantibodies to carbonic anhydrase-2 in the serum of 
women with unexplained infertility undergoing laparoscopy
769
. CA1 is closely linked to CA2 and CA3 on 
chromosome 8. Other studies have described similar antibodies against carbonic anhydrase in women 
with infertility suffering from endometriosis
773
. Increased levels of anti-CA antibodies have been reported 
in other autoimmune and inflammatory diseases such as primary biliary cirrhosis or Sjogren’s, further 
strengthening the link of its increased levels in autoimmune disorders. 
Other members of the carbonic anhydrase family such as CA9 have been implicated in hypoxic tumour 
survival and proliferation in head and neck tumours. Elevated levels are associated with tumour 
aggressiveness and poor disease free survival rates
774
. In this study, the presence of CA9 and the uptake 
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of a proliferative marker (IdUrd) were linked to the identification of a cellular subpopulation which might 
be the cause of disease progression and cellular repopulation. 
6.9.3 RUNX1T1 
FIGURE 6-37 
 
Predicted evidence view of interactions of RUNX1T1576 
 
Runt-related transcription factor 1 translocated to 1 (cyclin D-related) (RUNX1T1) codes for the protein 
CBFA2T1 (Figure 6-37). This protein is a zinc-finger transcription factor and an oncoprotein
775
 (Figure 
6-40). The translocation (8;21)(q22;q22) is seen in 12-15% of AML patients making it one of the most 
frequent translocations (Figure 6-38, Figure 6-39). The gene RUNX1 on chromosome 21 is rearranged 
with the RUNX1T1 on chromosome 8 leading to the expression of a fusion gene RUNX1-RUNX1t1 
(AML1-ETO) enabling haematopoietic cell renewal whilst inhibiting differentiation
775
. The resulting 
chimeric gene composed of the 5’region of RUNX1 with the 3’region of the translocation 
t(8;21)(q22;q22) creates a protein which is believed to link to the nuclear co-repressor/histone deacetylase 
complex blocking haematopoietic differentiation
776
 and repressing transactivation mediated by TCF12. 
This myeloid translocation gene on 8q22 codes for a member of the myeloid translocation gene family, 
interacting with DNA-bound transcription factors which recruit co-repressors and enable transcriptional 
repression of target genes
578
. The RUNX1t1 is implicated in lymphocyte signalling pathways. 
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RUNX1T1 has transcription factor and transcription co-factor activity. It modulates the transcription 
frequency from an RNA polymerase 2 promoter and it has a role in the eukaryotic chromatin structure. In 
ovarian cancer, the expression of RUNX1T1 is seen to suppress in vitro tumour growth
777
. These 
experiments suggest a tumour suppressor role of RUNX1T1 in ovarian cancer. Aberrations in the 
TGFbeta/SMAD4 signalling pathways cause silencing of the tumour suppressor RUNX1T1 causing 
ovarian cancer. Interestingly RUNX1T1 is also responsive to estradiol levels
778
. In the follicular phase of 
endometriosis, its elevation in levels might act as a tumour suppressor role similar to what occurs in 
epithelial ovarian cancer. 
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FIGURE 6-38 
 
Kegg pathway analysis- acute myeloid leukaemia526 
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FIGURE 6-39 
 
Kegg pathway analysis- transcriptional misregulation in cancer526 
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FIGURE 6-40 
 
Kegg pathway analysis showing various pathways implicated in cancer526 
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6.9.4 PRKCZ 
FIGURE 6-41 
 
Predicted evidence view of interactions of PRKCZ576 
 
Protein kinase C Zeta (PRKCZ) (Figure 6-41) is a kinase belonging to the family of seine/threonine 
kinases involved in cellular proliferation, differentiation and secretion. This has a kinase activity which 
unlike other family members is not Calcium dependent in its function. It does not respond to the typical 
PKC inhibitors and similarly does not respond to the usual activation of this family by phorbol esters
578
. It 
is involved in various pathways including the activation of NF-kappa beta activation, maintenance of 
cellular potentiation and mitogenic signalling, cellular proliferation and polarity and the inflammatory 
response. It also has a function phosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activated 
protein (MAP) kinase cascade
779,780
. The protein kinase C, zeta (PRKCZ) will activate the MAPK 
signalling pathway independently of the RAF- 1 activation signals. Its physiological roles are extensive. 
Multiple target proteins control receptor alterations, alterations of events within membranes and 
regulation of cellular growth, differentiation, angiogenesis and immune responses (Figure 6-42). 
Alterations in the PI3K pathway including the PRKCZ component of the pathway, have been linked to 
tumours
781
. In theory, aberrations in any segment of the complex pathways can impart cellular changes, 
promoting invasiveness, growth and dissemination. These same cellular characteristics might be 
attributed to the development of a disease like endometriosis. 
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FIGURE 6-42 
 
Figure demonstrating the effects of PRKCZ on various cellular functions and pathways 
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6.9.5 PCBD1 
FIGURE 6-43 
 
Predicted evidence view of interactions of PCBD1576 
 
Pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha 
(PCBD1) (Figure 6-43) is localised on the 10q22 chromosome. The gene encodes the pterin-4 alpha-
carbinolamine dehydratase enzyme which is involved in phenylalanine hydroxylation. Its deficiency 
causes hyperphenylalaninemia. The enzyme is also responsible for the homodimerization of the 
transcription factor hepatocyte nuclear factor 1 (HNF1)
578
. It is reported in various cellular compartments 
ranging from the nucleolus, nucleus, cytoplasm and cytosol. It has functions in cellular metabolism and is 
also mentioned to contribute to the DNA dependant regulator of transcription. Antibody staining of 
various malignant tissues has shown moderate staining to the antibody pertaining to the gene in around 
30% of cancers including endometrial and ovarian cancers
634
. 
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6.9.6 ALDOA 
FIGURE 6-44 
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Predicted evidence view of interactions of ALDOA576 
 
Aldolase A, Fructose-Bisphosphate (ALDOA) gene (Figure 6-44) is located on chromosome 16 and 
codes for protein Aldolase A. Aldolase A (fructose-biphosphate aldolase) is an enzyme that catalyses the 
conversion of fructose-1,6-biphosphate into glyceraldehyde 3-phospate and dihydroxyacetone phosphate 
in a reversible manner (Figure 6-45). It may also play a role as a scaffolding protein. Aldolase A is found 
in embryogenesis and in adult muscle tissue and its deficiency is linked to myopathy with rhabdoyosis 
and haemolytic anaemia. Aldolase A is seen in elevated levels in lung cancer
782
. It has also been 
implicated in the development of malignant pleural cell effusions which demonstrate aberrant glucose 
metabolism gene expression
783
. The aberrant expression of ALDOA in tumour cells leads to changes in 
glucose metabolism which is associated with cellular metastatic potential and poorer prognosis in 
malignancies. It is repressed in the liver, kidney, intestine, brain and other nerve tissues. Elevated levels 
identified in my study with endometriotic patients might explain changes in endometriotic cells including 
their potential to metastasise and grow. 
Gene, protein and miRNA expression in women with endometriosis 
306 
FIGURE 6-45 
 
Pathway analysis of glycogenolysis784 
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6.9.7 CASP10 
FIGURE 6-46 
 
Predicted evidence view of interactions of CASP10576 
 
Mutations in the CASP 10 gene (Figure 6-46) cause defects in the apoptosis pathways. Caspase-10 acts as 
a homologue to the cystene protease Caspase-8 which executes the apoptotic pathway (Figure 6-47). 
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FIGURE 6-47 
 
Pathway demonstrating death receptor activation785 
 
The CASP10 gene codes for the Caspase 10 enzyme
786
. Its activation causes the transformation and 
proteolysis of the inactive proenzyme into two subunits dimerising into the active form. The Caspase 10 
protein activates Caspases 3 and 7 and is processed by Caspase 8. Biologically, it is involved in the 
caspase pathway responsible for the execution of apoptosis and the FAS signalling pathway
787
. It is 
recruited to the TNFR-1 receptors and Fas receptors in a Fas-Associated protein Death effector Domain 
(FADD) in apoptosis
788
 (encoded for by the CFLAR gene
789
). It is linked to the RING1 and YY1-binding 
protein (RYBP)
790
, Tumour necrosis factor receptors 1A and 10B (TNFRSF1A and TNFRSF10B)
787
. 
There are various isoforms of caspase-10 which perform a different pro or anti-apoptosis function 
enabling fine regulation of the apoptotic cycle initiation
791
. It has been described as an initiator caspase in 
death receptor signalling and functions independently of Caspase-8 causing apoptosis mediated by the 
FAS and Tumour necrosis factor systems
788
. Both Caspase-10 and Caspase-8 interact with the Fas-
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Associated protein Death effector Domain (FADD) which serves to bridge the FAS receptor and form the 
death-inducing signalling complex (DISC) in apoptosis
792
 (Figure 6-48). Caspase levels are increased in a 
p53 dependant manner in the presence of DNA damage. Studies showing in vivo binding of p53 to 
multiple p53-specific binding sites located within the gene locus of Caspase 10
793
 suggest that Caspase 10 
is a direct transcription target of p53. Endometriosis has shown increased levels of p53 in my TMA 
studies. p53, a tumour suppressor, has been shown to be elevated in a proportion of endometriotic lesions 
with no obvious genetic aberrations
792
. 
FIGURE 6-48 
 
Demonstrating the activation of the apoptotic pathway 
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6.9.8 PYCR1 
FIGURE 6-49 
 
Predicted evidence view of interactions of PYCR1576 
 
PYCR1 gene (Figure 6-49) is on chromosome location 17q25.3 and codes for the protein Pyrroline-5-
carboxylate reductase 1, mitochondrial. This enzyme converts pyrroline-5-carboxylate to prolene in an 
NAD(P)H dependant manner
578
. In certain cells it is also responsible for the production of NADP(+). The 
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protein forms a homopolymer and localises to the mitochondrion. Its defect would cause an autosomal 
recessive type 2B connective tissue disorder known as cutis laxa. 
6.9.9 GGPS1 
FIGURE 6-50 
 
Predicted evidence view of interactions of GGPS1576 
 
Geranylgeranyl Diphosphate Synthase 1 (GGPS1) (Figure 6-50) is a member of the prenyltransferase 
family which catalyses GGPP synthesis from farnesyl diphosphate and isopentenyl diphosphate. GGPP is 
a molecule which regulates a nuclear hormone receptor and is responsible for the C20-prenylation of 
proteins
578
. 
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FIGURE 6-51 
 
Pathway demonstrating the biosynthesis of genanylgeranyl diphosphate794 
 
The isoprenoid biosynthetic pathway is a frequently targeted pathway in the treatment of disease. The 
isoprenoid inhibitors are of two main classes: the statins and the nitrogenous bisphosphonates which are 
used in osteoporosis and metastatic bone disease
794
. Statins have the ability to block modification of 
several oncogenes and are being explored as anticancer agents
795
. GGDPS inhibitors could be used as 
alternate disease therapeutics where geranylgeranylation has been implicated in the disease process, 
potentially even for endometriosis. The primary function of geranylgeranyl diphosphate is the post 
translational modification of proteins of the RAS family of small GTPases. The RHO members of this 
family are vital in the determination of malignant migration and metastasis. Geranylgeranyl diphosphate 
has been identified as an important metabolite in growth and metastasis in several human cancers (Figure 
6-51). Protein geranylgeranylation is also important in the activation of the signalling pathways of 
epidermal growth factor receptors which is upregulated in malignancies
796
. In breast cancer the increased 
expression of RAB27B, a member of the Rab subfamily of GTPases, is associated with a poor 
prognosis
797
. Rab27 geranylgeranylation has been seen to be necessary for the formation of xenograft 
tumours in breast cancer cell lines. Overall geranylgeranyl diphosphate is emerging as an important 
metabolite in the development and metastatic potential of human malignancies. It has also been 
implicated in animal models looking at infectious diseases such as cryptoosporidosis
798
 and Plasmodium 
in liver disease
799
. 
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6.9.10 MYCBP 
FIGURE 6-52 
 
Predicted evidence view of interactions of MYCBP576 
 
The MYC binding protein (MYCBP) gene (Figure 6-52) also known as V-Myc Avian Myelocytomatosis 
Viral Oncogene Homolog, codes for the C-myc binding protein which is a cytoplasmic protein 
translocating to the nucleus in the S phase of the cell cycle. The protein binds to the C-MYC oncogene 
protein at its N-terminus
578
. It was originally identified as the retroviral oncogene homologue within the 
human cell
800
. This protein has been linked to spermatogenesis and is silenced with miRNA-22. It is 
instrumental in the development of Burkitt’s Lymphoma and is elevated in aggressive tumours which are 
poorly differentiated and carry a poor prognosis
801
. Publications linking endometriosis to the presence of 
C-MYC are documented in the literature together with other oncogenes and tumour suppressor genes 
such as p53
802
. The c-MYC oncogene is overexpressed in certain cancers. It is also present with other 
oncogenes such as HER-2lneu, K-RAS mutations and p53 tumour suppressor gene mutations resulting in 
overexpression of p53 mutant proteins (Figure 6-53). 
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FIGURE 6-53 
 
Pathway analysis of C-MYC oncogene784 
 
One of the main functions of c-MYC is to promote progression through the cell cycle
803
 with in vitro 
experiments showing a rise in c-MYC expression at the onset of G1 phase in the cell cycle
804
. The c-
MYC sensitises cells pro-apoptotically and then causes the release of cytochrome C from the 
mitochondria into the cellular cytosol. It does this through the activation of BAX which is a pro-apoptotic 
molecule. The release of Cytochome C activates apoptotic protease-activating factor inducing apoptosis 
(Figure 6-54). The activation of BAX causes the change of mitochondrial membrane porosity and the 
presence of ATP activates the caspase cascade leading to cell death. The c-MYC also links to ADP-
ribosylation factor (ARF) and activates the p53 tumour suppressor. The c-MYC induced apoptosis can be 
blocked through the promotion of MOMP by the pro-apoptotic protein BID which is in turn activated by 
Caspase8 through the FADD receptor (Figure 6-54). 
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FIGURE 6-54 
 
Apoptotic activation mechanisms805 
6.9.11 CASP6 
FIGURE 6-55 
 
Predicted evidence view of interactions of CASP6576 
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The enzyme Caspase 6 (Cysteine-aspartic acid protease family) is coded for by the CASP6 gene
806
 
(Figure 6-55). Caspases are components of the apoptotic, inflammatory and necrotic pathways and can be 
divided into roles of initiators and effectors (Figure 6-56). They are crucial in inflammation and cell death 
and their disruption has been linked to disorders ranging from myocardial infarction to malignancies. 
More than 400 caspase substrates have been identified so far. Whereas initially they were believed to play 
a role solely in apoptosis, they are now also known to effect immune cell function, development and 
differentiation. They can even protect from certain forms of cell death
807
. 
FIGURE 6-56 
 
Apoptosis and survival TNFR1 signalling pathway784 
 
The caspase proteases are broadly divided into pro- apoptotic or pro-inflammatory. Caspase 6 is an 
apoptosis effector caspase which has the ability to self-activate independently of other caspase family 
members
808
. It acts through the extrinsic and intrinsic apoptotic pathways
809
 (Figure 6-57) and is induced 
by varied stimuli. It is known to interact with Caspase 8. Caspase 6 also has a role of B cell entry into the 
cell cycle. It has a negative regulatory effect on CD-40 and Toll-like receptor (TLR)-dependent G1 entry 
and conversely promotes S-phase entry later on in the cellular cycle
810
. Caspases are believed to have a 
role in activation of types of immune cells. The caspases involved in the development of haematopoietic 
cells and their activation include caspases- 6 and 8. Experimentally a caspase-8 deficiency has shown B 
cell, NK cell and T cell deficiencies
811
. Deficiency of Caspase 6 leads B-cells to differentiate rather than 
proliferate and its role in B-cell proliferation following activation with IgM or CD40 antibodies has also 
been shown in certain studies
812
. EBV is believed to induce apoptosis in a caspase dependant manner with 
the involvement of the mitochondrial pathway. Certain caspases including Caspase-3,8 and 9 are elevated 
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in EBV infected monocytes
813
 and in my study, I have already identified increased levels of EBV in the 
lymphocytes of patients with endometriosis (See section 4.4.3.5 and 4.5.2.1). Caspase-6 is a known co-
effector and activator of Caspase-8
814
 so it too might have a role in cells affected by viral EBV. 
FIGURE 6-57 
 
Extrinsic apoptotic pathway807 
Gene, protein and miRNA expression in women with endometriosis 
318 
6.9.12 GMEB1 
FIGURE 6-58 
 
Predicted evidence view of interactions of GMEB1576 
 
The GMEB1 gene (glucocorticoid modulatory element binding protein 1) (Figure 6-58) encodes for the 
KDWK gene family member which links to the GMEB2 protein. The resulting complex is essential for 
DNA replications in parvovirus. Animal studies indicate that this gene modulates the activation of 
glucocorticoid receptors which links to glucocorticoid responses
578
. Functionally, it is linked to Caspase 
8, an apoptosis related member of the Caspase family. Caspase 8 is responsible for the cell death through 
binding of the FADD adapter molecule and activation of the TNFRSF6/FAS and TNFRSF1A pathways 
(Figure 6-56). The death inducing signalling complex (DISC) is what activates proteolysis by CASP8 and 
its downstream apoptosis. GMEB1 is also related functionally to Caspase 9, another apoptotic Caspase 
family member. In neurons, its presence has been seen to counteract and prevent apoptosis induced by 
oxidative stresses. It is also seen as a Caspase activation inhibitor
815
. 
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6.9.13 TNFAIP8 
FIGURE 6-59 
 
Predicted evidence view of interactions of TNFAIP8576 
 
The tumour necrosis factor alpha-induced protein 8 (TNFAIP8) is a member of a family of proteins which 
regulate cellular and immune control
816
 (Figure 6-59). It is also known as the head and neck tumour and 
metastasis-related protein MDC-3.13. Its role is that of a negative apoptosis mediator and is linked to the 
ability of a tumour to invade, metastasis and proliferate
817
. It inhibits Caspase-8 resulting in the inhibition 
of BID cleavage and activation of Caspase 3. It does not affect the processing of procaspase-8
818-820
. 
Overexpression of TNFAIP8 is implicated in breast cancer, with its expression enhancing cellular 
invasion and proliferation
818,820,821
. It has also been linked to a poor prognosis and lymph node metastasis 
in non-small-cell lung cancer
822
. NDED (NF-kappa B-inducible death effector domain containing protein) 
is an alias for TNFAIP8. This has been shown experimentally to play an essential role in the suppression 
of TNF mediated apoptosis by the inhibition of Caspase-8
819
. In endometrial cancer, TNFAIP8 is linked 
to increased metastatic potential and reduced overall patient survival or disease recurrence rates
817
 and it 
has been proposed as a prognostic marker in the recurrence of endometrial cancer. In endometriosis, this 
protein might also contribute to increased cellular growth and metastatic potentials. I have identified this 
protein as a potential serum marker in endometriosis and it could potentially be used to predict relapse, 
aggressiveness or recurrence of disease. 
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6.9.14 HSPE1 
FIGURE 6-60 
 
Predicted evidence view of interactions of HSPE1576 
 
This gene encodes for heat shock 10 kDa protein 1 (Hsp10) also known as chaperonin 10 (cpn10) or 
early-pregnancy factor (EPF) (Figure 6-60). The heat shock protein encoded for by this gene is a major 
HSP functioning as a mitochondrial chaperonin. It enhances protein folding in an ATP dependant manner 
on binding to a second HSP (HSP60) forming a dimeric complex. It is not only limited to the 
mitochondrion, but can also be found in the cytosol, cell surfaces and peripheral blood
823
. Its 
dysregulation is related to pregnancy, cancer
824
 and autoimmune inhibition and diseases
825,826
. It has a role 
in cellular stress
827
 protection, immunomodulation and controls cellular proliferation and differentiation. 
Hsp10 is found in high levels in malignant cells and release into the extracellular space has tumour 
promoting effects
825
. In endometriosis the effects might potentially enable disease progression and 
dissemination As Hsp10 does not have an N-terminal peptide as a secretion signal, its transport is 
believed to occur through independent pathways, not the classic Golgi- dependant pathways. As the 
secretory pathway of Hsp60 is through exosome mediation
828
, it is not unreasonable to infer that a similar 
pathway might be used by HSPE1. 
Gene, protein and miRNA expression in women with endometriosis 
321 
EPF is the homolog of Hsp10. It is seen in the maternal circulation 24 hours post fertilisation and plays a 
vital role in maternal immunosuppression, enabling embryonic implantation
829
. Another role of Hsp10 is 
that of anti-autoimmunity. In rheumatoid arthritis it inhibits cytokine production improving clinical 
symptoms
830
. In multiple sclerosis it inhibits effector T-cell infiltration and downregulates adhesion 
molecules
831
. Potentially, Hsp10 may be used as a therapeutic agent in autoimmune disease treatment 
though the affected pathways are not entirely understood. If further studies can identify Hsp 10 as being 
particularly relevant to endometriosis in the clinical setting, it too might be used as therapeutic target for 
disease. 
6.9.15 EIF4EBP1 
FIGURE 6-61 
 
Predicted evidence view of interactions of EIF4EBP1576 
 
Human EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) is a translation repressor 
protein which interacts with translation initiation factor 4E in eukaryotes (Figure 6-61). This complex is 
responsible for the recruitment of the five end of mRNA to the 40S ribosomal subunits. Once EIF4EBP1 
interacts with elF4E cellular translation is repressed. Conversely, factors such as insulin signalling and 
irradiation causes phosphorylation of the complex resulting in mRNA translation
577
. Another role of 
EIF4EBP1 is that of mediation of protein translation regulation in response to hormonal and growth factor 
stimuli. The pathways involve include the MAP kinase 9 (Figure 6-63) 
526
and mTORC1 pathways (Figure 
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6-67)
526
. In an ovarian cancer study, 12% of patients exhibited aberrant expression of EIF4EBP1
832
 
showing worse outcomes in disease if the EIF4EBP1 was up or downregulated compared to normal 
levels. Elevated levels in the serum of women with endometriosis might also imply a worse outcome for 
patients with the disease, and it too could be potentially considered as a biomarker for endometriotic 
disease presence, response and prognosis. 
6.9.16 MAPK14 
FIGURE 6-62 
 
Predicted evidence view of interactions of MAPK14576 
 
This gene encodes for Mitogen-Activated Protein Kinase 14. It is a serine- threonine kinase which is a 
vital component for the signal transduction pathway (Figure 6-62). It is one of four p38 MAP kinases that 
have a role in cellular responses. MAP kinases are involved in cellular development, proliferation, 
transcription and differentiation. 
Environmental stresses or cytokines which are pro-inflammatory are the activating agents for the MAP 
kinase family. Activation also occurs through the MAPK14 protein phosphorylation by map kinase 
kinases, resulting in substrates such as transcription regulators activating transcription factor 2 (ATF2), 
Myocyte-specific enhancer factor 2C (MEF2C), MYC Associated Factor X (MAX), cell cycle regulators 
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cell division cycle 25B (CDC25B) and the tumour suppressor p53. Autophosphorylation also occurs 
through interaction with the protein TGF-Beta Activated Kinase 1/MAP3K7 Binding Protein 1 
(MAP3K7IP1/TAB1)
577
. 
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FIGURE 6-63 
 
MAPK signalling pathway526 
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MAPK14 interacts with a number of substrates causing various intercellular responses. Its interaction 
with casein kinase 2 and the autophosphorylation of TP53/p53 results in MAPK14 activation within the 
cellular MAPK pathways regulating protein turnover
577
. MAPK14 acts on ubiquitin ligases and can 
interfere with the movement of transmembrane protein ATG9 thereby inhibiting the lysosome 
degradation pathway of autophagy. It is also responsible through its action on GTPase Ras-Related 
Protein Rab-5A (RAB5A) for the endocytosis of cellular membrane receptors. MAPK14, is also 
responsible for the phosphorylation of epidermal growth factor receptors resulting in their cellular 
internalisation in the presence of inflammatory stresses or irradiation. MAPKs are seen to regulate 
chromatin modification thereby affecting cellular gene expression and nuclear transcription. There seems 
to be a direct functional relationship between the gene O-Linked N-Acetylglucosamine (GlcNAc) 
Transferase (OGT) and MAPK14. Studies have demonstrated that activation of MAPK14 through glucose 
deprivation increases the OGT interaction and the stimulation of o-Glc-N-acylation. This process is seen 
to be vital in the embryonically derived placental vessels. Dysregulation of the MAPkinase pathways are 
linked with inflammation, neurodegenerative diseases
833
 and malignancies
834
. They have been identified 
as a target for anti-cancer medications with various pathway targets being explored. It is interesting to 
note that MAP kinase pathways are also hormonally responsive. Estrogen-dependant disorders such as 
Polycystic Ovarian syndrome, leiomyomas and endometriosis have all been linked to the MAPK 
pathways
835
. 
6.9.17 ABCF1 
FIGURE 6-64 
 
Predicted evidence view of interactions of ABCF1576 
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ABC transporters are proteins responsible for the transmission of membrane molecules between the intra 
and extracellular domains. There are seven ABC gene subfamilies and ATP-Binding Cassette (Figure 
6-64), Sub-Family F (GCN20), Member 1 (also known as TNFalpha-Inducible ATP-Binding Protein) is a 
member of the GCN20 ABC transporter family
496,578,592. It is regulated by TNFα836 and has a role in 
inflammation and protein synthesis within the cell
577
. It is expressed in ribosomal proteins and has a role 
in mRNA translation. Unlike other members of its family, this protein lacks the transmembrane domains. 
Clinically ABC transporters, are linked to resistance to anti-cancer agents by the efflux of these agents 
outside of the tumour cells
837
. Transcript levels if ABCF1 were lower in non-responders. In 
endometriosis, the implications of elevated levels of ABCF1 are unexplored. Potentially it could be used 
to predict responses in patients to varied therapeutics in the future. 
6.9.18 IMPA1 
FIGURE 6-65 
 
Predicted evidence view of interactions of IMPA1576 
 
Inositol(Myo)-1(Or 4)-Monophosphatase 1 gene encodes an enzyme which demonstrates phosphatase 
activity which is magnesium dependant (Figure 6-65). It is inhibited by therapeutic lithium concentrations 
and is used as the pharmacological target for lithium in the brain
577
. Lithium is used to treat bipolar 
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disorders and their associated manic and depressive episodes. This can be explained when one looks at 
the inhibition lithium exerts on inositol monophosphate hydroylosis and the resulting depletion of inositol 
for phosphatidylinositol synthesis. One of the interactions of IMPA1 is the gene Phospholipase C delta 1 
which encodes a member of the phospholipase C family. This family of compounds acts in intracellular 
signalling and function as a tumour suppressor. It has been shown to have an essential role in 
trophoblastic and placental development. In a study which assessed autoantibodies against tumour 
associated antigens in women with endometriosis versus controls, IMP1 together with Cyclin B1 were 
postulated as potential clinical biomarkers of endometriomas
838
. It has not been used in the clinical setting 
so far. 
6.9.19 LDHB 
FIGURE 6-66 
 
Predicted evidence view of interactions of LDHB576 
 
Lactate dehydrogenase B is an enzyme in the glycolytic pathway which is a catalyst for the reversible 
reactions of nicotinamide adenine dinucleotide (NAD and NADH) and the conversions of lactate and 
pyruvate
577
 (Figure 6-66). Lactate dehydrogenase deficiency arises from gene mutations and gives rise to 
glycogen storage diseases with possible associated renal failure secondary to myoglobinuria. It has been 
reported in other studies to be elevated in women suffering from endometriosis, in benign and malignant 
ovarian tumours
839
 and in endometrial carcinomas. In endometrial cancer the mammalian target of 
rapamycin (mTOR) tumour pathway has been identified as a vital pathway in disease development
840
 
(Figure 6-67). Lactate Dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis
841
. In 
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medulloblastomas with high LDBH levels prognosis of the disease was found to be poor with an 
increased possibility of metastasis
842
. 
FIGURE 6-67 
 
mTOR signalling pathway526 
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6.9.20 ATXN3 
FIGURE 6-68 
 
Predicted evidence view of interactions of ATXN3576 
 
Ataxin3 is a deubiquinating enzyme which cleaves Ubiquitin from proteins (Figure 6-68). It has various 
cellular functions ranging between homeostasis protein maintenance, cytoplasmic trafficking, protein 
guiding through endocytic pathways, degradation of chaperone substrates which are misfolded, regulation 
of the cytoskeleton and myogenesis
843
. It has a role in the inhibition of transcription acting as a histone 
binding protein. Its precise biological function remains incompletely understood. A mutation in the 
ATXN3 gene causes a trinucleotide repeat expansion and leads to the disease of spinocerebellar ataxia 
type 3. The accumulation of incorrectly folded proteins affects brain cells and neurons giving rise to 
neurodegenerative disease such as the autosomal dominant Machado-Joseph disease. ATXN3 has been 
identified as an autonomous complimentary therapeutic target in cancers with downregulation of 
phosphatase and tensin homolog (PTEN)
844
. Silencing of PTEN is associated with a hyper-activation of 
the phosphatidylinositol-3-kinase (PI3K) pathway in cancer
844
. As yet there is no link to endometriosis. 
One could theorise that its presence may alter cellular characteristics potentially encouraging disease 
progression. If confirmed as a highly relevant protein in the disease of endometriosis, it might also be 
considered in the future as a main or complimentary therapeutic target for disease. 
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6.9.21 TOM1 
FIGURE 6-69 
 
Predicted evidence view of interactions of TOM1576 
 
Target of Myb1 (Chicken) is a gene which is a target of the viral myeloblastosis oncogene (Figure 6-69). 
The protein of this gene is associated with intracellular membrane and vesicular trafficking at the 
endosome as it shares an N-terminal in common with endosomal proteins
577
. It is recruited to the 
endomsomes through its interaction with endosomal protein endolfin
845
. Another function of this gene is 
the translocation of growth factor receptor complexes to the lysosome for degradation thereby affecting 
cellular growth. Studies looking at its antibody expression in various diseases show high levels in 
endometrial cancers
634
. TOM1 has also been described as a negative regulator of pathways such as IL-1 
and TNF
846
. When TOM1 is overexpressed it suppresses, through its VHS domain, the activation of pro 
inflammatory cytokines NF-κβ and Activating protein-1 (AP-1) (Figure 6-70) through the induction of 
Interleukin-1β (IL-1β) or Tumour necrosis factor-α (TNF-α)846 (Figure 6-71). AP-1 proteins control 
cellular cycle through the regulation of Cyclin D1, p53, p21, p19 and p16. The tumour suppressor p53, 
found in elevated levels in diseases such as endometriosis, is modulated by AP-1
847
. 
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FIGURE 6-70 
 
NF-κβ and activating protein-1 pathways848 
 
FIGURE 6-71 
 
Death receptor activation pathways785 
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7 Galectin as a therapeutic target in endometriosis - therapeutic 
experimentations  
7.1 Introduction 
Galectin-3 levels have been documented in endometriosis and levels were found to be elevated in my 
tissue microarray studies (4.4.3.7). In this study increased level of Cyclin D1 in endometriosis tissues was 
confirmed. Cyclin D1 is a substrate on which tested therapeutics such as GCS-100 are known to act, 
increasing the evidence of the potential use of a galectin-3 inhibitor as a novel therapeutic medication 
(Chapter 7). In vitro therapeutic experiments were carried out on primary ovarian and peritoneal 
endometriosis cells as well as normal uterine endometrial cells taken at laparoscopy to assess for cellular 
response to GCS-100 in endometriosis. 
7.2 Aims 
 To explore novel and alternate methods of treatment for endometriosis in an in vitro and in vivo 
setting 
7.3 Method 
7.3.1 In vitro studies on potential therapeutics 
Therapeutic studies were performed on fresh patient endometriosis cell samples taken at laparoscopy. 
Cells were processed as described above (primary patient cellular sample preparation (2.10.2)). They 
were transferred to a 96 well plate at a concentration of 1x10
5 
viable cells in 80µl of growth medium per 
well. The 96 well plate was left in the cell incubator overnight at 5% CO2 and 37°C to allow cells to 
acclimatise to their new environment and settle at the base of the plate. The ovarian endometriosis, 
cutaneous/peritoneal endometriosis and normal endometrial uterine cells were placed separately into 96 
well plates in preparation for therapeutic studies. 20µl of each drug at a specified concentration was 
added to each 80µl well containing cells in culture. Each therapeutic experiment was run in triplicate to 
strengthen result validity. Etoposide was added at different micro molar concentrations in respective wells 
(0.1µM, 1µM, 5µM, 10µM, 25µM, 50µM) as the standardised control cytotoxic agent to induce cellular 
death during experimentation. Three wells on each plate contained untreated cells (blank triplicates) to act 
as positive controls (Table 7-1). 
Gene, protein and miRNA expression in women with endometriosis 
333 
TABLE 7-1 
 
1 2 3 4 5 6 7 8 9 10 11 12 
a Blank triplicate Ovarian untreated cells Ovarian etoposide 0.1 Ovarian etoposide 1 
b Ovarian etoposide 5 Ovarian etoposide 10 Ovarian etoposide 25 Ovarian etoposide 50 
c Ovarian treated 10 Ovarian treated 25 Ovarian treated 50 Ovarian treated 100 
d Ovarian treated 250 Ovarian treated 500 Ovarian treated 750 Ovarian treated 1000 
e Cutaneous untreated cells Cutaneous etoposide 0.1 Cutaneous etoposide 1 Cutaneous etoposide 5 
f Cutaneous etoposide 10 Cutaneous etoposide 25 Cutaneous etoposide 50 Cutaneous treated 10 
g Cutaneous treated 25 Cutaneous treated 50 Cutaneous treated 100 Cutaneous treated 250 
h Cutaneous treated 500 Cutaneous treated 750 Cutaneous treated 1000 
 
An example of the setup of a 96 well plate with 32 triplicate experiments for different therapeutic concentrations. This 
demonstrates the setup of the plate at initial therapeutic concentrations in µg/mL 
 
Galectin-3 inhibitor (GCS-100) and NADPH oxidase enhancers, (CO-AAW1, PK-11195 and CO-
AAW14) were respectively tested on normal uterine endometrial cells, ovarian endometriosis cells and 
peritoneal endometriosis cells. Each experiment was repeated in triplicate wells over 12, 24, 48 and 72 
hours post treatments (7.3.1).The tested drugs were diluted to these respective concentrations (10µg/mL, 
25µg/mL, 50µg/mL, 100 µg/mL, 250µg/mL, 500µg/mL, 750µg/mL and 1000µg/mL). The FLUORstar 
OPTIMA a fully automated 96 fluorescence microplate based multi-detection reader (operating protocol 
by BMG Labtech) was used to scan the well plates and assesses for cellular viability. This was performed 
by reading fluorescence output levels that indicate the presence of ATP in viable cells.  The 96 well plates 
were read at 24, 48, 72 and 96 hours respectively to assess for timed therapeutic responses of the treated 
cells. The fluorescence outputs read by the FLUORstar OPTIMA for each respective well were compared 
between treated and untreated cells at various concentrations and across the defined timelines. All the 
output levels of fluorescence were then exported to an excel sheet and graphs plotted with the data. 
Results of these experiments are plotted and discussed further on in the thesis (Figure 7-6, Figure 7-7, 
Figure 7-8 and Figure 7-9 in Section 7). Graphs showing the results of percentage cell survival in the 
treated and untreated groups were plotted below (Figure 7-6) 
7.3.2 Zebrafish in vitro studies 
Attempts at creating in-vivo models of endometriosis using Zebrafish (Brachydanio rerio or Danio rerio) 
wild type AB strain as host organisms were performed. If successful, treating host Zebrafish in vivo with 
the therapeutics identified would give an insight as to in vivo therapeutic effects on disease. Cells from 
normally sited endometrium (control cells) and endometriosis (case cells) were processed from primary 
patient samples obtained at surgery (Section 2.10) and stained with Invitrogen™ fluorescent tracker 
probes for long-term tracing of living cells. A Femtojet microinjector was used for cell injection of 
sample cells directly into the embryonic tissues. Embryos with cells injected into the bloodstream or yolk 
sac were excluded as misinterpretation of cellular dissemination through the circulatory route could occur 
(Figure 7-1, Figure 7-2). 
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FIGURE 7-1 
 
Correctly injected fluorescent labelled endometriosis cells 
 
FIGURE 7-2 
 
Images of injected fish embryos as seen through the microscope 
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Non excluded embryos were analysed 24 to 48 hours post injection by fluorescence microscopy to select 
those which were morphologically normal and containing fluorescent cells. Preliminary images were 
obtained using the fluorescence stereomicroscope Leica MZ FL III Fluo Combi™ bearing appropriate 
filters and a fluorescence microscope Leitz Aristoplan coupled with a Leica D-LUX camera. Cellular 
viability, migration patterns and embryonic infiltration were assessed. Confirmation of the presence of 
cellular viability and migration was obtained (Figure 7-3, Figure 7-4, Figure 7-5). 
FIGURE 7-3 
 
Images of injected fish embryos as seen through the microscope 
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FIGURE 7-4 
 
Images of injected fish embryos as seen through the microscope with fluorescent markers 
 
FIGURE 7-5 
 
Images of injected fish embryos as seen through the microscope with fluorescent markers 
 
Endometriosis cellular survival could not be maintained over the 24 hour post injection. Whereas tumour 
cells have the ability of accelerated division and invasion, enabling them to grow successfully in the 
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zebrafish animal model, endometriosis cells were adherent and slow growing in vitro. This could possibly 
explain why the model could not be maintained. Discussions and collaborations were held with experts in 
the field and alterations in fish tank water temperature to accommodate for optimal cellular growth 
conditions resulted in embryonic disfigurement and demise. After multiple unsuccessful attempts at the 
creation of this in vivo model, a choice was made to continue pursuing the in vitro experimentation for 
therapeutic responses albeit recognising its limits in the mimicking of a living organism. 
7.4 Results 
From this set of experiments at 72 hours post treatment with GCS-100 there was an observed direct dose 
dependant relationship between treated endometriosis cells and percentage cell survival (Figure 7-6). Of 
note, untreated cells maintained viability supporting GCS-100 as a potential future therapeutic in 
endometriosis. The experiments using alternate compounds CO-AAW1, CO-AAW14 and PK11195 did 
not show similar tissue responses (Figure 7-7, Figure 7-8, Figure 7-9). 
7.4.1 GCS-100 
FIGURE 7-6  
0
20
40
60
80
100
120
T10 T50 T100 T125 T150 T175 T200
Ovarian Endometriosis Treated 72h
%of alive % of dead % untreated  
0
20
40
60
80
100
120
T10 T50 T100 T125 T150 T175 T200
Cutaneous Endometriosis Treated 72h
%of alive % of dead % untreated  
Graphs depicting % cell survival between treated and untreated endometriosis cells with GCS-100 
 
This figure demonstrates a direct dose dependant effect on Ovarian endometriosis cells at 72 hours of 
culture. Whereas the untreated cells maintain viability throughout the experiment, responses to GCS-100 
resulting in cell death are seen from concentrations around 20µg/mL. The cell death % increases 
proportionally to the drug dose levels reaching almost 100% cell death at 150µg/mL (T150). Further in 
vivo experimentation could be undertaken as a future body of work to assess GCS-100 as a potential 
novel therapeutic for endometriosis treatment. 
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7.4.2 CO-AAW1 
FIGURE 7-7 
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Graphs depicting % cell survival between treated and untreated endometriosis cells with CO-AAW1 
 
These graphs fail to demonstrate a dose dependant effect of treatment with CO-AAW1 on endometriosis. 
No correlation or response is seen to this drug treatment at any stage of the cellular culture (24 hrs, 48 hrs, 
72 hrs or 96 hrs) or to any drug dose. These preliminary tests indicate it is unlikely for CO0AAW1 to 
have any benefit as a therapeutic in endometriosis. 
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7.4.3 PK11195 
FIGURE 7-8 
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Graphs depicting % cell survival between treated and untreated endometriosis cells with PK11195 
 
These graphs fail to demonstrate a dose dependant effect of treatment with PK11195 on endometriosis. 
No correlation or response is seen to this drug treatment at any stage of the cellular culture (24 hrs, 48 hrs, 
72 hrs or 96 hrs) or to any drug dose. These preliminary tests indicate it is unlikely for PK11195 to have 
any benefit as a therapeutic in endometriosis. 
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7.4.4 CO-AAW14 
FIGURE 7-9 
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Graphs depicting % cell survival between treated and untreated endometriosis cells with CO-AAW14. 
 
These graphs fail to demonstrate a dose dependant effect of treatment with CO-AAW14 on 
endometriosis. No correlation or response is seen to this drug treatment at any stage of the cellular culture 
(24 hrs, 48 hrs, 72 hrs or 96 hrs) or to any drug dose. These preliminary tests indicate it is unlikely for 
CO-AAW14 to have any benefit as a therapeutic in endometriosis. 
7.5 Discussion 
7.5.1 GCS-100 
GCS-100 is a novel therapeutic that competes against galectin-3, but not galectin-1, off tumour cell 
surfaces
.
 Manufacturing is required for anti-tumour activity as the unmodified pectin has no anti-tumour 
activity. GCS-100 binds galectin-3 and has a role in anti-apoptosis, anti-angiogenesis and inhibits cellular 
migration (Figure 7-10). 
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FIGURE 7-10 
  
Effects of GCS-100 on cellular function. 
 
In cancers, GCS-100 has a potent anti-myeloma effect where it inhibits cellular proliferation, induces 
apoptosis, prevents cell cycle progression and reduces mcl-1 and bcl-xL whilst inducing noxa. It 
upregulates p21, downregulates cyclin D1, cyclin E2 and interrupts NFκB and akt signalling. The GCS-
100 has been identified as a new class of therapeutic molecule as a Galectin 3 antagonist and is already in 
use for treatment of CLL patients with poor prognostic outlooks who have attempted and not responded 
optimally to prior therapy. It controls cellular activity related to apoptosis and induces in vivo induction 
of caspases 8 and 9. It has no myelotoxicity, an acceptable toxicity profile and is also acceptable for 
elderly CLL. In view of these properties it could be a potentially acceptable treatment in severe forms of 
endometriosis in women wishing to maintain their fertility. Further trials would be necessary to confirm 
this in the clinical setting. 
FIGURE 7-11 
 
Galectin-glycan lattice formations849 
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Carbohydrates cover the outer cellular surface acting as marker tags to the microenvironment they are in. 
Carbohydrates are also the trigger for inflammatory reactions within the body and modified or synthetic 
carbohydrates as well as antibodies have all been used in the attempt of altering cellular functions and 
controlling disease. Tumorigenic cells utilize carbohydrates to mimic the body’s ‘normal’ cells and  
escape destruction by the body’s immune system. It is once again, these carbohydrates that are involved 
in inter and intra cellular interactions. 
Lectins are highly specific sugar binding proteins, able to detect changes between complex carbohydrate 
structures
850
. It is this ability that enables them to identify sugars which trigger cellular attachment, 
migration or invasion
850
. The ability of their monosaccharide units to link in a non-linear fashion at 
multiple points forming branches enable them to act as cell adhesion and interaction molecules making 
them an interesting focus for investigations 
850
. 
Galectins are water-soluble proteins and members of the animal lectin family, originating more than 800 
million years ago. They were discovered in 1981 in the electric organ of the electric eel Electrophorus 
electricus
851
. and have conserved their protein architecture and specificity
852
 exhibiting specificity for 
galactosides
852
 binding to β-galectosides849 via their carbohydrate-binding domain (CRD). CRD’s are 
composed of around 130 amino acids responsible for carbohydrate binding. They are able to decipher 
glycocodes which are sugar structures, triggering certain processes in a given circumstance. Outside the 
cellular environment they will cause effects on cellular processes by binding to cell surface and 
extracellular matrix glycans
849
 intracellularly. Within the cytosol or cell nucleus, they can regulate 
cellular functions and intracellular pathways via protein-protein interactions between nucleus and 
cytosol
849
. Their biological roles are difficult to specify as they correspond to a multitude of diverse 
biological processes
852
. In total around 15 mammalian galectins have been reported
849,853
, of which the 
best studied are galectin-1 and galectin-3. As yet, there are no characteristic endothelial cell-surface 
receptors for galectins, though, known ligands include the polylactosamine glycan-containing proteins: 
laminin, fibronectin, lamp-1, lamp-2, mucin, mac2-binding protein, integrin, CD43, CD45, Cytokeratins 
and IgE
854
. 
In 1981, Raz et al. observed that cancer cells aggregated in the presence of glycoproteins like asialofetuin 
and their protein extracts caused haemagglutination
855
. In 1986, the development of a monoclonal 
antibody to asialofetuin in B16 melanoma cells, inhibited tumour cell aggregation and adhesions
856
. Since 
then studies showing the expression of galectin-1 and galectin-3 in colon, thyroid and breast carcinomas 
has been shown, with the expression of galectin-1 being associated with metastatic and poorly 
differentiated phenotypes. Reports exist showing the association of galectin-3 and head and neck, thyroid, 
endometrial, gastric, colon and breast cancers. Reports on colon and breast are conflicting
850,857
. 
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FIGURE 7-12 
 
High Resolution X-Ray Structure of Human Galectin-3 in complex with LacNAc (N-Acetyllactosamine)- the key 
glycocode for galectins858 
 
Galectin-3 (Figure 7-12, Figure 7-13) is a member of the family of lectins and is a member of the b-
galactose binding protein family. It is structurally, Y shaped making it different to other proteins in its 
function. It is the only galectin member known so far to have a carbohydrate binding domain (similar to 
other galectins) with a 20-residue long nonlectin N-terminal 
850
 and another domain composed of Pro-
Gly-Tyr-rich repeating units
850
 and is encoded for by the gene LGALS3 on Chromosome 14, locus q21-
q22
853,859
. 
FIGURE 7-13 
Galectin-3 structure 
 
Diagram illustrating the Galectin-3 structure 
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It is approximately 30kDa and contains a carbohydrate- recognition binding site composed of 130 amino 
acids which allow the specific binding to β-galactosides860-862. The phosphorylation of galectin-3 reduces 
the binding to its ligands acting as a controlling mechanism for its binding
863
. 
Galectin 3 is a protein expressed in many types of human cells, especially those of the epithelial and 
immune systems
864
. It is synthesized in the cytoplasm and shuttles between cytoplasm and nucleus 
(monomer/dimer). It can be secreted onto the cell surface (multimer) and biological fluids. In the 
cytoplasm it binds to Bcl-2 to inhibit apoptosis and is involved in Kirsten rat sarcoma viral oncogene 
homolog (K-Ras) and rat sarcoma viral oncogene homolog (Ras) mediated Akt signalling 
(dephosphylates AKT). In the nucleus it forms part of the spliceosome assembly via Germin4 and 
upregulates gene transcription. It is expressed in immune cells, epithelial cells and sensory neurons. 
MMP-2 and MMP-9 matrix metalloproteases mediate proteolysis of galectin-3 in conjunction with p53. 
Galectins, due to their cellular interactions, affect cellular growth and survival and control processes 
important for the development of invasive pathology. Galectin-3 also has a role in cell cycling and causes 
Ras activation of Phosphatidylinositide 3-kinases (PI3-K) and Raf-1. It promotes cell cycling by causing 
b-catenin activation to enhance cyclin D and c-MYC. It has a role in avoidance of immune surveillance 
by extracellular binding to N-Glycans of monocytes and T cell to induce apoptosis. In metastasis, cells 
need to detach from the primary tissue, and intravasate into tissues or blood vessels using the cell-matrix 
adhesion processes. The basement membrane and cell matrix is composed of laminin, fibronectin and 
collagen IV. Galectin-3 promotes neutrophil attachment to fibronectin and laminin to varying degrees in 
different tissues
865
 with tissues having varied amounts of receptors for galectin-3. It is responsible for 
tumour adhesion to the extracellular matrix resulting in cytokine release (EGFR, TGFbR). It also binds to 
transmembrane mucin MUC1 to create ‘nicks’ and cell adhesion in vasculature and results in vascular 
endothelial growth factor (VEGF) activation. Experiments with Matrigel, a three dimensional matrix 
derived from basement membrane have shown that Galectin-3 increases cellular invasiveness of breast 
cancer cells in vitro
866
 and is also responsible for inducing tumour angiogenesis both in vitro and in vivo 
allowing for cellular dissemination from the original tumour site
867
. Galectin-3 has also been shown to 
mediate the aggregation of tumour cells forming emboli when induced by the multivalent glycoprotein 
Asialofetuin
868,869
. It is the only galectin which contains the NWGR domain of the Bcl-2 family which is 
an anti-apoptotic
870
 and may be responsible for the metastatic cell survival of ectopic tissue and 
infiltrative tumours. Other Galectins such as Galectin-1 induces T-cell apoptosis thereby protecting 
tumour cells from T-cell destruction
857
. 
Galectin-3 is over-expressed in human cancer cells of several tissue origins and facilitates their survival, 
growth, proliferation and migration. It acts as an anti-apoptotic protein protecting cells such as T-cells, 
macrophages and breast cancer cells from triggers of apoptosis
871
. Studies have indicated that increased 
levels of circulatory galectin-3 is found in cancer patients and these levels can help in metastasis by 
enhancing cellular adhesion and avoiding immune surveillance
864
. Over-expression of galectin-3 
correlates with tumour aggressiveness and relapse in multiple human cancers
 
and its expression via 
transfection in animal models increases metastasis. In galectin-3
-/- 
vs. wild-type mice
, 
lung tumorigenesis 
is reduced. In breast cancer studies, inhibition of Galectin-3 in mouse models showed breast cancer cell 
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loss of anchorage and serum independent growth. A similar pattern was observed in thyroid papillary 
cancer models. 
Studies assessing for mRNAs have shown that further galectins are implicated in disease and tumour 
pathology. Colorectal tumours show the presence of galectins-2, 4 and 9
872
, neural tumour cell lines 
express galectin-2 and 4
850
 whilst galectin-8 was found in almost all of the tested cell lines
872
. Other 
galectins such as galectin-12 when expressed ectopically in cancer cells cause cell cycle arrest at the G1 
phase and suppress cell growth
873
, thereby acting as a regulator for cellular homeostasis (Table 7-2). 
TABLE 7-2 
Galectin Associated Pathology 
Galectin-1 Tumour astrocyte invasion of the brain parenchyma, Induces T-cell apoptosis
857
 
Galectin-2 Fraction of Colorectal tumour cell lines, Neural tumour cell lines 
Galectin-3 Breast, Colon, Endometrial, Gastric, Head and Neck, Thyroid, Tumour astrocyte 
invasion of the brain parenchyma 
Galectin-4 Fraction of Colorectal tumour cell lines, Neural tumour cell lines 
Galectin-8 Most cell lines
872
, Tumour astrocyte invasion of the brain parenchyma 
Galectin-9 Fraction of Colorectal tumour cell lines 
Galectin-12 Ectopic expression of Galectin-12 in cancer cells causes cell cycle arrest in G1 
phase and cell growth suppression
865
. 
 
Galectin-3 is seen to be overexpressed in other diseases such as various forms of endometriosis
874
. In this 
pathology is again believed to play a role in the capacity for cellular invasion, proliferation and 
angiogenesis similar to tumorigenic mechanisms (Figure 4-23, Figure 4-25). 
7.5.2 PK11195, CO-AAW1 and CO-AAW14  
Mitochondria have been identified as central players in the process of apoptosis
875
 as the Bcl-2 family of 
proteins preventing apoptosis are localised in the outer mitochondrial membranes and regulate the release 
of proteins that would enable apoptosis
875
. Carcinoma cells such as cholangiocarcinoma cells are seen to 
express elevated levels of BcL-X(L) and Mcl-1 antiapoptotic proteins making them resistant to chemo or 
radiotherapy
875
. Subjects with moderate to severe endometriosis have shown that in the endometrium of 
women with the disease there is a higher level of expression of Bcl-2, Bax and Mcl-1
876
. These are 
believed to contribute to prolonged survival of retrograde menstrual cells with the pelvis thus developing 
the disease.  
The use of NADPH oxidase enhancer therapy aims to induce superoxides within mitochondria of tumour 
cells (independently of the peripheral benzodiazepine receptor) causing their selective apoptosis
877
. 
Compounds such as PK11195 act on the Caspase 9 apoptosis pathway, interact with mitochondria and 
result in mitochondrial superoxide generation. PK-11195 is also known as mitochondrial translocator 
protein (TSPO) and it binds selectively and with high affinity to peripheral benzodiazepine receptors 
(PBR)
878
. Like Bcl-2 peripheral benzodiazepine receptors (PBRs) reside in the mitochondria and protect 
cells from apoptotic cell death. PK11195 is seen to chemo sensitise the cells in acute myeloid leukaemias 
(AML) improving clinical outcomes
879
. CO-AAW1 and CO-AAW14 were other mitochondrial modifiers 
and NADPH oxidase enhancers which were tested on in vitro endometriosis cells. If these compounds 
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worked effectively on endometrial in vitro preliminary studies, they could potentially be explored as 
novel therapeutics in the field. 
As can be viewed from the results (Figure 7-7, Figure 7-8, Figure 7-9) there was no observed cell death 
response to treatment with CO-AAW1, CO-AAW14 and PK11195 at various concentrations and up to 96 
hours post treatments. These do not currently appear promising as potential future therapeutics in 
endometriosis however their action on eutopic endometrial cells in patients with endometriosis has not 
been explored. Potentially the reduction of Bcl-2, Bax and Mcl-1 from eutopic endometrial cells could 
render retrograde menstrual cells less likely to survive and invade, potentially preventing or reducing 
disease progression rather than causing cellular apoptosis and death.  
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8 Findings and future work  
In this thesis I have shown evidence of the EBV virus being a potential causative factor in the 
development of endometriosis. EBV-miR-BART2-5p was differentially upregulated in the endometriosis 
tissue samples when compared to other ectopic and eutopic unaffected tissue. This was confirmed by 
PCR. In situ hybridisation for EBV on tissue microarrays did not confirm the presence of EBV virus 
within the endometriotic epithelial cells (Figure 4-19) but 5 of the 42 endometriotic samples on TMA-A 
gave a positive reading for EBV presence in some of the lymphocytes seen at the base of endometriotic 
tissue infiltration. Blood taken at surgery was processed and serum and lymphocytes were subsequently 
separated. RNA extraction with quantitative PCR was performed on the serum lymphocytes to 
substantiate miRNA tissue findings. PCR on the peripheral blood monocytes confirmed overall higher 
levels of EBV DNA in the monocytes of people with endometriosis compared to controls. The surgically-
confirmed controls showed no EBV presence in the serum (Table 9-39). 
The downstream effects of EBV were explored by quantifying expression levels of E-Cadherin, Maspin, 
BCLAF-1, p53 and cyclin D1 from the endometriosis tissue microarrays. As predicted, E-Cadherin, 
Maspin and BCLAF-1 are downregulated in endometriosis whereas p53 and Cyclin D1 are elevated in 
disease. Future studies into the role of EBV and endometriosis could be undertaken. Potentially the 
exploration and use of a vaccine against EBV could prevent endometriosis formation or regress disease 
with improvement of the immune response. Immunotherapies for patients with endometriosis are another 
potential therapeutic route, allowing a healthy immune system to eliminate ectopic cells which develop 
into endometriosis. 
As Galectin-3 is seen to be elevated in many disseminative and metastatic tumours, Galectin-3 expression 
levels in endometriosis were performed with the aim of potentially using Galectin-3 inhibitors as novel 
therapeutics for the disease. Galectin-3 was upregulated in endometriotic tissues on my TMA studies. 
Subsequent in vitro endometriosis cellular experimentation from patient primary samples showed a good 
dose response to the galectin inhibitor GCS-100. This could potentially lead to novel therapeutic 
approaches to a disease which is as yet only hormonally suppressed but not eliminated. Further in vitro 
and in vivo studies on animal models are required to explore galectin inhibitor potentials as novel 
therapeutics. 
Proteomic antibody studies and miRNA extractions were performed on the serum samples with the aim of 
identifying a biomarker panel which had enough sensitivity and specificity to be used as a non-invasive 
test for the presence of disease. Evidence of differential antibody binding between cases and controls 
were noted and the top eight antibodies were explored at a molecular level to understand their interacting 
proteins and pathways. The antibodies explored included SH3GL1, aSEPT9, BCAR1, TNFRSF1A, 
TNFRSF10A, ESR1 and BIRC2. 
Endometriosis serum samples were processed for miRNA studies to identify serum miRNAs that were up 
or down regulated in patients compared to controls. The top 2 downregulated miRNAs by p-value were 
hsa-miR-150 and hsa-miR-122 whereas the top 2 upregulated miRNAs by p-value included hsa-miR-
1224-5p and hsa-miR-4274. Automated logistic regression models were run on the results obtained. A 
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combined panel composed of a combination of miR-150 and miR-574 and the addition of TPM-1 or RAN 
(has a marginal improvement) has been identified as a potential non-invasive blood test to identify 
patients enabling the avoidance of surgery. The panel combining TPM1, hsa-miR-150 and hsa-miR-574p 
gives a maximum sensitivity of 0.9 and a maximum specificity of 0.75. Care must be taken with any 
model derived from a small sample set but further studies using this biomarker panel in association with 
radiological and or clinical findings in the out-patient setting might potentially confirm this panel as a 
non-invasive diagnostic procedure. 
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9 Appendix 
TABLE 9-1 
13 upregulated miRNA in ES samples- follicular phase (see Section 4.4.1.2.1) 
Name miRNA P Value 
hsa-miR-1 (P=0.0013851) 
hsa-miR-22 (P=0.0382426) 
hsa-miR-29c (P=0.0001848) 
hsa-miR-99a (P=0.0031602) 
hsa-miR-100 (P=0.0001848) 
hsa-miR-126 (P=0.0184264) 
hsa-miR-143 (P=0.0031844) 
hsa-miR-150 (P=0.0001848) 
hsa-miR-193a-5p (P=0.0189913) 
hsa-miR-218 (P=0.0343199) 
hsa-miR-376a (P=0.0327831) 
hsa-miR-939 (P=0.0279198) 
ebv-miR-BART2-5p (P=0.0163829) 
 
TABLE 9-2 
16 downregulated miRNA in ES samples- follicular phase (see Section 4.4.1.2.1) 
Name miRNA P Value 
hsa-miR-9 (P=0.0090155) 
hsa-miR-96 (P=0.0001848) 
hsa-miR-106b (P=0.0009434) 
hsa-miR-135a (P=0.0382426) 
hsa-miR-141 (P=0.0001848) 
hsa-miR-183 (P=0.0192309) 
hsa-miR-196b (P=0.0030798) 
hsa-miR-200a (P=0.0021411) 
hsa-miR-200b (P=0.0001848) 
hsa-miR-200c (P=0.0034531) 
hsa-miR-203 (P=0.0036471) 
hsa-miR-205 (P=0.0090155) 
hsa-miR-375 (P=0.0001564) 
hsa-miR-429 (P=0.0034531) 
hsa-miR-483-3p (P=0.0009434) 
hsa-miR-875-5p (P=0.0153393) 
 
TABLE 9-3 
30 upregulated miRNA in ES samples- luteal phase (see Section 4.4.1.2.2) 
Name miRNA P Value 
hsa-miR-1 (P=0.0000075) 
hsa-miR-10b (P=0.0422002) 
hsa-miR-22 (P=0.0049591) 
hsa-miR-23a (P=0.0007025) 
hsa-miR-29c (P=0.0008691) 
hsa-miR-34a (P=0.0472068) 
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hsa-miR-95 (P=0.0015269) 
hsa-miR-99a (P=0.0003217) 
hsa-miR-100 (P=0.0000001) 
hsa-miR-126 (P=0.0002056) 
hsa-miR-129-3p (P=0.0142935) 
hsa-miR-133a (P=0.0240418) 
hsa-miR-140-3p (P=0.0015269) 
hsa-miR-140-5p (P=0.0142935) 
hsa-miR-143 (P=0.0000026) 
hsa-miR-145 (P=0.0035689) 
hsa-miR-146a (P=0.0013726) 
hsa-miR-150 (P=0.0000004) 
hsa-miR-152 (P=0.0489491) 
hsa-miR-218 (P=0.0087816) 
hsa-miR-222 (P=0.0196520) 
hsa-miR-223 (P=0.0418717) 
hsa-miR-296-5p (P=0.0108972) 
hsa-miR-320a (P=0.0054891) 
hsa-miR-342-3p (P=0.0215351) 
hsa-miR-490-5p (P=0.0019866) 
hsa-miR-520d-3p (P=0.0051538) 
hsa-miR-582-5p (P=0.0036917) 
hsa-miR-623 (P=0.0014631) 
hsa-miR-1178 (P=0.0036917) 
 
TABLE 9-4 
30 downregulated miRNA in ES samples- luteal phase (see Section 4.4.1.2.2) 
Name miRNA P Value 
hsa-let-7g (P=0.0057804) 
hsa-miR-9 (P=0.0041952) 
hsa-miR-18b (P=0.0145888) 
hsa-miR-19a (P=0.0498986) 
hsa-miR-19b (P=0.0035689) 
hsa-miR-30b (P=0.0000030) 
hsa-miR-30d (P=0.0036910) 
hsa-miR-92a (P=0.0044340) 
hsa-miR-96 (P=0.0000017) 
hsa-miR-106b (P=0.0002197) 
hsa-miR-130b (P=0.0026434) 
hsa-miR-141 (P=1.47x10
-08
) 
hsa-miR-183 (P=0.0077928) 
hsa-miR-196b (P=0.0128738) 
hsa-miR-200a (P=0.0000199) 
hsa-miR-200b (P=0.0000010) 
hsa-miR-200c (P=0.0000146) 
hsa-miR-203 (P=0.0000007) 
hsa-miR-205 (P=0.0006371) 
hsa-miR-210 (P=0.0001025) 
hsa-miR-345 (P=0.0017107) 
hsa-miR-363 (P=0.0265744) 
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hsa-miR-375 (P=0.0000004) 
hsa-miR-425 (P=0.0061429) 
hsa-miR-429 (P=0.0000067) 
hsa-miR-449a (P=0.0299261) 
hsa-miR-602 (P=0.0044340) 
hsa-miR-646 (P=0.0214837) 
hsa-miR-1266 (P=0.0007524) 
hsa-miR-1469 (P=0.0498986) 
 
TABLE 9-5 
53 upregulated miRNA in OvES samples- follicular phase (see section 4.4.1.2.4) 
Name miRNA P Value 
hsa-miR-22 (P=0.0269977) 
hsa-miR-29c (P=0.0000081) 
hsa-miR-34a (P=0.0047627) 
hsa-miR-99a (P=0.0240413) 
hsa-miR-100 (P=0.0018594) 
hsa-miR-146a (P=0.0012708) 
hsa-miR-150 (P=0.0004828) 
hsa-miR-154 (P=0.0097972) 
hsa-miR-155 (P=0.0004878) 
hsa-miR-204 (P=0.0003806) 
hsa-miR-211 (P=4.53x10
-08
) 
hsa-miR-216a (P=0.0236664) 
hsa-miR-223 (P=0.0050572) 
hsa-miR-330-5p (P=0.0000006) 
hsa-miR-371-5p (P=0.0000044) 
hsa-miR-376a (P=0.0003251) 
hsa-miR-376c (P=0.0279803) 
hsa-miR-377 (P=0.0033323) 
hsa-miR-379 (P=0.0440034) 
hsa-miR-421 (P=3.75x10
-08
) 
hsa-miR-486-3p (P=0.0023675) 
hsa-miR-493 (P=0.0008719) 
hsa-miR-507 (P=0.0088743) 
hsa-miR-514 (P=0.0013903) 
hsa-miR-517a (P=0.0246943) 
hsa-miR-520c-3p (P=3.10x10
-09
) 
hsa-miR-520g (P=0.0282320) 
hsa-miR-568 (P=0.0027626) 
hsa-miR-569 (P=4.53x10
-08
) 
hsa-miR-619 (P=0.0178596) 
hsa-miR-627 (P=0.0040777) 
hsa-miR-629 (P=2.33x10
-08
) 
hsa-miR-630 (P=0.0000098) 
hsa-miR-631 (P=0.0003168) 
hsa-miR-635 (P=0.0000154) 
hsa-miR-663 (P=0.0047797) 
hsa-miR-767-5p (P=0.0013903) 
hsa-miR-939 (P=0.0261161) 
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hsa-miR-1256 (P=0.0101225) 
hsa-miR-1262 (P=0.0018594) 
hsa-miR-1263 (P=0.0050428) 
hsa-miR-1288 (P=0.0236664) 
hsa-miR-1290 (P=0.0086393) 
hsa-miR-1297 (P=0.0430781) 
hsa-miR-1299 (P=0.0040035) 
hsa-miR-1305 (P=0.0035579) 
hsa-miR-1975 (P=0.0003998) 
hsa-miR-2110 (P=0.0489310) 
hsv1-miR-H2-3p (P=0.0077447) 
hsv1-miR-H8 (P=0.0000006) 
kshv-miR-K12-4-3p (P=0.0104343) 
kshv-miR-K12-4-5p (P=0.0081261) 
kshv-miR-K12-6-3p (P=0.0055298) 
 
TABLE 9-6 
77 downregulated miRNA in OvES samples- follicular phase (see section 4.4.1.2.4) 
Name miRNA P Value 
hsa-let-7a (P=0.0000135) 
hsa-let-7d (P=0.0013903) 
hsa-let-7e (P=2.33x10
-08
) 
hsa-let-7f (P=0.0008144) 
hsa-let-7g (P=0.0089419) 
hsa-miR-9 (P=0.0003322) 
hsa-miR-10a (P=2.33x10
-08
) 
hsa-miR-18a (P=0.0334227) 
hsa-miR-18b (P=0.0071868) 
hsa-miR-23b (P=0.0068376) 
hsa-miR-30b (P=0.0002213) 
hsa-miR-31 (P=0.0106252) 
hsa-miR-34c-3p (P=0.0497008) 
hsa-miR-34c-5p (P=0.0026755) 
hsa-miR-92b (P=0.0013903) 
hsa-miR-93 (P=0.0033802) 
hsa-miR-96 (P=0.0000055) 
hsa-miR-106a+hsa-miR-17 (P=0.0156961) 
hsa-miR-106b (P=0.0000081) 
hsa-miR-130a (P=0.0309362) 
hsa-miR-130b (P=0.0113215) 
hsa-miR-135a (P=0.0018594) 
hsa-miR-135b (P=0.0477802) 
hsa-miR-139-5p (P=6.12x10
-09
) 
hsa-miR-141 (P=6.11x10
-10
) 
hsa-miR-153 (P=0.0269977) 
hsa-miR-183 (P=0.0004793) 
hsa-miR-194 (P=0.0021532) 
hsa-miR-195 (P=0.0315490) 
hsa-miR-196b (P=0.0000012) 
hsa-miR-199b-5p (P=0.0171636) 
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hsa-miR-200a (P=0.0000001) 
hsa-miR-200b (P=3.21x10
-09
) 
hsa-miR-200c (P=0.0000001) 
hsa-miR-203 (P=0.0000354) 
hsa-miR-205 (P=0.0057847) 
hsa-miR-219-1-3p (P=0.0113388) 
hsa-miR-219-2-3p (P=0.0006949) 
hsa-miR-219-5p (P=0.0234177) 
hsa-miR-220b (P=0.0385562) 
hsa-miR-221 (P=0.0106250) 
hsa-miR-299-5p (P=0.0308716) 
hsa-miR-301a (P=0.0047474) 
hsa-miR-302e (P=0.0236664) 
hsa-miR-323-3p (P=0.0058083) 
hsa-miR-345 (P=0.0009592) 
hsa-miR-363 (P=0.0004793) 
hsa-miR-375 (P=0.0001810) 
hsa-miR-423-3p (P=0.0002109) 
hsa-miR-424 (P=0.0009592) 
hsa-miR-425 (P=0.0175318) 
hsa-miR-429 (P=0.0000010) 
hsa-miR-449a (P=0.0363696) 
hsa-miR-450a (P=0.0032276) 
hsa-miR-454 (P=0.0025762) 
hsa-miR-455-3p (P=0.0060934) 
hsa-miR-455-5p (P=0.0156961) 
hsa-miR-483-5p (P=0.0013038) 
hsa-miR-489 (P=0.0035579) 
hsa-miR-497 (P=0.0014855) 
hsa-miR-505 (P=0.0079510) 
hsa-miR-509-3p (P=0.0153506) 
hsa-miR-519d (P=0.0440034) 
hsa-miR-542-3p (P=0.0035690) 
hsa-miR-545 (P=0.0025052) 
hsa-miR-588 (P=0.0275377) 
hsa-miR-625 (P=0.0004573) 
hsa-miR-626 (P=0.0018895) 
hsa-miR-720 (P=0.0002386) 
hsa-miR-875-5p (P=0.0440381) 
hsa-miR-877 (P=0.0011233) 
hsa-miR-1260 (P=0.0089419) 
hsa-miR-1266 (P=0.0020872) 
hsa-miR-1274a (P=0.0040035) 
hsa-miR-1274b (P=0.0188569) 
hsv1-miR-H1 (P=0.0168708) 
kshv-miR-K12-6-5p (P=0.0269977) 
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TABLE 9-7 
28 upregulated miRNA in OvES samples- luteal phase (see Section 4.4.1.2.5) 
Name miRNA P Value 
hsa-miR-29c (P=0.0125318) 
hsa-miR-99a (P=0.0472493) 
hsa-miR-100 (P=0.0037619) 
hsa-miR-150 (P=0.0305308) 
hsa-miR-154 (P=0.0026819) 
hsa-miR-199a-3p+hsa-miR-199b-3p (P=0.0175525) 
hsa-miR-211 (P=0.0000008) 
hsa-miR-215 (P=0.0357541) 
hsa-miR-330-5p (P=0.0000018) 
hsa-miR-337-5p (P=0.0257030) 
hsa-miR-376a (P=0.0003855) 
hsa-miR-376c (P=0.0026819) 
hsa-miR-377 (P=0.0003556) 
hsa-miR-379 (P=0.0109079) 
hsa-miR-421 (P=4.38x10
-10
) 
hsa-miR-449b (P=0.0071211) 
hsa-miR-486-3p (P=0.0410767) 
hsa-miR-487a (P=0.0474365) 
hsa-miR-520c-3p (P=0.0000002) 
hsa-miR-569 (P=0.0000019) 
hsa-miR-629 (P=0.0000007) 
hsa-miR-630 (P=0.0121554) 
hsa-miR-635 (P=0.0118206) 
hsa-miR-767-5p (P=0.0001522) 
hsa-miR-1262 (P=0.0000005) 
hsa-miR-1263 (P=0.0023388) 
hsa-miR-1299 (P=0.0129081) 
hsv1-miR-H8 (P=0.0000644) 
 
TABLE 9-8 
26 downregulated miRNA in OvES samples-luteal phase (see Section 4.4.1.2.5) 
Name miRNA P Value 
hsa-miR-10a (P=0.0000393) 
hsa-miR-30b (P=0.0024421) 
hsa-miR-30d (P=0.0363820) 
hsa-miR-96 (P=0.0001068) 
hsa-miR-106b (P=0.0001505) 
hsa-miR-141 (P=0.0000489) 
hsa-miR-183 (P=0.0191037) 
hsa-miR-196b (P=0.0469507) 
hsa-miR-200a (P=0.0001606) 
hsa-miR-200b (P=0.0002046) 
hsa-miR-200c (P=0.0041374) 
hsa-miR-203 (P=0.0000393) 
hsa-miR-205 (P=0.0257030) 
hsa-miR-210 (P=0.0410767) 
hsa-miR-375 (P=0.0010806) 
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hsa-miR-423-3p (P=0.0026736) 
hsa-miR-425 (P=0.0015042) 
hsa-miR-429 (P=0.0422405) 
hsa-miR-509-3p (P=0.0111073) 
hsa-miR-588 (P=0.0121554) 
hsa-miR-642 (P=0.0000154) 
hsa-miR-720 (P=0.0035875) 
hsa-miR-758 (P=0.0250874) 
hsa-miR-1288 (P=0.0000277) 
hsa-miR-1911 (P=0.0022848) 
hcmv-miR-US33-3p (P=8.50x10
-13
) 
 
TABLE 9-9 
Upregulated miRNA in NP from cases- follicular phase (see Section 4.4.1.2.6) 
Name miRNA P Value 
hsa-miR-211 (P = 0.0208097) 
 
TABLE 9-10 
Downregulated miRNA in NP from cases- follicular phase (see Section 4.4.1.2.6) 
Name miRNA P Value 
hsa-miR-367 (P = 0.0139805) 
 
TABLE 9-11 
Significantly expressed miRNA in normal endometrium and fold change (see Section 4.4.1.3.1) 
Name miRNA P Value Fold Change Log Fold Change 
ebv-miR-BART8 (P=0.00505798) (FC=1.51398464) (LogFC=0.59835057) 
hsa-let-7a (P=0.00000251) (FC=1.66597274) (LogFC=0.73636479) 
hsa-let-7b (P=0.02874230) (FC=1.19786470) (LogFC=0.26046497) 
hsa-let-7e (P=0.00057974) (FC=1.70233796) (LogFC=0.76751748) 
hsa-let-7f (P=0.00000433) (FC=1.79790953) (LogFC=0.84632043) 
hsa-let-7g (P=0.00001000) (FC=1.76815166) (LogFC=0.82224203) 
hsa-miR-1 (P=0.00000008) (FC=6.29462395) (LogFC=-2.65412019) 
hsa-miR-100 (P=2.74x10
-13
) (FC=3.44456532) (LogFC=-1.78432194) 
hsa-miR-101 (P=0.04395167) (FC=1.28667492) (LogFC=-0.36364760) 
hsa-miR-106a+hsa-
miR-17 
(P=0.00003115) (FC=1.91814493) (LogFC=0.93971173) 
hsa-miR-106b (P=3.45x10
-14
) (FC=2.37745983) (LogFC=1.24942097) 
hsa-miR-10a (P=0.00000007) (FC=2.05545937) (LogFC=1.03946086) 
hsa-miR-1178 (P=0.01316635) (FC=1.81625144) (LogFC=-0.86096394) 
hsa-miR-1180 (P=0.01834692) (FC=1.36879970) (LogFC=-0.45291135) 
hsa-miR-1185 (P=0.01627138) (FC=1.39505879) (LogFC=-0.48032592) 
hsa-miR-125b (P=0.03090365) (FC=1.69368122) (LogFC=-0.76016236) 
hsa-miR-126 (P=0.00000004) (FC=2.16629361) (LogFC=-1.11522879) 
hsa-miR-1260 (P=0.01864118) (FC=2.88743529) (LogFC=1.52978861) 
hsa-miR-1262 (P=0.00090990) (FC=1.53848176) (LogFC=-0.62150734) 
hsa-miR-1263 (P=0.00309516) (FC=1.31748990) (LogFC=-0.39779190) 
hsa-miR-1266 (P=0.00000007) (FC=1.70454797) (LogFC=0.76938920) 
hsa-miR-127-3p (P=0.00342644) (FC=1.67369141) (LogFC=-0.74303355) 
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hsa-miR-1274a (P=0.00041533) (FC=4.02352296) (LogFC=2.00845926) 
hsa-miR-1274b (P=0.00091420) (FC=3.38463014) (LogFC=1.75899819) 
hsa-miR-1275 (P=0.00026765) (FC=1.54513439) (LogFC=0.62773233) 
hsa-miR-128 (P=0.01005680) (FC=1.48242508) (LogFC=0.56795920) 
hsa-miR-1281 (P=0.00946329) (FC=1.37396588) (LogFC=-0.45834618) 
hsa-miR-129-3p (P=0.00947061) (FC=10.94790396) (LogFC=-3.45258278) 
hsa-miR-1299 (P=0.01234786) (FC=1.42230363) (LogFC=-0.50822948) 
hsa-miR-1305 (P=0.03442910) (FC=1.44162000) (LogFC=-0.52769093) 
hsa-miR-130b (P=0.00000588) (FC=1.70582438) (LogFC=0.77046912) 
hsa-miR-133a (P=0.00319598) (FC=2.04985292) (LogFC=-1.03552040) 
hsa-miR-135a (P=0.00000002) (FC=3.13844656) (LogFC=1.65005065) 
hsa-miR-135b (P=0.00000461) (FC=2.29805013) (LogFC=1.20041027) 
hsa-miR-139-5p (P=0.00000447) (FC=2.25767313) (LogFC=1.17483662) 
hsa-miR-140-3p (P=0.00046038) (FC=1.57184833) (LogFC=-0.65246201) 
hsa-miR-140-5p (P=0.01687321) (FC=1.23734326) (LogFC=-0.30724578) 
hsa-miR-141 (P=1.15x10
-22
) (FC=27.10995536) (LogFC=4.76075083) 
hsa-miR-143 (P=0.00000126) (FC=2.95555221) (LogFC=-1.56342771) 
hsa-miR-144 (P=0.00729026) (FC=2.40073058) (LogFC=1.26347350) 
hsa-miR-145 (P=0.00794430) (FC=2.06035492) (LogFC=-1.04289288) 
hsa-miR-1469 (P=0.00729026) (FC=1.28232562) (LogFC=0.35876265) 
hsa-miR-146a (P=0.00000044) (FC=2.13583598) (LogFC=-1.09480086) 
hsa-miR-148a (P=0.00680033) (FC=1.29971423) (LogFC=-0.37819445) 
hsa-miR-148b (P=0.00710394) (FC=1.19567568) (LogFC=-0.25782612) 
hsa-miR-150 (P=6.92x10
-13
) (FC=4.99726455) (LogFC=-2.32113859) 
hsa-miR-151-5p (P=0.00013634) (FC=1.42348632) (LogFC=-0.50942862) 
hsa-miR-152 (P=0.00003918) (FC=1.65387694) (LogFC=-0.72585189) 
hsa-miR-154 (P=0.00000014) (FC=2.07797834) (LogFC=-1.05518062) 
hsa-miR-155 (P=0.00003660) (FC=1.68026099) (LogFC=-0.74868534) 
hsa-miR-181b+hsa-
miR-181d 
(P=0.02194210) (FC=1.20607846) (LogFC=0.27032376) 
hsa-miR-183 (P=0.00000008) (FC=1.76661962) (LogFC=0.82099144) 
hsa-miR-187 (P=0.01206995) (FC=1.38144645) (LogFC=0.46617964) 
hsa-miR-18a (P=0.00000064) (FC=2.09261706) (LogFC=1.06530833) 
hsa-miR-18b (P=0.00000007) (FC=2.21274487) (LogFC=1.14583712) 
hsa-miR-193a-5p (P=0.00022418) (FC=1.72439756) (LogFC=-0.78609243) 
hsa-miR-193b (P=0.00118296) (FC=1.67671480) (LogFC=-0.74563731) 
hsa-miR-194 (P=0.00051976) (FC=1.50342974) (LogFC=0.58825745) 
hsa-miR-196b (P=9.44x10
-13
) (FC=4.07133486) (LogFC=2.02550189) 
hsa-miR-1973 (P=0.01806446) (FC=1.43412023) (LogFC=0.52016598) 
hsa-miR-1974 (P=0.01302456) (FC=3.56667486) (LogFC=1.83457971) 
hsa-miR-1975 (P=0.00104324) (FC=2.06127647) (LogFC=-1.04353802) 
hsa-miR-199b-5p (P=0.00396826) (FC=1.51510858) (LogFC=0.59942119) 
hsa-miR-19a (P=0.00003799) (FC=1.67866553) (LogFC=0.74731481) 
hsa-miR-19b (P=0.00000399) (FC=1.76798464) (LogFC=0.82210574) 
hsa-miR-200a (P=2.80x10
-16
) (FC=8.36136228) (LogFC=3.06373801) 
hsa-miR-200b (P=1.50x10
-21
) (FC=15.24448495) (LogFC=3.93021550) 
hsa-miR-200c (P=3.04x10
-18
) (FC=33.82327084) (LogFC=5.07994428) 
hsa-miR-203 (P=2.36x10
-11
) (FC=2.41024882) (LogFC=1.26918209) 
hsa-miR-204 (P=0.00102080) (FC=2.43757903) (LogFC=-1.28544900) 
hsa-miR-205 (P=0.00000361) (FC=2.76944427) (LogFC=1.46959651) 
hsa-miR-20a+hsa-miR- (P=0.00057185) (FC=2.56299011) (LogFC=1.35782791) 
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20b 
hsa-miR-210 (P=0.00000910) (FC=2.62326433) (LogFC=1.39136319) 
hsa-miR-211 (P=0.00000250) (FC=4.55774934) (LogFC=-2.18832158) 
hsa-miR-214 (P=0.04395167) (FC=1.30330657) (LogFC=-0.38217649) 
hsa-miR-216a (P=0.01961445) (FC=1.45760169) (LogFC=-0.54359653) 
hsa-miR-218 (P=0.00124869) (FC=1.74810606) (LogFC=-0.80579272) 
hsa-miR-219-5p (P=0.00020553) (FC=1.46418538) (LogFC=0.55009822) 
hsa-miR-22 (P=0.00000001) (FC=2.13837562) (LogFC=-1.09651530) 
hsa-miR-220a (P=0.00609863) (FC=1.35786358) (LogFC=-0.44133854) 
hsa-miR-220b (P=0.01022798) (FC=1.34965902) (LogFC=0.43259497) 
hsa-miR-221 (P=0.00169890) (FC=1.43940216) (LogFC=0.52546973) 
hsa-miR-222 (P=0.00852146) (FC=1.28424145) (LogFC=-0.36091647) 
hsa-miR-223 (P=0.00000060) (FC=6.70247224) (LogFC=-2.74469334) 
hsa-miR-224 (P=0.01058583) (FC=1.25382357) (LogFC=-0.32633436) 
hsa-miR-23a (P=0.00000072) (FC=1.67649015) (LogFC=-0.74544400) 
hsa-miR-23b (P=0.00087905) (FC=1.49101153) (LogFC=0.57629141) 
hsa-miR-28-3p (P=0.01631191) (FC=1.57218877) (LogFC=-0.65277445) 
hsa-miR-28-5p (P=0.00272632) (FC=1.64608020) (LogFC=-0.71903463) 
hsa-miR-296-5p (P=0.02501809) (FC=1.23680978) (LogFC=-0.30662363) 
hsa-miR-29c (P=6.3x10
-12
) (FC=3.06372788) (LogFC=-1.61528816) 
hsa-miR-301a (P=0.00028807) (FC=1.40802930) (LogFC=0.49367736) 
hsa-miR-301b (P=0.00898576) (FC=1.32002010) (LogFC=0.40055990) 
hsa-miR-302e (P=0.00680033) (FC=1.32789486) (LogFC=0.40914092) 
hsa-miR-30b (P=0.00000011) (FC=2.34417947) (LogFC=1.22908303) 
hsa-miR-30d (P=0.02053904) (FC=1.45193484) (LogFC=0.53797671) 
hsa-miR-31 (P=0.00003557) (FC=1.98598431) (LogFC=0.98985422) 
hsa-miR-32 (P=0.04257970) (FC=30.69844914) (LogFC=4.94009387) 
hsa-miR-320a (P=0.00000011) (FC=1.69099803) (LogFC=-0.75787498) 
hsa-miR-328 (P=0.04482380) (FC=1.22842896) (LogFC=-0.29681443) 
hsa-miR-330-5p (P=0.00000025) (FC=3.24163632) (LogFC=-1.69672224) 
hsa-miR-337-3p (P=0.02042418) (FC=1.38210762) (LogFC=-0.46686996) 
hsa-miR-342-3p (P=0.02173614) (FC=1.32852773) (LogFC=-0.40982834) 
hsa-miR-345 (P=0.00000008) (FC=2.18133862) (LogFC=1.12521374) 
hsa-miR-34a (P=0.00018088) (FC=1.58942541) (LogFC=-0.66850531) 
hsa-miR-34c-3p (P=0.00193474) (FC=1.54233295) (LogFC=0.62511424) 
hsa-miR-34c-5p (P=0.00000105) (FC=2.42715114) (LogFC=1.27926395) 
hsa-miR-363 (P=0.00000629) (FC=1.69318914) (LogFC=0.75974314) 
hsa-miR-365 (P=0.02469991) (FC=1.46561829) (LogFC=-0.55150941) 
hsa-miR-371-5p (P=0.00045085) (FC=1.69488283) (LogFC=-0.76118554) 
hsa-miR-375 (P=1.87x10
-14
) (FC=6.34376647) (LogFC=2.66533966) 
hsa-miR-376a (P=0.00000014) (FC=2.11213730) (LogFC=-1.07870362) 
hsa-miR-376c (P=0.00027362) (FC=1.62504948) (LogFC=-0.70048364) 
hsa-miR-377 (P=0.00004983) (FC=1.84890286) (LogFC=-0.88666943) 
hsa-miR-378 (P=0.00618779) (FC=1.35163868) (LogFC=-0.43470954) 
hsa-miR-379 (P=0.00015049) (FC=1.39267807) (LogFC=-0.47786180) 
hsa-miR-381 (P=0.00697682) (FC=1.49068183) (LogFC=-0.57597237) 
hsa-miR-421 (P=0.00000004) (FC=2.15076029) (LogFC=-1.10484674) 
hsa-miR-423-3p (P=0.00000997) (FC=1.78939141) (LogFC=0.83946899) 
hsa-miR-423-5p (P=0.00081853) (FC=1.49420719) (LogFC=-0.57938021) 
hsa-miR-424 (P=0.00004875) (FC=2.15662398) (LogFC=1.10877466) 
hsa-miR-425 (P=0.00022842) (FC=1.40247626) (LogFC=0.48797635) 
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hsa-miR-429 (P=3.00x10
-14
) (FC=3.17689769) (LogFC=1.66761863) 
hsa-miR-433 (P=0.01234786) (FC=1.33707148) (LogFC=0.41907659) 
hsa-miR-449a (P=0.00000064) (FC=4.34121499) (LogFC=2.11809887) 
hsa-miR-450a (P=0.00000716) (FC=1.94304027) (LogFC=0.95831580) 
hsa-miR-454 (P=0.00025120) (FC=1.41272601) (LogFC=0.49848170) 
hsa-miR-455-3p (P=0.00002100) (FC=1.95771794) (LogFC=0.96917292) 
hsa-miR-455-5p (P=0.00622594) (FC=1.77929107) (LogFC=0.83130254) 
hsa-miR-483-3p (P=0.00000399) (FC=1.53144924) (LogFC=0.61489755) 
hsa-miR-486-3p (P=0.00022842) (FC=1.39297687) (LogFC=-0.47817130) 
hsa-miR-489 (P=0.03313859) (FC=1.28424696) (LogFC=0.36092266) 
hsa-miR-490-5p (P=0.00001277) (FC=1.89015222) (LogFC=-0.91850242) 
hsa-miR-493 (P=0.00113240) (FC=1.72733529) (LogFC=-0.78854815) 
hsa-miR-495 (P=0.04761080) (FC=1.32679226) (LogFC=-0.40794250) 
hsa-miR-501-3p (P=0.00047045) (FC=1.41586146) (LogFC=-0.50168011) 
hsa-miR-509-3p (P=0.00001664) (FC=1.64791112) (LogFC=0.72063844) 
hsa-miR-511 (P=0.01253795) (FC=1.72851614) (LogFC=-0.78953408) 
hsa-miR-514 (P=0.00092119) (FC=1.54583722) (LogFC=-0.62838841) 
hsa-miR-518f (P=0.03006973) (FC=291.24832021) (LogFC=8.18610592) 
hsa-miR-520c-3p (P=2.12x10
-09
) (FC=2.49012180) (LogFC=-1.31621631) 
hsa-miR-520d-3p (P=0.02062056) (FC=1.40482132) (LogFC=-0.49038665) 
hsa-miR-532-5p (P=0.00205317) (FC=1.43735131) (LogFC=-0.52341273) 
hsa-miR-542-3p (P=0.00004875) (FC=1.63741025) (LogFC=0.71141584) 
hsa-miR-542-5p (P=0.00074125) (FC=1.48395304) (LogFC=0.56944544) 
hsa-miR-545 (P=0.01243851) (FC=1.33251796) (LogFC=0.41415498) 
hsa-miR-561 (P=0.02691609) (FC=302.49915642) (LogFC=8.24078731) 
hsa-miR-569 (P=0.00000002) (FC=2.63562086) (LogFC=-1.39814285) 
hsa-miR-573 (P=0.02606924) (FC=1.58470522) (LogFC=0.66421450) 
hsa-miR-574-5p (P=0.00002085) (FC=1.55862002) (LogFC=-0.64026925) 
hsa-miR-582-5p (P=0.00935736) (FC=1.53014985) (LogFC=-0.61367294) 
hsa-miR-588 (P=0.01565072) (FC=2.45828384) (LogFC=1.29765150) 
hsa-miR-623 (P=0.00132349) (FC=1.63377067) (LogFC=-0.70820548) 
hsa-miR-626 (P=0.00000611) (FC=1.75289086) (LogFC=0.80973617) 
hsa-miR-629 (P=0.00000005) (FC=1.81536281) (LogFC=-0.86025791) 
hsa-miR-630 (P=0.00000008) (FC=13.15819204) (LogFC=-3.71788937) 
hsa-miR-631 (P=0.00132349) (FC=1.53182821) (LogFC=-0.61525452) 
hsa-miR-635 (P=0.00000187) (FC=2.33055858) (LogFC=-1.22067578) 
hsa-miR-646 (P=0.00020230) (FC=1.65563126) (LogFC=0.72738140) 
hsa-miR-663 (P=0.00129955) (FC=2.27550352) (LogFC=-1.18618582) 
hsa-miR-718 (P=0.02830143) (FC=1.36829178) (LogFC=-0.45237591) 
hsa-miR-720 (P=0.00000150) (FC=18.57641488) (LogFC=4.21540019) 
hsa-miR-758 (P=0.03839556) (FC=1.19579837) (LogFC=0.25797415) 
hsa-miR-767-5p (P=0.00208784) (FC=1.54925411) (LogFC=-0.63157379) 
hsa-miR-874 (P=0.00011429) (FC=1.47665695) (LogFC=-0.56233470) 
hsa-miR-875-5p (P=0.00078619) (FC=1.34808178) (LogFC=0.43090802) 
hsa-miR-876-3p (P=0.04478845) (FC=1.68743170) (LogFC=0.75482911) 
hsa-miR-885-5p (P=0.00710394) (FC=1.63775384) (LogFC=0.71171853) 
hsa-miR-891b (P=0.02514101) (FC=1.35399557) (LogFC=0.43722302) 
hsa-miR-9 (P=0.00000014) (FC=2.89372490) (LogFC=1.53292778) 
hsa-miR-92a (P=0.00312487) (FC=1.73407725) (LogFC=0.79416817) 
hsa-miR-92b (P=0.00003723) (FC=1.79495916) (LogFC=0.84395102) 
hsa-miR-93 (P=0.00002100) (FC=1.97920113) (LogFC=0.98491823) 
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hsa-miR-95 (P=0.00039672) (FC=1.45269534) (LogFC=-0.53873217) 
hsa-miR-96 (P=5.25x10
-14
) (FC=2.69472569) (LogFC=1.43013842) 
hsa-miR-98 (P=0.00205317) (FC=1.44392032) (LogFC=0.52999113) 
hsa-miR-99a (P=1.67x10
-10
) (FC=2.39671054) (LogFC=-1.26105568) 
hsv1-miR-H2-3p (P=0.03442910) (FC=1.41747184) (LogFC=-0.50332007) 
hsv1-miR-H8 (P=0.00610583) (FC=1.47639445) (LogFC=-0.56207822) 
kshv-miR-K12-4-5p (P=0.03794050) (FC=1.26614194) (LogFC=-0.34043915) 
kshv-miR-K12-6-5p (P=0.00123390) (FC=4.48259537) (LogFC=2.16433428) 
 
TABLE 9-12 
Significantly expressed miRNA in normal peritoneum and fold change (see Section 4.4.1.3.2) 
Name miRNA P Value Fold Change Log Fold Change 
ebv-miR-BART15 (P=0.03166570) (FC=4.44982929) (LogFC=-2.15374999) 
hcmv-miR-UL70-5p (P=0.03213399) (FC=1.30856848) (LogFC=0.38798943) 
hcmv-miR-US33-3p (P=0.00377182) (FC=1.64159489) (LogFC=0.71509815) 
hsa-let-7c (P=0.04760847) (FC=1.46702381) (LogFC=0.55289229) 
hsa-miR-1 (P=0.00007755) (FC=4.39948016) (LogFC=2.13733307) 
hsa-miR-100 (P=0.00026365) (FC=1.81437699) (LogFC=0.85947425) 
hsa-miR-10a (P=0.00000862) (FC=1.95062707) (LogFC=0.96393798) 
hsa-miR-10b (P=0.02152117) (FC=1.46442049) (LogFC=0.55032986) 
hsa-miR-1178 (P=0.03166570) (FC=1.84276887) (LogFC=0.88187513) 
hsa-miR-1180 (P=0.04760847) (FC=1.36242964) (LogFC=0.44618173) 
hsa-miR-1246 (P=0.00427491) (FC=850.56155731) (LogFC=-9.73227184) 
hsa-miR-126 (P=2.28x10
-09
) (FC=2.65596044) (LogFC=1.40923366) 
hsa-miR-1261 (P=0.04026781) (FC=1.42943613) (LogFC=-0.51544616) 
hsa-miR-1262 (P=0.00239241) (FC=1.58374676) (LogFC=-0.66334167) 
hsa-miR-1263 (P=0.04088867) (FC=1.25645341) (LogFC=-0.32935717) 
hsa-miR-1268 (P=0.01711734) (FC=1.33957558) (LogFC=0.42177598) 
hsa-miR-1269 (P=0.00498693) (FC=1.47009977) (LogFC=0.55591407) 
hsa-miR-1290 (P=0.03166570) (FC=1.86392067) (LogFC=-0.89834046) 
hsa-miR-1299 (P=0.00146646) (FC=1.66565664) (LogFC=-0.73609103) 
hsa-miR-1305 (P=0.00050420) (FC=1.95758721) (LogFC=-0.96907658) 
hsa-miR-133a (P=0.00004862) (FC=3.15376370) (LogFC=1.65707457) 
hsa-miR-134 (P=0.00073619) (FC=1.44028363) (LogFC=0.52635294) 
hsa-miR-135a (P=0.00001016) (FC=2.67884029) (LogFC=-1.42160857) 
hsa-miR-135b (P=0.00071256) (FC=2.00665672) (LogFC=-1.00479384) 
hsa-miR-138 (P=0.01711734) (FC=1.30080216) (LogFC=-0.37940156) 
hsa-miR-139-5p (P=0.00000068) (FC=2.84681614) (LogFC=1.50934932) 
hsa-miR-140-3p (P=0.00013886) (FC=1.77409020) (LogFC=0.82707936) 
hsa-miR-140-5p (P=0.02050398) (FC=1.27109414) (LogFC=0.34607088) 
hsa-miR-141 (P=1.87x10
-13
) (FC=8.78104414) (LogFC=-3.13439250) 
hsa-miR-142-5p (P=0.00508732) (FC=2.11255675) (LogFC=-1.07899010) 
hsa-miR-143 (P=0.00378696) (FC=2.06365873) (LogFC=1.04520441) 
hsa-miR-145 (P=0.00155893) (FC=2.68110576) (LogFC=1.42282813) 
hsa-miR-150 (P=0.00108959) (FC=2.03478580) (LogFC=1.02487693) 
hsa-miR-151-3p (P=0.00062258) (FC=1.45591663) (LogFC=0.54192774) 
hsa-miR-151-5p (P=0.04474434) (FC=1.24925157) (LogFC=0.32106403) 
hsa-miR-152 (P=0.04744256) (FC=1.33653928) (LogFC=0.41850224) 
hsa-miR-1538 (P=0.03236719) (FC=1.77535290) (LogFC=0.82810583) 
hsa-miR-1539 (P=0.00471221) (FC=1.55549135) (LogFC=0.63737037) 
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hsa-miR-186 (P=0.01711734) (FC=1.30314068) (LogFC=0.38199284) 
hsa-miR-18a (P=0.00992899) (FC=1.53982791) (LogFC=-0.62276913) 
hsa-miR-18b (P=0.02102226) (FC=1.45848484) (LogFC=-0.54447039) 
hsa-miR-1915 (P=0.00141685) (FC=1.59929217) (LogFC=0.67743353) 
hsa-miR-193a-5p (P=0.00022703) (FC=1.88059719) (LogFC=0.91119087) 
hsa-miR-195 (P=0.00106319) (FC=1.58519071) (LogFC=0.66465642) 
hsa-miR-199a-3p+hsa-
miR-199b-3p 
(P=0.00250134) (FC=1.49405513) (LogFC=-0.57923339) 
hsa-miR-19a (P=0.04558562) (FC=1.35054971) (LogFC=-0.43354675) 
hsa-miR-19b (P=0.00543809) (FC=1.47552565) (LogFC=-0.56122900) 
hsa-miR-200a (P=0.00008231) (FC=2.46894297) (LogFC=-1.30389351) 
hsa-miR-200b (P=5.94x10
-12
) (FC=5.59651469) (LogFC=-2.48452865) 
hsa-miR-200c (P=8.41x10
-12
) (FC=13.73103746) (LogFC=-3.77936873) 
hsa-miR-21 (P=0.00004836) (FC=2.90353576) (LogFC=-1.53781080) 
hsa-miR-210 (P=0.02033069) (FC=1.80578908) (LogFC=-0.85262939) 
hsa-miR-211 (P=0.00306621) (FC=2.93156183) (LogFC=-1.55166948) 
hsa-miR-218 (P=0.00000321) (FC=2.64151505) (LogFC=1.40136563) 
hsa-miR-219-2-3p (P=0.00689196) (FC=2.06366238) (LogFC=1.04520696) 
hsa-miR-22 (P=0.02642698) (FC=1.37972331) (LogFC=0.46437897) 
hsa-miR-220a (P=0.00304314) (FC=1.46084784) (LogFC=0.54680591) 
hsa-miR-222 (P=0.01602688) (FC=1.30859884) (LogFC=0.38802289) 
hsa-miR-224 (P=0.00002140) (FC=1.54848879) (LogFC=0.63086094) 
hsa-miR-23a (P=0.00044730) (FC=1.50491661) (LogFC=0.58968355) 
hsa-miR-296-5p (P=0.00002316) (FC=1.58041221) (LogFC=0.66030090) 
hsa-miR-29c (P=0.04358816) (FC=1.40541946) (LogFC=0.49100078) 
hsa-miR-300 (P=0.03166570) (FC=1.30906842) (LogFC=0.38854050) 
hsa-miR-301a (P=0.02023188) (FC=1.29888074) (LogFC=0.37726897) 
hsa-miR-301b (P=0.01475711) (FC=1.35535470) (LogFC=-0.43867046) 
hsa-miR-302f (P=0.03345878) (FC=1.32181872) (LogFC=0.40252433) 
hsa-miR-31 (P=0.00713714) (FC=1.67356259) (LogFC=-0.74292251) 
hsa-miR-32 (P=0.00039308) (FC=759.44619697) (LogFC=-9.56880395) 
hsa-miR-320a (P=0.00000067) (FC=1.76339502) (LogFC=0.81835569) 
hsa-miR-328 (P=0.00427006) (FC=1.38270272) (LogFC=0.46749101) 
hsa-miR-330-5p (P=0.01399704) (FC=1.88657227) (LogFC=-0.91576737) 
hsa-miR-34c-5p (P=0.00263032) (FC=1.84620376) (LogFC=-0.88456179) 
hsa-miR-361-5p (P=0.00259442) (FC=1.68836902) (LogFC=0.75563026) 
hsa-miR-363 (P=0.04853656) (FC=1.31124026) (LogFC=0.39093206) 
hsa-miR-365 (P=0.00320023) (FC=1.75953350) (LogFC=0.81519298) 
hsa-miR-371-5p (P=0.03189548) (FC=1.46832199) (LogFC=-0.55416837) 
hsa-miR-375 (P=0.00044730) (FC=2.18842713) (LogFC=-1.12989434) 
hsa-miR-376b (P=0.00277381) (FC=1.73438102) (LogFC=-0.79442088) 
hsa-miR-378 (P=0.00000293) (FC=1.84814554) (LogFC=0.88607838) 
hsa-miR-409-3p (P=0.02077483) (FC=1.48187908) (LogFC=-0.56742773) 
hsa-miR-412 (P=0.00277381) (FC=1.33629271) (LogFC=0.41823606) 
hsa-miR-421 (P=0.00004836) (FC=1.85311313) (LogFC=-0.88995096) 
hsa-miR-423-5p (P=0.00027567) (FC=1.66021005) (LogFC=0.73136578) 
hsa-miR-429 (P=0.00001818) (FC=1.86460563) (LogFC=-0.89887053) 
hsa-miR-449a (P=0.00001861) (FC=4.21583412) (LogFC=-2.07581810) 
hsa-miR-449b (P=0.00063668) (FC=1.74437606) (LogFC=-0.80271109) 
hsa-miR-452 (P=0.00907569) (FC=1.50352235) (LogFC=0.58834631) 
hsa-miR-483-3p (P=0.04410157) (FC=1.24435961) (LogFC=-0.31540347) 
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hsa-miR-487a (P=0.03166570) (FC=1.44122719) (LogFC=-0.52729777) 
hsa-miR-489 (P=0.04358816) (FC=1.31673202) (LogFC=0.39696176) 
hsa-miR-490-5p (P=0.00053905) (FC=1.78129990) (LogFC=0.83293043) 
hsa-miR-493 (P=0.04410157) (FC=1.50292090) (LogFC=-0.58776908) 
hsa-miR-496 (P=0.03434816) (FC=1.21155734) (LogFC=0.27686268) 
hsa-miR-497 (P=0.00017353) (FC=1.48540261) (LogFC=0.57085402) 
hsa-miR-501-3p (P=0.00001021) (FC=1.68641188) (LogFC=0.75395693) 
hsa-miR-505 (P=0.02752584) (FC=1.40256766) (LogFC=0.48807037) 
hsa-miR-509-5p (P=0.02050398) (FC=1.52658596) (LogFC=-0.61030883) 
hsa-miR-512-3p (P=0.04539679) (FC=1.83121699) (LogFC=0.87280275) 
hsa-miR-517a (P=0.01550478) (FC=1.76789342) (LogFC=-0.82203130) 
hsa-miR-519e (P=0.03033113) (FC=1.32323486) (LogFC=0.40406915) 
hsa-miR-520c-3p (P=0.00002140) (FC=1.99109161) (LogFC=-0.99355960) 
hsa-miR-520d-3p (P=0.00377182) (FC=1.61790615) (LogFC=0.69412793) 
hsa-miR-523 (P=0.02033069) (FC=1.38575601) (LogFC=0.47067327) 
hsa-miR-548i (P=0.04596312) (FC=1.40033405) (LogFC=0.48577102) 
hsa-miR-550 (P=0.04720322) (FC=1.27548667) (LogFC=0.35104783) 
hsa-miR-555 (P=0.02474211) (FC=1.27395781) (LogFC=0.34931750) 
hsa-miR-568 (P=0.03166570) (FC=1.38159664) (LogFC=-0.46633648) 
hsa-miR-569 (P=0.00016783) (FC=2.01589287) (LogFC=-1.01141897) 
hsa-miR-574-5p (P=0.00693101) (FC=1.38255987) (LogFC=0.46734196) 
hsa-miR-580 (P=0.00033866) (FC=1.37352548) (LogFC=0.45788368) 
hsa-miR-582-5p (P=0.00004862) (FC=2.14896536) (LogFC=1.10364222) 
hsa-miR-587 (P=0.02642698) (FC=14.47748321) (LogFC=3.85573892) 
hsa-miR-588 (P=0.00667038) (FC=3.16315816) (LogFC=1.66136569) 
hsa-miR-609 (P=0.03166570) (FC=1.28222233) (LogFC=0.35864644) 
hsa-miR-615-5p (P=0.01711734) (FC=1.37842810) (LogFC=0.46302402) 
hsa-miR-623 (P=0.00649584) (FC=1.62717936) (LogFC=0.70237328) 
hsa-miR-625 (P=0.01711734) (FC=4.71343892) (LogFC=2.23678003) 
hsa-miR-627 (P=0.04760847) (FC=1.35037162) (LogFC=-0.43335649) 
hsa-miR-629 (P=0.00345662) (FC=1.41232440) (LogFC=-0.49807151) 
hsa-miR-646 (P=0.02642698) (FC=1.43122468) (LogFC=-0.51725017) 
hsa-miR-655 (P=0.03166570) (FC=1.33959340) (LogFC=0.42179517) 
hsa-miR-759 (P=0.00371309) (FC=1.42582047) (LogFC=0.51179234) 
hsa-miR-767-5p (P=0.02050398) (FC=1.48052575) (LogFC=-0.56610959) 
hsa-miR-769-5p (P=0.00128056) (FC=1.35360314) (LogFC=0.43680482) 
hsa-miR-802 (P=0.04088867) (FC=1.31169406) (LogFC=0.39143127) 
hsa-miR-873 (P=0.00158165) (FC=1.99360769) (LogFC=0.99538154) 
hsa-miR-874 (P=0.01371266) (FC=1.34256531) (LogFC=0.42499227) 
hsa-miR-888 (P=0.01550478) (FC=1.35224836) (LogFC=0.43536015) 
hsa-miR-95 (P=0.00108959) (FC=1.48922696) (LogFC=0.57456364) 
hsa-miR-99a (P=0.00002316) (FC=1.82351238) (LogFC=0.86671999) 
hsv1-miR-H4-5p (P=0.01711734) (FC=1.23850398) (LogFC=0.30859851) 
hsv1-miR-H8 (P=0.00000007) (FC=2.54150480) (LogFC=-1.34568295) 
kshv-miR-K12-6-3p (P=0.02851070) (FC=1.37485025) (LogFC=-0.45927449) 
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TABLE 9-13 
Significantly expressed miRNA in peritoneal endometriosis and fold change (see Section 4.4.1.3.3) 
Name miRNA P Value Fold Change Log Fold Change 
ebv-miR-BART2-5p (P=0.02124769) (FC=1.44490270) (LogFC=0.53097235) 
hsa-miR-1 (P=0.02013876) (FC=2.93368027) (LogFC=1.55271164) 
hsa-miR-10a (P=0.00203621) (FC=1.70312850) (LogFC=0.76818729) 
hsa-miR-1262 (P=0.02064369) (FC=1.53933482) (LogFC=-0.62230707) 
hsa-miR-139-5p (P=0.02142404) (FC=1.76621442) (LogFC=0.82066050) 
hsa-miR-143 (P=0.02490722) (FC=2.00499997) (LogFC=1.00360221) 
hsa-miR-145 (P=0.00748715) (FC=2.70998561) (LogFC=1.43828519) 
hsa-miR-199a-3p+hsa-
miR-199b-3p 
(P=0.02500682) (FC=1.44051907) (LogFC=-0.52658876) 
hsa-miR-211 (P=0.01069430) (FC=3.04857435) (LogFC=-1.60813473) 
hsa-miR-218 (P=0.00120625) (FC=2.16212172) (LogFC=1.11244774) 
hsa-miR-220a (P=0.00748715) (FC=1.50712901) (LogFC=0.59180292) 
hsa-miR-330-5p (P=0.00572071) (FC=2.29938576) (LogFC=-1.20124852) 
hsa-miR-421 (P=0.00523286) (FC=1.65536435) (LogFC=-0.72714879) 
hsa-miR-497 (P=0.01407811) (FC=1.36887019) (LogFC=0.45298565) 
hsa-miR-520c-3p (P=0.00258764) (FC=1.76852812) (LogFC=-0.82254916) 
hsa-miR-564 (P=0.03679057) (FC=3.87816491) (LogFC=-1.95537415) 
hsa-miR-569 (P=0.00071097) (FC=2.16693340) (LogFC=-1.11565482) 
hsa-miR-623 (P=0.04123782) (FC=1.58242248) (LogFC=0.66213482) 
hsa-miR-625 (P=0.03579560) (FC=5.37709150) (LogFC=2.42682602) 
hsa-miR-629 (P=0.00120625) (FC=1.57961102) (LogFC=-0.65956934) 
hsa-miR-631 (P=0.01069430) (FC=1.61059601) (LogFC=-0.68759467) 
hsa-miR-635 (P=0.00523286) (FC=1.95335047) (LogFC=-0.96595082) 
hsa-miR-767-5p (P=0.04051340) (FC=1.53483832) (LogFC=-0.61808669) 
hsa-miR-877 (P=0.02876834) (FC=16.80983957) (LogFC=4.07123405) 
hsv1-miR-H8 (P=0.00071097) (FC=1.94775731) (LogFC=-0.96181393) 
 
TABLE 9-14 
Significantly expressed miRNA in ovarian endometriosis and fold change (see Section 4.4.1.3.4) 
Name miRNA P Value Fold Change Log Fold Change 
ebv-miR-BART15 (P=0.04274315) (FC=9.26498123) (LogFC=3.21178805) 
hcmv-miR-US33-3p (P=0.00011013) (FC=2.83049409) (LogFC=-1.50105391) 
hcmv-miR-US33-5p (P=0.00695055) (FC=5.00209455) (LogFC=2.32253233) 
hsa-let-7a (P=0.00005308) (FC=2.18209584) (LogFC=-1.12571447) 
hsa-let-7d (P=0.00057564) (FC=1.64854850) (LogFC=-0.72119633) 
hsa-let-7e (P=0.00002555) (FC=3.30773686) (LogFC=-1.72584447) 
hsa-let-7f (P=0.00172379) (FC=2.03017362) (LogFC=-1.02160311) 
hsa-let-7g (P=0.02787527) (FC=1.68910466) (LogFC=-0.75625872) 
hsa-miR-106a+hsa-
miR-17 
(P=0.01205552) (FC=2.05281418) (LogFC=-1.03760304) 
hsa-miR-106b (P=0.00005627) (FC=1.97352683) (LogFC=-0.98077613) 
hsa-miR-10a (P=7.06x10
-13
) (FC=6.82858250) (LogFC=-2.77158613) 
hsa-miR-1185 (P=0.01409928) (FC=1.84885230) (LogFC=0.88662998) 
hsa-miR-1256 (P=0.00286632) (FC=3.43541131) (LogFC=1.78048284) 
hsa-miR-1260 (P=0.00723064) (FC=8.77393890) (LogFC=-3.13322466) 
hsa-miR-1262 (P=0.00000008) (FC=3.75069011) (LogFC=1.90715607) 
hsa-miR-1263 (P=0.00000838) (FC=2.15611913) (LogFC=1.10843689) 
hsa-miR-1266 (P=0.01433699) (FC=1.51655281) (LogFC=-0.60079574) 
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hsa-miR-127-3p (P=0.04274315) (FC=1.95499755) (LogFC=0.96716680) 
hsa-miR-1274a (P=0.00541140) (FC=7.41300549) (LogFC=-2.89005858) 
hsa-miR-1274b (P=0.04448103) (FC=4.03859415) (LogFC=-2.01385317) 
hsa-miR-1278 (P=0.03209155) (FC=1.54443878) (LogFC=0.62708269) 
hsa-miR-128 (P=0.00972947) (FC=2.05271269) (LogFC=-1.03753171) 
hsa-miR-1290 (P=0.03329579) (FC=2.63164001) (LogFC=1.39596215) 
hsa-miR-1297 (P=0.01848158) (FC=3.12675153) (LogFC=1.64466458) 
hsa-miR-1299 (P=0.00001293) (FC=3.05339394) (LogFC=1.61041373) 
hsa-miR-1305 (P=0.00024794) (FC=3.03583487) (LogFC=1.60209332) 
hsa-miR-133a (P=0.01244194) (FC=3.06779640) (LogFC=-1.61720274) 
hsa-miR-134 (P=0.01351496) (FC=1.53131307) (LogFC=-0.61476927) 
hsa-miR-139-5p (P=8.17x10
-12
) (FC=11.35177854) (LogFC=-3.50484644) 
hsa-miR-140-3p (P=0.04702474) (FC=1.62467573) (LogFC=-0.70015180) 
hsa-miR-141 (P=0.00001235) (FC=5.53553258) (LogFC=-2.46872213) 
hsa-miR-142-3p (P=0.03682150) (FC=3.13276209) (LogFC=1.64743521) 
hsa-miR-145 (P=0.01129975) (FC=3.52645942) (LogFC=-1.81822044) 
hsa-miR-1539 (P=0.03300075) (FC=1.71769594) (LogFC=-0.78047468) 
hsa-miR-154 (P=0.00541140) (FC=1.95729988) (LogFC=0.96886481) 
hsa-miR-155 (P=0.00001720) (FC=2.68527870) (LogFC=1.42507183) 
hsa-miR-183 (P=0.01033006) (FC=1.60345030) (LogFC=-0.68117963) 
hsa-miR-186 (P=0.03205691) (FC=1.45853255) (LogFC=-0.54451758) 
hsa-miR-194 (P=0.00376535) (FC=1.86035545) (LogFC=-0.89557830) 
hsa-miR-195 (P=0.00115503) (FC=2.03698454) (LogFC=-1.02643503) 
hsa-miR-196b (P=0.00041998) (FC=2.89640928) (LogFC=-1.53426548) 
hsa-miR-197 (P=0.00631071) (FC=2.41107277) (LogFC=-1.26967520) 
hsa-miR-1979 (P=0.04970388) (FC=2.78997168) (LogFC=-1.48025048) 
hsa-miR-199a-3p+hsa-
miR-199b-3p 
(P=0.00012694) (FC=2.21277582) (LogFC=1.14585730) 
hsa-miR-200a (P=0.00001889) (FC=4.71909595) (LogFC=-2.23851050) 
hsa-miR-200b (P=0.00001430) (FC=4.48371093) (LogFC=-2.16469327) 
hsa-miR-200c (P=0.00113983) (FC=5.54545860) (LogFC=-2.47130677) 
hsa-miR-203 (P=0.00058047) (FC=2.04086983) (LogFC=-1.02918417) 
hsa-miR-204 (P=0.00090785) (FC=5.11456603) (LogFC=2.35461183) 
hsa-miR-21 (P=0.00140219) (FC=3.64106525) (LogFC=1.86436060) 
hsa-miR-211 (P=1.28x10
-09
) (FC=40.73298962) (LogFC=5.34812580) 
hsa-miR-215 (P=0.03676173) (FC=1.48354967) (LogFC=0.56905323) 
hsa-miR-218 (P=0.00017217) (FC=3.26712274) (LogFC=-1.70802065) 
hsa-miR-219-1-3p (P=0.00667623) (FC=25.81003296) (LogFC=-4.68986008) 
hsa-miR-219-2-3p (P=0.00008562) (FC=5.21336559) (LogFC=-2.38221503) 
hsa-miR-220a (P=0.01804971) (FC=1.62143399) (LogFC=-0.69727029) 
hsa-miR-220b (P=0.00090785) (FC=1.99775171) (LogFC=-0.99837729) 
hsa-miR-221 (P=0.02635739) (FC=1.62192245) (LogFC=-0.69770484) 
hsa-miR-223 (P=0.02037932) (FC=4.84752865) (LogFC=2.27724943) 
hsa-miR-296-3p (P=0.01351496) (FC=204.29181029) (LogFC=-7.67448756) 
hsa-miR-296-5p (P=0.00247925) (FC=1.65973992) (LogFC=-0.73095719) 
hsa-miR-29a (P=0.02864948) (FC=1.83073700) (LogFC=0.87242455) 
hsa-miR-29c (P=0.00376535) (FC=2.09582934) (LogFC=1.06752125) 
hsa-miR-301a (P=0.00050917) (FC=1.81349031) (LogFC=-0.85876903) 
hsa-miR-30b (P=0.00034310) (FC=2.68810940) (LogFC=-1.42659185) 
hsa-miR-31 (P=0.03861175) (FC=1.89767693) (LogFC=-0.92423440) 
hsa-miR-320c (P=0.03754534) (FC=31596.82496976) (LogFC=14.94749197) 
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hsa-miR-330-5p (P=6.35x10
-10
) (FC=14.06208029) (LogFC=3.81373813) 
hsa-miR-337-5p (P=0.01870955) (FC=1.93239668) (LogFC=0.95039128) 
hsa-miR-34a (P=0.00887036) (FC=1.81003861) (LogFC=0.85602048) 
hsa-miR-361-5p (P=0.00784110) (FC=2.07220478) (LogFC=-1.05116658) 
hsa-miR-363 (P=0.00048001) (FC=2.06715455) (LogFC=-1.04764626) 
hsa-miR-369-3p (P=0.03767510) (FC=1.62881316) (LogFC=0.70382112) 
hsa-miR-371-5p (P=0.00000273) (FC=3.72049974) (LogFC=1.89549642) 
hsa-miR-376a (P=0.00008291) (FC=2.64197179) (LogFC=1.40161506) 
hsa-miR-376c (P=0.00113843) (FC=2.19605364) (LogFC=1.13491330) 
hsa-miR-377 (P=0.00015672) (FC=2.82318381) (LogFC=1.49732306) 
hsa-miR-379 (P=0.01433699) (FC=1.48152977) (LogFC=0.56708762) 
hsa-miR-409-3p (P=0.02379735) (FC=1.83030133) (LogFC=0.87208119) 
hsa-miR-412 (P=0.00331150) (FC=1.56295392) (LogFC=-0.64427525) 
hsa-miR-421 (P=3.16x10
-12
) (FC=6.59762367) (LogFC=2.72194649) 
hsa-miR-423-3p (P=0.00000438) (FC=3.02951545) (LogFC=-1.59908706) 
hsa-miR-424 (P=0.02725434) (FC=2.18014226) (LogFC=-1.12442228) 
hsa-miR-425 (P=0.03585809) (FC=1.43772123) (LogFC=-0.52378396) 
hsa-miR-429 (P=0.01278033) (FC=1.75466486) (LogFC=-0.81119550) 
hsa-miR-449b (P=0.00239460) (FC=2.17647818) (LogFC=1.12199556) 
hsa-miR-450b-5p (P=0.03691754) (FC=2.04594636) (LogFC=1.03276832) 
hsa-miR-452 (P=0.02646289) (FC=1.74057844) (LogFC=-0.79956683) 
hsa-miR-454 (P=0.00034310) (FC=1.84617774) (LogFC=-0.88454145) 
hsa-miR-483-5p (P=0.00055147) (FC=4.96787661) (LogFC=-2.31262934) 
hsa-miR-486-3p (P=0.00113983) (FC=1.69599243) (LogFC=0.76212973) 
hsa-miR-489 (P=0.00087257) (FC=1.98093004) (LogFC=-0.98617793) 
hsa-miR-493 (P=0.00004817) (FC=3.50224887) (LogFC=1.80828161) 
hsa-miR-497 (P=0.00000132) (FC=2.28158651) (LogFC=-1.19003736) 
hsa-miR-505 (P=0.01173432) (FC=1.81909493) (LogFC=-0.86322083) 
hsa-miR-507 (P=0.00331150) (FC=2.07777507) (LogFC=1.05503948) 
hsa-miR-509-3p (P=0.01205552) (FC=1.70135718) (LogFC=-0.76668605) 
hsa-miR-514 (P=0.00044094) (FC=2.31775036) (LogFC=1.21272518) 
hsa-miR-517a (P=0.00401290) (FC=2.82193393) (LogFC=1.49668421) 
hsa-miR-517c+hsa-miR-
519a 
(P=0.01745716) (FC=1.59580067) (LogFC=0.67428046) 
hsa-miR-519d (P=0.03205691) (FC=1.48593033) (LogFC=-0.57136648) 
hsa-miR-520c-3p (P=6.41x10
-13
) (FC=8.76846963) (LogFC=3.13232507) 
hsa-miR-520g (P=0.00783409) (FC=5.36943217) (LogFC=2.42476953) 
hsa-miR-542-3p (P=0.04376897) (FC=1.58397276) (LogFC=-0.66354752) 
hsa-miR-545 (P=0.03650825) (FC=1.56201824) (LogFC=-0.64341130) 
hsa-miR-550 (P=0.02278982) (FC=1.54209764) (LogFC=-0.62489411) 
hsa-miR-568 (P=0.00331150) (FC=1.96519682) (LogFC=0.97467381) 
hsa-miR-569 (P=7.06x10
-13
) (FC=11.51319733) (LogFC=3.52521663) 
hsa-miR-576-5p (P=0.03925952) (FC=1.37065706) (LogFC=-0.45486766) 
hsa-miR-577 (P=0.00461837) (FC=1.78629697) (LogFC=0.83697195) 
hsa-miR-580 (P=0.01351496) (FC=1.41620522) (LogFC=-0.50203034) 
hsa-miR-582-5p (P=0.00784110) (FC=2.19718662) (LogFC=-1.13565741) 
hsa-miR-588 (P=0.00029757) (FC=11.01447486) (LogFC=-3.46132881) 
hsa-miR-604 (P=0.01020216) (FC=44.96461933) (LogFC=-5.49071835) 
hsa-miR-610 (P=0.01745716) (FC=1.58835399) (LogFC=0.66753247) 
hsa-miR-619 (P=0.02191077) (FC=1.82612430) (LogFC=0.86878497) 
hsa-miR-625 (P=0.00011013) (FC=47.23736529) (LogFC=-5.56185659) 
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hsa-miR-626 (P=0.00172379) (FC=1.99519480) (LogFC=-0.99652961) 
hsa-miR-627 (P=0.00069505) (FC=2.17518929) (LogFC=1.12114095) 
hsa-miR-629 (P=1.27x10
-11
) (FC=4.04993500) (LogFC=2.01789875) 
hsa-miR-630 (P=0.00000206) (FC=55.77586944) (LogFC=5.80156919) 
hsa-miR-631 (P=0.00002558) (FC=2.79663502) (LogFC=1.48369198) 
hsa-miR-635 (P=0.00000001) (FC=6.64105997) (LogFC=2.73141353) 
hsa-miR-663 (P=0.02284477) (FC=2.96875903) (LogFC=1.56986000) 
hsa-miR-720 (P=0.00010492) (FC=64.26142697) (LogFC=-6.00588111) 
hsa-miR-758 (P=0.02379735) (FC=1.41781663) (LogFC=-0.50367096) 
hsa-miR-767-5p (P=0.00000230) (FC=3.52047492) (LogFC=1.81577006) 
hsa-miR-873 (P=0.00469475) (FC=2.64852072) (LogFC=-1.40518679) 
hsa-miR-876-3p (P=0.03600156) (FC=2.67292678) (LogFC=-1.41842032) 
hsa-miR-877 (P=0.00115850) (FC=191.43675038) (LogFC=-7.58072400) 
hsa-miR-9 (P=0.03948874) (FC=2.09988134) (LogFC=-1.07030780) 
hsa-miR-92b (P=0.00383932) (FC=2.10020022) (LogFC=-1.07052687) 
hsa-miR-96 (P=0.00107762) (FC=1.88864082) (LogFC=-0.91734836) 
hsv1-miR-H1 (P=0.03948874) (FC=1.49996142) (LogFC=-0.58492539) 
hsv1-miR-H8 (P=6.22x10
-12
) (FC=7.30849882) (LogFC=2.86957510) 
kshv-miR-K12-6-3p (P=0.02037932) (FC=1.68877664) (LogFC=0.75597853) 
 
TABLE 9-15 
T-test results for case vs. control markers sorted by p-value order (see Section 6.4.3) 
Protein name p-value Corrected p-
value 
Fold change Log fold change 
CCNB1IP1 0.002807 1.00 0.98 -0.02 
TPM1 0.003941 1.00 1.08 0.07 
RORC 0.005463 1.00 0.96 -0.04 
TAOK3 0.006992 1.00 0.98 -0.02 
HSPD1 0.010996 1.00 0.97 -0.03 
PAX8 0.011430 1.00 0.97 -0.03 
NFYA 0.011460 1.00 0.98 -0.02 
ADSL 0.013800 1.00 1.03 0.03 
TRAF4 0.013886 1.00 0.98 -0.02 
GTF2H2 0.014579 1.00 0.98 -0.02 
USP10 0.016934 1.00 0.97 -0.03 
SRPK1 0.017187 1.00 0.96 -0.04 
CLK2 0.019237 1.00 0.98 -0.02 
CKB 0.021877 1.00 1.02 0.02 
ZNF41 0.022582 1.00 0.98 -0.02 
LYL1 0.023566 1.00 0.98 -0.02 
HRSP12 0.024406 1.00 1.03 0.03 
RB1 0.025281 1.00 0.98 -0.02 
AIFM2 0.025824 1.00 1.01 0.01 
NRAS 0.026865 1.00 1.01 0.01 
SCP2 0.027430 1.00 0.98 -0.02 
SOD2 0.027801 1.00 1.04 0.04 
PYGO2 0.028127 1.00 0.96 -0.04 
CDK17 0.030821 1.00 0.99 -0.01 
ALDOA 0.032673 1.00 1.05 0.05 
NRIP1 0.033093 1.00 0.98 -0.02 
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NAE1 0.033858 1.00 0.98 -0.02 
PHF1 0.037199 1.00 0.99 -0.01 
TRAIP 0.039599 1.00 0.98 -0.02 
FRK 0.039671 1.00 0.99 -0.01 
UCK2 0.039842 1.00 1.03 0.03 
TRIM37 0.041163 1.00 1.02 0.02 
PRPF4 0.042537 1.00 0.99 -0.01 
ATF3 0.046101 1.00 0.98 -0.02 
OAS2 0.046106 1.00 0.99 -0.01 
STUB1 0.047036 1.00 1.04 0.04 
LDB1 0.048186 1.00 0.99 -0.01 
SORD 0.050008 1.00 1.03 0.03 
LDHB 0.051880 1.00 1.05 0.05 
ZBTB16 0.053215 1.00 0.98 -0.02 
PLK4 0.053267 1.00 0.99 -0.01 
CAMKK1 0.053530 1.00 0.99 -0.01 
FIGF 0.053897 1.00 0.99 -0.01 
PTRH1 0.055434 1.00 0.99 -0.01 
NEK3 0.056092 1.00 0.99 -0.01 
PBK 0.056408 1.00 0.99 -0.01 
TPM3 0.056646 1.00 1.03 0.03 
HIPK1 0.057070 1.00 0.98 -0.02 
FUS 0.058571 1.00 0.99 -0.01 
PABPC1 0.058655 1.00 1.01 0.01 
SKAP1 0.059064 1.00 0.99 -0.01 
TESK2 0.059406 1.00 0.99 -0.01 
MYCBP 0.062102 1.00 1.04 0.04 
DNAJA1 0.062594 1.00 0.98 -0.02 
GATA3 0.062761 1.00 0.99 -0.01 
RPL32_a 0.063192 1.00 0.99 -0.01 
POU2F2 0.063701 1.00 0.99 -0.01 
TBX5 0.063718 1.00 0.98 -0.02 
RAN 0.064147 1.00 1.04 0.04 
MRPL55 0.065470 1.00 0.98 -0.02 
PSMB8 0.066103 1.00 0.98 -0.02 
ZNF256 0.066803 1.00 0.98 -0.02 
NEUROD1 0.067362 1.00 1.02 0.02 
STAU1 0.067895 1.00 0.98 -0.02 
IRAK1 0.068050 1.00 0.99 -0.01 
PXK 0.068444 1.00 0.99 -0.01 
ELMOD1 0.068633 1.00 0.99 -0.01 
KLHL12 0.069825 1.00 1.01 0.01 
FGFR2 0.072433 1.00 0.99 -0.01 
PPP4C 0.073516 1.00 0.98 -0.02 
ACVR1 0.075101 1.00 0.99 -0.01 
PMF1 0.076364 1.00 1.02 0.02 
STAP1 0.079181 1.00 0.97 -0.04 
MAK 0.079426 1.00 0.99 -0.01 
MMP2 0.080359 1.00 0.99 -0.01 
TK1 0.081251 1.00 1.02 0.02 
AK1 0.082886 1.00 1.03 0.03 
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PHF5A 0.083015 1.00 0.98 -0.02 
ZNF136 0.084197 1.00 0.99 -0.01 
SUB1 0.085490 1.00 1.02 0.02 
C9orf86 0.086850 1.00 0.98 -0.02 
GOLGA5 0.086962 1.00 0.96 -0.04 
ULK4 0.088482 1.00 0.99 -0.01 
GOT1 0.088825 1.00 1.06 0.06 
PLK2 0.090354 1.00 0.98 -0.02 
SPEG 0.093581 1.00 1.04 0.04 
TFAP4 0.094240 1.00 0.99 -0.01 
NICN1 0.094550 1.00 0.99 -0.01 
SIX1 0.096227 1.00 0.99 -0.01 
RUNX1T1 0.096594 1.00 1.05 0.05 
DUSP11 0.096795 1.00 0.99 -0.01 
HSBP1 0.096820 1.00 1.03 0.03 
TEAD2 0.097905 1.00 0.99 -0.01 
HBG1 0.098070 1.00 1.01 0.01 
ZNF169 0.098227 1.00 0.99 -0.01 
SPIB 0.101508 1.00 0.99 -0.01 
GAS7 0.101595 1.00 1.03 0.03 
SPIC 0.101600 1.00 0.99 -0.01 
SEPT9 0.102420 1.00 1.06 0.06 
MATK 0.102895 1.00 0.97 -0.03 
ELL3 0.103348 1.00 0.99 -0.01 
DBNL 0.103447 1.00 0.98 -0.02 
TOM1 0.104294 1.00 0.96 -0.04 
PYCR1 0.104565 1.00 1.04 0.04 
PTK2 0.105873 1.00 0.99 -0.01 
SH2B1 0.106135 1.00 0.97 -0.03 
UHMK1 0.106174 1.00 0.99 -0.01 
TRAF3IP1 0.106483 1.00 0.98 -0.02 
CKMT2 0.107279 1.00 1.02 0.02 
CARD8 0.108018 1.00 0.98 -0.02 
MASTL 0.109469 1.00 0.97 -0.03 
CBFB 0.109950 1.00 1.02 0.02 
KLF10 0.110097 1.00 0.99 -0.01 
TGIF1 0.111268 1.00 0.99 -0.01 
SRC 0.111374 1.00 0.99 -0.01 
C19orf50 0.111633 1.00 1.04 0.04 
ZKSCAN5 0.111805 1.00 0.99 -0.01 
IL1RN 0.113150 1.00 1.04 0.04 
RBKS 0.113307 1.00 1.02 0.02 
PDPK1_a 0.113863 1.00 0.98 -0.02 
ALOX15 0.114014 1.00 0.99 -0.02 
CA1 0.114095 1.00 1.04 0.04 
VPS4A 0.114444 1.00 0.98 -0.02 
ZKSCAN3 0.116107 1.00 0.99 -0.01 
IMPA1 0.117900 1.00 1.05 0.05 
ELF2 0.119761 1.00 0.99 -0.01 
CSNK1G2_a 0.120027 1.00 0.97 -0.03 
ZMYM2 0.120208 1.00 0.99 -0.01 
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DNM2_a 0.120485 1.00 0.97 -0.03 
DR1 0.120701 1.00 1.03 0.03 
HSP90AA1 0.120812 1.00 1.04 0.04 
SSBP4 0.122833 1.00 1.02 0.02 
CASP3 0.122956 1.00 1.01 0.01 
TCEB3 0.123697 1.00 0.99 -0.01 
FAF1 0.123772 1.00 1.02 0.02 
RET_a 0.123843 1.00 0.99 -0.01 
NFIL3 0.124791 1.00 0.99 -0.01 
MLLT6 0.125509 1.00 0.97 -0.03 
BTRC 0.126221 1.00 0.99 -0.01 
DDB1 0.126661 1.00 1.02 0.02 
MKNK1 0.127039 1.00 1.02 0.02 
CASP6 0.128854 1.00 1.04 0.04 
PHTF1 0.128947 1.00 0.99 -0.01 
OXSR1 0.129588 1.00 0.99 -0.01 
PCBD1 0.130100 1.00 1.04 0.04 
NCF2 0.130350 1.00 1.03 0.03 
BPI 0.130402 1.00 0.98 -0.02 
IRF4 0.130919 1.00 0.99 -0.01 
NUAK2 0.133718 1.00 0.99 -0.01 
HPRT1 0.133728 1.00 1.02 0.02 
FOXN2 0.134132 1.00 0.98 -0.02 
SOX10 0.134402 1.00 0.98 -0.02 
CTNNB1 0.135058 1.00 1.01 0.01 
PPP4R1 0.135170 1.00 0.99 -0.01 
FH 0.135342 1.00 1.01 0.01 
CASP10 0.136204 1.00 1.04 0.04 
GCLC 0.136875 1.00 0.99 -0.01 
TRIP6 0.137645 1.00 1.03 0.03 
RAC1 0.137871 1.00 0.97 -0.03 
GNB1 0.139308 1.00 0.99 -0.01 
PANK3 0.140779 1.00 1.02 0.02 
CKS1B 0.141110 1.00 1.04 0.04 
TAF6L 0.142368 1.00 0.99 -0.01 
NEK11 0.143246 1.00 0.99 -0.01 
VCL_a 0.143818 1.00 0.98 -0.03 
SOCS6 0.146584 1.00 0.97 -0.03 
SIVA1 0.146763 1.00 0.99 -0.01 
PSME3 0.148445 1.00 1.05 0.05 
C1D 0.149470 1.00 1.03 0.03 
LCP1 0.149534 1.00 1.03 0.03 
TGIF2 0.150022 1.00 0.99 -0.01 
IL1B 0.150519 1.00 0.98 -0.02 
MST4 0.152533 1.00 1.01 0.01 
HSF1 0.152941 1.00 1.01 0.01 
PDIK1L 0.153873 1.00 0.99 -0.01 
PPP3CC 0.154156 1.00 0.99 -0.01 
HES6 0.154676 1.00 0.98 -0.02 
UBA1 0.155584 1.00 1.02 0.02 
RPS7 0.156440 1.00 0.99 -0.01 
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CAMKK2 0.156536 1.00 0.98 -0.02 
PDK3 0.158920 1.00 0.99 -0.01 
CLK3 0.159879 1.00 0.98 -0.02 
MGC42105 0.160743 1.00 0.99 -0.01 
IFIT5 0.161973 1.00 0.99 -0.01 
ACAT2 0.163506 1.00 1.03 0.03 
TFDP2 0.163933 1.00 0.99 -0.01 
NDRG1 0.164144 1.00 0.99 -0.01 
HEXIM1 0.164628 1.00 0.98 -0.02 
MEIS3 0.164737 1.00 0.99 -0.01 
CTBP2 0.165147 1.00 0.99 -0.01 
MAPK9 0.165644 1.00 0.96 -0.04 
NME6 0.166358 1.00 0.99 -0.01 
TFG 0.168621 1.00 1.03 0.03 
SH3BGRL3 0.169277 1.00 1.04 0.03 
BRSK2 0.169837 1.00 0.99 -0.01 
DCLK2 0.170721 1.00 0.97 -0.03 
APEX1 0.171565 1.00 0.96 -0.04 
COTL1 0.174623 1.00 1.04 0.04 
TBPL1 0.175229 1.00 0.99 -0.01 
CDK2 0.175559 1.00 0.97 -0.03 
KLF12 0.175740 1.00 0.99 -0.01 
UTP14A 0.176145 1.00 1.01 0.01 
ACVR1C 0.177508 1.00 0.99 -0.01 
BAG3 0.177707 1.00 0.98 -0.02 
CHST4 0.178392 1.00 0.99 -0.01 
EIF4A2 0.178909 1.00 1.02 0.02 
AMOTL2 0.179267 1.00 0.96 -0.04 
NCOA4 0.180602 1.00 0.99 -0.01 
PLAGL2 0.180865 1.00 0.99 -0.01 
LY86 0.181431 1.00 1.01 0.01 
MTMR2 0.181763 1.00 0.99 -0.01 
RIOK2 0.182129 1.00 0.99 -0.01 
PDE4A_a 0.182835 1.00 0.98 -0.02 
FMNL2 0.183752 1.00 0.99 -0.01 
PLK1 0.184295 1.00 0.98 -0.02 
MYST2 0.185678 1.00 0.99 -0.01 
EIF4EBP1 0.185958 1.00 1.03 0.03 
ELF5 0.187441 1.00 0.99 -0.01 
LMNA 0.188709 1.00 0.97 -0.03 
GNAZ_a 0.188909 1.00 0.98 -0.02 
NPM1 0.189684 1.00 1.02 0.02 
ARRB1_a 0.191127 1.00 0.98 -0.02 
NR1D2 0.192498 1.00 0.98 -0.02 
TARDBP 0.195030 1.00 1.01 0.01 
NFKBIA 0.196295 1.00 0.99 -0.01 
TNFAIP8 0.197579 1.00 1.07 0.07 
CDK9 0.197952 1.00 0.99 -0.01 
VDR 0.198109 1.00 0.99 -0.01 
HIF3A 0.198322 1.00 0.99 -0.01 
S100A8 0.198542 1.00 1.01 0.01 
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NME7 0.198913 1.00 0.98 -0.02 
ATF5 0.199253 1.00 0.99 -0.01 
GNA15 0.199263 1.00 0.99 -0.01 
DCDC2 0.200802 1.00 0.97 -0.03 
GSTT1 0.201117 1.00 0.99 -0.01 
ATF4 0.202754 1.00 0.99 -0.01 
APOBEC3G 0.203715 1.00 1.02 0.02 
CASP3_a 0.203715 1.00 0.98 -0.02 
ZNF346 0.204347 1.00 1.02 0.02 
ASNA1 0.204865 1.00 1.01 0.01 
CXXC1 0.205840 1.00 0.99 -0.01 
MOBKL3 0.206873 1.00 1.02 0.02 
TPM4 0.207506 1.00 1.04 0.04 
CDK5R1 0.208172 1.00 0.99 -0.01 
FAM50B 0.209952 1.00 1.02 0.02 
ARHGDIB 0.212284 1.00 1.03 0.03 
IL24 0.213109 1.00 1.01 0.01 
NRF1 0.213713 1.00 0.99 -0.01 
GRK5 0.214371 1.00 0.99 -0.01 
KATNB1 0.214382 1.00 1.02 0.02 
BAG4 0.214793 1.00 1.02 0.02 
CUL1 0.215897 1.00 1.03 0.03 
PIM2 0.216470 1.00 0.98 -0.02 
ILF2 0.216553 1.00 1.04 0.04 
PPAT_a 0.217838 1.00 0.98 -0.02 
IRF2 0.218457 1.00 0.99 -0.01 
SGK2 0.218552 1.00 0.99 -0.01 
DNAJA2 0.218925 1.00 0.99 -0.01 
ZFP36L1 0.219151 1.00 0.99 -0.01 
AFP 0.220412 1.00 0.99 -0.01 
HNRNPUL1 0.223207 1.00 1.01 0.01 
ZKSCAN4 0.223826 1.00 0.99 -0.01 
SP2 0.224143 1.00 0.99 -0.01 
KRR1 0.225281 1.00 1.01 0.01 
HDAC4 0.225701 1.00 0.99 -0.01 
CCND2 0.226191 1.00 1.01 0.01 
HNF1B 0.227035 1.00 0.99 -0.01 
VAX2 0.227357 1.00 0.99 -0.01 
HSPE1 0.227578 1.00 1.04 0.04 
COPG2 0.228694 1.00 1.01 0.01 
ABCF3 0.229033 1.00 0.99 -0.01 
NR2E1 0.229481 1.00 1.01 0.01 
TLX2 0.229601 1.00 0.99 -0.01 
NME4 0.230389 1.00 1.01 0.01 
ENO1 0.230925 1.00 1.02 0.02 
TIMP3 0.231112 1.00 1.02 0.02 
BIRC3 0.231225 1.00 0.99 -0.01 
PELO 0.232862 1.00 1.01 0.01 
MCM5_a 0.233507 1.00 0.98 -0.02 
PHF11 0.233635 1.00 1.02 0.02 
STK11 0.233734 1.00 0.99 -0.01 
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MAP2K1 0.233928 1.00 1.01 0.01 
IRAK4 0.234381 1.00 1.01 0.01 
TADA3 0.235031 1.00 1.02 0.02 
FLT1_a 0.235351 1.00 0.98 -0.02 
PPARG 0.236194 1.00 0.99 -0.01 
HOXD3 0.237273 1.00 0.99 -0.01 
KLF7 0.238567 1.00 0.99 -0.01 
CSNK1G1 0.238770 1.00 0.99 -0.01 
ACTB 0.239192 1.00 0.99 -0.01 
ZNF207 0.239763 1.00 1.01 0.01 
TRIM32 0.241159 1.00 0.99 -0.01 
FEN1 0.241659 1.00 0.98 -0.02 
RPS6KA1 0.241915 1.00 0.98 -0.02 
ACVR2A 0.242105 1.00 0.99 -0.01 
ISG20 0.242188 1.00 1.02 0.02 
FANCG 0.242202 1.00 0.99 -0.01 
RFX3 0.242271 1.00 0.99 -0.01 
GALK1 0.242648 1.00 0.99 -0.01 
GAS2 0.242988 1.00 1.02 0.02 
TBL1X_a 0.243173 1.00 0.98 -0.02 
GRB10 0.243879 1.00 1.01 0.01 
SRPK2 0.244089 1.00 0.99 -0.01 
ALOX15B 0.244178 1.00 0.99 -0.01 
USF1 0.245860 1.00 1.02 0.02 
RPS2 0.246143 1.00 0.99 -0.01 
SDHB 0.247070 1.00 0.99 -0.01 
TBCK 0.247310 1.00 0.99 -0.01 
ID1 0.247365 1.00 1.03 0.02 
IP6K1 0.247489 1.00 0.99 -0.01 
GK2 0.248249 1.00 1.01 0.01 
GNG3 0.248255 1.00 1.01 0.01 
DYRK4 0.248427 1.00 0.99 -0.01 
RBM28 0.248514 1.00 1.03 0.03 
H2AFY 0.250098 1.00 1.02 0.02 
GADD45G 0.250202 1.00 0.98 -0.02 
PCK2 0.251778 1.00 0.99 -0.01 
VPS45 0.252596 1.00 1.01 0.01 
LASP1 0.253882 1.00 0.99 -0.01 
HLX 0.255035 1.00 0.99 -0.01 
CDC20 0.256359 1.00 0.98 -0.02 
CSTB 0.257047 1.00 1.01 0.01 
L3MBTL2 0.257070 1.00 1.03 0.03 
CYLD 0.257710 1.00 0.99 -0.01 
SDHC 0.257722 1.00 0.99 -0.01 
MYBL2 0.258178 1.00 0.98 -0.02 
STK25 0.258675 1.00 0.97 -0.03 
RPL37A 0.258800 1.00 1.01 0.01 
PRC1 0.259279 1.00 1.03 0.03 
EEF1G 0.260365 1.00 0.99 -0.01 
NR0B2 0.261395 1.00 0.99 -0.02 
KIF9 0.261752 1.00 1.01 0.01 
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GGPS1 0.262362 1.00 1.04 0.04 
PPP2R2C 0.262399 1.00 0.99 -0.01 
HOPX 0.262492 1.00 1.02 0.02 
C10orf119 0.263174 1.00 1.04 0.04 
CDK14 0.264239 1.00 0.99 -0.01 
NLK 0.264355 1.00 0.99 -0.01 
MAX 0.265404 1.00 1.02 0.02 
GNAI2 0.266469 1.00 0.99 -0.01 
SOD1 0.267661 1.00 1.03 0.03 
FLT1 0.267760 1.00 0.99 -0.01 
RDBP 0.268853 1.00 0.97 -0.03 
MEF2A_a 0.269091 1.00 0.98 -0.02 
CDK7 0.269164 1.00 1.01 0.01 
MAPK10 0.269271 1.00 0.99 -0.01 
GMEB2 0.272224 1.00 0.99 -0.01 
TBL1X 0.273942 1.00 1.05 0.04 
PRKRA 0.275423 1.00 0.99 -0.01 
HK1 0.275489 1.00 0.98 -0.02 
PSME2 0.276503 1.00 1.01 0.01 
MAP4K3 0.277721 1.00 0.99 -0.01 
DVL3 0.278044 1.00 0.99 -0.01 
SEPT6 0.278198 1.00 0.99 -0.01 
SRP19 0.279534 1.00 1.02 0.02 
EAPP 0.279782 1.00 0.98 -0.02 
XIAP 0.280710 1.00 0.99 -0.01 
TCEAL1 0.281697 1.00 1.02 0.02 
MEOX2 0.282380 1.00 0.99 -0.01 
EEF1A1_a 0.282500 1.00 0.98 -0.02 
FGFR10P 0.283162 1.00 1.01 0.01 
NR4A1 0.283478 1.00 0.98 -0.02 
BRD8 0.283680 1.00 0.99 -0.01 
RERG 0.284027 1.00 1.01 0.01 
EPS15 0.286553 1.00 0.98 -0.02 
DYNC1LI2 0.286588 1.00 1.02 0.02 
PRDX6_a 0.287558 1.00 0.98 -0.02 
PHLDA1 0.288883 1.00 1.05 0.05 
SSX3 0.291727 1.00 0.99 -0.01 
DSTYK 0.295776 1.00 0.99 -0.01 
KCMF1 0.296228 1.00 0.99 -0.01 
STK38L 0.296463 1.00 0.99 -0.01 
CD96 0.299897 1.00 1.05 0.05 
PDCD5 0.300040 1.00 1.02 0.02 
LTV1 0.300333 1.00 1.01 0.01 
SERPINF2 0.301303 1.00 0.99 -0.01 
CDK1 0.302697 1.00 0.99 -0.01 
SNX6 0.303669 1.00 1.01 0.01 
NSF 0.304829 1.00 1.01 0.01 
ITK 0.306096 1.00 1.01 0.01 
NFE2 0.306200 1.00 0.99 -0.01 
MAPK8 0.307603 1.00 1.01 0.01 
PIM1 0.307841 1.00 0.99 -0.01 
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STAT3 0.308259 1.00 1.01 0.01 
RHOXF2 0.308283 1.00 0.98 -0.02 
DNTT 0.308610 1.00 0.99 -0.01 
DVL2 0.309030 1.00 0.99 -0.01 
MAPK8_a 0.309208 1.00 1.01 0.01 
BFHD 0.309307 1.00 0.98 -0.02 
RPL18A 0.309732 1.00 1.01 0.01 
UBE2V1 0.311308 1.00 1.02 0.02 
NR1I2 0.311496 1.00 0.99 -0.01 
VEGFB 0.311958 1.00 1.02 0.02 
MYCBPAP 0.311968 1.00 1.01 0.01 
SCAND1 0.312826 1.00 1.01 0.01 
RRAS2_a 0.313036 1.00 0.98 -0.02 
FBXO9 0.313688 1.00 1.01 0.01 
VGLL1 0.314042 1.00 1.00 -0.00 
ZNF143 0.314160 1.00 0.99 -0.01 
PDE4A 0.316598 1.00 0.99 -0.01 
SIAH1 0.316773 1.00 0.99 -0.01 
ELK3 0.318719 1.00 1.01 0.01 
STK38 0.318770 1.00 0.99 -0.01 
NAB1 0.318798 1.00 1.00 0.00 
CDKN2B 0.319710 1.00 1.01 0.01 
HEYL 0.320843 1.00 0.99 -0.01 
ANXA1 0.320987 1.00 1.01 0.01 
PRKCZ 0.321614 1.00 1.06 0.06 
HSPA1A 0.324047 1.00 1.01 0.01 
DDR1_int 0.324310 1.00 1.01 0.01 
PPARD 0.325782 1.00 0.99 -0.01 
SFRS5 0.326242 1.00 0.99 -0.01 
STMN1 0.326455 1.00 1.02 0.02 
CDK16 0.326464 1.00 1.02 0.02 
GIPC1 0.326820 1.00 0.99 -0.01 
ENO2 0.326906 1.00 1.03 0.03 
MAZ 0.327315 1.00 1.02 0.02 
ZNF165 0.328852 1.00 0.99 -0.01 
IL1F5 0.328963 1.00 1.01 0.01 
ABI1 0.329303 1.00 1.02 0.02 
ZNF323 0.330897 1.00 0.99 -0.01 
HINFP 0.332253 1.00 0.99 -0.01 
IL1A 0.332754 1.00 0.98 -0.02 
IL18 0.333224 1.00 1.02 0.02 
ZC4H2 0.333994 1.00 0.97 -0.03 
EPHA10 0.334105 1.00 1.01 0.01 
PHKG1 0.334214 1.00 0.99 -0.01 
P4HB 0.334277 1.00 1.01 0.01 
TLK2 0.334887 1.00 1.01 0.01 
LYN 0.334940 1.00 0.99 -0.01 
ELK1 0.335158 1.00 1.02 0.02 
LIN28A 0.335860 1.00 1.01 0.01 
RIPK3 0.335948 1.00 0.99 -0.01 
EEF1A1 0.336404 1.00 1.01 0.01 
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DMRTC2 0.336429 1.00 0.99 -0.01 
SCYL3 0.336955 1.00 1.01 0.01 
RHOA 0.338240 1.00 0.99 -0.01 
CXCR4 0.339171 1.00 1.01 0.01 
BCL2A1 0.339534 1.00 1.00 -0.00 
PIR 0.340125 1.00 1.02 0.02 
PBX3 0.340661 1.00 1.00 -0.00 
THRB 0.341057 1.00 1.01 0.01 
MSN 0.342408 1.00 1.02 0.02 
BMX 0.342979 1.00 1.01 0.01 
JUNB 0.343519 1.00 1.00 -0.00 
RPL10 0.343575 1.00 0.99 -0.01 
ACSL6 0.345259 1.00 0.99 -0.01 
POLR2I 0.345820 1.00 1.00 0.00 
CDC25A 0.346295 1.00 0.99 -0.01 
ESR2 0.347802 1.00 0.99 -0.01 
PRKX 0.347965 1.00 1.01 0.01 
ERG 0.348404 1.00 1.01 0.01 
GMEB1 0.348575 1.00 1.02 0.02 
RBM6 0.348684 1.00 0.99 -0.01 
ADRBK1 0.348947 1.00 0.99 -0.01 
TNFAIP6 0.350418 1.00 0.99 -0.01 
MAP3K6 0.350723 1.00 0.99 -0.01 
GNB3 0.351041 1.00 1.00 -0.00 
PYGB 0.352123 1.00 0.99 -0.01 
PDGFRB 0.352333 1.00 1.03 0.03 
ESRRG 0.352655 1.00 1.02 0.02 
MED4 0.353662 1.00 1.03 0.03 
HAGHL 0.355442 1.00 1.01 0.01 
MTO1 0.357787 1.00 1.01 0.01 
STK32A 0.358100 1.00 1.02 0.02 
TNFRSF11B 0.358172 1.00 0.99 -0.01 
ZAK 0.358452 1.00 0.99 -0.01 
DLX4 0.360079 1.00 1.00 -0.00 
CLK4 0.361787 1.00 1.01 0.01 
MKNK2 0.362118 1.00 0.99 -0.01 
TROVE2 0.362210 1.00 1.02 0.02 
GTF2A1L 0.363761 1.00 0.99 -0.01 
PPP2R5A 0.363783 1.00 0.99 -0.01 
NR4A1_a 0.364085 1.00 0.99 -0.01 
ZNF394 0.364144 1.00 0.99 -0.01 
PQBP1 0.367481 1.00 0.99 -0.01 
CAMK2B 0.368194 1.00 1.02 0.02 
MXI1 0.368592 1.00 0.99 -0.01 
HOXA9 0.369732 1.00 1.01 0.01 
CDK5 0.370789 1.00 0.99 -0.01 
PHB2 0.371521 1.00 0.99 -0.01 
RNF7 0.372465 1.00 0.99 -0.01 
NMRAL1 0.373013 1.00 1.01 0.01 
CDK10 0.373287 1.00 0.99 -0.01 
MLLT11 0.373660 1.00 0.99 -0.01 
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ETS2 0.374266 1.00 0.99 -0.01 
BRSK1 0.374563 1.00 1.01 0.01 
RPL18 0.375302 1.00 1.01 0.01 
PDK1 0.375498 1.00 1.00 0.00 
CRYAB 0.375865 1.00 1.02 0.02 
DYRK2_a 0.376048 1.00 0.99 -0.01 
USH1C 0.378336 1.00 0.97 -0.03 
CUL4A 0.379160 1.00 1.01 0.01 
FTSJ3 0.379172 1.00 0.99 -0.01 
PRKAA2 0.379351 1.00 0.99 -0.01 
NKX2-5 0.380610 1.00 0.99 -0.01 
MLF1 0.380935 1.00 1.00 -0.00 
BOP1 0.381218 1.00 1.01 0.01 
LEF1 0.382495 1.00 0.99 -0.01 
TWIST2 0.382933 1.00 0.99 -0.01 
CLUAP1 0.383071 1.00 1.01 0.01 
MAP2K5_a 0.383229 1.00 0.99 -0.01 
TXN2 0.383351 1.00 0.99 -0.01 
PRKAG3 0.383891 1.00 1.01 0.01 
BMP7 0.383919 1.00 0.99 -0.01 
HMG20B 0.384246 1.00 0.99 -0.01 
ADRBK1_a 0.384795 1.00 0.99 -0.01 
KRT4 0.385373 1.00 0.99 -0.01 
GPHN 0.385474 1.00 0.99 -0.01 
PFN2 0.385692 1.00 1.01 0.01 
HMGN5 0.386276 1.00 0.99 -0.01 
ZNF19 0.386645 1.00 0.99 -0.01 
CNOT7 0.386950 1.00 0.99 -0.01 
CMPK1 0.387429 1.00 1.00 0.00 
ZSCAN12 0.387846 1.00 0.99 -0.01 
NAP1L1 0.388526 1.00 1.01 0.01 
PCBP2 0.388711 1.00 1.01 0.01 
BIRC5 0.388816 1.00 0.99 -0.01 
HK2 0.388989 1.00 1.01 0.01 
LZTR1 0.389454 1.00 0.99 -0.01 
PAK6 0.390310 1.00 1.02 0.02 
MAP3K2 0.391681 1.00 1.01 0.01 
ERCC2 0.391758 1.00 0.99 -0.01 
DUSP18 0.392509 1.00 1.00 -0.00 
PFKFB3 0.393114 1.00 1.02 0.02 
MIF 0.393643 1.00 1.02 0.02 
RAB11FIP3 0.394288 1.00 0.98 -0.02 
SYK 0.394591 1.00 1.00 -0.00 
SAV1 0.395319 1.00 0.99 -0.01 
ABCF1 0.395622 1.00 1.02 0.02 
ACTA1 0.395718 1.00 0.99 -0.01 
MAPK7 0.396163 1.00 0.99 -0.01 
ME2 0.397022 1.00 0.99 -0.01 
STK10 0.397273 1.00 0.99 -0.01 
CCNB1 0.398098 1.00 0.99 -0.01 
EHMT2 0.398124 1.00 1.01 0.01 
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AIM2 0.398220 1.00 0.99 -0.01 
SOCS2 0.398231 1.00 1.00 0.00 
AICDA 0.398591 1.00 1.02 0.02 
MLLT3 0.398821 1.00 0.99 -0.01 
AKT1 0.400142 1.00 1.02 0.02 
PTEN 0.400716 1.00 1.01 0.01 
MRPS30 0.402233 1.00 1.01 0.01 
NF2 0.402742 1.00 0.99 -0.01 
NFIB 0.403244 1.00 0.99 -0.01 
BLZF1 0.403749 1.00 0.99 -0.01 
SDCCAG8 0.404459 1.00 0.98 -0.02 
MITF 0.405052 1.00 1.01 0.01 
AAK1 0.405198 1.00 1.02 0.02 
MRPS26 0.405528 1.00 0.99 -0.01 
METTL3 0.405541 1.00 1.03 0.03 
CAMKV 0.405904 1.00 1.00 -0.00 
BDNF 0.406431 1.00 0.99 -0.01 
ZNF354A 0.406524 1.00 0.99 -0.01 
PAPSS2 0.406879 1.00 1.01 0.01 
RBMS1 0.408591 1.00 1.01 0.01 
SHPK 0.408700 1.00 1.01 0.01 
SMAD4 0.410416 1.00 1.01 0.01 
TPD52 0.410432 1.00 0.98 -0.02 
RPS6KA6 0.411641 1.00 1.01 0.01 
PTK2_a 0.411644 1.00 1.00 -0.00 
MLH1 0.411645 1.00 0.98 -0.03 
DUSP14 0.412199 1.00 0.99 -0.01 
GTPBP1 0.412808 1.00 0.99 -0.01 
SGSM3 0.413687 1.00 0.99 -0.01 
FOSL1 0.413891 1.00 1.00 -0.00 
ZNF70 0.414508 1.00 1.01 0.01 
MNAT1 0.414592 1.00 1.02 0.02 
SUFU 0.415958 1.00 1.01 0.01 
SOCS5_a 0.416780 1.00 0.99 -0.01 
FLI1 0.417013 1.00 0.99 -0.01 
DDR1_ext 0.418507 1.00 1.01 0.01 
WDR46 0.418591 1.00 0.99 -0.01 
SORD_a 0.419526 1.00 0.99 -0.01 
MEF2A 0.420587 1.00 1.02 0.02 
MED21 0.421009 1.00 1.00 -0.00 
RRAS 0.421472 1.00 1.00 -0.00 
RPS6KA5 0.422156 1.00 0.99 -0.01 
PC_a 0.422656 1.00 0.99 -0.01 
IFIT3 0.424852 1.00 1.02 0.02 
WDR45L 0.425047 1.00 0.99 -0.01 
PRKCI 0.427178 1.00 1.01 0.01 
PHF17 0.427217 1.00 1.02 0.02 
CYCS 0.427360 1.00 0.99 -0.01 
MYF6 0.427375 1.00 1.00 -0.00 
EZH2 0.428420 1.00 0.99 -0.01 
NR4A2 0.431811 1.00 0.99 -0.01 
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STK4 0.432684 1.00 0.99 -0.01 
ITPKB 0.433297 1.00 1.01 0.01 
STAM 0.436561 1.00 1.00 -0.00 
ACTR2 0.437699 1.00 1.02 0.02 
CARHSP1 0.438888 1.00 1.01 0.01 
ZNF496 0.439070 1.00 0.99 -0.01 
TRIB2 0.440219 1.00 1.02 0.02 
ADD1_a 0.440303 1.00 0.99 -0.01 
FRS2 0.440393 1.00 0.99 -0.01 
ZNF276 0.441651 1.00 0.99 -0.01 
NRIP3 0.442162 1.00 1.01 0.01 
SSX2 0.442212 1.00 1.01 0.01 
UBE2I 0.442229 1.00 1.02 0.02 
ZMYND8 0.442311 1.00 1.01 0.01 
NFE2L2 0.443922 1.00 1.00 -0.00 
PFKFB4 0.444712 1.00 1.01 0.01 
KRT19 0.445178 1.00 1.02 0.02 
KAT2A 0.446384 1.00 0.99 -0.01 
NDRG2 0.446804 1.00 1.01 0.01 
CBFA2T3 0.447299 1.00 1.01 0.01 
ALPK1 0.447511 1.00 1.00 -0.00 
GTF2E2 0.448449 1.00 1.00 -0.00 
AK3L1 0.448579 1.00 1.01 0.01 
THRA 0.452281 1.00 1.00 -0.00 
TBCB 0.452387 1.00 0.98 -0.02 
IMPDH1 0.452906 1.00 1.01 0.01 
FAIM 0.452946 1.00 1.01 0.01 
PDK4 0.453510 1.00 1.02 0.02 
PMVK 0.454478 1.00 1.00 0.00 
CALML4 0.455111 1.00 1.01 0.01 
SMN1 0.455215 1.00 1.00 -0.00 
PTP4A1 0.455631 1.00 0.99 -0.01 
BTG1 0.455801 1.00 0.99 -0.01 
OGG1 0.455830 1.00 0.99 -0.01 
ANXA11 0.456744 1.00 1.01 0.01 
BUB1 0.456783 1.00 1.00 -0.00 
SMAD5 0.457466 1.00 1.00 -0.00 
HOOK1 0.458028 1.00 1.01 0.01 
RPL30 0.458163 1.00 0.98 -0.02 
MNDA 0.460120 1.00 0.99 -0.01 
HSPB8 0.460360 1.00 1.02 0.02 
AURKA 0.460720 1.00 0.99 -0.01 
YWHAG 0.460981 1.00 1.02 0.02 
SNCA 0.462131 1.00 1.01 0.01 
CIDEC 0.462483 1.00 1.00 0.00 
C1orf57 0.464138 1.00 1.02 0.02 
PPP3R1 0.464442 1.00 1.00 -0.00 
MAP2K5 0.465158 1.00 0.99 -0.01 
PSMD4 0.465667 1.00 0.98 -0.02 
MYOZ2 0.466402 1.00 1.00 -0.00 
PAK7 0.467607 1.00 1.00 0.00 
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RAGE 0.467610 1.00 1.00 -0.00 
SET 0.467693 1.00 1.01 0.01 
ATG7 0.468084 1.00 1.00 0.00 
HCFC2 0.470783 1.00 0.99 -0.01 
LATS1 0.473280 1.00 1.01 0.01 
RNGTT 0.475696 1.00 0.99 -0.01 
BUD31 0.475734 1.00 0.99 -0.01 
PITRM1 0.476560 1.00 1.00 0.00 
BCKDK 0.476740 1.00 1.01 0.01 
PPP2R5C 0.476978 1.00 1.00 0.00 
AURKB 0.477415 1.00 0.99 -0.01 
NFIA 0.477781 1.00 1.00 -0.00 
CAMK1 0.477856 1.00 1.01 0.01 
BLK 0.477985 1.00 1.01 0.01 
PTPN1 0.477998 1.00 0.99 -0.01 
DEDD 0.478210 1.00 1.01 0.01 
CDKN2A 0.479703 1.00 1.01 0.01 
SCMH1 0.479785 1.00 1.00 0.00 
TCL1A 0.480925 1.00 1.04 0.04 
PIAS2 0.481404 1.00 1.00 0.00 
SSBP3 0.483148 1.00 1.00 -0.00 
NEK7 0.485359 1.00 1.00 0.00 
POLR2E 0.487856 1.00 1.01 0.01 
ALX1 0.487870 1.00 0.99 -0.01 
ZNF35 0.488004 1.00 1.00 -0.00 
HAGH 0.488063 1.00 1.01 0.01 
DUSP4 0.488298 1.00 0.99 -0.01 
SUPT4H1 0.488782 1.00 1.01 0.01 
ZSCAN16 0.488994 1.00 0.99 -0.01 
GRAP2 0.490493 1.00 0.99 -0.01 
TNK2 0.490594 1.00 0.99 -0.01 
BATF 0.490633 1.00 1.01 0.01 
EXOSC10 0.490935 1.00 0.99 -0.01 
GNG4 0.492058 1.00 1.00 -0.00 
STK33 0.493094 1.00 1.02 0.02 
NR2C2 0.493374 1.00 1.00 0.00 
CD5L 0.493794 1.00 1.00 -0.00 
STK16 0.495258 1.00 0.99 -0.01 
GTF2F1 0.495726 1.00 1.00 -0.00 
MX1 0.495911 1.00 0.98 -0.02 
FGF13 0.496983 1.00 1.00 0.00 
STAM2 0.497193 1.00 1.00 -0.00 
TFEB 0.499042 1.00 0.99 -0.01 
KIAA0101 0.500682 1.00 1.01 0.01 
TFCP2 0.504320 1.00 1.00 -0.00 
TBX6 0.504461 1.00 1.00 -0.00 
UXT 0.505586 1.00 1.00 0.00 
YTHDF2 0.506125 1.00 1.00 0.00 
CKM 0.506235 1.00 1.01 0.01 
DDB2 0.507191 1.00 1.00 -0.00 
DLX1 0.508058 1.00 1.00 -0.00 
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SMAD9 0.508678 1.00 1.00 0.00 
SSX1 0.508872 1.00 1.00 -0.00 
PTPN11 0.509285 1.00 1.01 0.01 
CCND1 0.512392 1.00 1.00 0.00 
CDKN2C 0.512721 1.00 1.00 -0.00 
FYN 0.513180 1.00 1.00 -0.00 
PNPT1 0.513687 1.00 0.99 -0.01 
LDHA 0.514436 1.00 1.00 0.00 
PPP2R2B 0.515600 1.00 1.00 -0.00 
ATF1 0.516832 1.00 1.00 -0.00 
TGFBR2 0.517202 1.00 1.00 -0.00 
OVOL1 0.517335 1.00 0.99 -0.01 
HCLS1 0.517843 1.00 1.02 0.02 
PRELID1 0.518886 1.00 1.01 0.01 
CDC42 0.519049 1.00 1.00 0.00 
ODC1 0.519979 1.00 1.02 0.02 
AK7 0.520170 1.00 1.01 0.01 
PLUNC 0.520485 1.00 1.01 0.01 
CDK20 0.520755 1.00 1.00 -0.00 
POU5F1 0.521833 1.00 1.00 -0.00 
CASP4 0.522682 1.00 1.00 -0.00 
TFDP1 0.524699 1.00 0.99 -0.01 
GK 0.525075 1.00 1.01 0.01 
TAF5L 0.527766 1.00 1.00 -0.00 
HUS1 0.529229 1.00 0.99 -0.01 
ZMAT3 0.529378 1.00 0.99 -0.01 
CALM2 0.529572 1.00 1.01 0.01 
SMARCD1 0.529862 1.00 0.99 -0.01 
BRD3 0.530702 1.00 1.00 -0.00 
SOX2 0.530900 1.00 1.01 0.01 
EXOSC8 0.531135 1.00 0.99 -0.01 
CSNK2A2 0.533480 1.00 0.99 -0.01 
DGUOK 0.534538 1.00 1.00 0.00 
PIP4K2B 0.534672 1.00 0.99 -0.01 
RPL10A 0.535663 1.00 1.00 -0.00 
MLPH 0.536187 1.00 1.00 0.00 
PPP2CB 0.536835 1.00 1.00 -0.00 
MAPKAPK3 0.539811 1.00 1.01 0.01 
CDK11B 0.540027 1.00 1.01 0.01 
IKZF1 0.541879 1.00 1.01 0.01 
SEPT4 0.541979 1.00 1.00 -0.00 
MTERF 0.542023 1.00 1.01 0.01 
ARL1 0.544055 1.00 1.01 0.01 
STYXL1 0.547200 1.00 1.00 -0.00 
RAD51L1 0.547298 1.00 1.00 -0.00 
SUMO2 0.548661 1.00 1.00 0.00 
TTK 0.549639 1.00 0.99 -0.01 
SECISBP2 0.550112 1.00 1.00 0.00 
STYX 0.550615 1.00 1.01 0.01 
NR2C1 0.551363 1.00 1.00 -0.00 
DUSP12 0.551491 1.00 1.00 0.00 
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CXCR2 0.552459 1.00 1.01 0.01 
RPS6KL1 0.553231 1.00 1.01 0.01 
CALM2_a 0.553920 1.00 0.99 -0.01 
KRAS 0.553920 1.00 1.01 0.01 
RPL32 0.554014 1.00 1.00 0.00 
ERCC3 0.554515 1.00 1.00 -0.00 
MPP1 0.555570 1.00 1.01 0.01 
FOXA3 0.556459 1.00 1.00 -0.00 
TUBGCP3 0.556772 1.00 1.01 0.01 
CDC25C 0.557257 1.00 0.99 -0.01 
ZNF274 0.558707 1.00 1.00 0.00 
GATAD2A 0.558823 1.00 1.00 -0.00 
PTP4A3 0.559127 1.00 1.00 -0.00 
CSK 0.559495 1.00 1.01 0.01 
CHEK2 0.560101 1.00 1.00 0.00 
ARNT 0.560346 1.00 0.99 -0.01 
KIT_fl 0.560507 1.00 1.00 -0.00 
GUK1 0.560961 1.00 1.01 0.01 
RPL28 0.561091 1.00 1.00 0.00 
EHF 0.561329 1.00 1.00 -0.00 
CBX5 0.561799 1.00 1.00 -0.00 
TFCP2L1 0.562150 1.00 1.00 -0.00 
MUTYH 0.562155 1.00 1.00 -0.00 
PRKAR1A 0.563217 1.00 1.02 0.02 
DYRK2 0.563365 1.00 1.00 -0.00 
CFL1 0.564024 1.00 1.01 0.01 
CARD9 0.564542 1.00 1.01 0.01 
SPG20 0.564576 1.00 0.98 -0.02 
MAP3K14 0.566369 1.00 1.00 -0.00 
TPI1 0.567914 1.00 1.02 0.02 
RALBP1 0.568053 1.00 1.00 0.00 
LTA4H 0.569438 1.00 1.01 0.01 
TSSK3 0.569472 1.00 1.01 0.01 
STAT4 0.569656 1.00 0.99 -0.01 
HMGB2 0.569677 1.00 0.99 -0.01 
TCEA2 0.569916 1.00 0.99 -0.01 
SPDEF 0.569935 1.00 1.01 0.01 
ZBTB25 0.570118 1.00 1.01 0.01 
GNAI3 0.570546 1.00 1.00 -0.00 
RRAGC 0.570874 1.00 1.00 -0.00 
PRKCH 0.571068 1.00 1.01 0.01 
ZHX2 0.571174 1.00 1.00 -0.00 
BCL10 0.572295 1.00 0.99 -0.01 
CRX 0.573457 1.00 1.00 -0.00 
ILK 0.574033 1.00 1.00 0.00 
NHLH1 0.574416 1.00 1.01 0.01 
NR1H2 0.576216 1.00 1.01 0.01 
CLK1 0.576291 1.00 1.00 0.00 
DDX5 0.576450 1.00 1.01 0.01 
FAS 0.578522 1.00 1.01 0.01 
CAMK1G 0.579800 1.00 0.99 -0.01 
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ARIH2 0.580427 1.00 1.01 0.01 
DFFA 0.580527 1.00 1.01 0.01 
SMAD2 0.580636 1.00 1.01 0.01 
KRT8 0.580637 1.00 0.99 -0.01 
FAM48A 0.582263 1.00 1.01 0.01 
EZR 0.582584 1.00 1.01 0.01 
COPS6 0.582899 1.00 0.99 -0.01 
LY96 0.583052 1.00 1.00 -0.00 
RAD23A 0.583869 1.00 1.02 0.02 
MUSK 0.583900 1.00 1.00 0.00 
ZMAT2 0.585376 1.00 1.02 0.02 
FANCC 0.585422 1.00 1.00 -0.00 
IKBKB 0.585514 1.00 1.00 -0.00 
EGR2 0.585764 1.00 1.00 -0.00 
PACSIN3 0.585789 1.00 1.01 0.01 
PPID 0.587701 1.00 1.00 -0.00 
AHSG 0.588933 1.00 1.00 0.00 
CROT 0.589359 1.00 1.00 0.00 
VHL 0.589846 1.00 1.00 -0.00 
RAP1GDS1 0.589888 1.00 1.00 0.00 
COMMD3 0.590031 1.00 1.00 0.00 
AK2 0.591046 1.00 1.01 0.01 
CITED1 0.591679 1.00 0.99 -0.01 
INPP1 0.592145 1.00 1.00 0.00 
FOLH1 0.592226 1.00 1.00 -0.00 
UQCRC1 0.592845 1.00 1.01 0.01 
BMPR1A 0.593016 1.00 1.00 -0.00 
ING4 0.593204 1.00 1.01 0.01 
ULK2 0.593282 1.00 0.99 -0.01 
MAP1S 0.593311 1.00 1.00 -0.00 
CDKN1A 0.593957 1.00 0.99 -0.01 
FGF1 0.594506 1.00 1.00 -0.00 
SOCS5 0.594641 1.00 1.00 0.00 
EXT2 0.596102 1.00 1.00 -0.00 
TWF2 0.596561 1.00 0.99 -0.01 
TRIM25 0.596726 1.00 1.00 -0.00 
MAP2K7 0.597305 1.00 1.00 -0.00 
CDH19 0.597833 1.00 0.99 -0.01 
RAD51 0.598438 1.00 1.00 -0.00 
CSNK1D 0.599339 1.00 0.99 -0.01 
SH3GLB1 0.600388 1.00 1.00 -0.00 
PDGFB 0.600977 1.00 1.00 -0.00 
ARRB1 0.601610 1.00 1.01 0.01 
RAD23B 0.602105 1.00 1.02 0.02 
ABT1 0.602900 1.00 0.99 -0.01 
NEUROD4 0.605194 1.00 1.00 -0.00 
NLRP2 0.605443 1.00 1.00 -0.00 
ZNRD1 0.606846 1.00 1.01 0.01 
CHIC2 0.612701 1.00 1.00 -0.00 
BAD 0.612840 1.00 1.01 0.01 
INPP5B 0.614532 1.00 1.00 0.00 
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YAF2 0.616771 1.00 0.99 -0.01 
RAPGEF4 0.617383 1.00 1.00 -0.00 
GTF2F2 0.618546 1.00 1.00 -0.00 
ZNF45 0.618933 1.00 1.00 -0.00 
RPL27A 0.619014 1.00 1.00 -0.00 
RABEP1 0.620552 1.00 1.01 0.01 
NPY5R 0.620617 1.00 1.00 0.00 
FLI1_a 0.621660 1.00 1.01 0.01 
CWC27 0.622158 1.00 0.99 -0.01 
MAPK12 0.622514 1.00 0.99 -0.01 
MX2 0.623418 1.00 1.00 -0.00 
GATA1 0.623511 1.00 1.00 -0.00 
VAV1 0.623882 1.00 1.00 0.00 
RBM7 0.624088 1.00 1.00 -0.00 
AXIN1 0.624358 1.00 1.00 -0.00 
ZNHIT3 0.624786 1.00 0.99 -0.01 
EXOSC4 0.624951 1.00 1.00 -0.00 
CDK16_a 0.625241 1.00 1.01 0.01 
PKDCC 0.625483 1.00 1.00 -0.00 
ELF1 0.625821 1.00 1.00 -0.00 
HDAC3 0.626474 1.00 1.01 0.01 
E2F6 0.627160 1.00 1.00 -0.00 
MLKL 0.627974 1.00 0.98 -0.02 
PTK6 0.628693 1.00 1.00 -0.00 
DMAP1 0.629399 1.00 1.00 -0.00 
CCT3 0.630217 1.00 1.00 -0.00 
FOXM1 0.631294 1.00 1.00 -0.00 
TSC22D4 0.632461 1.00 1.00 0.00 
RHOB 0.633693 1.00 1.01 0.01 
VRK3 0.634775 1.00 1.00 -0.00 
MCM5 0.636352 1.00 0.99 -0.01 
CRADD 0.638381 1.00 1.01 0.01 
PDGFRA_a 0.638419 1.00 1.00 -0.00 
MTCP1 0.640418 1.00 1.00 -0.00 
MRTO4 0.642045 1.00 1.00 0.00 
NTRK3_ext 0.642569 1.00 1.00 -0.00 
OLIG3 0.642588 1.00 1.00 -0.00 
STARD7 0.642806 1.00 1.01 0.01 
CSNK1G2 0.643003 1.00 1.01 0.01 
RUFY1 0.643980 1.00 1.01 0.01 
PSMD9 0.644289 1.00 0.99 -0.01 
STAT5A 0.644494 1.00 1.00 -0.00 
TP63 0.644511 1.00 0.99 -0.01 
AXL 0.645410 1.00 1.00 0.00 
LIMK2 0.645787 1.00 1.00 -0.00 
PDGFRB_ext 0.646257 1.00 1.00 0.00 
CAMKV_a 0.646460 1.00 1.00 -0.00 
SH2D1A 0.646570 1.00 1.00 0.00 
CNOT8 0.646622 1.00 1.00 -0.00 
TWF1 0.648711 1.00 0.99 -0.01 
FOXI1 0.649403 1.00 1.01 0.01 
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MARK4 0.650200 1.00 1.00 -0.00 
IL21R 0.650800 1.00 1.00 -0.00 
UCKL1 0.651208 1.00 1.00 0.00 
MECP2 0.652223 1.00 1.00 0.00 
IFI16 0.652425 1.00 1.00 -0.00 
SEPT5 0.652922 1.00 0.99 -0.01 
ASCL1 0.656185 1.00 1.00 -0.00 
FOSL2 0.656560 1.00 1.00 0.00 
PHIP 0.656984 1.00 1.00 -0.00 
RING1 0.660190 1.00 1.00 -0.00 
GFAP 0.660610 1.00 0.99 -0.01 
LRRFIP2 0.660817 1.00 0.99 -0.01 
CDK18 0.661018 1.00 1.00 0.00 
IKBKE 0.661721 1.00 1.00 0.00 
ZSCAN21 0.662612 1.00 0.99 -0.01 
ETV4 0.663510 1.00 1.01 0.01 
EIF4E 0.663924 1.00 1.00 0.00 
IL1F7 0.665081 1.00 1.01 0.01 
IPMK 0.666962 1.00 1.00 0.00 
MEF2C 0.667372 1.00 1.00 0.00 
KLK3 0.667646 1.00 1.00 0.00 
CASP9 0.667855 1.00 1.00 -0.00 
DGKA 0.668385 1.00 1.00 0.00 
TUBA4A 0.669109 1.00 1.00 -0.00 
VPS24 0.669180 1.00 0.99 -0.01 
TAF15 0.669977 1.00 1.01 0.01 
PIK3R1 0.670247 1.00 1.00 -0.00 
ARAF 0.672054 1.00 1.00 -0.00 
MAP3K7 0.672260 1.00 1.00 -0.00 
GNG11 0.674068 1.00 1.00 0.00 
SGK196 0.674918 1.00 1.00 0.00 
RPS6KB1 0.676117 1.00 1.01 0.01 
CHN1 0.676815 1.00 1.00 0.00 
RPL13A 0.677694 1.00 1.00 -0.00 
MAPK6 0.680054 1.00 1.00 -0.00 
CABC1 0.680668 1.00 1.01 0.01 
SUCLA2 0.680876 1.00 1.00 -0.00 
ZNF444 0.681233 1.00 1.00 -0.00 
KLF4 0.682090 1.00 1.00 0.00 
CTTN 0.682533 1.00 1.00 -0.00 
KRT15 0.682854 1.00 0.99 -0.01 
AFF4 0.683141 1.00 1.01 0.01 
ZNF174 0.683805 1.00 1.00 -0.00 
PDGFRA_ext 0.684395 1.00 1.00 0.00 
SP110 0.684857 1.00 1.00 -0.00 
CDC25B 0.685100 1.00 1.00 0.00 
MAPKSP1 0.685346 1.00 1.00 -0.00 
MARK2 0.685603 1.00 1.00 -0.00 
MAPK14 0.686784 1.00 1.01 0.01 
BUB1B 0.687300 1.00 1.01 0.01 
EGFR_ext 0.687550 1.00 1.00 0.00 
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ATXN3 0.688750 1.00 0.99 -0.01 
MYNN 0.689028 1.00 1.00 -0.00 
UBA3 0.689044 1.00 1.00 0.00 
ETV7 0.689189 1.00 1.00 -0.00 
FASTKD1 0.689530 1.00 1.01 0.01 
ISL1 0.690163 1.00 1.01 0.01 
BLK_a 0.691090 1.00 1.00 -0.00 
RUVBL1 0.692120 1.00 1.00 0.00 
TBK1 0.692944 1.00 1.00 -0.00 
IDO1 0.693352 1.00 1.00 0.00 
RIPK2 0.694485 1.00 0.99 -0.01 
CXCR6 0.694538 1.00 1.00 0.00 
GLRX3 0.696050 1.00 1.01 0.01 
ZNF193 0.696800 1.00 1.00 0.00 
DTYMK 0.696824 1.00 1.00 0.00 
PRIM1 0.699440 1.00 1.00 -0.00 
PDCD6 0.699963 1.00 1.00 0.00 
WT1 0.701928 1.00 1.00 -0.00 
CASP1 0.703898 1.00 1.00 -0.00 
CDKN2D 0.704766 1.00 1.01 0.01 
AKD1 0.704925 1.00 1.00 0.00 
STK32B 0.705051 1.00 1.00 -0.00 
NTRK2 0.706085 1.00 0.99 -0.01 
PRKD3 0.708080 1.00 1.00 -0.00 
PTGDR 0.708113 1.00 1.00 0.00 
STK17B 0.708402 1.00 1.01 0.01 
INHBA 0.708624 1.00 1.00 -0.00 
PSME1 0.708688 1.00 0.99 -0.01 
MAP2K3 0.708975 1.00 0.99 -0.01 
CALM1 0.709738 1.00 1.01 0.01 
HOXB7 0.709965 1.00 1.00 -0.00 
RPS6KA3 0.710614 1.00 1.00 -0.00 
TIRAP 0.710989 1.00 1.00 -0.00 
RXRB 0.713595 1.00 1.00 -0.00 
TSSKIB 0.713943 1.00 1.00 0.00 
PKLR 0.713974 1.00 1.00 0.00 
C20orf43 0.714215 1.00 1.00 -0.00 
PHF7 0.714754 1.00 1.00 0.00 
FASTK 0.715757 1.00 1.00 -0.00 
CTAG2 0.716942 1.00 1.00 0.00 
DLX3 0.717495 1.00 1.00 0.00 
CEACAM8 0.718896 1.00 1.00 0.00 
TAF9 0.719691 1.00 1.00 0.00 
GRB2 0.720259 1.00 1.01 0.01 
GEM 0.722453 1.00 1.00 -0.00 
DEK 0.722684 1.00 1.00 -0.00 
IDI1 0.724177 1.00 1.00 -0.00 
FOXR2 0.724329 1.00 1.01 0.01 
IFI35 0.724434 1.00 0.99 -0.01 
RIPK1 0.725215 1.00 1.00 0.00 
PRDX6 0.725215 1.00 1.01 0.01 
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BTF3 0.725600 1.00 1.00 -0.00 
CPA4 0.726381 1.00 1.00 -0.00 
LASS4 0.727706 1.00 1.00 0.00 
FKBP3 0.728125 1.00 1.00 -0.00 
VPS72 0.728527 1.00 1.01 0.01 
SMARCE1 0.729304 1.00 1.00 0.00 
GNGT2 0.729537 1.00 0.99 -0.01 
RCAN1 0.729936 1.00 1.00 -0.00 
CCNI 0.730244 1.00 1.00 0.00 
APCS 0.730936 1.00 1.01 0.01 
CHEK1 0.733956 1.00 1.01 0.01 
NR3C1 0.734672 1.00 1.00 0.00 
TRAF2 0.735158 1.00 1.01 0.01 
DMRTB1 0.735242 1.00 1.00 0.00 
HOXB6 0.735739 1.00 1.00 -0.00 
RNF6 0.736155 1.00 1.00 0.00 
EGFR_int 0.736522 1.00 1.00 0.00 
MLX 0.737823 1.00 1.01 0.01 
LIMS1 0.741001 1.00 1.00 -0.00 
PRKACG 0.741600 1.00 1.00 0.00 
CAMK2G 0.742475 1.00 1.00 0.00 
PPM1A 0.742579 1.00 1.01 0.01 
STRADB 0.743907 1.00 1.00 -0.00 
EXT1 0.745148 1.00 1.00 -0.00 
SP1 0.746681 1.00 1.00 -0.00 
FGFR1_int 0.746825 1.00 1.00 0.00 
TADA2A 0.746961 1.00 1.00 0.00 
TXNRD1 0.747104 1.00 1.00 -0.00 
PDK2 0.747976 1.00 1.00 -0.00 
PLD2 0.748545 1.00 1.00 -0.00 
ADCK4 0.749054 1.00 1.00 -0.00 
IFIT1 0.749071 1.00 1.00 -0.00 
KIT_int 0.750444 1.00 1.00 0.00 
CDK19 0.752833 1.00 1.00 -0.00 
TUBB 0.754032 1.00 1.00 0.00 
AMD1 0.754876 1.00 1.00 0.00 
PHB 0.755048 1.00 1.00 0.00 
SPARC 0.755735 1.00 1.00 0.00 
TFEC 0.755783 1.00 1.00 -0.00 
HRAS 0.759403 1.00 1.00 0.00 
ATG12 0.761487 1.00 1.00 0.00 
NCOA5 0.762280 1.00 1.00 0.00 
CSRNP1 0.764044 1.00 1.00 -0.00 
SOCS3 0.764477 1.00 1.00 -0.00 
IGHG1 0.765137 1.00 1.01 0.01 
MEIS2 0.766091 1.00 1.00 0.00 
ZNF232 0.766694 1.00 1.00 0.00 
FOS 0.769052 1.00 1.00 0.00 
TP53 0.769295 1.00 1.01 0.01 
PECI 0.769361 1.00 1.00 -0.00 
WAS 0.769496 1.00 1.00 0.00 
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CCM2 0.770647 1.00 1.00 -0.00 
MAGEA4 0.770820 1.00 1.00 0.00 
RG9MTD1 0.773555 1.00 1.00 -0.00 
SGK3 0.774091 1.00 1.00 0.00 
PPP3CA 0.774216 1.00 1.00 0.00 
RFK 0.774681 1.00 1.00 0.00 
EFS 0.774873 1.00 1.00 -0.00 
OSBPL9 0.775120 1.00 1.01 0.01 
TFRC 0.775813 1.00 1.00 -0.00 
VCL 0.775907 1.00 1.00 -0.00 
PAK2 0.776816 1.00 1.00 -0.00 
PCGF2 0.777941 1.00 1.00 0.00 
YWHAE 0.778032 1.00 1.01 0.01 
BIRC7 0.778061 1.00 0.99 -0.01 
HOXC8 0.779225 1.00 1.00 -0.00 
BOLA3 0.779936 1.00 1.00 -0.00 
CCR5 0.782440 1.00 1.00 0.00 
C9orf96 0.783403 1.00 1.00 0.00 
DNMT3L 0.784652 1.00 1.01 0.01 
NR6A1 0.785182 1.00 1.00 -0.00 
GPC3 0.786043 1.00 1.00 0.00 
CAMK4 0.786898 1.00 1.01 0.00 
PRCC 0.786984 1.00 1.01 0.01 
ZNF277 0.788928 1.00 1.00 -0.00 
AKT2 0.789682 1.00 1.00 0.00 
NDE1 0.790451 1.00 1.01 0.01 
PRKAA1 0.791096 1.00 1.00 -0.00 
PRKD2 0.791491 1.00 1.00 0.00 
PITX2 0.791953 1.00 1.00 0.00 
ZAP70 0.792079 1.00 1.00 0.00 
KCNIP3 0.792458 1.00 1.00 0.00 
NEDD9 0.793083 1.00 1.00 -0.00 
CDK4 0.793589 1.00 1.00 -0.00 
DAPK2 0.794910 1.00 1.00 0.00 
FGFR2_ext 0.795170 1.00 1.00 -0.00 
ZBTB32 0.796492 1.00 1.00 0.00 
TCF4 0.797969 1.00 1.00 -0.00 
SS18L1 0.799288 1.00 1.00 -0.00 
DNAJB1 0.800643 1.00 1.00 -0.00 
TFE3 0.801504 1.00 1.00 0.00 
SLA2 0.802926 1.00 1.00 -0.00 
BRD2 0.803183 1.00 1.00 -0.00 
PDXK 0.803226 1.00 1.00 -0.00 
C21orf2 0.805388 1.00 1.00 0.00 
XBP1 0.807003 1.00 1.00 -0.00 
CISH 0.807745 1.00 1.00 -0.00 
KRT14 0.809712 1.00 1.00 0.00 
AP2M1 0.810218 1.00 1.00 -0.00 
EEF1D 0.810548 1.00 1.00 0.00 
MRPL45 0.810688 1.00 0.99 -0.01 
PTPN22 0.812129 1.00 1.00 0.00 
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COX6C 0.812429 1.00 1.00 -0.00 
HSP90AB1 0.812512 1.00 1.00 0.00 
RAC2 0.812798 1.00 1.00 0.00 
MAPK1 0.814033 1.00 1.00 -0.00 
PATZ1 0.814407 1.00 1.00 -0.00 
EWSR1 0.814787 1.00 1.00 -0.00 
CAMK2D 0.815685 1.00 1.00 -0.00 
ATIC 0.817869 1.00 1.00 -0.00 
ITPK1 0.818699 1.00 1.00 0.00 
NME5 0.820586 1.00 1.00 -0.00 
RPL31 0.821071 1.00 1.00 -0.00 
RLIM 0.821573 1.00 1.00 0.00 
API5 0.821968 1.00 1.00 -0.00 
STK32C 0.822283 1.00 1.00 0.00 
ADRBK2 0.822569 1.00 1.00 0.00 
SH3GL1 0.822805 1.00 1.01 0.01 
STIP1 0.823498 1.00 0.99 -0.01 
FTH1 0.823845 1.00 1.01 0.01 
CCNH 0.824115 1.00 1.00 0.00 
MYD88 0.825600 1.00 1.00 -0.00 
PIP4K2C 0.826025 1.00 1.00 -0.00 
AARS 0.826324 1.00 1.00 -0.00 
MOBKL2A 0.827684 1.00 1.00 -0.00 
PKMYT1 0.828330 1.00 1.00 -0.00 
TDP2 0.828791 1.00 1.00 -0.00 
BACH1 0.828917 1.00 0.99 -0.01 
DMPK 0.829329 1.00 1.00 -0.00 
PIK3C3 0.830898 1.00 1.00 -0.00 
EPHB4 0.832105 1.00 1.00 0.00 
HOXA1 0.832334 1.00 1.00 -0.00 
GNAO1 0.832519 1.00 1.00 0.00 
KLF6 0.832912 1.00 1.00 -0.00 
TRAF5 0.837132 1.00 1.00 -0.00 
HOMER2 0.837564 1.00 1.00 0.00 
DPF2 0.838153 1.00 1.00 0.00 
PTPN4 0.838475 1.00 1.00 -0.00 
MYOG 0.840501 1.00 1.00 0.00 
AMT 0.841601 1.00 1.00 -0.00 
MED24 0.842839 1.00 1.00 -0.00 
AK3 0.843400 1.00 1.00 -0.00 
CNOT2 0.843477 1.00 1.00 0.00 
RPL34 0.843577 1.00 1.00 0.00 
ELMOD3 0.843671 1.00 1.00 0.00 
ZNF3 0.843793 1.00 1.00 0.00 
ASPSCR1 0.844192 1.00 1.01 0.01 
SLC25A6 0.844355 1.00 1.00 -0.00 
ZNF202 0.844510 1.00 1.00 -0.00 
TTF2 0.844964 1.00 1.00 -0.00 
ABL2 0.846805 1.00 1.00 -0.00 
COPB2 0.847884 1.00 1.00 0.00 
STK24 0.847963 1.00 1.00 0.00 
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NDUFAB1 0.848427 1.00 1.00 0.00 
ETNK2 0.848620 1.00 1.00 -0.00 
PKNOX1 0.848733 1.00 1.00 0.00 
CIDEB 0.849027 1.00 1.00 0.00 
TXNDC3 0.849194 1.00 1.00 -0.00 
HSFY1 0.850111 1.00 1.00 0.00 
FN3K 0.850158 1.00 1.00 0.00 
HOXB13 0.852799 1.00 1.00 0.00 
PTK7_int 0.852901 1.00 1.00 -0.00 
LDB2 0.853092 1.00 1.00 0.00 
NDUFV3 0.853336 1.00 1.00 0.00 
KIT_ext 0.854693 1.00 1.00 0.00 
ADD1 0.855033 1.00 1.00 -0.00 
DDX55 0.856046 1.00 1.00 0.00 
EPAS1 0.856774 1.00 1.00 -0.00 
DNM1L 0.857289 1.00 1.00 -0.00 
PDGFRL 0.858479 1.00 1.00 0.00 
LCK 0.860462 1.00 1.00 -0.00 
NAP1L3 0.861203 1.00 0.99 -0.01 
RARB 0.861751 1.00 1.00 0.00 
XYLB 0.863708 1.00 1.00 0.00 
NR2E3 0.863784 1.00 1.00 0.00 
RRAS2 0.863897 1.00 1.00 -0.00 
PRKCB 0.863996 1.00 1.00 -0.00 
ACTR2_a 0.864337 1.00 1.00 0.00 
DUSP10 0.864663 1.00 1.00 -0.00 
PTPN6 0.864916 1.00 1.00 0.00 
PBX1 0.866939 1.00 1.00 0.00 
ZNF384 0.867415 1.00 1.00 -0.00 
HTATIP2 0.867648 1.00 1.00 0.00 
AHCY 0.868759 1.00 1.00 0.00 
RET_int 0.869696 1.00 1.00 0.00 
TLK1 0.869849 1.00 1.00 -0.00 
EEF2K 0.869967 1.00 1.00 0.00 
ZNF449 0.871103 1.00 1.00 0.00 
ZNF593 0.871207 1.00 1.00 -0.00 
CAB39L 0.871831 1.00 1.00 0.00 
CREB1 0.872058 1.00 1.00 0.00 
STK3 0.872463 1.00 1.00 0.00 
PHLDA2 0.873037 1.00 1.00 -0.00 
PSMB3 0.873855 1.00 1.00 0.00 
YEATS4 0.873931 1.00 1.00 0.00 
TRAF6 0.874935 1.00 1.00 -0.00 
RHOH 0.875331 1.00 1.00 -0.00 
RET_ext 0.876299 1.00 1.00 0.00 
GTF2A2 0.876712 1.00 1.00 -0.00 
PFKP 0.877030 1.00 1.00 0.00 
SSNA1 0.878696 1.00 1.00 0.00 
SBDS 0.879670 1.00 1.00 -0.00 
SOX15 0.879836 1.00 1.00 0.00 
GNG2 0.880434 1.00 1.00 -0.00 
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MAP2K6 0.881285 1.00 1.00 0.00 
MARK3 0.882025 1.00 1.00 -0.00 
SSX4 0.882269 1.00 1.00 0.00 
GMPS 0.884282 1.00 1.00 0.00 
PTGER3 0.886250 1.00 1.00 -0.00 
NUBP2 0.887061 1.00 1.00 0.00 
S100A6 0.887087 1.00 1.00 -0.00 
PPP2R4 0.887719 1.00 1.00 0.00 
DDIT3 0.888496 1.00 1.00 -0.00 
PTP4A2 0.889386 1.00 1.00 0.00 
TRIB3 0.889566 1.00 1.00 -0.00 
RPS6KB2 0.890268 1.00 1.00 0.00 
ELMO3 0.891504 1.00 1.00 -0.00 
PC 0.892325 1.00 1.00 0.00 
TP53RK 0.893286 1.00 1.00 0.00 
TRAF1 0.894056 1.00 1.00 -0.00 
RPS6KA2 0.897636 1.00 1.00 -0.00 
PTPN2 0.898617 1.00 1.00 0.00 
ELF4 0.898868 1.00 1.00 0.00 
MED30 0.899680 1.00 1.00 -0.00 
NRBF2 0.903500 1.00 1.00 -0.00 
EPHA3_ext 0.903673 1.00 1.00 0.00 
CEBPG 0.903974 1.00 1.00 -0.00 
MYC 0.904304 1.00 1.00 0.00 
CCT5 0.904934 1.00 1.00 0.00 
C6 0.905031 1.00 1.00 -0.00 
COL4A3BP 0.905302 1.00 1.00 0.00 
RNF40 0.906133 1.00 1.00 -0.00 
FADD 0.907754 1.00 1.00 -0.00 
DUSP6 0.908155 1.00 1.00 0.00 
PRPS2 0.908481 1.00 1.00 0.00 
HAND1 0.908610 1.00 1.00 0.00 
BIRC2 0.909297 1.00 1.00 -0.00 
PRKACB 0.909795 1.00 1.00 -0.00 
RAF1 0.910338 1.00 1.00 0.00 
ZNF187 0.911419 1.00 1.00 -0.00 
TOLLIP 0.911963 1.00 1.00 0.00 
PIN1 0.912420 1.00 1.00 -0.00 
HDAC1 0.912931 1.00 1.00 -0.00 
HTR1D 0.912937 1.00 1.00 0.00 
ANKRD13A 0.913228 1.00 1.00 0.00 
PPAT 0.914044 1.00 1.00 -0.00 
RAD51L3 0.914820 1.00 1.00 0.00 
ASB1 0.915308 1.00 1.00 -0.00 
NRBP2 0.915795 1.00 1.00 -0.00 
GNGT1 0.916286 1.00 1.00 0.00 
AKT3 0.917269 1.00 1.00 0.00 
MYCL1 0.920854 1.00 1.00 0.00 
MSC 0.922952 1.00 1.00 0.00 
IKZF3 0.923242 1.00 1.00 -0.00 
MAPK3 0.923650 1.00 1.00 0.00 
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DDR1_a 0.924237 1.00 1.00 0.00 
FGFR4_ext 0.924407 1.00 1.00 0.00 
DOM3Z 0.924569 1.00 1.00 0.00 
MAPKAPK5 0.925422 1.00 1.00 0.00 
BTG3 0.926110 1.00 1.00 -0.00 
GRB7 0.928009 1.00 1.00 -0.00 
CASP7 0.928487 1.00 1.00 -0.00 
VIM 0.928771 1.00 1.00 0.00 
ERBB3_ext 0.929662 1.00 1.00 0.00 
CNN1 0.930405 1.00 1.00 -0.00 
WWTR1 0.932026 1.00 1.00 0.00 
TCF12 0.932276 1.00 1.00 -0.00 
RXRG 0.932663 1.00 1.00 0.00 
TACC1 0.933297 1.00 1.00 -0.00 
RHOT2 0.935442 1.00 1.00 -0.00 
TIE1 0.935519 1.00 1.00 0.00 
CALM3 0.936193 1.00 1.00 0.00 
BMPR2 0.938581 1.00 1.00 -0.00 
NUDT2 0.939418 1.00 1.00 -0.00 
MAPK11 0.940014 1.00 1.00 0.00 
SGK1 0.940194 1.00 1.00 -0.00 
PDCD2L 0.941040 1.00 1.00 -0.00 
CALU 0.941199 1.00 1.00 0.00 
RPL11 0.942001 1.00 1.00 -0.00 
GTF2B 0.942211 1.00 1.00 -0.00 
TRIP11 0.943139 1.00 1.00 -0.00 
REXO4 0.945209 1.00 1.00 0.00 
TYRO3 0.945291 1.00 1.00 -0.00 
ZMYND11 0.945468 1.00 1.00 0.00 
KIAA1984 0.946669 1.00 1.00 0.00 
TSG101 0.947213 1.00 1.00 -0.00 
LSM1 0.948193 1.00 1.00 -0.00 
LHFP 0.948517 1.00 1.00 0.00 
GRK6 0.949531 1.00 1.00 0.00 
PRDM4 0.950451 1.00 1.00 -0.00 
GTF2H1 0.950944 1.00 1.00 -0.00 
LNX1 0.951003 1.00 1.00 -0.00 
ETV6 0.951827 1.00 1.00 0.00 
TBC1D5 0.957470 1.00 1.00 0.00 
USF2 0.959791 1.00 1.00 0.00 
SLA 0.960273 1.00 1.00 -0.00 
BANK1 0.960930 1.00 1.00 0.00 
PAK4 0.961147 1.00 1.00 -0.00 
FOXS1 0.962093 1.00 1.00 -0.00 
MED17 0.963037 1.00 1.00 -0.00 
FES 0.963142 1.00 1.00 0.00 
FGFR4_int 0.963910 1.00 1.00 0.00 
FKBP5 0.964826 1.00 1.00 0.00 
MAP4K5 0.966312 1.00 1.00 0.00 
YARS 0.966446 1.00 1.00 -0.00 
GNAZ 0.967243 1.00 1.00 -0.00 
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THUMPD1 0.967538 1.00 1.00 0.00 
FGFR1_ext 0.967872 1.00 1.00 -0.00 
NFYB 0.968492 1.00 1.00 -0.00 
STAT1 0.970035 1.00 1.00 0.00 
PPP1R2P9 0.970043 1.00 1.00 -0.00 
TEK 0.970504 1.00 1.00 0.00 
DUSP13 0.970888 1.00 1.00 -0.00 
IRF5 0.971669 1.00 1.00 -0.00 
MPP3 0.971741 1.00 1.00 -0.00 
MSH2 0.973083 1.00 1.00 -0.00 
FIP1L1 0.974038 1.00 1.00 -0.00 
ID2 0.974165 1.00 1.00 0.00 
SERPINB5 0.974677 1.00 1.00 0.00 
SCFD1 0.975337 1.00 1.00 0.00 
AIF1 0.976806 1.00 1.00 0.00 
PTK7_ext 0.977935 1.00 1.00 0.00 
LMO2 0.979230 1.00 1.00 0.00 
RPLP1 0.980477 1.00 1.00 0.00 
MED22 0.980702 1.00 1.00 -0.00 
HIF1A 0.982107 1.00 1.00 0.00 
PDCL3 0.982420 1.00 1.00 -0.00 
HOXC10 0.982621 1.00 1.00 0.00 
GSK3B 0.984269 1.00 1.00 0.00 
PKM2 0.984455 1.00 1.00 -0.00 
S100A9 0.984900 1.00 1.00 0.00 
HIST1H4I 0.985037 1.00 1.00 -0.00 
ERCC5 0.985454 1.00 1.00 0.00 
FGFR2_int 0.986151 1.00 1.00 -0.00 
FASTK_a 0.986284 1.00 1.00 0.00 
CSNK2A1 0.986930 1.00 1.00 -0.00 
RIOK3 0.987442 1.00 1.00 -0.00 
MAPK13 0.988020 1.00 1.00 -0.00 
MAFG 0.989557 1.00 1.00 0.00 
LASS2 0.990424 1.00 1.00 0.00 
NCK1 0.991657 1.00 1.00 0.00 
HIF1A_a 0.994344 1.00 1.00 0.00 
PHKG2 0.995071 1.00 1.00 -0.00 
CHEK1_a 0.997296 1.00 1.00 0.00 
RNASEL 0.999426 1.00 1.00 0.00 
RARA 0.999971 1.00 1.00 0.00 
 
TABLE 9-16 
Table showing record of aliquots (see section 5.3) 
 Original 
sample 
order # 
SampleID Aliquots Box # Disease Location Reproductive 
phase 
1 24 1546126 5 Box1 Endometriosis Peritoneal Mid cycle 
2 26 3691029 5 Box1 Endometriosis Follicular Follicular 
3 40 6791921 5 Box1 Control   Luteal 
4 39 503819 5 Box1 Control   Follicular 
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5 49 3521231 3 Box1 Control   Luteal 
6 50 2357654 3 Box2 Control   Luteal 
7 21 497197 5 Box2 Endometriosis Peritoneal Luteal 
8 9 9153343 5 Box2 Endometriosis Peritoneal Follicular 
9 13 9673929 5 Box2 Endometriosis Peritoneal Follicular 
10 45 1335891 3 Box2 Control   Luteal 
11 10 6707519 5 Box3 Endometriosis Peritoneal Follicular 
12 22 2183016 5 Box3 Endometriosis Peritoneal Mid cycle 
13 8 8413629 5 Box3 Endometriosis Peritoneal Follicular 
14 44 5849813 3 Box3 Control   Luteal 
15 28 8973029 5 Box3 Endometriosis Follicular Follicular 
16 4 227536 4 Box4 Endometriosis Peritoneal Follicular 
17 51 1286503 3 Box4 Control   Luteal 
18 19 3850536 5 Box4 Endometriosis Peritoneal Luteal 
19 12 811109 3 Box4 Endometriosis Peritoneal Follicular 
20 2 6170020 2 Box4 Endometriosis Peritoneal Follicular 
21 15 439356 5 Box5 Endometriosis Peritoneal Luteal 
22 30 9661629 4 Box5 Endometriosis Follicular Follicular 
23 3 9066819 5 Box5 Endometriosis Peritoneal Follicular 
24 31 9410816 5 Box5 Endometriosis Follicular Follicular 
25 46 6371846 3 Box5 Control   Luteal 
26 43 3497512 3 Box6 Control   Luteal 
27 20 2487156 5 Box6 Endometriosis Peritoneal Luteal 
28 1 1602619 3 Box6 Endometriosis Peritoneal Follicular 
29 6 5938026 5 Box6 Endometriosis Peritoneal Follicular 
30 38 3140020 5 Box6 Control   Follicular 
31 17 9315020   Box7 Endometriosis Peritoneal Luteal 
32 7 588546 3 Box7 Endometriosis Peritoneal Follicular 
33 27 2684078 4 Box7 Endometriosis Follicular Follicular 
34 14 6095346 5 Box7 Endometriosis Peritoneal Luteal 
35 33 7036506 5 Box7 Endometriosis Ovarian Luteal 
36 29 8714246 5 Box8 Endometriosis Follicular Follicular 
37 18 4506746 5 Box8 Endometriosis Peritoneal Luteal 
38 32 2207656 5 Box8 Endometriosis Follicular Follicular 
39 23 6220521 5 Box8 Endometriosis Peritoneal Mid cycle 
40 36 5161629 5 Box8 Endometriosis Ovarian Luteal 
41 25 8417619 5 Box9 Endometriosis Follicular Follicular 
42 42 1289895 5 Box9 Control   Luteal 
43 47 8361972 3 Box9 Control   Luteal 
44 11 6239256 5 Box9 Endometriosis Peritoneal Follicular 
45 41 1113256 3 Box9 Control   Luteal 
46 48 1839711 3 Box10 Control   Luteal 
47 34 5044706 5 Box10 Endometriosis Ovarian Luteal 
48 16 3677410 5 Box10 Endometriosis Peritoneal Luteal 
49 35 629829 5 Box10 Endometriosis Ovarian Luteal 
50 5 316919 5 Box10 Endometriosis Peritoneal Follicular 
51 37 996579 3 Box11 Control   Follicular 
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TABLE 9-17 
Table showing sample identities (see section 5.3) 
# SampleID Disease Location Reproductive 
phase 
Ovarian 
endometriomas 
1 1602619 x Endometriosis Peritoneal Follicular None 
2 6170020 x Endometriosis Peritoneal Follicular None 
3 9066819 x Endometriosis Peritoneal Follicular None 
4 227536 x Endometriosis Peritoneal Follicular None 
5 316919 x Endometriosis Peritoneal Follicular None 
6 5938026 x Endometriosis Peritoneal Follicular None 
7 588546 x Endometriosis Peritoneal Follicular None 
8 8413629 x Endometriosis Peritoneal Follicular None 
9 9153343 x Endometriosis Peritoneal Follicular None 
10 6707519 x Endometriosis Peritoneal Follicular None 
11 6239256 x Endometriosis Peritoneal Follicular None 
12 811109 x Endometriosis Peritoneal Follicular None 
13 9673929 x Endometriosis Peritoneal Follicular None 
14 6095346 x Endometriosis Peritoneal Luteal None 
15 439356 x Endometriosis Peritoneal Luteal None 
16 3677410 x Endometriosis Peritoneal Luteal None 
17 9315020 x Endometriosis Peritoneal Luteal None 
18 4506746 x Endometriosis Peritoneal Luteal None 
19 3850536 x Endometriosis Peritoneal Luteal None 
20 2487156 x Endometriosis Peritoneal Luteal None 
21 497197 x Endometriosis Peritoneal Luteal None 
22 2183016 x Endometriosis Peritoneal Mid cycle None 
23 6220521 x Endometriosis Peritoneal Mid cycle None 
24 1546126 x Endometriosis Peritoneal Mid cycle None 
25 8417619 x Endometriosis Ovarian Follicular Endometrioma 
26 3691029 x Endometriosis Ovarian Follicular Endometrioma 
27 2684078 x Endometriosis Ovarian Follicular Endometrioma 
28 8973029 x Endometriosis Ovarian Follicular Endometrioma 
29 8714246 x Endometriosis Ovarian Follicular Endometrioma 
30 9661629 x Endometriosis Ovarian Follicular Endometrioma 
31 9410816 x Endometriosis Ovarian Follicular Endometrioma 
32 2207656 x Endometriosis Ovarian Follicular Endometrioma 
33 7036506 x Endometriosis Ovarian Luteal Endometrioma 
34 5044706 x Endometriosis Ovarian Luteal Endometrioma 
35 629829 x Endometriosis Ovarian Luteal Endometrioma 
36 5161629 x Endometriosis Ovarian Luteal Endometrioma 
37 996579 x Control   Follicular None 
38 3140020 x Control   Follicular None 
39 503819 x Control   Follicular None 
40 6791921 x Control   Luteal None 
41 1113256 x Control   Luteal None 
42 1289895 x Control   Luteal None 
43 3497512 x Control   Luteal None 
44 5849813 Control   Luteal   
45 1335891 Control   Luteal   
46 6371846 Control   Luteal   
47 8361972 Control   Luteal   
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48 1839711 Control   Luteal   
49 3521231 Control   Luteal   
50 2357654 Control   Luteal   
51 1286503 Control   Luteal   
 
TABLE 9-18 
Table showing individual biomarkers for endometriosis (see section 6.5) 
No.
(i)
 Symbol
(ii)
 Name
(iii)
 Type 
1 ACTB Homo sapiens actin beta Auto-antigen 
2 ADD1 Homo sapiens adducin 1 (alpha) Auto-antigen 
3 ADSL Homo sapiens adenylosuccinate lyase Auto-antigen 
4 AK2 Homo sapiens adenylate kinase 2 transcript variant 
AK2A 
Auto-antigen 
5 KLK3 Homo sapiens kallikrein 3 (prostate specific antigen) 
transcript variant 1 
Auto-antigen 
6 ATF1 Homo sapiens activating transcription factor 1 Auto-antigen 
7 CKM Homo sapiens creatine kinase muscle Auto-antigen 
8 CLK2 Homo sapiens CDC-like kinase 2 transcript variant 
phclk2 
Auto-antigen 
9 DDB2 Homo sapiens damage-specific DNA binding protein 
2 48kDa 
Auto-antigen 
10 DTYMK Homo sapiens deoxythymidylate kinase (thymidylate 
kinase) 
Auto-antigen 
11 DUSP4 Homo sapiens dual specificity phosphatase 4 
transcript variant 1 
Auto-antigen 
12 E2F6 Homo sapiens E2F transcription factor 6 Auto-antigen 
13 EXT2 Homo sapiens exostoses (multiple) 2 Auto-antigen 
14 FGFR4_ext Homo sapiens fibroblast growth factor receptor 4 
transcript variant 3 
Auto-antigen 
15 FIGF Homo sapiens c-fos induced growth factor (vascular 
endothelial growth factor D) 
Auto-antigen 
16 FKBP3 Homo sapiens FK506 binding protein 3 25kDa Auto-antigen 
17 GALK1 Homo sapiens galactokinase 1 Auto-antigen 
18 GK2 Homo sapiens glycerol kinase 2 Auto-antigen 
19 GRB7 Homo sapiens growth factor receptor-bound protein 7 Auto-antigen 
20 GTF2B Homo sapiens general transcription factor IIB Auto-antigen 
21 GTF2H1 Homo sapiens general transcription factor IIH 
polypeptide 1 62kDa 
Auto-antigen 
22 GTF2H2 Homo sapiens general transcription factor IIH 
polypeptide 2 44kDa 
Auto-antigen 
23 HSPD1 Homo sapiens heat shock 60kDa protein 1 
(chaperonin) 
Auto-antigen 
24 IDI1 Homo sapiens isopentenyl-diphosphate delta 
isomerase 
Auto-antigen 
25 IFI16 Homo sapiens interferon, gamma-inducible protein 
16, 
Auto-antigen 
26 LDHA Homo sapiens lactate dehydrogenase A Auto-antigen 
27 LYL1 Homo sapiens lymphoblastic leukemia derived 
sequence 1 
Auto-antigen 
28 MARK3 Homo sapiens MAP/microtubule affinity-regulating 
kinase 3 
Auto-antigen 
29 MPP3 Homo sapiens membrane protein palmitoylated 3 
(MAGUK p55 subfamily member 3) 
Auto-antigen 
30 TRIM37 Homo sapiens tripartite motif-containing 37, Auto-antigen 
31 NCF2 Homo sapiens neutrophil cytosolic factor 2 (65kDa, 
chronic granulomatous disease, autosomal 2), 
Auto-antigen 
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32 RPL10A Homo sapiens ribosomal protein L10a Auto-antigen 
33 NFYA Homo sapiens nuclear transcription factor Y alpha Auto-antigen 
34 NRAS Homo sapiens neuroblastoma RAS viral (v-ras) 
oncogene homolog 
Auto-antigen 
35 NTRK3_ext Homo sapiens neurotrophic tyrosine kinase receptor 
type 3 transcript variant 3 
Auto-antigen 
36 OAS2 Homo sapiens 2'-5'-oligoadenylate synthetase 2 
69/71kDa 
Auto-antigen 
37 endometriosis Homo sapiens pyruvate carboxylase Auto-antigen 
38 CDK17 Homo sapiens endometriosisTAIRE protein kinase 2 Auto-antigen 
39 PDE4A Homo sapiens Homo sapiens phosphodiesterase 4A, 
cAMP-specific (phosphodiesterase E2 dunce 
homolog, Dro 
Auto-antigen 
40 PHF1 Homo sapiens PHD finger protein 1 transcript variant 
2 
Auto-antigen 
41 PKM2 Homo sapiens pyruvate kinase muscle transcript 
variant 1 
Auto-antigen 
42 MAP2K5 Homo sapiens mitogen-activated protein kinase kinase 
5, transcript variant A 
Auto-antigen 
43 PRPS2 Homo sapiens phosphoribosyl pyrophosphate 
synthetase 2 
Auto-antigen 
44 RAN Homo sapiens RAN member RAS oncogene family Auto-antigen 
45 RB1 Homo sapiens retinoblastoma 1 (including 
osteosarcoma) 
Auto-antigen 
46 RBMS1 Homo sapiens Homo sapiens RNA binding motif 
single stranded interacting protein 1 transcript variant 
Auto-antigen 
47 RET_a Homo sapiens ret proto-oncogene (multiple endocrine 
neoplasia and medullary thyroid carci 
Auto-antigen 
48 RORC Homo sapiens RAR-related orphan receptor C Auto-antigen 
49 RPL18 Homo sapiens ribosomal protein L18 Auto-antigen 
50 RPL18A Homo sapiens ribosomal protein L18a Auto-antigen 
51 RPL28 Homo sapiens ribosomal protein L28 Auto-antigen 
52 RPL31 Homo sapiens ribosomal protein L31 Auto-antigen 
53 RPL32 Homo sapiens ribosomal protein L32 Auto-antigen 
54 S100A6 Homo sapiens S100 calcium binding protein A6 
(calcyclin) 
Auto-antigen 
55 SCP2 Homo sapiens sterol carrier protein 2 transcript variant 
2 
Auto-antigen 
56 SIAH1 Homo sapiens seven in absentia homolog 1 
(Drosophila) transcript variant 2 
Auto-antigen 
57 SMARCD1 Homo sapiens SWI/SNF related matrix associated 
actin dependent regulator of chromatin subfamily d 
member 1 
Auto-antigen 
58 SMARCE1 Homo sapiens SWI/SNF related matrix associated 
actin dependent regulator of chromatin 
Auto-antigen 
59 SOD2 Homo sapiens superoxide dismutase 2 mitochondrial Auto-antigen 
60 SOX2 Homo sapiens SRY (sex determining region Y)-box 2 Auto-antigen 
61 SRPK1 Homo sapiens SFRS protein kinase 1 Auto-antigen 
62 TPM1 Homo sapiens tropomyosin 1 (alpha) Auto-antigen 
63 NR2C1 Homo sapiens nuclear receptor subfamily 2 group C 
member 1 
Auto-antigen 
64 TRIP6 Homo sapiens thyroid hormone receptor interactor 6, Auto-antigen 
65 UBA1 Homo sapiens Homo sapiens ubiquitin-activating 
enzyme E1 (A1S9T and BN75 temperature sensitivity 
compl 
Auto-antigen 
66 VCL Homo sapiens vinculin Auto-antigen 
67 ZNF41 Homo sapiens zinc finger protein 41 transcript variant 
2 
Auto-antigen 
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68 PAX8 Homo sapiens paired box gene 8 transcript variant 
PAX8A 
Auto-antigen 
69 NRIP1 Homo sapiens nuclear receptor interacting protein 1 Auto-antigen 
70 PIP4K2B Homo sapiens phosphatidylinositol-4-phosphate 5-
kinase type II beta transcript variant 2 
Auto-antigen 
71 UXT Homo sapiens ubiquitously-expressed transcript Auto-antigen 
72 API5 Homo sapiens apoptosis inhibitor 5 Auto-antigen 
73 MKNK1 Homo sapiens MAP kinase-interacting 
serine/threonine kinase 1 
Auto-antigen 
74 SUCLA2 Homo sapiens succinate-CoA ligase ADP-forming 
beta subunit 
Auto-antigen 
75 LDB1 Homo sapiens LIM domain binding 1 Auto-antigen 
76 NAE1 Homo sapiens amyloid beta precursor protein binding 
protein 1 transcript variant 1 
Auto-antigen 
77 PAPSS2 Homo sapiens 3'-phosphoadenosine 5'-phosphosulfate 
synthase 2 
Auto-antigen 
78 USP10 Homo sapiens ubiquitin specific protease 10 Auto-antigen 
79 PRPF4 Homo sapiens Homo sapiens PRP4 pre- Auto-antigen 
80 AIM2 Homo sapiens absent in melanoma 2 Auto-antigen 
81 TBPL1 Homo sapiens TBP-like 1 Auto-antigen 
82 TRAF4 Homo sapiens TNF receptor-associated factor 4 
transcript variant 1 
Auto-antigen 
83 SOCS5 Homo sapiens suppressor of cytokine signaling 5 Auto-antigen 
84 ZSCAN12 Homo sapiens zinc finger protein 305 Auto-antigen 
85 HDAC4 Homo sapiens cDNA Auto-antigen 
86 KIAA0101 Homo sapiens KIAA0101 gene product Auto-antigen 
87 IP6K1 Homo sapiens inositol hexaphosphate kinase 1 Auto-antigen 
88 RNF40 Homo sapiens ring finger protein 40 transcript variant 
1 
Auto-antigen 
89 GPHN Homo sapiens gephyrin Auto-antigen 
90 HRSP12 Homo sapiens translational inhibitor protein p14.5 Auto-antigen 
91 STUB1 Homo sapiens STIP1 homology and U-Box containing 
protein 1 
Auto-antigen 
92 TRAIP Homo sapiens TRAF interacting protein Auto-antigen 
93 PLK4 Homo sapiens serine/threonine kinase 18 Auto-antigen 
94 CCNI Homo sapiens cyclin I Auto-antigen 
95 IL24 Homo sapiens interleukin 24 transcript variant 1 Auto-antigen 
96 CDK20 Homo sapiens cell cycle related kinase Auto-antigen 
97 PABendometri
osis1 
Homo sapiens poly(A) binding protein cytoplasmic 1 Auto-antigen 
98 MED4 Homo sapiens vitamin D receptor interacting protein Auto-antigen 
99 NME7 Homo sapiens non-metastatic cells 7 protein expressed 
in (nucleoside-diphosphate kinase) transcript variant 1 
Auto-antigen 
100 PHF11 Homo sapiens PHD finger protein 11 Auto-antigen 
101 IRAK4 Homo sapiens interleukin-1 receptor-associated kinase 
4 mRNA (cDNA clone MGC:13330 ) 
Auto-antigen 
102 TXNDC3 Homo sapiens thioredoxin domain containing 3 
(spermatozoa) 
Auto-antigen 
103 TAOK3 Homo sapiens STE20-like kinase Auto-antigen 
104 STYXL1 Homo sapiens dual specificity phosphatase 24 
(putative) 
Auto-antigen 
105 ASB1 Homo sapiens ankyrin repeat and SOCS box-
containing 1 
Auto-antigen 
106 MST4 Homo sapiens Mst3 and SOK1-related kinase 
(MASK) 
Auto-antigen 
107 PELO Homo sapiens pelota homolog (Drosophila) Auto-antigen 
108 ETNK2 Homo sapiens ethanolamine kinase 2 Auto-antigen 
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109 RFK Homo sapiens riboflavin kinase Auto-antigen 
110 C9orf86 Homo sapiens chromosome 9 open reading frame 86 Auto-antigen 
111 DDX55 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 55 
Auto-antigen 
112 CCNB1IP1 Homo sapiens cDNA Auto-antigen 
113 KLHL12 Homo sapiens kelch-like protein C3IP1 Auto-antigen 
114 SAV1 Homo sapiens salvador homolog 1 (Drosophila) Auto-antigen 
115 CAMKV Homo sapiens hypothetical protein MGC8407 Auto-antigen 
116 NSBP1 Homo sapiens nucleosomal binding protein 1, Auto-antigen 
117 ALPK1 Homo sapiens alpha-kinase 1 mRNA (cDNA clone 
MGC:71554 ) 
Auto-antigen 
118 ELMOD3 Homo sapiens RNA binding motif and ELMO domain 
1 
Auto-antigen 
119 AIFM2 Homo sapiens apoptosis-inducing factor (AIF)-like 
mitochondrion-associated inducer of death 
Auto-antigen 
120 RHOT2 Homo sapiens ras homolog gene family member T2 Auto-antigen 
121 PYGO2 Homo sapiens pygopus 2 Auto-antigen 
122 ebv-miR-
BART12 
ebv-miR-BART12 miRNA 
123 ebv-miR-
BART14 
ebv-miR-BART14 miRNA 
124 ebv-miR-
BART16 
ebv-miR-BART16 miRNA 
125 ebv-miR-
BART20-5p 
ebv-miR-BART20-5p miRNA 
126 ebv-miR-
BART2-5p 
ebv-miR-BART2-5p miRNA 
127 MIRLET7B hsa-let-7b* miRNA 
128 MIRLET7F1 hsa-let-7f miRNA 
129 MIRLET7F2 hsa-let-7f-1* miRNA 
130 MIRLET7G hsa-let-7g miRNA 
131 MIR103A1 hsa-miR-103a miRNA 
132 MIR10b hsa-miR-10b miRNA 
133 MIR1183 hsa-miR-1183 miRNA 
134 MIR1202 hsa-miR-1202 miRNA 
135 MIR1207 hsa-miR-1207-5p miRNA 
136 MIR122 hsa-miR-122 miRNA 
137 MIR1224 hsa-miR-1224-5p miRNA 
138 MIR1225 hsa-miR-1225-3p miRNA 
139 MIR1225 hsa-miR-1225-5p miRNA 
140 MIR1226 hsa-miR-1226* miRNA 
141 MIR1228 hsa-miR-1228* miRNA 
142 MIR1234 hsa-miR-1234 miRNA 
143 MIR1237 hsa-miR-1237 miRNA 
144 MIR1238 hsa-miR-1238 miRNA 
145 MIR125a hsa-miR-125a-5p miRNA 
146 MIR1260A hsa-miR-1260 miRNA 
147 MIR1260b hsa-miR-1260b miRNA 
148 MIR1280 hsa-miR-1280 miRNA 
149 MIR1281 hsa-miR-1281 miRNA 
150 MIR1290 hsa-miR-1290 miRNA 
151 MIR1291 hsa-miR-1291 miRNA 
152 MIR129-1 / 
MIR129-2 
hsa-miR-129-3p miRNA 
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153 MIR1301 hsa-miR-1301 miRNA 
154 MIR135A1 / hsa-miR-135a miRNA 
155 MIR135A1 / hsa-miR-135a* miRNA 
156 MIR141 hsa-miR-141 miRNA 
157 MIR142 hsa-miR-142-3p miRNA 
158 MIR149 hsa-miR-149 miRNA 
159 MIR150 hsa-miR-150 miRNA 
160 MIR150 hsa-miR-150* miRNA 
161 MIR1539 hsa-miR-1539 miRNA 
162 MIR181A2 hsa-miR-181a miRNA 
163 MIR1825 hsa-miR-1825 miRNA 
164 MIR186 hsa-miR-186 miRNA 
165 MIR18a hsa-miR-18a miRNA 
166 MIR18b hsa-miR-18b miRNA 
167 MIR191 hsa-miR-191* miRNA 
168 MIR197 hsa-miR-197 miRNA 
169 MIR198 hsa-miR-198 miRNA 
170 MIR205 hsa-miR-205 miRNA 
171 MIR2116 hsa-miR-2116* miRNA 
172 MIR215 hsa-miR-215 miRNA 
173 MIR22 hsa-miR-22 miRNA 
174 MIR223 hsa-miR-223 miRNA 
175 MIR2276 hsa-miR-2276 miRNA 
176 MIR23c hsa-miR-23c miRNA 
177 MIR26A1 / 
MIR26A2 
hsa-miR-26a miRNA 
178 MIR28 hsa-miR-28-3p miRNA 
179 MIR28 hsa-miR-28-5p miRNA 
180 MIR29B1 / 
MIR29B2 
hsa-miR-29b miRNA 
181 MIR30a hsa-miR-30a miRNA 
182 MIR30b hsa-miR-30b miRNA 
183 MIR3131 hsa-miR-3131 miRNA 
184 MIR3138 hsa-miR-3138 miRNA 
185 MIR3149 hsa-miR-3149 miRNA 
186 MIR3156-1 / 
MIR3156-3 
hsa-miR-3156-5p miRNA 
187 MIR3180-1 / 
MIR3180-2 / 
MIR3180-3 / 
MIR3180-4 / 
MIR3180-5 
hsa-miR-3180-5p miRNA 
188 MIR3194 hsa-miR-3194-5p miRNA 
189 MIR3195 hsa-miR-3195 miRNA 
190 MIR3196 hsa-miR-3196 miRNA 
191 MIR32 hsa-miR-32 miRNA 
192 MIR320C1 / 
MIR320C2 
hsa-miR-320c miRNA 
193 MIR324 hsa-miR-324-3p miRNA 
194 MIR328 hsa-miR-328 miRNA 
195 MIR331 hsa-miR-331-5p miRNA 
196 MIR33b hsa-miR-33b* miRNA 
197 MIR342 hsa-miR-342-3p miRNA 
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198 MIR34a hsa-miR-34a miRNA 
199 MIR3610 hsa-miR-3610 miRNA 
200 MIR3648 hsa-miR-3648 miRNA 
201 MIR3652 hsa-miR-3652 miRNA 
202 MIR3663 hsa-miR-3663-5p miRNA 
203 MIR3667 hsa-miR-3667-5p miRNA 
204 MIR382 hsa-miR-382 miRNA 
205 MIR3911 hsa-miR-3911 miRNA 
206 MIR3937 hsa-miR-3937 miRNA 
207 MIR4257 hsa-miR-4257 miRNA 
208 MIR425 hsa-miR-425* miRNA 
209 MIR4270 hsa-miR-4270 miRNA 
210 MIR4274 hsa-miR-4274 miRNA 
211 MIR4281 hsa-miR-4281 miRNA 
212 MIR4284 hsa-miR-4284 miRNA 
213 MIR4286 hsa-miR-4286 miRNA 
214 MIR429 hsa-miR-429 miRNA 
215 MIR4290 hsa-miR-4290 miRNA 
216 MIR4313 hsa-miR-4313 miRNA 
217 MIR4323 hsa-miR-4323 miRNA 
218 MIR466 hsa-miR-466 miRNA 
219 MIR483 hsa-miR-483-3p miRNA 
220 MIR484 hsa-miR-484 miRNA 
221 MIR485 hsa-miR-485-3p miRNA 
222 MIR486 hsa-miR-486-5p miRNA 
223 MIR488 hsa-miR-488 miRNA 
224 MIR497 hsa-miR-497 miRNA 
225 MIR511-1 hsa-miR-511 miRNA 
226 MIR511-2 hsa-miR-512 miRNA 
227 MIR520c hsa-miR-520c-3p miRNA 
228 MIR550A1 / 
MIR550A2 / 
MIR550A3 
hsa-miR-550a miRNA 
229 MIR556 hsa-miR-556-3p miRNA 
230 MIR557 hsa-miR-557 miRNA 
231 MIR561 hsa-miR-561 miRNA 
232 MIR572 hsa-miR-572 miRNA 
233 MIR574 hsa-miR-574-3p miRNA 
234 MIR574 hsa-miR-574-5p miRNA 
235 MIR595 hsa-miR-595 miRNA 
236 MIR630 hsa-miR-630 miRNA 
237 MIR642b hsa-miR-642b miRNA 
238 MIR646 hsa-miR-646 miRNA 
239 MIR659 hsa-miR-659 miRNA 
240 MIR660 hsa-miR-660 miRNA 
241 MIR663A hsa-miR-663 miRNA 
242 MIR664 hsa-miR-664 miRNA 
243 MIR720 hsa-miR-720 miRNA 
244 MIR762 hsa-miR-762 miRNA 
245 MIR766 hsa-miR-766 miRNA 
246 MIR877 hsa-miR-877* miRNA 
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247 MIR888 hsa-miR-888 miRNA 
248 MIR933 hsa-miR-933 miRNA 
249 MIR940 hsa-miR-940 miRNA 
250 MIR95 hsa-miR-95 miRNA 
251 hsv1-miR-H1* hsv1-miR-H1*/ hsv1-miR-H1-3p miRNA 
252 hsv1-miR-H2-
3p 
hsv1-miR-H2-3p miRNA 
253 hsv1-miR-H6-
3p 
hsv1-miR-H6-3p miRNA 
254 hsv1-miR-H7* hsv1-miR-H7* miRNA 
255 hsv1-miR-H8 hsv1-miR-H8 miRNA 
256 hsv2-miR-H22 hsv2-miR-H22 miRNA 
257 hsv2-miR-H25 hsv2-miR-H25 miRNA 
258 hsv2-miR-H6 hsv2-miR-H6 miRNA 
259 hsv2-miR-H6* hsv2-miR-H6* miRNA 
260 kshv-miR-
K12-10a 
kshv-miR-K12-10a miRNA 
261 kshv-miR-
K12-12* 
kshv-miR-K12-12* miRNA 
262 kshv-miR-
K12-8* 
kshv-miR-K12-8* miRNA 
263 MIR564 hsa-miR-564 miRNA 
264 MIRLET7D hsa-let-7d-5p miRNA 
265 MIRLET7D hsa-let-7d-3p miRNA 
266 MIR29A hsa-miR-29a miRNA 
267 MIR219 hsa-miR-219-1-3p miRNA 
268 MIR296 hsa-miR-296-3p miRNA 
269 MIR337 hsa-miR-337-5p miRNA 
270 MIR369 hsa-miR-369-3p miRNA 
271 MIR450 hsa-miR-450b-5p miRNA 
272 MIR483 hsa-miR-483-5p miRNA 
273 MIR507 hsa-miR-507 miRNA 
274 MIR517C hsa-miR-517c miRNA 
275 MIR519A hsa-miR-519a miRNA 
276 MIR519D hsa-miR-519d miRNA 
277 MIR520G hsa-miR-520g miRNA 
278 MIR576 hsa-miR-576-5p miRNA 
279 MIR577 hsa-miR-577 miRNA 
280 MIR604 hsa-miR-604 miRNA 
281 MIR610 hsa-miR-610 miRNA 
282 MIR619 hsa-miR-619 miRNA 
283 MIR1256 hsa-miR-1256 miRNA 
284 MIR1278 hsa-miR-1278 miRNA 
285 MIR1297 hsa-miR-1297 miRNA 
286 MIRUS33 hcmv-miR-US33-5p miRNA 
287 MIRH1 hsv1-miR-H1-5p miRNA 
288 MIR877 hsa-miR-877 miRNA 
289 LET7E hsa-let-7e-5p miRNA 
290 LET7E hsa-let-7e-3p miRNA 
291 MIR9 hsa-miR-9 miRNA 
292 MIR92B hsa-miR-92b miRNA 
293 MIR96 hsa-miR-96-5p miRNA 
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294 MIR96 hsa-miR-96-3p miRNA 
295 MIR106A hsa-miR-106a-5p miRNA 
296 MIR106A hsa-miR-106a-3p miRNA 
297 MIR17 hsa-miR-17-5p miRNA 
298 MIR17 hsa-miR-17-3p miRNA 
299 MIR106B hsa-miR-106b-5p miRNA 
300 MIR106B hsa-miR-106b-3p miRNA 
301 MIR127 hsa-miR-127-3p miRNA 
302 MIR128 hsa-miR-128 miRNA 
303 MIR154 hsa-miR-154 miRNA 
304 MIR155 hsa-miR-155 miRNA 
305 MIR183 hsa-miR-183-5p miRNA 
306 MIR183 hsa-miR-183-3p miRNA 
307 MIR194 hsa-miR-194 miRNA 
308 MIR196B hsa-miR-196b-5p miRNA 
309 MIR196B hsa-miR-196b-3p miRNA 
310 MIR203 hsa-miR-203 miRNA 
311 MIR204 hsa-miR-204 miRNA 
312 MIR221 hsa-miR-221-5p miRNA 
313 MIR221 hsa-miR-221-3p miRNA 
314 MIR376 hsa-miR-376a miRNA 
315 MIR376C hsa-miR-376c miRNA 
316 MIR377 hsa-miR-377 miRNA 
317 MIR379 hsa-miR-379 miRNA 
318 MIR423 hsa-miR-423-3p miRNA 
319 MIR424 hsa-miR-424-5p miRNA 
320 MIR424 hsa-miR-424-3p miRNA 
321 MIR425 hsa-miR-425-5p miRNA 
322 MIR425 hsa-miR-425-3p miRNA 
323 MIR454 hsa-miR-454-5p miRNA 
324 MIR454 hsa-miR-454-3p miRNA 
325 MIR486 hsa-miR-486-3p miRNA 
326 MIR509 hsa-miR-509-3p miRNA 
327 MIR514 hsa-miR-514 miRNA 
328 MIR542 hsa-miR-542-3p miRNA 
329 MIR545 hsa-miR-545-5p miRNA 
330 MIR545 hsa-miR-545-3p miRNA 
331 MIR626 hsa-miR-626 miRNA 
332 MIR758 hsa-miR-758-5p miRNA 
333 MIR758 hsa-miR-758-3p miRNA 
334 MIR876 hsa-miR-876-3p miRNA 
335 MIR1185 hsa-miR-1185 miRNA 
336 MIR1266 hsa-miR-1266-5p miRNA 
337 MIR1266 hsa-miR-1266-3p miRNA 
338 MIR199A hsa-miR-199a-3p miRNA 
339 MIR199B hsa-miR-199b-3p miRNA 
340 MIR625 hsa-miR-625-5p miRNA 
341 MIR625 hsa-miR-625-3p miRNA 
342 MIR631 hsa-miR-631 miRNA 
343 MIR635 hsa-miR-635 miRNA 
(i) This number is the SEQ ID NO as shown in the sequence listing. For an auto-antigen biomarker, the SEQ ID 
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NO in the sequence listing provides the coding sequence for the auto-antigen biomarker. For a miRNA biomarker, 
the SEQ ID NO in the sequence listing provides the sequence of the mature, expressed miRNA biomarker. 
(ii) The “Symbol” column gives the gene symbol which has been approved by the HGNC. The HGNC aims to give 
unique and meaningful names to every miRNA and human gene. An additional dash-number suffix indicates pre-
miRNAs that lead to identical mature miRNAs but that are located at different places in the genome. 
(iii) The names for auto-antigens are taken from the Official Full Name provided by NCBI. An auto-antigen may 
have been referred to by one or more pseudonyms in the prior art. The invention relates to these auto-antigens 
regardless of their nomenclature. The names of the miRNA are taken from the specialist database, miRBase, 
according to version 16 (released, August 2010). 
 
TABLE 9-19 
Autoantibody biomarkers identified from serum studies of subjects suffering from endometriosis 
(see section 6.5) 
No.
(i)
 Symbol ID
(iii)
 Name
(vi)
 HGNC
(v)
 GI
(vi)
 
1 ACTB 60 Homo sapiens actin beta 132 12654910 
2 ADD1 118 Homo sapiens adducin 1 (alpha) 243 33869910 
3 ADSL 158 Homo sapiens adenylosuccinate lyase 291 12652984 
4 AK2 204 Homo sapiens adenylate kinase 2 
transcript variant AK2A  
362 39645192 
5 KLK3 354 Homo sapiens kallikrein 3 (prostate 
specific antigen) transcript variant 1  
6364 34193547 
6 ATF1 466 Homo sapiens activating transcription 
factor 1  
783 20810444 
7 CKM 1158 Homo sapiens creatine kinase muscle 1994 13938618 
8 CLK2 1196 Homo sapiens CDC-like kinase 2 
transcript variant phclk2  
2069 33873844 
9 DDB2 1643 Homo sapiens damage-specific DNA 
binding protein 2 48kDa  
2718 34783036 
10 DTYMK 1841 Homo sapiens deoxythymidylate 
kinase (thymidylate kinase)  
3061 38114725 
11 DUSP4 1846 Homo sapiens dual specificity 
phosphatase 4 transcript variant 1  
3070 33869553 
12 E2F6 1876 Homo sapiens E2F transcription factor 
6 
3120 14249933 
13 EXT2 2132 Homo sapiens exostoses (multiple) 2 3513 14603195 
14 FGFR4_e 2264 Homo sapiens fibroblast growth factor 
receptor 4 transcript variant 3  
3691 33873872 
15 FIGF 2277 Homo sapiens c-fos induced growth 
factor (vascular endothelial growth 
factor D)  
3708 20379761 
16 FKBP3 2287 Homo sapiens FK506 binding protein 
3 25kDa 
3719 16740853 
17 GALK1 2584 Homo sapiens galactokinase 1 4118 12654656 
18 GK2 2712 Homo sapiens glycerol kinase 2 4291 20987489 
19 GRB7 2886 Homo sapiens growth factor receptor-
bound protein 7  
4567 33870450 
20 GTF2B 2959 Homo sapiens general transcription 
factor IIB 
4648 18088836 
21 GTF2H1 2965 Homo sapiens general transcription 
factor IIH polypeptide 1 62kDa  
4655 33991027 
22 GTF2H2 2966 Homo sapiens general transcription 
factor IIH polypeptide 2 44kDa  
4656 40674449 
23 HSPD1 3329 Homo sapiens heat shock 60kDa 
protein 1 (chaperonin)  
5261 38197215 
24 IDI1 3422 Homo sapiens isopentenyl-
diphosphate delta isomerase  
5387 34782883 
25 IFI16 3428 Homo sapiens interferon, gamma- 5395 16877621 
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inducible protein 16,  
26 LDHA 3939 Homo sapiens lactate dehydrogenase 
A 
6535 45501321 
27 LYL1 4066 Homo sapiens lymphoblastic leukemia 
derived sequence 1  
6734 33988028 
28 MARK3 4140 Homo sapiens MAP/microtubule 
affinity- regulating kinase 3  
6897 19353235 
29 MPP3 4356 Homo sapiens membrane protein 
palmitoylated 3 (MAGUK p55 
subfamily member 3) 
7221 34785138 
30 TRIM37 4591 Homo sapiens tripartite motif-
containing 37, 
7523 23271191 
31 NCF2 4688 Homo sapiens neutrophil cytosolic 
factor 2 (65kDa, chronic 
granulomatous disease, autosomal 2), 
7661 12804408 
32 RPL10A 4736 Homo sapiens ribosomal protein L10a 10299 13905015 
33 NFYA 4800 Homo sapiens nuclear transcription 
factor Y alpha  
7804 24660183 
34 NRAS 4893 Homo sapiens neuroblastoma RAS 
viral (v- ras) oncogene homolog  
7989 13528839 
35 NTRK3_e 4916 Homo sapiens neurotrophic tyrosine 
kinase receptor type 3 transcript 
variant 3  
8033 15489167 
36 OAS2 4939 Homo sapiens 2'-5'-oligoadenylate 
synthetase 2 69/71kDa  
8087 29351562 
37 endometrio
sis 
5091 Homo sapiens pyruvate carboxylase 8636 33871110 
38 CDK17 5128 Homo sapiens endometriosisTAIRE 
protein kinase 2  
8750 21542570 
39 PDE4A 5141 Homo sapiens Homo sapiens 
phosphodiesterase 4A, cAMP-specific 
(phosphodiesterase E2 dunce 
homolog, Dro 
8780 18043808 
40 PHF1 5252 Homo sapiens PHD finger protein 1 
transcript variant 2  
8919 33874006 
41 PKM2 5315 Homo sapiens pyruvate kinase muscle 
transcript variant 1  
9021 14043290 
42 MAP2K5 5607 Homo sapiens mitogen-activated 
protein kinase kinase 5, transcript 
variant A  
6845 33871775 
43 PRPS2 5634 Homo sapiens phosphoribosyl 
pyrophosphate synthetase 2  
9465 26251732 
44 RAN 5901 Homo sapiens RAN member RAS 
oncogene family  
9846 33871120 
45 RB1 5925 Homo sapiens retinoblastoma 1 
(including osteosarcoma)  
9884 24660139 
46 RBMS1 5937 Homo sapiens Homo sapiens RNA 
binding motif single stranded 
interacting protein 1 transcript variant 
9907 33869903 
47 RET_a 5979 Homo sapiens ret proto-oncogene 
(multiple endocrine neoplasia and 
medullary thyroid carci 
9967 13279040 
48 RORC 6097 Homo sapiens RAR-related orphan 
receptor C 
10260 21594879 
49 RPL18 6141 Homo sapiens ribosomal protein L18 10310 38197133 
50 RPL18A 6142 Homo sapiens ribosomal protein L18a 10311 38196939 
51 RPL28 6158 Homo sapiens ribosomal protein L28 10330 15079502 
52 RPL31 6160 Homo sapiens ribosomal protein L31 10334 40226052 
53 RPL32 6161 Homo sapiens ribosomal protein L32 10336 15079341 
54 S100A6 6277 Homo sapiens S100 calcium binding 
protein A6 (calcyclin)  
10496 33876209 
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55 SCP2 6342 Homo sapiens sterol carrier protein 2 
transcript variant 2  
10606 45501107 
56 SIAH1 6477 Homo sapiens seven in absentia 
homolog 1 (Drosophila) transcript 
variant 2  
10857 27503513 
57 SMARCD 6602 Homo sapiens SWI/SNF related 
matrix associated actin dependent 
regulator of chromatin subfamily d 
member 1 
11106 33874464 
58 SMARCE 6605 Homo sapiens SWI/SNF related 
matrix associated actin dependent 
regulator of chromatin 
11109 13937940 
59 SOD2 6648 Homo sapiens superoxide dismutase 2 
mitochondrial  
11180 15214594 
60 SOX2 6657 Homo sapiens SRY (sex determining 
region Y)-box 2  
11195 33869633 
61 SRPK1 6732 Homo sapiens SFRS protein kinase 1 11305 23468344 
62 TPM1 7168 Homo sapiens tropomyosin 1 (alpha) 12010 33873609 
63 NR2C1 7181 Homo sapiens nuclear receptor 
subfamily 2 group C member 1  
7971 25304018 
64 TRIP6 7205 Homo sapiens thyroid hormone 
receptor interactor 6,  
12311 13436460 
65 UBA1 7317 Homo sapiens Homo sapiens 
ubiquitin- activating enzyme E1 
(A1S9T and BN75 temperature 
sensitivity compl 
12469 33989140 
66 VCL 7414 Homo sapiens vinculin 12665 24657578 
67 ZNF41 7592 Homo sapiens zinc finger protein 41 
transcript variant 2  
13107 21955337 
68 PAX8 7849 Homo sapiens paired box gene 8 
transcript variant PAX8A  
8622 33987990 
69 NRIP1 8204 Homo sapiens nuclear receptor 
interacting protein 1  
8001 25955638 
70 PIP4K2B 8396 Homo sapiens phosphatidylinositol-4- 
phosphate 5-kinase type II beta 
transcript variant 2 
8998 20071965 
71 UXT 8409 Homo sapiens ubiquitously-expressed 
transcript  
12641 14424496 
72 API5 8539 Homo sapiens apoptosis inhibitor 5 594 17389324 
73 MKNK1 8569 Homo sapiens MAP kinase-interacting 
serine/threonine kinase 1  
7110 33877125 
74 SUCLA2 8803 Homo sapiens succinate-CoA ligase 
ADP- forming beta subunit  
11448 34783884 
75 LDB1 8861 Homo sapiens LIM domain binding 1 6532 38197167 
76 NAE1 8883 Homo sapiens amyloid beta precursor 
protein binding protein 1 transcript 
variant 1  
621 38197227 
77 PAPSS2 9060 Homo sapiens 3'-phosphoadenosine 
5'- phosphosulfate synthase 2  
8604 33869502 
78 USP10 9100 Homo sapiens ubiquitin specific 
protease 10 
12608 12653004 
79 PRPF4 9128 Homo sapiens Homo sapiens PRP4 
pre- 
17349 33876345 
80 AIM2 9447 Homo sapiens absent in melanoma 2 357 15012076 
81 TBPL1 9519 Homo sapiens TBP-like 1 11589 33988482 
82 TRAF4 9618 Homo sapiens TNF receptor-
associated factor 4 transcript variant 1  
12034 12804686 
83 SOCS5 9655 Homo sapiens suppressor of cytokine 
signaling 5  
16852 23273933 
84 ZSCAN12 9753 Homo sapiens zinc finger protein 305 13172 27371192 
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85 HDAC4 9759 Homo sapiens cDNA 14063 25058272 
86 KIAA0101 9768 Homo sapiens KIAA0101 gene 
product 
28961 33873244 
87 IP6K1 9807 Homo sapiens inositol hexaphosphate 
kinase 1 
18360 15277916 
88 RNF40 9810 Homo sapiens ring finger protein 40 
transcript variant 1  
16867 13543993 
89 GPHN 10243 Homo sapiens gephyrin 15465 34783414 
90 HRSP12 10247 Homo sapiens translational inhibitor 
protein p14.5 
16897 16307462 
91 STUB1 10273 Homo sapiens STIP1 homology and 
U-Box containing protein 1 
11427 14043118 
92 TRAIP 10293 Homo sapiens TRAF interacting 
protein 
30764 17939476 
93 PLK4 10733 Homo sapiens serine/threonine kinase 
18 
11397 23243308 
94 CCNI 10983 Homo sapiens cyclin I 1595 38197480 
95 IL24 11009 Homo sapiens interleukin 24 
transcript variant 1  
11346 16307184 
96 CDK20 23552 Homo sapiens cell cycle related kinase 21420 33988018 
97 PABendo 
metriosis 1 
26986 Homo sapiens poly(A) binding protein 
cytoplasmic 1  
8554 33872187 
98 MED4 29079 Homo sapiens vitamin D receptor 
interacting protein  
17903 13528773 
99 NME7 29922 Homo sapiens non-metastatic cells 7 
protein expressed in (nucleoside-
diphosphate kinase) transcript variant 
1 
20461 13937770 
100 PHF11 51131 Homo sapiens PHD finger protein 11 17024 33880652 
101 IRAK4 51135 Homo sapiens interleukin-1 receptor- 
associated kinase 4 mRNA (cDNA 
clone MGC:13330 ) 
17967 15426431 
102 TXNDC3 51314 Homo sapiens thioredoxin domain 
containing 3 (spermatozoa)  
16473 22477641 
103 TAOK3 51347 Homo sapiens STE20-like kinase 18133 33877128 
104 STYXL1 51657 Homo sapiens dual specificity 
phosphatase 24 (putative)  
18165 33869206 
105 ASB1 51665 Homo sapiens ankyrin repeat and 
SOCS box- containing 1  
16011 33878672 
106 MST4 51765 Homo sapiens Mst3 and SOK1-related 
kinase (MASK)  
na 109633024 
107 PELO 53918 Homo sapiens pelota homolog 
(Drosophila) 
8829 33870521 
108 ETNK2 55224 Homo sapiens ethanolamine kinase 2 25575 33873304 
109 RFK 55312 Homo sapiens riboflavin kinase 30324 13937919 
110 C9orf86 55684 Homo sapiens chromosome 9 open 
reading frame 86  
24703 18089263 
111 DDX55 57696 Homo sapiens DEAD (Asp-Glu-Ala-
Asp) box polypeptide 55  
20085 34190861 
112 CCNB1IP 57820 Homo sapiens cDNA 19437 12654750 
113 KLHL12 59349 Homo sapiens kelch-like protein 
C3IP1 
19360 13112018 
114 SAV1 60485 Homo sapiens salvador homolog 1 
(Drosophila)  
17795 18088227 
115 CAMKV 79012 Homo sapiens hypothetical protein 
MGC8407 
28788 33875513 
116 NSBP1 79366 Homo sapiens nucleosomal binding 
protein 1, 
8013 13529139 
117 ALPK1 80216 Homo sapiens alpha-kinase 1 mRNA 
(cDNA clone MGC:71554 )  
20917 38174241 
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118 ELMOD3 84173 Homo sapiens RNA binding motif and 
ELMO domain 1  
26158 33877554 
119 AIFM2 84883 Homo sapiens apoptosis-inducing 
factor (AIF)-like mitochondrion-
associated inducer of death 
21411 13543963 
120 RHOT2 89941 Homo sapiens ras homolog gene 
family member T2  
21169 15928946 
121 PYGO2 90780 Homo sapiens pygopus 2 30257 33991480 
(i) This number is the SEQ ID NO: for the coding sequence for the auto-antigen biomarker, as shown in the 
sequence listing. 
(ii)The “ID” column shows the Entrez GeneID number for the antigen marker. An Entrez GeneID value is unique 
across all taxa. 
(iii)The “Symbol” column gives the gene symbol which has been approved by the HGNC. The HGNC aims to 
give unique and meaningful names to every miRNA and human gene. 
(iv) This name is taken from the Official Full Name provided by NCBI. An auto-antigen may have been referred 
to by one or more pseudonyms in the prior art. The invention relates to these auto-antigens regardless of their 
nomenclature. 
(v) The HUGO Gene Nomenclature Committee aims to give unique and meaningful names to every human gene. 
The HGNC number thus identifies a unique human gene. An additional dash-number suffix indicates pre-miRNAs 
that lead to identical mature miRNAs but that are located at different places in the genome. 
(vi)A “GI” number, or “GenInfo Identifier”, is a series of digits assigned consecutively to each sequence record 
processed by NCBI when sequences are added to its databases. The GI number bears no resemblance to the 
accession number of the sequence record. When a sequence is updated (e.g. for correction, or to add more 
annotation or information) it receives a new GI number. Thus the sequence associated with a given GI number is 
never changed. 
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TABLE 9-20 
Table listing relevant miRNAs (see section 6.5) 
No.
(i)
 miRNA name
(ii)
 Symbol
(iii)
 HGNC
(iv)
 Sequence 
122 ebv-miR-BART12 ebv-miR-BART12   UCCUGUGGUGUUUGGUGUGGUU 
123 ebv-miR-BART14 ebv-miR-BART14   UAAAUGCUGCAGUAGUAGGGAU 
124 ebv-miR-BART16 ebv-miR-BART16   UUAGAUAGAGUGGGUGUGUGCUCU 
125 ebv-miR-BART20-5p ebv-miR-BART20-5p   UAGCAGGCAUGUCUUCAUUCC 
126 ebv-miR-BART2-5p ebv-miR-BART2-5p   UAUUUUCUGCAUUCGCCCUUGC 
127 hsa-let-7b* MIRLET7B HGNC:31479 UGAGGUAGUAGGUUGUGUGGUU 
128 hsa-let-7f MIRLET7F1 HGNC:31483 UGAGGUAGUAGAUUGUAUAGUU 
129 hsa-let-7f-1* MIRLET7F2 HGNC:31484 UGAGGUAGUAGAUUGUAUAGUU 
130 hsa-let-7g MIRLET7G HGNC:31485 UGAGGUAGUAGUUUGUACAGUU 
131 hsa-miR-103a MIR103A1 HGNC:31490 AGCAGCAUUGUACAGGGCUAUGA 
132 hsa-miR-10b MIR10b HGNC:31498 UACCCUGUAGAACCGAAUUUGUG 
133 hsa-miR-1183 MIR1183 HGNC:35264 CACUGUAGGUGAUGGUGAGAGUGGGCA 
134 hsa-miR-1202 MIR1202 HGNC:35268 GUGCCAGCUGCAGUGGGGGAG 
135 hsa-miR-1207-5p MIR1207 HGNC:35273 UGGCAGGGAGGCUGGGAGGGG 
136 hsa-miR-122 MIR122 HGNC:31501 UGGAGUGUGACAAUGGUGUUUG 
137 hsa-miR-1224-5p MIR1224 HGNC:33923 GUGAGGACUCGGGAGGUGG 
138 hsa-miR-1225-3p MIR1225 HGNC:33931 GUGGGUACGGCCCAGUGGGGGG 
139 hsa-miR-1225-5p MIR1225 HGNC:33931 GUGGGUACGGCCCAGUGGGGGG 
140 hsa-miR-1226* MIR1226 HGNC:33922 UCACCAGCCCUGUGUUCCCUAG 
141 hsa-miR-1228* MIR1228 HGNC:33928 UCACACCUGCCUCGCCCCCC 
142 hsa-miR-1234 MIR1234 HGNC:33926 UCGGCCUGACCACCCACCCCAC 
143 hsa-miR-1237 MIR1237 HGNC:33927 UCCUUCUGCUCCGUCCCCCAG 
144 hsa-miR-1238 MIR1238 HGNC:33933 CUUCCUCGUCUGUCUGCCCC 
145 hsa-miR-125a-5p MIR125a HGNC:31505 UCCCUGAGACCCUUUAACCUGUGA 
146 hsa-miR-1260 MIR1260A HGNC:35325 AUCCCACCUCUGCCACCA 
147 hsa-miR-1260b MIR1260b HGNC:38258 AUCCCACCACUGCCACCAU 
148 hsa-miR-1280 MIR1280 HGNC:35368 UCCCACCGCUGCCACCC 
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149 hsa-miR-1281 MIR1281 HGNC:35359 UCGCCUCCUCCUCUCCC 
150 hsa-miR-1290 MIR1290 HGNC:35283 UGGAUUUUUGGAUCAGGGA 
151 hsa-miR-1291 MIR1291 HGNC:35284 UGGCCCUGACUGAAGACCAGCAGU 
152 hsa-miR-129-3p MIR129-1/ MIR129-2 HGNC:31512/ 31513 CUUUUUGCGGUCUGGGCUUGC 
153 hsa-miR-1301 MIR1301 HGNC:35253 UUGCAGCUGCCUGGGAGUGACUUC 
154 hsa-miR-135a MIR135A1/ MIR135A2 HGNC:31520/ 31521 UAUGGCUUUUUAUUCCUAUGUGA 
155 hsa-miR-135a* MIR135A1/ MIR135A2 HGNC:31520/ 31521 UAUGGCUUUUUAUUCCUAUGUGA 
156 hsa-miR-141 MIR141 HGNC:31528 UAACACUGUCUGGUAAAGAUGG 
157 hsa-miR-142-3p MIR142 HGNC:31529 CAUAAAGUAGAAAGCACUACU 
158 hsa-miR-149 MIR149 HGNC:31536 UCUGGCUCCGUGUCUUCACUCCC 
159 hsa-miR-150 MIR150 HGNC:31537 UCUCCCAACCCUUGUACCAGUG 
160 hsa-miR-150* MIR150 HGNC:31537 UCUCCCAACCCUUGUACCAGUG 
161 hsa-miR-1539 MIR1539 HGNC:35383 UCCUGCGCGUCCCAGAUGCCC 
162 hsa-miR-181a MIR181A2 HGNC:31549 AACAUUCAACGCUGUCGGUGAGU 
163 hsa-miR-1825 MIR1825 HGNC:35389 UCCAGUGCCCUCCUCUCC 
164 hsa-miR-186 MIR186 HGNC:31557 CAAAGAAUUCUCCUUUUGGGCU 
165 hsa-miR-18a MIR18a HGNC:31548 UAAGGUGCAUCUAGUGCAGAUAG 
166 hsa-miR-18b MIR18b HGNC:32025 UAAGGUGCAUCUAGUGCAGUUAG 
167 hsa-miR-191* MIR191 HGNC:31561 CAACGGAAUCCCAAAAGCAGCUG 
168 hsa-miR-197 MIR197 HGNC:31569 UUCACCACCUUCUCCACCCAGC 
169 hsa-miR-198 MIR198 HGNC:31570 GGUCCAGAGGGGAGAUAGGUUC 
170 hsa-miR-205 MIR205 HGNC:31583 UCCUUCAUUCCACCGGAGUCUG 
171 hsa-miR-2116* MIR2116 HGNC:37310 GGUUCUUAGCAUAGGAGGUCU 
172 hsa-miR-215 MIR215 HGNC:31592 AUGACCUAUGAAUUGACAGAC 
173 hsa-miR-22 MIR22 HGNC:31599 AAGCUGCCAGUUGAAGAACUGU 
174 hsa-miR-223 MIR223 HGNC:31603 UGUCAGUUUGUCAAAUACCCCA 
175 hsa-miR-2276 MIR2276 HGNC:37313 UCUGCAAGUGUCAGAGGCGAGG 
176 hsa-miR-23c MIR23c HGNC:38913 AUCACAUUGCCAGUGAUUACCC 
177 hsa-miR-26a MIR26A1/ MIR26A2 HGNC:31610/ 31611 UUCAAGUAAUCCAGGAUAGGCU 
178 hsa-miR-28-3p MIR28 HGNC:31615 AAGGAGCUCACAGUCUAUUGAG 
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179 hsa-miR-28-5p MIR28 HGNC:31615 AAGGAGCUCACAGUCUAUUGAG 
180 hsa-miR-29b MIR29B1/ MIR29B2 HGNC:31619/ 31620 UAGCACCAUUUGAAAUCAGUGUU 
181 hsa-miR-30a MIR30a HGNC:31624 UGUAAACAUCCUCGACUGGAAG 
182 hsa-miR-30b MIR30b HGNC:31625 UGUAAACAUCCUACACUCAGCU 
183 hsa-miR-3131 MIR3131 HGNC:38347 UCGAGGACUGGUGGAAGGGCCUU 
184 hsa-miR-3138 MIR3138 HGNC:38341 UGUGGACAGUGAGGUAGAGGGAGU 
185 hsa-miR-3149 MIR3149 HGNC:38251 UUUGUAUGGAUAUGUGUGUGUAU 
186 hsa-miR-3156-5p MIR3156-1/ MIR3156-2/ MIR3156-3 HGNC:38241/ 
38213/ 38229 
AAAGAUCUGGAAGUGGGAGACA 
187 hsa-miR-3180-5p MIR3180-1/ MIR3180-2/ MIR3180-3/ 
MIR3180-4/ MIR3180-5 
HGNC:38382/ 
38343/ 38239/ 
38920/ 38969 
UGGGGCGGAGCUUCCGGAG 
188 hsa-miR-3194-5p MIR3194 HGNC:38346 GGCCAGCCACCAGGAGGGCUG 
189 hsa-miR-3195 MIR3195 HGNC:38250 CGCGCCGGGCCCGGGUU 
190 hsa-miR-3196 MIR3196 HGNC:38198 CGGGGCGGCAGGGGCCUC 
191 hsa-miR-32 MIR32 HGNC:31631 UAUUGCACAUUACUAAGUUGCA 
192 hsa-miR-320c MIR320C1/ MIR320C2 HGNC:35248/ 35387 AAAAGCUGGGUUGAGAGGGU 
193 hsa-miR-324-3p MIR324 HGNC:31767 CGCAUCCCCUAGGGCAUUGGUGU 
194 hsa-miR-328 MIR328 HGNC:31770 CUGGCCCUCUCUGCCCUUCCGU 
195 hsa-miR-331-5p MIR331 HGNC:31772 CUAGGUAUGGUCCCAGGGAUCC 
196 hsa-miR-33b* MIR33b HGNC:32791 GUGCAUUGCUGUUGCAUUGC 
197 hsa-miR-342-3p MIR342 HGNC:31778 AGGGGUGCUAUCUGUGAUUGA 
198 hsa-miR-34a MIR34a HGNC:31635 UGGCAGUGUCUUAGCUGGUUGU 
199 hsa-miR-3610 MIR3610 HGNC:38942 GAAUCGGAAAGGAGGCGCCG 
200 hsa-miR-3648 MIR3648 HGNC:38941 AGCCGCGGGGAUCGCCGAGGG 
201 hsa-miR-3652 MIR3652 HGNC:38894 CGGCUGGAGGUGUGAGGA 
202 hsa-miR-3663-5p MIR3663 HGNC:38958 GCUGGUCUGCGUGGUGCUCGG 
203 hsa-miR-3667-5p MIR3667 HGNC:38990 AAAGACCCAUUGAGGAGAAGGU 
204 hsa-miR-382 MIR382 HGNC:31875 GAAGUUGUUCGUGGUGGAUUCG 
205 hsa-miR-3911 MIR3911 HGNC:38962 UGUGUGGAUCCUGGAGGAGGCA 
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206 hsa-miR-3937 MIR3937 HGNC:38970 ACAGGCGGCUGUAGCAAUGGGGG 
207 hsa-miR-4257 MIR4257 HGNC:38312 CCAGAGGUGGGGACUGAG 
208 hsa-miR-425* MIR425 HGNC:31882 AAUGACACGAUCACUCCCGUUGA 
209 hsa-miR-4270 MIR4270 HGNC:38377 UCAGGGAGUCAGGGGAGGGC 
210 hsa-miR-4274 MIR4274 HGNC:38194 CAGCAGUCCCUCCCCCUG 
211 hsa-miR-4281 MIR4281 HGNC:38357 GGGUCCCGGGGAGGGGGG 
212 hsa-miR-4284 MIR4284 HGNC:38322 GGGCUCACAUCACCCCAU 
213 hsa-miR-4286 MIR4286 HGNC:38186 ACCCCACUCCUGGUACC 
214 hsa-miR-429 MIR429 HGNC:13784 UAAUACUGUCUGGUAAAACCGU 
215 hsa-miR-4290 MIR4290 HGNC:38360 UGCCCUCCUUUCUUCCCUC 
216 hsa-miR-4313 MIR4313 HGNC:38310 AGCCCCCUGGCCCCAAACCC 
217 hsa-miR-4323 MIR4323 HGNC:38394 CAGCCCCACAGCCUCAGA 
218 hsa-miR-466 MIR466 HGNC:38359 AUACACAUACACGCAACACACAU 
219 hsa-miR-483-3p MIR483 HGNC:32340 AAGACGGGAGGAAAGAAGGGAG 
220 hsa-miR-484 MIR484 HGNC:32341 UCAGGCUCAGUCCCCUCCCGAU 
221 hsa-miR-485-3p MIR485 HGNC:32067 AGAGGCUGGCCGUGAUGAAUUC 
222 hsa-miR-486-5p MIR486 HGNC:32342 UCCUGUACUGAGCUGCCCCGAG 
223 hsa-miR-488 MIR488 HGNC:32073 UUGAAAGGCUAUUUCUUGGUC 
224 hsa-miR-497 MIR497 HGNC:32088 CAGCAGCACACUGUGGUUUGU 
225 hsa-miR-511 MIR511-1 HGNC:32077 GUGUCUUUUGCUCUGCAGUCA 
226 hsa-miR-512 MIR511-2 HGNC:32078 GUGUCUUUUGCUCUGCAGUCA 
227 hsa-miR-520c-3p MIR520c HGNC:32108 CUCUAGAGGGAAGCACUUUCUG 
228 hsa-miR-550a MIR550A1/ MIR550A2/ MIR550A3 HGNC:32804/ 
32805/ 41870 
AGUGCCUGAGGGAGUAAGAGCCC 
229 hsa-miR-556-3p MIR556 HGNC:32812 GAUGAGCUCAUUGUAAUAUGAG 
230 hsa-miR-557 MIR557 HGNC:32813 GUUUGCACGGGUGGGCCUUGUCU 
231 hsa-miR-561 MIR561 HGNC:32817 CAAAGUUUAAGAUCCUUGAAGU 
232 hsa-miR-572 MIR572 HGNC:32828 GUCCGCUCGGCGGUGGCCCA 
233 hsa-miR-574-3p MIR574 HGNC:32830 UGAGUGUGUGUGUGUGAGUGUGU 
234 hsa-miR-574-5p MIR574 HGNC:32830 UGAGUGUGUGUGUGUGAGUGUGU 
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235 hsa-miR-595 MIR595 HGNC:32851 GAAGUGUGCCGUGGUGUGUCU 
236 hsa-miR-630 MIR630 HGNC:32886 AGUAUUCUGUACCAGGGAAGGU 
237 hsa-miR-642b MIR642b HGNC:38902 AGACACAUUUGGAGAGGGACCC 
238 hsa-miR-646 MIR646 HGNC:32902 AAGCAGCUGCCUCUGAGGC 
239 hsa-miR-659 MIR659 HGNC:32915 CUUGGUUCAGGGAGGGUCCCCA 
240 hsa-miR-660 MIR660 HGNC:32916 UACCCAUUGCAUAUCGGAGUUG 
241 hsa-miR-663 MIR663A HGNC:32919 AGGCGGGGCGCCGCGGGACCGC 
242 hsa-miR-664 MIR664 HGNC:35370 UAUUCAUUUAUCCCCAGCCUACA 
243 hsa-miR-720 MIR720 HGNC:35375 UCUCGCUGGGGCCUCCA 
244 hsa-miR-762 MIR762 HGNC:37303 GGGGCUGGGGCCGGGGCCGAGC 
245 hsa-miR-766 MIR766 HGNC:33139 ACUCCAGCCCCACAGCCUCAGC 
246 hsa-miR-877* MIR877 HGNC:33660 GUAGAGGAGAUGGCGCAGGG 
247 hsa-miR-888 MIR888 HGNC:33648 UACUCAAAAAGCUGUCAGUCA 
248 hsa-miR-933 MIR933 HGNC:33676 UGUGCGCAGGGAGACCUCUCCC 
249 hsa-miR-940 MIR940 HGNC:33683 AAGGCAGGGCCCCCGCUCCCC 
250 hsa-miR-95 MIR95 HGNC:31647 UUCAACGGGUAUUUAUUGAGCA 
251 hsv1-miR-H1*/ hsv1-miR-H1-3p hsv1-miR-H1*   UACACCCCCCUGCCUUCCACCCU 
252 hsv1-miR-H2-3p hsv1-miR-H2-3p   CCUGAGCCAGGGACGAGUGCGACU 
253 hsv1-miR-H6-3p hsv1-miR-H6-3p   CACUUCCCGUCCUUCCAUCCC 
254 hsv1-miR-H7* hsv1-miR-H7*   UUUGGAUCCCGACCCCUCUUC 
255 hsv1-miR-H8 hsv1-miR-H8   UAUAUAGGGUCAGGGGGUUC 
256 hsv2-miR-H22 hsv2-miR-H22   AGGGGUCUGGACGUGGGUGGGC 
257 hsv2-miR-H25 hsv2-miR-H25   CUGCGCGGCGGAGACCGGGAC 
258 hsv2-miR-H6 hsv2-miR-H6   AAUGGAAGGCGAGGGGAUGC 
259 hsv2-miR-H6* hsv2-miR-H6*   CCCAUCUUCUGCCCUUCCAUCCU 
260 kshv-miR-K12-10a kshv-miR-K12-10a   UAGUGUUGUCCCCCCGAGUGGC 
261 kshv-miR-K12-12* kshv-miR-K12-12*   UGGGGGAGGGUGCCCUGGUUGA 
262 kshv-miR-K12-8* kshv-miR-K12-8*   ACUCCCUCACUAACGCCCCGCU 
(i) The SEQ ID NO: for the sequence of the mature, expressed miRNA biomarker. 
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(ii) The “miRNA name” column gives the name of the human miRNA as provided by the specialist database, miRBase, according to version 16 (released, August 2010). 
(iii) The “Symbol” column gives the gene symbol which has been approved by the HGNC. The HGNC aims to give unique and meaningful names to every miRNA and human gene. An 
additional dash-number suffix indicates premiRNAs that lead to identical mature miRNAs but that are located at different places in the genome. 
(iv) The HGNC aims to give unique and meaningful names to every miRNA (and human gene). The HGNC number thus identifies a unique human gene. Inclusion on to HUGO is for human 
genes only. 
 
TABLE 9-21 
Table listing identified miRNAs  (see section 6.5) 
No. miRNA name
(i)
 Symbol
(ii)
 HGNC
(iii)
 Sequence 
126 ebv-miR-BART2-5p ebv-miR-BART2-5p N/A UAUUUUCUGCAUUCGCCCUUGC 
263 hsa-miR-564 MIR564 32820 AGGCACGGUGUCAGCAGGC 
264 hsa-let-7d-5p MIRLET7D 31481 AGAGGUAGUAGGUUGCAUAGUU 
265 hsa-let-7d-3p MIRLET7D 31481 CUAUACGACCUGCUGCCUUUCU 
266 hsa-miR-29a MIR29A 31616 UAGCACCAUCUGAAAUCGGUUA 
157 hsa-miR-142-3p MIR142 31529 CAUAAAGUAGAAAGCACUACU 
168 hsa-miR-197 MIR197 31569 UUCACCACCUUCUCCACCCAGC 
172 hsa-miR-215 MIR215 31592 AUGACCUAUGAAUUGACAGAC 
267 hsa-miR-219-1-3p MIR-219-1 31597 AGAGUUGAGUCUGGACGUCCCG 
268 hsa-miR-296-3p MIR296 31617 GAGGGUUGGGUGGAGGCUCUCC 
192 hsa-miR-320c MIR320C 35248 AAAAGCUGGGUUGAGAGGGU 
269 hsa-miR-337-5p MIR337 31774 GAACGGCUUCAUACAGGAGUU 
270 hsa-miR-369-3p MIR369 31783 AAUAAUACAUGGUUGAUCUUU 
271 hsa-miR-450b-5p MIR450B 33642 UUUUGCAAUAUGUUCCUGAAUA 
272 hsa-miR-483-5p MIR483 32340 AAGACGGGAGGAAAGAAGGGAG 
273 hsa-miR-507 MIR507 32144 UUUUGCACCUUUUGGAGUGAA 
274 hsa-miR-517c MIR517C 32124 AUCGUGCAUCCUUUUAGAGUGU 
275 hsa-miR-519a MIR519A1/ MIR519A2 32128/ 32132 AAAGUGCAUCCUUUUAGAGUGU 
276 hsa-miR-519d MIR519D 32112 CAAAGUGCCUCCCUUUAGAGUG 
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277 hsa-miR-520g MIR520G 32116 ACAAAGUGCUUCCCUUUAGAGUGU 
278 hsa-miR-576-5p MIR576 32832 AUUCUAAUUUCUCCACGUCUUU 
279 hsa-miR-577 MIR577 32833 UAGAUAAAAUAUUGGUACCUG 
280 hsa-miR-604 MIR604 32860 AGGCUGCGGAAUUCAGGAC 
281 hsa-miR-610 MIR610 32866 UGAGCUAAAUGUGUGCUGGGA 
282 hsa-miR-619 MIR619 32875 GACCUGGACAUGUUUGUGCCCAGU 
283 hsa-miR-1256 MIR1256 35321 AGGCAUUGACUUCUCACUAGCU 
284 hsa-miR-1278 MIR1278 35356 UAGUACUGUGCAUAUCAUCUAU 
285 hsa-miR-1297 MIR1297 35289 UUCAAGUAAUUCAGGUG 
286 hcmv-miR-US33-5p N/A N/A GAUUGUGCCCGGACCGUGGGCG 
287 hsv1-miR-H1-5p N/A N/A GAUGGAAGGACGGGAAGUGGA 
288 hsa-miR-877 MIR877 33660 GUAGAGGAGAUGGCGCAGGG 
289 hsa-let-7e-5p MIRLET7E 31482 UGAGGUAGGAGGUUGUAUAGUU 
290 hsa-let-7e-3p MIRLET7E 31482 CUAUACGGCCUCCUAGCUUUCC 
128 hsa-let-7f MIRLET7F1 31483 UGAGGUAGUAGAUUGUAUAGUU 
130 hsa-let-7g MIRLET7G 31485 UGAGGUAGUAGUUUGUACAGUU 
291 hsa-miR-9 MIR9-1/ MIR9-2/ MIR9-3 31641/ 31642/ 31646 UCUUUGGUUAUCUAGCUGUAUGA 
182 hsa-miR-30b MIR30a 31624 UGUAAACAUCCUCGACUGGAAG 
198 hsa-miR-34a MIR34A 31635 UGGCAGUGUCUUAGCUGGUUGU 
292 hsa-miR-92b MIR92B 32920 UAUUGCACUCGUCCCGGCCUCC 
293 hsa-miR-96-5p MIR96 31648 UUUGGCACUAGCACAUUUUUGCU 
294 hsa-miR-96-3p MIR96 31648 AAUCAUGUGCAGUGCCAAUAUG 
295 hsa-miR-106a-5p MIR106A 31494 AAAAGUGCUUACAGUGCAGGUAG 
296 hsa-miR-106a-3p MIR106A 31494 CUGCAAUGUAAGCACUUCUUAC 
297 hsa-miR-17-5p MIR17 31547 CAAAGUGCUUACAGUGCAGGUAG 
298 hsa-miR-17-3p MIR17 31547 ACUGCAGUGAAGGCACUUGUAG 
299 hsa-miR-106b-5p MIR106B 31495 UAAAGUGCUGACAGUGCAGAU 
300 hsa-miR-106b-3p MIR106B 31495 CCGCACUGUGGGUACUUGCUGC 
301 hsa-miR-127-3p MIR127 31509 UCGGAUCCGUCUGAGCUUGGCU 
302 hsa-miR-128 MIR128-1/MIR128-2 31510/31511 UCACAGUGAACCGGUCUCUUU 
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303 hsa-miR-154 MIR154 31541 UAGGUUAUCCGUGUUGCCUUCG 
304 hsa-miR-155 MIR155 31542 UUAAUGCUAAUCGUGAUAGGGGU 
305 hsa-miR-183-5p MIR183 31554 UAUGGCACUGGUAGAAUUCACU 
306 hsa-miR-183-3p MIR183 31554 GUGAAUUACCGAAGGGCCAUAA 
307 hsa-miR-194 MIR194-1/ MIR194-2 31564/ 31565 UGUAACAGCAACUCCAUGUGGA 
308 hsa-miR-196b-5p MIR196B 31790 UAGGUAGUUUCCUGUUGUUGGG 
309 hsa-miR-196b-3p MIR196B 31790 UCGACAGCACGACACUGCCUUC 
310 hsa-miR-203 MIR203 31581 GUGAAAUGUUUAGGACCACUAG 
311 hsa-miR-204 MIR204 31582 UUCCCUUUGUCAUCCUAUGCCU 
312 hsa-miR-221-5p MIR221 31601 ACCUGGCAUACAAUGUAGAUUU 
313 hsa-miR-221-3p MIR221 31601 AGCUACAUUGUCUGCUGGGUUUC 
174 hsa-miR-223 MIR223 31603 UGUCAGUUUGUCAAAUACCCCA 
314 hsa-miR-376a MIR376A1/ MIR376A2 31869/ 32532 AUCAUAGAGGAAAAUCCACGU 
315 hsa-miR-376c MIR376C 31782 AACAUAGAGGAAAUUCCACGU 
316 hsa-miR-377 MIR377 31870 AUCACACAAAGGCAACUUUUGU 
317 hsa-miR-379 MIR379 31872 UGGUAGACUAUGGAACGUAGG 
318 hsa-miR-423-3p MIR423 31880 AGCUCGGUCUGAGGCCCCUCAGU 
319 hsa-miR-424-5p MIR424 31881 CAGCAGCAAUUCAUGUUUUGAA 
320 hsa-miR-424-3p MIR424 31881 CAAAACGUGAGGCGCUGCUAU 
321 hsa-miR-425-5p MIR425 31882 AAUGACACGAUCACUCCCGUUGA 
322 hsa-miR-425-3p MIR425 31882 AUCGGGAAUGUCGUGUCCGCCC 
323 hsa-miR-454-5p MIR454 33137 ACCCUAUCAAUAUUGUCUCUGC 
324 hsa-miR-454-3p MIR454 33137 UAGUGCAAUAUUGCUUAUAGGGU 
325 hsa-miR-486-3p hsa-miR-486/ MIR486 32342 CGGGGCAGCUCAGUACAGGAU 
326 hsa-miR-509-3p MIR509-3 33675 UGAUUGGUACGUCUGUGGGUAG 
327 hsa-miR-514 MIR514-1/ MIR514-2/ MIR514-3 32148/ 32149/ 32150 AUUGACACUUCUGUGAGUAGA 
328 hsa-miR-542-3p MIR542 32534 UGUGACAGAUUGAUAACUGAAA 
329 hsa-miR-545-5p MIR545 32531 UCAGUAAAUGUUUAUUAGAUGA 
330 hsa-miR-545-3p MIR545 32531 UCAGCAAACAUUUAUUGUGUGC 
331 hsa-miR-626 MIR626 32882 AGCUGUCUGAAAAUGUCUU 
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236 hsa-miR-630 MIR630 32886 AGUAUUCUGUACCAGGGAAGGU 
241 hsa-miR-663 MIR663A 32919 AGGCGGGGCGCCGCGGGACCGC 
243 hsa-miR-720 MIR720 35375 UCUCGCUGGGGCCUCCA 
332 hsa-miR-758-5p MIR758 33133 GAUGGUUGACCAGAGAGCACAC 
333 hsa-miR-758-3p MIR758 33133 UUUGUGACCUGGUCCACUAACC 
334 hsa-miR-876-3p MIR876 33653 UGGUGGUUUACAAAGUAAUUCA 
335 hsa-miR-1185 MIR1185-1 /MIR1185-2 35257 /35254 AGAGGAUACCCUUUGUAUGUU 
146 hsa-miR-1260 MIR1260A 35325 AUCCCACCUCUGCCACCA 
336 hsa-miR-1266-5p MIR1266 35334 CCUCAGGGCUGUAGAACAGGGCU 
337 hsa-miR-1266-3p MIR1266 35334 CCCUGUUCUAUGCCCUGAGGGA 
338 hsa-miR-199a-3p MIR199A1 /MIR199A2 31571 /31572 ACAGUAGUCUGCACAUUGGUUA 
339 hsa-miR-199b-3p MIR199B 31573 ACAGUAGUCUGCACAUUGGUUA 
224 hsa-miR-497 MIR497 32088 CAGCAGCACACUGUGGUUUGU 
340 hsa-miR-625-5p MIR625 32881 AGGGGGAAAGUUCUAUAGUCC 
341 hsa-miR-625-3p MIR625 32881 GACUAUAGAACUUUCCCCCUCA 
342 hsa-miR-631 MIR631 32887 AGACCUGGCCCAGACCUCAGC 
343 hsa-miR-635 MIR635 32891 ACUUGGGCACUGAAACAAUGUCC 
(i) The SEQ ID NO: for the sequence of the mature, expressed miRNA biomarker. 
(ii) The “miRNA name” column gives the name of the human miRNA as provided by the specialist database, miRBase, according to version 16 (released, August 2010). 
(iii) The “Symbol” column gives the gene symbol which has been approved by the HGNC. The HGNC aims to give unique and meaningful names to every miRNA and 
human gene. An additional dash-number suffix indicates premiRNAs that lead to identical mature miRNAs but that are located at different places in the genome. 
(iv) The HGNC aims to give unique and meaningful names to every miRNA (and human gene). The HGNC number thus identifies a unique human gene. Inclusion on to 
HUGO is for human genes only. 
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TABLE 9-22 
Table listing relevant genes (see section 6.5) 
No.
(i)
 Symbol
(ii)
 ID
(iii)
 Name
(iv)
 HGNC
(v)
 GI
(vi)
 
344 CDC42 998 Homo sapiens cell division cycle 42 (GTP 
binding protein 25kDa) transcript variant 1  
1736 33990903 
345 EGFR_int 1956 Homo sapiens epidermal growth factor 
receptor (erythroblastic leukemia viral (v-
erb- b) oncogene homolog avian) 
3236 63101669 
346 KIT_ext 3815 Homo sapiens v-kit Hardy-Zuckerman 4 
feline sarcoma viral oncogene homolog  
6342 47938801 
347 PPARG 5468 Homo sapiens peroxisome proliferative 
activated receptor gamma transcript variant 
3  
9236 13905055 
348 WT1 7490 Homo sapiens Wilms tumor 1   12796 34190661 
(i) This number is the SEQ ID NO: for the coding sequence for the auto-antigen biomarker, as shown in the 
sequence listing. 
(ii) The “ID” column shows the Entrez GeneID number for the antigen marker. An Entrez GeneID value is unique 
across all taxa. 
(iii) The “Symbol” column gives the gene symbol which has been approved by the HGNC. The HGNC aims to 
give unique and meaningful names to every miRNA and human gene. 
(iv) This name is taken from the Official Full Name provided by NCBI. An auto-antigen may have been referred 
to by one or more pseudonyms in the prior art. The invention relates to these auto-antigens regardless of their 
nomenclature. 
(v) The HUGO Gene Nomenclature Committee aims to give unique and meaningful names to every human gene. 
The HGNC number thus identifies a unique human gene. An additional dash-number suffix indicates pre-miRNAs 
that lead to identical mature miRNAs but that are located at different places in the genome. 
(vi) A “GI” number, or “GenInfo Identifier”, is a series of digits assigned consecutively to each sequence record 
processed by NCBI when sequences are added to its databases. The GI number bears no resemblance to the 
accession number of the sequence record. When a sequence is updated (e.g. for correction, or to add more 
annotation or information) it receives a new GI number. Thus the sequence associated with a given GI number is 
never changed. 
 
TABLE 9-23 
Table listing identified genes/proteins (see section 6.5) 
Symbol
(i)
 ID
(ii)
 P. Value
(iii)
 Expression
(iv)
 
CCNB1IP1 57820 0.000000816 Down 
HSPD1 3329 0.00000196 Down 
PRPF4 9128 0.00000296 Down 
STYXL1 51657 0.0000222 Down 
ETNK2 55224 0.0000223 Down 
GALK1 2584 0.0000275 Down 
RNF40 9810 0.0000295 Down 
NTRK3_ext 4916 0.0000498 Down 
UBA1 7317 0.0000854 Up 
GTF2H1 2965 0.0000923 Down 
PDE4A 5141 0.000115 Down 
SMARCE1 6605 0.000133 Up 
TBPL1 9519 0.000197 Down 
PIP4K2B 8396 0.000252 Down 
LDB1 8861 0.000304 Down 
RHOT2 89941 0.00037 Down 
SMARCD1 6602 0.000384 Down 
Gene, protein and miRNA expression in women with endometriosis 
417 
SAV1 60485 0.000403 Down 
ZSCAN12 9753 0.000412 Down 
ASB1 51665 0.000414 Down 
KLHL12 59349 0.000428 Up 
UXT 8409 0.000642 Down 
E2F6 1876 0.000747 Up 
RBMS1 5937 0.000829 Up 
MAP2K5 5607 0.000909 Down 
PAPSS2 9060 0.001015 Down 
RAN 5901 0.001377 Up 
STUB1 10273 0.015531 Up 
TPM1 7168 0.022489 Up 
(i) The “ID” column shows the Entrez GeneID number for the antigen marker. An Entrez GeneID value is unique 
across all taxa.  
(ii) The “Symbol” column gives the gene symbol which has been approved by the HGNC. The HGNC aims to 
give 5 unique and meaningful names to every miRNA and human gene.  
(iii) The “p-value” represents the p-value of a microarray T-test derived from comparing case with control, as 
determined in study 1.  
(iv) The biomarkers can be up-regulated (i.e. an increase in fold-change, when compared to control samples) or 
down-regulated (i.e. a decrease in fold-change, when compared to control samples), as determined in study 1. 
 
TABLE 9-24 
Table listing identified genes/proteins (see section 6.5) 
Symbol
(i)
 ID
(ii)
 P. Value
(iii)
 Expression
(iv)
 
TPM1 7168 0.002915091 Up 
RORC 6097 0.006178466 Down 
HSPD1 3329 0.008954673 Down 
SRPK1 6732 0.015397291 Down 
PYGO2 90780 0.024303172 Down 
SOD2 6648 0.028978148 Up 
STUB1 10273 0.039435959 Up 
RAN 5901 0.02988746 Up 
(i) The “ID” column shows the Entrez GeneID number for the antigen marker. An Entrez GeneID value is unique 
across all taxa.  
(ii) The “Symbol” column gives the gene symbol which has been approved by the HGNC. The HGNC aims to 
give 5 unique and meaningful names to every miRNA and human gene.  
(iii) The “p-value” represents the p-value of a microarray T-test derived from comparing case with control, as 
determined in study 1.  
(iv) The biomarkers can be up-regulated (i.e. an increase in fold-change, when compared to control samples) or 
down-regulated (i.e. a decrease in fold-change, when compared to control samples), as determined in study 1. 
 
TABLE 9-25 
Table listing identified miRNAs(see section 6.5) 
miRNA Name
(i)
 P. Value
(ii)
 Expression
(iii)
 
hsa-miR-150 0.00006394 Down 
hsa-miR-122 0.02533983 Down 
hsa-miR-342-3p 0.00003342 Down 
hsa-miR-3648 0.00558781 Up 
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hsa-miR-574-5p 0.00002921 Down 
hsa-miR-1224-5p 0.00565712 Up 
hsa-miR-483-3p 0.00000011 Down 
hsa-miR-1290 0.02750229 Down 
hsa-miR-630 0.00000073 Down 
hsa-miR-4284 0.00000622 Down 
hsa-miR-4274 0.00578241 Down 
hsa-miR-1539 0.01689898 Down 
hsa-miR-484 0.00005860 Down 
hsa-miR-150* 0.00015240 Up 
hsa-miR-103a 0.00015153 Down 
hsa-miR-595 0.00000370 Down 
hsa-let-7f 0.01103692 Down 
hsa-miR-2116* 0.00966057 Down 
hsa-let-7g 0.01804877 Down 
hsa-miR-10b 0.00037142 Up 
hsa-miR-557 0.00171716 Up 
hsa-miR-574-3p 0.00001553 Down 
hsa-miR-29b 0.02130244 Down 
hsa-miR-3675-3p 0.02426579 Down 
hsa-miR-3196 0.00077761 Up 
hsa-miR-142-3p 0.00184763 Down 
hsa-miR-762 0.00310027 Up 
hsv2-miR-H22 0.01761904 Up 
hsa-miR-1260 0.00000231 Down 
hsv1-miR-H17 0.04790461 Up 
hsa-miR-1281 0.00000779 Down 
hsa-miR-720 0.00001081 Down 
ebv-miR-BART12 0.00005959 Down 
hsa-miR-146a 0.04352182 Down 
hsa-miR-1183 0.01111370 Up 
hsa-miR-1228* 0.00000083 Down 
hsa-miR-3131 0.00077353 Up 
hsa-miR-1825 0.00000149 Down 
hsa-miR-30b 0.00644932 Down 
kshv-miR-K12-12* 0.00002874 Down 
hsv2-miR-H6 0.00825432 Up 
hsa-miR-26a 0.00002875 Down 
hsa-miR-4281 0.00008771 Up 
hsa-miR-3911 0.01275802 Up 
ebv-miR-BART16 0.00004541 Down 
hsv1-miR-H1* 0.00000324 Down 
hsa-miR-1202 0.00055105 Up 
hsa-miR-3610 0.00687590 Up 
hsv1-miR-H6-3p 0.00004842 Down 
hsa-miR-3138 0.00899372 Up 
hsa-miR-1207-5p 0.00281946 Up 
hsa-miR-3149 0.00009532 Down 
hsa-miR-4270 0.00004371 Up 
hsa-miR-3195 0.00682325 Up 
hsv1-miR-H8 0.00202682 Down 
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hsa-miR-4257 0.00287878 Down 
hsa-miR-1225-5p 0.00003946 Up 
hsa-miR-142-5p 0.02297944 Down 
hsa-miR-320c 0.00490620 Up 
hsa-miR-466 0.00012439 Down 
hsa-miR-3665 0.02194315 Down 
hsa-miR-3180-5p 0.00000784 Down 
hsa-miR-572 0.00003356 Down 
hsa-miR-498 0.03899671 Down 
hsv1-miR-H7* 0.00000153 Down 
hsa-miR-4290 0.00008972 Down 
hsa-miR-766 0.00005281 Down 
hsa-miR-550a 0.00000246 Down 
hsa-miR-642b 0.00038856 Up 
hiv1-miR-H1 0.02389090 Up 
hsa-miR-4286 0.00000972 Down 
hsa-miR-1275 0.02853258 Up 
hsa-miR-328 0.00000589 Down 
hsa-miR-940 0.00085814 Down 
hsa-miR-425* 0.00000196 Down 
hsa-miR-877* 0.00000197 Down 
hsa-miR-1237 0.00473766 Down 
hsa-miR-197 0.00689774 Down 
hsa-miR-30a 0.00237993 Up 
hsa-miR-23c 0.00008162 Down 
hsa-miR-3652 0.00008498 Down 
hsa-miR-22 0.00512710 Up 
hsa-miR-181a 0.00132119 Down 
hsa-miR-3663-3p 0.02216322 Up 
hsv2-miR-H25 0.01841174 Up 
hsa-miR-485-3p 0.00003097 Down 
hsa-miR-324-3p 0.00034769 Down 
hsa-miR-486-5p 0.00864165 Up 
hsa-miR-1238 0.00119172 Down 
hsa-miR-1280 0.00021707 Down 
hsa-miR-129* 0.02477021 Down 
hsa-miR-1225-3p 0.00018305 Down 
hsa-let-7f-1* 0.01068060 Down 
hsa-miR-4313 0.00072572 Down 
hsa-miR-4323 0.00014421 Down 
hsa-miR-149 0.00009577 Down 
hsa-miR-199a-5p 0.03839473 Down 
hsa-miR-19b 0.03402975 Up 
hsa-miR-92a 0.03160700 Up 
hsv2-miR-H6* 0.00006381 Down 
hsa-miR-16-2* 0.03334112 Up 
hsa-miR-933 0.00000019 Down 
hsa-miR-660 0.00700913 Up 
hsa-miR-494 0.04910243 Down 
hsa-miR-1260b 0.00050477 Down 
hsa-miR-33b* 0.00000225 Down 
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hsa-miR-186 0.02114488 Up 
hsa-let-7b* 0.00029688 Down 
hsa-miR-424 0.02888965 Up 
kshv-miR-K12-8* 0.00002078 Down 
hsa-miR-191* 0.00253484 Down 
hsa-miR-1234 0.00947810 Down 
(i) The “miRNA name” column gives the name of the human miRNA as provided by the specialist database, 
miRBase, according to version 16 (released, August 2010). 
(ii) The “p-value” represents the p-value of a microarray T-test derived from comparing case with control, as 
determined in study 1. 
(iii) The biomarkers can be up-regulated (i.e. an increase in fold-change, when compared to control samples) or 
down-regulated (i.e. a decrease in fold-change, when compared to control samples), as determined in study 1. 
 
TABLE 9-26 
Table listing identified miRNAs (see section 6.5) 
miRNA Name
(i)
 P. Value
(ii)
 Expression
(iii)
 
hsa-miR-150 0.000731818 Down 
hsa-miR-122 0.001736842 Down 
hsa-miR-1224-5p 0.005657118 Up 
hsa-miR-342-3p 0.007122454 Down 
hsa-miR-3648 0.038141456 Up 
hsa-miR-574-5p 0.043514783 Down 
(i) The “miRNA name” column gives the name of the human miRNA as provided by the specialist database, 
miRBase, according to version 16 (released, August 2010). 
(ii) The “p-value” represents the p-value of a microarray T-test derived from comparing case with control, as 
determined in study 1. 
(iii) The biomarkers can be up-regulated (i.e. an increase in fold-change, when compared to control samples) or 
down-regulated (i.e. a decrease in fold-change, when compared to control samples), as determined in study 1. 
 
TABLE 9-27 
Table listing identified biomarkers (see section 6.5) 
Biomarker AUC S+S
(i)
 Sensitivity
(ii)
 Specificity
(iii)
 Assay
(iv)
 
hsa-miR-122 0.66 1.25 0.4 0.85 qPCR 
hsa-miR-122 0.65 1.19 0.55 0.65 microarray 
hsa-miR-150 0.8 1.44 0.8 0.65 microarray 
hsa-miR-150 0.69 1.31 0.47 0.85 qPCR 
hsa-miR-342-3p 0.78 1.42 0.66 0.76 microarray 
hsa-miR-342-3p 0.62 1.14 0.76 0.38 qPCR 
hsa-miR-1224-5p 0.48 1.06 0.06 1 microarray 
hsa-miR-3194-5p 0.62 1.14 0.68 0.46 qPCR 
hsa-miR-3648 0.63 1.21 0.85 0.35 microarray 
hsa-miR-3663-5p 0.7 1.26 0.41 0.85 qPCR 
hsa-miR-574-5p 0.8 1.43 0.73 0.71 microarray 
HSPD1 0.62 1.15 0.81 0.33 autoAb 
RAN 0.54 1.1 0.87 0.22 autoAb 
STUB1 0.66 1.21 0.65 0.56 autoAb 
TPM1 0.67 1.25 0.69 0.56 autoAb 
(i)  S+S is the sum of the sensitivity and specificity columns, as determined in study 1. 
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(ii)  and (iii) These two columns show the sensitivity and specificity of a test based solely on the relevant 
biomarker (or, for Tables 11-15, panel) shown in the left-hand column in the same row when applied to the 
samples used in study 1. 
(iv) For miRNA analysis, data was generated using either a microarray (“microarray“) or qPCR (“qPCR“) 
platform, as described in study 1. Autoantbody (“autoAb”) biomarkers were identified using the protein array 
platform described in study 1. Where panels were developed incorporating both miRNA and autoantibody 
biomarkers as variables (see study 1), these are described as “combiAbMir”. 
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TABLE 9-28 
Table listing identified biomarkers (panel of two combinations) (see section 6.5) 
Panel AUC S+S
(i)
 Sensitivity
(ii)
 Specificity
(iii)
 Assay
(iv)
 
hsa-miR-150, hsa-miR-574-5p 0.9100 1.6300 0.8600 0.7600 microarray 
hsa-miR-342-3p, hsa-miR-574-5p 0.8600 1.5200 0.7600 0.7600 microarray 
hsa-miR-122, hsa-miR-574-5p 0.8400 1.5100 0.7500 0.7600 microarray 
hsa-miR-3648, hsa-miR-574-5p 0.8300 1.4900 0.7900 0.7100 microarray 
hsa-miR-150, hsa-miR-342-3p 0.8100 1.4500 0.6800 0.7600 microarray 
TPM1, hsa-miR-150 0.8119 1.4825 0.8575 0.6250 combiAbMir 
hsa-miR-342-3p, hsa-miR-3648 0.8100 1.4500 0.6900 0.7600 microarray 
RAN, hsa-miR-574-5p 0.8102 1.4306 0.8056 0.6250 combiAbMir 
HSPD1, hsa-miR-342-3p 0.8092 1.4506 0.5756 0.8750 combiAbMir 
RAN, hsa-miR-342-3p 0.8078 1.4594 0.7094 0.7500 combiAbMir 
TPM1, hsa-miR-342-3p 0.8064 1.4456 0.6956 0.7500 combiAbMir 
hsa-miR-1224-5p, hsa-miR-342-3p 0.8000 1.4500 0.6800 0.7600 microarray 
TPM1, hsa-miR-574-5p 0.7964 1.4350 0.8100 0.6250 combiAbMir 
HSPD1, hsa-miR-150 0.7956 1.4288 0.6788 0.7500 combiAbMir 
RAN, hsa-miR-150 0.7841 1.3856 0.7606 0.6250 combiAbMir 
hsa-miR-1224-5p, hsa-miR-574-5p 0.7800 1.4200 0.6600 0.7600 microarray 
hsa-miR-150, hsa-miR-3648 0.7800 1.3900 0.7400 0.6500 microarray 
hsa-miR-150, hsa-miR-1224-5p 0.7800 1.3900 0.6800 0.7100 microarray 
STUB1, hsa-miR-150 0.7773 1.4044 0.6544 0.7500 combiAbMir 
HSPD1, hsa-miR-574-5p 0.7750 1.3875 0.7625 0.6250 combiAbMir 
STUB1, hsa-miR-342-3p 0.7745 1.4113 0.6613 0.7500 combiAbMir 
hsa-miR-122, hsa-miR-342-3p 0.7700 1.4000 0.6300 0.7600 microarray 
STUB1, hsa-miR-574-5p 0.7697 1.3800 0.6300 0.7500 combiAbMir 
hsa-miR-150, hsa-miR-122 0.7700 1.3800 0.6100 0.7600 microarray 
hsa-miR-122, hsa-miR-3663-5p 0.7600 1.3700 0.6000 0.7700 qPCR 
hsa-miR-150, hsa-miR-3663-5p 0.7500 1.3500 0.5000 0.8500 qPCR 
hsa-miR-342-3p, hsa-miR-3663-5p 0.7200 1.3000 0.6000 0.6900 qPCR 
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TPM1, hsa-miR-122 0.6947 1.2813 0.6563 0.6250 combiAbMir 
TPM1, HSPD1 0.6900 1.2800 0.8400 0.4400 autoAb 
TPM1, hsa-miR-3648 0.6842 1.2400 0.7400 0.5000 combiAbMir 
HSPD1, hsa-miR-3648 0.6727 1.2544 0.7544 0.5000 combiAbMir 
hsa-miR-150, hsa-miR-3194-5p 0.6700 1.2800 0.4300 0.8500 qPCR 
hsa-miR-122, hsa-miR-3648 0.6700 1.2300 0.8200 0.4100 microarray 
STUB1, hsa-miR-122 0.6611 1.2650 0.6400 0.6250 combiAbMir 
RAN, hsa-miR-3648 0.6611 1.2556 0.8806 0.3750 combiAbMir 
TPM1, STUB1 0.6600 1.2500 0.8100 0.4400 autoAb 
hsa-miR-3663-5p, hsa-miR-3194-5p 0.6600 1.1800 0.6400 0.5400 qPCR 
HSPD1, STUB1 0.6500 1.1900 0.6400 0.5600 autoAb 
hsa-miR-342-3p, hsa-miR-3194-5p 0.6400 1.1800 0.3300 0.8500 qPCR 
STUB1, hsa-miR-3648 0.6398 1.2013 0.8263 0.3750 combiAbMir 
TPM1, hsa-miR-1224-5p 0.6395 1.1956 0.5706 0.6250 combiAbMir 
HSPD1, hsa-miR-122 0.6391 1.1925 0.4425 0.7500 combiAbMir 
hsa-miR-122, hsa-miR-3194-5p 0.6400 1.2600 0.4100 0.8500 qPCR 
HSPD1, RAN 0.6300 1.1700 0.8400 0.3300 autoAb 
hsa-miR-150, hsa-miR-122 0.6300 1.2100 0.3600 0.8500 qPCR 
hsa-miR-150, hsa-miR-342-3p 0.6300 1.2100 0.3600 0.8500 qPCR 
TPM1, RAN 0.6300 1.1800 0.7300 0.4400 autoAb 
hsa-miR-122, hsa-miR-342-3p 0.6200 1.2000 0.3500 0.8500 qPCR 
RAN, hsa-miR-122 0.6178 1.1594 0.5344 0.6250 combiAbMir 
STUB1, hsa-miR-1224-5p 0.6122 1.1731 0.4231 0.7500 combiAbMir 
hsa-miR-122, hsa-miR-1224-5p 0.5900 1.1100 0.7000 0.4100 microarray 
HSPD1, hsa-miR-1224-5p 0.5870 1.1206 0.6206 0.5000 combiAbMir 
RAN, STUB1 0.5900 1.1500 0.8200 0.3300 autoAb 
hsa-miR-1224-5p, hsa-miR-3648 0.5800 1.1100 0.8100 0.2900 microarray 
RAN, hsa-miR-1224-5p 0.5373 1.0844 0.8344 0.2500 combiAbMir 
(i)  S+S is the sum of the sensitivity and specificity columns, as determined in study 1.  
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(ii)  and (iii) These two columns show the sensitivity and specificity of a test based solely on the relevant biomarker (or, for Tables 11-15, panel) shown in the left-hand 
column in the same row when applied to the samples used in study 1. 
(iv) For miRNA analysis, data was generated using either a microarray (“microarray“) or qPCR (“qPCR“) platform, as described in study 1. Autoantbody (“autoAb”) 
biomarkers were identified using the protein array platform described in study 1. Where panels were developed incorporating both miRNA and autoantibody biomarkers as 
variables (see study 1), these are described as “combiAbMir”. 
 
TABLE 9-29 
Table listing identified biomarkers (panel of three combinations) (see section 6.5) 
Panel AUC S+S
(i)
 Sensitivity
(ii)
 Specificity
(iii)
 Assay
(iv)
 
RAN, hsa-miR-150, hsa-miR-574-5p 0.92359 1.65750 0.78250 0.87500 combiAbMir 
TPM1, hsa-miR-150, hsa-miR-574-5p 0.92359 1.65500 0.90500 0.75000 combiAbMir 
hsa-miR-150, hsa-miR-342-3p, hsa-miR-574-5p 0.90000 1.61000 0.85000 0.76000 microarray 
STUB1, hsa-miR-150, hsa-miR-574-5p 0.90078 1.61625 0.86625 0.75000 combiAbMir 
hsa-miR-150, hsa-miR-122, hsa-miR-574-5p 0.90000 1.60000 0.83000 0.76000 microarray 
HSPD1, hsa-miR-150, hsa-miR-574-5p 0.89719 1.60063 0.85063 0.75000 combiAbMir 
hsa-miR-122, hsa-miR-342-3p, hsa-miR-574-5p 0.90000 1.60000 0.78000 0.82000 microarray 
TPM1, hsa-miR-342-3p, hsa-miR-574-5p 0.89297 1.57125 0.69625 0.87500 combiAbMir 
hsa-miR-150, hsa-miR-1224-5p, hsa-miR-574-5p 0.89000 1.59000 0.83000 0.76000 microarray 
hsa-miR-150, hsa-miR-3648, hsa-miR-574-5p 0.89000 1.59000 0.83000 0.76000 microarray 
RAN, hsa-miR-342-3p, hsa-miR-574-5p 0.87891 1.55375 0.67875 0.87500 combiAbMir 
hsa-miR-1224-5p, hsa-miR-342-3p, hsa-miR-574-5p 0.88000 1.57000 0.81000 0.76000 microarray 
TPM1, hsa-miR-122, hsa-miR-574-5p 0.87234 1.55000 0.80000 0.75000 combiAbMir 
STUB1, hsa-miR-342-3p, hsa-miR-574-5p 0.86703 1.53500 0.78500 0.75000 combiAbMir 
RAN, hsa-miR-122, hsa-miR-574-5p 0.86422 1.52875 0.77875 0.75000 combiAbMir 
hsa-miR-342-3p, hsa-miR-3648, hsa-miR-574-5p 0.86000 1.54000 0.77000 0.76000 microarray 
HSPD1, hsa-miR-342-3p, hsa-miR-574-5p 0.86266 1.51875 0.76875 0.75000 combiAbMir 
RAN, hsa-miR-3648, hsa-miR-574-5p 0.86078 1.51563 0.76563 0.75000 combiAbMir 
hsa-miR-122, hsa-miR-3648, hsa-miR-574-5p 0.85000 1.51000 0.75000 0.76000 microarray 
TPM1, hsa-miR-3648, hsa-miR-574-5p 0.84250 1.51813 0.76813 0.75000 combiAbMir 
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TPM1, RAN, hsa-miR-574-5p 0.82516 1.45875 0.70875 0.75000 combiAbMir 
hsa-miR-122, hsa-miR-1224-5p, hsa-miR-574-5p 0.82000 1.49000 0.72000 0.76000 microarray 
HSPD1, hsa-miR-122, hsa-miR-574-5p 0.82172 1.46125 0.71125 0.75000 combiAbMir 
STUB1, hsa-miR-122, hsa-miR-574-5p 0.81938 1.47125 0.72125 0.75000 combiAbMir 
TPM1, RAN, hsa-miR-342-3p 0.81578 1.45750 0.58250 0.87500 combiAbMir 
HSPD1, RAN, hsa-miR-574-5p 0.81406 1.45500 0.83000 0.62500 combiAbMir 
RAN, hsa-miR-342-3p, hsa-miR-3648 0.81109 1.43875 0.68875 0.75000 combiAbMir 
TPM1, STUB1, hsa-miR-574-5p 0.81094 1.45438 0.82938 0.62500 combiAbMir 
TPM1, RAN, hsa-miR-150 0.81063 1.47500 0.85000 0.62500 combiAbMir 
TPM1, HSPD1, hsa-miR-342-3p 0.80969 1.47313 0.72313 0.75000 combiAbMir 
RAN, hsa-miR-1224-5p, hsa-miR-574-5p 0.80875 1.45625 0.70625 0.75000 combiAbMir 
hsa-miR-1224-5p,  hsa-miR-3648,  hsa-miR-574-5p 0.81000 1.44000 0.74000 0.71000 microarray 
HSPD1, hsa-miR-342-3p, hsa-miR-3648 0.80344 1.44000 0.69000 0.75000 combiAbMir 
RAN, hsa-miR-150, hsa-miR-342-3p 0.80281 1.45688 0.58188 0.87500 combiAbMir 
TPM1, hsa-miR-150, hsa-miR-342-3p 0.80219 1.43688 0.68688 0.75000 combiAbMir 
TPM1, HSPD1, hsa-miR-574-5p 0.80203 1.43500 0.81000 0.62500 combiAbMir 
TPM1, hsa-miR-342-3p, hsa-miR-3648 0.80109 1.43938 0.68938 0.75000 combiAbMir 
TPM1, HSPD1, hsa-miR-150 0.80063 1.45375 0.82875 0.62500 combiAbMir 
STUB1, hsa-miR-3648, hsa-miR-574-5p 0.80047 1.42563 0.67563 0.75000 combiAbMir 
hsa-miR-150, hsa-miR-1224-5p, hsa-miR-342-3p 0.80000 1.42000 0.65000 0.76000 microarray 
HSPD1, RAN, hsa-miR-150 0.79984 1.44000 0.69000 0.75000 combiAbMir 
HSPD1, hsa-miR-150, hsa-miR-342-3p 0.79922 1.41938 0.66938 0.75000 combiAbMir 
RAN, hsa-miR-122, hsa-miR-342-3p 0.79828 1.43125 0.68125 0.75000 combiAbMir 
TPM1, hsa-miR-1224-5p, hsa-miR-574-5p 0.79813 1.45188 0.82688 0.62500 combiAbMir 
RAN, STUB1, hsa-miR-574-5p 0.79750 1.41563 0.66563 0.75000 combiAbMir 
TPM1, STUB1, hsa-miR-342-3p 0.79719 1.43563 0.68563 0.75000 combiAbMir 
TPM1, hsa-miR-122, hsa-miR-342-3p 0.79672 1.42313 0.54813 0.87500 combiAbMir 
TPM1, hsa-miR-150, hsa-miR-3648 0.79406 1.46250 0.83750 0.62500 combiAbMir 
TPM1, hsa-miR-1224-5p, hsa-miR-342-3p 0.79391 1.44375 0.56875 0.87500 combiAbMir 
HSPD1, RAN, hsa-miR-342-3p 0.79328 1.44688 0.57188 0.87500 combiAbMir 
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RAN, hsa-miR-1224-5p, hsa-miR-342-3p 0.79313 1.42563 0.55063 0.87500 combiAbMir 
HSPD1, STUB1, hsa-miR-342-3p 0.79250 1.43250 0.68250 0.75000 combiAbMir 
HSPD1, hsa-miR-150, hsa-miR-1224-5p 0.79078 1.41938 0.66938 0.75000 combiAbMir 
STUB1, hsa-miR-342-3p, hsa-miR-3648 0.78688 1.40875 0.65875 0.75000 combiAbMir 
HSPD1, hsa-miR-3648, hsa-miR-574-5p 0.78156 1.38938 0.88938 0.50000 combiAbMir 
STUB1, hsa-miR-1224-5p, hsa-miR-574-5p 0.78141 1.40438 0.65438 0.75000 combiAbMir 
STUB1, hsa-miR-122, hsa-miR-342-3p 0.78125 1.42063 0.54563 0.87500 combiAbMir 
RAN, hsa-miR-150, hsa-miR-1224-5p 0.78125 1.39000 0.76500 0.62500 combiAbMir 
TPM1, hsa-miR-150, hsa-miR-122 0.77844 1.43688 0.81188 0.62500 combiAbMir 
TPM1, STUB1, hsa-miR-150 0.77750 1.42438 0.79938 0.62500 combiAbMir 
hsa-miR-150, hsa-miR-342-3p, hsa-miR-3648 0.78000 1.40000 0.63000 0.76000 microarray 
hsa-miR-150, hsa-miR-122, hsa-miR-342-3p 0.78000 1.40000 0.64000 0.76000 microarray 
STUB1, hsa-miR-1224-5p, hsa-miR-342-3p 0.77594 1.39563 0.52063 0.87500 combiAbMir 
RAN, hsa-miR-150, hsa-miR-3648 0.77516 1.38125 0.75625 0.62500 combiAbMir 
TPM1, hsa-miR-150, hsa-miR-1224-5p 0.77406 1.42250 0.79750 0.62500 combiAbMir 
hsa-miR-122, hsa-miR-1224-5p, hsa-miR-342-3p 0.77000 1.38000 0.61000 0.76000 microarray 
STUB1, hsa-miR-150, hsa-miR-342-3p 0.77094 1.39813 0.64813 0.75000 combiAbMir 
HSPD1, hsa-miR-150, hsa-miR-3648 0.76953 1.38375 0.75875 0.62500 combiAbMir 
HSPD1, STUB1, hsa-miR-574-5p 0.76672 1.35500 0.73000 0.62500 combiAbMir 
RAN, STUB1, hsa-miR-342-3p 0.76484 1.38375 0.63375 0.75000 combiAbMir 
HSPD1, hsa-miR-1224-5p, hsa-miR-342-3p 0.76453 1.37375 0.49875 0.87500 combiAbMir 
HSPD1, hsa-miR-122, hsa-miR-342-3p 0.76344 1.39313 0.51813 0.87500 combiAbMir 
hsa-miR-1224-5p, hsa-miR-342-3p, hsa-miR-3648 0.76000 1.37000 0.72000 0.65000 microarray 
hsa-miR-122, hsa-miR-342-3p, hsa-miR-3648 0.76000 1.36000 0.71000 0.65000 microarray 
HSPD1, hsa-miR-150, hsa-miR-122 0.76109 1.36875 0.61875 0.75000 combiAbMir 
HSPD1, STUB1, hsa-miR-150 0.76094 1.38250 0.75750 0.62500 combiAbMir 
STUB1, hsa-miR-150, hsa-miR-122 0.76063 1.36438 0.73938 0.62500 combiAbMir 
hsa-miR-150,   hsa-miR-1224-5p,   hsa-miR-3648 0.76000 1.35000 0.71000 0.65000 microarray 
RAN, hsa-miR-150, hsa-miR-122 0.75563 1.35875 0.73375 0.62500 combiAbMir 
HSPD1, hsa-miR-1224-5p, hsa-miR-574-5p 0.75469 1.36188 0.73688 0.62500 combiAbMir 
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RAN, STUB1, hsa-miR-150 0.75453 1.37188 0.74688 0.62500 combiAbMir 
STUB1, hsa-miR-150, hsa-miR-1224-5p 0.75422 1.37063 0.74563 0.62500 combiAbMir 
STUB1, hsa-miR-150, hsa-miR-3648 0.74891 1.35188 0.72688 0.62500 combiAbMir 
hsa-miR-150, hsa-miR-122, hsa-miR-1224-5p 0.75000 1.35000 0.65000 0.71000 microarray 
hsa-miR-150, hsa-miR-122, hsa-miR-3648 0.75000 1.35000 0.71000 0.65000 microarray 
hsa-miR-150,   hsa-miR-3663-5p,   hsa-miR-3194-5p 0.74000 1.34000 0.65000 0.69000 qPCR 
TPM1, HSPD1, hsa-miR-122 0.73094 1.34688 0.72188 0.62500 combiAbMir 
hsa-miR-122,   hsa-miR-3663-5p,   hsa-miR-3194-5p 0.72000 1.32000 0.47000 0.85000 qPCR 
hsa-miR-150, hsa-miR-122, hsa-miR-3663-5p 0.72000 1.31000 0.46000 0.85000 qPCR 
hsa-miR-122, hsa-miR-342-3p, hsa-miR-3663-5p 0.72000 1.32000 0.63000 0.69000 qPCR 
hsa-miR-150, hsa-miR-342-3p, hsa-miR-3663-5p 0.72000 1.31000 0.61000 0.69000 qPCR 
hsa-miR-342-3p, hsa-miR-3663-5p, hsa-miR-3194-5p 0.70000 1.28000 0.59000 0.69000 qPCR 
TPM1, HSPD1, hsa-miR-3648 0.70000 1.28063 0.78063 0.50000 combiAbMir 
TPM1, RAN, hsa-miR-3648 0.69766 1.25813 0.75813 0.50000 combiAbMir 
TPM1, hsa-miR-122, hsa-miR-3648 0.69375 1.25750 0.75750 0.50000 combiAbMir 
HSPD1, RAN, hsa-miR-3648 0.68813 1.28813 0.91313 0.37500 combiAbMir 
HSPD1, STUB1, hsa-miR-3648 0.68641 1.24875 0.74875 0.50000 combiAbMir 
TPM1, HSPD1, RAN 0.68000 1.28000 0.83000 0.44000 autoAb 
TPM1, HSPD1, STUB1 0.68000 1.29000 0.84000 0.44000 autoAb 
TPM1, STUB1, hsa-miR-122 0.68078 1.28938 0.78938 0.50000 combiAbMir 
RAN, hsa-miR-122, hsa-miR-3648 0.68000 1.26313 0.88813 0.37500 combiAbMir 
TPM1, hsa-miR-1224-5p, hsa-miR-3648 0.68000 1.23500 0.73500 0.50000 combiAbMir 
STUB1, hsa-miR-122, hsa-miR-3648 0.67938 1.25750 0.75750 0.50000 combiAbMir 
HSPD1, hsa-miR-122, hsa-miR-3648 0.67453 1.21875 0.71875 0.50000 combiAbMir 
TPM1, hsa-miR-122, hsa-miR-1224-5p 0.67438 1.26813 0.64313 0.62500 combiAbMir 
TPM1, STUB1, hsa-miR-3648 0.66438 1.23438 0.73438 0.50000 combiAbMir 
RAN, STUB1, hsa-miR-3648 0.66359 1.24563 0.87063 0.37500 combiAbMir 
TPM1, HSPD1, hsa-miR-1224-5p 0.66188 1.22125 0.72125 0.50000 combiAbMir 
TPM1, RAN, hsa-miR-122 0.65563 1.24000 0.74000 0.50000 combiAbMir 
HSPD1, RAN, hsa-miR-122 0.65563 1.18375 0.80875 0.37500 combiAbMir 
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hsa-miR-150, hsa-miR-342-3p, hsa-miR-3194-5p 0.65000 1.25000 0.41000 0.85000 qPCR 
hsa-miR-150, hsa-miR-122, hsa-miR-342-3p 0.65000 1.21000 0.36000 0.85000 qPCR 
HSPD1, RAN, STUB1 0.65000 1.21000 0.76000 0.44000 autoAb 
HSPD1, STUB1, hsa-miR-122 0.64828 1.20875 0.58375 0.62500 combiAbMir 
hsa-miR-122,   hsa-miR-1224-5p,   hsa-miR-3648 0.64000 1.17000 0.82000 0.35000 microarray 
hsa-miR-150, hsa-miR-122, hsa-miR-3194-5p 0.64000 1.25000 0.41000 0.85000 qPCR 
TPM1, STUB1, hsa-miR-1224-5p 0.63531 1.20438 0.70438 0.50000 combiAbMir 
HSPD1, STUB1, hsa-miR-1224-5p 0.63375 1.19938 0.69938 0.50000 combiAbMir 
RAN, hsa-miR-1224-5p, hsa-miR-3648 0.63266 1.19188 0.81688 0.37500 combiAbMir 
RAN, STUB1, hsa-miR-122 0.62906 1.19688 0.57188 0.62500 combiAbMir 
TPM1, RAN, STUB1 0.62000 1.19000 0.64000 0.56000 autoAb 
TPM1, RAN, hsa-miR-1224-5p 0.61922 1.15188 0.65188 0.50000 combiAbMir 
hsa-miR-122, hsa-miR-342-3p, hsa-miR-3194-5p 0.62000 1.22000 0.37000 0.85000 qPCR 
STUB1, hsa-miR-122, hsa-miR-1224-5p 0.61469 1.18250 0.55750 0.62500 combiAbMir 
HSPD1, hsa-miR-122, hsa-miR-1224-5p 0.61406 1.15813 0.40813 0.75000 combiAbMir 
HSPD1, RAN, hsa-miR-1224-5p 0.61328 1.17250 0.79750 0.37500 combiAbMir 
STUB1, hsa-miR-1224-5p, hsa-miR-3648 0.60922 1.15500 0.78000 0.37500 combiAbMir 
HSPD1, hsa-miR-1224-5p, hsa-miR-3648 0.60438 1.15000 0.90000 0.25000 combiAbMir 
RAN, hsa-miR-122, hsa-miR-1224-5p 0.59906 1.11625 0.61625 0.50000 combiAbMir 
RAN, STUB1, hsa-miR-1224-5p 0.57453 1.13688 0.76188 0.37500 combiAbMir 
(i)  S+S is the sum of the sensitivity and specificity columns, as determined in study 1.  
(ii)  and (iii) These two columns show the sensitivity and specificity of a test based solely on the relevant biomarker (or, for Tables 11-15, panel) shown in the left-hand 
column in the same row when applied to the samples used in study 1.  
(iv) For miRNA analysis, data was generated using either a microarray (“microarray“) or qPCR (“qPCR“) platform, as described in study 1. Autoantbody (“autoAb”) 
biomarkers were identified using the protein array platform described in study 1. Where panels were developed incorporating both miRNA and autoantibody biomarkers as 
variables (see study 1), these are described as “combiAbMir”. 
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TABLE 9-30 
Table listing identified biomarkers (panel of four combinations) (see section 6.5) 
Panel AUC S+S (i) Sensitivity
(ii)
 Specificity
(iii)
 Assay
(iv)
 
TPM1,  hsa-miR-150,  hsa-miR-342-3p,  hsa-miR-574-5p 0.928594 1.652500 0.902500 0.750000 combiAbMir 
TPM1, hsa-miR-150, hsa-miR-122, hsa-miR-574-5p 0.928125 1.649375 0.899375 0.750000 combiAbMir 
RAN, hsa-miR-150, hsa-miR-3648, hsa-miR-574-5p 0.925469 1.646250 0.771250 0.875000 combiAbMir 
TPM1, RAN, hsa-miR-150, hsa-miR-574-5p 0.923125 1.646875 0.896875 0.750000 combiAbMir 
TPM1, STUB1, hsa-miR-150, hsa-miR-574-5p 0.919844 1.635000 0.760000 0.875000 combiAbMir 
RAN,  hsa-miR-150,  hsa-miR-122,  hsa-miR-574-5p 0.914375 1.635000 0.760000 0.875000 combiAbMir 
TPM1, hsa-miR-150, hsa-miR-3648, hsa-miR-574-5p 0.913594 1.612500 0.862500 0.750000 combiAbMir 
RAN, STUB1, hsa-miR-150, hsa-miR-574-5p 0.913438 1.635625 0.760625 0.875000 combiAbMir 
TPM1, hsa-miR-150, hsa-miR-1224-5p, hsa-miR-574-5p 0.913438 1.631875 0.881875 0.750000 combiAbMir 
HSPD1, RAN, hsa-miR-150, hsa-miR-574-5p 0.912031 1.623750 0.748750 0.875000 combiAbMir 
RAN, hsa-miR-150, hsa-miR-342-3p, hsa-miR-574-5p 0.908594 1.619375 0.869375 0.750000 combiAbMir 
RAN,  hsa-miR-150,  hsa-miR-1224-5p,  hsa-miR-574-5p 0.906719 1.618125 0.868125 0.750000 combiAbMir 
TPM1,  hsa-miR-122,  hsa-miR-342-3p,  hsa-miR-574-5p 0.906563 1.611250 0.861250 0.750000 combiAbMir 
TPM1, HSPD1, hsa-miR-150, hsa-miR-574-5p 0.906406 1.612500 0.862500 0.750000 combiAbMir 
HSPD1, hsa-miR-150, hsa-miR-342-3p, hsa-miR-574-5p 0.903906 1.607500 0.857500 0.750000 combiAbMir 
STUB1, hsa-miR-150, hsa-miR-342-3p, hsa-miR-574-5p 0.902031 1.615625 0.865625 0.750000 combiAbMir 
TPM1, RAN, hsa-miR-342-3p, hsa-miR-574-5p 0.901406 1.584375 0.834375 0.750000 combiAbMir 
hsa-miR-150,  hsa-miR-122,  hsa-miR-3648,hsa-miR-574-5p 0.900000 1.610000 0.840000 0.760000 microarray 
HSPD1, hsa-miR-150, hsa-miR-122, hsa-miR-574-5p 0.900625 1.593125 0.843125 0.750000 combiAbMir 
HSPD1, hsa-miR-150, hsa-miR-1224-5p, hsa-miR-574-5p 0.898125 1.605625 0.855625 0.750000 combiAbMir 
hsa-miR-150, hsa-miR-122, hsa-miR-342-3p,hsa-miR-574-5p 0.900000 1.590000 0.830000 0.760000 microarray 
TPM1, HSPD1, hsa-miR-342-3p, hsa-miR-574-5p 0.895781 1.586250 0.836250 0.750000 combiAbMir 
HSPD1, STUB1, hsa-miR-150, hsa-miR-574-5p 0.895313 1.600000 0.850000 0.750000 combiAbMir 
TPM1, STUB1, hsa-miR-342-3p, hsa-miR-574-5p 0.893125 1.579375 0.829375 0.750000 combiAbMir 
STUB1, hsa-miR-150, hsa-miR-3648, hsa-miR-574-5p 0.891563 1.595000 0.845000 0.750000 combiAbMir 
HSPD1, hsa-miR-122, hsa-miR-342-3p, hsa-miR-574-5p 0.890938 1.607500 0.732500 0.875000 combiAbMir 
STUB1, hsa-miR-150, hsa-miR-122, hsa-miR-574-5p 0.890625 1.583750 0.833750 0.750000 combiAbMir 
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HSPD1, hsa-miR-150, hsa-miR-3648, hsa-miR-574-5p 0.889063 1.592500 0.842500 0.750000 combiAbMir 
STUB1, hsa-miR-122, hsa-miR-342-3p, hsa-miR-574-5p 0.888594 1.585625 0.835625 0.750000 combiAbMir 
RAN, hsa-miR-122, hsa-miR-342-3p, hsa-miR-574-5p 0.886719 1.600000 0.725000 0.875000 combiAbMir 
hsa-miR-150,   hsa-miR-1224-5p,   hsa-miR-3648, hsa-miR-574-5p 0.890000 1.570000 0.810000 0.760000 microarray 
RAN,  hsa-miR-342-3p,  hsa-miR-3648,  hsa-miR-574-5p 0.884375 1.560625 0.810625 0.750000 combiAbMir 
STUB1, hsa-miR-150, hsa-miR-1224-5p, hsa-miR-574-5p 0.882344 1.575625 0.825625 0.750000 combiAbMir 
hsa-miR-150, hsa-miR-342-3p, hsa-miR-3648,hsa-miR-574-5p 0.880000 1.570000 0.800000 0.760000 microarray 
RAN, STUB1, hsa-miR-342-3p, hsa-miR-574-5p 0.881250 1.555625 0.680625 0.875000 combiAbMir 
hsa-miR-150, hsa-miR-122, hsa-miR-1224-5p,hsa-miR-574-5p 0.880000 1.560000 0.800000 0.760000 microarray 
TPM1, hsa-miR-342-3p, hsa-miR-3648, hsa-miR-574-5p 0.880313 1.555625 0.805625 0.750000 combiAbMir 
TPM1, hsa-miR-122, hsa-miR-3648, hsa-miR-574-5p 0.877813 1.572500 0.822500 0.750000 combiAbMir 
TPM1, hsa-miR-1224-5p,  hsa-miR-342-3p,hsa-miR-574-5p 0.877813 1.556875 0.806875 0.750000 combiAbMir 
hsa-miR-150, hsa-miR-1224-5p, hsa-miR-342-3p, hsa-miR-574-5p 0.880000 1.570000 0.810000 0.760000 microarray 
hsa-miR-122, hsa-miR-342-3p, hsa-miR-3648,hsa-miR-574-5p 0.880000 1.560000 0.800000 0.760000 microarray 
HSPD1,  STUB1,  hsa-miR-342-3p,  hsa-miR-574-5p 0.874688 1.546250 0.796250 0.750000 combiAbMir 
RAN, hsa-miR-1224-5p, hsa-miR-342-3p, hsa-miR-574-5p 0.872031 1.565000 0.690000 0.875000 combiAbMir 
HSPD1,  hsa-miR-1224-5p,  hsa-miR-342-3p,hsa-miR-574-5p 0.870156 1.552500 0.802500 0.750000 combiAbMir 
HSPD1, RAN, hsa-miR-342-3p, hsa-miR-574-5p 0.870000 1.546875 0.671875 0.875000 combiAbMir 
hsa-miR-122, hsa-miR-1224-5p, hsa-miR-342-3p, hsa-miR-574-5p 0.870000 1.550000 0.730000 0.820000 microarray 
TPM1, RAN, hsa-miR-3648, hsa-miR-574-5p 0.862500 1.542500 0.792500 0.750000 combiAbMir 
TPM1, hsa-miR-122, hsa-miR-1224-5p, hsa-miR-574-5p 0.861094 1.536875 0.786875 0.750000 combiAbMir 
STUB1,  hsa-miR-1224-5p,  hsa-miR-342-3p,hsa-miR-574-5p 0.859844 1.530625 0.780625 0.750000 combiAbMir 
hsa-miR-1224-5p, hsa-miR-342-3p, hsa-miR-3648, hsa-miR-574-5p 0.860000 1.520000 0.760000 0.760000 microarray 
STUB1, hsa-miR-342-3p, hsa-miR-3648, hsa-miR-574-5p 0.855156 1.502500 0.752500 0.750000 combiAbMir 
RAN, hsa-miR-122, hsa-miR-3648, hsa-miR-574-5p 0.854219 1.500000 0.750000 0.750000 combiAbMir 
TPM1, HSPD1, hsa-miR-122, hsa-miR-574-5p 0.852969 1.500000 0.750000 0.750000 combiAbMir 
HSPD1, hsa-miR-342-3p, hsa-miR-3648, hsa-miR-574-5p 0.850625 1.506250 0.756250 0.750000 combiAbMir 
TPM1, RAN, hsa-miR-122, hsa-miR-574-5p 0.848281 1.497500 0.747500 0.750000 combiAbMir 
TPM1, STUB1, hsa-miR-122, hsa-miR-574-5p 0.847813 1.509375 0.759375 0.750000 combiAbMir 
HSPD1, hsa-miR-122, hsa-miR-3648, hsa-miR-574-5p 0.846719 1.496875 0.621875 0.875000 combiAbMir 
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STUB1, hsa-miR-122, hsa-miR-3648, hsa-miR-574-5p 0.841406 1.498750 0.748750 0.750000 combiAbMir 
HSPD1, RAN, hsa-miR-122, hsa-miR-574-5p 0.839531 1.470625 0.720625 0.750000 combiAbMir 
RAN,  hsa-miR-122,  hsa-miR-1224-5p,  hsa-miR-574-5p 0.837969 1.503750 0.753750 0.750000 combiAbMir 
HSPD1, hsa-miR-122, hsa-miR-1224-5p, hsa-miR-574-5p 0.837188 1.492500 0.617500 0.875000 combiAbMir 
hsa-miR-122,   hsa-miR-1224-5p,   hsa-miR-3648, hsa-miR-574-5p 0.830000 1.500000 0.730000 0.760000 microarray 
TPM1, HSPD1, RAN, hsa-miR-342-3p 0.832656 1.505000 0.755000 0.750000 combiAbMir 
HSPD1, RAN, hsa-miR-3648, hsa-miR-574-5p 0.832656 1.440625 0.690625 0.750000 combiAbMir 
TPM1, RAN, hsa-miR-150, hsa-miR-342-3p 0.832188 1.486875 0.736875 0.750000 combiAbMir 
RAN, hsa-miR-1224-5p, hsa-miR-3648, hsa-miR-574-5p 0.830625 1.468125 0.718125 0.750000 combiAbMir 
TPM1, RAN, hsa-miR-342-3p, hsa-miR-3648 0.828125 1.485000 0.735000 0.750000 combiAbMir 
TPM1, STUB1, hsa-miR-3648, hsa-miR-574-5p 0.827969 1.476875 0.726875 0.750000 combiAbMir 
RAN, STUB1, hsa-miR-122, hsa-miR-574-5p 0.827500 1.470625 0.720625 0.750000 combiAbMir 
HSPD1, STUB1, hsa-miR-122, hsa-miR-574-5p 0.826563 1.470625 0.720625 0.750000 combiAbMir 
RAN, STUB1, hsa-miR-3648, hsa-miR-574-5p 0.823125 1.428125 0.678125 0.750000 combiAbMir 
TPM1, HSPD1, STUB1, hsa-miR-342-3p 0.822656 1.483125 0.733125 0.750000 combiAbMir 
TPM1, hsa-miR-1224-5p, hsa-miR-3648, hsa-miR-574-5p 0.822031 1.467500 0.717500 0.750000 combiAbMir 
TPM1, HSPD1, hsa-miR-122, hsa-miR-342-3p 0.821563 1.485625 0.735625 0.750000 combiAbMir 
TPM1, HSPD1, RAN, hsa-miR-150 0.818906 1.473750 0.848750 0.625000 combiAbMir 
TPM1, HSPD1, hsa-miR-342-3p, hsa-miR-3648 0.817813 1.453750 0.703750 0.750000 combiAbMir 
TPM1, HSPD1, hsa-miR-3648, hsa-miR-574-5p 0.817031 1.443750 0.818750 0.625000 combiAbMir 
TPM1, HSPD1, hsa-miR-150, hsa-miR-342-3p 0.815938 1.477500 0.727500 0.750000 combiAbMir 
TPM1, HSPD1, RAN, hsa-miR-574-5p 0.815000 1.430625 0.805625 0.625000 combiAbMir 
TPM1, HSPD1, STUB1, hsa-miR-574-5p 0.812656 1.433125 0.808125 0.625000 combiAbMir 
HSPD1, RAN, hsa-miR-342-3p, hsa-miR-3648 0.810781 1.438750 0.688750 0.750000 combiAbMir 
TPM1, HSPD1, hsa-miR-150, hsa-miR-122 0.810625 1.455625 0.830625 0.625000 combiAbMir 
TPM1, RAN, STUB1, hsa-miR-150 0.810156 1.470625 0.845625 0.625000 combiAbMir 
TPM1, RAN, hsa-miR-1224-5p, hsa-miR-342-3p 0.806094 1.448750 0.698750 0.750000 combiAbMir 
TPM1, RAN, hsa-miR-150, hsa-miR-1224-5p 0.805469 1.469375 0.844375 0.625000 combiAbMir 
RAN, hsa-miR-150, hsa-miR-342-3p, hsa-miR-3648 0.805000 1.424375 0.674375 0.750000 combiAbMir 
TPM1, STUB1, hsa-miR-122, hsa-miR-342-3p 0.803438 1.449375 0.699375 0.750000 combiAbMir 
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RAN,  hsa-miR-150,  hsa-miR-122,  hsa-miR-342-3p 0.802188 1.434375 0.559375 0.875000 combiAbMir 
STUB1, hsa-miR-122, hsa-miR-1224-5p, hsa-miR-574-5p 0.801875 1.463125 0.713125 0.750000 combiAbMir 
HSPD1, RAN, hsa-miR-150, hsa-miR-1224-5p 0.800781 1.457500 0.707500 0.750000 combiAbMir 
TPM1,  hsa-miR-122,  hsa-miR-342-3p,  hsa-miR-3648 0.800781 1.434375 0.684375 0.750000 combiAbMir 
TPM1, RAN, hsa-miR-1224-5p, hsa-miR-574-5p 0.800000 1.426250 0.801250 0.625000 combiAbMir 
TPM1,  HSPD1,  hsa-miR-1224-5p,  hsa-miR-342-3p 0.799375 1.443750 0.693750 0.750000 combiAbMir 
TPM1, RAN, STUB1, hsa-miR-574-5p 0.798281 1.415000 0.790000 0.625000 combiAbMir 
TPM1, HSPD1, hsa-miR-150, hsa-miR-3648 0.796875 1.451250 0.826250 0.625000 combiAbMir 
HSPD1, RAN, hsa-miR-1224-5p, hsa-miR-574-5p 0.795938 1.431250 0.806250 0.625000 combiAbMir 
HSPD1, RAN, hsa-miR-150, hsa-miR-342-3p 0.795625 1.449375 0.574375 0.875000 combiAbMir 
TPM1, HSPD1, STUB1, hsa-miR-150 0.794844 1.441250 0.816250 0.625000 combiAbMir 
HSPD1, hsa-miR-150, hsa-miR-342-3p, hsa-miR-3648 0.793750 1.419375 0.669375 0.750000 combiAbMir 
HSPD1, STUB1, hsa-miR-3648, hsa-miR-574-5p 0.792813 1.402500 0.777500 0.625000 combiAbMir 
HSPD1, hsa-miR-150, hsa-miR-122, hsa-miR-342-3p 0.792656 1.426875 0.551875 0.875000 combiAbMir 
HSPD1, hsa-miR-1224-5p, hsa-miR-3648, hsa-miR-574-5p 0.792500 1.416875 0.791875 0.625000 combiAbMir 
RAN, STUB1, hsa-miR-342-3p, hsa-miR-3648 0.792500 1.411250 0.661250 0.750000 combiAbMir 
TPM1, RAN, hsa-miR-150, hsa-miR-3648 0.792344 1.432500 0.807500 0.625000 combiAbMir 
HSPD1, RAN, STUB1, hsa-miR-574-5p 0.790938 1.400625 0.775625 0.625000 combiAbMir 
TPM1,  hsa-miR-150,  hsa-miR-342-3p,  hsa-miR-3648 0.790469 1.405625 0.780625 0.625000 combiAbMir 
TPM1, HSPD1, hsa-miR-150, hsa-miR-1224-5p 0.790313 1.421875 0.796875 0.625000 combiAbMir 
TPM1,  HSPD1,  hsa-miR-1224-5p,  hsa-miR-574-5p 0.790313 1.415625 0.790625 0.625000 combiAbMir 
HSPD1, STUB1, hsa-miR-150, hsa-miR-342-3p 0.790156 1.431250 0.681250 0.750000 combiAbMir 
HSPD1, RAN, STUB1, hsa-miR-342-3p 0.788438 1.424375 0.549375 0.875000 combiAbMir 
TPM1, STUB1, hsa-miR-150, hsa-miR-342-3p 0.788281 1.413750 0.663750 0.750000 combiAbMir 
TPM1, hsa-miR-150, hsa-miR-1224-5p, hsa-miR-342-3p 0.787500 1.406875 0.781875 0.625000 combiAbMir 
HSPD1, STUB1, hsa-miR-150, hsa-miR-122 0.787031 1.435625 0.685625 0.750000 combiAbMir 
HSPD1,  STUB1,  hsa-miR-342-3p,  hsa-miR-3648 0.785938 1.414375 0.664375 0.750000 combiAbMir 
RAN,  hsa-miR-150,  hsa-miR-1224-5p,  hsa-miR-342-3p 0.785313 1.420000 0.545000 0.875000 combiAbMir 
TPM1, STUB1, hsa-miR-342-3p, hsa-miR-3648 0.785313 1.403750 0.653750 0.750000 combiAbMir 
HSPD1,  hsa-miR-1224-5p,  hsa-miR-342-3p,hsa-miR-3648 0.785156 1.410625 0.660625 0.750000 combiAbMir 
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hsa-miR-150, hsa-miR-122, hsa-miR-342-3p,hsa-miR-3648 0.780000 1.390000 0.750000 0.650000 microarray 
TPM1,  STUB1,  hsa-miR-1224-5p,  hsa-miR-342-3p 0.783906 1.424375 0.674375 0.750000 combiAbMir 
STUB1, hsa-miR-1224-5p, hsa-miR-3648, hsa-miR-574-5p 0.783750 1.404375 0.654375 0.750000 combiAbMir 
HSPD1, hsa-miR-150, hsa-miR-122, hsa-miR-1224-5p 0.783281 1.419375 0.669375 0.750000 combiAbMir 
hsa-miR-150, hsa-miR-1224-5p, hsa-miR-342-3p, hsa-miR-3648 0.780000 1.400000 0.750000 0.650000 microarray 
TPM1,  STUB1,  hsa-miR-1224-5p,  hsa-miR-574-5p 0.782188 1.431250 0.681250 0.750000 combiAbMir 
HSPD1, RAN, hsa-miR-1224-5p, hsa-miR-342-3p 0.782188 1.427500 0.552500 0.875000 combiAbMir 
TPM1, hsa-miR-150, hsa-miR-122, hsa-miR-342-3p 0.782188 1.407500 0.657500 0.750000 combiAbMir 
HSPD1, RAN, hsa-miR-122, hsa-miR-342-3p 0.782188 1.405625 0.530625 0.875000 combiAbMir 
TPM1, RAN, hsa-miR-122, hsa-miR-342-3p 0.781875 1.418125 0.543125 0.875000 combiAbMir 
RAN, STUB1, hsa-miR-1224-5p, hsa-miR-574-5p 0.781719 1.413125 0.663125 0.750000 combiAbMir 
HSPD1, RAN, hsa-miR-150, hsa-miR-3648 0.781719 1.396875 0.771875 0.625000 combiAbMir 
TPM1,  hsa-miR-1224-5p,  hsa-miR-342-3p,hsa-miR-3648 0.780938 1.396250 0.771250 0.625000 combiAbMir 
RAN, STUB1, hsa-miR-1224-5p, hsa-miR-342-3p 0.780469 1.396875 0.646875 0.750000 combiAbMir 
TPM1, RAN, STUB1, hsa-miR-342-3p 0.780313 1.408125 0.658125 0.750000 combiAbMir 
RAN, hsa-miR-122, hsa-miR-342-3p, hsa-miR-3648 0.779063 1.376250 0.751250 0.625000 combiAbMir 
HSPD1, STUB1, hsa-miR-150, hsa-miR-1224-5p 0.778125 1.401250 0.651250 0.750000 combiAbMir 
TPM1, hsa-miR-122, hsa-miR-1224-5p, hsa-miR-342-3p 0.777969 1.409375 0.659375 0.750000 combiAbMir 
HSPD1, RAN, hsa-miR-150, hsa-miR-122 0.777188 1.395000 0.770000 0.625000 combiAbMir 
HSPD1, hsa-miR-150, hsa-miR-1224-5p, hsa-miR-342-3p 0.776875 1.395625 0.645625 0.750000 combiAbMir 
TPM1, hsa-miR-150, hsa-miR-1224-5p, hsa-miR-3648 0.773281 1.415625 0.790625 0.625000 combiAbMir 
RAN,  hsa-miR-122,  hsa-miR-1224-5p,  hsa-miR-342-3p 0.772344 1.406250 0.531250 0.875000 combiAbMir 
HSPD1, RAN, STUB1, hsa-miR-150 0.772344 1.384375 0.634375 0.750000 combiAbMir 
HSPD1, STUB1, hsa-miR-122, hsa-miR-342-3p 0.772188 1.381875 0.506875 0.875000 combiAbMir 
TPM1, STUB1, hsa-miR-150, hsa-miR-122 0.770469 1.426875 0.801875 0.625000 combiAbMir 
HSPD1, hsa-miR-122, hsa-miR-342-3p, hsa-miR-3648 0.770156 1.370625 0.620625 0.750000 combiAbMir 
RAN, hsa-miR-1224-5p, hsa-miR-342-3p, hsa-miR-3648 0.769688 1.381250 0.756250 0.625000 combiAbMir 
RAN,  hsa-miR-150,  hsa-miR-1224-5p,  hsa-miR-3648 0.769063 1.373750 0.748750 0.625000 combiAbMir 
hsa-miR-150, hsa-miR-122, hsa-miR-1224-5p,hsa-miR-342-3p 0.770000 1.380000 0.620000 0.760000 microarray 
TPM1, hsa-miR-150, hsa-miR-122, hsa-miR-1224-5p 0.768750 1.406250 0.781250 0.625000 combiAbMir 
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HSPD1, STUB1, hsa-miR-1224-5p, hsa-miR-342-3p 0.768125 1.398125 0.523125 0.875000 combiAbMir 
RAN, STUB1, hsa-miR-122, hsa-miR-342-3p 0.767969 1.378750 0.628750 0.750000 combiAbMir 
HSPD1, hsa-miR-150, hsa-miR-122, hsa-miR-3648 0.767344 1.376250 0.751250 0.625000 combiAbMir 
HSPD1, STUB1, hsa-miR-1224-5p, hsa-miR-574-5p 0.766094 1.378125 0.628125 0.750000 combiAbMir 
TPM1, RAN, hsa-miR-150, hsa-miR-122 0.765938 1.405000 0.780000 0.625000 combiAbMir 
TPM1, STUB1, hsa-miR-150, hsa-miR-1224-5p 0.764219 1.415000 0.790000 0.625000 combiAbMir 
HSPD1, hsa-miR-122, hsa-miR-1224-5p, hsa-miR-342-3p 0.763594 1.373750 0.498750 0.875000 combiAbMir 
RAN, STUB1, hsa-miR-150, hsa-miR-1224-5p 0.763281 1.385000 0.760000 0.625000 combiAbMir 
HSPD1, hsa-miR-150, hsa-miR-1224-5p, hsa-miR-3648 0.758438 1.370000 0.745000 0.625000 combiAbMir 
RAN, STUB1, hsa-miR-150, hsa-miR-342-3p 0.757813 1.376875 0.501875 0.875000 combiAbMir 
STUB1, hsa-miR-122, hsa-miR-1224-5p, hsa-miR-342-3p 0.757344 1.351875 0.601875 0.750000 combiAbMir 
RAN, STUB1, hsa-miR-150, hsa-miR-3648 0.755781 1.373125 0.748125 0.625000 combiAbMir 
hsa-miR-122, hsa-miR-1224-5p, hsa-miR-342-3p, hsa-miR-3648 0.760000 1.360000 0.660000 0.710000 microarray 
TPM1, STUB1, hsa-miR-150, hsa-miR-3648 0.755469 1.392500 0.767500 0.625000 combiAbMir 
RAN,  hsa-miR-150,  hsa-miR-122,  hsa-miR-1224-5p 0.753594 1.351250 0.726250 0.625000 combiAbMir 
TPM1, hsa-miR-150, hsa-miR-122, hsa-miR-3648 0.753438 1.376250 0.751250 0.625000 combiAbMir 
RAN, STUB1, hsa-miR-150, hsa-miR-122 0.752500 1.355000 0.730000 0.625000 combiAbMir 
STUB1, hsa-miR-122, hsa-miR-342-3p, hsa-miR-3648 0.752500 1.343750 0.593750 0.750000 combiAbMir 
STUB1, hsa-miR-150, hsa-miR-122, hsa-miR-342-3p 0.751250 1.353750 0.603750 0.750000 combiAbMir 
STUB1, hsa-miR-150, hsa-miR-1224-5p, hsa-miR-342-3p 0.749688 1.346250 0.471250 0.875000 combiAbMir 
HSPD1, STUB1, hsa-miR-150, hsa-miR-3648 0.748750 1.352500 0.727500 0.625000 combiAbMir 
STUB1, hsa-miR-150, hsa-miR-122, hsa-miR-3648 0.748750 1.343750 0.718750 0.625000 combiAbMir 
STUB1,  hsa-miR-1224-5p,  hsa-miR-342-3p,hsa-miR-3648 0.746406 1.344375 0.719375 0.625000 combiAbMir 
STUB1, hsa-miR-150, hsa-miR-342-3p, hsa-miR-3648 0.742969 1.332500 0.582500 0.750000 combiAbMir 
RAN,  hsa-miR-150,  hsa-miR-122,  hsa-miR-3648 0.740938 1.323125 0.698125 0.625000 combiAbMir 
hsa-miR-150, hsa-miR-122, hsa-miR-1224-5p,hsa-miR-3648 0.740000 1.320000 0.680000 0.650000 microarray 
STUB1, hsa-miR-150, hsa-miR-122, hsa-miR-1224-5p 0.736719 1.325000 0.575000 0.750000 combiAbMir 
STUB1, hsa-miR-150, hsa-miR-1224-5p, hsa-miR-3648 0.730313 1.313750 0.688750 0.625000 combiAbMir 
hsa-miR-150, hsa-miR-122, hsa-miR-3663-5p,hsa-miR-3194-5p 0.730000 1.300000 0.450000 0.850000 qPCR 
hsa-miR-150, hsa-miR-122, hsa-miR-342-3p,hsa-miR-3663-5p 0.720000 1.310000 0.470000 0.850000 qPCR 
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hsa-miR-150, hsa-miR-342-3p, hsa-miR-3663-5p, hsa-miR-3194-5p 0.720000 1.310000 0.610000 0.690000 qPCR 
TPM1, RAN, hsa-miR-122, hsa-miR-3648 0.720156 1.309375 0.809375 0.500000 combiAbMir 
TPM1, HSPD1, RAN, hsa-miR-122 0.718438 1.318125 0.693125 0.625000 combiAbMir 
TPM1, HSPD1, RAN, hsa-miR-3648 0.715469 1.281250 0.781250 0.500000 combiAbMir 
TPM1, RAN, hsa-miR-1224-5p, hsa-miR-3648 0.710156 1.280625 0.780625 0.500000 combiAbMir 
TPM1, hsa-miR-122, hsa-miR-1224-5p, hsa-miR-3648 0.709063 1.278750 0.778750 0.500000 combiAbMir 
hsa-miR-122, hsa-miR-342-3p, hsa-miR-3663-5p, hsa-miR-3194-5p 0.710000 1.290000 0.600000 0.690000 qPCR 
TPM1, HSPD1, STUB1, hsa-miR-3648 0.704531 1.276250 0.776250 0.500000 combiAbMir 
TPM1, HSPD1, hsa-miR-122, hsa-miR-3648 0.697500 1.283125 0.658125 0.625000 combiAbMir 
TPM1, HSPD1, STUB1, hsa-miR-122 0.696719 1.298125 0.673125 0.625000 combiAbMir 
HSPD1, RAN, hsa-miR-122, hsa-miR-3648 0.692656 1.270625 0.770625 0.500000 combiAbMir 
TPM1,  HSPD1,  hsa-miR-1224-5p,  hsa-miR-3648 0.688281 1.258750 0.758750 0.500000 combiAbMir 
TPM1, STUB1, hsa-miR-122, hsa-miR-3648 0.687656 1.269375 0.769375 0.500000 combiAbMir 
TPM1, HSPD1, RAN, STUB1 0.690000 1.280000 0.830000 0.440000 autoAb 
TPM1, HSPD1, hsa-miR-122, hsa-miR-1224-5p 0.684063 1.286250 0.661250 0.625000 combiAbMir 
HSPD1, RAN, hsa-miR-1224-5p, hsa-miR-3648 0.682656 1.234375 0.734375 0.500000 combiAbMir 
TPM1, HSPD1, STUB1, hsa-miR-1224-5p 0.682344 1.286250 0.786250 0.500000 combiAbMir 
TPM1, RAN, STUB1, hsa-miR-3648 0.680000 1.250000 0.750000 0.500000 combiAbMir 
HSPD1, STUB1, hsa-miR-122, hsa-miR-3648 0.678125 1.249375 0.749375 0.500000 combiAbMir 
RAN, STUB1, hsa-miR-122, hsa-miR-3648 0.669531 1.255000 0.755000 0.500000 combiAbMir 
TPM1, RAN, STUB1, hsa-miR-122 0.669219 1.273125 0.773125 0.500000 combiAbMir 
HSPD1, RAN, STUB1, hsa-miR-3648 0.669063 1.235000 0.860000 0.375000 combiAbMir 
STUB1, hsa-miR-122, hsa-miR-1224-5p, hsa-miR-3648 0.668750 1.234375 0.734375 0.500000 combiAbMir 
TPM1, HSPD1, RAN, hsa-miR-1224-5p 0.666094 1.242500 0.742500 0.500000 combiAbMir 
HSPD1, RAN, STUB1, hsa-miR-122 0.663281 1.237500 0.737500 0.500000 combiAbMir 
TPM1,  STUB1,  hsa-miR-1224-5p,  hsa-miR-3648 0.661250 1.200000 0.700000 0.500000 combiAbMir 
TPM1, STUB1, hsa-miR-122, hsa-miR-1224-5p 0.657500 1.270625 0.770625 0.500000 combiAbMir 
TPM1, RAN, hsa-miR-122, hsa-miR-1224-5p 0.651406 1.221875 0.596875 0.625000 combiAbMir 
HSPD1, hsa-miR-122, hsa-miR-1224-5p, hsa-miR-3648 0.649219 1.192500 0.817500 0.375000 combiAbMir 
hsa-miR-150, hsa-miR-122, hsa-miR-342-3p,hsa-miR-3194-5p 0.650000 1.250000 0.410000 0.850000 qPCR 
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HSPD1, STUB1, hsa-miR-122, hsa-miR-1224-5p 0.642031 1.193750 0.568750 0.625000 combiAbMir 
HSPD1, STUB1, hsa-miR-1224-5p, hsa-miR-3648 0.631250 1.166250 0.791250 0.375000 combiAbMir 
HSPD1, RAN, hsa-miR-122, hsa-miR-1224-5p 0.628438 1.147500 0.647500 0.500000 combiAbMir 
RAN, STUB1, hsa-miR-1224-5p, hsa-miR-3648 0.622656 1.210625 0.835625 0.375000 combiAbMir 
HSPD1, RAN, STUB1, hsa-miR-1224-5p 0.618906 1.156875 0.781875 0.375000 combiAbMir 
RAN,  hsa-miR-122,  hsa-miR-1224-5p,  hsa-miR-3648 0.617656 1.180000 0.805000 0.375000 combiAbMir 
TPM1, RAN, STUB1, hsa-miR-1224-5p 0.614531 1.177500 0.802500 0.375000 combiAbMir 
RAN, STUB1, hsa-miR-122, hsa-miR-1224-5p 0.603125 1.141875 0.516875 0.625000 combiAbMir 
(i)  S+S is the sum of the sensitivity and specificity columns, as determined in study 1. 
(ii)  and (iii) These two columns show the sensitivity and specificity of a test based solely on the relevant biomarker (or, for Tables 11-15, panel) shown in the left-hand column in the 
same row when applied to the samples used in study 1. 
(iv) For miRNA analysis, data was generated using either a microarray (“microarray“) or qPCR (“qPCR“) platform, as described in study 1. Autoantbody (“autoAb”) biomarkers were 
identified using the protein array platform described in study 1. Where panels were developed incorporating both miRNA and autoantibody biomarkers as variables (see study 1), these 
are described as “combiAbMir”. 
 
TABLE 9-31 
Table listing identified biomarkers (panel of five combinations) (see section 6.5) 
Panel AUC S+S(i) Sensitivity(ii) Specificity(iii) Assay(iv) 
hsa-miR-150, hsa-miR-122, hsa-miR-1224-5p,hsa-miR-342-3p, hsa-miR-574-5p 0.9 1.59 0.77 0.82 microarray 
hsa-miR-150, hsa-miR-122, hsa-miR-342-3p,hsa-miR-3648, hsa-miR-574-5p 0.89 1.57 0.8 0.76 microarray 
hsa-miR-150, hsa-miR-122, hsa-miR-1224-5p,hsa-miR-3648, hsa-miR-574-5p 0.88 1.57 0.8 0.76 microarray 
hsa-miR-122, hsa-miR-1224-5p, hsa-miR-342-3p, hsa-miR-3648, hsa-miR-574-5p 0.88 1.57 0.81 0.76 microarray 
hsa-miR-150, hsa-miR-1224-5p, hsa-miR-342-3p, hsa-miR-3648, hsa-miR-574-5p 0.88 1.56 0.8 0.76 microarray 
hsa-miR-150, hsa-miR-122, hsa-miR-1224-5p,hsa-miR-342-3p, hsa-miR-3648 0.77 1.38 0.73 0.65 microarray 
hsa-miR-150, hsa-miR-122, hsa-miR-342-3p,hsa-miR-3663-5p, hsa-miR-3194-5p 0.71 1.28 0.44 0.85 qPCR 
(i)  S+S is the sum of the sensitivity and specificity columns, as determined in study 1. 
(ii)  and (iii) These two columns show the sensitivity and specificity of a test based solely on the relevant biomarker (or, for Tables 11-15, panel) shown in the left-hand column in the 
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same row when applied to the samples used in study 1. 
(iv) For miRNA analysis, data was generated using either a microarray (“microarray“) or qPCR (“qPCR“) platform, as described in study 1. Autoantbody (“autoAb”) biomarkers were 
identified using the protein array platform described in study 1. Where panels were developed incorporating both miRNA and autoantibody biomarkers as variables (see study 1), these 
are described as “combiAbMir”. 
 
TABLE 9-32 
Table listing identified biomarkers (panel of six combinations) (see section 6.5) 
Panel AUC S+S
(i)
 Sensitivity
(ii)
 Specificity
(iii)
 Assay
(iv)
 
hsa-miR-150, hsa-miR-122, hsa-miR-1224-5p, 
hsa-miR-342-3p, hsa-miR-3648, hsa-miR-574-5p 
0.89 1.58 0.81 0.76 microarray 
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TABLE 9-33 
The levels of expression of the following 2 miRNAs are significantly different in ES samples 
compared to that in OvES, NE and NP samples (see Section 4.4.1.1) 
miRNA Expression in ES samples compared to that in OvES, NE 
and NP samples 
ebv-miR-BART2-5p Up 
hsa-miR-564 Down 
 
TABLE 9-34 
The levels of expression of the following miRNAs are significantly different in OvES samples 
compared to that in ES, NE and NP samples (see Section 4.4.1.1) 
miRNA Expression in OvES samples compared to that in ES, NE 
and NP samples 
hsa-let-7d-5p/3p Up 
hsa-miR-29a Down 
hsa-miR-142-3p Down 
hsa-miR-197 Up 
hsa-miR-215 Down 
hsa-miR-219-1-3p Up 
hsa-miR-296-3p Up 
hsa-miR-320c Down 
hsa-miR-337-5p Down 
hsa-miR-369-3p Down 
hsa-miR-450b-5p Down 
hsa-miR-483-5p Up 
hsa-miR-507 Down 
hsa-miR-517c / hsa-miR-519a Down 
hsa-miR-519d Up 
hsa-miR-520g Down 
hsa-miR-576-5p Up 
hsa-miR-577 Down 
hsa-miR-604 Up 
hsa-miR-610 Down 
hsa-miR-619 Down 
hsa-miR-1256 Down 
hsa-miR-1278 Down 
hsa-miR-1297 Down 
hcmv-miR-US33-5p Down 
hsv1-miR-H1-5p Up 
 
TABLE 9-35 
The level of expression of the following miRNA in OvES and ES samples is significantly different 
from that in NE and NP samples (see Section 4.4.1.1) 
miRNA Expression in OvES and ES samples compared to that in 
NE and NP samples 
hsa-miR-877 Down 
 
TABLE 9-36 
The levels of expression of the following miRNAs in OvES and NE samples are significantly 
different from that in ES and NP samples (see Section 4.4.1.1) 
miRNA Expression in OvES and NE samples compared to that in ES 
and NP samples 
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hsa-let-7e-5p/3p Up 
hsa-let-7f Up 
hsa-let-7g Up 
hsa-miR-9 Up 
hsa-miR-30b Up 
hsa-miR-34a Up 
hsa-miR-92b Up 
hsa-miR-96-5p/3p Up 
hsa-miR-106a-5p/3p Up 
hsa-miR-17-5p/3p Up 
hsa-miR-106b-5p/3p Up 
hsa-miR-127-3p Up 
hsa-miR-128 Up 
hsa-miR-154 Up 
hsa-miR-155 Up 
hsa-miR-183-5p/3p Up 
hsa-miR-194 Up 
hsa-miR-196b-5p/3p Up 
hsa-miR-203 Up 
hsa-miR-204 Up 
hsa-miR-221-5p/3p Up 
hsa-miR-223 Up 
hsa-miR-376a Up 
hsa-miR-376c Up 
hsa-miR-377 Up 
hsa-miR-379 Up 
hsa-miR-423-3p Up 
hsa-miR-424-5p/3p Up 
hsa-miR-425-5p/3p Up 
hsa-miR-454-5p/3p Up 
hsa-miR-486-3p Up 
hsa-miR-509-3p Up 
hsa-miR-514 Up 
hsa-miR-542-3p Up 
hsa-miR-545-5p/3p Up 
hsa-miR-626 Up 
hsa-miR-630 Up 
hsa-miR-663 Up 
hsa-miR-720 Up 
hsa-miR-758-5p/3p Up 
hsa-miR-876-3p Up 
hsa-miR-1185 Up 
hsa-miR-1260 Up 
hsa-miR-1266-5p/3p Up 
 
TABLE 9-37 
The levels of expression of the following miRNAs are significantly different in OvES, ES and NP 
samples compared to that in NE samples (see Section 4.4.1.1) 
miRNA Expression in OvES, ES and NP compared to that in NE 
samples 
hsa-miR-199a-3p Up 
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hsa-miR-199b-3p Up 
hsa-miR-497 Up 
hsa-miR-625-5p/3p Up 
 
TABLE 9-38 
The levels of expression of the following miRNAs are significantly different in OvES, ES and NE 
samples compared to that in NP samples (see Section 4.4.1.1) 
miRNA Expression in OvES, ES and NE samples compared to 
that in NP samples 
hsa-miR-631 Up 
hsa-miR-635 Up 
 
TABLE 9-39 
Table showing the results for EBV PCR from patient peripheral blood lymphocytes (see Section 
4.5.2.1) 
Case Control Phase of 
menstrual 
cycle 
Coding DNA 
ng/microl 
260/280 260/230 PCR 
 S Control Follicular 503819 38.00 1.88 2.21 0 
 S Control Follicular 2573709 27.70 1.92 1.62 0 
 S Control Luteal 6371846 49.30 1.95 2.44 0 
 S Control Luteal 2839865 44.40 1.87 2.31 0 
 S Control Luteal 6471336 63.70 2.00 2.30 0 
 S Control Luteal 1624876 87.90 1.92 2.28 0 
 S Control Follicular 3140020 74.00 1.90 2.29 0 
 S Control Follicular 1872461 43.10 1.99 2.28 0 
 Control Follicular 1577512 51.20 1.95 2.35 45 
 Control Follicular 7891234 31.50 2.12 1.94 82 
 Control Luteal 9155193 49.60 1.92 2.29 118 
 Control Luteal 9123853 58.30 1.97 2.23 162 
 Control  7891234 31.50 2.12 1.94 82 
Case  Follicular 1602619 61.70 1.94 2.09 0 
Case  Follicular 6170020 32.60 1.74 0.27 1,041 
Case  Follicular 9066819 33.00 1.73 1.80 469 
Case  Follicular 227536 72.00 1.89 1.96 35 
Case  Follicular 316919 91.70 1.88 1.77 0 
Case  Follicular 5938026 9.10 1.72 0.76 76 
Case  Follicular 588546 63.40 1.90 1.93 1,843 
Case  Follicular 8413629 192.00 1.86 1.77 0 
Case  Follicular 8947629 11.80 2.02 1.52 0 
Case  Follicular 811109 54.90 2.01 2.11 6,594 
Case  Follicular 6707519 30.00 2.01 1.53 0 
Case  Follicular 8417619 39.70 1.95 0.81 51 
Case  Follicular 3691029 21.00 2.21 2.80 59 
Case Ov  Follicular 8973029 26.70 2.17 2.55 3,014 
Case Ov  Follicular 8714246 33.10 1.84 2.47 56 
Case  Follicular 1802116 6.70 1.26 0.38 0 
Case  Luteal 6095346 83.00 1.85 2.10 0 
Case  Luteal 439356 5.80 2.01 0.35 0 
Case  Luteal 3677410 28.80 1.85 1.71 0 
Case  Luteal 4506746 61.30 1.99 2.45 51 
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Case  Luteal 3850536 50.00 1.77 1.66 0 
Case Ov  Luteal 7036506 20.10 2.27 2.35 0 
Case Ov  Luteal 5044706 57.40 1.98 0.93 76 
Case  Mid Cycle 2183016 71.00 1.91 0.68 0 
Case  Luteal 2207656 333.80 1.87 1.48 147 
Case  Mid Cycle 6220521 14.20 1.86 1.05 76 
Case  Mid Cycle 1546126 10.40 1.67 0.96 0 
Case  Mid Cycle 2487156 27.50 1.96 2.27 64 
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